ASI,ASSTY,ASTTY,ASSTI,ASSTR,Ti,CURB,Des,SRASSI,CHEI,ASCATE,CONSC,SI,CI,BFOR,TII,VARII
7524,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL618647,,1,1,,BAO_0000218,2113.0,
7525,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL618648,,1,1,,BAO_0000218,2113.0,
7526,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL618649,,1,1,,BAO_0000218,2113.0,
7527,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL618650,,1,1,,BAO_0000218,2107.0,
7528,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL618651,,1,1,,BAO_0000218,2107.0,
7529,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL876497,,1,1,,BAO_0000218,2107.0,
7530,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL618652,,1,1,,BAO_0000218,2048.0,
7531,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL618653,,1,1,,BAO_0000218,2048.0,
7532,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL618654,,1,1,,BAO_0000218,2048.0,
7533,A,,10116.0,,50597,Intermediate,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,CHEMBL618655,,1,1,,BAO_0000218,,
7534,A,,10116.0,,50597,Intermediate,Compound was tested for solubility in water,,CHEMBL618656,,1,1,,BAO_0000218,,
7535,P,,,,22229,Intermediate,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,CHEMBL618657,,0,1,,BAO_0000100,,
7536,A,,10116.0,,50597,Intermediate,Solubility was determined,,CHEMBL618658,,1,1,,BAO_0000218,,
7537,A,,10116.0,,50597,Intermediate,solubility in water (ug/mL) at 37 degree C.,,CHEMBL618659,,1,1,,BAO_0000218,,
7538,A,,10116.0,,50597,Intermediate,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,CHEMBL618660,,1,1,,BAO_0000218,,
7539,A,,10116.0,,50597,Intermediate,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,CHEMBL618661,,1,1,,BAO_0000218,,
7540,A,,10116.0,,50597,Intermediate,Half life in rats,,CHEMBL873807,,1,1,,BAO_0000218,,
7541,A,,10116.0,,50597,Intermediate,Half life in Dawley rat,,CHEMBL618662,,1,1,,BAO_0000218,,
7542,A,In vivo,10116.0,,50597,Intermediate,Half life period after 3 mg/kg iv administration,,CHEMBL618663,,1,1,,BAO_0000218,,
7543,A,In vivo,10116.0,,50597,Intermediate,Half life period after 3 mg/kg iv administration in rat,,CHEMBL618664,,1,1,,BAO_0000218,,
7544,A,In vivo,10116.0,,50597,Intermediate,Half life period after 3 mg/kg iv administration in the rat,,CHEMBL618665,,1,1,,BAO_0000218,,
7545,A,,10116.0,,50597,Intermediate,Half life period in female Sprague-Dawley rats,,CHEMBL876498,,1,1,,BAO_0000218,,
7546,A,,10116.0,,50597,Intermediate,Half life period in rat,,CHEMBL618666,,1,1,,BAO_0000218,,
7547,A,,10116.0,,50597,Intermediate,Half-life in rats was determined,,CHEMBL620440,,1,1,,BAO_0000218,,
7548,A,,10116.0,,50597,Intermediate,Half-life in rats with metabolic oxidation,,CHEMBL620441,,1,1,,BAO_0000218,,
7549,A,,10116.0,,50597,Intermediate,Half-life in rats,,CHEMBL620442,,1,1,,BAO_0000218,,
7550,A,In vivo,10116.0,,50597,Intermediate,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,CHEMBL620443,,1,1,,BAO_0000218,,
7551,A,In vivo,10116.0,,50597,Intermediate,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,CHEMBL620444,,1,1,,BAO_0000218,,
7552,A,In vivo,10116.0,,50597,Intermediate,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,CHEMBL620445,,1,1,,BAO_0000218,,
7553,A,In vivo,10116.0,,50597,Intermediate,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,CHEMBL620446,,1,1,,BAO_0000218,,
7554,A,,10116.0,,50597,Intermediate,Biological half-life measured in plasma of rat,,CHEMBL620447,,1,1,,BAO_0000218,1969.0,
7555,A,,10116.0,,50597,Intermediate,Biological half-life measured in plasma of rat; 22-25,,CHEMBL621129,,1,1,,BAO_0000218,1969.0,
7556,A,,10116.0,,50597,Intermediate,Biological half-life measured in plasma of rat; 9-16,,CHEMBL621130,,1,1,,BAO_0000218,1969.0,
7557,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for its half life when administered intravenously in rat,,CHEMBL873808,,1,1,,BAO_0000218,,
7558,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,CHEMBL876598,,1,1,,BAO_0000218,,
7559,A,In vivo,10116.0,,50597,Intermediate,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,CHEMBL621131,,1,1,,BAO_0000218,,
7560,A,In vivo,10116.0,,50597,Intermediate,Half life (T1/2) after oral administration in rat,,CHEMBL621132,,1,1,,BAO_0000218,,
7561,A,In vivo,10116.0,,50597,Intermediate,Half life of compound after iv administration of 20 mg/kg dose in rat,,CHEMBL621133,,1,1,,BAO_0000218,,
7562,A,In vivo,10116.0,,50597,Expert,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL621312,,1,1,,BAO_0000218,,
7563,A,,10116.0,,50597,Intermediate,Half life of compound was determined in rat,,CHEMBL621313,,1,1,,BAO_0000218,,
7564,A,,10116.0,,50597,Intermediate,Half life of compound was determined in rat blood,,CHEMBL621314,,1,1,,BAO_0000218,178.0,
7565,A,In vivo,10116.0,,50597,Intermediate,Half life at 1 mg/kg was determined in rat,,CHEMBL621315,,1,1,,BAO_0000218,,
7566,A,In vivo,10116.0,,50597,Intermediate,Half life at 10 mg/kg was determined in rat,,CHEMBL621316,,1,1,,BAO_0000218,,
7567,A,,10116.0,,50597,Intermediate,Half life in rats,,CHEMBL621317,,1,1,,BAO_0000218,,
7568,A,,10116.0,,50597,Intermediate,Half life in rats in hours,,CHEMBL621318,,1,1,,BAO_0000218,,
7569,A,In vivo,10116.0,,50597,Intermediate,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,CHEMBL621319,,1,1,,BAO_0000218,,
7570,A,In vivo,10116.0,,50597,Intermediate,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,CHEMBL621377,,1,1,,BAO_0000218,,
7571,A,,10116.0,,50597,Intermediate,Half life was determined,,CHEMBL621378,,1,1,,BAO_0000218,,
7572,A,In vivo,10116.0,,50597,Intermediate,Half life after i.v. administration,,CHEMBL876599,,1,1,,BAO_0000218,,
7573,A,In vivo,10116.0,,50597,Intermediate,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,CHEMBL621379,,1,1,,BAO_0000218,,
7574,A,,10116.0,,50597,Intermediate,Half life in rat plasma,,CHEMBL621380,,1,1,,BAO_0000218,1969.0,
7575,A,,10116.0,,50597,Intermediate,Half life in rat plasma; Not detected,,CHEMBL621381,,1,1,,BAO_0000218,1969.0,
7576,A,,10116.0,,50597,Intermediate,Half life in rats,,CHEMBL618515,,1,1,,BAO_0000218,,
7577,A,In vivo,10116.0,,50597,Intermediate,Half life period of compound was determined after peroral administration,,CHEMBL618516,,1,1,,BAO_0000218,,
7578,A,In vivo,10116.0,,50597,Intermediate,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,CHEMBL618517,,1,1,,BAO_0000218,,
7579,A,,10116.0,,50597,Intermediate,Half life period in rat,,CHEMBL618518,,1,1,,BAO_0000218,,
7580,A,In vivo,10116.0,,50597,Intermediate,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,CHEMBL618519,,1,1,,BAO_0000218,,
7581,A,In vivo,10116.0,,50597,Intermediate,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,CHEMBL618698,,1,1,,BAO_0000218,,
7582,A,In vivo,10116.0,,50597,Intermediate,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,CHEMBL618862,,1,1,,BAO_0000218,,
7583,A,In vivo,10116.0,,50597,Intermediate,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,CHEMBL618863,,1,1,,BAO_0000218,,
7584,A,In vivo,10116.0,,50597,Intermediate,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,CHEMBL618864,,1,1,,BAO_0000218,,
7585,A,In vivo,10116.0,,50597,Intermediate,Half life time in rat the dose of 2 mg/kg,,CHEMBL618865,,1,1,,BAO_0000218,,
7586,A,In vivo,10116.0,,50597,Intermediate,Half-life 24 hr after 10 mg/kg iv administration in rats,,CHEMBL618866,,1,1,,BAO_0000218,,
7587,A,In vivo,10116.0,,50597,Intermediate,Half-life 24 hr after 2 mg/kg iv administration in rats,,CHEMBL618867,,1,1,,BAO_0000218,,
7588,A,,10116.0,,50597,Intermediate,Half-life consistent with the observed metabolic steady state in rats,,CHEMBL875828,,1,1,,BAO_0000218,,
7589,A,In vivo,10116.0,,50597,Intermediate,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,CHEMBL618868,,1,1,,BAO_0000218,,
7590,A,,10116.0,,50597,Intermediate,Half-life for oxidative metabolic stability was determined using male human,,CHEMBL618869,,1,1,,BAO_0000218,,
7591,A,In vivo,10116.0,,50597,Intermediate,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,CHEMBL618870,,1,1,,BAO_0000218,,
7592,A,,10116.0,,50597,Intermediate,Half-life in rat plasma,,CHEMBL618871,,1,1,,BAO_0000218,1969.0,
7593,A,,10116.0,,50597,Intermediate,Half-life in rat plasma was determined,,CHEMBL618872,,1,1,,BAO_0000218,1969.0,
7594,A,,10116.0,,50597,Intermediate,Half-life in rats was determined,,CHEMBL873816,,1,1,,BAO_0000218,,
7595,A,,,,22224,Autocuration,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,CHEMBL618873,,0,1,,BAO_0000218,,
7596,A,,,,22224,Autocuration,Area under curve after oral dose of 0.1 mg//kg,,CHEMBL621602,,0,1,,BAO_0000019,,
7597,A,,,,22224,Autocuration,Area under curve after oral dose of 0.3 mg/kg,,CHEMBL621603,,0,1,,BAO_0000218,,
7598,A,,,,22224,Autocuration,Area under curve after oral dose of 1 mg/kg,,CHEMBL621604,,0,1,,BAO_0000218,,
7599,A,,,,22224,Autocuration,Area under curve after oral dose of 10 mg/kg,,CHEMBL621605,,0,1,,BAO_0000218,,
7600,A,,,,22224,Autocuration,Area under curve after oral dose of 23.4 mg/kg,,CHEMBL621606,,0,1,,BAO_0000218,,
7601,A,,,,22224,Autocuration,Area under curve after oral dose of 3 mg/kg,,CHEMBL621607,,0,1,,BAO_0000218,,
7602,A,,,,22224,Autocuration,Area under curve after oral dose of 3.87 mg/kg,,CHEMBL621608,,0,1,,BAO_0000218,,
7603,A,,,,22224,Autocuration,Area under curve was determined,,CHEMBL621609,,0,1,,BAO_0000019,,
7604,A,,,,22224,Autocuration,Area under curve at a dose of 10 mg/kg,,CHEMBL621610,,0,1,,BAO_0000218,,
7605,A,,10116.0,,50597,Intermediate,Area under curve was determined; ND=No data,,CHEMBL621611,,1,1,,BAO_0000218,,
7606,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL621612,,1,1,,BAO_0000218,,
7607,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,CHEMBL622308,,1,1,,BAO_0000218,,
7608,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL622309,,1,1,,BAO_0000218,,
7609,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,CHEMBL622310,,1,1,,BAO_0000218,,
7610,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,CHEMBL622311,,1,1,,BAO_0000218,,
7611,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,CHEMBL622312,,1,1,,BAO_0000218,,
7612,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL622931,,1,1,,BAO_0000218,,
7613,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,CHEMBL622932,,1,1,,BAO_0000218,,
7614,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL622736,,1,1,,BAO_0000218,1969.0,
7615,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,CHEMBL622737,,1,1,,BAO_0000218,1969.0,
7616,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL622738,,1,1,,BAO_0000218,1969.0,
7617,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,,CHEMBL622739,,1,1,,BAO_0000218,1969.0,
7618,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,CHEMBL622740,,1,1,,BAO_0000218,1969.0,
7619,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,,CHEMBL622741,,1,1,,BAO_0000218,1969.0,
7620,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,CHEMBL622742,,1,1,,BAO_0000218,1969.0,
7621,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,,CHEMBL622743,,1,1,,BAO_0000218,1969.0,
7622,A,,10090.0,,50594,Intermediate,AUC in mice,,CHEMBL622744,,1,1,,BAO_0000218,1969.0,
7623,A,,,,22224,Autocuration,Area under curve was measured from the graph obtained from concentration Vs time,,CHEMBL624134,,0,1,,BAO_0000019,,
7624,A,,,,22224,Autocuration,Area under curve value of compound per hour after oral administration,,CHEMBL624135,,0,1,,BAO_0000019,,
7625,A,,10116.0,,50597,Intermediate,Area under curve was determined after oral administration in rats,,CHEMBL624136,,1,1,,BAO_0000218,,
7626,A,,10116.0,,50597,Intermediate,Area under curve was determined after oral administration in rats; No data,,CHEMBL624137,,1,1,,BAO_0000218,,
7627,A,,10116.0,,50597,Intermediate,Area under curve was determined after oral administration in rats;No data,,CHEMBL624320,,1,1,,BAO_0000218,,
7628,A,,9615.0,,50588,Intermediate,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,CHEMBL624321,,1,1,,BAO_0000218,,
7629,A,,10116.0,,50597,Intermediate,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,CHEMBL624322,,1,1,,BAO_0000218,,
7630,A,,10116.0,,50597,Intermediate,Area under curve was determined for the compound after iv dose of 5.06 in rats,,CHEMBL624323,,1,1,,BAO_0000218,,
7631,A,,10116.0,,50597,Intermediate,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,CHEMBL624324,,1,1,,BAO_0000218,,
7632,A,,10116.0,,50597,Intermediate,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,CHEMBL624325,,1,1,,BAO_0000218,,
7633,A,,10116.0,,50597,Intermediate,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,CHEMBL624326,,1,1,,BAO_0000218,,
7634,A,,10116.0,,50597,Intermediate,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,CHEMBL624327,,1,1,,BAO_0000218,,
7635,A,,10116.0,,50597,Intermediate,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,CHEMBL624328,,1,1,,BAO_0000218,,
7636,A,,9615.0,,50588,Intermediate,Area under curve was determined in Dogs after peroral administration,,CHEMBL627848,,1,1,,BAO_0000218,,
7637,A,,10116.0,,50597,Intermediate,Area under curve was determined in Rats after peroral administration,,CHEMBL627849,,1,1,,BAO_0000218,,
7638,A,,10116.0,,50597,Intermediate,Area under curve was determined in carotid blood of rat when administered intradermally,,CHEMBL627850,,1,1,,BAO_0000218,,
7639,A,,10116.0,,50597,Intermediate,Area under curve was determined in portal blood of rat when administered intradermally,,CHEMBL627851,,1,1,,BAO_0000218,,
7640,A,,10090.0,,50594,Intermediate,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,CHEMBL627852,,1,1,,BAO_0000218,,
7641,A,,10090.0,,50594,Intermediate,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,CHEMBL627853,,1,1,,BAO_0000218,,
7642,A,,10090.0,,50594,Intermediate,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,CHEMBL627854,,1,1,,BAO_0000218,,
7643,A,,10090.0,,50594,Intermediate,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,CHEMBL627855,,1,1,,BAO_0000218,,
7644,A,,10090.0,,50594,Intermediate,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,CHEMBL627856,,1,1,,BAO_0000218,,
7645,A,,10090.0,,50594,Intermediate,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,CHEMBL875339,,1,1,,BAO_0000218,,
7646,A,,10090.0,,50594,Intermediate,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,CHEMBL627857,,1,1,,BAO_0000218,,
7647,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,,CHEMBL627858,,1,1,,BAO_0000218,2106.0,
7648,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,,CHEMBL627859,,1,1,,BAO_0000218,178.0,
7649,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,,CHEMBL627860,,1,1,,BAO_0000218,955.0,
7650,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,,CHEMBL627019,,1,1,,BAO_0000218,948.0,
7651,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,,CHEMBL627020,,1,1,,BAO_0000218,2107.0,
7652,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,,CHEMBL627021,,1,1,,BAO_0000218,2048.0,
7653,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,,CHEMBL627022,,1,1,,BAO_0000218,2385.0,
7654,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,CHEMBL627023,,1,1,,BAO_0000218,,
7655,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,,CHEMBL627024,,1,1,,BAO_0000218,2106.0,
7656,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,,CHEMBL627025,,1,1,,BAO_0000218,2046.0,
7657,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,,CHEMBL627026,,1,1,,BAO_0000218,2113.0,
7658,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,,CHEMBL627027,,1,1,,BAO_0000218,178.0,
7659,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,,CHEMBL627028,,1,1,,BAO_0000218,955.0,
7660,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,,CHEMBL627029,,1,1,,BAO_0000218,948.0,
7661,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,,CHEMBL627030,,1,1,,BAO_0000218,2113.0,
7662,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,,CHEMBL627031,,1,1,,BAO_0000218,2107.0,
7663,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,,CHEMBL627032,,1,1,,BAO_0000218,2048.0,
7664,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,,CHEMBL627033,,1,1,,BAO_0000218,2385.0,
7665,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,CHEMBL627034,,1,1,,BAO_0000218,,
7666,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,,CHEMBL627035,,1,1,,BAO_0000218,2106.0,
7667,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,,CHEMBL627036,,1,1,,BAO_0000218,2046.0,
7668,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,,CHEMBL875340,,1,1,,BAO_0000218,178.0,
7669,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,,CHEMBL627037,,1,1,,BAO_0000218,948.0,
7670,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,,CHEMBL627038,,1,1,,BAO_0000218,2113.0,
7671,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,,CHEMBL627039,,1,1,,BAO_0000218,2107.0,
7672,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,,CHEMBL627040,,1,1,,BAO_0000218,2385.0,
7673,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,,CHEMBL624663,,1,1,,BAO_0000218,2106.0,
7674,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,,CHEMBL625963,,1,1,,BAO_0000218,2046.0,
7675,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,,CHEMBL876799,,1,1,,BAO_0000218,955.0,
7676,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,,CHEMBL626133,,1,1,,BAO_0000218,2048.0,
7677,A,,10116.0,,50597,Intermediate,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,CHEMBL626134,,1,1,,BAO_0000218,,
7678,A,,10116.0,,50597,Intermediate,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,CHEMBL626135,,1,1,,BAO_0000218,,
7679,A,,10116.0,,50597,Intermediate,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,CHEMBL626136,,1,1,,BAO_0000218,,
7680,A,,10116.0,,50597,Intermediate,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,CHEMBL626137,,1,1,,BAO_0000218,,
7681,A,,10116.0,,50597,Intermediate,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,CHEMBL626138,,1,1,,BAO_0000218,,
7682,A,,10116.0,,50597,Intermediate,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,CHEMBL626139,,1,1,,BAO_0000218,,
7683,A,In vivo,10116.0,,50597,Intermediate,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,CHEMBL626140,,1,1,,BAO_0000218,,
7684,A,In vivo,10116.0,,50597,Intermediate,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,CHEMBL626141,,1,1,,BAO_0000218,,
7685,A,,10116.0,,50597,Intermediate,C24h in rat p.o. at 20 mg/kg concentration,,CHEMBL626142,,1,1,,BAO_0000218,,
7686,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL627930,,1,1,,BAO_0000218,2385.0,
7687,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL627931,,1,1,,BAO_0000218,2385.0,
7688,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL627932,,1,1,,BAO_0000218,2385.0,
7689,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,CHEMBL627933,,1,1,,BAO_0000218,2106.0,
7690,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,,CHEMBL627934,,1,1,,BAO_0000218,2106.0,
7691,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,,CHEMBL627935,,1,1,,BAO_0000218,2106.0,
7692,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,,CHEMBL627936,,1,1,,BAO_0000218,178.0,
7693,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,,CHEMBL627937,,1,1,,BAO_0000218,178.0,
7694,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,,CHEMBL627938,,1,1,,BAO_0000218,178.0,
7695,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL627939,,1,1,,BAO_0000218,178.0,
7696,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,,CHEMBL627940,,1,1,,BAO_0000218,178.0,
7697,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,,CHEMBL627941,,1,1,,BAO_0000218,178.0,
7698,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,CHEMBL876800,,1,1,,BAO_0000218,178.0,
7699,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,,CHEMBL627942,,1,1,,BAO_0000218,178.0,
7700,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,,CHEMBL627943,,1,1,,BAO_0000218,178.0,
7701,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,,CHEMBL627944,,1,1,,BAO_0000218,178.0,
7702,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,,CHEMBL627945,,1,1,,BAO_0000218,178.0,
7703,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,,CHEMBL628584,,1,1,,BAO_0000218,178.0,
7704,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA at 15 min,,CHEMBL628585,,1,1,,BAO_0000218,178.0,
7705,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,,CHEMBL628586,,1,1,,BAO_0000218,178.0,
7706,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA at 30 min,,CHEMBL628587,,1,1,,BAO_0000218,178.0,
7707,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,,CHEMBL628588,,1,1,,BAO_0000218,178.0,
7708,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,,CHEMBL628589,,1,1,,BAO_0000218,178.0,
7709,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,,CHEMBL625304,,1,1,,BAO_0000218,178.0,
7710,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,,CHEMBL625305,,1,1,,BAO_0000218,178.0,
7711,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,,CHEMBL625306,,1,1,,BAO_0000218,178.0,
7712,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,,CHEMBL625307,,1,1,,BAO_0000218,178.0,
7713,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,,CHEMBL625308,,1,1,,BAO_0000218,178.0,
7714,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,,CHEMBL627740,,1,1,,BAO_0000218,178.0,
7715,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,,CHEMBL627741,,1,1,,BAO_0000218,178.0,
7716,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,CHEMBL627742,,1,1,,BAO_0000218,178.0,
7717,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,,CHEMBL627743,,1,1,,BAO_0000218,178.0,
7718,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,,CHEMBL627744,,1,1,,BAO_0000218,178.0,
7719,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,,CHEMBL627745,,1,1,,BAO_0000218,10000001.0,
7720,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,,CHEMBL627746,,1,1,,BAO_0000218,10000001.0,
7721,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,,CHEMBL627747,,1,1,,BAO_0000218,10000001.0,
7722,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL876810,,1,1,,BAO_0000218,10000001.0,
7723,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,,CHEMBL627748,,1,1,,BAO_0000218,10000001.0,
7724,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,,CHEMBL627749,,1,1,,BAO_0000218,10000001.0,
7725,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,CHEMBL627750,,1,1,,BAO_0000218,10000001.0,
7726,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,,CHEMBL618728,,1,1,,BAO_0000218,10000001.0,
7727,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,,CHEMBL618729,,1,1,,BAO_0000218,10000001.0,
7728,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA at 15 min,,CHEMBL618730,,1,1,,BAO_0000218,10000001.0,
7729,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,,CHEMBL618731,,1,1,,BAO_0000218,10000001.0,
7730,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA at 30 min,,CHEMBL618732,,1,1,,BAO_0000218,10000001.0,
7731,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,,CHEMBL618733,,1,1,,BAO_0000218,10000001.0,
7732,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,,CHEMBL618734,,1,1,,BAO_0000218,10000001.0,
7733,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,,CHEMBL618735,,1,1,,BAO_0000218,10000001.0,
7734,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,,CHEMBL876602,,1,1,,BAO_0000218,10000001.0,
7735,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,,CHEMBL618736,,1,1,,BAO_0000218,10000001.0,
7736,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,,CHEMBL618737,,1,1,,BAO_0000218,10000001.0,
7737,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,,CHEMBL618738,,1,1,,BAO_0000218,10000001.0,
7738,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,,CHEMBL618739,,1,1,,BAO_0000218,10000001.0,
7739,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,,CHEMBL618740,,1,1,,BAO_0000218,10000001.0,
7740,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,CHEMBL618741,,1,1,,BAO_0000218,10000001.0,
7741,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,,CHEMBL618742,,1,1,,BAO_0000218,10000001.0,
7742,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,,CHEMBL618743,,1,1,,BAO_0000218,10000001.0,
7743,A,In vivo,10116.0,,50597,Intermediate,Half-life from rat plasma at a single oral dose of 25 mg/kg,,CHEMBL618744,,1,1,,BAO_0000218,1969.0,
7744,A,,10116.0,,50597,Intermediate,Half-life in male rat,,CHEMBL618745,,1,1,,BAO_0000218,,
7745,A,In vivo,10116.0,,50597,Intermediate,Half-life in rat after peroral administration at 10 mg/kg concentration,,CHEMBL620479,,1,1,,BAO_0000218,,
7746,A,In vivo,10116.0,,50597,Intermediate,Half-life in rat after peroral administration at 5 mg/kg concentration,,CHEMBL620480,,1,1,,BAO_0000218,,
7747,A,In vivo,10116.0,,50597,Intermediate,Half-life in rat at a dose of 3 mg/kg,,CHEMBL620481,,1,1,,BAO_0000218,,
7748,A,,10116.0,,50597,Intermediate,Half-life was evaluated in rats,,CHEMBL620482,,1,1,,BAO_0000218,,
7749,A,,10116.0,,50597,Intermediate,Half-life was measured in rat,,CHEMBL876603,,1,1,,BAO_0000218,,
7750,A,In vivo,10116.0,,50597,Intermediate,Half-life period for the compound was determined in rats at 50 mg/kg dose,,CHEMBL620483,,1,1,,BAO_0000218,,
7751,A,In vivo,10116.0,,50597,Intermediate,Half-life period in rats after intravenous administration at 5 mg/kg,,CHEMBL620484,,1,1,,BAO_0000218,,
7752,A,In vivo,10116.0,,50597,Intermediate,Half-life period in rat at 10 mg/kg,,CHEMBL620485,,1,1,,BAO_0000218,,
7753,A,In vivo,10116.0,,50597,Intermediate,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,CHEMBL620486,,1,1,,BAO_0000218,,
7754,A,In vivo,10116.0,,50597,Intermediate,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,CHEMBL620487,,1,1,,BAO_0000218,,
7755,A,In vivo,10116.0,,50597,Intermediate,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,CHEMBL620488,,1,1,,BAO_0000218,,
7756,A,In vivo,10116.0,,50597,Intermediate,Half-life time in rat the dose of 2 mg/kg,,CHEMBL620489,,1,1,,BAO_0000218,,
7757,A,In vivo,10116.0,,50597,Intermediate,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,CHEMBL620490,,1,1,,BAO_0000218,,
7758,A,In vivo,10116.0,,50597,Intermediate,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,CHEMBL620491,,1,1,,BAO_0000218,,
7759,A,In vivo,10116.0,,50597,Intermediate,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,CHEMBL876604,,1,1,,BAO_0000218,1969.0,
7760,A,In vivo,10116.0,,50597,Intermediate,Oral half life was determined,,CHEMBL620492,,1,1,,BAO_0000218,,
7761,A,In vivo,10116.0,,50597,Intermediate,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL620493,,1,1,,BAO_0000218,,
7762,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (t1/2) in rat,,CHEMBL620494,,1,1,,BAO_0000218,,
7763,A,,10116.0,,50597,Intermediate,Plasma elimination half-life was determined,,CHEMBL620495,,1,1,,BAO_0000218,1969.0,
7764,A,In vivo,10116.0,,50597,Intermediate,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,CHEMBL620496,,1,1,,BAO_0000218,1969.0,
7765,A,In vivo,10116.0,,50597,Intermediate,Plasma half life was observed after intravenous administration in rat,,CHEMBL620497,,1,1,,BAO_0000218,1969.0,
7766,A,,10116.0,,50597,Intermediate,Plasma half-life was determined,,CHEMBL620498,,1,1,,BAO_0000218,1969.0,
7767,A,In vivo,10116.0,,50597,Intermediate,Plasma half-life following oral administration in Fisher rats,,CHEMBL620499,,1,1,,BAO_0000218,1969.0,
7768,A,,10116.0,,50597,Intermediate,Plasma half-life in rat,,CHEMBL620500,,1,1,,BAO_0000218,1969.0,
7769,A,In vivo,10116.0,,50597,Intermediate,Plasmatic Half-life after intravenous administration to rat,,CHEMBL873809,,1,1,,BAO_0000218,1969.0,
7770,A,In vivo,10116.0,,50597,Intermediate,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,CHEMBL620501,,1,1,,BAO_0000218,,
7771,A,In vivo,10116.0,,50597,Intermediate,Terminal half life after intravenous administration (1 mg/kg) in rat,,CHEMBL620502,,1,1,,BAO_0000218,,
7772,A,In vivo,10116.0,,50597,Intermediate,Terminal half life in Rat at a oral dose of 5 mg/kg,,CHEMBL620503,,1,1,,BAO_0000218,,
7773,A,In vivo,10116.0,,50597,Intermediate,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,CHEMBL620504,,1,1,,BAO_0000218,,
7774,A,In vivo,10116.0,,50597,Intermediate,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,CHEMBL876605,,1,1,,BAO_0000218,,
7775,A,In vivo,10116.0,,50597,Intermediate,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,CHEMBL620505,,1,1,,BAO_0000218,,
7776,A,In vivo,10116.0,,50597,Intermediate,plasma half life was observed after intravenous administration in rat,,CHEMBL873811,,1,1,,BAO_0000218,1969.0,
7777,A,In vivo,10116.0,,50597,Expert,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL624016,,1,1,,BAO_0000218,,
7778,A,,10116.0,,50597,Intermediate,Half life of compound determined in rat,,CHEMBL624017,,1,1,,BAO_0000218,,
7779,A,,10116.0,,50597,Intermediate,Mean residence time determined in rat,,CHEMBL624018,,1,1,,BAO_0000218,,
7780,A,,10116.0,,50597,Intermediate,Plasma half life determined in rat,,CHEMBL624019,,1,1,,BAO_0000218,,
7781,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for Tmax in brain after intravenous administration in male rats,,CHEMBL624020,,1,1,,BAO_0000218,955.0,
7782,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for pharmacokinetic parameter maximum time period,,CHEMBL624201,,1,1,,BAO_0000218,,
7783,A,In vivo,10116.0,,50597,Intermediate,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,CHEMBL872528,,1,1,,BAO_0000218,,
7784,A,In vivo,10116.0,,50597,Intermediate,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL624202,,1,1,,BAO_0000218,,
7785,A,In vivo,10116.0,,50597,Intermediate,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL624203,,1,1,,BAO_0000218,,
7786,A,In vivo,10116.0,,50597,Intermediate,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,CHEMBL624350,,1,1,,BAO_0000218,,
7787,A,In vivo,10116.0,,50597,Intermediate,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL621320,,1,1,,BAO_0000218,,
7788,A,In vivo,10116.0,,50597,Intermediate,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,CHEMBL621321,,1,1,,BAO_0000218,,
7789,A,,10116.0,,50597,Intermediate,Maximum time (Tmax) required to reach Cmax in rats,,CHEMBL621322,,1,1,,BAO_0000218,,
7790,A,In vivo,10116.0,,50597,Intermediate,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,CHEMBL621323,,1,1,,BAO_0000218,,
7791,A,In vivo,10116.0,,50597,Intermediate,Maximum time of clearance of compound in rats after peroral administration,,CHEMBL621324,,1,1,,BAO_0000218,,
7792,A,,10116.0,,50597,Intermediate,Maximum time at the dose of 2 mg/kg in rat,,CHEMBL621325,,1,1,,BAO_0000218,,
7793,A,In vivo,10116.0,,50597,Intermediate,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,,CHEMBL875837,,1,1,,BAO_0000218,1969.0,
7794,A,In vivo,10116.0,,50597,Intermediate,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,,CHEMBL621326,,1,1,,BAO_0000218,1969.0,
7795,A,In vivo,10116.0,,50597,Intermediate,Tmax in Guinea pig (PO dose),,CHEMBL621327,,1,1,,BAO_0000218,,
7796,A,In vivo,10116.0,,50597,Intermediate,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL621328,,1,1,,BAO_0000218,,
7797,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter (Tmax) in rat,,CHEMBL621329,,1,1,,BAO_0000218,,
7798,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter (Tmax) was estimated,,CHEMBL621330,,1,1,,BAO_0000218,,
7799,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Tmax) in rat,,CHEMBL621331,,1,1,,BAO_0000218,,
7800,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,CHEMBL621332,,1,1,,BAO_0000218,,
7801,A,In vivo,10116.0,,50597,Intermediate,T max in Rat at a oral dose of 5 mg/kg,,CHEMBL621333,,1,1,,BAO_0000218,,
7802,A,In vivo,10116.0,,50597,Intermediate,T max was determined at 10 mg/kg po dose in rats,,CHEMBL621334,,1,1,,BAO_0000218,,
7803,A,,10090.0,,50594,Intermediate,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,CHEMBL621335,,1,1,,BAO_0000218,,
7804,A,,9615.0,,50588,Intermediate,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,CHEMBL621336,,1,1,,BAO_0000218,,
7805,A,,10116.0,,50597,Intermediate,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,CHEMBL621337,,1,1,,BAO_0000218,,
7806,A,,9615.0,,50588,Intermediate,Area under curve was measured after i.v. administration into Beagle dog.,,CHEMBL621338,,1,1,,BAO_0000218,,
7807,A,,9615.0,,50588,Intermediate,Area under curve was measured after iv administration into Beagle dog,,CHEMBL875838,,1,1,,BAO_0000218,,
7808,A,,9615.0,,50588,Intermediate,Area under curve was measured after po administration into Beagle dog,,CHEMBL621339,,1,1,,BAO_0000218,,
7809,A,,9615.0,,50588,Intermediate,Area under curve was measured after po administration into Beagle dog.,,CHEMBL621340,,1,1,,BAO_0000218,,
7810,A,,,,22224,Autocuration,Area under curve was measured at peroral dose of 3 mg/kg,,CHEMBL621341,,0,1,,BAO_0000218,,
7811,A,,,,22224,Autocuration,Area under curve was measured by using concentration Vs time,,CHEMBL621342,,0,1,,BAO_0000019,,
7812,A,,,,22224,Autocuration,Area under curve was measured by using concentration Vs time; not tested,,CHEMBL621343,,0,1,,BAO_0000019,,
7813,A,,10090.0,,50594,Intermediate,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,CHEMBL621344,,1,1,,BAO_0000218,,
7814,A,,10090.0,,50594,Intermediate,Area under curve(AUC) was measured in mice after oral administration.,,CHEMBL621345,,1,1,,BAO_0000218,,
7815,A,,,,22224,Autocuration,Area under curve(AUC) value of the compound,,CHEMBL621346,,0,1,,BAO_0000019,,
7816,A,,,,22224,Autocuration,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,CHEMBL621347,,0,1,,BAO_0000218,,
7817,A,,9615.0,,50588,Intermediate,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,CHEMBL621348,,1,1,,BAO_0000218,,
7818,A,,,,22224,Autocuration,Area under curve(carotid artery) was determined by the availability in blood,,CHEMBL621349,,0,1,,BAO_0000019,178.0,
7819,A,,,,22224,Autocuration,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,CHEMBL621350,,0,1,,BAO_0000019,178.0,
7820,A,,,,22224,Autocuration,Area under curve(carotid artery) was determined by the availability in blood; No data,,CHEMBL875839,,0,1,,BAO_0000019,178.0,
7821,A,,,,22224,Autocuration,Area under curve(portal vein) was determined by the availability in blood,,CHEMBL620211,,0,1,,BAO_0000019,178.0,
7822,A,,,,22224,Autocuration,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,CHEMBL620212,,0,1,,BAO_0000019,178.0,
7823,A,,,,22224,Autocuration,Area under curve(portal vein) was determined by the availability in blood; No data,,CHEMBL620213,,0,1,,BAO_0000019,178.0,
7824,A,,9544.0,,50797,Intermediate,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,CHEMBL620214,,1,1,,BAO_0000218,1969.0,
7825,A,,9544.0,,50797,Intermediate,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,CHEMBL620215,,1,1,,BAO_0000218,1969.0,
7826,A,,9544.0,,50797,Intermediate,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,,CHEMBL620216,,1,1,,BAO_0000218,1969.0,
7827,A,,9615.0,,50588,Intermediate,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",,CHEMBL620888,,1,1,,BAO_0000218,1969.0,
7828,A,,9615.0,,50588,Intermediate,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",,CHEMBL620889,,1,1,,BAO_0000218,1969.0,
7829,A,,,,22224,Autocuration,Area under plasma concentration vs time curve observed in rats for 0-3 h,,CHEMBL620890,,0,1,,BAO_0000019,1969.0,
7830,A,,10116.0,,50597,Intermediate,Area under plasma time curve determined in male rat,,CHEMBL620891,,1,1,,BAO_0000218,1969.0,
7831,A,,,,22224,Autocuration,Area under the MAP curve measured over 5 min.,,CHEMBL620892,,0,1,,BAO_0000019,,
7832,A,,10090.0,,50594,Intermediate,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,CHEMBL621079,,1,1,,BAO_0000218,,
7833,A,,10090.0,,50594,Intermediate,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,CHEMBL621080,,1,1,,BAO_0000218,,
7834,A,,9615.0,,50588,Intermediate,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,CHEMBL621081,,1,1,,BAO_0000218,,
7835,A,,10026.0,,100712,Intermediate,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,CHEMBL621082,,1,1,,BAO_0000218,,
7836,A,,10116.0,,50597,Intermediate,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,CHEMBL621083,,1,1,,BAO_0000218,,
7837,A,,9615.0,,50588,Intermediate,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,CHEMBL621084,,1,1,,BAO_0000218,,
7838,A,,9615.0,,50588,Intermediate,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,CHEMBL621085,,1,1,,BAO_0000218,,
7839,A,,9615.0,,50588,Intermediate,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,CHEMBL621086,,1,1,,BAO_0000218,,
7840,A,,9615.0,,50588,Intermediate,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,CHEMBL621087,,1,1,,BAO_0000218,,
7841,A,,9615.0,,50588,Intermediate,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,CHEMBL622607,,1,1,,BAO_0000218,,
7842,A,,9615.0,,50588,Intermediate,Serum AUC in marmosets (IV dose),,CHEMBL622608,,1,1,,BAO_0000218,,
7843,A,,,,22224,Autocuration,Area under the curve after intravenous administration at a dose of 10 umol/kg,,CHEMBL624481,,0,1,,BAO_0000019,,
7844,A,,,,22224,Autocuration,Area under the curve after intravenous administration at a dose of 2 umol/kg,,CHEMBL624482,,0,1,,BAO_0000019,,
7845,A,,,,22224,Autocuration,Area under the curve after intravenous administration at a dose of 4 umol/kg,,CHEMBL624483,,0,1,,BAO_0000019,,
7846,A,,,,22224,Autocuration,Area under the curve after intravenous administration at a dose of 40 umol/kg,,CHEMBL624484,,0,1,,BAO_0000019,,
7847,A,,,,22224,Autocuration,Area under the curve after intravenous administration at a dose of 5 umol/kg,,CHEMBL624485,,0,1,,BAO_0000019,,
7848,A,,10116.0,,50597,Intermediate,Area under the curve for fumarate salt was evaluated in F344 Rats.,,CHEMBL624486,,1,1,,BAO_0000218,,
7849,A,,,,22224,Autocuration,Area under the curve for the compound was calculated.,,CHEMBL624487,,0,1,,BAO_0000019,,
7850,A,,,,22224,Autocuration,Area under the curve in concentration/ time,,CHEMBL624488,,0,1,,BAO_0000019,,
7851,A,,10116.0,,50597,Intermediate,Area under the curve administered intraintestinal in rats.,,CHEMBL624489,,1,1,,BAO_0000218,,
7852,A,,10116.0,,50597,Intermediate,Area under the curve administered intravenously in rats.,,CHEMBL625184,,1,1,,BAO_0000218,,
7853,A,,,,22224,Autocuration,Area under the curve during intravenous administration,,CHEMBL625185,,0,1,,BAO_0000019,,
7854,A,,,,22224,Autocuration,Area under the curve during intravenous administration; Not determined,,CHEMBL875954,,0,1,,BAO_0000019,,
7855,A,,,,22224,Autocuration,Area under the curve during systemic administration,,CHEMBL625186,,0,1,,BAO_0000019,,
7856,A,,,,22224,Autocuration,Area under the curve during systemic administration; Not determined,,CHEMBL625187,,0,1,,BAO_0000019,,
7857,A,,,,22224,Autocuration,Area under the curve was calculated for the compound.,,CHEMBL625188,,0,1,,BAO_0000019,,
7858,A,,9615.0,,50588,Intermediate,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,CHEMBL625189,,1,1,,BAO_0000218,,
7859,A,,9615.0,,50588,Intermediate,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,CHEMBL625190,,1,1,,BAO_0000218,,
7860,A,,10116.0,,50597,Intermediate,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,CHEMBL621733,,1,1,,BAO_0000218,,
7861,A,,10116.0,,50597,Intermediate,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,CHEMBL621734,,1,1,,BAO_0000218,,
7862,A,,10116.0,,50597,Intermediate,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,CHEMBL621735,,1,1,,BAO_0000218,,
7863,A,,10116.0,,50597,Intermediate,Clearance of the drug was measured in the plasma of rat; No data,,CHEMBL621736,,1,1,,BAO_0000218,1969.0,
7864,A,,10116.0,,50597,Intermediate,The pharmacokinetic parameter plasma clearance in vivo in rats,,CHEMBL621737,,1,1,,BAO_0000218,1969.0,
7865,A,,10116.0,,50597,Intermediate,Plasma clearance at the dose of 2 mg/kg in rat,,CHEMBL621738,,1,1,,BAO_0000218,,
7866,A,In vivo,10116.0,,50597,Intermediate,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,CHEMBL622806,,1,1,,BAO_0000218,,
7867,A,In vivo,10116.0,,50597,Intermediate,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,CHEMBL623519,,1,1,,BAO_0000218,,
7868,A,In vivo,10116.0,,50597,Intermediate,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,CHEMBL623520,,1,1,,BAO_0000218,,
7869,A,In vivo,10116.0,,50597,Intermediate,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,CHEMBL623521,,1,1,,BAO_0000218,,
7870,A,In vivo,10116.0,,50597,Intermediate,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,CHEMBL623522,,1,1,,BAO_0000218,,
7871,A,In vivo,10116.0,,50597,Intermediate,Clearance rate in rat,,CHEMBL623523,,1,1,,BAO_0000218,,
7872,A,In vivo,10116.0,,50597,Intermediate,Clearance rate in rat,,CHEMBL623690,,1,1,,BAO_0000218,,
7873,A,In vivo,10116.0,,50597,Intermediate,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL623691,,1,1,,BAO_0000218,,
7874,A,In vivo,10116.0,,50597,Intermediate,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL623692,,1,1,,BAO_0000218,,
7875,A,In vivo,10116.0,,50597,Intermediate,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL623693,,1,1,,BAO_0000218,,
7876,A,In vivo,10116.0,,50597,Intermediate,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL623694,,1,1,,BAO_0000218,,
7877,A,In vivo,10116.0,,50597,Intermediate,Clearance of compound after iv administration of 20 mg/kg dose in rat,,CHEMBL623695,,1,1,,BAO_0000218,,
7878,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,CHEMBL623696,,1,1,,BAO_0000218,,
7879,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,CHEMBL623697,,1,1,,BAO_0000218,,
7880,A,In vivo,9544.0,,22224,Intermediate,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,CHEMBL623698,,0,1,,BAO_0000218,1969.0,
7881,A,In vivo,10116.0,,22224,Intermediate,Compound was tested for its plasma clearance rate in Sprague Dawley rats,,CHEMBL623699,,0,1,,BAO_0000218,1969.0,
7882,A,In vivo,10116.0,,50597,Intermediate,Mean (%CV) PK parameters for CL(mL/min/kg).,,CHEMBL623700,,1,1,,BAO_0000218,,
7883,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,CHEMBL623701,,1,1,,BAO_0000218,,
7884,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,,CHEMBL623702,,1,1,,BAO_0000218,1969.0,
7885,A,In vivo,10116.0,,50597,Intermediate,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,CHEMBL623703,,1,1,,BAO_0000218,,
7886,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat was determined,,CHEMBL623704,,1,1,,BAO_0000218,,
7887,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat after administration of 2 mg/kg iv,,CHEMBL623705,,1,1,,BAO_0000218,,
7888,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat after administration of 2 mg/kg iv,,CHEMBL623706,,1,1,,BAO_0000218,,
7889,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was determined,,CHEMBL623707,,1,1,,BAO_0000218,,
7890,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat,,CHEMBL623708,,1,1,,BAO_0000218,,
7891,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,CHEMBL623709,,1,1,,BAO_0000218,,
7892,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat by iv administration,,CHEMBL623710,,1,1,,BAO_0000218,,
7893,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,CHEMBL623711,,1,1,,BAO_0000218,,
7894,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat p.o.,,CHEMBL623712,,1,1,,BAO_0000218,,
7895,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rats,,CHEMBL623713,,1,1,,BAO_0000218,,
7896,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was determined; ND denotes no data,,CHEMBL623714,,1,1,,BAO_0000218,,
7897,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was determined; ND denotes not determined,,CHEMBL623715,,1,1,,BAO_0000218,,
7898,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,CHEMBL623716,,1,1,,BAO_0000218,,
7899,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,CHEMBL622980,,1,1,,BAO_0000218,,
7900,A,In vivo,10116.0,,50597,Intermediate,Plasma administration to rats,,CHEMBL622981,,1,1,,BAO_0000218,,
7901,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance of the compound in female Sprague-Dawley rats,,CHEMBL622982,,1,1,,BAO_0000218,,
7902,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was observed after intravenous administration in rat,,CHEMBL622983,,1,1,,BAO_0000218,,
7903,A,In vivo,10116.0,,50597,Intermediate,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,CHEMBL622984,,1,1,,BAO_0000218,,
7904,A,In vivo,10116.0,,50597,Intermediate,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,CHEMBL622985,,1,1,,BAO_0000218,,
7905,A,In vivo,10116.0,,50597,Intermediate,plasma clearance was observed after intravenous administration in rat,,CHEMBL623631,,1,1,,BAO_0000218,1969.0,
7906,A,In vivo,10116.0,,50597,Intermediate,In vivo CL/F determined,,CHEMBL623632,,1,1,,BAO_0000218,,
7907,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,,CHEMBL623633,,1,1,,BAO_0000218,1969.0,
7908,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,,CHEMBL623634,,1,1,,BAO_0000218,1969.0,
7909,A,In vivo,10116.0,,50597,Intermediate,Compound was tested for the lower blood clearance in rat,,CHEMBL623635,,1,1,,BAO_0000218,,
7910,A,In vivo,10116.0,,50597,Intermediate,Evaluated for the low clearance in rat (in vivo),,CHEMBL621195,,1,1,,BAO_0000218,,
7911,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (CLb)of the compound was determined in rat,,CHEMBL621196,,1,1,,BAO_0000218,,
7912,A,In vivo,10116.0,,50597,Intermediate,Rapid clearance after intravenous administration in rat was determined,,CHEMBL875287,,1,1,,BAO_0000218,,
7913,A,In vivo,10116.0,,50597,Intermediate,Clearance measured in rat,,CHEMBL621197,,1,1,,BAO_0000218,,
7914,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for plasma clearance in rat,,CHEMBL621198,,1,1,,BAO_0000218,1969.0,
7915,A,In vivo,10116.0,,50597,Intermediate,Low plasma clearance was calculated in rat,,CHEMBL621199,,1,1,,BAO_0000218,1969.0,
7916,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Clp) in rat,,CHEMBL621200,,1,1,,BAO_0000218,,
7917,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,CHEMBL621201,,1,1,,BAO_0000218,,
7918,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,CHEMBL621202,,1,1,,BAO_0000218,,
7919,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,CHEMBL621203,,1,1,,BAO_0000218,,
7920,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance after IV dosing at 1 mg/kg in rat,,CHEMBL621204,,1,1,,BAO_0000218,,
7921,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,,CHEMBL621205,,1,1,,BAO_0000218,948.0,
7922,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,,CHEMBL621206,,1,1,,BAO_0000218,948.0,
7923,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,,CHEMBL621207,,1,1,,BAO_0000218,948.0,
7924,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,,CHEMBL621208,,1,1,,BAO_0000218,948.0,
7925,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL621209,,1,1,,BAO_0000218,948.0,
7926,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,,CHEMBL876484,,1,1,,BAO_0000218,948.0,
7927,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,CHEMBL621210,,1,1,,BAO_0000218,948.0,
7928,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,,CHEMBL621211,,1,1,,BAO_0000218,948.0,
7929,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,,CHEMBL621212,,1,1,,BAO_0000218,948.0,
7930,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA at 15 min,,CHEMBL621213,,1,1,,BAO_0000218,948.0,
7931,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,,CHEMBL621214,,1,1,,BAO_0000218,948.0,
7932,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA at 30 min,,CHEMBL621215,,1,1,,BAO_0000218,948.0,
7933,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,,CHEMBL621216,,1,1,,BAO_0000218,948.0,
7934,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,,CHEMBL621217,,1,1,,BAO_0000218,948.0,
7935,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,,CHEMBL621218,,1,1,,BAO_0000218,948.0,
7936,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,,CHEMBL621219,,1,1,,BAO_0000218,948.0,
7937,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,,CHEMBL621220,,1,1,,BAO_0000218,948.0,
7938,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,,CHEMBL621221,,1,1,,BAO_0000218,948.0,
7939,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,,CHEMBL621222,,1,1,,BAO_0000218,948.0,
7940,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,,CHEMBL621223,,1,1,,BAO_0000218,948.0,
7941,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,,CHEMBL876485,,1,1,,BAO_0000218,948.0,
7942,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,CHEMBL621224,,1,1,,BAO_0000218,948.0,
7943,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,,CHEMBL621225,,1,1,,BAO_0000218,948.0,
7944,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,,CHEMBL621226,,1,1,,BAO_0000218,948.0,
7945,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,,CHEMBL621227,,1,1,,BAO_0000218,2113.0,
7946,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,,CHEMBL621228,,1,1,,BAO_0000218,2113.0,
7947,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,,CHEMBL621229,,1,1,,BAO_0000218,2113.0,
7948,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL621230,,1,1,,BAO_0000218,2113.0,
7949,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,,CHEMBL621231,,1,1,,BAO_0000218,2113.0,
7950,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,,CHEMBL621232,,1,1,,BAO_0000218,2113.0,
7951,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,CHEMBL621233,,1,1,,BAO_0000218,2113.0,
7952,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,,CHEMBL621234,,1,1,,BAO_0000218,2113.0,
7953,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,CHEMBL621235,,1,1,,BAO_0000218,2113.0,
7954,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,CHEMBL621236,,1,1,,BAO_0000218,2113.0,
7955,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,,CHEMBL621237,,1,1,,BAO_0000218,2113.0,
7956,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,,CHEMBL876486,,1,1,,BAO_0000218,2113.0,
7957,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,,CHEMBL622436,,1,1,,BAO_0000218,160.0,
7958,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,,CHEMBL622437,,1,1,,BAO_0000218,160.0,
7959,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,,CHEMBL622438,,1,1,,BAO_0000218,160.0,
7960,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,,CHEMBL622439,,1,1,,BAO_0000218,2107.0,
7961,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL622440,,1,1,,BAO_0000218,2107.0,
7962,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,,CHEMBL622441,,1,1,,BAO_0000218,2107.0,
7963,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,,CHEMBL622442,,1,1,,BAO_0000218,2107.0,
7964,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,,CHEMBL622443,,1,1,,BAO_0000218,2107.0,
7965,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,,CHEMBL622444,,1,1,,BAO_0000218,2107.0,
7966,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,,CHEMBL622445,,1,1,,BAO_0000218,2107.0,
7967,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,,CHEMBL622446,,1,1,,BAO_0000218,2107.0,
7968,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,CHEMBL622447,,1,1,,BAO_0000218,2107.0,
7969,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,,CHEMBL622448,,1,1,,BAO_0000218,2107.0,
7970,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,CHEMBL622449,,1,1,,BAO_0000218,2107.0,
7971,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,,CHEMBL622450,,1,1,,BAO_0000218,2107.0,
7972,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,,CHEMBL622451,,1,1,,BAO_0000218,2107.0,
7973,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA at 15 min,,CHEMBL622452,,1,1,,BAO_0000218,2107.0,
7974,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,,CHEMBL622453,,1,1,,BAO_0000218,2107.0,
7975,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA at 30 min,,CHEMBL622454,,1,1,,BAO_0000218,2107.0,
7976,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,,CHEMBL622455,,1,1,,BAO_0000218,2107.0,
7977,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,,CHEMBL876024,,1,1,,BAO_0000218,2107.0,
7978,A,In vivo,10116.0,,50597,Intermediate,T max was determined at 3 mg/kg po dose in rats,,CHEMBL622456,,1,1,,BAO_0000218,,
7979,A,In vivo,10116.0,,50597,Intermediate,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622457,,1,1,,BAO_0000218,,
7980,A,In vivo,10116.0,,50597,Intermediate,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622458,,1,1,,BAO_0000218,,
7981,A,,10116.0,,50597,Intermediate,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,CHEMBL622459,,1,1,,BAO_0000218,,
7982,A,,10116.0,,50597,Intermediate,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,CHEMBL873343,,1,1,,BAO_0000218,,
7983,A,,10116.0,,50597,Intermediate,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,CHEMBL622460,,1,1,,BAO_0000218,,
7984,A,,10116.0,,50597,Intermediate,Time for maximum plasma concentration determined in rat,,CHEMBL622461,,1,1,,BAO_0000218,1969.0,
7985,A,In vivo,10116.0,,50597,Intermediate,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,CHEMBL622462,,1,1,,BAO_0000218,1969.0,
7986,A,In vivo,10116.0,,50597,Intermediate,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,CHEMBL622463,,1,1,,BAO_0000218,,
7987,A,In vivo,10116.0,,50597,Intermediate,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,CHEMBL622464,,1,1,,BAO_0000218,,
7988,A,In vivo,10116.0,,50597,Intermediate,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,CHEMBL622465,,1,1,,BAO_0000218,,
7989,A,In vivo,10116.0,,50597,Intermediate,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,CHEMBL622466,,1,1,,BAO_0000218,,
7990,A,In vivo,10116.0,,50597,Intermediate,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,CHEMBL622467,,1,1,,BAO_0000218,,
7991,A,,10116.0,,50597,Intermediate,Time of maximum plasma concentration in rat,,CHEMBL622468,,1,1,,BAO_0000218,1969.0,
7992,A,,10116.0,,50597,Intermediate,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,CHEMBL876025,,1,1,,BAO_0000218,1969.0,
7993,A,,10116.0,,50597,Intermediate,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,CHEMBL622469,,1,1,,BAO_0000218,1969.0,
7994,A,,10116.0,,50597,Intermediate,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,CHEMBL622470,,1,1,,BAO_0000218,1969.0,
7995,A,In vivo,10116.0,,50597,Intermediate,Time required to reach maximum concentration (Cmax) after oral administration in rat,,CHEMBL622471,,1,1,,BAO_0000218,,
7996,A,,10116.0,,50597,Intermediate,Time required to reach maximum concentration in rat plasma,,CHEMBL622472,,1,1,,BAO_0000218,1969.0,
7997,A,In vivo,10116.0,,50597,Intermediate,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,CHEMBL622473,,1,1,,BAO_0000218,1969.0,
7998,A,In vivo,10116.0,,50597,Intermediate,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,CHEMBL624282,,1,1,,BAO_0000218,1969.0,
7999,A,In vivo,10116.0,,50597,Intermediate,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,CHEMBL624283,,1,1,,BAO_0000218,1969.0,
8000,A,In vivo,10116.0,,50597,Intermediate,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,CHEMBL624284,,1,1,,BAO_0000218,1969.0,
8001,A,In vivo,10116.0,,50597,Intermediate,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,CHEMBL624285,,1,1,,BAO_0000218,1969.0,
8002,A,In vivo,10116.0,,50597,Intermediate,Time to reach Cmax after oral administration to rats,,CHEMBL624286,,1,1,,BAO_0000218,,
8003,A,In vivo,10116.0,,50597,Intermediate,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,CHEMBL624287,,1,1,,BAO_0000218,,
8004,A,,10116.0,,50597,Intermediate,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,CHEMBL624288,,1,1,,BAO_0000218,,
8005,A,In vivo,10116.0,,50597,Intermediate,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,,CHEMBL624289,,1,1,,BAO_0000218,1969.0,
8006,A,In vivo,10116.0,,50597,Intermediate,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,,CHEMBL873344,,1,1,,BAO_0000218,1969.0,
8007,A,In vivo,10116.0,,50597,Intermediate,Tmax after peroral administration (10 mg/kg) was determined in rat,,CHEMBL619623,,1,1,,BAO_0000218,,
8008,A,In vivo,10116.0,,50597,Expert,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL621399,,1,1,,BAO_0000218,,
8009,A,In vivo,10116.0,,50597,Intermediate,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,CHEMBL621400,,1,1,,BAO_0000218,,
8010,A,In vivo,10116.0,,50597,Intermediate,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,CHEMBL621401,,1,1,,BAO_0000218,,
8011,A,,10116.0,,50597,Intermediate,Tmax was determined,,CHEMBL621402,,1,1,,BAO_0000218,,
8012,A,,10116.0,,50597,Intermediate,Tmax was determined,,CHEMBL621403,,1,1,,BAO_0000218,,
8013,A,In vivo,10116.0,,50597,Intermediate,Tmax after oral administration in rat,,CHEMBL621121,,1,1,,BAO_0000218,,
8014,A,In vivo,10116.0,,50597,Intermediate,Tmax after peroral administration in rats at 2.4 uM/kg,,CHEMBL872525,,1,1,,BAO_0000218,,
8015,A,,10116.0,,50597,Intermediate,Tmax in male rat,,CHEMBL621122,,1,1,,BAO_0000218,,
8016,A,In vivo,10116.0,,50597,Intermediate,Tmax in rat at 10 mg/kg,,CHEMBL621123,,1,1,,BAO_0000218,,
8017,A,In vivo,10116.0,,50597,Intermediate,Tmax in rat by po administration at a dose of 40 mg/kg,,CHEMBL621124,,1,1,,BAO_0000218,,
8018,A,,10116.0,,50597,Intermediate,Tmax in rats,,CHEMBL621125,,1,1,,BAO_0000218,,
8019,A,In vivo,10116.0,,50597,Intermediate,Tmax was measured in rats after peroral administration at 5 mg/kg,,CHEMBL621126,,1,1,,BAO_0000218,,
8020,A,In vivo,10116.0,,50597,Intermediate,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,CHEMBL621127,,1,1,,BAO_0000218,,
8021,A,In vivo,10116.0,,50597,Intermediate,Tmax value after administration of 20 mg/Kg oral dose in rat,,CHEMBL621128,,1,1,,BAO_0000218,,
8022,A,In vivo,10116.0,,50597,Intermediate,Tmax value at a dose of 10 mg/kg in male SD rats,,CHEMBL618263,,1,1,,BAO_0000218,,
8023,A,In vivo,10116.0,,50597,Intermediate,Tmax value at a dose of 100 mg/kg in male SD rats,,CHEMBL618264,,1,1,,BAO_0000218,,
8024,A,In vivo,10116.0,,50597,Intermediate,Tmax value at a dose of 50 mg/kg in male SD rats,,CHEMBL618265,,1,1,,BAO_0000218,,
8025,A,In vivo,10116.0,,50597,Intermediate,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,CHEMBL618266,,1,1,,BAO_0000218,1969.0,
8026,A,In vivo,10116.0,,50597,Intermediate,time required to reach maximum concentration (Cmax) after oral administration in rat,,CHEMBL618267,,1,1,,BAO_0000218,,
8027,A,,10116.0,,50597,Intermediate,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),,CHEMBL618450,,1,1,,BAO_0000218,1088.0,
8028,A,,10116.0,,50597,Intermediate,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),,CHEMBL618451,,1,1,,BAO_0000218,1088.0,
8029,A,,10116.0,,50597,Intermediate,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,CHEMBL618452,,1,1,,BAO_0000218,,
8030,A,,10116.0,,50597,Intermediate,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,,CHEMBL618453,,1,1,,BAO_0000218,1088.0,
8031,A,,10116.0,,50597,Intermediate,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,,CHEMBL618454,,1,1,,BAO_0000218,1088.0,
8032,A,,10116.0,,50597,Intermediate,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,,CHEMBL618455,,1,1,,BAO_0000218,1088.0,
8033,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,CHEMBL618456,,1,1,,BAO_0000218,,
8034,A,In vivo,10116.0,,50597,Intermediate,Compound distribution in rat tissues was determined,,CHEMBL618457,,1,1,,BAO_0000218,,
8035,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was evaluated in rat,,CHEMBL618458,,1,1,,BAO_0000218,,
8036,A,,10116.0,,50597,Intermediate,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,CHEMBL618459,,1,1,,BAO_0000218,,
8037,A,,10116.0,,50597,Intermediate,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,CHEMBL876733,,1,1,,BAO_0000218,,
8038,A,,9615.0,,50588,Intermediate,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,CHEMBL618460,,1,1,,BAO_0000218,,
8039,A,,10116.0,,50597,Intermediate,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,CHEMBL618461,,1,1,,BAO_0000218,,
8040,A,,,,22224,Autocuration,Area under the curve was determined after oral administration (300 uM/Kg),,CHEMBL618462,,0,1,,BAO_0000019,,
8041,A,,10116.0,,50597,Intermediate,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,CHEMBL618463,,1,1,,BAO_0000218,,
8042,A,,10116.0,,50597,Intermediate,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,CHEMBL618464,,1,1,,BAO_0000218,,
8043,A,,10116.0,,50597,Intermediate,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,CHEMBL618465,,1,1,,BAO_0000218,,
8044,A,,10116.0,,50597,Intermediate,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,CHEMBL618466,,1,1,,BAO_0000218,,
8045,A,,10116.0,,50597,Intermediate,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,CHEMBL618467,,1,1,,BAO_0000218,,
8046,A,,10116.0,,50597,Intermediate,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,CHEMBL618468,,1,1,,BAO_0000218,,
8047,A,,9615.0,,50588,Intermediate,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,,CHEMBL618469,,1,1,,BAO_0000218,1969.0,
8048,A,,9615.0,,50588,Intermediate,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,,CHEMBL618470,,1,1,,BAO_0000218,1969.0,
8049,A,,,,22224,Autocuration,Plasma drug AUC in rat (PO dose),,CHEMBL618471,,0,1,,BAO_0000218,,
8050,A,,10090.0,,50594,Intermediate,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,CHEMBL618472,,1,1,,BAO_0000218,,
8051,A,,,,22224,Autocuration,Area under was determined at a dose of 30 mg/kg,,CHEMBL618473,,0,1,,BAO_0000218,,
8052,A,,9669.0,,50506,Intermediate,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,CHEMBL621699,,1,1,,BAO_0000218,,
8053,A,,10116.0,,50597,Intermediate,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,CHEMBL621700,,1,1,,BAO_0000218,,
8054,A,,10116.0,,50597,Intermediate,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,CHEMBL621701,,1,1,,BAO_0000218,,
8055,A,,9669.0,,50506,Intermediate,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,CHEMBL621702,,1,1,,BAO_0000218,,
8056,A,,9615.0,,50588,Intermediate,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,CHEMBL621703,,1,1,,BAO_0000218,,
8057,A,,9615.0,,50588,Intermediate,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,CHEMBL621704,,1,1,,BAO_0000218,,
8058,A,,10116.0,,50597,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,CHEMBL624259,,1,1,,BAO_0000218,,
8059,A,,10116.0,,50597,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,CHEMBL624260,,1,1,,BAO_0000218,,
8060,A,,10116.0,,50597,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,CHEMBL624430,,1,1,,BAO_0000218,,
8061,A,,10116.0,,50597,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,CHEMBL624431,,1,1,,BAO_0000218,,
8062,A,,10116.0,,50597,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,CHEMBL624432,,1,1,,BAO_0000218,,
8063,A,,10116.0,,50597,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,CHEMBL624433,,1,1,,BAO_0000218,,
8064,A,,10116.0,,50597,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,CHEMBL624434,,1,1,,BAO_0000218,,
8065,A,,10116.0,,50597,Intermediate,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,CHEMBL624435,,1,1,,BAO_0000218,,
8066,A,,10090.0,,50594,Intermediate,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,CHEMBL618570,,1,1,,BAO_0000218,,
8067,A,,10090.0,,50594,Intermediate,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,CHEMBL618571,,1,1,,BAO_0000218,,
8068,A,,10090.0,,50594,Intermediate,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,CHEMBL618572,,1,1,,BAO_0000218,,
8069,A,,10090.0,,50594,Intermediate,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,CHEMBL618573,,1,1,,BAO_0000218,,
8070,A,,10090.0,,50594,Intermediate,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,CHEMBL619267,,1,1,,BAO_0000218,,
8071,A,,10090.0,,50594,Intermediate,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,CHEMBL619431,,1,1,,BAO_0000218,,
8072,A,,10090.0,,50594,Intermediate,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,CHEMBL619432,,1,1,,BAO_0000218,,
8073,A,,10090.0,,50594,Intermediate,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,CHEMBL619433,,1,1,,BAO_0000218,,
8074,A,,,,22224,Autocuration,AUC in mice after oral dose (50 mg/kg),,CHEMBL619434,,0,1,,BAO_0000218,1969.0,
8075,A,,10090.0,,50594,Intermediate,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,,CHEMBL619435,,1,1,,BAO_0000218,1977.0,
8076,A,,,,22224,Autocuration,AUC (0-4 hr) ug/ml/h,,CHEMBL619436,,0,1,,BAO_0000019,1969.0,
8077,A,,10116.0,,50597,Intermediate,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,CHEMBL619437,,1,1,,BAO_0000218,,
8078,A,,,,22224,Autocuration,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,CHEMBL619438,,0,1,,BAO_0000218,,
8079,A,,10090.0,,50594,Intermediate,Compound was evaluated for Area under curve in mice,,CHEMBL619439,,1,1,,BAO_0000218,,
8080,A,,10116.0,,50597,Intermediate,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,CHEMBL619440,,1,1,,BAO_0000218,,
8081,F,,,,22224,Autocuration,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,CHEMBL619441,,0,1,,BAO_0000218,,
8082,A,,10116.0,,50597,Intermediate,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,CHEMBL619442,,1,1,,BAO_0000218,,
8083,A,,,,22224,Autocuration,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,CHEMBL875156,,0,1,,BAO_0000019,,
8084,A,,,,22224,Autocuration,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,CHEMBL619443,,0,1,,BAO_0000019,,
8085,A,,,,22224,Autocuration,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,CHEMBL619444,,0,1,,BAO_0000019,,
8086,A,,,,22224,Autocuration,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,CHEMBL623464,,0,1,,BAO_0000019,,
8087,A,,10090.0,,50594,Intermediate,Compound was evaluated for area under curve when administered through oral route in mouse,,CHEMBL623465,,1,1,,BAO_0000218,,
8088,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,CHEMBL623466,,1,1,,BAO_0000218,,
8089,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,CHEMBL623467,,1,1,,BAO_0000218,,
8090,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat,,CHEMBL623468,,1,1,,BAO_0000218,,
8091,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,CHEMBL622660,,1,1,,BAO_0000218,,
8092,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance rate in Sprague-Dawley rats,,CHEMBL622661,,1,1,,BAO_0000218,,
8093,F,In vivo,10116.0,,50597,Intermediate,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL622662,,1,1,,BAO_0000218,,
8094,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (total body clearance) in rat,,CHEMBL622663,,1,1,,BAO_0000218,,
8095,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,CHEMBL622664,,1,1,,BAO_0000218,,
8096,A,,10116.0,,50597,Intermediate,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,CHEMBL622665,,1,1,,BAO_0000218,,
8097,A,,10116.0,,50597,Intermediate,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,CHEMBL622666,,1,1,,BAO_0000218,,
8098,A,In vivo,10116.0,,50597,Intermediate,Cl in rat i.v. at 2 mg/kg concentration,,CHEMBL621615,,1,1,,BAO_0000218,,
8099,A,In vivo,10116.0,,50597,Intermediate,Clearance of compound after intravenous administration in rats at 24 uM/kg,,CHEMBL621616,,1,1,,BAO_0000218,,
8100,A,In vivo,10116.0,,50597,Intermediate,Clearance was determined,,CHEMBL621617,,1,1,,BAO_0000218,,
8101,A,In vivo,10116.0,,50597,Intermediate,Clearance by intravenous administration of 3.4 mg/kg in rat,,CHEMBL621618,,1,1,,BAO_0000218,,
8102,A,In vivo,10116.0,,50597,Intermediate,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,CHEMBL621619,,1,1,,BAO_0000218,,
8103,A,In vivo,10116.0,,50597,Intermediate,Clearance rate after i.v. administration in rats,,CHEMBL621620,,1,1,,BAO_0000218,,
8104,A,In vivo,10116.0,,50597,Intermediate,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,CHEMBL621786,,1,1,,BAO_0000218,,
8105,A,In vivo,10116.0,,50597,Intermediate,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,CHEMBL621787,,1,1,,BAO_0000218,,
8106,A,In vivo,10116.0,,50597,Intermediate,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,CHEMBL621788,,1,1,,BAO_0000218,,
8107,A,In vivo,10116.0,,50597,Intermediate,Clearance (Cl) after oral administration in rat,,CHEMBL621789,,1,1,,BAO_0000218,,
8108,A,In vivo,10116.0,,50597,Intermediate,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,CHEMBL621790,,1,1,,BAO_0000218,,
8109,A,In vivo,10116.0,,50597,Intermediate,Compound was tested for plasma clearance in rat,,CHEMBL621791,,1,1,,BAO_0000218,1969.0,
8110,A,In vitro,10116.0,,50597,Intermediate,In vitro microsome metabolism clearance in rat was determined,,CHEMBL621792,,1,1,,BAO_0000218,,
8111,A,In vitro,10116.0,,50597,Intermediate,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,CHEMBL621793,,1,1,,BAO_0000218,,
8112,A,In vivo,10116.0,,50597,Intermediate,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL621794,,1,1,,BAO_0000218,,
8113,A,In vivo,10116.0,,50597,Intermediate,In vivo plasma clearance was determined,,CHEMBL621795,,1,1,,BAO_0000218,1969.0,
8114,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,CHEMBL621796,,1,1,,BAO_0000218,,
8115,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,,CHEMBL621797,,1,1,401.0,BAO_0000218,2107.0,
8116,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Plasma clearance) was measured in rat,,CHEMBL621798,,1,1,,BAO_0000218,,
8117,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (clearance) in rat i.v.,,CHEMBL621799,,1,1,,BAO_0000218,,
8118,A,In vivo,10116.0,,50597,Intermediate,"Plasma Clearance was evaluated in rats, iv",,CHEMBL621800,,1,1,,BAO_0000218,,
8119,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance (in vivo) in rats was determined,,CHEMBL621801,,1,1,,BAO_0000218,,
8120,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,CHEMBL621802,,1,1,,BAO_0000218,,
8121,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was determined,,CHEMBL618596,,1,1,,BAO_0000218,,
8122,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,CHEMBL618597,,1,1,,BAO_0000218,,
8123,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,CHEMBL618598,,1,1,,BAO_0000218,,
8124,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rats,,CHEMBL618599,,1,1,,BAO_0000218,,
8125,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance rate determined in rat,,CHEMBL618600,,1,1,,BAO_0000218,,
8126,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was determined in rat,,CHEMBL618601,,1,1,,BAO_0000218,,
8127,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was determined,,CHEMBL618602,,1,1,,BAO_0000218,,
8128,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance value in rat,,CHEMBL618603,,1,1,,BAO_0000218,,
8129,A,Ex vivo,10116.0,,50597,Intermediate,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,CHEMBL618604,,1,1,,BAO_0000218,2107.0,
8130,A,In vivo,10116.0,,50597,Intermediate,Clearance in rat,,CHEMBL618605,,1,1,,BAO_0000218,,
8131,A,In vivo,10116.0,,50597,Intermediate,Total body clearance in rat i.v. at 2 mg/kg concentration,,CHEMBL618606,,1,1,,BAO_0000218,,
8132,A,In vivo,10116.0,,50597,Intermediate,Clearance of compound in rats after intravenous administration,,CHEMBL618607,,1,1,,BAO_0000218,,
8133,A,In vivo,10116.0,,50597,Intermediate,Clearance after iv administration to rats,,CHEMBL618608,,1,1,,BAO_0000218,,
8134,A,In vivo,10116.0,,50597,Intermediate,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,CHEMBL618609,,1,1,,BAO_0000218,,
8135,A,In vivo,10116.0,,50597,Intermediate,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,CHEMBL618610,,1,1,,BAO_0000218,,
8136,A,In vivo,10116.0,,50597,Intermediate,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,CHEMBL618611,,1,1,,BAO_0000218,,
8137,A,In vivo,10116.0,,50597,Intermediate,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,CHEMBL618612,,1,1,,BAO_0000218,,
8138,A,In vivo,10116.0,,50597,Intermediate,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,CHEMBL618613,,1,1,,BAO_0000218,,
8139,A,In vivo,10116.0,,50597,Intermediate,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,CHEMBL621076,,1,1,,BAO_0000218,,
8140,A,In vivo,10116.0,,50597,Intermediate,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,CHEMBL621077,,1,1,,BAO_0000218,,
8141,A,In vivo,10116.0,,50597,Intermediate,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,CHEMBL621078,,1,1,,BAO_0000218,,
8142,A,In vivo,10116.0,,50597,Intermediate,Clearance in rat,,CHEMBL621251,,1,1,,BAO_0000218,,
8143,A,In vivo,10116.0,,50597,Intermediate,Clearance in rat after oral administration at 10 mg/kg,,CHEMBL621252,,1,1,,BAO_0000218,,
8144,A,In vivo,10116.0,,50597,Intermediate,Clearance in rat.,,CHEMBL621253,,1,1,,BAO_0000218,,
8145,A,In vivo,10116.0,,50597,Intermediate,Clearance rate following an oral dose of 20 mg/kg in rats,,CHEMBL621254,,1,1,,BAO_0000218,,
8146,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,CHEMBL621255,,1,1,,BAO_0000218,,
8147,A,In vivo,10116.0,,50597,Intermediate,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,,CHEMBL621256,,1,1,,BAO_0000218,1969.0,
8148,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,,CHEMBL621257,,1,1,,BAO_0000218,2107.0,
8149,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,,CHEMBL621258,,1,1,,BAO_0000218,2107.0,
8150,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,,CHEMBL621259,,1,1,,BAO_0000218,2107.0,
8151,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,,CHEMBL621260,,1,1,,BAO_0000218,2107.0,
8152,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,,CHEMBL876494,,1,1,,BAO_0000218,2107.0,
8153,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,,CHEMBL621261,,1,1,,BAO_0000218,2107.0,
8154,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,,CHEMBL621262,,1,1,,BAO_0000218,2107.0,
8155,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,CHEMBL621263,,1,1,,BAO_0000218,2107.0,
8156,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,,CHEMBL621264,,1,1,,BAO_0000218,2107.0,
8157,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,,CHEMBL621265,,1,1,,BAO_0000218,2385.0,
8158,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,,CHEMBL621266,,1,1,,BAO_0000218,2385.0,
8159,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,,CHEMBL621267,,1,1,,BAO_0000218,2385.0,
8160,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,,CHEMBL621268,,1,1,,BAO_0000218,2385.0,
8161,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,,CHEMBL621269,,1,1,,BAO_0000218,2385.0,
8162,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,,CHEMBL621270,,1,1,,BAO_0000218,2385.0,
8163,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,,CHEMBL621271,,1,1,,BAO_0000218,2385.0,
8164,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,,CHEMBL621272,,1,1,,BAO_0000218,2385.0,
8165,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,,CHEMBL621273,,1,1,,BAO_0000218,2385.0,
8166,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,,CHEMBL621274,,1,1,,BAO_0000218,2385.0,
8167,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,,CHEMBL876495,,1,1,,BAO_0000218,2385.0,
8168,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,,CHEMBL621275,,1,1,,BAO_0000218,2385.0,
8169,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,,CHEMBL621276,,1,1,,BAO_0000218,2385.0,
8170,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,,CHEMBL621277,,1,1,,BAO_0000218,2385.0,
8171,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,,CHEMBL621278,,1,1,,BAO_0000218,160.0,
8172,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,,CHEMBL621279,,1,1,,BAO_0000218,160.0,
8173,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),,CHEMBL621280,,1,1,,BAO_0000218,160.0,
8174,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,,CHEMBL621281,,1,1,,BAO_0000218,2106.0,
8175,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,,CHEMBL621282,,1,1,,BAO_0000218,2106.0,
8176,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,,CHEMBL621283,,1,1,,BAO_0000218,2106.0,
8177,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,,CHEMBL621284,,1,1,,BAO_0000218,2106.0,
8178,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,,CHEMBL621285,,1,1,,BAO_0000218,2106.0,
8179,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,,CHEMBL621286,,1,1,,BAO_0000218,2106.0,
8180,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,,CHEMBL623220,,1,1,,BAO_0000218,2106.0,
8181,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,,CHEMBL623221,,1,1,,BAO_0000218,2106.0,
8182,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,,CHEMBL876029,,1,1,,BAO_0000218,2106.0,
8183,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,,CHEMBL623222,,1,1,,BAO_0000218,945.0,
8184,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,,CHEMBL623223,,1,1,,BAO_0000218,945.0,
8185,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,,CHEMBL621445,,1,1,,BAO_0000218,945.0,
8186,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621446,,1,1,,BAO_0000218,178.0,
8187,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621447,,1,1,,BAO_0000218,178.0,
8188,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619681,,1,1,,BAO_0000218,178.0,
8189,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619682,,1,1,,BAO_0000218,178.0,
8190,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619683,,1,1,,BAO_0000218,178.0,
8191,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619684,,1,1,,BAO_0000218,955.0,
8192,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619685,,1,1,,BAO_0000218,955.0,
8193,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619686,,1,1,,BAO_0000218,955.0,
8194,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619687,,1,1,,BAO_0000218,955.0,
8195,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619688,,1,1,,BAO_0000218,955.0,
8196,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619689,,1,1,,BAO_0000218,948.0,
8197,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619690,,1,1,,BAO_0000218,948.0,
8198,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619691,,1,1,,BAO_0000218,948.0,
8199,A,In vivo,10116.0,,50597,Intermediate,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,CHEMBL619692,,1,1,,BAO_0000218,,
8200,A,,10116.0,,50597,Expert,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL619693,,1,1,,BAO_0000218,,
8201,A,In vivo,10116.0,,50597,Intermediate,Vc value after IV dose at a dose of 5 mg/kg in rats.,,CHEMBL619694,,1,1,,BAO_0000218,,
8202,A,In vivo,10116.0,,50597,Intermediate,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,CHEMBL619695,,1,1,,BAO_0000218,,
8203,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for pharmacokinetic parameter volume of distribution,,CHEMBL619696,,1,1,,BAO_0000218,,
8204,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for volume of distribution in rat,,CHEMBL619697,,1,1,,BAO_0000218,,
8205,A,In vivo,10116.0,,50597,Intermediate,Steady state volume distribution was determined; steady state(ss),,CHEMBL619698,,1,1,,BAO_0000218,,
8206,A,In vivo,10116.0,,50597,Intermediate,Steady state volume of distribution after iv administration to rats,,CHEMBL619699,,1,1,,BAO_0000218,,
8207,A,In vivo,10116.0,,50597,Intermediate,Steady state volume of distribution dosing at 3 mg/kg iv,,CHEMBL619700,,1,1,,BAO_0000218,,
8208,A,In vivo,10116.0,,50597,Intermediate,The compound was evaluated for volume of distribution in rat,,CHEMBL619701,,1,1,,BAO_0000218,,
8209,A,In vivo,10116.0,,50597,Intermediate,The compound was tested for volume of distribution in rat,,CHEMBL619702,,1,1,,BAO_0000218,,
8210,A,In vivo,10116.0,,50597,Intermediate,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,CHEMBL620335,,1,1,,BAO_0000218,,
8211,A,In vivo,10116.0,,50597,Intermediate,Volume distribution (VD) after oral administration in rat,,CHEMBL620336,,1,1,,BAO_0000218,,
8212,A,In vivo,10116.0,,50597,Intermediate,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,CHEMBL620337,,1,1,,BAO_0000218,,
8213,A,In vivo,10116.0,,50597,Intermediate,Volume distribution in rat,,CHEMBL620520,,1,1,,BAO_0000218,,
8214,A,In vivo,10116.0,,50597,Intermediate,Volume distribution in rat,,CHEMBL620521,,1,1,,BAO_0000218,,
8215,A,In vivo,10116.0,,50597,Intermediate,Volume distribution in rat after peroral administration at 10 mg/kg,,CHEMBL875825,,1,1,,BAO_0000218,,
8216,A,In vivo,10116.0,,50597,Intermediate,Volume distribution in rat after peroral administration at 5 mg/kg,,CHEMBL620522,,1,1,,BAO_0000218,,
8217,A,In vivo,10116.0,,50597,Intermediate,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,CHEMBL620523,,1,1,,BAO_0000218,,
8218,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in rat.,,CHEMBL620524,,1,1,,BAO_0000218,,
8219,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in rat,,CHEMBL620525,,1,1,,BAO_0000218,,
8220,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in rat,,CHEMBL620526,,1,1,,BAO_0000218,,
8221,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in rat by iv administration,,CHEMBL620527,,1,1,,BAO_0000218,,
8222,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in rats,,CHEMBL620528,,1,1,,BAO_0000218,,
8223,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,CHEMBL620529,,1,1,,BAO_0000218,,
8224,A,,10116.0,,50597,Intermediate,Volume distribution at the dose of 2 mg/kg in rat,,CHEMBL620530,,1,1,,BAO_0000218,,
8225,A,In vivo,10116.0,,50597,Intermediate,Steady state volume of distribution was determined,,CHEMBL620531,,1,1,,BAO_0000218,,
8226,A,In vivo,9544.0,,22224,Intermediate,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,CHEMBL620532,,0,1,,BAO_0000218,,
8227,A,In vivo,10116.0,,22224,Intermediate,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,CHEMBL620533,,0,1,,BAO_0000218,,
8228,A,In vivo,10116.0,,22224,Intermediate,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,CHEMBL620534,,0,1,,BAO_0000218,,
8229,A,In vivo,10116.0,,50597,Intermediate,Mean (%CV) PK parameters for Vdss(mL/kg).,,CHEMBL620535,,1,1,,BAO_0000218,,
8230,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,CHEMBL875826,,1,1,,BAO_0000218,,
8231,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,CHEMBL620536,,1,1,,BAO_0000218,,
8232,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,CHEMBL620537,,1,1,,BAO_0000218,,
8233,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,CHEMBL618526,,1,1,,BAO_0000218,,
8234,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,CHEMBL618527,,1,1,,BAO_0000218,,
8235,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Vdss) in rat,,CHEMBL618528,,1,1,,BAO_0000218,,
8236,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (vdss) was measured in rat,,CHEMBL618529,,1,1,,BAO_0000218,,
8237,A,In vivo,10116.0,,50597,Intermediate,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,CHEMBL618530,,1,1,,BAO_0000218,,
8238,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in rat,,CHEMBL618531,,1,1,,BAO_0000218,,
8239,A,In vivo,10116.0,,50597,Intermediate,The pharmacokinetic parameter volume of distribution in vivo in rats,,CHEMBL618532,,1,1,,BAO_0000218,,
8240,F,In vivo,10116.0,,50597,Intermediate,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL618533,,1,1,,BAO_0000218,,
8241,A,In vivo,10116.0,,50597,Intermediate,Vdss in rat i.v. at 2 mg/kg concentration,,CHEMBL618534,,1,1,,BAO_0000218,,
8242,A,In vivo,10116.0,,50597,Intermediate,Volume distribution after intravenous administration (1 mg/kg) in rat,,CHEMBL618535,,1,1,,BAO_0000218,,
8243,A,In vivo,10116.0,,50597,Intermediate,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,CHEMBL618536,,1,1,,BAO_0000218,,
8244,A,In vivo,10116.0,,50597,Intermediate,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,CHEMBL618537,,1,1,,BAO_0000218,,
8245,A,In vivo,10116.0,,50597,Intermediate,Volume distribution at a dose of 10 uM/kg in rat was determined,,CHEMBL618538,,1,1,,BAO_0000218,,
8246,A,In vivo,10116.0,,50597,Intermediate,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,CHEMBL618539,,1,1,,BAO_0000218,,
8247,A,In vivo,10116.0,,50597,Intermediate,Volume distribution was calculated in rat,,CHEMBL618540,,1,1,,BAO_0000218,,
8248,A,In vivo,10116.0,,50597,Intermediate,Volume distribution was determined,,CHEMBL618541,,1,1,,BAO_0000218,,
8249,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution after intravenous administration was evaluated in rat,,CHEMBL618542,,1,1,,BAO_0000218,,
8250,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL622544,,1,1,,BAO_0000218,,
8251,A,In vivo,10116.0,,50597,Intermediate,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,CHEMBL622545,,1,1,,BAO_0000218,,
8252,A,In vivo,10116.0,,50597,Intermediate,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,CHEMBL622546,,1,1,,BAO_0000218,,
8253,A,In vivo,10116.0,,50597,Intermediate,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,CHEMBL622547,,1,1,,BAO_0000218,,
8254,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in steady state was determined in rat,,CHEMBL622548,,1,1,,BAO_0000218,,
8255,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,CHEMBL622549,,1,1,,BAO_0000218,,
8256,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,CHEMBL622550,,1,1,,BAO_0000218,,
8257,A,,10090.0,,50594,Intermediate,Compound was evaluated for area under curve when administered through oral route to mouse,,CHEMBL622551,,1,1,,BAO_0000218,,
8258,A,,10116.0,,50597,Intermediate,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,CHEMBL622552,,1,1,,BAO_0000218,,
8259,A,,10116.0,,50597,Intermediate,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,CHEMBL622553,,1,1,,BAO_0000218,,
8260,F,In vivo,,,22224,Autocuration,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,CHEMBL622554,,0,1,,BAO_0000218,,
8261,A,,9615.0,,50588,Intermediate,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,CHEMBL622555,,1,1,,BAO_0000218,,
8262,A,,10090.0,,50594,Intermediate,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,CHEMBL622556,,1,1,,BAO_0000218,,
8263,A,,10090.0,,50594,Intermediate,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,CHEMBL622557,,1,1,,BAO_0000218,,
8264,A,,10090.0,,50594,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,,CHEMBL622558,,1,1,,BAO_0000218,178.0,
8265,A,,10090.0,,50594,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,,CHEMBL622559,,1,1,,BAO_0000218,178.0,
8266,A,,9615.0,,50588,Intermediate,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,CHEMBL622560,,1,1,,BAO_0000218,,
8267,A,,10116.0,,50597,Intermediate,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,CHEMBL622561,,1,1,,BAO_0000218,,
8268,A,,10116.0,,50597,Intermediate,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,CHEMBL622562,,1,1,,BAO_0000218,,
8269,A,,10116.0,,50597,Intermediate,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,CHEMBL622563,,1,1,,BAO_0000218,,
8270,A,,,,22224,Autocuration,Concentration of compound in Central nervous system,,CHEMBL622564,,0,1,,BAO_0000019,,
8271,A,,,,22224,Autocuration,Concentration of compound in Central nervous system; Not detectable,,CHEMBL622565,,0,1,,BAO_0000019,,
8272,A,,10090.0,,50594,Intermediate,"Concentration of diester in the blood, following oral administration in mice",,CHEMBL622566,,1,1,,BAO_0000218,,
8273,A,,10090.0,,50594,Intermediate,"Concentration of monoester in the blood, following oral administration in mice",,CHEMBL624515,,1,1,,BAO_0000218,,
8274,A,,10090.0,,50594,Intermediate,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,CHEMBL624516,,1,1,,BAO_0000218,,
8275,A,,,,22224,Autocuration,Evaluated for Pharmacokinetic property: Area under the curve,,CHEMBL624517,,0,1,,BAO_0000019,,
8276,A,,10090.0,,50594,Intermediate,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,CHEMBL624518,,1,1,,BAO_0000218,,
8277,A,,9541.0,,100710,Intermediate,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,CHEMBL624519,,1,1,,BAO_0000218,,
8278,A,,9541.0,,100710,Intermediate,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,CHEMBL624520,,1,1,,BAO_0000218,,
8279,A,,9541.0,,100710,Intermediate,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,CHEMBL624521,,1,1,,BAO_0000218,,
8280,A,,9541.0,,100710,Intermediate,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,CHEMBL624522,,1,1,,BAO_0000218,,
8281,A,,9541.0,,100710,Intermediate,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,CHEMBL624523,,1,1,,BAO_0000218,,
8282,A,,9541.0,,100710,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,CHEMBL624409,,1,1,,BAO_0000218,,
8283,A,,9541.0,,100710,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,CHEMBL624410,,1,1,,BAO_0000218,,
8284,A,,9541.0,,100710,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,CHEMBL624411,,1,1,,BAO_0000218,,
8285,A,,9541.0,,100710,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,CHEMBL623531,,1,1,,BAO_0000218,,
8286,A,,9541.0,,100710,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,CHEMBL623532,,1,1,,BAO_0000218,,
8287,A,,9541.0,,100710,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,CHEMBL623533,,1,1,,BAO_0000218,,
8288,A,,9541.0,,100710,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,CHEMBL623534,,1,1,,BAO_0000218,,
8289,A,,10090.0,,50594,Intermediate,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,CHEMBL623535,,1,1,,BAO_0000218,,
8290,A,,10090.0,,50594,Intermediate,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,CHEMBL623536,,1,1,,BAO_0000218,,
8291,A,,10090.0,,50594,Intermediate,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,CHEMBL623537,,1,1,,BAO_0000218,,
8292,A,,10090.0,,50594,Intermediate,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,CHEMBL623538,,1,1,,BAO_0000218,,
8293,A,,10090.0,,50594,Intermediate,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,CHEMBL623539,,1,1,,BAO_0000218,,
8294,A,,10090.0,,50594,Intermediate,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,CHEMBL623540,,1,1,,BAO_0000218,,
8295,A,,10090.0,,50594,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,CHEMBL623541,,1,1,,BAO_0000218,,
8296,A,,10090.0,,50594,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,CHEMBL623542,,1,1,,BAO_0000218,,
8297,A,,10090.0,,50594,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,CHEMBL623543,,1,1,,BAO_0000218,,
8298,A,,10090.0,,50594,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,CHEMBL623544,,1,1,,BAO_0000218,,
8299,A,,10090.0,,50594,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,CHEMBL623545,,1,1,,BAO_0000218,,
8300,A,,10090.0,,50594,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,CHEMBL623546,,1,1,,BAO_0000218,,
8301,A,In vivo,10116.0,,50597,Intermediate,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,,CHEMBL623547,,1,1,,BAO_0000218,1969.0,
8302,A,In vivo,10116.0,,50597,Intermediate,High i.v. clearance in Dawley rats,,CHEMBL623548,,1,1,,BAO_0000218,,
8303,A,In vitro,10116.0,,50597,Intermediate,In vitro clearance in rat liver microsomes,,CHEMBL623549,,1,1,,BAO_0000218,2107.0,
8304,A,In vitro,10116.0,,50597,Intermediate,Intrinsic clearance in rat liver microsomes was determined,,CHEMBL623550,,1,1,,BAO_0000218,2107.0,
8305,A,In vitro,10116.0,,50597,Intermediate,Intrinsic clearance in rat hepatocytes was determined,,CHEMBL875276,,1,1,401.0,BAO_0000218,2107.0,
8306,A,In vivo,10116.0,,50597,Intermediate,Plasma Clearance was determined,,CHEMBL621872,,1,1,,BAO_0000218,,
8307,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,CHEMBL621873,,1,1,,BAO_0000218,,
8308,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat.,,CHEMBL621874,,1,1,,BAO_0000218,,
8309,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rats,,CHEMBL621875,,1,1,,BAO_0000218,,
8310,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,CHEMBL621876,,1,1,,BAO_0000218,,
8311,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,CHEMBL621877,,1,1,,BAO_0000218,,
8312,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was measured in rat,,CHEMBL621878,,1,1,,BAO_0000218,,
8313,A,In vivo,10116.0,,50597,Intermediate,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,CHEMBL621879,,1,1,,BAO_0000218,,
8314,A,In vivo,10116.0,,50597,Intermediate,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",,CHEMBL621880,,1,1,,BAO_0000218,1969.0,
8315,A,In vivo,10116.0,,50597,Intermediate,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,CHEMBL621881,,1,1,,BAO_0000218,,
8316,A,In vivo,10116.0,,50597,Intermediate,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,CHEMBL621882,,1,1,,BAO_0000218,,
8317,A,In vivo,10116.0,,50597,Intermediate,Total clearance at 1 mg/kg was determined in rat,,CHEMBL875283,,1,1,,BAO_0000218,,
8318,A,In vivo,10116.0,,50597,Intermediate,Total clearance at 10 mg/kg was determined in rat,,CHEMBL621883,,1,1,,BAO_0000218,,
8319,A,In vivo,10116.0,,50597,Intermediate,Clearance in rat,,CHEMBL621884,,1,1,,BAO_0000218,,
8320,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance rate determined in rats,,CHEMBL621885,,1,1,,BAO_0000218,,
8321,A,In vivo,10116.0,,50597,Intermediate,Clearance of compound in rat was evaluated,,CHEMBL621886,,1,1,,BAO_0000218,,
8322,A,In vivo,10116.0,,50597,Intermediate,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,CHEMBL621887,,1,1,,BAO_0000218,1969.0,
8323,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (blood clearance) in rat,,CHEMBL621888,,1,1,,BAO_0000218,,
8324,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat,,CHEMBL621889,,1,1,,BAO_0000218,,
8325,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rats,,CHEMBL621890,,1,1,,BAO_0000218,,
8326,A,In vitro,10116.0,,50597,Intermediate,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,,CHEMBL621891,,1,1,,BAO_0000218,2107.0,
8327,A,In vivo,10116.0,,50597,Intermediate,Clearance in Dawley rat,,CHEMBL621892,,1,1,,BAO_0000218,,
8328,A,In vivo,10116.0,,50597,Intermediate,Clearance rat,,CHEMBL621893,,1,1,,BAO_0000218,,
8329,A,In vivo,10116.0,,50597,Intermediate,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,CHEMBL621894,,1,1,,BAO_0000218,,
8330,A,In vivo,10116.0,,50597,Intermediate,Clearance rat; Not determined,,CHEMBL621895,,1,1,,BAO_0000218,,
8331,A,In vivo,10116.0,,50597,Intermediate,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,CHEMBL875284,,1,1,,BAO_0000218,,
8332,A,In vivo,10116.0,,50597,Intermediate,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,CHEMBL618699,,1,1,,BAO_0000218,,
8333,A,In vivo,10116.0,,50597,Intermediate,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,CHEMBL618700,,1,1,,BAO_0000218,,
8334,A,In vivo,10116.0,,50597,Intermediate,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,CHEMBL618701,,1,1,,BAO_0000218,,
8335,A,In vivo,10116.0,,50597,Intermediate,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,CHEMBL876600,,1,1,,BAO_0000218,1969.0,
8336,A,In vivo,10116.0,,50597,Intermediate,Clearance of compound in rat after 1 mg/kg i.v. administration,,CHEMBL618702,,1,1,,BAO_0000218,,
8337,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for Hepatic clearance in rat,,CHEMBL618703,,1,1,,BAO_0000218,,
8338,A,In vivo,10116.0,,50597,Intermediate,In vivo clearance after 5 mg/kg dose,,CHEMBL618704,,1,1,,BAO_0000218,,
8339,A,In vivo,10116.0,,50597,Intermediate,Compound was tested for plasma clearance in rats,,CHEMBL618705,,1,1,,BAO_0000218,1969.0,
8340,A,In vivo,10116.0,,50597,Intermediate,Hepatic clearance after intravenous administration was evaluated in rat,,CHEMBL618706,,1,1,,BAO_0000218,,
8341,A,In vivo,10116.0,,50597,Intermediate,Lower clearance in rat (i.v.) at 0.5 mpk,,CHEMBL618707,,1,1,,BAO_0000218,,
8342,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter expressed as plasma clearance in rat,,CHEMBL618708,,1,1,,BAO_0000218,1969.0,
8343,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Clp) in rat,,CHEMBL618709,,1,1,,BAO_0000218,,
8344,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in Sprague-Dawley rats,,CHEMBL618710,,1,1,,BAO_0000218,,
8345,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance (Clp) in rat,,CHEMBL618711,,1,1,,BAO_0000218,,
8346,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,CHEMBL618712,,1,1,,BAO_0000218,,
8347,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,CHEMBL618713,,1,1,,BAO_0000218,,
8348,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance after intravenous administration of 1 mg/kg in rat,,CHEMBL618714,,1,1,,BAO_0000218,,
8349,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,CHEMBL618715,,1,1,,BAO_0000218,,
8350,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat was determined,,CHEMBL618716,,1,1,,BAO_0000218,,
8351,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance measured in rat,,CHEMBL876601,,1,1,,BAO_0000218,,
8352,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was calculated in rat,,CHEMBL618717,,1,1,,BAO_0000218,,
8353,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat,,CHEMBL618718,,1,1,,BAO_0000218,,
8354,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat,,CHEMBL618719,,1,1,,BAO_0000218,,
8355,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat,,CHEMBL618720,,1,1,,BAO_0000218,,
8356,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat,,CHEMBL618721,,1,1,,BAO_0000218,,
8357,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rats,,CHEMBL621477,,1,1,,BAO_0000218,,
8358,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat,,CHEMBL621478,,1,1,,BAO_0000218,,
8359,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was evaluated in rat,,CHEMBL621479,,1,1,,BAO_0000218,,
8360,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was evaluated in rat; Not tested,,CHEMBL621480,,1,1,,BAO_0000218,,
8361,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance rate was determined for the compound in rat,,CHEMBL621481,,1,1,,BAO_0000218,,
8362,A,In vivo,10116.0,,50597,Intermediate,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,CHEMBL621482,,1,1,,BAO_0000218,,
8363,A,In vivo,10116.0,,50597,Intermediate,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,CHEMBL621483,,1,1,,BAO_0000218,,
8364,A,In vivo,10116.0,,50597,Intermediate,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,CHEMBL621484,,1,1,,BAO_0000218,,
8365,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621485,,1,1,,BAO_0000218,948.0,
8366,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621486,,1,1,,BAO_0000218,948.0,
8367,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621487,,1,1,,BAO_0000218,160.0,
8368,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621488,,1,1,,BAO_0000218,160.0,
8369,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621489,,1,1,,BAO_0000218,160.0,
8370,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621490,,1,1,,BAO_0000218,160.0,
8371,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621491,,1,1,,BAO_0000218,160.0,
8372,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621492,,1,1,,BAO_0000218,2113.0,
8373,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,,CHEMBL621493,,1,1,,BAO_0000218,2113.0,
8374,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621494,,1,1,,BAO_0000218,2113.0,
8375,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621495,,1,1,,BAO_0000218,2113.0,
8376,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621496,,1,1,,BAO_0000218,2113.0,
8377,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621497,,1,1,,BAO_0000218,2107.0,
8378,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621498,,1,1,,BAO_0000218,2107.0,
8379,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL621499,,1,1,,BAO_0000218,2107.0,
8380,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,,CHEMBL618634,,1,1,,BAO_0000218,2107.0,
8381,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL618635,,1,1,,BAO_0000218,2107.0,
8382,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL618636,,1,1,,BAO_0000218,2048.0,
8383,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619737,,1,1,,BAO_0000218,2048.0,
8384,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL619738,,1,1,,BAO_0000218,2048.0,
8385,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624329,,1,1,,BAO_0000218,2048.0,
8386,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624330,,1,1,,BAO_0000218,2048.0,
8387,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624331,,1,1,,BAO_0000218,2385.0,
8388,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624332,,1,1,,BAO_0000218,2385.0,
8389,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624333,,1,1,,BAO_0000218,2385.0,
8390,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624334,,1,1,,BAO_0000218,2385.0,
8391,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL624335,,1,1,,BAO_0000218,2385.0,
8392,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620016,,1,1,,BAO_0000218,2106.0,
8393,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620169,,1,1,,BAO_0000218,2106.0,
8394,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620170,,1,1,,BAO_0000218,2106.0,
8395,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,,CHEMBL620171,,1,1,,BAO_0000218,2106.0,
8396,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620172,,1,1,,BAO_0000218,2106.0,
8397,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620173,,1,1,,BAO_0000218,945.0,
8398,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,,CHEMBL620174,,1,1,,BAO_0000218,945.0,
8399,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620175,,1,1,,BAO_0000218,945.0,
8400,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620176,,1,1,,BAO_0000218,945.0,
8401,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,,CHEMBL620177,,1,1,,BAO_0000218,945.0,
8402,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620178,,1,1,,BAO_0000218,2037.0,
8403,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620179,,1,1,,BAO_0000218,2037.0,
8404,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620180,,1,1,,BAO_0000218,,
8405,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,CHEMBL620181,,1,1,,BAO_0000218,,
8406,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution of compound in rats after intravenous administration,,CHEMBL620182,,1,1,,BAO_0000218,,
8407,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in rat,,CHEMBL620183,,1,1,,BAO_0000218,,
8408,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,CHEMBL620184,,1,1,,BAO_0000218,,
8409,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,CHEMBL620185,,1,1,,BAO_0000218,,
8410,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,CHEMBL620186,,1,1,,BAO_0000218,,
8411,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was determined in Dawley rat,,CHEMBL620187,,1,1,,BAO_0000218,,
8412,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,CHEMBL620188,,1,1,,BAO_0000218,,
8413,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was reported in Sprague-Dawley rat,,CHEMBL620189,,1,1,,BAO_0000218,,
8414,A,In vivo,10116.0,,50597,Intermediate,Volumes of distribution in rat after peroral administration,,CHEMBL620190,,1,1,,BAO_0000218,,
8415,A,In vivo,10116.0,,50597,Intermediate,Volumes of distribution in rat after po administration,,CHEMBL620191,,1,1,,BAO_0000218,,
8416,A,In vivo,10116.0,,50597,Intermediate,Volumes of distribution in rat after po administration; Not determined,,CHEMBL620192,,1,1,,BAO_0000218,,
8417,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Volume) in rat i.v.,,CHEMBL620193,,1,1,,BAO_0000218,,
8418,A,In vivo,10116.0,,50597,Intermediate,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,CHEMBL620194,,1,1,,BAO_0000218,,
8419,A,In vivo,10116.0,,50597,Intermediate,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,CHEMBL876730,,1,1,,BAO_0000218,,
8420,A,In vivo,10116.0,,50597,Intermediate,Volume distribution in rat after oral administration at 10 mg/kg,,CHEMBL620195,,1,1,,BAO_0000218,,
8421,A,In vivo,10116.0,,50597,Intermediate,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,CHEMBL620196,,1,1,,BAO_0000218,,
8422,A,In vivo,10116.0,,50597,Intermediate,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,CHEMBL620197,,1,1,,BAO_0000218,,
8423,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,CHEMBL620198,,1,1,,BAO_0000218,,
8424,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in rats,,CHEMBL620199,,1,1,,BAO_0000218,,
8425,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,CHEMBL620200,,1,1,,BAO_0000218,,
8426,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,CHEMBL620201,,1,1,,BAO_0000218,,
8427,A,In vivo,10116.0,,50597,Intermediate,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL620202,,1,1,,BAO_0000218,,
8428,A,In vivo,10116.0,,50597,Intermediate,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL620203,,1,1,,BAO_0000218,,
8429,A,In vivo,10116.0,,50597,Intermediate,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,CHEMBL620204,,1,1,,BAO_0000218,,
8430,A,In vivo,10116.0,,50597,Intermediate,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL620205,,1,1,,BAO_0000218,,
8431,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter (Vss) in rat,,CHEMBL624664,,1,1,,BAO_0000218,,
8432,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Volume) in rat i.v.,,CHEMBL624665,,1,1,,BAO_0000218,,
8433,A,,10116.0,,50597,Intermediate,Pharmacokinetic property (Vss) in rat,,CHEMBL624666,,1,1,,BAO_0000218,,
8434,A,In vivo,10116.0,,50597,Intermediate,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,CHEMBL624667,,1,1,,BAO_0000218,,
8435,A,In vivo,10116.0,,50597,Intermediate,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,CHEMBL624668,,1,1,,BAO_0000218,,
8436,A,In vivo,10116.0,,50597,Intermediate,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL624669,,1,1,,BAO_0000218,,
8437,A,In vivo,10116.0,,50597,Intermediate,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL624670,,1,1,,BAO_0000218,,
8438,A,In vivo,10116.0,,50597,Intermediate,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL624671,,1,1,,BAO_0000218,,
8439,A,In vivo,10116.0,,50597,Intermediate,Steady state volume distribution in rat,,CHEMBL624672,,1,1,,BAO_0000218,,
8440,A,In vivo,10116.0,,50597,Intermediate,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",,CHEMBL624673,,1,1,,BAO_0000218,1969.0,
8441,A,In vivo,10116.0,,50597,Intermediate,Steady state volume of distribution determined in rat,,CHEMBL624674,,1,1,,BAO_0000218,,
8442,A,In vivo,10116.0,,50597,Intermediate,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,CHEMBL624675,,1,1,,BAO_0000218,,
8443,A,In vivo,10116.0,,50597,Intermediate,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,CHEMBL621728,,1,1,,BAO_0000218,,
8444,A,,10116.0,,50597,Intermediate,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,CHEMBL621729,,1,1,,BAO_0000218,,
8445,A,,10116.0,,50597,Intermediate,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,CHEMBL621730,,1,1,,BAO_0000218,,
8446,A,In vivo,10116.0,,50597,Intermediate,Volume distribution in rat after administration of 2 mg/kg iv,,CHEMBL621731,,1,1,,BAO_0000218,,
8447,A,In vivo,10116.0,,50597,Intermediate,Volume distribution in rat after administration of 2 mg/kg iv,,CHEMBL621732,,1,1,,BAO_0000218,,
8448,A,In vivo,10116.0,,50597,Intermediate,Volume in steady state distribution value was determined,,CHEMBL621908,,1,1,,BAO_0000218,,
8449,A,In vivo,10116.0,,50597,Intermediate,Volume in steady state distribution value was determined; ND denotes no data,,CHEMBL875347,,1,1,,BAO_0000218,,
8450,A,In vivo,10116.0,,50597,Intermediate,Volume in steady state distribution value was determined; ND denotes not determined,,CHEMBL621909,,1,1,,BAO_0000218,,
8451,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,CHEMBL621910,,1,1,,BAO_0000218,,
8452,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution at steady state was evaluated in rats,,CHEMBL621911,,1,1,,BAO_0000218,,
8453,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution at steady state was observed after intravenous administration in rat,,CHEMBL621912,,1,1,,BAO_0000218,,
8454,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in steady state was determined in rat,,CHEMBL621913,,1,1,,BAO_0000218,,
8455,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in steady state was determined in rat,,CHEMBL621914,,1,1,,BAO_0000218,,
8456,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution after i.v. administration,,CHEMBL621915,,1,1,,BAO_0000218,,
8457,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,CHEMBL621916,,1,1,,BAO_0000218,,
8458,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL621917,,1,1,,BAO_0000218,2107.0,
8459,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL621918,,1,1,,BAO_0000218,2107.0,
8460,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of compound (oxidized form) in spleen tissue,,CHEMBL621919,,1,1,,BAO_0000218,2106.0,
8461,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,CHEMBL621920,,1,1,,BAO_0000218,2106.0,
8462,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,CHEMBL621921,,1,1,,BAO_0000218,2106.0,
8463,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622401,,1,1,,BAO_0000218,2106.0,
8464,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,CHEMBL875348,,1,1,,BAO_0000218,2106.0,
8465,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,CHEMBL622402,,1,1,,BAO_0000218,2106.0,
8466,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,,CHEMBL622403,,1,1,,BAO_0000218,178.0,
8467,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622404,,1,1,,BAO_0000218,178.0,
8468,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,,CHEMBL622405,,1,1,,BAO_0000218,955.0,
8469,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,CHEMBL622406,,1,1,,BAO_0000218,955.0,
8470,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622407,,1,1,,BAO_0000218,955.0,
8471,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,,CHEMBL622408,,1,1,,BAO_0000218,948.0,
8472,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,CHEMBL622409,,1,1,,BAO_0000218,948.0,
8473,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL622410,,1,1,,BAO_0000218,948.0,
8474,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,,CHEMBL622411,,1,1,,BAO_0000218,2113.0,
8475,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",,CHEMBL627864,,1,1,,BAO_0000218,2113.0,
8476,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL627865,,1,1,,BAO_0000218,2113.0,
8477,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,,CHEMBL627866,,1,1,,BAO_0000218,2107.0,
8478,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL627751,,1,1,,BAO_0000218,2107.0,
8479,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,,CHEMBL627752,,1,1,,BAO_0000218,2106.0,
8480,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",,CHEMBL627753,,1,1,,BAO_0000218,2106.0,
8481,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,CHEMBL627754,,1,1,,BAO_0000218,2106.0,
8482,A,,10090.0,,50594,Intermediate,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,CHEMBL627755,,1,1,,BAO_0000218,,
8483,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL627756,,1,1,,BAO_0000218,955.0,
8484,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627757,,1,1,,BAO_0000218,955.0,
8485,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL627758,,1,1,,BAO_0000218,955.0,
8486,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627759,,1,1,,BAO_0000218,955.0,
8487,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL627760,,1,1,,BAO_0000218,955.0,
8488,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627761,,1,1,,BAO_0000218,955.0,
8489,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL876811,,1,1,,BAO_0000218,948.0,
8490,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627762,,1,1,,BAO_0000218,948.0,
8491,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL627763,,1,1,,BAO_0000218,948.0,
8492,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627764,,1,1,,BAO_0000218,948.0,
8493,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL627765,,1,1,,BAO_0000218,948.0,
8494,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627766,,1,1,,BAO_0000218,948.0,
8495,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL627767,,1,1,,BAO_0000218,2113.0,
8496,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627768,,1,1,,BAO_0000218,2113.0,
8497,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL628422,,1,1,,BAO_0000218,2113.0,
8498,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL628423,,1,1,,BAO_0000218,2113.0,
8499,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,CHEMBL628424,,1,1,,BAO_0000218,,
8500,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,CHEMBL628425,,1,1,,BAO_0000218,,
8501,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,CHEMBL628426,,1,1,,BAO_0000218,,
8502,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL628427,,1,1,,BAO_0000218,,
8503,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,CHEMBL626938,,1,1,,BAO_0000218,,
8504,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,CHEMBL626939,,1,1,,BAO_0000218,,
8505,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,CHEMBL626940,,1,1,,BAO_0000218,,
8506,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,CHEMBL626941,,1,1,,BAO_0000218,,
8507,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was reported in Sprague-Dawley rat,,CHEMBL626942,,1,1,,BAO_0000218,,
8508,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance after intravenous administration (1 mg/kg) in rat,,CHEMBL876812,,1,1,,BAO_0000218,,
8509,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance of compound in rats was evaluated,,CHEMBL626943,,1,1,,BAO_0000218,,
8510,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,CHEMBL626944,,1,1,,BAO_0000218,,
8511,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,CHEMBL626945,,1,1,,BAO_0000218,,
8512,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,CHEMBL626946,,1,1,,BAO_0000218,,
8513,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance rate in Sprague-Dawley rats,,CHEMBL626856,,1,1,,BAO_0000218,,
8514,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,CHEMBL626857,,1,1,,BAO_0000218,,
8515,A,In vivo,10116.0,,50597,Intermediate,The compound was evaluated for plasma clearance in rat,,CHEMBL626858,,1,1,,BAO_0000218,1969.0,
8516,A,In vivo,10116.0,,50597,Intermediate,Total plasma clearance in rat,,CHEMBL627018,,1,1,,BAO_0000218,1969.0,
8517,A,In vivo,10116.0,,50597,Intermediate,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,,CHEMBL625331,,1,1,,BAO_0000218,178.0,
8518,A,In vivo,10116.0,,50597,Intermediate,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,,CHEMBL625332,,1,1,,BAO_0000218,178.0,
8519,A,In vivo,10116.0,,50597,Intermediate,C max was determined at 10 mg/kg po dose in rats,,CHEMBL877590,,1,1,,BAO_0000218,,
8520,A,In vivo,10116.0,,50597,Intermediate,C max was determined at 3 mg/kg po dose in rats,,CHEMBL625333,,1,1,,BAO_0000218,,
8521,A,In vivo,10116.0,,50597,Intermediate,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,CHEMBL625334,,1,1,,BAO_0000218,,
8522,A,In vivo,10116.0,,50597,Intermediate,Cmax after single intravenous bolus of 1 mg/kg in rats,,CHEMBL625335,,1,1,,BAO_0000218,,
8523,A,In vivo,10116.0,,50597,Intermediate,Cmax of compound at 5 mg/kg after po administration was determined in rat,,CHEMBL625336,,1,1,,BAO_0000218,,
8524,A,In vivo,10116.0,,50597,Intermediate,Cmax 24 hr after 10 mg/kg oral administration in rats,,CHEMBL625337,,1,1,,BAO_0000218,,
8525,A,In vivo,10116.0,,50597,Intermediate,Cmax 24 hr after 2 mg/kg oral administration in rats,,CHEMBL625338,,1,1,,BAO_0000218,,
8526,A,In vivo,10116.0,,50597,Intermediate,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,,CHEMBL625339,,1,1,,BAO_0000218,1969.0,
8527,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat after administration of 2 mg/kg iv,,CHEMBL625340,,1,1,,BAO_0000218,,
8528,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat after administration of 2 mg/kg iv,,CHEMBL625341,,1,1,,BAO_0000218,,
8529,A,In vivo,10116.0,,50597,Intermediate,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,CHEMBL622687,,1,1,,BAO_0000218,,
8530,A,In vivo,10116.0,,50597,Intermediate,Cmax wa determined in rat plasma at 30 mg/kg after po administration,,CHEMBL622688,,1,1,,BAO_0000218,1969.0,
8531,A,In vivo,10116.0,,50597,Intermediate,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,,CHEMBL622689,,1,1,,BAO_0000218,178.0,
8532,A,In vivo,10116.0,,50597,Intermediate,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,,CHEMBL620295,,1,1,,BAO_0000218,178.0,
8533,A,In vivo,10116.0,,50597,Intermediate,Cmax after 10 mg/kg oral administration in rat,,CHEMBL620296,,1,1,,BAO_0000218,,
8534,A,In vivo,10116.0,,50597,Intermediate,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,CHEMBL620297,,1,1,,BAO_0000218,,
8535,A,In vivo,10116.0,,50597,Intermediate,Cmax after IV dosing at 1 mg/kg in rat; no data,,CHEMBL620298,,1,1,,BAO_0000218,,
8536,A,In vivo,10116.0,,50597,Intermediate,Cmax after oral administration at 20 mpk in rats,,CHEMBL620299,,1,1,,BAO_0000218,,
8537,A,In vivo,10116.0,,50597,Intermediate,Cmax after oral administration at 20 mpk in rats; Not performed.,,CHEMBL620300,,1,1,,BAO_0000218,,
8538,A,In vivo,10116.0,,50597,Intermediate,Cmax after oral administration at 20 mpk in rats d; Not performed.,,CHEMBL620301,,1,1,,BAO_0000218,,
8539,A,In vivo,10116.0,,50597,Intermediate,Cmax after oral administration in rat,,CHEMBL620302,,1,1,,BAO_0000218,,
8540,A,In vivo,10116.0,,50597,Intermediate,Cmax after oral administration at a dose of 2 mg/kg in rat,,CHEMBL620303,,1,1,,BAO_0000218,,
8541,A,In vivo,10116.0,,50597,Intermediate,Cmax after oral administration at a dose of 4 mg/kg in rat,,CHEMBL620304,,1,1,,BAO_0000218,,
8542,A,In vivo,10116.0,,50597,Intermediate,Cmax in rats after 20 mg/kg oral dose,,CHEMBL620305,,1,1,,BAO_0000218,,
8543,A,In vivo,10116.0,,50597,Intermediate,Cmax after peroral administration in rats at 2.4 uM/kg,,CHEMBL620306,,1,1,,BAO_0000218,,
8544,A,In vivo,10116.0,,50597,Intermediate,Cmax at the dose of 2 mg/Kg administered perorally in rats,,CHEMBL620307,,1,1,,BAO_0000218,,
8545,A,In vivo,10116.0,,50597,Intermediate,Cmax at the dose of 5 mg/Kg administered perorally in rats,,CHEMBL620308,,1,1,,BAO_0000218,,
8546,A,In vivo,10116.0,,50597,Intermediate,Cmax by administering at 20 mg/kg p.o. in rats,,CHEMBL620309,,1,1,,BAO_0000218,,
8547,A,In vivo,10116.0,,50597,Intermediate,Cmax in male rat,,CHEMBL620310,,1,1,,BAO_0000218,,
8548,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat,,CHEMBL620311,,1,1,,BAO_0000218,,
8549,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat,,CHEMBL620312,,1,1,,BAO_0000218,,
8550,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat,,CHEMBL620313,,1,1,,BAO_0000218,,
8551,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat at 10 mg/kg,,CHEMBL620314,,1,1,,BAO_0000218,,
8552,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat at the dose of 1 mg/kg i.v.,,CHEMBL620315,,1,1,,BAO_0000218,,
8553,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat by po administration at a dose of 40 mg/kg,,CHEMBL620316,,1,1,,BAO_0000218,,
8554,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat p.o. at 20 mg/kg concentration,,CHEMBL620317,,1,1,,BAO_0000218,,
8555,A,In vivo,10116.0,,50597,Intermediate,Cmax in rats,,CHEMBL620318,,1,1,,BAO_0000218,,
8556,A,In vivo,10116.0,,50597,Intermediate,Cmax in rats,,CHEMBL620319,,1,1,,BAO_0000218,,
8557,A,In vivo,10116.0,,50597,Intermediate,Cmax was evaluated after 20 uM/kg of peroral administration,,CHEMBL620320,,1,1,,BAO_0000218,,
8558,A,In vivo,10116.0,,50597,Intermediate,Cmax was measured in rats after peroral administration at 3 mg/kg,,CHEMBL620321,,1,1,,BAO_0000218,,
8559,A,In vivo,10116.0,,50597,Intermediate,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,CHEMBL620322,,1,1,,BAO_0000218,,
8560,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620323,,1,1,,BAO_0000218,,
8561,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620324,,1,1,,BAO_0000218,1870.0,
8562,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620325,,1,1,,BAO_0000218,1870.0,
8563,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620326,,1,1,,BAO_0000218,10000000.0,
8564,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620327,,1,1,,BAO_0000218,10000000.0,
8565,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620328,,1,1,,BAO_0000218,,
8566,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620329,,1,1,,BAO_0000218,,
8567,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620330,,1,1,,BAO_0000218,1891.0,
8568,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL875286,,1,1,,BAO_0000218,1891.0,
8569,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620331,,1,1,,BAO_0000218,,
8570,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620332,,1,1,,BAO_0000218,,
8571,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,CHEMBL620333,,1,1,,BAO_0000218,2435.0,
8572,A,,10116.0,,50597,Intermediate,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,CHEMBL620334,,1,1,,BAO_0000218,2435.0,
8573,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL621015,,1,1,,BAO_0000218,178.0,
8574,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL621016,,1,1,,BAO_0000218,178.0,
8575,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL621191,,1,1,,BAO_0000218,178.0,
8576,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL621192,,1,1,,BAO_0000218,178.0,
8577,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL621193,,1,1,,BAO_0000218,178.0,
8578,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL621194,,1,1,,BAO_0000218,178.0,
8579,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL624204,,1,1,,BAO_0000218,178.0,
8580,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL624205,,1,1,,BAO_0000218,178.0,
8581,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL624206,,1,1,,BAO_0000218,178.0,
8582,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL624207,,1,1,,BAO_0000218,178.0,
8583,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL624208,,1,1,,BAO_0000218,178.0,
8584,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL624209,,1,1,,BAO_0000218,178.0,
8585,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL624210,,1,1,,BAO_0000218,178.0,
8586,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL624211,,1,1,,BAO_0000218,178.0,
8587,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL624212,,1,1,,BAO_0000218,178.0,
8588,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL624213,,1,1,,BAO_0000218,178.0,
8589,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL876611,,1,1,,BAO_0000218,178.0,
8590,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL624214,,1,1,,BAO_0000218,178.0,
8591,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL624215,,1,1,,BAO_0000218,178.0,
8592,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL624216,,1,1,,BAO_0000218,178.0,
8593,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL624217,,1,1,,BAO_0000218,178.0,
8594,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL624218,,1,1,,BAO_0000218,178.0,
8595,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL624219,,1,1,,BAO_0000218,178.0,
8596,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL624220,,1,1,,BAO_0000218,178.0,
8597,A,,10116.0,,50597,Intermediate,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL624221,,1,1,,BAO_0000218,178.0,
8598,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL624222,,1,1,,BAO_0000218,,
8599,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL624223,,1,1,,BAO_0000218,,
8600,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL624224,,1,1,,BAO_0000218,,
8601,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL624225,,1,1,,BAO_0000218,,
8602,A,In vivo,10116.0,,50597,Intermediate,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,CHEMBL622420,,1,1,,BAO_0000218,,
8603,A,In vivo,10116.0,,50597,Intermediate,Volume of steady state distribution after i.v. administration in rats,,CHEMBL622421,,1,1,,BAO_0000218,,
8604,A,In vivo,10116.0,,50597,Intermediate,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,CHEMBL622422,,1,1,,BAO_0000218,,
8605,A,In vivo,10116.0,,50597,Intermediate,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,CHEMBL622423,,1,1,,BAO_0000218,,
8606,A,In vivo,10116.0,,50597,Intermediate,Vss was determined,,CHEMBL622424,,1,1,,BAO_0000218,,
8607,A,In vivo,10116.0,,50597,Intermediate,Vss in rat,,CHEMBL622425,,1,1,,BAO_0000218,,
8608,A,In vivo,10116.0,,50597,Intermediate,Vss was evaluated after 10 uM/kg of intra arterial administration,,CHEMBL876612,,1,1,,BAO_0000218,,
8609,A,In vivo,10116.0,,50597,Intermediate,volume of distribution at steady state was observed after intravenous administration in rat,,CHEMBL622426,,1,1,,BAO_0000218,,
8610,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,CHEMBL622427,,1,1,,BAO_0000218,,
8611,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic (PK) parameter Vz in rat,,CHEMBL622428,,1,1,,BAO_0000218,,
8612,A,In vivo,10116.0,,50597,Intermediate,Volume distribution in rats,,CHEMBL622429,,1,1,,BAO_0000218,,
8613,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in rat; No data,,CHEMBL622430,,1,1,,BAO_0000218,,
8614,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,CHEMBL622431,,1,1,,BAO_0000218,,
8615,A,,10116.0,,50597,Intermediate,% absorption predicted from in vitro rat ileum transport studies,,CHEMBL622432,,1,1,,BAO_0000218,2116.0,
8616,A,In vivo,10116.0,,50597,Intermediate,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,CHEMBL622433,,1,1,,BAO_0000218,,
8617,A,In vivo,10116.0,,50597,Intermediate,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,CHEMBL622434,,1,1,,BAO_0000218,,
8618,A,In vivo,10116.0,,50597,Intermediate,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,CHEMBL622435,,1,1,,BAO_0000218,,
8619,A,In vivo,10116.0,,50597,Intermediate,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,CHEMBL618748,,1,1,,BAO_0000218,,
8620,A,In vivo,10116.0,,50597,Intermediate,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,CHEMBL618749,,1,1,,BAO_0000218,,
8621,A,In vivo,10116.0,,50597,Intermediate,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,CHEMBL618750,,1,1,,BAO_0000218,,
8622,A,In vivo,10116.0,,50597,Intermediate,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,CHEMBL618751,,1,1,,BAO_0000218,,
8623,A,In vivo,10116.0,,50597,Intermediate,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,CHEMBL618752,,1,1,,BAO_0000218,,
8624,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL618753,,1,1,,BAO_0000218,,
8625,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,,CHEMBL618754,,1,1,,BAO_0000218,1969.0,
8626,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL618755,,1,1,,BAO_0000218,,
8627,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL618756,,1,1,,BAO_0000218,,
8628,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL618757,,1,1,,BAO_0000218,,
8629,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL618758,,1,1,,BAO_0000218,,
8630,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 30 mg/kg),,CHEMBL621088,,1,1,,BAO_0000218,,
8631,A,,10116.0,,50597,Intermediate,Pharmacokinetic property (cLogP) in rat,,CHEMBL621089,,1,1,,BAO_0000218,,
8632,F,,10116.0,,50597,Intermediate,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,,CHEMBL621090,,1,1,,BAO_0000218,178.0,
8633,F,,10116.0,,50597,Intermediate,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,,CHEMBL621091,,1,1,,BAO_0000218,178.0,
8634,A,In vivo,10116.0,,50597,Intermediate,Clearance in rat.,,CHEMBL876731,,1,1,,BAO_0000218,,
8635,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for its clearance when administered intravenously in rat,,CHEMBL621092,,1,1,,BAO_0000218,,
8636,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,CHEMBL621093,,1,1,,BAO_0000218,,
8637,A,,10116.0,,50597,Intermediate,Blood: Brain distribution ratio is determined in rat,,CHEMBL621094,,1,1,,BAO_0000218,,
8638,A,,10116.0,,50597,Intermediate,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,CHEMBL621095,,1,1,,BAO_0000218,,
8639,A,,10116.0,,50597,Intermediate,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,CHEMBL621096,,1,1,,BAO_0000218,,
8640,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL621097,,1,1,,BAO_0000218,2113.0,
8641,F,,10116.0,,50597,Intermediate,Percent dose excreted in 0-48 hours administered ip to male rat,,CHEMBL621098,,1,1,,BAO_0000218,,
8642,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621099,,1,1,,BAO_0000218,2037.0,
8643,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621100,,1,1,,BAO_0000218,2037.0,
8644,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL621101,,1,1,,BAO_0000218,2037.0,
8645,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621102,,1,1,,BAO_0000218,2037.0,
8646,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL876732,,1,1,,BAO_0000218,2037.0,
8647,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621103,,1,1,,BAO_0000218,,
8648,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621104,,1,1,,BAO_0000218,,
8649,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL621105,,1,1,,BAO_0000218,,
8650,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621106,,1,1,,BAO_0000218,,
8651,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621107,,1,1,,BAO_0000218,,
8652,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621108,,1,1,,BAO_0000218,,
8653,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621109,,1,1,,BAO_0000218,,
8654,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL621110,,1,1,,BAO_0000218,2113.0,
8655,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL621111,,1,1,,BAO_0000218,2113.0,
8656,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL622541,,1,1,,BAO_0000218,2107.0,
8657,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL622542,,1,1,,BAO_0000218,2107.0,
8658,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL622543,,1,1,,BAO_0000218,2107.0,
8659,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624412,,1,1,,BAO_0000218,2107.0,
8660,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL624413,,1,1,,BAO_0000218,2107.0,
8661,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624414,,1,1,,BAO_0000218,2107.0,
8662,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL624415,,1,1,,BAO_0000218,2048.0,
8663,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624416,,1,1,,BAO_0000218,2048.0,
8664,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL624417,,1,1,,BAO_0000218,2048.0,
8665,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624418,,1,1,,BAO_0000218,2048.0,
8666,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL624419,,1,1,,BAO_0000218,2048.0,
8667,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624420,,1,1,,BAO_0000218,2048.0,
8668,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),,CHEMBL624421,,1,1,,BAO_0000218,2385.0,
8669,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL624422,,1,1,,BAO_0000218,2385.0,
8670,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL624423,,1,1,,BAO_0000218,2385.0,
8671,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL625123,,1,1,,BAO_0000218,2385.0,
8672,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL625124,,1,1,,BAO_0000218,2385.0,
8673,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL625125,,1,1,,BAO_0000218,2385.0,
8674,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL625126,,1,1,,BAO_0000218,14.0,
8675,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626947,,1,1,,BAO_0000218,14.0,
8676,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL626948,,1,1,,BAO_0000218,14.0,
8677,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626949,,1,1,,BAO_0000218,14.0,
8678,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL626950,,1,1,,BAO_0000218,14.0,
8679,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626951,,1,1,,BAO_0000218,14.0,
8680,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL626952,,1,1,,BAO_0000218,2106.0,
8681,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626953,,1,1,,BAO_0000218,2106.0,
8682,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL626954,,1,1,,BAO_0000218,2106.0,
8683,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626955,,1,1,,BAO_0000218,2106.0,
8684,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL626956,,1,1,,BAO_0000218,2106.0,
8685,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626957,,1,1,,BAO_0000218,2106.0,
8686,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),,CHEMBL626958,,1,1,,BAO_0000218,178.0,
8687,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626959,,1,1,,BAO_0000218,178.0,
8688,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL626960,,1,1,,BAO_0000218,178.0,
8689,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL626961,,1,1,,BAO_0000218,178.0,
8690,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),,CHEMBL627589,,1,1,,BAO_0000218,178.0,
8691,A,In vivo,10090.0,,50594,Intermediate,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),,CHEMBL627590,,1,1,,BAO_0000218,178.0,
8692,A,,10090.0,,50594,Intermediate,Time taken for EC90 was determined when tested in mouse,,CHEMBL627591,,1,1,,BAO_0000218,,
8693,A,,10090.0,,50594,Intermediate,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,CHEMBL627592,,1,1,,BAO_0000218,,
8694,A,In vivo,10090.0,,50594,Intermediate,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,CHEMBL627593,,1,1,,BAO_0000218,,
8695,A,,10090.0,,50594,Intermediate,Half life in mice,,CHEMBL627594,,1,1,,BAO_0000218,,
8696,A,In vivo,10090.0,,50594,Intermediate,Half life period in mouse after 10 mg/Kg dose,,CHEMBL876813,,1,1,,BAO_0000218,,
8697,A,In vivo,10090.0,,50594,Intermediate,Half life period in mouse after 10 mg/kg dose,,CHEMBL627595,,1,1,,BAO_0000218,,
8698,A,In vivo,10090.0,,50594,Intermediate,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,CHEMBL627596,,1,1,,BAO_0000218,,
8699,A,In vivo,10116.0,,50597,Intermediate,Cmax value at 5 mg/kg po was determined in rat,,CHEMBL627597,,1,1,,BAO_0000218,,
8700,A,In vivo,10116.0,,50597,Intermediate,Cmax value evaluated in rat,,CHEMBL627598,,1,1,,BAO_0000218,,
8701,A,In vivo,10116.0,,50597,Intermediate,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,,CHEMBL627599,,1,1,,BAO_0000218,955.0,
8702,A,In vivo,10116.0,,50597,Intermediate,Cmax value after administration of 20 mg/Kg oral dose in rat,,CHEMBL627600,,1,1,,BAO_0000218,,
8703,A,In vivo,10116.0,,50597,Intermediate,Cmax value at 1 mg/kg po in rat,,CHEMBL627601,,1,1,,BAO_0000218,,
8704,A,In vivo,10116.0,,50597,Intermediate,Cmax value at 5 mg/kg po in rat,,CHEMBL627776,,1,1,,BAO_0000218,,
8705,A,In vivo,10116.0,,50597,Intermediate,Cmax value at a dose of 10 mg/kg in male SD rats,,CHEMBL627777,,1,1,,BAO_0000218,,
8706,A,In vivo,10116.0,,50597,Intermediate,Cmax value at a dose of 100 mg/kg in male SD rats,,CHEMBL627778,,1,1,,BAO_0000218,,
8707,A,In vivo,10116.0,,50597,Intermediate,Cmax value at a dose of 50 mg/kg in male SD rats,,CHEMBL627779,,1,1,,BAO_0000218,,
8708,A,In vivo,10116.0,,50597,Intermediate,Cmax value in rats at 10 mg/kg,,CHEMBL876814,,1,1,,BAO_0000218,,
8709,A,In vivo,10116.0,,50597,Intermediate,Cmax value was evaluated in rats at a dose of 20 mg/kg,,CHEMBL627780,,1,1,,BAO_0000218,,
8710,A,In vivo,10116.0,,50597,Intermediate,Cmax value was determined after peroral administration of 20 mg/kg in rat,,CHEMBL627781,,1,1,,BAO_0000218,,
8711,A,In vivo,10116.0,,50597,Intermediate,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,CHEMBL627782,,1,1,,BAO_0000218,,
8712,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,,CHEMBL627783,,1,1,,BAO_0000218,1969.0,
8713,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,,CHEMBL627784,,1,1,,BAO_0000218,1969.0,
8714,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,CHEMBL627785,,1,1,,BAO_0000218,,
8715,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,CHEMBL627786,,1,1,,BAO_0000218,,
8716,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,,CHEMBL627787,,1,1,,BAO_0000218,1969.0,
8717,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,,CHEMBL627788,,1,1,,BAO_0000218,1969.0,
8718,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,,CHEMBL626579,,1,1,,BAO_0000218,1969.0,
8719,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,,CHEMBL626580,,1,1,,BAO_0000218,1969.0,
8720,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,CHEMBL876815,,1,1,,BAO_0000218,,
8721,A,In vivo,10116.0,,50597,Intermediate,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,,CHEMBL626581,,1,1,,BAO_0000218,1969.0,
8722,A,In vivo,10116.0,,50597,Intermediate,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,,CHEMBL626582,,1,1,,BAO_0000218,1969.0,
8723,A,In vivo,10116.0,,50597,Intermediate,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,CHEMBL626583,,1,1,,BAO_0000218,,
8724,A,In vivo,10116.0,,50597,Intermediate,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL626205,,1,1,,BAO_0000218,,
8725,A,In vivo,10116.0,,50597,Intermediate,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL626206,,1,1,,BAO_0000218,,
8726,A,In vivo,10116.0,,50597,Intermediate,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,CHEMBL626207,,1,1,,BAO_0000218,,
8727,A,In vivo,10116.0,,50597,Intermediate,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL623882,,1,1,,BAO_0000218,,
8728,A,In vivo,10116.0,,50597,Intermediate,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,CHEMBL623883,,1,1,,BAO_0000218,,
8729,A,In vivo,10116.0,,50597,Intermediate,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,CHEMBL623884,,1,1,,BAO_0000218,,
8730,A,In vivo,10116.0,,50597,Intermediate,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,CHEMBL623885,,1,1,,BAO_0000218,1969.0,
8731,A,In vivo,10116.0,,50597,Intermediate,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,,CHEMBL623886,,1,1,,BAO_0000218,1969.0,
8732,A,In vivo,10116.0,,50597,Intermediate,Maximal concentration in rat was determined,,CHEMBL623887,,1,1,,BAO_0000218,,
8733,A,In vivo,10116.0,,50597,Intermediate,Maximal concentration after i.v. administration,,CHEMBL623888,,1,1,,BAO_0000218,,
8734,A,In vivo,10116.0,,50597,Intermediate,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,,CHEMBL623889,,1,1,,BAO_0000218,1969.0,
8735,A,In vivo,10116.0,,50597,Intermediate,Maximal plasma concentration in rat after oral administration at 50 mg/kg,,CHEMBL623890,,1,1,,BAO_0000218,1969.0,
8736,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat plasma after oral dose (50 mg/Kg),,CHEMBL623891,,1,1,,BAO_0000218,1969.0,
8737,A,In vivo,10116.0,,50597,Intermediate,Maximal plasma concentration was determined.,,CHEMBL623892,,1,1,,BAO_0000218,1969.0,
8738,A,In vivo,10116.0,,50597,Intermediate,Maximal plasma drug concentration was determined,,CHEMBL623893,,1,1,,BAO_0000218,1969.0,
8739,A,In vivo,10116.0,,50597,Intermediate,Maximal concentration in rats after peroral administration,,CHEMBL877616,,1,1,,BAO_0000218,,
8740,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in rat after 2 mg/kg peroral administration,,CHEMBL623894,,1,1,,BAO_0000218,,
8741,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in rat plasma after 5 mg/kg oral gavage,,CHEMBL623895,,1,1,,BAO_0000218,1969.0,
8742,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration of compound in rat was evaluated.,,CHEMBL623896,,1,1,,BAO_0000218,,
8743,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,CHEMBL623897,,1,1,,BAO_0000218,,
8744,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,CHEMBL623898,,1,1,,BAO_0000218,,
8745,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,CHEMBL623899,,1,1,,BAO_0000218,,
8746,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,CHEMBL623900,,1,1,,BAO_0000218,,
8747,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,CHEMBL623901,,1,1,,BAO_0000218,,
8748,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration was evaluated in rats,,CHEMBL623902,,1,1,,BAO_0000218,,
8749,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,,CHEMBL623903,,1,1,,BAO_0000218,1359.0,
8750,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,,CHEMBL623904,,1,1,,BAO_0000218,1969.0,
8751,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,CHEMBL877617,,1,1,,BAO_0000218,1969.0,
8752,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,CHEMBL623905,,1,1,,BAO_0000218,,
8753,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,CHEMBL623906,,1,1,,BAO_0000218,,
8754,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,CHEMBL623907,,1,1,,BAO_0000218,1969.0,
8755,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL623908,,1,1,,BAO_0000218,,
8756,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL623909,,1,1,,BAO_0000218,,
8757,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL623910,,1,1,,BAO_0000218,,
8758,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL623911,,1,1,,BAO_0000218,,
8759,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL623912,,1,1,,BAO_0000218,,
8760,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL624616,,1,1,,BAO_0000218,,
8761,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL624617,,1,1,,BAO_0000218,,
8762,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL624618,,1,1,,BAO_0000218,,
8763,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL624619,,1,1,,BAO_0000218,,
8764,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL624794,,1,1,,BAO_0000218,,
8765,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL624795,,1,1,,BAO_0000218,,
8766,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL623921,,1,1,,BAO_0000218,,
8767,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL623922,,1,1,,BAO_0000218,,
8768,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL623923,,1,1,,BAO_0000218,,
8769,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL623924,,1,1,,BAO_0000218,,
8770,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL623925,,1,1,,BAO_0000218,,
8771,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL623926,,1,1,,BAO_0000218,,
8772,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL623927,,1,1,,BAO_0000218,,
8773,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL623928,,1,1,,BAO_0000218,,
8774,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL623929,,1,1,,BAO_0000218,,
8775,A,,10116.0,,50597,Intermediate,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL623930,,1,1,,BAO_0000218,,
8776,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL623931,,1,1,,BAO_0000218,955.0,
8777,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL622165,,1,1,,BAO_0000218,955.0,
8778,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL621249,,1,1,,BAO_0000218,955.0,
8779,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL621250,,1,1,,BAO_0000218,955.0,
8780,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL621448,,1,1,,BAO_0000218,955.0,
8781,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL621449,,1,1,,BAO_0000218,955.0,
8782,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL621450,,1,1,,BAO_0000218,955.0,
8783,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL621451,,1,1,,BAO_0000218,955.0,
8784,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL621452,,1,1,,BAO_0000218,955.0,
8785,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL621453,,1,1,,BAO_0000218,955.0,
8786,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL621454,,1,1,,BAO_0000218,955.0,
8787,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL621455,,1,1,,BAO_0000218,955.0,
8788,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL621456,,1,1,,BAO_0000218,955.0,
8789,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL625145,,1,1,,BAO_0000218,955.0,
8790,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL875847,,1,1,,BAO_0000218,955.0,
8791,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL625146,,1,1,,BAO_0000218,955.0,
8792,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL625147,,1,1,,BAO_0000218,955.0,
8793,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL625148,,1,1,,BAO_0000218,955.0,
8794,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL625149,,1,1,,BAO_0000218,955.0,
8795,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL625150,,1,1,,BAO_0000218,955.0,
8796,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL625151,,1,1,,BAO_0000218,955.0,
8797,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL625152,,1,1,,BAO_0000218,955.0,
8798,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL625153,,1,1,,BAO_0000218,955.0,
8799,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL625154,,1,1,,BAO_0000218,955.0,
8800,A,,10116.0,,50597,Intermediate,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL625155,,1,1,,BAO_0000218,955.0,
8801,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL625156,,1,1,,BAO_0000218,,
8802,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624354,,1,1,,BAO_0000218,,
8803,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624355,,1,1,,BAO_0000218,10000000.0,
8804,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624356,,1,1,,BAO_0000218,10000000.0,
8805,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624357,,1,1,,BAO_0000218,10000000.0,
8806,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624358,,1,1,,BAO_0000218,10000000.0,
8807,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624359,,1,1,,BAO_0000218,2435.0,
8808,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624360,,1,1,,BAO_0000218,2435.0,
8809,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL624361,,1,1,,BAO_0000218,2435.0,
8810,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624362,,1,1,,BAO_0000218,2435.0,
8811,A,,10116.0,,50597,Intermediate,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624363,,1,1,,BAO_0000218,2435.0,
8812,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624364,,1,1,,BAO_0000218,178.0,
8813,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624365,,1,1,,BAO_0000218,178.0,
8814,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624366,,1,1,,BAO_0000218,178.0,
8815,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624367,,1,1,,BAO_0000218,178.0,
8816,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624368,,1,1,,BAO_0000218,955.0,
8817,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL624369,,1,1,,BAO_0000218,955.0,
8818,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL624370,,1,1,,BAO_0000218,955.0,
8819,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625069,,1,1,,BAO_0000218,955.0,
8820,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625070,,1,1,,BAO_0000218,955.0,
8821,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626051,,1,1,,BAO_0000218,948.0,
8822,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626052,,1,1,,BAO_0000218,948.0,
8823,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL626053,,1,1,,BAO_0000218,948.0,
8824,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626054,,1,1,,BAO_0000218,948.0,
8825,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626055,,1,1,,BAO_0000218,948.0,
8826,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626056,,1,1,,BAO_0000218,2113.0,
8827,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626057,,1,1,,BAO_0000218,2113.0,
8828,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625193,,1,1,,BAO_0000218,2113.0,
8829,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625194,,1,1,,BAO_0000218,2113.0,
8830,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625195,,1,1,,BAO_0000218,2107.0,
8831,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625196,,1,1,,BAO_0000218,2107.0,
8832,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL625197,,1,1,,BAO_0000218,2107.0,
8833,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625198,,1,1,,BAO_0000218,2107.0,
8834,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL627929,,1,1,,BAO_0000218,2107.0,
8835,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL627074,,1,1,,BAO_0000218,2048.0,
8836,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL627075,,1,1,,BAO_0000218,2048.0,
8837,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL627076,,1,1,,BAO_0000218,2048.0,
8838,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL627077,,1,1,,BAO_0000218,2048.0,
8839,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL627078,,1,1,,BAO_0000218,2048.0,
8840,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL627079,,1,1,,BAO_0000218,2385.0,
8841,A,In vivo,10090.0,,50594,Intermediate,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,CHEMBL873824,,1,1,,BAO_0000218,,
8842,A,In vivo,10090.0,,50594,Intermediate,Half life in mouse plasma was determined at dose 25 mg/kg,,CHEMBL627080,,1,1,,BAO_0000218,1969.0,
8843,A,,10090.0,,50594,Intermediate,Half life was determined,,CHEMBL627081,,1,1,,BAO_0000218,,
8844,A,In vivo,10090.0,,50594,Intermediate,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,CHEMBL627082,,1,1,,BAO_0000218,,
8845,A,In vivo,10090.0,,50594,Intermediate,Half-life in male mice after 1 mg/kg intravenous dose,,CHEMBL627083,,1,1,,BAO_0000218,,
8847,A,,10090.0,,50594,Intermediate,Half life in mice plasma,,CHEMBL627085,,1,1,,BAO_0000218,1969.0,
8848,A,,10090.0,,50594,Intermediate,Half life in mouse,,CHEMBL627086,,1,1,,BAO_0000218,,
8849,A,In vivo,10090.0,,50594,Intermediate,Half life in mouse plasma at dose 25 mg/kg,,CHEMBL627087,,1,1,,BAO_0000218,1969.0,
8850,A,In vivo,10090.0,,50594,Intermediate,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,CHEMBL627088,,1,1,,BAO_0000218,,
8851,A,In vivo,10090.0,,50594,Intermediate,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,CHEMBL627089,,1,1,,BAO_0000218,,
8852,A,In vivo,10090.0,,50594,Intermediate,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,CHEMBL627090,,1,1,,BAO_0000218,,
8853,A,In vivo,10090.0,,50594,Intermediate,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,CHEMBL627091,,1,1,,BAO_0000218,,
8854,A,In vivo,10090.0,,50594,Intermediate,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,CHEMBL627092,,1,1,,BAO_0000218,,
8855,A,In vivo,10090.0,,50594,Intermediate,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,CHEMBL876785,,1,1,,BAO_0000218,,
8856,A,In vivo,10090.0,,50594,Intermediate,Half-life by iv administration in mouse,,CHEMBL627093,,1,1,,BAO_0000218,,
8857,A,In vivo,10090.0,,50594,Intermediate,Half-life by oral administration in mouse,,CHEMBL627094,,1,1,,BAO_0000218,,
8858,A,,10090.0,,50594,Intermediate,Half-life in mice,,CHEMBL627095,,1,1,,BAO_0000218,,
8859,A,,10090.0,,50594,Intermediate,Half-life using mouse brain homogenate,,CHEMBL627096,,1,1,,BAO_0000218,955.0,
8860,A,,10090.0,,50594,Intermediate,Half-life was measured in mice,,CHEMBL627097,,1,1,,BAO_0000218,,
8861,A,In vivo,10090.0,,50594,Intermediate,Half-life was measured in mouse after an iv dose of 1 mg/kg,,CHEMBL627098,,1,1,,BAO_0000218,,
8862,A,,10090.0,,50594,Intermediate,Half-life period was determined in mouse blood,,CHEMBL627099,,1,1,,BAO_0000218,178.0,
8863,A,,10090.0,,50594,Intermediate,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",,CHEMBL627100,,1,1,,BAO_0000218,955.0,
8864,A,,10090.0,,50594,Intermediate,Plasma half life in mouse,,CHEMBL627101,,1,1,,BAO_0000218,1969.0,
8865,A,,10090.0,,50594,Intermediate,Stability of the peptide in the presence of mouse serum,,CHEMBL627102,,1,1,,BAO_0000218,,
8866,A,,10090.0,,50594,Intermediate,Terminal half life of compound was determined in mouse,,CHEMBL627103,,1,1,,BAO_0000218,,
8867,A,In vivo,10090.0,,50594,Intermediate,Terminal half life was evaluated in mice after intravenous administration,,CHEMBL627104,,1,1,,BAO_0000218,,
8868,A,In vivo,10090.0,,50594,Intermediate,Terminal half life was evaluated in mice after oral administration,,CHEMBL627105,,1,1,,BAO_0000218,,
8869,A,,10090.0,,50594,Intermediate,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,CHEMBL876786,,1,1,,BAO_0000218,,
8870,A,,10090.0,,50594,Intermediate,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,CHEMBL873825,,1,1,,BAO_0000218,,
8871,A,,10090.0,,50594,Intermediate,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,CHEMBL627106,,1,1,,BAO_0000218,,
8872,A,In vivo,10090.0,,50594,Intermediate,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,CHEMBL626336,,1,1,,BAO_0000218,,
8873,A,In vivo,10090.0,,50594,Intermediate,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,CHEMBL877462,,1,1,,BAO_0000218,,
8874,A,In vivo,10090.0,,50594,Intermediate,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,CHEMBL626337,,1,1,,BAO_0000218,,
8875,A,,10090.0,,50594,Intermediate,Half life after intraperitoneal administration of 100 mg/kg in mice,,CHEMBL626338,,1,1,,BAO_0000218,,
8876,A,In vivo,10090.0,,50594,Intermediate,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,CHEMBL626339,,1,1,,BAO_0000218,,
8877,A,In vivo,10090.0,,50594,Intermediate,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,CHEMBL626340,,1,1,,BAO_0000218,,
8878,A,In vivo,10090.0,,50594,Intermediate,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,CHEMBL625377,,1,1,,BAO_0000218,,
8879,A,In vivo,10090.0,,50594,Intermediate,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,CHEMBL625378,,1,1,,BAO_0000218,,
8880,A,In vivo,10090.0,,50594,Intermediate,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,CHEMBL625379,,1,1,,BAO_0000218,,
8881,A,,9823.0,,22224,Autocuration,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,CHEMBL625380,,0,1,,BAO_0000251,,
8882,A,,9823.0,,22224,Autocuration,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,CHEMBL625381,,0,1,,BAO_0000251,,
8883,A,,9823.0,,22224,Autocuration,Stability to porcine renal DHP-I,,CHEMBL625382,,0,1,,BAO_0000019,,
8884,A,In vivo,9823.0,,22224,Autocuration,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,CHEMBL873828,,0,1,,BAO_0000218,,
8885,A,In vivo,9823.0,,22224,Autocuration,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,CHEMBL625383,,0,1,,BAO_0000218,,
8886,A,,9823.0,,22224,Autocuration,Half-life of the parent prodrug in porcine esterase solution,,CHEMBL625384,,0,1,,BAO_0000019,,
8887,A,,9823.0,,22224,Autocuration,"First order rate constant, k was determined in in pig liver Esterase",,CHEMBL625385,,0,1,,BAO_0000019,,
8888,A,,9823.0,,22224,Autocuration,Half life of the in pig liver Esterase,,CHEMBL625386,,0,1,,BAO_0000221,2107.0,
8889,A,,9823.0,,22224,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,,CHEMBL623571,,0,1,,BAO_0000221,2107.0,
8890,A,,9823.0,,22224,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,,CHEMBL623572,,0,1,,BAO_0000221,2107.0,
8891,A,,9823.0,,22224,Autocuration,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,,CHEMBL623573,,0,1,,BAO_0000221,2107.0,
8892,A,,9823.0,,22224,Autocuration,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,,CHEMBL623574,,0,1,,BAO_0000221,2107.0,
8893,A,,9823.0,,22224,Autocuration,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,,CHEMBL623575,,0,1,,BAO_0000221,2107.0,
8894,A,,9823.0,,22224,Autocuration,Half-life in the presence of pig liver esterase(PLE) was evaluated.,,CHEMBL623749,,0,1,,BAO_0000221,2107.0,
8895,A,,9823.0,,22224,Autocuration,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,,CHEMBL623750,,0,1,,BAO_0000221,2107.0,
8896,A,In vitro,9823.0,,22224,Autocuration,Half-life in vitro in pig liver,,CHEMBL623751,,0,1,,BAO_0000221,2107.0,
8897,A,,9823.0,,22224,Autocuration,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,,CHEMBL623752,,0,1,,BAO_0000221,2107.0,
8898,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,CHEMBL623753,,1,1,,BAO_0000218,1969.0,
8899,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,CHEMBL623754,,1,1,,BAO_0000218,1969.0,
8900,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in rat plasma was determined,,CHEMBL623755,,1,1,,BAO_0000218,1969.0,
8901,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in rats,,CHEMBL623756,,1,1,,BAO_0000218,,
8902,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in rats at 1-2 hours,,CHEMBL623757,,1,1,,BAO_0000218,,
8903,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,CHEMBL623758,,1,1,,BAO_0000218,,
8904,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,,CHEMBL623759,,1,1,,BAO_0000218,955.0,
8905,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration at the dose of 2 mg/kg in rat,,CHEMBL623760,,1,1,,BAO_0000218,,
8906,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration was evaluated in rats,,CHEMBL623761,,1,1,,BAO_0000218,,
8907,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,,CHEMBL623762,,1,1,,BAO_0000218,1969.0,
8908,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,,CHEMBL877594,,1,1,,BAO_0000218,1969.0,
8909,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,,CHEMBL623763,,1,1,,BAO_0000218,1969.0,
8910,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,,CHEMBL623764,,1,1,,BAO_0000218,1969.0,
8911,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,,CHEMBL623765,,1,1,,BAO_0000218,1969.0,
8912,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,,CHEMBL623766,,1,1,,BAO_0000218,178.0,
8913,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,,CHEMBL623767,,1,1,,BAO_0000218,178.0,
8914,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,,CHEMBL623768,,1,1,,BAO_0000218,178.0,
8915,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,,CHEMBL623769,,1,1,,BAO_0000218,1969.0,
8916,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,,CHEMBL623770,,1,1,,BAO_0000218,1969.0,
8917,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,,CHEMBL623771,,1,1,,BAO_0000218,1969.0,
8918,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,,CHEMBL623772,,1,1,,BAO_0000218,1969.0,
8919,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,,CHEMBL623773,,1,1,,BAO_0000218,1969.0,
8920,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,,CHEMBL623774,,1,1,,BAO_0000218,1969.0,
8921,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,,CHEMBL623775,,1,1,,BAO_0000218,1969.0,
8922,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat (PO dose),,CHEMBL623776,,1,1,,BAO_0000218,,
8923,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL622191,,1,1,,BAO_0000218,1969.0,
8924,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL622192,,1,1,,BAO_0000218,1969.0,
8925,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration determined in rat,,CHEMBL622193,,1,1,,BAO_0000218,1969.0,
8926,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,CHEMBL622194,,1,1,,BAO_0000218,1969.0,
8927,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,CHEMBL622195,,1,1,,BAO_0000218,1969.0,
8928,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration in rat,,CHEMBL622196,,1,1,,BAO_0000218,1969.0,
8929,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,,CHEMBL622197,,1,1,,BAO_0000218,1969.0,
8930,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,,CHEMBL622198,,1,1,,BAO_0000218,1969.0,
8931,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,,CHEMBL622199,,1,1,,BAO_0000218,1969.0,
8932,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration of compound was measured in rat,,CHEMBL622200,,1,1,,BAO_0000218,1969.0,
8933,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration after 20 mg/kg oral administration in rat,,CHEMBL622201,,1,1,,BAO_0000218,1969.0,
8934,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration after oral administration to rats,,CHEMBL623990,,1,1,,BAO_0000218,1969.0,
8935,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL623991,,1,1,,BAO_0000218,1969.0,
8936,A,In vivo,10116.0,,50597,Intermediate,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",,CHEMBL623992,,1,1,,BAO_0000218,1969.0,
8937,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL623993,,1,1,,BAO_0000218,1969.0,
8938,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,,CHEMBL623994,,1,1,,BAO_0000218,1969.0,
8939,F,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,,CHEMBL623995,,1,1,,BAO_0000218,1969.0,
8940,F,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL623996,,1,1,,BAO_0000218,1969.0,
8941,F,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,,CHEMBL623997,,1,1,,BAO_0000218,1969.0,
8942,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration dosed orally in rats,,CHEMBL623998,,1,1,,BAO_0000218,1969.0,
8943,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration dosed orally in rats after 6 hours,,CHEMBL623999,,1,1,,BAO_0000218,1969.0,
8944,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,,CHEMBL624000,,1,1,,BAO_0000218,1969.0,
8945,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,CHEMBL624001,,1,1,,BAO_0000218,1969.0,
8946,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration in rat after po administration,,CHEMBL624002,,1,1,,BAO_0000218,1969.0,
8947,A,In vivo,10116.0,,50597,Intermediate,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",,CHEMBL624003,,1,1,,BAO_0000218,1969.0,
8948,A,In vivo,10116.0,,50597,Intermediate,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",,CHEMBL624004,,1,1,,BAO_0000218,1969.0,
8949,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL624005,,1,1,,BAO_0000218,948.0,
8950,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL624006,,1,1,,BAO_0000218,948.0,
8951,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL624007,,1,1,,BAO_0000218,948.0,
8952,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL624008,,1,1,,BAO_0000218,948.0,
8953,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL624009,,1,1,,BAO_0000218,948.0,
8954,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL874387,,1,1,,BAO_0000218,948.0,
8955,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL624010,,1,1,,BAO_0000218,948.0,
8956,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL624011,,1,1,,BAO_0000218,948.0,
8957,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL624012,,1,1,,BAO_0000218,948.0,
8958,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL624013,,1,1,,BAO_0000218,948.0,
8959,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL624736,,1,1,,BAO_0000218,948.0,
8960,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL624737,,1,1,,BAO_0000218,948.0,
8961,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL624738,,1,1,,BAO_0000218,948.0,
8962,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL624739,,1,1,,BAO_0000218,948.0,
8963,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL624740,,1,1,,BAO_0000218,948.0,
8964,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL624896,,1,1,,BAO_0000218,948.0,
8965,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL624897,,1,1,,BAO_0000218,948.0,
8966,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL624108,,1,1,,BAO_0000218,948.0,
8967,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL624109,,1,1,,BAO_0000218,948.0,
8968,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL624110,,1,1,,BAO_0000218,948.0,
8969,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL624111,,1,1,,BAO_0000218,948.0,
8970,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL624112,,1,1,,BAO_0000218,948.0,
8971,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL624113,,1,1,,BAO_0000218,948.0,
8972,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL619709,,1,1,,BAO_0000218,948.0,
8973,A,,10116.0,,50597,Intermediate,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL619710,,1,1,,BAO_0000218,948.0,
8974,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL619711,,1,1,,BAO_0000218,2113.0,
8975,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL619712,,1,1,,BAO_0000218,2113.0,
8976,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL619713,,1,1,,BAO_0000218,2113.0,
8977,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL619714,,1,1,,BAO_0000218,2113.0,
8978,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL619715,,1,1,,BAO_0000218,2113.0,
8979,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL619716,,1,1,,BAO_0000218,2113.0,
8980,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL619717,,1,1,,BAO_0000218,2113.0,
8981,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL619718,,1,1,,BAO_0000218,2113.0,
8982,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL619719,,1,1,,BAO_0000218,2113.0,
8983,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL875329,,1,1,,BAO_0000218,2113.0,
8984,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL619720,,1,1,,BAO_0000218,2113.0,
8985,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL619721,,1,1,,BAO_0000218,2113.0,
8986,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL619722,,1,1,,BAO_0000218,2113.0,
8987,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL619723,,1,1,,BAO_0000218,2113.0,
8988,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL619724,,1,1,,BAO_0000218,2113.0,
8989,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL619725,,1,1,,BAO_0000218,2113.0,
8990,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL619726,,1,1,,BAO_0000218,2113.0,
8991,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL619727,,1,1,,BAO_0000218,2113.0,
8992,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL619728,,1,1,,BAO_0000218,2113.0,
8993,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL619729,,1,1,,BAO_0000218,2113.0,
8994,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL619730,,1,1,,BAO_0000218,2385.0,
8995,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL619731,,1,1,,BAO_0000218,2385.0,
8996,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL619732,,1,1,,BAO_0000218,2385.0,
8997,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL619733,,1,1,,BAO_0000218,2385.0,
8998,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL619734,,1,1,,BAO_0000218,2385.0,
8999,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL619735,,1,1,,BAO_0000218,14.0,
9000,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL875330,,1,1,,BAO_0000218,14.0,
9001,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL628465,,1,1,,BAO_0000218,14.0,
9002,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628466,,1,1,,BAO_0000218,14.0,
9003,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628467,,1,1,,BAO_0000218,14.0,
9004,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628468,,1,1,,BAO_0000218,2106.0,
9005,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628469,,1,1,,BAO_0000218,2106.0,
9006,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL628470,,1,1,,BAO_0000218,2106.0,
9007,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628471,,1,1,,BAO_0000218,2106.0,
9008,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL628472,,1,1,,BAO_0000218,2106.0,
9009,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625191,,1,1,,BAO_0000218,2046.0,
9010,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL625192,,1,1,,BAO_0000218,2046.0,
9011,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,CHEMBL875337,,1,1,,BAO_0000218,2046.0,
9012,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626341,,1,1,,BAO_0000218,2046.0,
9013,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL626342,,1,1,,BAO_0000218,2046.0,
9014,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,CHEMBL621943,,1,1,,BAO_0000218,2107.0,
9015,A,,10116.0,,50597,Intermediate,Half life in rats,,CHEMBL621944,,1,1,,BAO_0000218,,
9016,A,,10116.0,,50597,Intermediate,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,CHEMBL621945,,1,1,,BAO_0000218,,
9017,A,,10116.0,,50597,Intermediate,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,CHEMBL621946,,1,1,,BAO_0000218,,
9018,A,,10116.0,,50597,Intermediate,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,CHEMBL621947,,1,1,,BAO_0000218,,
9019,A,,10116.0,,50597,Intermediate,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,CHEMBL621948,,1,1,,BAO_0000218,,
9020,A,,10116.0,,50597,Intermediate,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,CHEMBL621949,,1,1,,BAO_0000218,,
9021,A,,10116.0,,50597,Intermediate,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,CHEMBL621950,,1,1,,BAO_0000218,,
9022,A,,10116.0,,50597,Intermediate,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,CHEMBL621951,,1,1,,BAO_0000218,,
9023,A,In vivo,10116.0,,50597,Intermediate,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,,CHEMBL621952,,1,1,,BAO_0000218,178.0,
9024,A,,10116.0,,50597,Intermediate,Stability (%) in rat liver microsomes,,CHEMBL621953,,1,1,,BAO_0000218,2107.0,
9025,A,,10116.0,,50597,Intermediate,Area under curve was calculated after intravenous administration,,CHEMBL621954,,1,1,,BAO_0000218,,
9026,A,,10116.0,,50597,Intermediate,Area under the curve was calculated after iv administration in rat,,CHEMBL621955,,1,1,,BAO_0000218,,
9027,A,,10116.0,,50597,Intermediate,Area under the curve was calculated in rat after peroral administration,,CHEMBL621956,,1,1,,BAO_0000218,,
9028,A,,10116.0,,50597,Intermediate,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,CHEMBL621957,,1,1,,BAO_0000218,,
9029,A,,10116.0,,50597,Intermediate,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,CHEMBL621958,,1,1,,BAO_0000218,,
9030,A,,10116.0,,50597,Intermediate,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,CHEMBL621959,,1,1,,BAO_0000218,,
9031,A,,10116.0,,50597,Intermediate,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,CHEMBL621960,,1,1,,BAO_0000218,,
9032,A,,10116.0,,50597,Intermediate,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,CHEMBL621961,,1,1,,BAO_0000218,,
9033,A,,10116.0,,50597,Intermediate,p value of the compound,,CHEMBL621962,,1,1,,BAO_0000218,,
9034,F,,10116.0,,50597,Intermediate,p value of the compound,,CHEMBL876787,,1,1,,BAO_0000218,,
9035,A,,10116.0,,50597,Intermediate,p value of the compound,,CHEMBL621963,,1,1,,BAO_0000218,,
9036,A,,10116.0,,50597,Intermediate,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL622637,,1,1,,BAO_0000218,945.0,
9037,A,,10116.0,,50597,Intermediate,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL622638,,1,1,,BAO_0000218,945.0,
9038,A,,10116.0,,50597,Intermediate,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL626561,,1,1,,BAO_0000218,945.0,
9039,F,,9986.0,,22224,Autocuration,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,CHEMBL626562,,0,1,,BAO_0000019,,
9040,A,,9986.0,,22224,Autocuration,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,CHEMBL626563,,0,1,,BAO_0000218,,
9041,A,,9986.0,,22224,Autocuration,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,CHEMBL626564,,0,1,,BAO_0000218,,
9042,A,In vivo,9986.0,,22224,Autocuration,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,CHEMBL626565,,0,1,,BAO_0000218,,
9043,A,In vivo,9986.0,,22224,Autocuration,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,CHEMBL626566,,0,1,,BAO_0000218,,
9044,A,In vivo,9986.0,,22224,Autocuration,Clearance rate in rabbits,,CHEMBL626567,,0,1,,BAO_0000218,,
9045,A,In vivo,9986.0,,22224,Autocuration,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,CHEMBL626568,,0,1,,BAO_0000218,,
9046,A,In vivo,9986.0,,22224,Autocuration,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,CHEMBL626569,,0,1,,BAO_0000218,,
9047,A,In vivo,9986.0,,22224,Autocuration,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,CHEMBL626570,,0,1,,BAO_0000218,,
9048,A,In vivo,9986.0,,22224,Autocuration,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,CHEMBL626571,,0,1,,BAO_0000218,,
9049,A,In vivo,9986.0,,22224,Autocuration,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,CHEMBL626572,,0,1,,BAO_0000218,,
9050,A,In vivo,9986.0,,22224,Autocuration,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,CHEMBL626573,,0,1,,BAO_0000218,1969.0,
9051,A,,9986.0,,22224,Autocuration,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,,CHEMBL626574,,0,1,,BAO_0000251,2107.0,
9052,A,,9986.0,,22224,Autocuration,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,,CHEMBL626575,,0,1,,BAO_0000251,2107.0,
9053,A,,9986.0,,22224,Autocuration,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,CHEMBL626576,,0,1,,BAO_0000218,,
9054,A,,9986.0,,22224,Autocuration,Dose at which bioavailability of perorally administered compound was tested in rabbit,,CHEMBL626577,,0,1,,BAO_0000218,,
9055,A,In vivo,9986.0,,22224,Autocuration,The compound was tested for its bioavailability in rabbit (by oral dosage).,,CHEMBL626578,,0,1,,BAO_0000218,,
9056,A,In vivo,9986.0,,22224,Autocuration,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,CHEMBL625263,,0,1,,BAO_0000218,,
9057,A,In vivo,9986.0,,22224,Autocuration,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,CHEMBL625264,,0,1,,BAO_0000218,,
9058,A,In vivo,9986.0,,22224,Autocuration,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,CHEMBL625265,,0,1,,BAO_0000218,,
9059,A,,9986.0,,22224,Autocuration,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,CHEMBL625266,,0,1,,BAO_0000251,,
9060,A,,9986.0,,22224,Autocuration,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,CHEMBL876796,,0,1,,BAO_0000251,,
9061,A,In vivo,9986.0,,22224,Autocuration,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,CHEMBL625267,,0,1,,BAO_0000218,,
9062,A,In vivo,9986.0,,22224,Autocuration,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,CHEMBL625268,,0,1,,BAO_0000218,1969.0,
9063,A,In vivo,9986.0,,22224,Autocuration,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,CHEMBL625269,,0,1,,BAO_0000218,1969.0,
9064,A,In vivo,9986.0,,22224,Autocuration,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,CHEMBL624689,,0,1,,BAO_0000218,1969.0,
9065,A,In vivo,9986.0,,22224,Autocuration,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,CHEMBL624690,,0,1,,BAO_0000218,,
9066,A,,9986.0,,22224,Autocuration,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),,CHEMBL624691,,0,1,,BAO_0000218,1088.0,
9067,A,,9986.0,,22224,Autocuration,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),,CHEMBL624692,,0,1,,BAO_0000218,1088.0,
9068,A,In vivo,9986.0,,22224,Autocuration,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,CHEMBL624693,,0,1,,BAO_0000218,,
9069,A,In vivo,9986.0,,22224,Autocuration,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,CHEMBL624694,,0,1,,BAO_0000218,,
9070,A,In vitro,9986.0,,22224,Autocuration,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,CHEMBL877596,,0,1,,BAO_0000221,,
9071,A,,9986.0,,22224,Autocuration,Time within which only 10% of the drug was degraded,,CHEMBL624695,,0,1,,BAO_0000019,,
9072,A,,9986.0,,22224,Autocuration,Half life period in rabbit liver homogenate,,CHEMBL624696,,0,1,,BAO_0000221,2107.0,
9073,A,,9986.0,,22224,Autocuration,Half life value in rabbits,,CHEMBL624697,,0,1,,BAO_0000019,,
9074,A,In vivo,9986.0,,22224,Autocuration,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,CHEMBL624698,,0,1,,BAO_0000218,178.0,
9075,A,In vivo,9986.0,,22224,Autocuration,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,CHEMBL624699,,0,1,,BAO_0000218,178.0,
9076,A,In vivo,9986.0,,22224,Autocuration,Half-life period in rabbits following intravenous administration at 2 mg/kg,,CHEMBL624700,,0,1,,BAO_0000218,,
9077,A,,10116.0,,50597,Intermediate,AUC 0-8 hr value in rats at 10 mg/kg,,CHEMBL622903,,1,1,,BAO_0000218,1969.0,
9078,A,,10116.0,,50597,Intermediate,AUC after administration at 2000 mg/kg/day in rats,,CHEMBL622904,,1,1,,BAO_0000218,1969.0,
9079,A,,10116.0,,50597,Intermediate,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,,CHEMBL622905,,1,1,,BAO_0000218,1969.0,
9080,A,,10116.0,,50597,Intermediate,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,CHEMBL622906,,1,1,,BAO_0000218,1969.0,
9081,A,,10116.0,,50597,Intermediate,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,CHEMBL622907,,1,1,,BAO_0000218,1969.0,
9082,A,,10116.0,,50597,Intermediate,AUC in rat after oral administration at 10.5 mg/kg dose,,CHEMBL622908,,1,1,,BAO_0000218,1969.0,
9083,A,,10116.0,,50597,Intermediate,AUC in rat after oral administration at 11.2 mg/kg dose,,CHEMBL622909,,1,1,,BAO_0000218,1969.0,
9084,A,,10116.0,,50597,Intermediate,AUC in rat after oral administration at 9.7 mg/kg dose,,CHEMBL622910,,1,1,,BAO_0000218,1969.0,
9085,A,,10116.0,,50597,Intermediate,AUC in rat brain after oral administration at 10 mg/kg,,CHEMBL622911,,1,1,,BAO_0000218,955.0,
9086,A,,10116.0,,50597,Intermediate,AUC in rat p.o.,,CHEMBL622912,,1,1,,BAO_0000218,1969.0,
9087,A,,10116.0,,50597,Intermediate,AUC in rat p.o. at 20 mg/kg concentration,,CHEMBL622913,,1,1,,BAO_0000218,1969.0,
9088,A,,10116.0,,50597,Intermediate,AUC in rat plasma after oral administration at 10 mg/kg,,CHEMBL622914,,1,1,,BAO_0000218,1969.0,
9089,A,,10116.0,,50597,Intermediate,AUC in rats,,CHEMBL622915,,1,1,,BAO_0000218,1969.0,
9090,A,,10116.0,,50597,Intermediate,AUC value after IV dose at a dose of 5 mg/kg in rats.,,CHEMBL622916,,1,1,,BAO_0000218,1969.0,
9091,A,,10116.0,,50597,Intermediate,AUC value after oral dose at a dose of 10 mg/kg in rats.,,CHEMBL622917,,1,1,,BAO_0000218,1969.0,
9092,A,In vivo,10116.0,,50597,Intermediate,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,CHEMBL622918,,1,1,,BAO_0000218,1969.0,
9093,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,,CHEMBL622919,,1,1,,BAO_0000218,1969.0,
9094,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration was evaluated in rat,,CHEMBL622920,,1,1,,BAO_0000218,1969.0,
9095,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,CHEMBL622921,,1,1,,BAO_0000218,1969.0,
9096,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,CHEMBL622922,,1,1,,BAO_0000218,1969.0,
9097,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,CHEMBL622923,,1,1,,BAO_0000218,1969.0,
9098,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,CHEMBL877604,,1,1,,BAO_0000218,1969.0,
9099,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,,CHEMBL622924,,1,1,,BAO_0000218,1969.0,
9100,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,,CHEMBL622925,,1,1,,BAO_0000218,1969.0,
9101,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,,CHEMBL622926,,1,1,,BAO_0000218,1969.0,
9102,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,,CHEMBL623625,,1,1,,BAO_0000218,1969.0,
9103,A,In vivo,10116.0,,50597,Expert,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL623626,,1,1,,BAO_0000218,1969.0,
9104,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma drug concentration was determined,,CHEMBL623627,,1,1,,BAO_0000218,1969.0,
9105,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,CHEMBL623628,,1,1,,BAO_0000218,,
9106,A,In vivo,10116.0,,50597,Intermediate,Mean peak plasma concentration was observed after intravenous administration in rat,,CHEMBL623629,,1,1,,BAO_0000218,1969.0,
9107,A,In vivo,10116.0,,50597,Intermediate,Mean peak plasma concentration was observed after oral administration in rat,,CHEMBL623630,,1,1,,BAO_0000218,1969.0,
9108,A,In vivo,10116.0,,50597,Intermediate,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,CHEMBL623804,,1,1,,BAO_0000218,,
9109,A,In vivo,10116.0,,50597,Intermediate,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,CHEMBL623805,,1,1,,BAO_0000218,,
9110,A,In vivo,10116.0,,50597,Intermediate,Peak oral plasma concentration was determined in rats by oral administration,,CHEMBL623806,,1,1,,BAO_0000218,1969.0,
9111,A,In vivo,10116.0,,50597,Intermediate,Peak plasma concentration (Cmax) was determined,,CHEMBL623807,,1,1,,BAO_0000218,1969.0,
9112,A,In vivo,10116.0,,50597,Intermediate,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,,CHEMBL623808,,1,1,,BAO_0000218,1969.0,
9113,A,In vivo,10116.0,,50597,Intermediate,Peak plasma concentration (Cmax) in rats,,CHEMBL623809,,1,1,,BAO_0000218,1969.0,
9114,A,In vivo,10116.0,,50597,Intermediate,Peak plasma concentration at 1 mg/kg peroral administration,,CHEMBL623810,,1,1,,BAO_0000218,1969.0,
9115,A,In vivo,10116.0,,50597,Intermediate,Peak plasma concentration in rat,,CHEMBL623811,,1,1,,BAO_0000218,1969.0,
9116,A,In vivo,10116.0,,50597,Intermediate,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL623812,,1,1,,BAO_0000218,1969.0,
9117,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,CHEMBL877605,,1,1,,BAO_0000218,,
9118,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Cmax) in rat,,CHEMBL623813,,1,1,,BAO_0000218,,
9119,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,CHEMBL623814,,1,1,,BAO_0000218,,
9120,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat after 3mg/kg oral dose,,CHEMBL623815,,1,1,,BAO_0000218,,
9121,A,In vivo,10116.0,Sprague-Dawley,50597,Intermediate,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,CHEMBL623816,,1,1,,BAO_0000218,,
9122,A,In vivo,10116.0,,50597,Intermediate,Cmax in rats after 20 mg/kg oral dose,,CHEMBL623145,,1,1,,BAO_0000218,,
9123,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat plasma after 30mg/kg oral dose,,CHEMBL623146,,1,1,,BAO_0000218,1969.0,
9124,A,In vivo,10116.0,,50597,Intermediate,Plasma concentration after oral administration of 100 mg/kg to rats,,CHEMBL623147,,1,1,,BAO_0000218,1969.0,
9125,A,In vivo,10116.0,,50597,Intermediate,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,CHEMBL623042,,1,1,,BAO_0000218,955.0,
9126,A,In vivo,10116.0,,50597,Intermediate,Tested for the Cmax in rat at 10 mg/kg per orally,,CHEMBL623043,,1,1,,BAO_0000218,,
9127,A,In vivo,10116.0,,50597,Intermediate,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL623044,,1,1,,BAO_0000218,,
9128,A,In vivo,10116.0,,50597,Intermediate,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL623045,,1,1,,BAO_0000218,,
9129,A,In vivo,10116.0,,50597,Intermediate,Bioavailability as oral Cmax in rats at 30 mins,,CHEMBL623046,,1,1,,BAO_0000218,,
9130,A,In vivo,10116.0,,50597,Intermediate,Bioavailability as oral Cmax in rats at 6hr,,CHEMBL623226,,1,1,,BAO_0000218,,
9131,A,In vivo,10116.0,,50597,Intermediate,The maximum concentration of compound was measured at the dose of 100 umol/kg,,CHEMBL623227,,1,1,,BAO_0000218,,
9132,A,In vivo,10116.0,,50597,Intermediate,The maximum concentration of compound was measured at the dose of 300 umol/kg,,CHEMBL623228,,1,1,,BAO_0000218,,
9133,A,In vivo,10116.0,,50597,Intermediate,The maximum concentration of compound was measured at the dose of 30 umol/kg,,CHEMBL623229,,1,1,,BAO_0000218,,
9134,A,In vivo,10116.0,,50597,Intermediate,The maximum plasma levels for the compounds were determined by LC-MS.,,CHEMBL623230,,1,1,,BAO_0000218,1969.0,
9135,A,In vivo,10116.0,,50597,Intermediate,mean peak plasma concentration was observed after intravenous administration in rat,,CHEMBL623231,,1,1,,BAO_0000218,1969.0,
9136,A,In vivo,10116.0,,50597,Intermediate,mean peak plasma concentration was observed after oral administration in rat,,CHEMBL623232,,1,1,,BAO_0000218,1969.0,
9137,A,,10116.0,,50597,Intermediate,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,CHEMBL623233,,1,1,,BAO_0000218,,
9138,A,,10116.0,,50597,Intermediate,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,CHEMBL623234,,1,1,,BAO_0000218,,
9139,A,,10116.0,,50597,Intermediate,Concentration in plasma (portal) following oral dose in rats at 1 hr,,CHEMBL623235,,1,1,,BAO_0000218,,
9140,A,,10116.0,,50597,Intermediate,Concentration in plasma (portal) following oral dose in rats at 2 hr,,CHEMBL623236,,1,1,,BAO_0000218,,
9141,A,,10116.0,,50597,Intermediate,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,CHEMBL623237,,1,1,,BAO_0000218,,
9142,A,,10116.0,,50597,Intermediate,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,CHEMBL623238,,1,1,,BAO_0000218,,
9143,A,,10116.0,,50597,Intermediate,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,CHEMBL623239,,1,1,,BAO_0000218,,
9144,A,In vivo,10116.0,,22224,Intermediate,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,,CHEMBL623240,,0,1,,BAO_0000218,1969.0,
9145,A,,10116.0,,50597,Intermediate,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",,CHEMBL623241,,1,1,,BAO_0000218,1898.0,
9146,A,,10116.0,,50597,Intermediate,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",,CHEMBL623242,,1,1,,BAO_0000218,1898.0,
9147,A,,10116.0,,50597,Intermediate,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,CHEMBL874394,,1,1,,BAO_0000218,,
9148,A,,10116.0,,50597,Intermediate,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,CHEMBL623243,,1,1,,BAO_0000218,,
9149,A,,10116.0,,50597,Intermediate,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL623244,,1,1,,BAO_0000218,,
9150,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL623245,,1,1,,BAO_0000218,2113.0,
9151,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL623246,,1,1,,BAO_0000218,2113.0,
9152,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL623247,,1,1,,BAO_0000218,2113.0,
9153,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL623248,,1,1,,BAO_0000218,2113.0,
9154,A,,10116.0,,50597,Intermediate,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL623249,,1,1,,BAO_0000218,2113.0,
9155,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL625072,,1,1,,BAO_0000218,2107.0,
9156,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL625073,,1,1,,BAO_0000218,2107.0,
9157,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL625074,,1,1,,BAO_0000218,2107.0,
9158,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL625075,,1,1,,BAO_0000218,2107.0,
9159,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL625076,,1,1,,BAO_0000218,2107.0,
9160,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL625077,,1,1,,BAO_0000218,2107.0,
9161,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL625078,,1,1,,BAO_0000218,2107.0,
9162,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL874395,,1,1,,BAO_0000218,2107.0,
9163,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL625079,,1,1,,BAO_0000218,2107.0,
9164,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL625080,,1,1,,BAO_0000218,2107.0,
9165,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL625081,,1,1,,BAO_0000218,2107.0,
9166,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL625082,,1,1,,BAO_0000218,2107.0,
9167,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL625083,,1,1,,BAO_0000218,2107.0,
9168,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL625084,,1,1,,BAO_0000218,2107.0,
9169,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL625085,,1,1,,BAO_0000218,2107.0,
9170,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL625086,,1,1,,BAO_0000218,2107.0,
9171,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL625087,,1,1,,BAO_0000218,2107.0,
9172,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL625088,,1,1,,BAO_0000218,2107.0,
9173,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL622205,,1,1,,BAO_0000218,2107.0,
9174,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL622206,,1,1,,BAO_0000218,2107.0,
9175,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL622207,,1,1,,BAO_0000218,2107.0,
9176,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL622366,,1,1,,BAO_0000218,2107.0,
9177,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL622367,,1,1,,BAO_0000218,2107.0,
9178,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL875331,,1,1,,BAO_0000218,2107.0,
9179,A,,10116.0,,50597,Intermediate,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL622368,,1,1,,BAO_0000218,2107.0,
9180,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL622369,,1,1,,BAO_0000218,2048.0,
9181,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL622370,,1,1,,BAO_0000218,2048.0,
9182,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL622371,,1,1,,BAO_0000218,2048.0,
9183,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL622372,,1,1,,BAO_0000218,2048.0,
9184,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL622373,,1,1,,BAO_0000218,2048.0,
9185,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL622374,,1,1,,BAO_0000218,2048.0,
9186,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL622375,,1,1,,BAO_0000218,2048.0,
9187,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL622376,,1,1,,BAO_0000218,2048.0,
9188,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL622377,,1,1,,BAO_0000218,2048.0,
9189,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL622378,,1,1,,BAO_0000218,2048.0,
9190,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL622379,,1,1,,BAO_0000218,2048.0,
9191,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL622380,,1,1,,BAO_0000218,2048.0,
9192,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL622381,,1,1,,BAO_0000218,2048.0,
9193,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL622382,,1,1,,BAO_0000218,2048.0,
9194,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,,CHEMBL622383,,1,1,,BAO_0000218,2048.0,
9195,A,,10116.0,,50597,Intermediate,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL875332,,1,1,,BAO_0000218,945.0,
9196,A,,10116.0,,50597,Intermediate,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL622384,,1,1,,BAO_0000218,945.0,
9197,A,,10116.0,,50597,Intermediate,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL622385,,1,1,,BAO_0000218,945.0,
9198,A,,10116.0,,50597,Intermediate,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,CHEMBL622386,,1,1,,BAO_0000218,945.0,
9199,A,,10116.0,,50597,Intermediate,The compound was tested for the plasma binding in rat,,CHEMBL622387,,1,1,,BAO_0000218,,
9200,A,,10116.0,,50597,Intermediate,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,CHEMBL622388,,1,1,,BAO_0000218,,
9201,A,,10116.0,,50597,Intermediate,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,CHEMBL622389,,1,1,,BAO_0000218,,
9202,A,,10116.0,,50597,Intermediate,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,CHEMBL622390,,1,1,,BAO_0000218,,
9203,A,,10116.0,,50597,Intermediate,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,CHEMBL622391,,1,1,,BAO_0000218,,
9204,A,,10116.0,,50597,Intermediate,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,CHEMBL622392,,1,1,,BAO_0000218,,
9205,A,,10116.0,,50597,Intermediate,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,CHEMBL622393,,1,1,,BAO_0000218,,
9206,A,,10116.0,,50597,Intermediate,Plasma level at 2 hr after administration of the compound,,CHEMBL622394,,1,1,,BAO_0000218,,
9207,A,,10116.0,,50597,Intermediate,plasma level at 2 hr after administration of the compound,,CHEMBL622395,,1,1,,BAO_0000218,,
9208,A,,10116.0,,50597,Intermediate,Stability in rat serum measured as % recovery at 1 min,,CHEMBL622396,,1,1,,BAO_0000218,1977.0,
9209,A,,10116.0,,50597,Intermediate,Stability in rat serum measured as % recovery at 10 min,,CHEMBL624894,,1,1,,BAO_0000218,1977.0,
9210,A,,10116.0,,50597,Intermediate,Stability in rat serum measured as % recovery at 10 mins,,CHEMBL624895,,1,1,,BAO_0000218,1977.0,
9211,A,,10116.0,,50597,Intermediate,Stability in rat serum measured as % recovery at 2 hr,,CHEMBL624058,,1,1,,BAO_0000218,1977.0,
9212,A,,10116.0,,50597,Intermediate,Stability in rat serum measured as % recovery at 3 min,,CHEMBL624059,,1,1,,BAO_0000218,1977.0,
9213,A,,10116.0,,50597,Intermediate,Stability in rat serum measured as % recovery at 3 mins,,CHEMBL624060,,1,1,,BAO_0000218,1977.0,
9214,A,,10116.0,,50597,Intermediate,Stability in rat serum measured as % recovery at 5 min,,CHEMBL624061,,1,1,,BAO_0000218,1977.0,
9215,A,,10116.0,,50597,Intermediate,Stability in rat serum measured as % recovery at 5 mins,,CHEMBL624062,,1,1,,BAO_0000218,1977.0,
9216,A,In vivo,10116.0,,50597,Intermediate,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,CHEMBL624063,,1,1,,BAO_0000218,,
9217,A,In vivo,10116.0,,50597,Intermediate,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,CHEMBL624064,,1,1,,BAO_0000218,,
9218,A,,10116.0,,50597,Intermediate,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,,CHEMBL624065,,1,1,,BAO_0000218,1969.0,
9219,A,,10116.0,,50597,Intermediate,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,,CHEMBL624066,,1,1,,BAO_0000218,1969.0,
9220,A,In vivo,10116.0,,50597,Intermediate,Half life tested in mature male rat at a dose of 30 mg/kg,,CHEMBL877490,,1,1,,BAO_0000218,,
9221,A,In vivo,10116.0,,50597,Intermediate,Half life after intravenous administration of 1 mg/kg in rat,,CHEMBL874442,,1,1,,BAO_0000218,,
9222,A,In vivo,10116.0,,50597,Intermediate,Half life period after administration (30 mg/kg) in rat,,CHEMBL626890,,1,1,,BAO_0000218,,
9223,A,In vivo,10116.0,,50597,Intermediate,Half life period in rat after 5 mg/Kg dose,,CHEMBL626891,,1,1,,BAO_0000218,,
9224,A,In vivo,10116.0,,50597,Intermediate,Half life period in rat after 5 mg/kg dose,,CHEMBL626892,,1,1,,BAO_0000218,,
9225,A,,10116.0,,50597,Intermediate,Half life period was determined,,CHEMBL626893,,1,1,,BAO_0000218,,
9226,A,,10116.0,,50597,Intermediate,Half life period was evaluated in rat,,CHEMBL626894,,1,1,,BAO_0000218,,
9227,A,,10116.0,,50597,Intermediate,Half life period was evaluated in rat; 0.5-1.0,,CHEMBL626895,,1,1,,BAO_0000218,,
9228,A,,10116.0,,50597,Intermediate,Half life period was evaluated in rat; 5.9-7.5,,CHEMBL626896,,1,1,,BAO_0000218,,
9229,A,,10116.0,,50597,Intermediate,Half-life in rat plasma,,CHEMBL626897,,1,1,,BAO_0000218,1969.0,
9230,A,,10116.0,,50597,Intermediate,Half-life time in rat was determined,,CHEMBL626898,,1,1,,BAO_0000218,,
9231,A,In vivo,10116.0,,50597,Intermediate,Terminal half-life after iv administration to rats,,CHEMBL626899,,1,1,,BAO_0000218,,
9232,A,In vivo,10116.0,,50597,Intermediate,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,CHEMBL626900,,1,1,,BAO_0000218,,
9233,A,,10116.0,,50597,Intermediate,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,CHEMBL626901,,1,1,,BAO_0000218,,
9234,A,In vivo,10116.0,,50597,Intermediate,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,CHEMBL626902,,1,1,,BAO_0000218,,
9235,A,In vivo,10116.0,,50597,Intermediate,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,CHEMBL626903,,1,1,,BAO_0000218,,
9236,A,In vivo,10116.0,,50597,Intermediate,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,CHEMBL874443,,1,1,,BAO_0000218,,
9237,A,In vivo,10116.0,,50597,Intermediate,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,CHEMBL626904,,1,1,,BAO_0000218,,
9238,A,,10116.0,,50597,Intermediate,Half life in rats,,CHEMBL626905,,1,1,,BAO_0000218,,
9239,A,In vivo,10116.0,,50597,Intermediate,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,,CHEMBL873830,,1,1,,BAO_0000218,1969.0,
9240,A,In vivo,10116.0,,50597,Intermediate,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,CHEMBL626906,,1,1,,BAO_0000218,,
9241,A,In vivo,10116.0,,50597,Intermediate,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,CHEMBL631076,,1,1,,BAO_0000218,1969.0,
9242,A,,10116.0,,50597,Intermediate,Biological half-life was measured in plasma of rats,,CHEMBL631077,,1,1,,BAO_0000218,1969.0,
9243,A,In vivo,10116.0,,50597,Intermediate,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,CHEMBL631078,,1,1,,BAO_0000218,,
9244,A,In vivo,10116.0,,50597,Intermediate,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,CHEMBL631079,,1,1,,BAO_0000218,,
9245,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,CHEMBL631080,,1,1,,BAO_0000218,,
9246,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,CHEMBL631081,,1,1,,BAO_0000218,,
9247,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,CHEMBL631239,,1,1,,BAO_0000218,,
9248,A,,10116.0,,50597,Intermediate,Compound was evaluated for plasma half life in rat,,CHEMBL631240,,1,1,,BAO_0000218,1969.0,
9249,A,,10116.0,,50597,Intermediate,AUC value at a dose of 5 mg/kg (p.o.) in rats,,CHEMBL631241,,1,1,,BAO_0000218,1969.0,
9250,A,,10116.0,,50597,Intermediate,AUC value after administration of 20 mg/Kg oral dose in rat,,CHEMBL631242,,1,1,,BAO_0000218,1969.0,
9251,A,,10116.0,,50597,Intermediate,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,,CHEMBL631243,,1,1,,BAO_0000218,1969.0,
9252,A,,10116.0,,50597,Intermediate,AUC0-96 after administration at 50 mg/kg,,CHEMBL874444,,1,1,,BAO_0000218,1969.0,
9253,A,,10116.0,,50597,Intermediate,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,,CHEMBL631244,,1,1,,BAO_0000218,1969.0,
9254,A,,10116.0,,50597,Intermediate,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,CHEMBL631245,,1,1,,BAO_0000218,,
9255,A,,10116.0,,50597,Intermediate,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,CHEMBL627162,,1,1,,BAO_0000218,,
9256,A,,10116.0,,50597,Intermediate,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,CHEMBL627163,,1,1,,BAO_0000218,,
9257,A,,10116.0,,50597,Intermediate,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,CHEMBL627164,,1,1,,BAO_0000218,,
9258,A,,10116.0,,50597,Intermediate,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,,CHEMBL627165,,1,1,,BAO_0000218,2113.0,
9259,A,,10116.0,,50597,Intermediate,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,CHEMBL627166,,1,1,,BAO_0000218,,
9260,A,,10116.0,,50597,Intermediate,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,CHEMBL627167,,1,1,,BAO_0000218,,
9261,A,,10116.0,,50597,Intermediate,Area under curve (AUC) at a dose of 30 mg/kg in rats,,CHEMBL627822,,1,1,,BAO_0000218,,
9262,A,,10116.0,,50597,Intermediate,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,CHEMBL627823,,1,1,,BAO_0000218,,
9263,A,,10116.0,,50597,Intermediate,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,CHEMBL627824,,1,1,,BAO_0000218,,
9264,A,,10116.0,,50597,Intermediate,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,CHEMBL627825,,1,1,,BAO_0000218,,
9265,A,,10116.0,,50597,Intermediate,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,CHEMBL627826,,1,1,,BAO_0000218,,
9266,A,,10116.0,,50597,Intermediate,Area under curve (Pharmacokinetic property) was determined,,CHEMBL627827,,1,1,,BAO_0000218,,
9267,A,,10116.0,,50597,Intermediate,Area under curve (Pharmacokinetic property) of the compound; Not determined,,CHEMBL627828,,1,1,,BAO_0000218,,
9268,A,,10116.0,,50597,Intermediate,Area under curve after intravenous administration (1 mg/kg) in rat,,CHEMBL627829,,1,1,,BAO_0000218,,
9269,A,,10116.0,,50597,Intermediate,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,CHEMBL627830,,1,1,,BAO_0000218,,
9270,A,,10116.0,,50597,Intermediate,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,CHEMBL627831,,1,1,,BAO_0000218,,
9271,A,,10116.0,,50597,Intermediate,Area under curve in male SD rats was observed after oral administration in rat,,CHEMBL627832,,1,1,,BAO_0000218,,
9272,A,,10116.0,,50597,Intermediate,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,CHEMBL627833,,1,1,,BAO_0000218,,
9273,A,,10116.0,,50597,Expert,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL627834,,1,1,,BAO_0000218,,
9274,A,,10116.0,,50597,Expert,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL628004,,1,1,,BAO_0000218,,
9275,A,,10116.0,,50597,Intermediate,Area under curve at 5 mg/kg po was determined in rat,,CHEMBL628005,,1,1,,BAO_0000218,,
9276,A,,10116.0,,50597,Intermediate,Area under curve in Rat at a oral dose of 5 mg/kg,,CHEMBL628006,,1,1,,BAO_0000218,,
9277,A,,10116.0,,50597,Intermediate,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,CHEMBL628007,,1,1,,BAO_0000218,,
9278,A,,10116.0,,50597,Intermediate,Area under curve was determined,,CHEMBL625676,,1,1,,BAO_0000218,,
9279,A,,10116.0,,50597,Intermediate,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,CHEMBL631309,,1,1,,BAO_0000218,,
9280,A,,10116.0,,50597,Intermediate,Area under curve after intravenous administration at 3 mg/kg,,CHEMBL631310,,1,1,,BAO_0000218,,
9281,A,,10116.0,,50597,Intermediate,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,CHEMBL631311,,1,1,,BAO_0000218,,
9282,A,,10116.0,,50597,Intermediate,Area under curve at 4 hr in rat,,CHEMBL631312,,1,1,,BAO_0000218,,
9283,A,,10116.0,,50597,Intermediate,Area under curve at a dose of 30 mg/kg,,CHEMBL631313,,1,1,,BAO_0000218,,
9284,A,,10116.0,,50597,Intermediate,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,CHEMBL631314,,1,1,,BAO_0000218,,
9285,A,,10116.0,,50597,Intermediate,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,CHEMBL631315,,1,1,,BAO_0000218,,
9286,A,,10116.0,,50597,Intermediate,Area under curve for a 2-mpk po dose in SD rats,,CHEMBL631316,,1,1,,BAO_0000218,,
9287,A,,10116.0,,50597,Intermediate,Area under curve in SD rats,,CHEMBL631317,,1,1,,BAO_0000218,,
9288,A,,10116.0,,50597,Intermediate,Area under curve in rat after oral administration at 13 mg/kg dose,,CHEMBL874471,,1,1,,BAO_0000218,,
9289,A,,10116.0,,50597,Intermediate,Area under curve in rat by po administration at 0-24 hr,,CHEMBL631318,,1,1,,BAO_0000218,,
9290,A,,10116.0,,50597,Intermediate,Area under curve in rat plasma,,CHEMBL631319,,1,1,,BAO_0000218,1969.0,
9291,A,,10116.0,,50597,Intermediate,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,CHEMBL631320,,1,1,,BAO_0000218,,
9292,A,,10116.0,,50597,Intermediate,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,CHEMBL631321,,1,1,,BAO_0000218,,
9293,A,,10116.0,,50597,Intermediate,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,CHEMBL631322,,1,1,,BAO_0000218,,
9294,A,,10116.0,,50597,Intermediate,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,CHEMBL631323,,1,1,,BAO_0000218,,
9295,A,,10116.0,,50597,Intermediate,Area under curve value in rat at a dose of 5 mg/kg,,CHEMBL631324,,1,1,,BAO_0000218,,
9296,A,,10116.0,,50597,Intermediate,Area under curve was determined after oral administration in rats,,CHEMBL631325,,1,1,,BAO_0000218,,
9297,A,,10116.0,,50597,Intermediate,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,CHEMBL631326,,1,1,,BAO_0000218,,
9298,A,,10116.0,,50597,Intermediate,Area under curve was determined after peroral administration in rat,,CHEMBL631327,,1,1,,BAO_0000218,,
9299,A,,10116.0,,50597,Intermediate,Area under curve was determined at a dose 30 mpk administered orally.,,CHEMBL631328,,1,1,,BAO_0000218,,
9300,A,,10116.0,,50597,Intermediate,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,CHEMBL631329,,1,1,,BAO_0000218,,
9301,A,,10116.0,,50597,Intermediate,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,CHEMBL627217,,1,1,,BAO_0000218,,
9302,A,,10116.0,,50597,Intermediate,Area under curve was determined in male rat,,CHEMBL626352,,1,1,,BAO_0000218,,
9303,A,,10116.0,,50597,Intermediate,Area under curve was determined in rat after PO administration,,CHEMBL626353,,1,1,,BAO_0000218,,
9304,A,,10116.0,,50597,Intermediate,Area under curve was determined in rat after a 3 mg/kg of oral dose,,CHEMBL626354,,1,1,,BAO_0000218,,
9305,A,,10116.0,,50597,Intermediate,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,CHEMBL626355,,1,1,,BAO_0000218,,
9306,A,,10116.0,,50597,Intermediate,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,CHEMBL626356,,1,1,,BAO_0000218,,
9307,A,,10116.0,,50597,Intermediate,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,CHEMBL626357,,1,1,,BAO_0000218,,
9308,A,,10116.0,,50597,Intermediate,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL626358,,1,1,,BAO_0000218,,
9309,A,,10116.0,,50597,Intermediate,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL626359,,1,1,,BAO_0000218,,
9310,A,,10116.0,,50597,Intermediate,Peak plasma concentration in rat at a dose of 3 mg/kg,,CHEMBL626360,,1,1,,BAO_0000218,1969.0,
9311,A,,10116.0,,50597,Intermediate,Plasma concentration at 2 hr in rats was evaluated.,,CHEMBL626361,,1,1,,BAO_0000218,,
9312,A,,10116.0,,50597,Intermediate,Plasma concentration at 2 hr in rats was evaluated; Not available,,CHEMBL626362,,1,1,,BAO_0000218,,
9313,A,,10116.0,,50597,Intermediate,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL626363,,1,1,,BAO_0000218,,
9314,A,,10116.0,,50597,Intermediate,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL626970,,1,1,,BAO_0000218,,
9315,A,,10116.0,,50597,Intermediate,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL626971,,1,1,,BAO_0000218,,
9316,A,,10116.0,,50597,Intermediate,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL626972,,1,1,,BAO_0000218,1969.0,
9317,A,,10116.0,,50597,Intermediate,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL626973,,1,1,,BAO_0000218,1969.0,
9318,A,,10116.0,,50597,Intermediate,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL626974,,1,1,,BAO_0000218,1969.0,
9319,A,,10116.0,,50597,Intermediate,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL874592,,1,1,,BAO_0000218,1969.0,
9320,A,,10116.0,,50597,Intermediate,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,CHEMBL626975,,1,1,,BAO_0000218,,
9321,A,,10116.0,,50597,Intermediate,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,CHEMBL626976,,1,1,,BAO_0000218,,
9322,A,,10116.0,,50597,Intermediate,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,CHEMBL626977,,1,1,,BAO_0000218,,
9323,A,,10116.0,,50597,Intermediate,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,CHEMBL626978,,1,1,,BAO_0000218,,
9324,A,,10116.0,,50597,Intermediate,PK study was carried to determine the relative absorption ranking in rat.,,CHEMBL626979,,1,1,,BAO_0000218,,
9325,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,,CHEMBL626980,,1,1,,BAO_0000218,1969.0,
9326,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",,CHEMBL626981,,1,1,,BAO_0000218,178.0,
9327,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",,CHEMBL626982,,1,1,,BAO_0000218,178.0,
9328,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",,CHEMBL626983,,1,1,,BAO_0000218,178.0,
9329,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",,CHEMBL622522,,1,1,,BAO_0000218,178.0,
9330,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",,CHEMBL622523,,1,1,,BAO_0000218,178.0,
9331,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",,CHEMBL622524,,1,1,,BAO_0000218,178.0,
9332,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",,CHEMBL622525,,1,1,,BAO_0000218,955.0,
9333,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",,CHEMBL622526,,1,1,,BAO_0000218,955.0,
9334,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",,CHEMBL619849,,1,1,,BAO_0000218,955.0,
9335,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",,CHEMBL619850,,1,1,,BAO_0000218,955.0,
9336,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",,CHEMBL623864,,1,1,,BAO_0000218,955.0,
9337,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",,CHEMBL623865,,1,1,,BAO_0000218,955.0,
9338,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",,CHEMBL623866,,1,1,,BAO_0000218,948.0,
9339,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",,CHEMBL623867,,1,1,,BAO_0000218,948.0,
9340,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",,CHEMBL877615,,1,1,,BAO_0000218,948.0,
9341,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",,CHEMBL623868,,1,1,,BAO_0000218,948.0,
9342,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",,CHEMBL623869,,1,1,,BAO_0000218,948.0,
9343,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",,CHEMBL623870,,1,1,,BAO_0000218,948.0,
9344,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,CHEMBL623871,,1,1,,BAO_0000218,2048.0,
9345,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL623872,,1,1,,BAO_0000218,2048.0,
9346,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL622129,,1,1,,BAO_0000218,2048.0,
9347,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL622130,,1,1,,BAO_0000218,2048.0,
9348,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL622131,,1,1,,BAO_0000218,2048.0,
9349,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL622132,,1,1,,BAO_0000218,2048.0,
9350,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL622133,,1,1,,BAO_0000218,2048.0,
9351,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL622134,,1,1,,BAO_0000218,2048.0,
9352,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL622135,,1,1,,BAO_0000218,2048.0,
9353,A,,10116.0,,50597,Intermediate,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL622136,,1,1,,BAO_0000218,2048.0,
9354,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL622137,,1,1,,BAO_0000218,2385.0,
9355,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL622138,,1,1,,BAO_0000218,2385.0,
9356,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL623017,,1,1,,BAO_0000218,2385.0,
9357,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL623018,,1,1,,BAO_0000218,2385.0,
9358,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL623019,,1,1,,BAO_0000218,2385.0,
9359,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL623020,,1,1,,BAO_0000218,2385.0,
9360,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL623021,,1,1,,BAO_0000218,2385.0,
9361,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL623022,,1,1,,BAO_0000218,2385.0,
9362,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL623023,,1,1,,BAO_0000218,2385.0,
9363,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL623024,,1,1,,BAO_0000218,2385.0,
9364,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL623025,,1,1,,BAO_0000218,2385.0,
9365,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL620545,,1,1,,BAO_0000218,2385.0,
9366,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL620546,,1,1,,BAO_0000218,2385.0,
9367,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL620547,,1,1,,BAO_0000218,2385.0,
9368,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL620548,,1,1,,BAO_0000218,2385.0,
9369,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL620549,,1,1,,BAO_0000218,2385.0,
9370,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL620550,,1,1,,BAO_0000218,2385.0,
9371,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,CHEMBL620551,,1,1,,BAO_0000218,2385.0,
9372,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL620552,,1,1,,BAO_0000218,2385.0,
9373,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL620553,,1,1,,BAO_0000218,2385.0,
9374,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL620554,,1,1,,BAO_0000218,2385.0,
9375,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL875845,,1,1,,BAO_0000218,2385.0,
9376,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL620555,,1,1,,BAO_0000218,2385.0,
9377,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL620556,,1,1,,BAO_0000218,2385.0,
9378,A,,10116.0,,50597,Intermediate,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL620557,,1,1,,BAO_0000218,2385.0,
9379,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL620558,,1,1,,BAO_0000218,,
9380,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL620559,,1,1,,BAO_0000218,,
9381,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL622939,,1,1,,BAO_0000218,,
9382,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL622940,,1,1,,BAO_0000218,,
9383,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL622941,,1,1,,BAO_0000218,,
9384,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL622942,,1,1,,BAO_0000218,,
9385,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL622943,,1,1,,BAO_0000218,,
9386,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL622944,,1,1,,BAO_0000218,,
9387,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL622945,,1,1,,BAO_0000218,,
9388,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL622946,,1,1,,BAO_0000218,,
9389,A,,10116.0,,50597,Intermediate,Compound was evaluated for terminal half life in rat,,CHEMBL622947,,1,1,,BAO_0000218,,
9390,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,,CHEMBL622948,,1,1,,BAO_0000218,1969.0,
9391,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,,CHEMBL622949,,1,1,,BAO_0000218,1969.0,
9392,A,,10116.0,,50597,Intermediate,Compound was tested for its half life in rat,,CHEMBL622950,,1,1,,BAO_0000218,,
9393,A,In vivo,9544.0,,22224,Intermediate,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,CHEMBL622951,,0,1,,BAO_0000218,1969.0,
9394,A,,10116.0,,22224,Intermediate,Compound was tested for its plasma half life in Sprague Dawley rats,,CHEMBL622952,,0,1,,BAO_0000366,1969.0,
9395,A,,10116.0,,22224,Intermediate,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,,CHEMBL622953,,0,1,,BAO_0000366,1969.0,
9396,A,,10116.0,,50597,Intermediate,Compound was tested for plasma half-life period in rat,,CHEMBL873818,,1,1,,BAO_0000218,1969.0,
9397,A,In vivo,10116.0,,50597,Intermediate,Elimination half life after i.v. administration of compound in rats,,CHEMBL622954,,1,1,,BAO_0000218,,
9398,A,In vivo,10116.0,,50597,Intermediate,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,CHEMBL622955,,1,1,,BAO_0000218,,
9399,A,In vivo,10116.0,,50597,Intermediate,Elimination half-life after IV dosing at 1 mg/kg in rat,,CHEMBL875229,,1,1,,BAO_0000218,,
9400,A,In vivo,10116.0,,50597,Intermediate,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,CHEMBL622956,,1,1,,BAO_0000218,,
9401,A,In vivo,10116.0,,50597,Intermediate,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,CHEMBL622957,,1,1,,BAO_0000218,,
9402,A,In vivo,10116.0,,50597,Intermediate,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,CHEMBL622958,,1,1,,BAO_0000218,955.0,
9403,A,In vivo,10116.0,,50597,Intermediate,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,CHEMBL622959,,1,1,,BAO_0000218,1969.0,
9404,A,In vivo,10116.0,,50597,Intermediate,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,CHEMBL622960,,1,1,,BAO_0000218,955.0,
9405,A,In vivo,10116.0,,50597,Intermediate,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,CHEMBL622961,,1,1,,BAO_0000218,1969.0,
9406,A,In vivo,10116.0,,50597,Intermediate,Evaluated for the half life in rat (in vivo),,CHEMBL622962,,1,1,,BAO_0000218,,
9407,A,,10116.0,,50597,Intermediate,Hafl life in rat,,CHEMBL622963,,1,1,,BAO_0000218,,
9408,A,,10116.0,,50597,Intermediate,Hafl life rat,,CHEMBL622964,,1,1,,BAO_0000218,,
9409,A,,10116.0,,50597,Intermediate,Hafl life rat,,CHEMBL622965,,1,1,,BAO_0000218,,
9410,A,,10116.0,,50597,Intermediate,Hafl life rat; Not determined,,CHEMBL622966,,1,1,,BAO_0000218,,
9411,A,,10116.0,,50597,Intermediate,Hafl life rat; Not determined,,CHEMBL622967,,1,1,,BAO_0000218,,
9412,A,In vivo,10116.0,,50597,Intermediate,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL622968,,1,1,,BAO_0000218,2113.0,
9413,A,In vivo,10116.0,,50597,Intermediate,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL622969,,1,1,,BAO_0000218,2107.0,
9414,A,In vivo,10116.0,,50597,Intermediate,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL875327,,1,1,,BAO_0000218,2048.0,
9415,A,In vivo,10116.0,,50597,Intermediate,Half life in rat after 1 mg/kg i.v. administration,,CHEMBL628638,,1,1,,BAO_0000218,,
9416,A,In vivo,10116.0,,50597,Intermediate,Half life in rat after 2 mg/kg peroral administration,,CHEMBL628639,,1,1,,BAO_0000218,,
9417,A,In vivo,10116.0,,50597,Intermediate,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL625840,,1,1,,BAO_0000218,,
9418,A,In vivo,10116.0,,50597,Intermediate,Half life of 10 mg/kg oral dose determined in rats,,CHEMBL625841,,1,1,,BAO_0000218,,
9419,A,In vivo,10116.0,,50597,Intermediate,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL625842,,1,1,,BAO_0000218,,
9420,A,In vivo,10116.0,,50597,Intermediate,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL625843,,1,1,,BAO_0000218,,
9421,A,In vivo,10116.0,,50597,Intermediate,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL625844,,1,1,,BAO_0000218,,
9422,A,In vivo,10116.0,,50597,Intermediate,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL873822,,1,1,,BAO_0000218,,
9423,A,In vivo,10116.0,,50597,Intermediate,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL625845,,1,1,,BAO_0000218,,
9424,A,In vivo,10116.0,,50597,Intermediate,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL627059,,1,1,,BAO_0000218,,
9425,A,In vivo,10116.0,,50597,Intermediate,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL627060,,1,1,,BAO_0000218,,
9426,A,In vivo,10116.0,,50597,Intermediate,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,CHEMBL627061,,1,1,,BAO_0000218,,
9427,A,In vivo,10116.0,,50597,Intermediate,Half life of compound at 5 mg/kg after po administration was determined in rat,,CHEMBL627709,,1,1,,BAO_0000218,,
9428,A,In vivo,10116.0,,50597,Intermediate,Half life of compound determined after intravenous administration to rat,,CHEMBL627710,,1,1,,BAO_0000218,,
9429,A,,10116.0,,50597,Intermediate,Half life of compound was determined in rat,,CHEMBL627711,,1,1,,BAO_0000218,,
9430,A,In vivo,10116.0,,50597,Intermediate,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL627712,,1,1,,BAO_0000218,1969.0,
9431,A,In vivo,10116.0,,50597,Intermediate,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL627713,,1,1,,BAO_0000218,,
9432,A,In vivo,10116.0,,50597,Intermediate,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL627714,,1,1,,BAO_0000218,,
9433,A,In vivo,9541.0,,22224,Intermediate,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,CHEMBL627889,,0,1,,BAO_0000218,,
9434,A,In vivo,10116.0,,22224,Intermediate,Half life determined in rat by intravenous administration,,CHEMBL627890,,0,1,,BAO_0000218,,
9435,A,In vivo,10116.0,,50597,Intermediate,Half life determined in rats after iv administration,,CHEMBL627891,,1,1,,BAO_0000218,,
9436,A,In vivo,10116.0,,50597,Intermediate,Half life in rat plasma after administration of 2 mg/kg iv,,CHEMBL627892,,1,1,,BAO_0000218,1969.0,
9437,A,In vivo,10116.0,,50597,Intermediate,Half life in rat plasma after administration of 2 mg/kg iv,,CHEMBL627893,,1,1,,BAO_0000218,1969.0,
9438,A,,10116.0,,50597,Intermediate,Half life in rat plasma was determined,,CHEMBL627894,,1,1,,BAO_0000218,1969.0,
9439,A,,10116.0,,50597,Intermediate,Half life in rat plasma was determined; NA means not applicable,,CHEMBL627895,,1,1,,BAO_0000218,1969.0,
9440,A,,10116.0,,50597,Intermediate,Half life in rat was tested,,CHEMBL627896,,1,1,,BAO_0000218,,
9441,A,,10116.0,,50597,Intermediate,Half life measured in rat plasma,,CHEMBL627897,,1,1,,BAO_0000218,1969.0,
9442,A,,10116.0,,50597,Intermediate,Half life recorded in rats,,CHEMBL627898,,1,1,,BAO_0000218,,
9443,A,,10116.0,,50597,Intermediate,Half life was calculated,,CHEMBL627899,,1,1,,BAO_0000218,,
9444,A,,10116.0,,50597,Intermediate,Half life was calculated in rat,,CHEMBL873823,,1,1,,BAO_0000218,,
9445,A,,10116.0,,50597,Intermediate,Half life was determined,,CHEMBL627900,,1,1,,BAO_0000218,,
9446,A,In vivo,10116.0,,50597,Intermediate,Half life after 10 mg/kg oral administration in rat,,CHEMBL627901,,1,1,,BAO_0000218,,
9447,A,In vivo,10116.0,,50597,Intermediate,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,CHEMBL627902,,1,1,,BAO_0000218,,
9448,A,In vivo,10116.0,,50597,Intermediate,Half life after administering orally a dose of 30 mg/kg,,CHEMBL627903,,1,1,,BAO_0000218,,
9449,A,,10116.0,,50597,Intermediate,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,CHEMBL627904,,1,1,,BAO_0000218,,
9450,A,,10116.0,,50597,Intermediate,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,CHEMBL627905,,1,1,,BAO_0000218,,
9451,A,,10116.0,,50597,Intermediate,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,CHEMBL627906,,1,1,,BAO_0000218,,
9452,A,,10116.0,,50597,Intermediate,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,CHEMBL627907,,1,1,,BAO_0000218,,
9453,A,,10116.0,,50597,Intermediate,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,CHEMBL876783,,1,1,,BAO_0000218,,
9454,A,,10116.0,,50597,Intermediate,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,CHEMBL627908,,1,1,,BAO_0000218,,
9455,A,,10116.0,,50597,Intermediate,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,CHEMBL627909,,1,1,,BAO_0000218,,
9456,A,,10116.0,,50597,Intermediate,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,CHEMBL627910,,1,1,,BAO_0000218,,
9457,A,,10116.0,,50597,Intermediate,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,CHEMBL627911,,1,1,,BAO_0000218,,
9458,A,,10116.0,,50597,Intermediate,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,CHEMBL627912,,1,1,,BAO_0000218,,
9459,A,,10116.0,,50597,Intermediate,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,CHEMBL627913,,1,1,,BAO_0000218,,
9460,A,,10116.0,,50597,Intermediate,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,CHEMBL627914,,1,1,,BAO_0000218,,
9461,A,,10116.0,,50597,Intermediate,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,CHEMBL627915,,1,1,,BAO_0000218,,
9462,A,,10116.0,,50597,Intermediate,Area under the curve was evaluated after 20 uM/kg of peroral administration,,CHEMBL627916,,1,1,,BAO_0000218,,
9463,A,,10116.0,,50597,Intermediate,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,CHEMBL627917,,1,1,,BAO_0000218,,
9464,A,,10116.0,,50597,Intermediate,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,CHEMBL627918,,1,1,,BAO_0000218,,
9465,A,,10116.0,,50597,Intermediate,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,CHEMBL627919,,1,1,,BAO_0000218,,
9466,A,,10116.0,,50597,Intermediate,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,CHEMBL627920,,1,1,,BAO_0000218,,
9467,A,,10116.0,,50597,Intermediate,Area under the curve was evaluated at an oral dose of 30 mg/kg,,CHEMBL627921,,1,1,,BAO_0000218,,
9468,A,,10116.0,,50597,Intermediate,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL627922,,1,1,,BAO_0000218,,
9469,A,,10116.0,,50597,Intermediate,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL876784,,1,1,,BAO_0000218,,
9470,A,,10116.0,,50597,Intermediate,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL627923,,1,1,,BAO_0000218,,
9471,A,,10116.0,,50597,Intermediate,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL626208,,1,1,,BAO_0000218,,
9472,A,,10116.0,,50597,Intermediate,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL626209,,1,1,,BAO_0000218,,
9473,A,,10116.0,,50597,Intermediate,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL626210,,1,1,,BAO_0000218,,
9474,A,,10116.0,,50597,Intermediate,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,CHEMBL627994,,1,1,,BAO_0000218,1969.0,
9475,A,,10116.0,,50597,Intermediate,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,CHEMBL627995,,1,1,,BAO_0000218,,
9476,A,,10116.0,,50597,Intermediate,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,CHEMBL627996,,1,1,,BAO_0000218,,
9477,A,,10116.0,,50597,Intermediate,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,CHEMBL627997,,1,1,,BAO_0000218,,
9478,A,,10116.0,,50597,Intermediate,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,CHEMBL627998,,1,1,,BAO_0000218,,
9479,A,,10116.0,,50597,Intermediate,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,CHEMBL628640,,1,1,,BAO_0000218,,
9480,A,,10116.0,,50597,Intermediate,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,CHEMBL628641,,1,1,,BAO_0000218,,
9481,A,,10116.0,,50597,Intermediate,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,CHEMBL628642,,1,1,,BAO_0000218,,
9482,A,,10116.0,,50597,Intermediate,Compound was evaluated for area under the curve expressed as (h*ug/ml),,CHEMBL628643,,1,1,,BAO_0000218,,
9483,A,,10116.0,,50597,Intermediate,Compound was tested for area under curve in rat,,CHEMBL628644,,1,1,,BAO_0000218,,
9484,A,,10116.0,,50597,Intermediate,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,CHEMBL628645,,1,1,,BAO_0000218,,
9485,A,,10116.0,,50597,Intermediate,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,CHEMBL628646,,1,1,,BAO_0000218,,
9486,A,,10116.0,,50597,Intermediate,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,CHEMBL628647,,1,1,,BAO_0000218,,
9487,A,,10116.0,,50597,Intermediate,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,CHEMBL628648,,1,1,,BAO_0000218,,
9488,A,,10116.0,,50597,Intermediate,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,CHEMBL625358,,1,1,,BAO_0000218,,
9489,A,,10116.0,,50597,Intermediate,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,CHEMBL625359,,1,1,,BAO_0000218,,
9490,A,,10116.0,,50597,Intermediate,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,CHEMBL625360,,1,1,,BAO_0000218,,
9491,A,,10116.0,,50597,Intermediate,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,CHEMBL625361,,1,1,,BAO_0000218,,
9492,A,,10116.0,,50597,Intermediate,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,CHEMBL625362,,1,1,,BAO_0000218,,
9493,A,,10116.0,,50597,Intermediate,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,CHEMBL625363,,1,1,,BAO_0000218,,
9494,A,,10116.0,,50597,Intermediate,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,CHEMBL625364,,1,1,,BAO_0000218,,
9495,A,,10116.0,,50597,Intermediate,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL625365,,1,1,,BAO_0000218,,
9496,A,,10116.0,,50597,Intermediate,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL625366,,1,1,,BAO_0000218,,
9497,A,,10116.0,,50597,Intermediate,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,CHEMBL625367,,1,1,,BAO_0000218,,
9498,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",,CHEMBL625368,,1,1,,BAO_0000218,2113.0,
9499,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",,CHEMBL625369,,1,1,,BAO_0000218,2113.0,
9500,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",,CHEMBL625370,,1,1,,BAO_0000218,2113.0,
9501,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",,CHEMBL625371,,1,1,,BAO_0000218,2113.0,
9502,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",,CHEMBL625372,,1,1,,BAO_0000218,2113.0,
9503,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",,CHEMBL625373,,1,1,,BAO_0000218,2113.0,
9504,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",,CHEMBL625374,,1,1,,BAO_0000218,2107.0,
9505,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",,CHEMBL877593,,1,1,,BAO_0000218,2107.0,
9506,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",,CHEMBL625375,,1,1,,BAO_0000218,2107.0,
9507,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",,CHEMBL625376,,1,1,,BAO_0000218,2107.0,
9508,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",,CHEMBL621973,,1,1,,BAO_0000218,2107.0,
9509,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",,CHEMBL621974,,1,1,,BAO_0000218,2107.0,
9510,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",,CHEMBL621975,,1,1,,BAO_0000218,2048.0,
9511,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",,CHEMBL622166,,1,1,,BAO_0000218,2048.0,
9512,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",,CHEMBL622167,,1,1,,BAO_0000218,2048.0,
9513,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",,CHEMBL622168,,1,1,,BAO_0000218,2048.0,
9514,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",,CHEMBL622169,,1,1,,BAO_0000218,2048.0,
9515,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",,CHEMBL622170,,1,1,,BAO_0000218,2048.0,
9516,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",,CHEMBL622171,,1,1,,BAO_0000218,2046.0,
9517,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",,CHEMBL622172,,1,1,,BAO_0000218,2046.0,
9518,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",,CHEMBL622173,,1,1,,BAO_0000218,2046.0,
9519,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",,CHEMBL622174,,1,1,,BAO_0000218,2046.0,
9520,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",,CHEMBL622175,,1,1,,BAO_0000218,2046.0,
9521,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",,CHEMBL622176,,1,1,,BAO_0000218,2046.0,
9522,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",,CHEMBL622177,,1,1,,BAO_0000218,2046.0,
9523,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",,CHEMBL622178,,1,1,,BAO_0000218,2046.0,
9524,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",,CHEMBL622179,,1,1,,BAO_0000218,2046.0,
9525,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",,CHEMBL622180,,1,1,,BAO_0000218,2046.0,
9526,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL622181,,1,1,,BAO_0000218,,
9527,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL622182,,1,1,,BAO_0000218,,
9528,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL622183,,1,1,,BAO_0000218,,
9529,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL622184,,1,1,,BAO_0000218,,
9530,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL622185,,1,1,,BAO_0000218,,
9531,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL622186,,1,1,,BAO_0000218,,
9532,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL622187,,1,1,,BAO_0000218,,
9533,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,CHEMBL625002,,1,1,,BAO_0000218,,
9534,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,CHEMBL622090,,1,1,,BAO_0000218,,
9535,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL622091,,1,1,,BAO_0000218,,
9536,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL622092,,1,1,,BAO_0000218,,
9537,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL622093,,1,1,,BAO_0000218,,
9538,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL622094,,1,1,,BAO_0000218,,
9539,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL622095,,1,1,,BAO_0000218,,
9540,A,,10116.0,,50597,Intermediate,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL622264,,1,1,,BAO_0000218,,
9541,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL622265,,1,1,,BAO_0000218,2106.0,
9542,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL622266,,1,1,,BAO_0000218,2106.0,
9543,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL622267,,1,1,,BAO_0000218,2106.0,
9544,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL622268,,1,1,,BAO_0000218,2106.0,
9545,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL622269,,1,1,,BAO_0000218,2106.0,
9546,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL625071,,1,1,,BAO_0000218,2106.0,
9547,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL621621,,1,1,,BAO_0000218,2106.0,
9548,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL621622,,1,1,,BAO_0000218,2106.0,
9549,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL621623,,1,1,,BAO_0000218,2106.0,
9550,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL621624,,1,1,,BAO_0000218,2106.0,
9551,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL621625,,1,1,,BAO_0000218,2106.0,
9552,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL621626,,1,1,,BAO_0000218,2106.0,
9553,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL621627,,1,1,,BAO_0000218,2106.0,
9554,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL621628,,1,1,,BAO_0000218,2106.0,
9555,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL875328,,1,1,,BAO_0000218,2106.0,
9556,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL621629,,1,1,,BAO_0000218,2106.0,
9557,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL621630,,1,1,,BAO_0000218,2106.0,
9558,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL621631,,1,1,,BAO_0000218,2106.0,
9559,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL621632,,1,1,,BAO_0000218,2106.0,
9560,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL621633,,1,1,,BAO_0000218,2106.0,
9561,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL621634,,1,1,,BAO_0000218,2106.0,
9562,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL621635,,1,1,,BAO_0000218,2106.0,
9563,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL621636,,1,1,,BAO_0000218,2106.0,
9564,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL621637,,1,1,,BAO_0000218,2106.0,
9565,A,,10116.0,,50597,Intermediate,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL621638,,1,1,,BAO_0000218,2106.0,
9566,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL618883,,1,1,,BAO_0000218,,
9567,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,CHEMBL618884,,1,1,,BAO_0000218,,
9568,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL628627,,1,1,,BAO_0000218,,
9569,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL628628,,1,1,,BAO_0000218,,
9570,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,CHEMBL628629,,1,1,,BAO_0000218,,
9571,A,In vivo,10116.0,,50597,Intermediate,Half life after administering orally a dose of 3 mg/kg,,CHEMBL628630,,1,1,,BAO_0000218,,
9572,A,In vivo,10116.0,,50597,Intermediate,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,CHEMBL628631,,1,1,,BAO_0000218,,
9573,A,In vivo,10116.0,,50597,Intermediate,Half life after administering intravenously a dose of 1 mg/kg,,CHEMBL628632,,1,1,,BAO_0000218,,
9574,A,In vivo,10116.0,,50597,Intermediate,Half life after oral dosing in rats,,CHEMBL628633,,1,1,,BAO_0000218,,
9575,A,In vivo,10116.0,,50597,Intermediate,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,CHEMBL628634,,1,1,,BAO_0000218,,
9576,A,In vivo,10116.0,,50597,Intermediate,Half life by intravenous administration of 3.4 mg/kg in rat,,CHEMBL627789,,1,1,,BAO_0000218,,
9577,A,,10116.0,,50597,Intermediate,Half life in rat,,CHEMBL627790,,1,1,,BAO_0000218,,
9578,A,,10116.0,,50597,Intermediate,Half life in rat,,CHEMBL627791,,1,1,,BAO_0000218,,
9579,A,,10116.0,,50597,Intermediate,Half life in rat,,CHEMBL627792,,1,1,,BAO_0000218,,
9580,A,In vivo,10116.0,,50597,Intermediate,Half life in rat after intravenous administration of the compound,,CHEMBL627793,,1,1,,BAO_0000218,,
9581,A,In vivo,10116.0,,50597,Intermediate,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,,CHEMBL627794,,1,1,,BAO_0000218,1969.0,
9582,A,In vivo,10116.0,,50597,Intermediate,Half life in rat after po administration of the compound,,CHEMBL627795,,1,1,,BAO_0000218,,
9583,A,In vivo,10116.0,,50597,Intermediate,Half life in rat after po administration of the compound; ND means Not determined,,CHEMBL627796,,1,1,,BAO_0000218,,
9584,A,In vivo,10116.0,,50597,Intermediate,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,,CHEMBL875335,,1,1,,BAO_0000218,1969.0,
9585,A,In vivo,10116.0,,50597,Intermediate,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,,CHEMBL627797,,1,1,,BAO_0000218,1969.0,
9586,A,In vivo,10116.0,,50597,Intermediate,Half life in rat i.v.,,CHEMBL627798,,1,1,,BAO_0000218,,
9587,A,In vivo,10116.0,,50597,Intermediate,Half life in rat i.v. at 2 mg/kg concentration,,CHEMBL627799,,1,1,,BAO_0000218,,
9588,A,,10116.0,,50597,Intermediate,Half life in rats,,CHEMBL627800,,1,1,,BAO_0000218,,
9589,A,In vivo,10116.0,,50597,Intermediate,Half life in rats after intravenous administration,,CHEMBL627801,,1,1,,BAO_0000218,,
9590,A,In vivo,10116.0,,50597,Intermediate,Half life in rats at the dose of 1.0 mpk by i.v. administration,,CHEMBL627802,,1,1,,BAO_0000218,,
9591,A,,10116.0,,50597,Expert,Half life in rat,,CHEMBL627803,,1,1,,BAO_0000218,,
9592,A,In vivo,10116.0,,50597,Intermediate,Half life was evaluated after intravenous administration to rats,,CHEMBL873820,,1,1,,BAO_0000218,,
9593,A,,10116.0,,50597,Intermediate,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,CHEMBL627804,,1,1,,BAO_0000218,,
9594,A,,10116.0,,50597,Intermediate,Half life was evaluated in rat,,CHEMBL627805,,1,1,,BAO_0000218,,
9595,A,,10116.0,,50597,Intermediate,Half life was evaluated in rat,,CHEMBL627806,,1,1,,BAO_0000218,,
9596,A,,10116.0,,50597,Intermediate,Half life was evaluated in rat; Not tested,,CHEMBL627107,,1,1,,BAO_0000218,,
9597,A,In vivo,10116.0,,50597,Intermediate,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,CHEMBL627108,,1,1,,BAO_0000218,,
9598,A,In vivo,10116.0,,50597,Intermediate,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,CHEMBL627109,,1,1,,BAO_0000218,,
9599,A,In vivo,10116.0,,50597,Intermediate,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,,CHEMBL627110,,1,1,,BAO_0000218,178.0,
9600,A,In vivo,9443.0,,22224,Intermediate,Half life was measured in monkey at dose of 10 mg/kg by po administration,,CHEMBL627111,,0,1,,BAO_0000218,,
9601,A,In vivo,9443.0,,22224,Intermediate,Half life was measured in monkey at dose of 10 mg/kg by po administration,,CHEMBL627112,,0,1,,BAO_0000218,,
9602,A,In vivo,10116.0,,22224,Intermediate,Half life was measured in rat at dose of 30 mg/kg by iv administration,,CHEMBL627113,,0,1,,BAO_0000218,,
9603,A,In vivo,10116.0,,22224,Intermediate,Half life was measured in rat at dose of 30 mg/kg by po administration,,CHEMBL627114,,0,1,,BAO_0000218,,
9604,A,,10116.0,,50597,Intermediate,Half life (t1/2) was determined,,CHEMBL627115,,1,1,,BAO_0000218,,
9605,A,,10116.0,,50597,Intermediate,Half life period at a dose of 10 uM/kg in rat was determined,,CHEMBL627116,,1,1,,BAO_0000218,,
9606,A,In vivo,10116.0,,50597,Intermediate,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,CHEMBL627117,,1,1,,BAO_0000218,,
9607,A,,10116.0,,50597,Intermediate,Half life period was determined,,CHEMBL627118,,1,1,,BAO_0000218,,
9608,A,In vivo,10116.0,,50597,Intermediate,Half life period after intravenous administration at 20 mpk in rats,,CHEMBL627119,,1,1,,BAO_0000218,,
9609,A,In vivo,10116.0,,50597,Intermediate,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,CHEMBL627120,,1,1,,BAO_0000218,,
9610,A,In vivo,10116.0,,50597,Intermediate,Half life period after intravenous administration in rat,,CHEMBL626922,,1,1,,BAO_0000218,,
9611,A,In vivo,10116.0,,50597,Intermediate,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,CHEMBL626923,,1,1,,BAO_0000218,,
9612,A,In vivo,10116.0,,50597,Intermediate,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,CHEMBL626924,,1,1,,BAO_0000218,,
9613,A,,10116.0,,50597,Intermediate,Half life period in 80% rat plasma at 37 degree Centigrade,,CHEMBL626925,,1,1,,BAO_0000218,1969.0,
9614,A,,10116.0,,50597,Intermediate,Half life period in SD rats,,CHEMBL626926,,1,1,,BAO_0000218,,
9615,A,,10116.0,,50597,Intermediate,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),,CHEMBL626927,,1,1,,BAO_0000218,1969.0,
9616,A,,10116.0,,50597,Intermediate,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),,CHEMBL626928,,1,1,,BAO_0000218,1969.0,
9617,A,,10116.0,,50597,Intermediate,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,CHEMBL626929,,1,1,,BAO_0000218,1969.0,
9618,A,,10116.0,,50597,Intermediate,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,CHEMBL626930,,1,1,,BAO_0000218,1969.0,
9619,A,,10116.0,,50597,Intermediate,Half life period in rat,,CHEMBL626931,,1,1,,BAO_0000218,,
9620,A,,10116.0,,50597,Intermediate,Half life period in rat,,CHEMBL626932,,1,1,,BAO_0000218,,
9621,A,,10116.0,,50597,Intermediate,Half life period in rat,,CHEMBL626933,,1,1,,BAO_0000218,,
9622,A,In vivo,10116.0,,50597,Intermediate,Half life period in rat after oral administration at 10.5 mg/kg dose,,CHEMBL873826,,1,1,,BAO_0000218,,
9623,A,In vivo,10116.0,,50597,Intermediate,Half life period in rat after oral administration at 11.2 mg/kg dose,,CHEMBL626934,,1,1,,BAO_0000218,,
9624,A,In vivo,10116.0,,50597,Intermediate,Half life period in rat after oral administration at 13 mg/kg dose,,CHEMBL626935,,1,1,,BAO_0000218,,
9625,A,In vivo,10116.0,,50597,Intermediate,Half life period in rat after oral administration at 9.7 mg/kg dose,,CHEMBL626936,,1,1,,BAO_0000218,,
9626,A,,10116.0,,50597,Intermediate,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL626937,,1,1,,BAO_0000218,,
9627,A,,10116.0,,50597,Intermediate,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,CHEMBL625906,,1,1,,BAO_0000218,,
9628,A,,10116.0,,50597,Intermediate,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,CHEMBL625907,,1,1,,BAO_0000218,,
9629,A,,10116.0,,50597,Intermediate,PK study was carried to determine AUC (area under curve) value in rat,,CHEMBL625908,,1,1,,BAO_0000218,,
9630,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC after intravenous administration to rats,,CHEMBL625909,,1,1,,BAO_0000218,,
9631,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC after oral administration to rats,,CHEMBL625910,,1,1,,BAO_0000218,,
9632,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,CHEMBL625911,,1,1,,BAO_0000218,,
9633,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,CHEMBL625912,,1,1,,BAO_0000218,,
9634,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,CHEMBL626538,,1,1,,BAO_0000218,,
9635,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,CHEMBL876794,,1,1,,BAO_0000218,,
9636,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,CHEMBL626539,,1,1,,BAO_0000218,,
9637,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,CHEMBL626540,,1,1,,BAO_0000218,,
9638,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,CHEMBL626541,,1,1,,BAO_0000218,,
9639,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,CHEMBL626542,,1,1,,BAO_0000218,,
9640,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,CHEMBL626543,,1,1,,BAO_0000218,,
9641,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,CHEMBL626544,,1,1,,BAO_0000218,,
9642,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,CHEMBL626545,,1,1,,BAO_0000218,,
9643,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,CHEMBL626546,,1,1,,BAO_0000218,,
9644,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter area under curve was reported,,CHEMBL626547,,1,1,,BAO_0000218,,
9645,A,,10116.0,,50597,Intermediate,Pharmacokinetic property (AUC) in rat,,CHEMBL626548,,1,1,,BAO_0000218,,
9646,A,,10116.0,,50597,Intermediate,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,CHEMBL626549,,1,1,,BAO_0000218,,
9647,A,,10116.0,,50597,Intermediate,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,CHEMBL626550,,1,1,,BAO_0000218,,
9648,A,,10116.0,,50597,Intermediate,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,CHEMBL626551,,1,1,,BAO_0000218,,
9649,A,,10116.0,,50597,Intermediate,Pharmacokinetic property was determined,,CHEMBL623777,,1,1,,BAO_0000218,,
9650,A,,10116.0,,50597,Intermediate,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,CHEMBL623778,,1,1,,BAO_0000218,,
9651,A,,10116.0,,50597,Intermediate,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,CHEMBL623779,,1,1,,BAO_0000218,,
9652,A,,10116.0,,50597,Intermediate,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,CHEMBL623780,,1,1,,BAO_0000218,1969.0,
9653,A,,10116.0,,50597,Intermediate,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,,CHEMBL622015,,1,1,,BAO_0000218,1969.0,
9654,A,,10116.0,,50597,Intermediate,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,,CHEMBL622016,,1,1,,BAO_0000218,1969.0,
9655,A,,10116.0,,50597,Intermediate,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,CHEMBL622017,,1,1,,BAO_0000218,,
9656,A,,10116.0,,50597,Intermediate,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,CHEMBL622018,,1,1,,BAO_0000218,,
9657,A,,10116.0,,50597,Intermediate,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,CHEMBL622019,,1,1,,BAO_0000218,,
9658,A,,10116.0,,50597,Intermediate,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,CHEMBL622020,,1,1,,BAO_0000218,,
9659,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,CHEMBL622021,,1,1,,BAO_0000218,,
9660,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,CHEMBL622022,,1,1,,BAO_0000218,,
9661,A,,10116.0,,50597,Intermediate,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,CHEMBL622023,,1,1,,BAO_0000218,,
9662,A,,10116.0,,50597,Intermediate,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,CHEMBL622024,,1,1,,BAO_0000218,,
9663,A,,10116.0,,50597,Intermediate,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,CHEMBL622693,,1,1,,BAO_0000218,,
9664,A,,10116.0,,50597,Intermediate,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,CHEMBL622694,,1,1,,BAO_0000218,,
9665,A,,10116.0,,50597,Intermediate,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,CHEMBL622695,,1,1,,BAO_0000218,,
9666,A,,10116.0,,50597,Intermediate,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,CHEMBL622696,,1,1,,BAO_0000218,,
9667,A,,10116.0,,50597,Intermediate,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,CHEMBL622697,,1,1,,BAO_0000218,,
9668,A,,10116.0,,50597,Intermediate,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,CHEMBL622874,,1,1,,BAO_0000218,,
9669,A,,10116.0,,50597,Intermediate,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,CHEMBL622875,,1,1,,BAO_0000218,,
9670,A,,10116.0,,50597,Intermediate,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,CHEMBL622876,,1,1,,BAO_0000218,,
9671,A,,10116.0,,50597,Intermediate,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,CHEMBL622877,,1,1,,BAO_0000218,,
9672,A,,10116.0,,50597,Intermediate,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,CHEMBL622878,,1,1,,BAO_0000218,,
9673,A,,10116.0,,50597,Intermediate,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,,CHEMBL622879,,1,1,,BAO_0000218,1969.0,
9674,A,,10116.0,,50597,Intermediate,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,CHEMBL877602,,1,1,,BAO_0000218,,
9675,A,,10116.0,,50597,Intermediate,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622880,,1,1,,BAO_0000218,,
9676,A,,10116.0,,50597,Intermediate,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622881,,1,1,,BAO_0000218,,
9677,A,,10116.0,,50597,Intermediate,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622882,,1,1,,BAO_0000218,,
9678,A,,10116.0,,50597,Intermediate,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL622883,,1,1,,BAO_0000218,,
9679,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",,CHEMBL622884,,1,1,,BAO_0000218,2046.0,
9680,A,,10116.0,,50597,Intermediate,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",,CHEMBL622885,,1,1,,BAO_0000218,2046.0,
9681,A,,10116.0,,50597,Intermediate,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,CHEMBL622886,,1,1,,BAO_0000218,,
9682,A,,10116.0,,50597,Intermediate,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,CHEMBL622887,,1,1,,BAO_0000218,,
9683,A,,10116.0,,50597,Intermediate,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,CHEMBL622888,,1,1,,BAO_0000218,1088.0,
9684,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622889,,1,1,,BAO_0000218,178.0,
9685,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622890,,1,1,,BAO_0000218,178.0,
9686,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622891,,1,1,,BAO_0000218,178.0,
9687,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL877603,,1,1,,BAO_0000218,178.0,
9688,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622892,,1,1,,BAO_0000218,955.0,
9689,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622893,,1,1,,BAO_0000218,955.0,
9690,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622894,,1,1,,BAO_0000218,955.0,
9691,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622895,,1,1,,BAO_0000218,955.0,
9692,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,,CHEMBL622896,,1,1,,BAO_0000218,955.0,
9693,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622897,,1,1,,BAO_0000218,948.0,
9694,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622898,,1,1,,BAO_0000218,948.0,
9695,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622899,,1,1,,BAO_0000218,948.0,
9696,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622900,,1,1,,BAO_0000218,2113.0,
9697,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624114,,1,1,,BAO_0000218,2113.0,
9698,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624115,,1,1,,BAO_0000218,2113.0,
9699,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624116,,1,1,,BAO_0000218,2113.0,
9700,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624117,,1,1,,BAO_0000218,2107.0,
9701,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624118,,1,1,,BAO_0000218,2107.0,
9702,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624119,,1,1,,BAO_0000218,2107.0,
9703,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624120,,1,1,,BAO_0000218,2107.0,
9704,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624121,,1,1,,BAO_0000218,2048.0,
9705,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624122,,1,1,,BAO_0000218,2048.0,
9706,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624123,,1,1,,BAO_0000218,2048.0,
9707,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624124,,1,1,,BAO_0000218,2048.0,
9708,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624125,,1,1,,BAO_0000218,2385.0,
9709,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624126,,1,1,,BAO_0000218,2385.0,
9710,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624127,,1,1,,BAO_0000218,2385.0,
9711,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624128,,1,1,,BAO_0000218,2385.0,
9712,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL624129,,1,1,,BAO_0000218,14.0,
9713,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL624130,,1,1,,BAO_0000218,14.0,
9714,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622340,,1,1,,BAO_0000218,14.0,
9715,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622341,,1,1,,BAO_0000218,14.0,
9716,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622342,,1,1,,BAO_0000218,160.0,
9717,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622343,,1,1,,BAO_0000218,160.0,
9718,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622344,,1,1,,BAO_0000218,160.0,
9719,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622345,,1,1,,BAO_0000218,160.0,
9720,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622346,,1,1,,BAO_0000218,2106.0,
9721,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622347,,1,1,,BAO_0000218,2106.0,
9722,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622348,,1,1,,BAO_0000218,2106.0,
9723,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622349,,1,1,,BAO_0000218,2106.0,
9724,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,CHEMBL622350,,1,1,,BAO_0000218,,
9725,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,CHEMBL622351,,1,1,,BAO_0000218,,
9726,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,CHEMBL622352,,1,1,,BAO_0000218,,
9727,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,CHEMBL622353,,1,1,,BAO_0000218,,
9728,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,CHEMBL622354,,1,1,,BAO_0000218,,
9729,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,CHEMBL622355,,1,1,,BAO_0000218,,
9730,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,CHEMBL622356,,1,1,,BAO_0000218,,
9731,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,CHEMBL622357,,1,1,,BAO_0000218,,
9732,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,CHEMBL622358,,1,1,,BAO_0000218,,
9733,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,CHEMBL622359,,1,1,,BAO_0000218,,
9734,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,CHEMBL874393,,1,1,,BAO_0000218,,
9735,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL622872,,1,1,,BAO_0000218,,
9736,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL622873,,1,1,,BAO_0000218,,
9737,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL623047,,1,1,,BAO_0000218,,
9738,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL623048,,1,1,,BAO_0000218,,
9739,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL623049,,1,1,,BAO_0000218,,
9740,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL623050,,1,1,,BAO_0000218,,
9741,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL623051,,1,1,,BAO_0000218,,
9742,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL623052,,1,1,,BAO_0000218,,
9743,A,,10116.0,,50597,Intermediate,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL626343,,1,1,,BAO_0000218,,
9744,A,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,CHEMBL626344,,1,1,,BAO_0000218,,
9745,A,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,CHEMBL626345,,1,1,,BAO_0000218,,
9746,A,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,CHEMBL626346,,1,1,,BAO_0000218,,
9747,A,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,CHEMBL626347,,1,1,,BAO_0000218,,
9748,A,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,CHEMBL626348,,1,1,,BAO_0000218,,
9749,A,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,CHEMBL626349,,1,1,,BAO_0000218,,
9750,F,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,CHEMBL626350,,1,1,,BAO_0000218,,
9751,A,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,CHEMBL626351,,1,1,,BAO_0000218,,
9752,A,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,CHEMBL627650,,1,1,,BAO_0000218,,
9753,F,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,CHEMBL627651,,1,1,,BAO_0000218,,
9754,A,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,CHEMBL627652,,1,1,,BAO_0000218,,
9755,A,,10116.0,,50597,Intermediate,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,CHEMBL627653,,1,1,,BAO_0000218,,
9756,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,CHEMBL627654,,1,1,,BAO_0000218,,
9757,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,CHEMBL627835,,1,1,,BAO_0000218,,
9758,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,CHEMBL627836,,1,1,,BAO_0000218,,
9759,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,CHEMBL627837,,1,1,,BAO_0000218,,
9760,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,CHEMBL627838,,1,1,,BAO_0000218,,
9761,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,CHEMBL875338,,1,1,,BAO_0000218,,
9762,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,CHEMBL627839,,1,1,,BAO_0000218,,
9763,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,CHEMBL627840,,1,1,,BAO_0000218,,
9764,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,CHEMBL627841,,1,1,,BAO_0000218,,
9765,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,CHEMBL627842,,1,1,,BAO_0000218,,
9766,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,CHEMBL627843,,1,1,,BAO_0000218,,
9767,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,CHEMBL627844,,1,1,,BAO_0000218,,
9768,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,CHEMBL627845,,1,1,,BAO_0000218,,
9769,A,In vivo,10116.0,,50597,Intermediate,Half life period in rat by iv administration at a dose of 3 mg/kg,,CHEMBL627846,,1,1,,BAO_0000218,,
9770,A,,10116.0,,50597,Intermediate,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),,CHEMBL627847,,1,1,,BAO_0000218,1969.0,
9771,A,,10116.0,,50597,Intermediate,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),,CHEMBL873821,,1,1,,BAO_0000218,1969.0,
9772,A,,10116.0,,50597,Intermediate,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,CHEMBL626079,,1,1,,BAO_0000218,1969.0,
9773,A,,10116.0,,50597,Intermediate,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,CHEMBL626080,,1,1,,BAO_0000218,1969.0,
9774,A,,10116.0,,50597,Intermediate,Half life period was evaluated in rat plasma,,CHEMBL626081,,1,1,,BAO_0000218,1969.0,
9775,A,,10116.0,,50597,Intermediate,Half life period was evaluated in rat plasma; Not tested,,CHEMBL875344,,1,1,,BAO_0000218,1969.0,
9776,A,,10116.0,,50597,Intermediate,Half life period was evaluated in rats,,CHEMBL626082,,1,1,,BAO_0000218,,
9777,A,In vivo,10116.0,,50597,Intermediate,"Half life period was evaluated in rats, iv",,CHEMBL626250,,1,1,,BAO_0000218,,
9778,A,In vivo,10116.0,,50597,Intermediate,Half life period after intravenous administration at 5 mg/kg in rat,,CHEMBL626251,,1,1,,BAO_0000218,,
9779,A,In vivo,10116.0,,50597,Intermediate,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,CHEMBL626252,,1,1,,BAO_0000218,,
9780,A,In vivo,10116.0,,50597,Intermediate,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,CHEMBL626253,,1,1,,BAO_0000218,,
9781,A,,10116.0,,50597,Intermediate,Half life stability of compound was evaluated in rat plasma,,CHEMBL626254,,1,1,,BAO_0000218,1969.0,
9782,A,In vivo,10116.0,,50597,Intermediate,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,CHEMBL626255,,1,1,,BAO_0000218,,
9783,A,In vivo,10116.0,,50597,Intermediate,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,CHEMBL626256,,1,1,,BAO_0000218,,
9784,A,In vivo,10116.0,,50597,Intermediate,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,CHEMBL626257,,1,1,,BAO_0000218,,
9785,A,In vivo,10116.0,,50597,Intermediate,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,CHEMBL626258,,1,1,,BAO_0000218,,
9786,A,In vivo,10116.0,,50597,Intermediate,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,CHEMBL626259,,1,1,,BAO_0000218,,
9787,A,In vivo,10116.0,,50597,Intermediate,Half in rat i.v.,,CHEMBL626260,,1,1,,BAO_0000218,,
9788,A,In vivo,10116.0,,50597,Intermediate,Half period in rat after intravenous administration,,CHEMBL875345,,1,1,,BAO_0000218,,
9789,A,In vivo,10116.0,,50597,Intermediate,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,CHEMBL626261,,1,1,,BAO_0000218,,
9790,A,In vitro,10116.0,,50597,Intermediate,Half-life measured in in vitro Cathepsin B assay in rat liver,,CHEMBL626262,,1,1,,BAO_0000218,2107.0,
9791,A,,10116.0,,50597,Intermediate,Half-life of compound was determined in rats,,CHEMBL626263,,1,1,,BAO_0000218,,
9792,A,In vivo,10116.0,,50597,Intermediate,Half-life at 10 mg/kg in rat upon intravenous administration,,CHEMBL625270,,1,1,,BAO_0000218,,
9793,A,,10116.0,,50597,Intermediate,Half-life determined in rat,,CHEMBL625271,,1,1,,BAO_0000218,,
9794,A,,10116.0,,50597,Intermediate,Half-life determined in rat,,CHEMBL625272,,1,1,,BAO_0000218,,
9795,A,In vivo,10116.0,,50597,Intermediate,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,,CHEMBL625273,,1,1,,BAO_0000218,955.0,
9796,A,,10116.0,,50597,Intermediate,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",,CHEMBL625274,,1,1,,BAO_0000218,1969.0,
9797,A,In vivo,10116.0,,50597,Intermediate,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,CHEMBL625275,,1,1,,BAO_0000218,,
9798,A,In vivo,10116.0,,50597,Intermediate,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,,CHEMBL625276,,1,1,,BAO_0000218,1969.0,
9799,A,,10116.0,,50597,Intermediate,Half-life in rat plasma,,CHEMBL625277,,1,1,,BAO_0000218,1969.0,
9800,A,,10116.0,,50597,Intermediate,Half-life in rat plasma was determined,,CHEMBL625278,,1,1,,BAO_0000218,1969.0,
9801,A,,10116.0,,50597,Intermediate,Half-life in rat plasma; Not tested,,CHEMBL625279,,1,1,,BAO_0000218,1969.0,
9802,A,,10116.0,,50597,Intermediate,Half-life in rat serum,,CHEMBL625280,,1,1,,BAO_0000218,1977.0,
9803,A,,10116.0,,50597,Intermediate,Half-life in rat serum; na is not available,,CHEMBL876797,,1,1,,BAO_0000218,1977.0,
9804,A,,10116.0,,50597,Intermediate,Half-life was calculated in rat,,CHEMBL625281,,1,1,,BAO_0000218,,
9805,A,,10116.0,,50597,Intermediate,Half-life was calculated in rat plasma,,CHEMBL873827,,1,1,,BAO_0000218,1969.0,
9806,A,,10116.0,,50597,Intermediate,Half-life was determined,,CHEMBL625282,,1,1,,BAO_0000218,,
9807,A,,10116.0,,50597,Intermediate,Half-life was determined,,CHEMBL625283,,1,1,,BAO_0000218,,
9808,A,In vivo,10116.0,,50597,Intermediate,Half-life after administration of 20 mg/Kg oral dose in rat,,CHEMBL625284,,1,1,,BAO_0000218,,
9809,A,In vivo,10116.0,,50597,Intermediate,Half-life after administration of 3.2 mg/kg intravenously in male rat,,CHEMBL625285,,1,1,,BAO_0000218,,
9810,A,In vivo,10116.0,,50597,Intermediate,Half-life after intravenous administration in female rat,,CHEMBL625286,,1,1,,BAO_0000218,,
9811,A,In vivo,10116.0,,50597,Intermediate,Half-life after intravenous administration in male rat,,CHEMBL625287,,1,1,,BAO_0000218,,
9812,A,In vivo,10116.0,,50597,Intermediate,Half-life after intravenous dose in rat,,CHEMBL625288,,1,1,,BAO_0000218,,
9813,A,,10116.0,,50597,Intermediate,Half-life in a rat liver homogenate preparation,,CHEMBL625289,,1,1,,BAO_0000218,2107.0,
9814,A,,10116.0,,50597,Intermediate,Half-life in plasma of rat,,CHEMBL625290,,1,1,,BAO_0000218,1969.0,
9815,A,,10116.0,,50597,Intermediate,Half-life in plasma of rat at dose of 3-10 mgkg,,CHEMBL876798,,1,1,,BAO_0000218,1969.0,
9816,A,,10116.0,,50597,Intermediate,Half-life in rat,,CHEMBL625291,,1,1,,BAO_0000218,,
9817,A,,10116.0,,50597,Intermediate,Half-life in rat,,CHEMBL625292,,1,1,,BAO_0000218,,
9818,A,,10116.0,,50597,Intermediate,Half-life in rat,,CHEMBL625293,,1,1,,BAO_0000218,,
9819,A,,10116.0,,50597,Intermediate,Half-life in rat,,CHEMBL622832,,1,1,,BAO_0000218,,
9820,A,,10116.0,,50597,Intermediate,Half-life in rat,,CHEMBL622833,,1,1,,BAO_0000218,,
9821,A,,10116.0,,50597,Intermediate,Half-life in rat,,CHEMBL622834,,1,1,,BAO_0000218,,
9822,A,In vivo,10116.0,,50597,Intermediate,Half-life in rat after oral administration at 10 mg/kg,,CHEMBL622835,,1,1,,BAO_0000218,,
9823,A,In vivo,10116.0,,50597,Intermediate,Half-life in rat after po administration at a dose of 10 mg/kg,,CHEMBL622836,,1,1,,BAO_0000218,,
9824,A,In vivo,10116.0,,50597,Intermediate,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,CHEMBL622837,,1,1,,BAO_0000218,,
9825,A,In vivo,10116.0,,50597,Intermediate,Half-life in rat at 3 mg/kg dose administered intravenously,,CHEMBL622838,,1,1,,BAO_0000218,,
9826,A,,10116.0,,50597,Intermediate,Half-life in rat brain homogenate,,CHEMBL622839,,1,1,,BAO_0000218,955.0,
9827,A,,10116.0,,50597,Intermediate,Half-life in rat plasma,,CHEMBL622840,,1,1,,BAO_0000218,1969.0,
9828,A,,10116.0,,50597,Intermediate,Half-life in rats,,CHEMBL622841,,1,1,,BAO_0000218,,
9829,A,,10116.0,,50597,Intermediate,Half-life in Dawley rats,,CHEMBL622842,,1,1,,BAO_0000218,,
9830,A,In vitro,10116.0,,50597,Intermediate,Half-life in vitro in rat plasma,,CHEMBL622843,,1,1,,BAO_0000218,1969.0,
9831,A,In vitro,10116.0,,50597,Intermediate,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,,CHEMBL622844,,1,1,,BAO_0000218,1969.0,
9832,A,,10116.0,,50597,Intermediate,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,CHEMBL622845,,1,1,,BAO_0000218,,
9833,A,,10116.0,,50597,Intermediate,The area under the curve of compound was measured at the dose of 100 umol/kg,,CHEMBL622846,,1,1,,BAO_0000218,,
9834,A,,10116.0,,50597,Intermediate,The area under the curve of compound was measured at the dose of 300 umol/kg,,CHEMBL622847,,1,1,,BAO_0000218,,
9835,A,,10116.0,,50597,Intermediate,The area under the curve of compound was measured at the dose of 30 umol/kg,,CHEMBL622848,,1,1,,BAO_0000218,,
9836,A,In vivo,10116.0,,50597,Intermediate,Bioavailability as oral AUC in rats,,CHEMBL622849,,1,1,,BAO_0000218,,
9837,A,,10116.0,,50597,Intermediate,The plasma concentration versus time curve (AUC) was determined,,CHEMBL622850,,1,1,,BAO_0000218,1969.0,
9838,A,,10116.0,,50597,Intermediate,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL876807,,1,1,,BAO_0000218,,
9839,A,,10116.0,,50597,Intermediate,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL622851,,1,1,,BAO_0000218,,
9840,A,,10116.0,,50597,Intermediate,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL622852,,1,1,,BAO_0000218,,
9841,A,,10116.0,,50597,Intermediate,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,CHEMBL622853,,1,1,,BAO_0000218,,
9842,A,,10116.0,,50597,Intermediate,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,CHEMBL622854,,1,1,,BAO_0000218,,
9843,A,,10116.0,,50597,Intermediate,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,CHEMBL622855,,1,1,,BAO_0000218,,
9844,A,,10116.0,,50597,Intermediate,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL622856,,1,1,,BAO_0000218,1969.0,
9845,A,,10116.0,,50597,Intermediate,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL622857,,1,1,,BAO_0000218,1969.0,
9846,A,,10116.0,,50597,Intermediate,AUC in rat after po administration at a dose of 10 mg/kg,,CHEMBL622858,,1,1,,BAO_0000218,1969.0,
9847,A,,10116.0,,50597,Intermediate,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,,CHEMBL622859,,1,1,,BAO_0000218,1969.0,
9848,A,,10116.0,,50597,Intermediate,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,CHEMBL622860,,1,1,,BAO_0000218,,
9849,A,,10116.0,,50597,Intermediate,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,CHEMBL622861,,1,1,,BAO_0000218,,
9850,A,,10116.0,,50597,Intermediate,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,CHEMBL622862,,1,1,,BAO_0000218,,
9851,A,,10116.0,,50597,Intermediate,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,CHEMBL622863,,1,1,,BAO_0000218,,
9852,A,,10116.0,,50597,Intermediate,Area under curve value 6 hr after po administration in rat,,CHEMBL623817,,1,1,,BAO_0000218,,
9853,A,,10116.0,,50597,Intermediate,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL623818,,1,1,,BAO_0000218,,
9854,A,,10116.0,,50597,Intermediate,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,CHEMBL623819,,1,1,,BAO_0000218,,
9855,A,,10116.0,,50597,Intermediate,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL623820,,1,1,,BAO_0000218,,
9856,A,,10116.0,,50597,Intermediate,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,CHEMBL623821,,1,1,,BAO_0000218,,
9857,A,,10116.0,,50597,Intermediate,AUC normalized for dose (AUCN) in rat,,CHEMBL623822,,1,1,,BAO_0000218,1969.0,
9858,A,,10116.0,,50597,Intermediate,Area under curve in rat after p.o. administration,,CHEMBL623823,,1,1,,BAO_0000218,,
9859,A,,10116.0,,50597,Intermediate,Area under curve in rat after p.o. administration,,CHEMBL623824,,1,1,,BAO_0000218,,
9860,A,,10116.0,,50597,Intermediate,Area under curve in rat after p.o. administration; Not determined,,CHEMBL623825,,1,1,,BAO_0000218,,
9861,A,,10116.0,,50597,Intermediate,Area under curve in rat after peroral administration,,CHEMBL622070,,1,1,,BAO_0000218,,
9862,A,,10116.0,,50597,Intermediate,Area under curve (carotid artery) value of the compound,,CHEMBL622071,,1,1,,BAO_0000218,,
9863,A,,10116.0,,50597,Intermediate,Bioavailability expressed as the area under curve of rat carotid artery,,CHEMBL622072,,1,1,,BAO_0000218,,
9864,A,,10116.0,,50597,Intermediate,Area under curve in male SD rats was observed after intravenous administration in rat,,CHEMBL622073,,1,1,,BAO_0000218,,
9865,A,,10116.0,,50597,Intermediate,Area under curve of the compound was determined,,CHEMBL622074,,1,1,,BAO_0000218,,
9866,A,,10116.0,,50597,Intermediate,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,CHEMBL622075,,1,1,,BAO_0000218,,
9867,A,,10116.0,,50597,Intermediate,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,,CHEMBL622076,,1,1,,BAO_0000218,1969.0,
9868,A,,10116.0,,50597,Intermediate,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,,CHEMBL622077,,1,1,,BAO_0000218,1969.0,
9869,A,,10116.0,,50597,Intermediate,Area under curve (portal vein) value of the compound,,CHEMBL622078,,1,1,,BAO_0000218,,
9870,A,,10116.0,,50597,Intermediate,Bioavailability expressed as the area under curve of rat portal vein,,CHEMBL622079,,1,1,,BAO_0000218,,
9871,A,,10116.0,,50597,Intermediate,Area Under plasma concentration time curve in rat upon peroral administration,,CHEMBL622080,,1,1,,BAO_0000218,1969.0,
9872,A,,10116.0,,50597,Intermediate,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,CHEMBL877612,,1,1,,BAO_0000218,,
9873,A,,10116.0,,50597,Intermediate,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,CHEMBL622081,,1,1,,BAO_0000218,,
9874,A,,10116.0,,50597,Intermediate,Compound was evaluated for oral bioavailability in rats,,CHEMBL622082,,1,1,,BAO_0000218,,
9875,A,,10116.0,,50597,Intermediate,Compound was evaluated for oral bioavailability in rats after iv administration,,CHEMBL622083,,1,1,,BAO_0000218,,
9876,A,,10116.0,,50597,Intermediate,Compound was evaluated for oral bioavailability in rats; 30-80,,CHEMBL622084,,1,1,,BAO_0000218,,
9877,A,,10116.0,,50597,Intermediate,Compound was evaluated for oral bioavailability in rats; 50-60,,CHEMBL622085,,1,1,,BAO_0000218,,
9878,A,,10116.0,,50597,Intermediate,Compound was evaluated for oral bioavailability in rats; no data,,CHEMBL622086,,1,1,,BAO_0000218,,
9879,A,,10116.0,,50597,Intermediate,Compound was evaluated for oral bioavailability in rats; peptide,,CHEMBL622087,,1,1,,BAO_0000218,,
9880,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",,CHEMBL622088,,1,1,,BAO_0000218,178.0,
9881,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",,CHEMBL622089,,1,1,,BAO_0000218,178.0,
9882,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",,CHEMBL623685,,1,1,,BAO_0000218,178.0,
9883,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",,CHEMBL623686,,1,1,,BAO_0000218,178.0,
9884,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL623687,,1,1,,BAO_0000218,945.0,
9885,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL623688,,1,1,,BAO_0000218,945.0,
9886,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL623689,,1,1,,BAO_0000218,945.0,
9887,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622485,,1,1,,BAO_0000218,945.0,
9888,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622486,,1,1,,BAO_0000218,2046.0,
9889,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL877613,,1,1,,BAO_0000218,2046.0,
9890,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622487,,1,1,,BAO_0000218,2046.0,
9891,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622488,,1,1,,BAO_0000218,2046.0,
9892,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,CHEMBL622489,,1,1,,BAO_0000218,948.0,
9893,A,,10116.0,,50597,Intermediate,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,CHEMBL622490,,1,1,,BAO_0000218,1088.0,
9894,A,,10116.0,,50597,Intermediate,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,CHEMBL622491,,1,1,,BAO_0000218,1088.0,
9895,A,,10116.0,,50597,Intermediate,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,,CHEMBL622492,,1,1,,BAO_0000218,2107.0,
9896,A,,10116.0,,50597,Intermediate,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,CHEMBL622493,,1,1,,BAO_0000218,1088.0,
9897,A,,10116.0,,50597,Intermediate,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,CHEMBL622494,,1,1,,BAO_0000218,1088.0,
9898,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,CHEMBL622495,,1,1,,BAO_0000218,2385.0,
9899,A,,10116.0,,50597,Intermediate,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,CHEMBL622496,,1,1,,BAO_0000218,,
9900,A,,10116.0,,50597,Intermediate,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,CHEMBL622497,,1,1,,BAO_0000218,1088.0,
9901,A,,10116.0,,50597,Intermediate,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,CHEMBL622498,,1,1,,BAO_0000218,,
9902,A,,10116.0,,50597,Intermediate,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,,CHEMBL624918,,1,1,,BAO_0000218,1088.0,
9903,A,,10116.0,,50597,Intermediate,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,,CHEMBL624919,,1,1,,BAO_0000218,1088.0,
9904,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat blood after 5 min of administration,,CHEMBL624920,,1,1,,BAO_0000218,178.0,
9905,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat blood after 5 min of administration.,,CHEMBL624921,,1,1,,BAO_0000218,178.0,
9906,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat brain after 5 min of administration,,CHEMBL624922,,1,1,,BAO_0000218,955.0,
9907,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat heart after 5 min of administration,,CHEMBL624923,,1,1,,BAO_0000218,948.0,
9908,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat heart after 5 min of administration.,,CHEMBL624924,,1,1,,BAO_0000218,948.0,
9909,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat kidney after 5 min of administration,,CHEMBL624925,,1,1,,BAO_0000218,2113.0,
9910,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat kidney after 5 min of administration.,,CHEMBL624926,,1,1,,BAO_0000218,2113.0,
9911,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat liver after 5 min of administration,,CHEMBL624927,,1,1,,BAO_0000218,2107.0,
9912,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat liver after 5 min of administration.,,CHEMBL874402,,1,1,,BAO_0000218,2107.0,
9913,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat lung after 5 min of administration,,CHEMBL624928,,1,1,,BAO_0000218,2048.0,
9914,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat lung after 5 min of administration.,,CHEMBL624929,,1,1,,BAO_0000218,2048.0,
9915,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat muscle after 5 min of administration,,CHEMBL624930,,1,1,,BAO_0000218,2385.0,
9916,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of compound in rat muscle after 5 min of administration.,,CHEMBL624931,,1,1,,BAO_0000218,2385.0,
9917,A,,10116.0,,50597,Intermediate,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624932,,1,1,,BAO_0000218,948.0,
9918,A,,10116.0,,50597,Intermediate,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624933,,1,1,,BAO_0000218,948.0,
9919,A,,10116.0,,50597,Intermediate,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624934,,1,1,,BAO_0000218,2107.0,
9920,A,,10116.0,,50597,Intermediate,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624935,,1,1,,BAO_0000218,2107.0,
9921,A,,10116.0,,50597,Intermediate,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624936,,1,1,,BAO_0000218,,
9922,A,,10116.0,,50597,Intermediate,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624937,,1,1,,BAO_0000218,,
9923,A,,10116.0,,50597,Intermediate,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624938,,1,1,,BAO_0000218,2106.0,
9924,A,,10116.0,,50597,Intermediate,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624939,,1,1,,BAO_0000218,2106.0,
9925,A,,10116.0,,50597,Intermediate,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL624940,,1,1,,BAO_0000218,,
9926,A,,10116.0,,50597,Intermediate,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,CHEMBL874403,,1,1,,BAO_0000218,,
9927,A,,10116.0,,50597,Intermediate,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,CHEMBL624941,,1,1,,BAO_0000218,,
9928,A,,10116.0,,50597,Intermediate,Dose required to lower urine osmolality to 300 mOsm/kg in rat,,CHEMBL624942,,1,1,,BAO_0000218,1088.0,
9929,A,,10116.0,,50597,Intermediate,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,,CHEMBL624943,,1,1,,BAO_0000218,1088.0,
9930,A,In vivo,10116.0,,50597,Intermediate,% Bioavailability after 1 day of the drug administration in rats,,CHEMBL624944,,1,1,,BAO_0000218,,
9931,A,In vivo,10116.0,,50597,Intermediate,% Bioavailability after 4 day of the drug administration in rats,,CHEMBL624945,,1,1,,BAO_0000218,,
9932,A,In vivo,10116.0,,50597,Intermediate,Absolute bioavailability was evaluated in rat,,CHEMBL624946,,1,1,,BAO_0000218,,
9933,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,CHEMBL624947,,1,1,,BAO_0000218,,
9934,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,CHEMBL624948,,1,1,,BAO_0000218,,
9935,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,CHEMBL624949,,1,1,,BAO_0000218,,
9936,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,,CHEMBL622025,,1,1,,BAO_0000218,2113.0,
9937,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,,CHEMBL622026,,1,1,,BAO_0000218,2113.0,
9938,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,,CHEMBL622027,,1,1,,BAO_0000218,2113.0,
9939,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,,CHEMBL622028,,1,1,,BAO_0000218,2113.0,
9940,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,,CHEMBL622029,,1,1,,BAO_0000218,2107.0,
9941,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,,CHEMBL622208,,1,1,,BAO_0000218,2107.0,
9942,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,,CHEMBL622209,,1,1,,BAO_0000218,2107.0,
9943,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,,CHEMBL622210,,1,1,,BAO_0000218,2107.0,
9944,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,CHEMBL622211,,1,1,,BAO_0000218,,
9945,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,CHEMBL622212,,1,1,,BAO_0000218,,
9946,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,CHEMBL622213,,1,1,,BAO_0000218,,
9947,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,CHEMBL874404,,1,1,,BAO_0000218,,
9948,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,,CHEMBL620452,,1,1,,BAO_0000218,2385.0,
9949,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,,CHEMBL620453,,1,1,,BAO_0000218,2385.0,
9950,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,,CHEMBL620454,,1,1,,BAO_0000218,2385.0,
9951,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,,CHEMBL624067,,1,1,,BAO_0000218,2385.0,
9952,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,CHEMBL624068,,1,1,,BAO_0000218,,
9953,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,,CHEMBL624069,,1,1,,BAO_0000218,992.0,
9954,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,,CHEMBL624070,,1,1,,BAO_0000218,992.0,
9955,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,,CHEMBL624071,,1,1,,BAO_0000218,992.0,
9956,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,,CHEMBL624072,,1,1,,BAO_0000218,995.0,
9957,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,,CHEMBL624073,,1,1,,BAO_0000218,995.0,
9958,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,,CHEMBL624788,,1,1,,BAO_0000218,995.0,
9959,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,,CHEMBL624789,,1,1,,BAO_0000218,995.0,
9960,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,CHEMBL624790,,1,1,,BAO_0000218,,
9961,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,CHEMBL624791,,1,1,,BAO_0000218,,
9962,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,CHEMBL624792,,1,1,,BAO_0000218,,
9963,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,CHEMBL624793,,1,1,,BAO_0000218,,
9964,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,,CHEMBL877491,,1,1,,BAO_0000218,2385.0,
9965,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,,CHEMBL624957,,1,1,,BAO_0000218,2385.0,
9966,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,,CHEMBL624958,,1,1,,BAO_0000218,2385.0,
9967,A,,10116.0,,50597,Intermediate,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,,CHEMBL624959,,1,1,,BAO_0000218,2385.0,
9968,A,,10116.0,,50597,Intermediate,Dissociation constant was determined,,CHEMBL624960,,1,1,,BAO_0000218,,
9969,A,,10116.0,,50597,Intermediate,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,CHEMBL624961,,1,1,,BAO_0000218,,
9970,A,,10116.0,,50597,Intermediate,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL624962,,1,1,,BAO_0000218,,
9971,A,,10116.0,,50597,Intermediate,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL624963,,1,1,,BAO_0000218,,
9972,A,,10116.0,,50597,Intermediate,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,CHEMBL624964,,1,1,,BAO_0000218,,
9973,A,,10116.0,,50597,Intermediate,LogP value was evaluated in the in situ rat gut perfusion assay,,CHEMBL624965,,1,1,,BAO_0000218,,
9974,A,In vivo,10116.0,,50597,Intermediate,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,CHEMBL624966,,1,1,,BAO_0000218,,
9975,A,In vivo,10116.0,,50597,Intermediate,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,CHEMBL624967,,1,1,,BAO_0000218,,
9976,A,In vivo,10116.0,,50597,Intermediate,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,CHEMBL624968,,1,1,,BAO_0000218,,
9977,A,,10116.0,,50597,Intermediate,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL624969,,1,1,,BAO_0000218,,
9978,F,,10116.0,,50597,Expert,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,CHEMBL624970,,1,1,,BAO_0000218,,
9979,A,,10116.0,,50597,Intermediate,Half-life was evaluated after 10 uM/kg of intra arterial administration,,CHEMBL624971,,1,1,,BAO_0000218,,
9980,A,In vivo,10116.0,,50597,Intermediate,Half-life was evaluated after 20 uM/kg of peroral administration,,CHEMBL624972,,1,1,,BAO_0000218,,
9981,A,In vivo,10116.0,,50597,Intermediate,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,CHEMBL624973,,1,1,,BAO_0000218,,
9982,A,,10116.0,,50597,Intermediate,Half-life was evaluated in plasma of rat,,CHEMBL624974,,1,1,,BAO_0000218,1969.0,
9983,A,In vivo,10116.0,,50597,Intermediate,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,CHEMBL624975,,1,1,,BAO_0000218,,
9984,A,In vivo,10116.0,,50597,Intermediate,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,CHEMBL877492,,1,1,,BAO_0000218,,
9985,A,In vivo,10116.0,,50597,Intermediate,Half-life was measured in rat after an iv dose of 1 mg/kg,,CHEMBL624976,,1,1,,BAO_0000218,,
9986,A,In vivo,10116.0,,50597,Intermediate,Half-life period of compound in rats after peroral administration,,CHEMBL624977,,1,1,,BAO_0000218,,
9987,A,,10116.0,,50597,Intermediate,Half-life period of compound was measured in rat plasma.,,CHEMBL626848,,1,1,,BAO_0000218,1969.0,
9988,A,,10116.0,,50597,Intermediate,Half-life period of compound was measured in rat plasma; ND is not determined,,CHEMBL626849,,1,1,,BAO_0000218,1969.0,
9989,A,,10116.0,,50597,Intermediate,Half-life period of compound was measured in rat plasma; not determined,,CHEMBL626850,,1,1,,BAO_0000218,1969.0,
9990,A,In vivo,10116.0,,50597,Intermediate,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,CHEMBL626851,,1,1,,BAO_0000218,,
9991,A,In vivo,10116.0,,50597,Intermediate,Half-life period in rat by iv administration,,CHEMBL626852,,1,1,,BAO_0000218,,
9992,A,In vivo,10116.0,,50597,Intermediate,Half-life period in rats following intravenous administration at 2 mg/kg,,CHEMBL626853,,1,1,,BAO_0000218,,
9993,A,In vivo,10116.0,,50597,Intermediate,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL626854,,1,1,,BAO_0000218,,
9994,A,,10116.0,,50597,Intermediate,Half-life period was determined for the compound in rat,,CHEMBL627486,,1,1,,BAO_0000218,,
9995,A,In vivo,10116.0,,50597,Intermediate,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,CHEMBL627487,,1,1,,BAO_0000218,,
9996,A,In vivo,10116.0,,50597,Intermediate,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,CHEMBL627488,,1,1,,BAO_0000218,,
9997,A,In vivo,10116.0,,50597,Intermediate,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,CHEMBL627489,,1,1,,BAO_0000218,,
9998,A,In vivo,10116.0,,50597,Intermediate,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,CHEMBL627490,,1,1,,BAO_0000218,,
9999,A,In vivo,10116.0,,50597,Intermediate,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,CHEMBL873829,,1,1,,BAO_0000218,,
10000,A,In vivo,10116.0,,50597,Intermediate,Half-life was determined in rat at a dose of 1 mpk i.v.,,CHEMBL627655,,1,1,,BAO_0000218,,
10001,A,In vivo,10116.0,,50597,Intermediate,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,CHEMBL625994,,1,1,,BAO_0000218,,
10002,A,In vivo,10116.0,,50597,Intermediate,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,CHEMBL625995,,1,1,,BAO_0000218,,
10003,A,,10116.0,,50597,Intermediate,Half-life in rat,,CHEMBL625996,,1,1,,BAO_0000218,,
10004,A,In vitro,10116.0,,50597,Intermediate,In vitro half life in rat plasma,,CHEMBL625850,,1,1,,BAO_0000218,1969.0,
10005,A,In vitro,10116.0,,50597,Intermediate,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",,CHEMBL625851,,1,1,,BAO_0000218,1969.0,
10006,A,In vitro,10116.0,,50597,Intermediate,In vitro half life in rat,,CHEMBL625852,,1,1,,BAO_0000218,,
10007,A,In vivo,10116.0,,50597,Intermediate,In vivo half life period after intravenous administration in rat,,CHEMBL625853,,1,1,,BAO_0000218,,
10008,A,In vivo,10116.0,,50597,Intermediate,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,CHEMBL625854,,1,1,,BAO_0000218,,
10009,A,In vivo,10116.0,,50597,Intermediate,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,CHEMBL874450,,1,1,,BAO_0000218,,
10010,A,In vivo,10116.0,,50597,Intermediate,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL625855,,1,1,,BAO_0000218,,
10011,A,In vivo,10116.0,,50597,Intermediate,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL625856,,1,1,,BAO_0000218,,
10012,A,In vivo,10116.0,,50597,Intermediate,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,CHEMBL625857,,1,1,,BAO_0000218,,
10013,A,In vivo,10116.0,,50597,Intermediate,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL873831,,1,1,,BAO_0000218,,
10014,A,In vivo,10116.0,,50597,Intermediate,Longer half-life in rat (i.v.) at 0.5 mpk,,CHEMBL625858,,1,1,,BAO_0000218,,
10015,A,In vivo,10116.0,,50597,Intermediate,Longer half-life in rat (p.o.) at 2.0 mpk,,CHEMBL625859,,1,1,,BAO_0000218,,
10016,A,,10116.0,,50597,Intermediate,Pharmacokinetic property (half life) in rat,,CHEMBL625860,,1,1,,BAO_0000218,,
10017,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,CHEMBL625861,,1,1,,BAO_0000218,,
10018,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,CHEMBL625862,,1,1,,BAO_0000218,,
10019,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,CHEMBL625863,,1,1,,BAO_0000218,,
10020,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,CHEMBL625864,,1,1,,BAO_0000218,,
10021,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,CHEMBL625865,,1,1,,BAO_0000218,,
10022,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic half time was determined intravenously in rats.,,CHEMBL625866,,1,1,,BAO_0000218,,
10023,A,In vivo,10116.0,,50597,Intermediate,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,,CHEMBL625867,,1,1,,BAO_0000218,1969.0,
10024,A,,10116.0,,50597,Intermediate,Plasma half life of hydrolysis of the compound,,CHEMBL625868,,1,1,,BAO_0000218,1969.0,
10025,A,In vivo,10116.0,,50597,Intermediate,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,,CHEMBL625869,,1,1,,BAO_0000218,1969.0,
10026,A,,10116.0,,50597,Intermediate,Plasma half life period was calculated in rat,,CHEMBL874451,,1,1,,BAO_0000218,1969.0,
10027,A,,10116.0,,50597,Intermediate,Plasma half-life in Sprague-Dawley rats,,CHEMBL625870,,1,1,,BAO_0000218,1969.0,
10028,A,,10116.0,,50597,Intermediate,Plasma half-life in Sprague-Dawley rats; Not determined,,CHEMBL625871,,1,1,,BAO_0000218,1969.0,
10029,A,,10116.0,,50597,Intermediate,Plasma half-life in rats,,CHEMBL625872,,1,1,,BAO_0000218,1969.0,
10030,A,,10116.0,,50597,Intermediate,Plasma half-life in rats; <MQL,,CHEMBL625873,,1,1,,BAO_0000218,1969.0,
10031,A,,10116.0,,50597,Intermediate,Plasma half-life period (0-8 h) was determined,,CHEMBL625874,,1,1,,BAO_0000218,1969.0,
10032,A,,10116.0,,50597,Intermediate,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,,CHEMBL625875,,1,1,,BAO_0000218,1969.0,
10033,A,In vivo,10116.0,,50597,Intermediate,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,CHEMBL625876,,1,1,,BAO_0000218,1969.0,
10034,A,In vivo,10116.0,,50597,Intermediate,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,CHEMBL631258,,1,1,,BAO_0000218,1969.0,
10035,A,,10116.0,,50597,Intermediate,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,,CHEMBL631259,,1,1,,BAO_0000218,1969.0,
10036,A,,10116.0,,50597,Intermediate,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,,CHEMBL631260,,1,1,,BAO_0000218,1969.0,
10037,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",,CHEMBL631261,,1,1,,BAO_0000218,178.0,
10038,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",,CHEMBL631262,,1,1,,BAO_0000218,178.0,
10039,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",,CHEMBL631263,,1,1,,BAO_0000218,178.0,
10040,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,CHEMBL631264,,1,1,,BAO_0000218,,
10041,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,CHEMBL631265,,1,1,,BAO_0000218,,
10042,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,CHEMBL631266,,1,1,,BAO_0000218,,
10043,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,CHEMBL631267,,1,1,,BAO_0000218,,
10044,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,CHEMBL631268,,1,1,,BAO_0000218,,
10045,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,CHEMBL631269,,1,1,,BAO_0000218,,
10046,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,CHEMBL631270,,1,1,,BAO_0000218,,
10047,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,CHEMBL631271,,1,1,,BAO_0000218,948.0,
10048,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",,CHEMBL631272,,1,1,,BAO_0000218,948.0,
10049,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",,CHEMBL631273,,1,1,,BAO_0000218,948.0,
10050,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",,CHEMBL631274,,1,1,,BAO_0000218,948.0,
10051,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",,CHEMBL631275,,1,1,,BAO_0000218,948.0,
10052,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",,CHEMBL626984,,1,1,,BAO_0000218,948.0,
10053,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",,CHEMBL626985,,1,1,,BAO_0000218,948.0,
10054,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,CHEMBL626986,,1,1,,BAO_0000218,2107.0,
10055,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",,CHEMBL626987,,1,1,,BAO_0000218,2107.0,
10056,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",,CHEMBL626988,,1,1,,BAO_0000218,2107.0,
10057,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",,CHEMBL626989,,1,1,,BAO_0000218,2107.0,
10058,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",,CHEMBL626990,,1,1,,BAO_0000218,2107.0,
10059,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",,CHEMBL626991,,1,1,,BAO_0000218,2107.0,
10060,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",,CHEMBL626992,,1,1,,BAO_0000218,2107.0,
10061,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",,CHEMBL626993,,1,1,,BAO_0000218,2048.0,
10062,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",,CHEMBL874593,,1,1,,BAO_0000218,2048.0,
10063,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",,CHEMBL626994,,1,1,,BAO_0000218,2048.0,
10064,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",,CHEMBL626995,,1,1,,BAO_0000218,2048.0,
10065,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",,CHEMBL626190,,1,1,,BAO_0000218,2048.0,
10066,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",,CHEMBL626191,,1,1,,BAO_0000218,2048.0,
10067,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",,CHEMBL626364,,1,1,,BAO_0000218,2048.0,
10068,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",,CHEMBL626365,,1,1,,BAO_0000218,2046.0,
10069,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",,CHEMBL626366,,1,1,,BAO_0000218,2046.0,
10070,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",,CHEMBL626367,,1,1,,BAO_0000218,2046.0,
10071,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",,CHEMBL626368,,1,1,,BAO_0000218,2046.0,
10072,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",,CHEMBL626369,,1,1,,BAO_0000218,2046.0,
10073,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",,CHEMBL626370,,1,1,,BAO_0000218,2046.0,
10074,A,In vivo,10116.0,,50597,Intermediate,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,CHEMBL626371,,1,1,,BAO_0000218,,
10075,A,In vivo,10116.0,,50597,Intermediate,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,CHEMBL626372,,1,1,,BAO_0000218,,
10076,A,In vivo,10116.0,,50597,Intermediate,Bioavailability after a dose of 10 mg/kg p.o.,,CHEMBL626373,,1,1,,BAO_0000218,,
10077,A,In vivo,10116.0,,50597,Intermediate,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,CHEMBL626374,,1,1,,BAO_0000218,,
10078,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,CHEMBL626375,,1,1,,BAO_0000218,,
10079,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,CHEMBL626376,,1,1,,BAO_0000218,,
10080,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat po was determined,,CHEMBL626377,,1,1,,BAO_0000218,,
10081,A,In vivo,10116.0,,50597,Intermediate,Bioavailability of compound at 10 mg/kg in rat after oral administration,,CHEMBL626378,,1,1,,BAO_0000218,,
10082,A,In vivo,10116.0,,50597,Intermediate,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,CHEMBL626379,,1,1,,BAO_0000218,,
10083,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,CHEMBL626380,,1,1,,BAO_0000218,,
10084,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,CHEMBL626381,,1,1,,BAO_0000218,,
10085,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL626382,,1,1,,BAO_0000218,,
10086,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (Sprague-Dawley) (female),,CHEMBL626383,,1,1,,BAO_0000218,,
10087,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,CHEMBL874652,,1,1,,BAO_0000218,,
10088,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,CHEMBL626384,,1,1,,BAO_0000218,,
10089,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,CHEMBL626385,,1,1,,BAO_0000218,,
10090,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat at an oral dose of 2 mg/kg,,CHEMBL626386,,1,1,,BAO_0000218,,
10091,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL626387,,1,1,,BAO_0000218,,
10092,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL626388,,1,1,,BAO_0000218,,
10093,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL626389,,1,1,,BAO_0000218,,
10094,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL626390,,1,1,,BAO_0000218,,
10095,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,CHEMBL626391,,1,1,,BAO_0000218,,
10096,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL626392,,1,1,,BAO_0000218,,
10097,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL626393,,1,1,,BAO_0000218,,
10098,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was determined in rat,,CHEMBL623026,,1,1,,BAO_0000218,,
10099,A,In vivo,10116.0,,50597,Intermediate,Bioavailability,,CHEMBL623027,,1,1,,BAO_0000218,,
10100,A,In vivo,10116.0,,50597,Intermediate,Bioavailability,,CHEMBL623028,,1,1,,BAO_0000218,,
10101,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat after 1 day dosing,,CHEMBL623029,,1,1,,BAO_0000218,,
10102,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat after 4 day dosing,,CHEMBL623030,,1,1,,BAO_0000218,,
10103,A,In vivo,10116.0,,50597,Intermediate,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,CHEMBL623031,,1,1,,BAO_0000218,,
10104,A,In vivo,10116.0,,50597,Intermediate,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,CHEMBL623032,,1,1,,BAO_0000218,,
10105,A,In vivo,10116.0,,50597,Intermediate,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,CHEMBL623033,,1,1,,BAO_0000218,,
10106,A,In vivo,10116.0,,50597,Intermediate,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,CHEMBL623034,,1,1,,BAO_0000218,,
10107,A,In vivo,10116.0,,50597,Intermediate,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,CHEMBL623035,,1,1,,BAO_0000218,,
10108,A,In vivo,10116.0,,50597,Intermediate,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,CHEMBL623036,,1,1,,BAO_0000218,,
10109,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,CHEMBL623037,,1,1,,BAO_0000218,,
10110,A,In vivo,10116.0,,50597,Intermediate,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,CHEMBL623038,,1,1,,BAO_0000218,,
10111,A,In vivo,10116.0,,50597,Intermediate,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,,CHEMBL874385,,1,1,,BAO_0000218,1969.0,
10112,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (Fisher) (fasted),,CHEMBL623039,,1,1,,BAO_0000218,,
10113,A,In vivo,9443.0,,22224,Intermediate,Bioavailability in monkey after po administration of 10 mg/kg dose,,CHEMBL623040,,0,1,,BAO_0000218,,
10114,A,In vivo,9443.0,,22224,Intermediate,Oral bioavailability in monkey (dose 10 mg/kg),,CHEMBL623041,,0,1,,BAO_0000218,,
10115,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL623741,,1,1,,BAO_0000218,,
10116,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL623742,,1,1,,BAO_0000218,,
10117,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL623743,,1,1,,BAO_0000218,,
10118,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL623744,,1,1,,BAO_0000218,,
10119,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 2.0 mg/kg p.o.),,CHEMBL623745,,1,1,,BAO_0000218,,
10120,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,CHEMBL623746,,1,1,,BAO_0000218,,
10121,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 5 mg/kg p.o.),,CHEMBL623747,,1,1,,BAO_0000218,,
10122,A,In vivo,10116.0,,22224,Intermediate,Bioavailability in rat after po administration of 30 mg/kg dose,,CHEMBL623748,,0,1,,BAO_0000218,,
10123,A,In vivo,10116.0,,22224,Intermediate,Bioavailability in rat after po administration of 30 mg/kg dose,,CHEMBL623916,,0,1,,BAO_0000218,,
10124,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,CHEMBL623917,,1,1,,BAO_0000218,,
10125,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 2 mg/kg i.v.),,CHEMBL623918,,1,1,,BAO_0000218,,
10126,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL874386,,1,1,,BAO_0000218,,
10127,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat; Only traces detected in rat plasma,,CHEMBL623919,,1,1,,BAO_0000218,1969.0,
10128,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL623920,,1,1,,BAO_0000218,,
10129,A,In vivo,10116.0,,50597,Intermediate,Bioavailability upon oral administration of compound,,CHEMBL623148,,1,1,,BAO_0000218,,
10130,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,CHEMBL623149,,1,1,,BAO_0000218,,
10131,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL623150,,1,1,,BAO_0000218,,
10132,A,In vivo,10116.0,,50597,Intermediate,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,CHEMBL623151,,1,1,,BAO_0000218,,
10133,A,In vivo,10116.0,,50597,Intermediate,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,CHEMBL623152,,1,1,,BAO_0000218,,
10134,F,,10116.0,,50597,Expert,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,CHEMBL623153,,1,1,,BAO_0000218,,
10135,F,,10116.0,,50597,Expert,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,CHEMBL623154,,1,1,,BAO_0000218,,
10136,A,,10116.0,,50597,Intermediate,In vitro and metabolic stability was determined,,CHEMBL623155,,1,1,,BAO_0000218,,
10137,A,,10116.0,,50597,Intermediate,In vitro metabolic stability in rat hepatocytes,,CHEMBL623156,,1,1,,BAO_0000218,,
10138,A,,10116.0,,50597,Intermediate,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,CHEMBL623157,,1,1,,BAO_0000218,,
10139,A,In vitro,10116.0,,50597,Intermediate,Metabolic rate for compound was observed in rat hepatocytes,,CHEMBL623158,,1,1,401.0,BAO_0000218,2107.0,
10140,A,,10116.0,,50597,Intermediate,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,CHEMBL623159,,1,1,,BAO_0000218,,
10141,A,,10116.0,,50597,Intermediate,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,CHEMBL874390,,1,1,,BAO_0000218,,
10142,A,,10116.0,,50597,Intermediate,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,CHEMBL623160,,1,1,,BAO_0000218,,
10143,A,,10116.0,,50597,Intermediate,Metabolism of compound in rat S9 microsomes; Trace,,CHEMBL623161,,1,1,,BAO_0000218,,
10144,A,,10116.0,,50597,Intermediate,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,CHEMBL623162,,1,1,,BAO_0000218,,
10145,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,CHEMBL623163,,1,1,,BAO_0000218,,
10146,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,CHEMBL623164,,1,1,,BAO_0000218,,
10147,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,CHEMBL623165,,1,1,,BAO_0000218,,
10148,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,CHEMBL623166,,1,1,,BAO_0000218,,
10149,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,CHEMBL624983,,1,1,,BAO_0000218,,
10150,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,CHEMBL624984,,1,1,,BAO_0000218,,
10151,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,CHEMBL624985,,1,1,,BAO_0000218,,
10152,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,CHEMBL622970,,1,1,,BAO_0000218,,
10153,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,CHEMBL622971,,1,1,,BAO_0000218,,
10154,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,CHEMBL622972,,1,1,,BAO_0000218,,
10155,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,CHEMBL622973,,1,1,,BAO_0000218,,
10156,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,CHEMBL622974,,1,1,,BAO_0000218,,
10157,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,CHEMBL622975,,1,1,,BAO_0000218,,
10158,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,CHEMBL622976,,1,1,,BAO_0000218,,
10159,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,CHEMBL622977,,1,1,,BAO_0000218,,
10160,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,CHEMBL624351,,1,1,,BAO_0000218,,
10161,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,CHEMBL624352,,1,1,,BAO_0000218,,
10162,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,CHEMBL624353,,1,1,,BAO_0000218,,
10163,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,CHEMBL622397,,1,1,,BAO_0000218,,
10164,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,CHEMBL622398,,1,1,,BAO_0000218,,
10165,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,CHEMBL622399,,1,1,,BAO_0000218,,
10166,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,CHEMBL622400,,1,1,,BAO_0000218,,
10167,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,CHEMBL628428,,1,1,,BAO_0000218,,
10168,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,CHEMBL628590,,1,1,,BAO_0000218,,
10169,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,CHEMBL628591,,1,1,,BAO_0000218,,
10170,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,CHEMBL628592,,1,1,,BAO_0000218,,
10171,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,CHEMBL628593,,1,1,,BAO_0000218,,
10172,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,CHEMBL875333,,1,1,,BAO_0000218,,
10173,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,CHEMBL628594,,1,1,,BAO_0000218,,
10174,A,,10116.0,,50597,Intermediate,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,,CHEMBL628595,,1,1,,BAO_0000218,1969.0,
10175,A,,10116.0,,50597,Intermediate,Stability in rat plasma was determined,,CHEMBL628596,,1,1,,BAO_0000218,1969.0,
10176,A,,10116.0,,50597,Intermediate,Stability in rat plasma was determined; ND= no data,,CHEMBL628597,,1,1,,BAO_0000218,1969.0,
10177,A,,10116.0,,50597,Intermediate,Tested for plasma half life period in rat (0-8 hr),,CHEMBL628598,,1,1,,BAO_0000218,1969.0,
10178,A,,10116.0,,50597,Intermediate,Tested for plasma half life period in rat (0-8 hr); Not determined,,CHEMBL628599,,1,1,,BAO_0000218,1969.0,
10179,A,In vivo,10116.0,,50597,Intermediate,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,CHEMBL628600,,1,1,,BAO_0000218,,
10180,A,In vivo,10116.0,,50597,Intermediate,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,CHEMBL628601,,1,1,,BAO_0000218,,
10181,A,,10116.0,,50597,Intermediate,Tested for the half life in rat,,CHEMBL628602,,1,1,,BAO_0000218,,
10182,A,In vitro,10116.0,,50597,Intermediate,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,CHEMBL628603,,1,1,,BAO_0000218,,
10183,A,In vitro,10116.0,,50597,Intermediate,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,CHEMBL628604,,1,1,,BAO_0000218,,
10184,A,In vitro,10116.0,,50597,Intermediate,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,CHEMBL628605,,1,1,,BAO_0000218,,
10185,A,In vitro,10116.0,,50597,Intermediate,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,CHEMBL628606,,1,1,,BAO_0000218,,
10186,A,In vitro,10116.0,,50597,Intermediate,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,CHEMBL628607,,1,1,,BAO_0000218,,
10187,A,,10116.0,,50597,Intermediate,The biological half life the compound was measured at the dose of 100 umol/kg,,CHEMBL628608,,1,1,,BAO_0000218,,
10188,A,,10116.0,,50597,Intermediate,The biological half life the compound was measured at the dose of 30 umol/kg,,CHEMBL628609,,1,1,,BAO_0000218,,
10189,A,,10116.0,,50597,Intermediate,The compound was evaluated for plasma half life period in rat,,CHEMBL628610,,1,1,,BAO_0000218,1969.0,
10190,A,In vivo,10116.0,,50597,Intermediate,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL873819,,1,1,,BAO_0000218,,
10191,A,In vivo,10116.0,,50597,Intermediate,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,CHEMBL628611,,1,1,,BAO_0000218,,
10192,A,In vivo,10116.0,,50597,Intermediate,The pharmacokinetic parameter half-life period in vivo in rats,,CHEMBL628612,,1,1,,BAO_0000218,,
10193,A,In vivo,10116.0,,50597,Intermediate,"The pharmacokinetic property, Half-life was determined",,CHEMBL628613,,1,1,,BAO_0000218,,
10194,A,In vivo,10116.0,,50597,Intermediate,"The pharmacokinetic property, Half-life in rat in vivo",,CHEMBL628614,,1,1,,BAO_0000218,,
10195,A,In vivo,10116.0,,50597,Intermediate,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,CHEMBL628615,,1,1,,BAO_0000218,,
10196,A,In vivo,10116.0,,50597,Intermediate,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,CHEMBL628616,,1,1,,BAO_0000218,,
10197,A,,10116.0,,50597,Intermediate,The plasma half life period in rats,,CHEMBL627924,,1,1,,BAO_0000218,1969.0,
10198,A,,10116.0,,50597,Intermediate,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,,CHEMBL627925,,1,1,,BAO_0000218,2107.0,
10199,A,In vivo,10116.0,,50597,Intermediate,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,CHEMBL627926,,1,1,,BAO_0000218,,
10200,A,,10116.0,,50597,Intermediate,t1/2 (apparent elimination)of the compound was determined,,CHEMBL627927,,1,1,,BAO_0000218,,
10201,A,,10116.0,,50597,Intermediate,t1/2 value in rat,,CHEMBL627928,,1,1,,BAO_0000218,,
10202,A,,10116.0,,50597,Intermediate,Half life in rat,,CHEMBL627539,,1,1,,BAO_0000218,,
10203,A,In vivo,10116.0,,50597,Intermediate,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,CHEMBL876790,,1,1,,BAO_0000218,1969.0,
10204,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,CHEMBL858186,,1,1,,BAO_0000218,,
10205,A,,10116.0,,50597,Intermediate,Half-life period in fasted rats,,CHEMBL627540,,1,1,,BAO_0000218,,
10206,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,CHEMBL627541,,1,1,,BAO_0000218,,
10207,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,CHEMBL627715,,1,1,,BAO_0000218,,
10208,A,In vivo,10116.0,,50597,Intermediate,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,CHEMBL627716,,1,1,,BAO_0000218,,
10209,A,,10116.0,,50597,Intermediate,Maximum time required to achieve Cmax was determined in rat,,CHEMBL627717,,1,1,,BAO_0000218,,
10210,A,In vivo,10116.0,,50597,Intermediate,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL627718,,1,1,,BAO_0000218,,
10211,A,In vivo,10116.0,,50597,Intermediate,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,CHEMBL627719,,1,1,,BAO_0000218,,
10212,A,In vivo,10116.0,,50597,Intermediate,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,CHEMBL627720,,1,1,,BAO_0000218,,
10213,A,In vivo,10116.0,,50597,Intermediate,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,CHEMBL627721,,1,1,,BAO_0000218,,
10214,A,In vivo,10116.0,,50597,Intermediate,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,CHEMBL627722,,1,1,,BAO_0000218,,
10215,A,In vivo,10116.0,,50597,Intermediate,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL627723,,1,1,,BAO_0000218,,
10216,A,In vivo,10116.0,,50597,Intermediate,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL626058,,1,1,,BAO_0000218,,
10217,A,In vivo,10116.0,,50597,Intermediate,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL626059,,1,1,,BAO_0000218,,
10218,A,In vivo,10116.0,,50597,Intermediate,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL626060,,1,1,,BAO_0000218,,
10219,A,In vivo,10116.0,,50597,Intermediate,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,,CHEMBL626061,,1,1,,BAO_0000218,1969.0,
10220,A,In vivo,10116.0,,50597,Intermediate,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL876791,,1,1,,BAO_0000218,,
10221,A,In vivo,10116.0,,50597,Intermediate,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,CHEMBL626062,,1,1,,BAO_0000218,,
10222,A,In vivo,10116.0,,50597,Intermediate,Tmax at the dose of 2 mg/Kg administered perorally in rats,,CHEMBL626063,,1,1,,BAO_0000218,,
10223,A,In vivo,10116.0,,50597,Intermediate,Tmax at the dose of 5 mg/Kg administered perorally in rats,,CHEMBL626064,,1,1,,BAO_0000218,,
10224,A,In vivo,10116.0,,50597,Intermediate,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,,CHEMBL626065,,1,1,,BAO_0000218,1969.0,
10225,A,In vivo,10116.0,,50597,Intermediate,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,,CHEMBL626066,,1,1,,BAO_0000218,1969.0,
10226,A,In vivo,10116.0,,50597,Intermediate,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,CHEMBL626067,,1,1,,BAO_0000218,,
10227,F,,10116.0,,50597,Intermediate,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,CHEMBL626068,,1,1,,BAO_0000218,,
10228,F,,10116.0,,50597,Intermediate,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,CHEMBL626069,,1,1,,BAO_0000218,,
10229,F,,10116.0,,50597,Intermediate,Percent total excretion of 3-methoxyacetaminophen glucuronide,,CHEMBL626070,,1,1,,BAO_0000218,,
10230,F,,10116.0,,50597,Intermediate,Percent total excretion of N-methoxyacetaminophen glucuronide,,CHEMBL626071,,1,1,,BAO_0000218,,
10231,F,,10116.0,,50597,Intermediate,Percent total excretion of N-methoxyacetaminophen sulfate,,CHEMBL626072,,1,1,,BAO_0000218,,
10232,F,,10116.0,,50597,Intermediate,Percent total excretion of acetaminophen,,CHEMBL626073,,1,1,,BAO_0000218,,
10233,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",,CHEMBL626741,,1,1,,BAO_0000218,2046.0,
10234,A,,10116.0,,50597,Intermediate,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,CHEMBL626742,,1,1,,BAO_0000218,,
10235,A,,10116.0,,50597,Intermediate,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,CHEMBL626743,,1,1,,BAO_0000218,,
10236,A,,10116.0,,50597,Intermediate,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,CHEMBL876792,,1,1,,BAO_0000218,,
10237,A,,10116.0,,50597,Intermediate,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,CHEMBL626744,,1,1,,BAO_0000218,,
10238,A,,10116.0,,50597,Intermediate,Compound was tested for antidiuretic activity in rats,,CHEMBL626745,,1,1,,BAO_0000218,,
10239,A,In vivo,10116.0,,50597,Intermediate,AUC in rat after 3mg/kg oral dose,,CHEMBL626746,,1,1,,BAO_0000218,1969.0,
10240,A,,10116.0,,50597,Intermediate,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,CHEMBL626747,,1,1,,BAO_0000218,,
10241,A,,10116.0,,50597,Intermediate,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,CHEMBL626748,,1,1,,BAO_0000218,,
10242,A,,10116.0,,50597,Intermediate,Bioavailability administered orally at a dose of 10 mg/kg to rats,,CHEMBL626749,,1,1,,BAO_0000218,,
10243,A,,10116.0,,50597,Intermediate,Oral Bioavailability was determined,,CHEMBL626750,,1,1,,BAO_0000218,,
10244,A,,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL626751,,1,1,,BAO_0000218,,
10245,A,,10116.0,,50597,Intermediate,Oral bioavailability in rat; Not performed.,,CHEMBL626913,,1,1,,BAO_0000218,,
10246,A,,10116.0,,50597,Intermediate,Bioavailability,,CHEMBL626914,,1,1,,BAO_0000218,,
10247,A,,10116.0,,50597,Intermediate,Bioavailability was determined; ND denotes no data,,CHEMBL626915,,1,1,,BAO_0000218,,
10248,A,,10116.0,,50597,Intermediate,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,CHEMBL626916,,1,1,,BAO_0000218,,
10249,A,,10116.0,,50597,Intermediate,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,CHEMBL626917,,1,1,,BAO_0000218,,
10250,A,,10116.0,,50597,Intermediate,Binding towards rat plasma protein at 10 uM,,CHEMBL626918,,1,1,,BAO_0000218,,
10251,A,,10116.0,,50597,Intermediate,Binding towards rat plasma protein at 100 uM,,CHEMBL626919,,1,1,,BAO_0000218,,
10252,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 20 mg/kg p.o.),,CHEMBL626920,,1,1,,BAO_0000218,,
10253,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,CHEMBL621976,,1,1,,BAO_0000218,,
10254,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat after 5 mg/kg oral gavage,,CHEMBL877599,,1,1,,BAO_0000218,,
10255,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL621977,,1,1,,BAO_0000218,,
10256,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 1 mg/kg i.v.),,CHEMBL621978,,1,1,,BAO_0000218,,
10257,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 3 mg/kg p.o.),,CHEMBL621979,,1,1,,BAO_0000218,,
10258,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL621980,,1,1,,BAO_0000218,,
10259,A,In vivo,10116.0,,50597,Intermediate,Bioavailability of the compound in rats after administration of 30 mg/kg,,CHEMBL621981,,1,1,,BAO_0000218,,
10260,A,In vivo,10116.0,,50597,Intermediate,Bioavailability after administration of 10 mg/kg in rats,,CHEMBL621982,,1,1,,BAO_0000218,,
10261,A,In vivo,10116.0,,50597,Intermediate,Bioavailability after administration of 2 mg/kg in rats,,CHEMBL882953,,1,1,,BAO_0000218,,
10262,A,In vivo,10116.0,,50597,Intermediate,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,CHEMBL621983,,1,1,,BAO_0000218,,
10263,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in dogs was determined; high,,CHEMBL621984,,1,1,,BAO_0000218,,
10264,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in monkey after intravenous administration at 1 mpk,,CHEMBL621985,,1,1,,BAO_0000218,,
10265,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in monkey after peroral administration at 10 mpk,,CHEMBL621986,,1,1,,BAO_0000218,,
10266,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat after intravenous administration at 1 mpk,,CHEMBL621987,,1,1,,BAO_0000218,,
10267,F,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat after intravenous administration at 2 mpk,,CHEMBL877600,,1,1,,BAO_0000218,,
10268,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat after peroral administration at 30 mpk,,CHEMBL621988,,1,1,,BAO_0000218,,
10269,F,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat after peroral administration at at 100 mpk,,CHEMBL621989,,1,1,,BAO_0000218,,
10270,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rats was evaluated,,CHEMBL621990,,1,1,,BAO_0000218,,
10271,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,CHEMBL621991,,1,1,,BAO_0000218,,
10272,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,CHEMBL621992,,1,1,,BAO_0000218,,
10273,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,CHEMBL621993,,1,1,,BAO_0000218,,
10274,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,CHEMBL621994,,1,1,,BAO_0000218,,
10275,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL621995,,1,1,,BAO_0000218,,
10276,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL621996,,1,1,,BAO_0000218,,
10277,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 10 mg/kg),,CHEMBL621997,,1,1,,BAO_0000218,,
10278,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,CHEMBL621998,,1,1,,BAO_0000218,,
10279,A,In vivo,10116.0,,50597,Intermediate,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,CHEMBL621999,,1,1,,BAO_0000218,,
10280,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622000,,1,1,,BAO_0000218,,
10281,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was measured in rat after oral administration; 2-4,,CHEMBL622001,,1,1,,BAO_0000218,,
10282,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was measured in rat after oral administration; 3-7,,CHEMBL622002,,1,1,,BAO_0000218,,
10283,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (intraduodenal administration),,CHEMBL622003,,1,1,,BAO_0000218,,
10284,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (intraduodenal administration),,CHEMBL877601,,1,1,,BAO_0000218,,
10285,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL624871,,1,1,,BAO_0000218,,
10286,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622004,,1,1,,BAO_0000218,,
10287,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,CHEMBL882954,,1,1,,BAO_0000218,,
10288,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,CHEMBL622005,,1,1,,BAO_0000218,,
10289,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,CHEMBL622006,,1,1,,BAO_0000218,,
10290,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was measured in rat,,CHEMBL622007,,1,1,,BAO_0000218,,
10291,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was reported,,CHEMBL622008,,1,1,,BAO_0000218,,
10292,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,CHEMBL622009,,1,1,,BAO_0000218,,
10293,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,CHEMBL622010,,1,1,,BAO_0000218,,
10294,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,CHEMBL622011,,1,1,,BAO_0000218,,
10295,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,CHEMBL622012,,1,1,,BAO_0000218,,
10296,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,CHEMBL622013,,1,1,,BAO_0000218,,
10297,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,CHEMBL622014,,1,1,,BAO_0000218,,
10298,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was determined at 3 mg/kg po dose in rats,,CHEMBL624749,,1,1,,BAO_0000218,,
10299,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 2 mg/kg),,CHEMBL624750,,1,1,,BAO_0000218,,
10300,A,In vivo,10116.0,,50597,Intermediate,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,CHEMBL624751,,1,1,,BAO_0000218,,
10301,A,In vivo,10116.0,,50597,Intermediate,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,CHEMBL624752,,1,1,,BAO_0000218,,
10302,A,In vivo,10116.0,,50597,Intermediate,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,CHEMBL624753,,1,1,,BAO_0000218,,
10303,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,CHEMBL624754,,1,1,,BAO_0000218,,
10304,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,CHEMBL624755,,1,1,,BAO_0000218,,
10305,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,CHEMBL624756,,1,1,,BAO_0000218,,
10306,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL624757,,1,1,,BAO_0000218,,
10307,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,CHEMBL624758,,1,1,,BAO_0000218,,
10308,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,CHEMBL622270,,1,1,,BAO_0000218,,
10309,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (Sprague-Dawley),,CHEMBL622271,,1,1,,BAO_0000218,,
10310,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat at the dose of 2 mg/kg,,CHEMBL622272,,1,1,,BAO_0000218,,
10311,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622273,,1,1,,BAO_0000218,,
10312,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (cannulated) (dose 2 mg/kg),,CHEMBL622274,,1,1,,BAO_0000218,,
10313,A,In vivo,10116.0,,50597,Intermediate,Bioavailability value of compound in rats was determined after peroral administration,,CHEMBL622275,,1,1,,BAO_0000218,,
10314,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 20 mg/kg),,CHEMBL622276,,1,1,,BAO_0000218,,
10315,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622277,,1,1,,BAO_0000218,,
10316,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 5 mg/kg),,CHEMBL622278,,1,1,,BAO_0000218,,
10317,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622279,,1,1,,BAO_0000218,,
10318,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622280,,1,1,,BAO_0000218,,
10319,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for oral bioavailability in rats; 15-27 %,,CHEMBL624083,,1,1,,BAO_0000218,,
10320,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,CHEMBL624084,,1,1,,BAO_0000218,,
10321,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,CHEMBL624085,,1,1,,BAO_0000218,,
10322,A,In vivo,10116.0,,50597,Intermediate,Compound was tested for bioavailability in rats,,CHEMBL624086,,1,1,,BAO_0000218,,
10323,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL624087,,1,1,,BAO_0000218,,
10324,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL624088,,1,1,,BAO_0000218,,
10325,A,In vivo,9544.0,,22224,Intermediate,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,CHEMBL624089,,0,1,,BAO_0000218,,
10326,A,In vivo,10116.0,,22224,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,CHEMBL624090,,0,1,,BAO_0000218,,
10327,A,In vivo,10116.0,,50597,Intermediate,Evaluated for the bioavailability in rat (in vivo),,CHEMBL624091,,1,1,,BAO_0000218,,
10328,A,In vivo,10116.0,,50597,Intermediate,F value of compound in rats was determined after peroral administration,,CHEMBL624092,,1,1,,BAO_0000218,,
10329,A,In vivo,10116.0,,50597,Intermediate,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,CHEMBL624093,,1,1,,BAO_0000218,,
10330,A,In vivo,10116.0,,50597,Intermediate,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,CHEMBL624094,,1,1,,BAO_0000218,,
10331,A,In vivo,10116.0,,50597,Intermediate,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,CHEMBL624095,,1,1,,BAO_0000218,,
10332,A,In vivo,10116.0,,50597,Intermediate,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,CHEMBL624096,,1,1,,BAO_0000218,,
10333,A,In vivo,10116.0,,50597,Intermediate,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,CHEMBL624097,,1,1,,BAO_0000218,,
10334,A,In vivo,10116.0,,50597,Intermediate,Maximum fall in carotid flow in rat,,CHEMBL624098,,1,1,,BAO_0000218,,
10335,A,In vivo,10116.0,,50597,Intermediate,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,CHEMBL874392,,1,1,,BAO_0000218,,
10336,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 5 mg/kg),,CHEMBL624099,,1,1,,BAO_0000218,,
10337,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,CHEMBL624100,,1,1,,BAO_0000218,,
10338,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,CHEMBL624101,,1,1,,BAO_0000218,,
10339,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (male Wistar),,CHEMBL624102,,1,1,,BAO_0000218,,
10340,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability after administration (30 mg/kg) in rat; good,,CHEMBL624103,,1,1,,BAO_0000218,,
10341,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability at the dose of 2 mg/kg in rat,,CHEMBL624104,,1,1,,BAO_0000218,,
10342,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability determined in rats,,CHEMBL624105,,1,1,,BAO_0000218,,
10343,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,CHEMBL624106,,1,1,,BAO_0000218,,
10344,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose single 10 mg/kg),,CHEMBL624107,,1,1,,BAO_0000218,,
10345,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose single 10 mg/kg),,CHEMBL623943,,1,1,,BAO_0000218,,
10346,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 5 mg/kg,,CHEMBL623944,,1,1,,BAO_0000218,,
10347,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,CHEMBL623945,,1,1,,BAO_0000218,,
10348,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,CHEMBL623946,,1,1,,BAO_0000218,,
10349,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,CHEMBL623947,,1,1,,BAO_0000218,,
10350,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,CHEMBL623948,,1,1,,BAO_0000218,,
10351,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,CHEMBL623949,,1,1,,BAO_0000218,,
10352,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,CHEMBL623950,,1,1,,BAO_0000218,,
10353,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,CHEMBL874398,,1,1,,BAO_0000218,,
10354,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,CHEMBL623951,,1,1,,BAO_0000218,,
10355,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,CHEMBL623952,,1,1,,BAO_0000218,,
10356,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,CHEMBL623953,,1,1,,BAO_0000218,,
10357,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,CHEMBL623954,,1,1,,BAO_0000218,,
10358,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,CHEMBL623955,,1,1,,BAO_0000218,,
10359,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,CHEMBL623956,,1,1,,BAO_0000218,,
10360,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,CHEMBL627807,,1,1,,BAO_0000218,,
10361,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,CHEMBL627808,,1,1,,BAO_0000218,,
10362,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,CHEMBL627809,,1,1,,BAO_0000218,,
10363,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,CHEMBL627810,,1,1,,BAO_0000218,,
10364,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,CHEMBL627811,,1,1,,BAO_0000218,,
10365,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,CHEMBL627812,,1,1,,BAO_0000218,,
10366,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,CHEMBL627813,,1,1,,BAO_0000218,,
10367,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,CHEMBL627814,,1,1,,BAO_0000218,,
10368,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,CHEMBL875336,,1,1,,BAO_0000218,,
10369,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,CHEMBL627815,,1,1,,BAO_0000218,,
10370,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,CHEMBL627816,,1,1,,BAO_0000218,,
10371,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,CHEMBL627817,,1,1,,BAO_0000218,,
10372,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,CHEMBL627818,,1,1,,BAO_0000218,,
10373,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,CHEMBL627819,,1,1,,BAO_0000218,,
10374,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,CHEMBL627820,,1,1,,BAO_0000218,,
10375,A,,10116.0,,50597,Intermediate,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,CHEMBL627821,,1,1,,BAO_0000218,,
10376,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,CHEMBL628464,,1,1,,BAO_0000218,,
10377,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,CHEMBL626239,,1,1,,BAO_0000218,,
10378,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,CHEMBL626240,,1,1,,BAO_0000218,,
10379,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,CHEMBL626241,,1,1,,BAO_0000218,,
10380,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,CHEMBL626242,,1,1,,BAO_0000218,,
10381,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,CHEMBL626243,,1,1,,BAO_0000218,,
10382,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,CHEMBL626244,,1,1,,BAO_0000218,,
10383,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,CHEMBL626907,,1,1,,BAO_0000218,,
10384,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,CHEMBL626908,,1,1,,BAO_0000218,,
10385,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,CHEMBL626909,,1,1,,BAO_0000218,,
10386,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,CHEMBL626910,,1,1,,BAO_0000218,,
10387,F,,10116.0,,50597,Intermediate,Percent total excretion of acetaminophen cysteine conjugate,,CHEMBL875342,,1,1,,BAO_0000218,,
10388,F,,10116.0,,50597,Intermediate,Percent total excretion of acetaminophen glucuronide,,CHEMBL626911,,1,1,,BAO_0000218,,
10389,F,,10116.0,,50597,Intermediate,Percent total excretion of acetaminophen sulfate,,CHEMBL626912,,1,1,,BAO_0000218,,
10390,F,,10116.0,,50597,Intermediate,Percent total excretion of acetaminophen-mercapturic acid,,CHEMBL627065,,1,1,,BAO_0000218,,
10391,A,,10116.0,,50597,Intermediate,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,,CHEMBL627066,,1,1,,BAO_0000218,1088.0,
10392,A,In vivo,10116.0,,50597,Intermediate,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,CHEMBL627067,,1,1,,BAO_0000218,,
10393,A,In vivo,8656.0,,22224,Autocuration,Biodistribution of compound in rat muscle after 5 min of administration,,CHEMBL627068,,0,1,,BAO_0000218,2385.0,
10394,A,In vivo,8656.0,,22224,Autocuration,Biodistribution of compound in rat muscle after 5 min of administration.,,CHEMBL627069,,0,1,,BAO_0000218,2385.0,
10395,A,In vivo,9940.0,,22224,Autocuration,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,CHEMBL627070,,0,1,,BAO_0000218,,
10396,A,In vivo,9940.0,,22224,Autocuration,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,CHEMBL627071,,0,1,,BAO_0000218,,
10397,A,In vivo,9940.0,,22224,Autocuration,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,CHEMBL627072,,0,1,,BAO_0000218,,
10398,A,In vivo,9940.0,,22224,Autocuration,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,CHEMBL627073,,0,1,,BAO_0000218,,
10399,A,In vivo,9940.0,,22224,Autocuration,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,CHEMBL625387,,0,1,,BAO_0000218,,
10400,A,In vivo,9940.0,,22224,Autocuration,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,CHEMBL625388,,0,1,,BAO_0000218,,
10401,A,In vivo,9940.0,,22224,Autocuration,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,CHEMBL625389,,0,1,,BAO_0000218,1969.0,
10402,A,In vivo,9940.0,,22224,Autocuration,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,CHEMBL875343,,0,1,,BAO_0000218,1969.0,
10403,A,,8570.0,,50497,Intermediate,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,CHEMBL876795,,1,1,,BAO_0000218,,
10404,A,,8570.0,,50497,Intermediate,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,CHEMBL626552,,1,1,,BAO_0000218,,
10405,A,,8570.0,,50497,Intermediate,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,CHEMBL626553,,1,1,,BAO_0000218,,
10406,A,,9606.0,,22224,Autocuration,The human biological plasma half life of the compound,,CHEMBL626554,,0,1,,BAO_0000366,1969.0,
10407,A,,10116.0,,50597,Intermediate,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,CHEMBL626555,,1,1,,BAO_0000218,1088.0,
10408,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,CHEMBL626556,,1,1,,BAO_0000218,,
10409,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,CHEMBL626557,,1,1,,BAO_0000218,,
10410,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,CHEMBL626558,,1,1,,BAO_0000218,,
10411,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,CHEMBL626559,,1,1,,BAO_0000218,,
10412,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,CHEMBL626560,,1,1,,BAO_0000218,,
10413,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,CHEMBL876803,,1,1,,BAO_0000218,,
10414,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,CHEMBL627964,,1,1,,BAO_0000218,,
10415,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,CHEMBL627965,,1,1,,BAO_0000218,,
10416,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,CHEMBL627966,,1,1,,BAO_0000218,,
10417,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,CHEMBL627967,,1,1,,BAO_0000218,,
10418,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,CHEMBL627968,,1,1,,BAO_0000218,,
10419,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,CHEMBL627969,,1,1,,BAO_0000218,,
10420,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,CHEMBL627970,,1,1,,BAO_0000218,,
10421,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,,CHEMBL627971,,1,1,,BAO_0000218,178.0,
10422,A,,10116.0,,50597,Intermediate,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,,CHEMBL627972,,1,1,,BAO_0000218,178.0,
10423,B,,9606.0,,180,Expert,Dissociation constant against binding to human cyclophilin A,,CHEMBL856029,,9,1,,BAO_0000357,,
10424,B,,9913.0,,11591,Expert,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,CHEMBL627973,,8,1,,BAO_0000019,,
10425,A,,,,22224,Autocuration,-Log C was determined by performing the electroshock minimum test,,CHEMBL627974,,0,1,,BAO_0000019,,
10426,A,,,,22224,Autocuration,-Log C was determined by performing the foot shock test,,CHEMBL627975,,0,1,,BAO_0000019,,
10427,A,,,,22224,Autocuration,-Log C was determined by performing the incl screen test,,CHEMBL627976,,0,1,,BAO_0000019,,
10428,A,,,,22224,Autocuration,-Log C was determined by performing the maximum electroshock test,,CHEMBL627977,,0,1,,BAO_0000019,,
10429,A,,,,22224,Autocuration,-Log C was determined by performing the pentylenetetrazole test,,CHEMBL627978,,0,1,,BAO_0000019,,
10430,A,,,,22224,Autocuration,Tested for experimental arotinoid inhibitory dose,,CHEMBL627979,,0,1,,BAO_0000019,,
10431,A,,,,22224,Autocuration,Negative log transformed activity,,CHEMBL876804,,0,1,,BAO_0000019,,
10432,A,,,,22224,Autocuration,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,CHEMBL627980,,0,1,,BAO_0000019,,
10433,A,,10141.0,,50512,Intermediate,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,CHEMBL627981,,1,1,,BAO_0000218,,
10434,A,,10141.0,,50512,Intermediate,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,CHEMBL627982,,1,1,,BAO_0000218,,
10435,A,,10141.0,,50512,Intermediate,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,CHEMBL627983,,1,1,,BAO_0000218,,
10436,A,,10141.0,,50512,Intermediate,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,,CHEMBL627984,,1,1,,BAO_0000218,2116.0,
10437,P,,,,22229,Autocuration,Solubility in water was determined; values expressed as -log,,CHEMBL627985,,0,1,,BAO_0000100,,
10438,A,,,,22224,Autocuration,Ratio of Kcat to that of Km was determined,,CHEMBL627986,,0,1,,BAO_0000019,,
10439,A,,,,22224,Autocuration,Observed first order rate constant,,CHEMBL627987,,0,1,,BAO_0000019,,
10440,A,,,,22224,Autocuration,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,CHEMBL627988,,0,1,,BAO_0000019,,
10441,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,CHEMBL627989,,1,1,,BAO_0000218,,
10442,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,CHEMBL627990,,1,1,,BAO_0000218,,
10443,A,In vivo,10116.0,,50597,Intermediate,Oral Bioavailability after administration of 10 mg/kg in male rat,,CHEMBL876805,,1,1,,BAO_0000218,,
10444,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,CHEMBL627991,,1,1,,BAO_0000218,,
10445,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL627992,,1,1,,BAO_0000218,,
10446,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,CHEMBL627993,,1,1,,BAO_0000218,,
10447,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability at 1 mg/kg was determined in rat,,CHEMBL622817,,1,1,,BAO_0000218,,
10448,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability at 10 mg/kg was determined in rat,,CHEMBL622818,,1,1,,BAO_0000218,,
10449,A,In vivo,10116.0,,50597,Intermediate,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,CHEMBL622819,,1,1,,BAO_0000218,,
10450,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL872267,,1,1,,BAO_0000218,,
10451,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622820,,1,1,,BAO_0000218,,
10452,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,CHEMBL622821,,1,1,,BAO_0000218,,
10453,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622822,,1,1,,BAO_0000218,,
10454,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622823,,1,1,,BAO_0000218,,
10455,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622824,,1,1,,BAO_0000218,,
10456,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat at a dose of 3 mg/kg,,CHEMBL622825,,1,1,,BAO_0000218,,
10457,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat after oral administration at 10 mg/kg,,CHEMBL622901,,1,1,,BAO_0000218,,
10458,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622902,,1,1,,BAO_0000218,,
10459,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL621844,,1,1,,BAO_0000218,,
10460,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in Dawley rats,,CHEMBL621845,,1,1,,BAO_0000218,,
10461,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability,,CHEMBL621846,,1,1,,BAO_0000218,,
10462,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 30 mg/kg),,CHEMBL621847,,1,1,,BAO_0000218,,
10463,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,CHEMBL877609,,1,1,,BAO_0000218,,
10464,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 3 mg/kg i.v.),,CHEMBL621848,,1,1,,BAO_0000218,,
10465,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,CHEMBL621849,,1,1,,BAO_0000218,,
10466,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 60 mg/kg p.o.),,CHEMBL622030,,1,1,,BAO_0000218,,
10467,A,In vivo,10116.0,,50597,Intermediate,Percent oral bioavailability determined in rats,,CHEMBL622031,,1,1,,BAO_0000218,,
10468,A,In vivo,10116.0,,50597,Intermediate,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,CHEMBL622032,,1,1,,BAO_0000218,,
10469,A,In vivo,10116.0,,50597,Intermediate,The compound was evaluated for bioavailability in rats; 32-51,,CHEMBL622033,,1,1,,BAO_0000218,,
10470,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 20 mg/kg p.o.),,CHEMBL622034,,1,1,,BAO_0000218,,
10471,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622035,,1,1,,BAO_0000218,,
10472,A,In vivo,10116.0,,50597,Intermediate,Bioavailability percent in rat at the dose of 2 mg/kg,,CHEMBL882966,,1,1,,BAO_0000218,,
10473,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was evaluated after 20 uM/kg of peroral administration,,CHEMBL622036,,1,1,,BAO_0000218,,
10474,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622037,,1,1,,BAO_0000218,,
10475,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622038,,1,1,,BAO_0000218,,
10476,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rats,,CHEMBL622039,,1,1,,BAO_0000218,,
10477,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,,CHEMBL622040,,1,1,,BAO_0000218,178.0,
10478,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,,CHEMBL622041,,1,1,,BAO_0000218,178.0,
10479,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,,CHEMBL622042,,1,1,,BAO_0000218,178.0,
10480,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,,CHEMBL622043,,1,1,,BAO_0000218,178.0,
10481,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,,CHEMBL622044,,1,1,,BAO_0000218,178.0,
10482,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,,CHEMBL622045,,1,1,,BAO_0000218,10000001.0,
10483,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,,CHEMBL622046,,1,1,,BAO_0000218,10000001.0,
10484,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,,CHEMBL622047,,1,1,,BAO_0000218,10000001.0,
10485,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,,CHEMBL877610,,1,1,,BAO_0000218,10000001.0,
10486,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,,CHEMBL622048,,1,1,,BAO_0000218,955.0,
10487,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,,CHEMBL622049,,1,1,,BAO_0000218,955.0,
10488,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,,CHEMBL622050,,1,1,,BAO_0000218,955.0,
10489,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,,CHEMBL622051,,1,1,,BAO_0000218,955.0,
10490,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,CHEMBL622052,,1,1,,BAO_0000218,,
10491,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,CHEMBL622053,,1,1,,BAO_0000218,,
10492,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,CHEMBL622054,,1,1,,BAO_0000218,,
10493,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,CHEMBL622055,,1,1,,BAO_0000218,,
10494,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rats was determined; High,,CHEMBL622056,,1,1,,BAO_0000218,,
10495,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in the rat was determined,,CHEMBL622057,,1,1,,BAO_0000218,,
10496,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,CHEMBL628008,,1,1,,BAO_0000218,,
10497,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,CHEMBL622058,,1,1,,BAO_0000218,,
10498,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL622059,,1,1,,BAO_0000218,,
10499,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL622060,,1,1,,BAO_0000218,,
10500,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL622061,,1,1,,BAO_0000218,,
10501,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,CHEMBL622062,,1,1,,BAO_0000218,,
10502,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,CHEMBL622063,,1,1,,BAO_0000218,,
10503,A,In vivo,10116.0,,50597,Expert,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,CHEMBL877611,,1,1,,BAO_0000218,,
10504,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound in Sprague Dawley rats,,CHEMBL622064,,1,1,,BAO_0000218,,
10505,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound in rat,,CHEMBL622065,,1,1,,BAO_0000218,,
10506,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 2 mg/kg),,CHEMBL622066,,1,1,,BAO_0000218,,
10507,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound in rat was determined,,CHEMBL622067,,1,1,,BAO_0000218,,
10508,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound in rats,,CHEMBL622068,,1,1,,BAO_0000218,,
10509,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound was determined in rats,,CHEMBL622069,,1,1,,BAO_0000218,,
10510,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability at a dose of 30 mg/kg in rats,,CHEMBL624796,,1,1,,BAO_0000218,,
10511,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 10 mg/kg),,CHEMBL624797,,1,1,,BAO_0000218,,
10512,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 10 mg/kg),,CHEMBL623053,,1,1,,BAO_0000218,,
10513,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability evaluated in rat,,CHEMBL623054,,1,1,,BAO_0000218,,
10514,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in fasted rat,,CHEMBL623055,,1,1,,BAO_0000218,,
10515,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in fed rat,,CHEMBL623056,,1,1,,BAO_0000218,,
10516,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,CHEMBL623057,,1,1,,BAO_0000218,,
10517,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623058,,1,1,,BAO_0000218,,
10518,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 10 mg/kg p.o.),,CHEMBL623059,,1,1,,BAO_0000218,,
10519,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat after administration of 10 mg/kg po,,CHEMBL623060,,1,1,,BAO_0000218,,
10520,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623061,,1,1,,BAO_0000218,,
10521,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623062,,1,1,,BAO_0000218,,
10522,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623063,,1,1,,BAO_0000218,,
10523,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623064,,1,1,,BAO_0000218,,
10524,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in ratrs,,CHEMBL623065,,1,1,,BAO_0000218,,
10525,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623066,,1,1,,BAO_0000218,,
10526,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623067,,1,1,,BAO_0000218,,
10527,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rats was determined; High,,CHEMBL623068,,1,1,,BAO_0000218,,
10528,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623069,,1,1,,BAO_0000218,,
10529,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623070,,1,1,,BAO_0000218,,
10530,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability was calculated in rat,,CHEMBL623071,,1,1,,BAO_0000218,,
10531,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability,,CHEMBL623072,,1,1,,BAO_0000218,,
10532,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability,,CHEMBL623073,,1,1,,BAO_0000218,,
10533,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability,,CHEMBL623074,,1,1,,BAO_0000218,,
10534,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability,,CHEMBL623075,,1,1,,BAO_0000218,,
10535,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability after i.v. administration,,CHEMBL623076,,1,1,,BAO_0000218,,
10536,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,CHEMBL623077,,1,1,,BAO_0000218,,
10537,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley),,CHEMBL623078,,1,1,,BAO_0000218,,
10538,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in Sprague-Dawley rats,,CHEMBL623079,,1,1,,BAO_0000218,,
10539,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,CHEMBL623080,,1,1,,BAO_0000218,,
10540,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,CHEMBL623081,,1,1,,BAO_0000218,,
10541,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,CHEMBL623082,,1,1,,BAO_0000218,,
10542,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in fasted rat,,CHEMBL874400,,1,1,,BAO_0000218,,
10543,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in fed rat,,CHEMBL623083,,1,1,,BAO_0000218,,
10544,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623084,,1,1,,BAO_0000218,,
10545,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623085,,1,1,,BAO_0000218,,
10546,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623086,,1,1,,BAO_0000218,,
10547,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623087,,1,1,,BAO_0000218,,
10548,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623088,,1,1,,BAO_0000218,,
10549,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623089,,1,1,,BAO_0000218,,
10550,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623090,,1,1,,BAO_0000218,,
10551,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623091,,1,1,,BAO_0000218,,
10552,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623092,,1,1,,BAO_0000218,,
10553,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623093,,1,1,,BAO_0000218,,
10554,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL874401,,1,1,,BAO_0000218,,
10555,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623094,,1,1,,BAO_0000218,,
10556,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL623095,,1,1,,BAO_0000218,,
10557,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat after peroral administration at 10 mg/kg,,CHEMBL623096,,1,1,,BAO_0000218,,
10558,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat after peroral administration at 5 mg/kg,,CHEMBL624913,,1,1,,BAO_0000218,,
10559,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,CHEMBL624914,,1,1,,BAO_0000218,,
10560,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,CHEMBL624915,,1,1,,BAO_0000218,,
10561,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat; Not measured,,CHEMBL624916,,1,1,,BAO_0000218,,
10562,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL624917,,1,1,,BAO_0000218,,
10563,A,,10116.0,,50597,Intermediate,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,CHEMBL625157,,1,1,,BAO_0000218,,
10564,A,,10116.0,,50597,Intermediate,In vitro metabolic potential in rat liver microsomes,,CHEMBL625158,,1,1,,BAO_0000218,2107.0,
10565,A,In vivo,10116.0,,50597,Intermediate,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,CHEMBL625159,,1,1,,BAO_0000218,,
10566,A,In vivo,10116.0,,50597,Intermediate,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,CHEMBL625160,,1,1,,BAO_0000218,,
10567,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,CHEMBL625161,,1,1,,BAO_0000218,,
10568,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL625162,,1,1,,BAO_0000218,,
10569,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL625163,,1,1,,BAO_0000218,,
10570,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rats at 10 mg/kg,,CHEMBL625164,,1,1,,BAO_0000218,,
10571,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,CHEMBL625165,,1,1,,BAO_0000218,,
10572,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL625166,,1,1,,BAO_0000218,,
10573,A,,10116.0,,50597,Intermediate,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,CHEMBL625167,,1,1,,BAO_0000218,,
10574,A,,10116.0,,50597,Intermediate,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,CHEMBL625168,,1,1,,BAO_0000218,,
10575,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance of the compound,,CHEMBL625169,,1,1,,BAO_0000218,,
10576,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,CHEMBL626264,,1,1,,BAO_0000218,,
10577,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,CHEMBL626265,,1,1,,BAO_0000218,,
10578,A,In vivo,10116.0,,50597,Intermediate,The compound was tested for plasma clearance in rat,,CHEMBL626266,,1,1,,BAO_0000218,1969.0,
10579,A,In vivo,10116.0,,50597,Intermediate,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,,CHEMBL626267,,1,1,,BAO_0000218,1969.0,
10580,A,,10116.0,,50597,Intermediate,Plasma concentration upon oral administration of 1 mg/Kg in rats,,CHEMBL626268,,1,1,,BAO_0000218,,
10581,A,,10116.0,,50597,Intermediate,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,CHEMBL626269,,1,1,,BAO_0000218,,
10582,A,,10116.0,,50597,Intermediate,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,CHEMBL626270,,1,1,,BAO_0000218,,
10583,A,,10116.0,,50597,Intermediate,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,CHEMBL626271,,1,1,,BAO_0000218,,
10584,A,,10116.0,,50597,Intermediate,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,CHEMBL626272,,1,1,,BAO_0000218,,
10585,A,,10116.0,,50597,Intermediate,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,CHEMBL626273,,1,1,,BAO_0000218,,
10586,A,,10116.0,,50597,Intermediate,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,CHEMBL875346,,1,1,,BAO_0000218,,
10587,A,,10116.0,,50597,Intermediate,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,CHEMBL626274,,1,1,,BAO_0000218,,
10588,A,,10116.0,,50597,Intermediate,Compound was tested for protein binding in rat plasma,,CHEMBL626275,,1,1,,BAO_0000218,,
10589,A,,10116.0,,50597,Intermediate,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,CHEMBL624646,,1,1,,BAO_0000218,,
10590,A,,10116.0,,50597,Intermediate,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,CHEMBL624647,,1,1,,BAO_0000218,,
10591,A,,10116.0,,50597,Intermediate,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,,CHEMBL624648,,1,1,,BAO_0000218,2107.0,
10592,A,,10116.0,,50597,Intermediate,Area under curve ratio was determined (po/iv) in rat,,CHEMBL624649,,1,1,,BAO_0000218,,
10593,A,,10116.0,,50597,Intermediate,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,CHEMBL624650,,1,1,,BAO_0000218,,
10594,A,,10116.0,,50597,Intermediate,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,CHEMBL624651,,1,1,,BAO_0000218,,
10595,A,,10116.0,,50597,Intermediate,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,CHEMBL624652,,1,1,,BAO_0000218,,
10596,A,,10116.0,,50597,Intermediate,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,CHEMBL624653,,1,1,,BAO_0000218,,
10597,A,,10116.0,,50597,Intermediate,Ratio of AUCbrain to AUCplasma,,CHEMBL624654,,1,1,,BAO_0000218,,
10598,A,,10116.0,,50597,Intermediate,Ratio of brain to plasma,,CHEMBL624655,,1,1,,BAO_0000218,,
10599,A,,10116.0,,50597,Intermediate,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,CHEMBL624656,,1,1,,BAO_0000218,,
10600,A,,10116.0,,50597,Intermediate,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,CHEMBL624657,,1,1,,BAO_0000218,,
10601,A,,10116.0,,50597,Intermediate,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,CHEMBL624658,,1,1,,BAO_0000218,,
10602,A,,10116.0,,50597,Intermediate,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,CHEMBL624659,,1,1,,BAO_0000218,,
10603,A,,10116.0,,50597,Intermediate,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,CHEMBL624660,,1,1,,BAO_0000218,,
10604,A,,10116.0,,50597,Intermediate,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,CHEMBL624661,,1,1,,BAO_0000218,,
10605,A,,10116.0,,50597,Intermediate,Steady state brain :blood ratio was determined,,CHEMBL624662,,1,1,,BAO_0000218,,
10606,A,,10116.0,,50597,Intermediate,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL625199,,1,1,,BAO_0000218,,
10607,A,,10116.0,,50597,Intermediate,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,CHEMBL625200,,1,1,,BAO_0000218,,
10608,A,,10116.0,,50597,Intermediate,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,CHEMBL625201,,1,1,,BAO_0000218,,
10609,A,,10116.0,,50597,Intermediate,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,CHEMBL625202,,1,1,,BAO_0000218,,
10610,A,,10116.0,,50597,Intermediate,Percentage recovery after 3h incubation with rat hapatocytes was determined,,CHEMBL625203,,1,1,,BAO_0000218,,
10611,A,,10116.0,,50597,Intermediate,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,CHEMBL625204,,1,1,,BAO_0000218,,
10612,A,,10116.0,,50597,Intermediate,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,CHEMBL625205,,1,1,,BAO_0000218,,
10613,A,,10116.0,,50597,Intermediate,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,CHEMBL625206,,1,1,,BAO_0000218,,
10614,A,,,,22224,Autocuration,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,CHEMBL625207,,0,1,,BAO_0000019,,
10615,A,,,,22224,Autocuration,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,CHEMBL625208,,0,1,,BAO_0000019,,
10616,A,,9606.0,,50587,Intermediate,In vivo absorption in Caco-2 cell line monolayers was determined,,CHEMBL625209,,1,1,495.0,BAO_0000218,,
10617,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625210,,0,1,,BAO_0000100,,
10618,A,,10116.0,,50597,Intermediate,Area under curve was determine after peroral administration at 10 mpk in Rat,,CHEMBL625211,,1,1,,BAO_0000218,,
10619,A,,9544.0,,50797,Intermediate,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,CHEMBL625212,,1,1,,BAO_0000218,,
10620,A,,10116.0,,50597,Intermediate,Area under curve was determine after peroral administration at 160 mpk in Rat,,CHEMBL625213,,1,1,,BAO_0000218,,
10621,A,,10116.0,,50597,Intermediate,Area under curve was determine after peroral administration at 20 mpk in Rat,,CHEMBL625214,,1,1,,BAO_0000218,,
10622,A,,10116.0,,50597,Intermediate,Area under curve was determine after peroral administration at 50 mpk in Rat,,CHEMBL874542,,1,1,,BAO_0000218,,
10623,P,,,,22229,Autocuration,Calculated partition coefficient (clogP) (AlogP),,CHEMBL625215,,0,1,,BAO_0000100,,
10624,A,,,,22224,Autocuration,Activated partial thromboplastin time measured,,CHEMBL625216,,0,1,,BAO_0000019,,
10625,P,,,,22224,Autocuration,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,CHEMBL625217,,0,1,,BAO_0000100,,
10626,P,,,,22224,Autocuration,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,CHEMBL625218,,0,1,,BAO_0000100,,
10627,A,,9615.0,,50588,Intermediate,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,,CHEMBL622864,,1,1,,BAO_0000218,1969.0,
10628,A,,10116.0,,50597,Intermediate,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,,CHEMBL622865,,1,1,,BAO_0000218,1969.0,
10629,A,,10116.0,,50597,Intermediate,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,,CHEMBL622866,,1,1,,BAO_0000218,1969.0,
10630,A,,9615.0,,50588,Intermediate,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,,CHEMBL622867,,1,1,,BAO_0000218,1969.0,
10631,A,,10141.0,,50512,Intermediate,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,,CHEMBL876808,,1,1,,BAO_0000218,1969.0,
10632,A,,,,22224,Autocuration,AUC in brain,,CHEMBL627725,,0,1,,BAO_0000019,955.0,
10633,A,,,,22224,Autocuration,AUC in serum,,CHEMBL627726,,0,1,,BAO_0000019,1977.0,
10634,A,,,,22224,Autocuration,AUC was determined,,CHEMBL627727,,0,1,,BAO_0000019,1969.0,
10635,A,,,,22224,Autocuration,AUC of the compound.,,CHEMBL627728,,0,1,,BAO_0000019,1969.0,
10636,A,,,,22224,Autocuration,AUC value (0-4 hr),,CHEMBL627729,,0,1,,BAO_0000019,1969.0,
10637,A,,,,22224,Autocuration,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,CHEMBL627730,,0,1,,BAO_0000019,1969.0,
10638,A,,,,22224,Autocuration,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,CHEMBL627731,,0,1,,BAO_0000019,1969.0,
10639,A,,,,22224,Autocuration,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,CHEMBL627732,,0,1,,BAO_0000019,1969.0,
10640,A,,,,22224,Autocuration,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,CHEMBL627733,,0,1,,BAO_0000019,1969.0,
10641,A,,10116.0,,50597,Intermediate,AUC(area under curve) was determined after intravenous administration in rats,,CHEMBL627734,,1,1,,BAO_0000218,1969.0,
10642,A,,10116.0,,50597,Intermediate,AUC(area under curve) was determined after oral administration in rats,,CHEMBL627735,,1,1,,BAO_0000218,1969.0,
10643,A,,10141.0,,50512,Intermediate,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,,CHEMBL627736,,1,1,,BAO_0000218,1969.0,
10644,A,,10116.0,,50597,Intermediate,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,,CHEMBL876809,,1,1,,BAO_0000218,1969.0,
10645,A,,,,22224,Autocuration,Area Under Curve after oral dosing of 100 uM/Kg,,CHEMBL627737,,0,1,,BAO_0000019,,
10646,A,,,,22224,Autocuration,Area Under Curve after oral dosing of 30 uM/Kg,,CHEMBL627738,,0,1,,BAO_0000019,,
10647,A,,,,22224,Autocuration,Area Under Curve was measured by ploting the graph between concentration verses time,,CHEMBL627739,,0,1,,BAO_0000019,,
10648,A,,9615.0,,50588,Intermediate,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,CHEMBL626143,,1,1,,BAO_0000218,,
10649,A,,314293.0,,22224,Autocuration,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,CHEMBL626144,,0,1,,BAO_0000218,,
10650,A,,9986.0,,50592,Intermediate,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,CHEMBL626145,,1,1,,BAO_0000218,,
10651,A,,10116.0,,50597,Intermediate,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,CHEMBL626146,,1,1,,BAO_0000218,,
10652,A,,10116.0,,50597,Intermediate,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,,CHEMBL626147,,1,1,,BAO_0000218,178.0,
10653,A,,,,22224,Autocuration,Area under curve (AUC) was determined,,CHEMBL626148,,0,1,,BAO_0000019,,
10654,A,,,,22224,Autocuration,Area under curve (AUC) following ip administration at 1 mg/kg,,CHEMBL626149,,0,1,,BAO_0000218,,
10655,A,,,,22224,Autocuration,Area under curve (AUC) was determined; ND is Not determined,,CHEMBL626150,,0,1,,BAO_0000019,,
10656,A,,9615.0,,50588,Intermediate,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,CHEMBL626151,,1,1,,BAO_0000218,,
10657,A,,9615.0,,50588,Intermediate,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,CHEMBL626152,,1,1,,BAO_0000218,,
10658,A,,9615.0,,50588,Intermediate,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,CHEMBL626153,,1,1,,BAO_0000218,,
10659,A,,,,22224,Autocuration,Area under curve (AUR) was determined,,CHEMBL626154,,0,1,,BAO_0000019,,
10660,A,,,,22224,Autocuration,Area under curve at 1 uM/dg administered intravenously,,CHEMBL626155,,0,1,,BAO_0000019,,
10661,A,,,,22224,Autocuration,Area under curve at 10 uM/dg administered perorally,,CHEMBL626156,,0,1,,BAO_0000019,,
10662,A,,,,22224,Autocuration,Area under curve at 2 uM/dg administered intravenously,,CHEMBL626157,,0,1,,BAO_0000019,,
10663,A,,,,22224,Autocuration,Area under curve at 20 uM/dg administered perorally,,CHEMBL626158,,0,1,,BAO_0000019,,
10664,A,,9615.0,,50588,Intermediate,Area under curve at a peroral dose of 3 mg/kg in dog,,CHEMBL626159,,1,1,,BAO_0000218,,
10665,A,,10116.0,,50597,Intermediate,Area under curve at a peroral dose of 3 mg/kg in rat,,CHEMBL626160,,1,1,,BAO_0000218,,
10666,A,,9615.0,,50588,Intermediate,Area under curve at an iv dose of 1 mg/kg in dog,,CHEMBL626161,,1,1,,BAO_0000218,,
10667,A,,10116.0,,50597,Intermediate,Area under curve at an iv dose of 1 mg/kg in rat,,CHEMBL626162,,1,1,,BAO_0000218,,
10668,A,,,,22224,Autocuration,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,CHEMBL626163,,0,1,,BAO_0000019,,
10669,A,,,,22224,Autocuration,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,CHEMBL626164,,0,1,,BAO_0000019,,
10670,A,,10090.0,,50594,Intermediate,Area under curve measured as conc vs time after intravenous administration to mice.,,CHEMBL626165,,1,1,,BAO_0000218,,
10671,A,,10090.0,,50594,Intermediate,Area under curve measured as conc vs time after peroral administration to mice.,,CHEMBL626166,,1,1,,BAO_0000218,,
10672,A,,9615.0,,50588,Intermediate,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,CHEMBL626167,,1,1,,BAO_0000218,,
10673,A,,9615.0,,50588,Intermediate,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,CHEMBL626168,,1,1,,BAO_0000218,,
10674,A,,9615.0,,50588,Intermediate,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,CHEMBL877463,,1,1,,BAO_0000218,,
10675,A,,9615.0,,50588,Intermediate,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,CHEMBL626169,,1,1,,BAO_0000218,,
10676,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,,CHEMBL626170,,1,1,,BAO_0000218,948.0,
10677,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,,CHEMBL626171,,1,1,,BAO_0000218,948.0,
10678,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,,CHEMBL626172,,1,1,,BAO_0000218,948.0,
10679,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,,CHEMBL626173,,1,1,,BAO_0000218,948.0,
10680,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,,CHEMBL626174,,1,1,,BAO_0000218,2113.0,
10681,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,,CHEMBL626175,,1,1,,BAO_0000218,2113.0,
10682,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,,CHEMBL626176,,1,1,,BAO_0000218,2113.0,
10683,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,,CHEMBL626177,,1,1,,BAO_0000218,2113.0,
10684,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,,CHEMBL622499,,1,1,,BAO_0000218,2113.0,
10685,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,,CHEMBL622500,,1,1,,BAO_0000218,2107.0,
10686,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,,CHEMBL622501,,1,1,,BAO_0000218,2107.0,
10687,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,,CHEMBL622502,,1,1,,BAO_0000218,2107.0,
10688,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,,CHEMBL622503,,1,1,,BAO_0000218,2107.0,
10689,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,,CHEMBL877614,,1,1,,BAO_0000218,2107.0,
10690,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,,CHEMBL624839,,1,1,,BAO_0000218,2048.0,
10691,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,,CHEMBL624840,,1,1,,BAO_0000218,2048.0,
10692,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,,CHEMBL624841,,1,1,,BAO_0000218,2048.0,
10693,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,,CHEMBL624842,,1,1,,BAO_0000218,2048.0,
10694,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,,CHEMBL624843,,1,1,,BAO_0000218,2385.0,
10695,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,,CHEMBL624844,,1,1,,BAO_0000218,2385.0,
10696,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,,CHEMBL624845,,1,1,,BAO_0000218,2385.0,
10697,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,,CHEMBL621904,,1,1,,BAO_0000218,2385.0,
10698,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,,CHEMBL621905,,1,1,,BAO_0000218,178.0,
10699,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,,CHEMBL874382,,1,1,,BAO_0000218,178.0,
10700,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,,CHEMBL621906,,1,1,,BAO_0000218,178.0,
10701,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,,CHEMBL621907,,1,1,,BAO_0000218,955.0,
10702,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,,CHEMBL622096,,1,1,,BAO_0000218,955.0,
10703,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,,CHEMBL622097,,1,1,,BAO_0000218,955.0,
10704,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,,CHEMBL622098,,1,1,,BAO_0000218,948.0,
10705,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,,CHEMBL622099,,1,1,,BAO_0000218,948.0,
10706,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,,CHEMBL622100,,1,1,,BAO_0000218,948.0,
10707,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,,CHEMBL622101,,1,1,,BAO_0000218,2113.0,
10708,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,,CHEMBL622102,,1,1,,BAO_0000218,2113.0,
10709,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,,CHEMBL622103,,1,1,,BAO_0000218,2113.0,
10710,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,,CHEMBL622104,,1,1,,BAO_0000218,2107.0,
10711,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,,CHEMBL622105,,1,1,,BAO_0000218,2107.0,
10712,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,,CHEMBL622106,,1,1,,BAO_0000218,2107.0,
10713,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,,CHEMBL622107,,1,1,,BAO_0000218,2048.0,
10714,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,,CHEMBL622108,,1,1,,BAO_0000218,2048.0,
10715,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,,CHEMBL622109,,1,1,,BAO_0000218,2048.0,
10716,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,,CHEMBL622110,,1,1,,BAO_0000218,2385.0,
10717,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,,CHEMBL622111,,1,1,,BAO_0000218,2385.0,
10718,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,,CHEMBL874383,,1,1,,BAO_0000218,2385.0,
10719,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,,CHEMBL622112,,1,1,,BAO_0000218,14.0,
10720,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,,CHEMBL622113,,1,1,,BAO_0000218,14.0,
10721,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,,CHEMBL622114,,1,1,,BAO_0000218,14.0,
10722,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,,CHEMBL622115,,1,1,,BAO_0000218,2106.0,
10723,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,,CHEMBL622116,,1,1,,BAO_0000218,2106.0,
10724,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622117,,1,1,,BAO_0000218,,
10725,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622118,,1,1,,BAO_0000218,,
10726,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rats at 6 mg/kg,,CHEMBL622119,,1,1,,BAO_0000218,,
10727,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 6 mg/kg),,CHEMBL622120,,1,1,,BAO_0000218,,
10728,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,CHEMBL622121,,1,1,,BAO_0000218,,
10729,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622122,,1,1,,BAO_0000218,,
10730,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622123,,1,1,,BAO_0000218,,
10731,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL622124,,1,1,,BAO_0000218,,
10732,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL622125,,1,1,,BAO_0000218,,
10733,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability,,CHEMBL622126,,1,1,,BAO_0000218,,
10734,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,CHEMBL620455,,1,1,,BAO_0000218,,
10735,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL620456,,1,1,,BAO_0000218,,
10736,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL620457,,1,1,,BAO_0000218,,
10737,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability was evaluated; Not tested,,CHEMBL620458,,1,1,,BAO_0000218,,
10738,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability,,CHEMBL620459,,1,1,,BAO_0000218,,
10739,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat by oral dosing,,CHEMBL620460,,1,1,,BAO_0000218,,
10740,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 10 mg/kg p.o.),,CHEMBL620461,,1,1,,BAO_0000218,,
10741,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley),,CHEMBL620462,,1,1,,BAO_0000218,,
10742,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,CHEMBL620463,,1,1,,BAO_0000218,,
10743,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,CHEMBL620464,,1,1,,BAO_0000218,,
10744,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,CHEMBL620465,,1,1,,BAO_0000218,,
10745,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,CHEMBL620466,,1,1,,BAO_0000218,,
10746,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,CHEMBL620467,,1,1,,BAO_0000218,,
10747,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,CHEMBL620468,,1,1,,BAO_0000218,,
10748,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,CHEMBL620469,,1,1,,BAO_0000218,,
10749,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,CHEMBL620470,,1,1,,BAO_0000218,,
10750,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL620471,,1,1,,BAO_0000218,,
10751,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL620472,,1,1,,BAO_0000218,,
10752,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,CHEMBL620473,,1,1,,BAO_0000218,,
10753,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL620474,,1,1,,BAO_0000218,,
10754,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,CHEMBL620475,,1,1,,BAO_0000218,,
10755,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL620476,,1,1,,BAO_0000218,,
10756,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL620477,,1,1,,BAO_0000218,,
10757,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,CHEMBL620478,,1,1,,BAO_0000218,,
10758,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,CHEMBL618768,,1,1,,BAO_0000218,,
10759,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,CHEMBL618769,,1,1,,BAO_0000218,,
10760,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,CHEMBL618770,,1,1,,BAO_0000218,,
10761,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability (dose 20 mg/kg p.o.),,CHEMBL618771,,1,1,,BAO_0000218,,
10762,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,CHEMBL618772,,1,1,,BAO_0000218,,
10763,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat at 10 mg/kg of the compound,,CHEMBL618773,,1,1,,BAO_0000218,,
10764,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,CHEMBL875842,,1,1,,BAO_0000218,,
10765,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 3 mg/kg i.v.),,CHEMBL618774,,1,1,,BAO_0000218,,
10766,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,CHEMBL618775,,1,1,,BAO_0000218,,
10767,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 60 mg/kg p.o.),,CHEMBL618776,,1,1,,BAO_0000218,,
10768,A,In vivo,10116.0,,50597,Intermediate,Percent bioavailability (F) in rats after iv administration,,CHEMBL618777,,1,1,,BAO_0000218,,
10769,A,In vivo,10116.0,,50597,Intermediate,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,CHEMBL618778,,1,1,,BAO_0000218,,
10770,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 5 uM/kg p.o.),,CHEMBL618779,,1,1,,BAO_0000218,,
10771,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability,,CHEMBL618780,,1,1,,BAO_0000218,,
10772,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat (dose 2 mg/kg p.o.),,CHEMBL618781,,1,1,,BAO_0000218,,
10773,A,In vivo,10116.0,,50597,Intermediate,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,CHEMBL618782,,1,1,,BAO_0000218,,
10774,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 20 mg/kg),,CHEMBL618783,,1,1,,BAO_0000218,,
10775,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL618784,,1,1,,BAO_0000218,,
10776,A,In vivo,10116.0,,50597,Intermediate,Percent oral bioavailability evaluated in rat,,CHEMBL618785,,1,1,,BAO_0000218,,
10777,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL618786,,1,1,,BAO_0000218,,
10778,A,In vivo,10116.0,,50597,Intermediate,Percent oral bioavailability in rat; Not determined,,CHEMBL618787,,1,1,,BAO_0000218,,
10779,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat,,CHEMBL618788,,1,1,,BAO_0000218,,
10780,A,In vivo,10116.0,,50597,Intermediate,Bioavailability in rat,,CHEMBL618789,,1,1,,BAO_0000218,,
10781,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,CHEMBL618790,,1,1,,BAO_0000218,,
10782,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,CHEMBL618791,,1,1,,BAO_0000218,,
10783,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,CHEMBL875843,,1,1,,BAO_0000218,,
10784,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat (dose 20 mg/kg p.o.),,CHEMBL618792,,1,1,,BAO_0000218,,
10785,A,In vivo,10116.0,,50597,Intermediate,Cmax at a dose of 30 mg/kg in rat,,CHEMBL623395,,1,1,,BAO_0000218,,
10786,A,In vivo,314293.0,,22224,Autocuration,Cmax in monkeys at a dose of 1 mg/kg,,CHEMBL623396,,0,1,,BAO_0000218,,
10787,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat,,CHEMBL623397,,1,1,,BAO_0000218,,
10788,A,In vivo,10116.0,,50597,Intermediate,Cmax in rats at a dose of 1 mg/kg,,CHEMBL623398,,1,1,,BAO_0000218,,
10789,A,In vivo,10090.0,,50594,Intermediate,Cmax was measured in mice after an oral dose of 50 mg/kg.,,CHEMBL623399,,1,1,,BAO_0000218,,
10790,A,In vivo,,,22224,Autocuration,"Cmax value at a dose of 12.7 uM/kg, po",,CHEMBL623400,,0,1,,BAO_0000218,,
10791,A,In vivo,,,22224,Autocuration,"Cmax value at a dose of 6.3 uM/kg, iv",,CHEMBL623401,,0,1,,BAO_0000218,,
10792,A,In vivo,,,22224,Autocuration,"Cmax value at a dose of 7.1 uM/kg, iv",,CHEMBL623402,,0,1,,BAO_0000218,,
10793,A,In vivo,,,22224,Autocuration,Cmax value of compound was determined after 1 hr,,CHEMBL623403,,0,1,,BAO_0000218,,
10794,A,In vivo,,,22224,Autocuration,Cmax value of the compound,,CHEMBL623404,,0,1,,BAO_0000218,,
10795,A,In vivo,10116.0,,50597,Intermediate,Cmax value administered intraintestinal in rats.,,CHEMBL625997,,1,1,,BAO_0000218,,
10796,A,In vivo,10116.0,,50597,Intermediate,Cmax value administered perorally was determined in rat; Not determined,,CHEMBL625998,,1,1,,BAO_0000218,,
10797,A,In vivo,,,22224,Autocuration,Cmax value at the dose of 2.3 mg/kg,,CHEMBL625999,,0,1,,BAO_0000218,,
10798,A,In vivo,,,22224,Autocuration,Cmax value at the dose of 5 mg/kg,,CHEMBL626000,,0,1,,BAO_0000218,,
10799,A,In vivo,,,22224,Autocuration,Cmax value in the period of 8 hr after dosing. ,,CHEMBL626001,,0,1,,BAO_0000218,,
10800,A,In vivo,,,22224,Autocuration,Cmax value at a oral dose of 20 mg/kg; Not tested,,CHEMBL626002,,0,1,,BAO_0000218,,
10801,A,In vivo,,,22224,Autocuration,Cmax value at a oral dose of 20 mg/kg,,CHEMBL626003,,0,1,,BAO_0000218,,
10802,A,In vivo,10116.0,,50597,Intermediate,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,CHEMBL626004,,1,1,,BAO_0000218,,
10803,A,In vivo,10141.0,,50512,Intermediate,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,CHEMBL626005,,1,1,,BAO_0000218,,
10804,A,In vivo,10116.0,,50597,Intermediate,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,CHEMBL626006,,1,1,,BAO_0000218,,
10805,A,In vivo,10116.0,,50597,Intermediate,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,,CHEMBL626007,,1,1,,BAO_0000218,1969.0,
10806,A,In vivo,10090.0,,50594,Intermediate,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,CHEMBL626008,,1,1,,BAO_0000218,1969.0,
10807,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,,CHEMBL626009,,1,1,,BAO_0000218,2107.0,
10808,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,CHEMBL626010,,1,1,,BAO_0000218,,
10809,A,In vivo,10090.0,,50594,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,,CHEMBL626011,,1,1,,BAO_0000218,178.0,
10810,A,In vivo,10090.0,,50594,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,,CHEMBL626012,,1,1,,BAO_0000218,178.0,
10811,A,In vivo,10090.0,,50594,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,,CHEMBL626013,,1,1,,BAO_0000218,178.0,
10812,A,In vivo,10090.0,,50594,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,,CHEMBL626014,,1,1,,BAO_0000218,178.0,
10813,A,In vivo,10090.0,,50594,Intermediate,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,,CHEMBL877496,,1,1,,BAO_0000218,178.0,
10814,F,In vivo,9615.0,,50588,Intermediate,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,CHEMBL626015,,1,1,,BAO_0000218,,
10815,F,In vivo,9615.0,,50588,Intermediate,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,CHEMBL626016,,1,1,,BAO_0000218,,
10816,F,In vivo,9615.0,,50588,Intermediate,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,CHEMBL626017,,1,1,,BAO_0000218,,
10817,A,In vivo,9615.0,,50588,Intermediate,Bioavailability as maximal plasma concentration in dogs,,CHEMBL626018,,1,1,,BAO_0000218,1969.0,
10818,A,In vivo,9615.0,,50588,Intermediate,Bioavailability as maximal plasma concentration in dogs,,CHEMBL626692,,1,1,,BAO_0000218,1969.0,
10819,A,In vivo,10116.0,,50597,Intermediate,Bioavailability as maximal plasma concentration in rats,,CHEMBL626693,,1,1,,BAO_0000218,1969.0,
10820,A,In vivo,10116.0,,22224,Autocuration,Bioavailability as maximal plasma concentration in rats,,CHEMBL626694,,0,1,,BAO_0000218,1969.0,
10821,A,In vivo,9615.0,,50588,Intermediate,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,CHEMBL626695,,1,1,,BAO_0000218,178.0,
10822,A,In vivo,9615.0,,50588,Intermediate,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,CHEMBL626696,,1,1,,BAO_0000218,178.0,
10823,A,In vivo,9615.0,,50588,Intermediate,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,CHEMBL626697,,1,1,,BAO_0000218,178.0,
10824,A,In vivo,9615.0,,50588,Intermediate,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,,CHEMBL626859,,1,1,,BAO_0000218,178.0,
10825,A,In vivo,9615.0,,50588,Intermediate,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,CHEMBL626860,,1,1,,BAO_0000218,178.0,
10826,A,In vivo,9615.0,,50588,Intermediate,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,CHEMBL626861,,1,1,,BAO_0000218,178.0,
10827,A,In vivo,10116.0,,50597,Intermediate,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,CHEMBL626296,,1,1,,BAO_0000218,,
10828,A,In vivo,,,22224,Autocuration,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,CHEMBL626297,,0,1,,BAO_0000218,,
10829,A,In vivo,,,22224,Autocuration,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,,CHEMBL626298,,0,1,,BAO_0000218,1969.0,
10830,A,In vivo,10116.0,,50597,Intermediate,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",,CHEMBL626299,,1,1,,BAO_0000218,1969.0,
10831,A,In vivo,10116.0,,50597,Intermediate,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,,CHEMBL626300,,1,1,,BAO_0000218,1969.0,
10832,A,In vivo,10116.0,,50597,Intermediate,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,,CHEMBL626301,,1,1,,BAO_0000218,1969.0,
10833,A,In vivo,10116.0,,50597,Intermediate,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,,CHEMBL626962,,1,1,,BAO_0000218,1969.0,
10834,A,In vivo,10116.0,,50597,Intermediate,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,,CHEMBL626963,,1,1,,BAO_0000218,1969.0,
10835,A,In vivo,10116.0,,50597,Intermediate,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,,CHEMBL626964,,1,1,,BAO_0000218,1969.0,
10836,A,In vivo,9541.0,,100710,Intermediate,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,,CHEMBL626965,,1,1,,BAO_0000218,1969.0,
10837,A,In vivo,10090.0,,50594,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL626966,,1,1,,BAO_0000218,1969.0,
10838,A,In vivo,10090.0,,50594,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL626967,,1,1,,BAO_0000218,1969.0,
10839,A,In vivo,9541.0,,100710,Intermediate,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,,CHEMBL626968,,1,1,,BAO_0000218,1969.0,
10840,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,,CHEMBL626969,,1,1,,BAO_0000218,948.0,
10841,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,,CHEMBL627126,,1,1,,BAO_0000218,948.0,
10842,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,,CHEMBL631276,,1,1,,BAO_0000218,948.0,
10843,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,,CHEMBL631277,,1,1,,BAO_0000218,948.0,
10844,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,,CHEMBL631278,,1,1,,BAO_0000218,948.0,
10845,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,,CHEMBL874457,,1,1,,BAO_0000218,948.0,
10846,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,,CHEMBL631279,,1,1,,BAO_0000218,948.0,
10847,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,,CHEMBL631280,,1,1,,BAO_0000218,948.0,
10848,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,,CHEMBL631281,,1,1,,BAO_0000218,948.0,
10849,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,,CHEMBL631968,,1,1,,BAO_0000218,948.0,
10850,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,,CHEMBL631969,,1,1,,BAO_0000218,948.0,
10851,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,,CHEMBL631970,,1,1,,BAO_0000218,948.0,
10852,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,,CHEMBL631971,,1,1,,BAO_0000218,948.0,
10853,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,,CHEMBL631972,,1,1,,BAO_0000218,948.0,
10854,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,,CHEMBL630435,,1,1,,BAO_0000218,948.0,
10855,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,,CHEMBL630436,,1,1,,BAO_0000218,948.0,
10856,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,,CHEMBL630437,,1,1,,BAO_0000218,948.0,
10857,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,,CHEMBL630438,,1,1,,BAO_0000218,948.0,
10858,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,,CHEMBL630439,,1,1,,BAO_0000218,948.0,
10859,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,,CHEMBL630440,,1,1,,BAO_0000218,2113.0,
10860,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,,CHEMBL630441,,1,1,,BAO_0000218,2113.0,
10861,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,,CHEMBL630442,,1,1,,BAO_0000218,2113.0,
10862,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,,CHEMBL625234,,1,1,,BAO_0000218,2113.0,
10863,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,,CHEMBL625235,,1,1,,BAO_0000218,2113.0,
10864,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,,CHEMBL625236,,1,1,,BAO_0000218,2113.0,
10865,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,,CHEMBL625237,,1,1,,BAO_0000218,2113.0,
10866,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,,CHEMBL626125,,1,1,,BAO_0000218,2113.0,
10867,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,,CHEMBL626126,,1,1,,BAO_0000218,2113.0,
10868,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,,CHEMBL626127,,1,1,,BAO_0000218,2113.0,
10869,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,,CHEMBL626128,,1,1,,BAO_0000218,2113.0,
10870,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,,CHEMBL626129,,1,1,,BAO_0000218,2113.0,
10871,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,,CHEMBL626130,,1,1,,BAO_0000218,2113.0,
10872,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,,CHEMBL626131,,1,1,,BAO_0000218,2113.0,
10873,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,,CHEMBL626132,,1,1,,BAO_0000218,2113.0,
10874,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,,CHEMBL626752,,1,1,,BAO_0000218,2113.0,
10875,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,,CHEMBL626753,,1,1,,BAO_0000218,2113.0,
10876,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,,CHEMBL626754,,1,1,,BAO_0000218,2113.0,
10877,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,,CHEMBL626755,,1,1,,BAO_0000218,2113.0,
10878,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,,CHEMBL626756,,1,1,,BAO_0000218,2107.0,
10879,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,,CHEMBL626757,,1,1,,BAO_0000218,2107.0,
10880,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,,CHEMBL626758,,1,1,,BAO_0000218,2107.0,
10881,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,,CHEMBL626759,,1,1,,BAO_0000218,2107.0,
10882,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,,CHEMBL626760,,1,1,,BAO_0000218,2107.0,
10883,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,CHEMBL626394,,1,1,,BAO_0000218,,
10884,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,CHEMBL626395,,1,1,,BAO_0000218,,
10885,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,CHEMBL626396,,1,1,,BAO_0000218,,
10886,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL626397,,1,1,,BAO_0000218,,
10887,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,CHEMBL626398,,1,1,,BAO_0000218,,
10888,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,CHEMBL626399,,1,1,,BAO_0000218,,
10889,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,CHEMBL874653,,1,1,,BAO_0000218,,
10890,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL626400,,1,1,,BAO_0000218,,
10891,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,CHEMBL626401,,1,1,,BAO_0000218,,
10892,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL626402,,1,1,,BAO_0000218,,
10893,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,CHEMBL626403,,1,1,,BAO_0000218,,
10894,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL626404,,1,1,,BAO_0000218,,
10895,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,CHEMBL626405,,1,1,,BAO_0000218,,
10896,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL625529,,1,1,,BAO_0000218,,
10897,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,CHEMBL625530,,1,1,,BAO_0000218,,
10898,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL625531,,1,1,,BAO_0000218,,
10899,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,CHEMBL625532,,1,1,,BAO_0000218,,
10900,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL625533,,1,1,,BAO_0000218,,
10901,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,CHEMBL875474,,1,1,,BAO_0000218,,
10902,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL625534,,1,1,,BAO_0000218,,
10903,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,CHEMBL625535,,1,1,,BAO_0000218,,
10904,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL625536,,1,1,,BAO_0000218,,
10905,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,CHEMBL625537,,1,1,,BAO_0000218,,
10906,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL625538,,1,1,,BAO_0000218,,
10907,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,CHEMBL625539,,1,1,,BAO_0000218,,
10908,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL625540,,1,1,,BAO_0000218,,
10909,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,CHEMBL625541,,1,1,,BAO_0000218,,
10910,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL625542,,1,1,,BAO_0000218,,
10911,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,CHEMBL625543,,1,1,,BAO_0000218,,
10912,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL625544,,1,1,,BAO_0000218,,
10913,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,CHEMBL625545,,1,1,,BAO_0000218,,
10914,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,CHEMBL625546,,1,1,,BAO_0000218,,
10915,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,CHEMBL625547,,1,1,,BAO_0000218,,
10916,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,CHEMBL625548,,1,1,,BAO_0000218,,
10917,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,CHEMBL625549,,1,1,,BAO_0000218,,
10918,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,CHEMBL625550,,1,1,,BAO_0000218,,
10919,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,CHEMBL625551,,1,1,,BAO_0000218,,
10920,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,CHEMBL875475,,1,1,,BAO_0000218,,
10921,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,CHEMBL625552,,1,1,,BAO_0000218,,
10922,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,CHEMBL625553,,1,1,,BAO_0000218,,
10923,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL625554,,1,1,,BAO_0000218,,
10924,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,CHEMBL625555,,1,1,,BAO_0000218,,
10925,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,CHEMBL625556,,1,1,,BAO_0000218,,
10926,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,CHEMBL624986,,1,1,,BAO_0000218,,
10927,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,CHEMBL624987,,1,1,,BAO_0000218,,
10928,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL624988,,1,1,,BAO_0000218,,
10929,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,,CHEMBL624989,,1,1,,BAO_0000218,1637.0,
10930,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,,CHEMBL624990,,1,1,,BAO_0000218,1637.0,
10931,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,,CHEMBL874391,,1,1,,BAO_0000218,1637.0,
10932,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,,CHEMBL624991,,1,1,,BAO_0000218,1637.0,
10933,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,,CHEMBL624992,,1,1,,BAO_0000218,1637.0,
10934,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,,CHEMBL624993,,1,1,,BAO_0000218,1637.0,
10935,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,,CHEMBL624994,,1,1,,BAO_0000218,1637.0,
10936,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,,CHEMBL624995,,1,1,,BAO_0000218,1637.0,
10937,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,,CHEMBL624996,,1,1,,BAO_0000218,1637.0,
10938,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,,CHEMBL624997,,1,1,,BAO_0000218,1637.0,
10939,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,,CHEMBL624998,,1,1,,BAO_0000218,1637.0,
10940,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,,CHEMBL624999,,1,1,,BAO_0000218,1637.0,
10941,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,,CHEMBL882955,,1,1,,BAO_0000218,1637.0,
10942,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,,CHEMBL625000,,1,1,,BAO_0000218,1637.0,
10943,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,,CHEMBL625001,,1,1,,BAO_0000218,1637.0,
10944,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,,CHEMBL625089,,1,1,,BAO_0000218,1637.0,
10945,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,,CHEMBL625090,,1,1,,BAO_0000218,1637.0,
10946,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,,CHEMBL625091,,1,1,,BAO_0000218,1637.0,
10947,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,,CHEMBL625092,,1,1,,BAO_0000218,1637.0,
10948,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,,CHEMBL625093,,1,1,,BAO_0000218,1637.0,
10949,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,,CHEMBL625094,,1,1,,BAO_0000218,1637.0,
10950,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,,CHEMBL625095,,1,1,,BAO_0000218,1637.0,
10951,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for its bioavailability in the dogs,,CHEMBL625096,,1,1,,BAO_0000218,,
10952,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for its bioavailability in the rats,,CHEMBL625097,,1,1,,BAO_0000218,,
10953,A,In vivo,,,22224,Autocuration,Compound was evaluated for oral bioavailability,,CHEMBL882956,,0,1,,BAO_0000218,,
10954,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for percentage of Oral bioavailability in rats,,CHEMBL625098,,1,1,,BAO_0000218,,
10955,A,In vivo,10141.0,,22224,Autocuration,Bioavailability in guinea pig,,CHEMBL625099,,0,1,,BAO_0000218,,
10956,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for the oral bioavailability in rat,,CHEMBL625100,,1,1,,BAO_0000218,,
10957,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for the oral bioavailability in dog,,CHEMBL625101,,1,1,,BAO_0000218,,
10958,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for the oral bioavailability in rat,,CHEMBL874396,,1,1,,BAO_0000218,,
10959,F,In vivo,9615.0,,22224,Autocuration,Bioavailability in dog (dosed i.v.),,CHEMBL625102,,0,1,,BAO_0000218,,
10960,A,In vivo,9615.0,,50588,Intermediate,Compound was tested for in vivo bioavailability in dog,,CHEMBL625103,,1,1,,BAO_0000218,,
10961,A,In vivo,10026.0,,100712,Intermediate,Compound was tested for in vivo bioavailability in hamsters,,CHEMBL625104,,1,1,,BAO_0000218,,
10962,A,In vivo,314293.0,,22224,Autocuration,Compound was tested for in vivo bioavailability in monkey,,CHEMBL625105,,0,1,,BAO_0000218,,
10963,A,In vivo,10116.0,,50597,Intermediate,Compound was tested for in vivo bioavailability in rat,,CHEMBL625106,,1,1,,BAO_0000218,,
10964,A,In vivo,10090.0,,22224,Autocuration,Oral bioavailability in mouse,,CHEMBL625107,,0,1,,BAO_0000218,,
10965,A,In vivo,10090.0,,50594,Intermediate,Compound was tested for percent of oral bioavailability in mice; 56-74,,CHEMBL625108,,1,1,,BAO_0000218,,
10966,A,In vivo,10090.0,,22224,Autocuration,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,CHEMBL625109,,0,1,,BAO_0000218,,
10967,A,In vivo,9541.0,,22224,Autocuration,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,CHEMBL625110,,0,1,,BAO_0000218,,
10968,A,In vivo,9541.0,,22224,Autocuration,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,CHEMBL625111,,0,1,,BAO_0000218,,
10969,A,In vivo,10090.0,,50594,Intermediate,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,CHEMBL625112,,1,1,,BAO_0000218,,
10970,A,In vivo,10090.0,,50594,Intermediate,Oral bioavailability in nude mice,,CHEMBL875334,,1,1,,BAO_0000218,,
10971,A,In vivo,9443.0,,22224,Autocuration,Bioavailability in monkey (i.d. dosing),,CHEMBL628617,,0,1,,BAO_0000218,,
10972,A,In vivo,10116.0,,22224,Autocuration,Bioavailability in rat,,CHEMBL628618,,0,1,,BAO_0000218,,
10973,A,In vivo,,,22224,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,CHEMBL628619,,0,1,,BAO_0000218,,
10974,A,In vivo,,,22224,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,CHEMBL628620,,0,1,,BAO_0000218,,
10975,A,In vivo,9541.0,,100710,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,CHEMBL628621,,1,1,,BAO_0000218,,
10976,A,In vivo,9541.0,,100710,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,CHEMBL628622,,1,1,,BAO_0000218,,
10977,A,In vivo,9541.0,,100710,Intermediate,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,CHEMBL628623,,1,1,,BAO_0000218,,
10978,A,In vivo,9541.0,,100710,Intermediate,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,,CHEMBL628624,,1,1,,BAO_0000218,1969.0,
10979,A,In vivo,10090.0,,50594,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL628625,,1,1,,BAO_0000218,1969.0,
10980,A,In vivo,9541.0,,100710,Intermediate,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,,CHEMBL628626,,1,1,,BAO_0000218,1969.0,
10981,A,In vivo,10090.0,,50594,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL627041,,1,1,,BAO_0000218,1969.0,
10982,A,In vivo,10090.0,,50594,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL627042,,1,1,,BAO_0000218,1969.0,
10983,A,In vivo,10090.0,,50594,Intermediate,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,CHEMBL627043,,1,1,,BAO_0000218,1969.0,
10984,A,In vivo,,,22224,Autocuration,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,,CHEMBL627044,,0,1,,BAO_0000218,1969.0,
10985,A,In vivo,10090.0,,50594,Intermediate,Cmax in mouse plasma,,CHEMBL627045,,1,1,,BAO_0000218,1969.0,
10986,A,In vivo,,,22224,Autocuration,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,,CHEMBL627046,,0,1,,BAO_0000218,1969.0,
10987,A,In vivo,10116.0,,50597,Intermediate,Maximal plasma concentration in rat,,CHEMBL627047,,1,1,,BAO_0000218,1969.0,
10988,A,In vivo,10116.0,,50597,Intermediate,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,,CHEMBL627048,,1,1,,BAO_0000218,1969.0,
10989,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,CHEMBL627049,,1,1,,BAO_0000218,,
10990,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,CHEMBL627050,,1,1,,BAO_0000218,,
10991,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,CHEMBL627051,,1,1,,BAO_0000218,,
10992,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,CHEMBL627052,,1,1,,BAO_0000218,,
10993,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,CHEMBL627053,,1,1,,BAO_0000218,,
10994,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,CHEMBL627054,,1,1,,BAO_0000218,,
10995,A,In vivo,10090.0,,50594,Intermediate,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,CHEMBL627055,,1,1,,BAO_0000218,,
10996,A,In vivo,10090.0,,50594,Intermediate,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,CHEMBL627056,,1,1,,BAO_0000218,,
10997,A,In vivo,10090.0,,50594,Intermediate,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,CHEMBL627057,,1,1,,BAO_0000218,,
10998,A,In vivo,10090.0,,50594,Intermediate,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,CHEMBL627058,,1,1,,BAO_0000218,,
10999,A,In vivo,10090.0,,50594,Intermediate,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,CHEMBL626211,,1,1,,BAO_0000218,,
11000,A,In vivo,,,22224,Autocuration,Maximum Concentration of the compound.,,CHEMBL626212,,0,1,,BAO_0000218,,
11001,A,In vivo,9615.0,,50588,Intermediate,Maximum Concentration was measured after iv administration into Beagle dog,,CHEMBL626213,,1,1,,BAO_0000218,,
11002,A,In vivo,9615.0,,50588,Intermediate,Maximum Concentration was measured after iv administration into Beagle dog.,,CHEMBL626214,,1,1,,BAO_0000218,,
11003,A,In vivo,9615.0,,50588,Intermediate,Maximum Concentration was measured after po administration into Beagle dog,,CHEMBL626215,,1,1,,BAO_0000218,,
11004,A,In vivo,9615.0,,50588,Intermediate,Maximum Concentration was measured after po administration into Beagle dog.,,CHEMBL626216,,1,1,,BAO_0000218,,
11005,A,In vivo,,,22224,Autocuration,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,,CHEMBL626217,,0,1,,BAO_0000218,178.0,
11006,A,In vivo,,,22224,Autocuration,Maximum blood level reached after an iv dose of 12.2 uM/kg,,CHEMBL626218,,0,1,,BAO_0000218,178.0,
11007,A,In vivo,,,22224,Autocuration,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,,CHEMBL626219,,0,1,,BAO_0000218,178.0,
11008,A,In vivo,,,22224,Autocuration,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,,CHEMBL626220,,0,1,,BAO_0000218,178.0,
11009,A,In vivo,,,22224,Autocuration,Maximum blood level reached after an oral dose of 5.0 mg/kg,,CHEMBL626221,,0,1,,BAO_0000218,178.0,
11010,A,In vivo,,,22224,Autocuration,Maximum blood level reached at dose of 10.6 uM/kg orally,,CHEMBL626222,,0,1,,BAO_0000218,178.0,
11011,A,In vivo,10141.0,,50512,Intermediate,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,CHEMBL626223,,1,1,,BAO_0000218,,
11012,A,In vivo,10141.0,,50512,Intermediate,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,CHEMBL626224,,1,1,,BAO_0000218,,
11013,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,,CHEMBL626225,,1,1,,BAO_0000218,955.0,
11014,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,,CHEMBL626226,,1,1,,BAO_0000218,955.0,
11015,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,,CHEMBL626227,,1,1,,BAO_0000218,955.0,
11016,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,,CHEMBL626228,,1,1,,BAO_0000218,955.0,
11017,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,CHEMBL626229,,1,1,,BAO_0000218,,
11018,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,CHEMBL626921,,1,1,,BAO_0000218,,
11019,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,CHEMBL876793,,1,1,,BAO_0000218,,
11020,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,CHEMBL625309,,1,1,,BAO_0000218,,
11021,A,In vivo,1423.0,,50278,Intermediate,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,CHEMBL625310,,1,1,,BAO_0000218,,
11022,A,In vivo,314293.0,,22224,Autocuration,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,CHEMBL625311,,0,1,,BAO_0000218,,
11023,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,CHEMBL625312,,1,1,,BAO_0000218,,
11024,A,In vivo,,,22224,Autocuration,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,CHEMBL625313,,0,1,,BAO_0000218,,
11025,A,In vivo,10090.0,,50594,Intermediate,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,CHEMBL625314,,1,1,,BAO_0000218,,
11026,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in male rats after iv administration of 20 mg/kg,,CHEMBL625315,,1,1,,BAO_0000218,,
11027,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,,CHEMBL625316,,1,1,,BAO_0000218,2107.0,
11028,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,,CHEMBL625317,,1,1,,BAO_0000218,2107.0,
11029,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,,CHEMBL625318,,1,1,,BAO_0000218,2107.0,
11030,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,,CHEMBL625319,,1,1,,BAO_0000218,2107.0,
11031,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,,CHEMBL625320,,1,1,,BAO_0000218,2107.0,
11032,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,,CHEMBL625321,,1,1,,BAO_0000218,2107.0,
11033,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,,CHEMBL625322,,1,1,,BAO_0000218,2107.0,
11034,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,,CHEMBL876801,,1,1,,BAO_0000218,2107.0,
11035,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,,CHEMBL625323,,1,1,,BAO_0000218,2107.0,
11036,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,,CHEMBL625324,,1,1,,BAO_0000218,2107.0,
11037,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,,CHEMBL625325,,1,1,,BAO_0000218,2107.0,
11038,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,,CHEMBL625326,,1,1,,BAO_0000218,2107.0,
11039,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,,CHEMBL625327,,1,1,,BAO_0000218,2107.0,
11040,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,,CHEMBL625328,,1,1,,BAO_0000218,2107.0,
11041,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,,CHEMBL625329,,1,1,,BAO_0000218,2048.0,
11042,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,,CHEMBL625330,,1,1,,BAO_0000218,2048.0,
11043,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,,CHEMBL627774,,1,1,,BAO_0000218,2048.0,
11044,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,,CHEMBL627775,,1,1,,BAO_0000218,2048.0,
11045,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,,CHEMBL627949,,1,1,,BAO_0000218,2048.0,
11046,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,,CHEMBL627950,,1,1,,BAO_0000218,2048.0,
11047,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,,CHEMBL627951,,1,1,,BAO_0000218,2048.0,
11048,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,,CHEMBL627952,,1,1,,BAO_0000218,2048.0,
11049,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,,CHEMBL627953,,1,1,,BAO_0000218,2048.0,
11050,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,,CHEMBL627954,,1,1,,BAO_0000218,2048.0,
11051,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,,CHEMBL627955,,1,1,,BAO_0000218,2048.0,
11052,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,,CHEMBL627956,,1,1,,BAO_0000218,2048.0,
11053,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,,CHEMBL876802,,1,1,,BAO_0000218,2048.0,
11054,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,,CHEMBL627957,,1,1,,BAO_0000218,2048.0,
11055,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,,CHEMBL627958,,1,1,,BAO_0000218,2048.0,
11056,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,,CHEMBL627959,,1,1,,BAO_0000218,2048.0,
11057,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,,CHEMBL627960,,1,1,,BAO_0000218,2048.0,
11058,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,,CHEMBL627961,,1,1,,BAO_0000218,2048.0,
11059,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,,CHEMBL627962,,1,1,,BAO_0000218,2048.0,
11060,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,CHEMBL627963,,1,1,,BAO_0000218,,
11061,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL624759,,1,1,,BAO_0000218,,
11062,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,CHEMBL624760,,1,1,,BAO_0000218,,
11063,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL624761,,1,1,,BAO_0000218,,
11064,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL877607,,1,1,,BAO_0000218,,
11065,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,CHEMBL624762,,1,1,,BAO_0000218,2107.0,
11066,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL624763,,1,1,,BAO_0000218,2107.0,
11067,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,CHEMBL624764,,1,1,,BAO_0000218,2107.0,
11068,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL624765,,1,1,,BAO_0000218,2107.0,
11069,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL624766,,1,1,,BAO_0000218,2107.0,
11070,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,CHEMBL624767,,1,1,,BAO_0000218,,
11071,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,CHEMBL624768,,1,1,,BAO_0000218,,
11072,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,CHEMBL624769,,1,1,,BAO_0000218,,
11073,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL624770,,1,1,,BAO_0000218,,
11074,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,CHEMBL624771,,1,1,,BAO_0000218,,
11075,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,CHEMBL624772,,1,1,,BAO_0000218,,
11076,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,CHEMBL624773,,1,1,,BAO_0000218,,
11077,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL624774,,1,1,,BAO_0000218,,
11078,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,CHEMBL624775,,1,1,,BAO_0000218,,
11079,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL624776,,1,1,,BAO_0000218,,
11080,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,CHEMBL624777,,1,1,,BAO_0000218,,
11081,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL624778,,1,1,,BAO_0000218,,
11082,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,CHEMBL624779,,1,1,,BAO_0000218,,
11083,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL624780,,1,1,,BAO_0000218,,
11084,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,CHEMBL624781,,1,1,,BAO_0000218,,
11085,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL877608,,1,1,,BAO_0000218,,
11086,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,CHEMBL624782,,1,1,,BAO_0000218,,
11087,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL624783,,1,1,,BAO_0000218,,
11088,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,CHEMBL624784,,1,1,,BAO_0000218,,
11089,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL624785,,1,1,,BAO_0000218,,
11090,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,CHEMBL624786,,1,1,,BAO_0000218,,
11091,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,CHEMBL624787,,1,1,,BAO_0000218,,
11092,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL628676,,1,1,,BAO_0000218,,
11093,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,CHEMBL621842,,1,1,,BAO_0000218,,
11094,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL621843,,1,1,,BAO_0000218,,
11095,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,CHEMBL623873,,1,1,,BAO_0000218,,
11096,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL623874,,1,1,,BAO_0000218,,
11097,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,CHEMBL623875,,1,1,,BAO_0000218,,
11098,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL623876,,1,1,,BAO_0000218,,
11099,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,CHEMBL623877,,1,1,,BAO_0000218,,
11100,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,CHEMBL623878,,1,1,,BAO_0000218,,
11101,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,CHEMBL623879,,1,1,,BAO_0000218,,
11102,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,CHEMBL623880,,1,1,,BAO_0000218,,
11103,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,CHEMBL623881,,1,1,,BAO_0000218,,
11104,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,CHEMBL623957,,1,1,,BAO_0000218,,
11105,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,CHEMBL623958,,1,1,,BAO_0000218,,
11106,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,CHEMBL623959,,1,1,,BAO_0000218,,
11107,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,CHEMBL623960,,1,1,,BAO_0000218,,
11108,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,CHEMBL623961,,1,1,,BAO_0000218,,
11109,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL623962,,1,1,,BAO_0000218,,
11110,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,CHEMBL624676,,1,1,,BAO_0000218,,
11111,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,CHEMBL624677,,1,1,,BAO_0000218,,
11112,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,CHEMBL624678,,1,1,,BAO_0000218,,
11113,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,CHEMBL624679,,1,1,,BAO_0000218,,
11114,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL624680,,1,1,,BAO_0000218,,
11115,A,In vivo,,,22224,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,CHEMBL624849,,0,1,,BAO_0000218,,
11116,A,In vivo,,,22224,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,CHEMBL624850,,0,1,,BAO_0000218,,
11117,A,In vivo,,,22224,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,CHEMBL874399,,0,1,,BAO_0000218,,
11118,A,In vivo,,,22224,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,CHEMBL624851,,0,1,,BAO_0000218,,
11119,A,In vivo,,,22224,Autocuration,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,CHEMBL624852,,0,1,,BAO_0000218,,
11120,A,In vivo,10116.0,,22224,Autocuration,Oral bioavailability in rat (dose 10 mg/kg),,CHEMBL624853,,0,1,,BAO_0000218,,
11121,A,In vivo,10116.0,,22224,Autocuration,Oral bioavailability in rat (Sprague-Dawley),,CHEMBL624854,,0,1,,BAO_0000218,,
11122,A,In vivo,10116.0,,22224,Autocuration,Oral bioavailability in rat,,CHEMBL624855,,0,1,,BAO_0000218,,
11123,A,In vivo,10116.0,,22224,Autocuration,Oral bioavailability in rats was determined in vivo,,CHEMBL624856,,0,1,,BAO_0000218,,
11124,A,In vivo,9615.0,,22224,Autocuration,Oral bioavailability in dog,,CHEMBL882957,,0,1,,BAO_0000218,,
11125,A,In vivo,314293.0,,22224,Autocuration,Oral bioavailability of compound in monkey,,CHEMBL624857,,0,1,,BAO_0000218,,
11126,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound in rat,,CHEMBL622202,,1,1,,BAO_0000218,,
11127,A,In vivo,10116.0,,22224,Autocuration,Bioavailability in rat of PMEA prodrug,,CHEMBL622203,,0,1,,BAO_0000218,,
11128,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,CHEMBL625522,,1,1,,BAO_0000218,,
11129,A,In vivo,9544.0,,22224,Autocuration,Serum conc at 3 hours following 25 mg/kg dose,,CHEMBL622868,,0,1,,BAO_0000218,,
11130,A,In vivo,9544.0,,22224,Autocuration,Urine conc 0-5 hours following 25 mg/kg dose,,CHEMBL622869,,0,1,,BAO_0000218,1088.0,
11131,A,In vivo,9544.0,,22224,Autocuration,Urine conc 0-24 hours following 25 mg/kg dose,,CHEMBL622870,,0,1,,BAO_0000218,1088.0,
11132,A,In vivo,9534.0,,22224,Autocuration,Oral bioavailability in African green monkeys; 20-25,,CHEMBL622871,,0,1,,BAO_0000218,,
11133,A,In vivo,9541.0,,100710,Intermediate,Oral bioavailability in cynomolgus monkey.,,CHEMBL620560,,1,1,,BAO_0000218,,
11134,A,In vivo,9615.0,,22224,Autocuration,Oral bioavailability in dog,,CHEMBL620561,,0,1,,BAO_0000218,,
11135,A,In vivo,9615.0,,50588,Intermediate,Oral bioavailability in dog at 10 mg/kg oral dose,,CHEMBL620562,,1,1,,BAO_0000218,,
11136,A,In vivo,10026.0,,100712,Intermediate,Oral bioavailability in hamster at 10 mg/kg oral dose,,CHEMBL620563,,1,1,,BAO_0000218,,
11137,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability in rat at 10 mg/kg oral dose,,CHEMBL620564,,1,1,,BAO_0000218,,
11138,A,In vivo,10116.0,,22224,Autocuration,Oral bioavailability in rat,,CHEMBL872265,,0,1,,BAO_0000218,,
11139,A,In vivo,10116.0,,22224,Autocuration,Oral bioavailability in rat,,CHEMBL620565,,0,1,,BAO_0000218,,
11140,A,In vivo,9347.0,,22224,Autocuration,Oral bioavailability,,CHEMBL620566,,0,1,,BAO_0000218,,
11141,A,In vivo,,,22224,Autocuration,Oral bioavailability was determined; range 49-102%,,CHEMBL620567,,0,1,,BAO_0000218,,
11142,A,In vivo,9615.0,,50588,Intermediate,Oral bioavailability was determined in dogs,,CHEMBL620568,,1,1,,BAO_0000218,,
11143,A,In vivo,10116.0,,22224,Autocuration,Oral bioavailability in rat,,CHEMBL620569,,0,1,,BAO_0000218,,
11144,A,In vivo,9347.0,,22224,Autocuration,Oral bioavailability,,CHEMBL620570,,0,1,,BAO_0000218,,
11145,A,In vivo,,,22224,Autocuration,Oral bioavailability was determined; Not orally available,,CHEMBL620571,,0,1,,BAO_0000218,,
11146,A,In vivo,10090.0,,50594,Intermediate,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,CHEMBL620572,,1,1,,BAO_0000218,,
11147,A,In vivo,10090.0,,22224,Autocuration,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,CHEMBL620573,,0,1,,BAO_0000218,,
11148,A,In vivo,10090.0,,22224,Autocuration,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,CHEMBL620574,,0,1,,BAO_0000218,,
11149,A,In vivo,9544.0,,22224,Autocuration,Oral bioavailability in Rhesus monkey,,CHEMBL620575,,0,1,,BAO_0000218,,
11150,A,In vivo,9615.0,,22224,Autocuration,Oral bioavailability in dog (female mongrel),,CHEMBL620576,,0,1,,BAO_0000218,,
11151,A,In vivo,,,22224,Autocuration,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,CHEMBL875846,,0,1,,BAO_0000218,,
11152,A,In vivo,9615.0,,22224,Autocuration,Oral bioavailability in dog,,CHEMBL620577,,0,1,,BAO_0000218,,
11153,A,In vivo,,,22224,Autocuration,Percentage Bioavailability was evaluated.,,CHEMBL620578,,0,1,,BAO_0000218,,
11154,A,In vivo,10116.0,,22224,Autocuration,Bioavailability in rat administered i.d.,,CHEMBL620579,,0,1,,BAO_0000218,,
11155,A,In vivo,9347.0,,22224,Autocuration,Bioavailability,,CHEMBL621248,,0,1,,BAO_0000218,,
11156,A,In vivo,9615.0,,22224,Autocuration,Bioavailability in dog (male Beagle) i.v. administration,,CHEMBL625390,,0,1,,BAO_0000218,,
11157,A,In vivo,10116.0,,22224,Autocuration,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,CHEMBL625391,,0,1,,BAO_0000218,,
11158,A,In vivo,9443.0,,22224,Autocuration,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,CHEMBL872266,,0,1,,BAO_0000218,,
11159,A,In vivo,10116.0,,22224,Autocuration,Oral bioavailability in rat (Sprague-Dawley) (male),,CHEMBL625392,,0,1,,BAO_0000218,,
11160,A,In vivo,10116.0,,50597,Intermediate,The oral bioavailability was measured on rats after oral administration,,CHEMBL625393,,1,1,,BAO_0000218,,
11161,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,CHEMBL625394,,1,1,,BAO_0000218,,
11162,A,In vivo,9544.0,,50797,Intermediate,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,CHEMBL625395,,1,1,,BAO_0000218,,
11163,A,In vivo,10116.0,,22224,Autocuration,Bioavailability in rat (dose 10 mg/kg i.d.),,CHEMBL625396,,0,1,,BAO_0000218,,
11164,A,In vivo,9615.0,,22224,Autocuration,Bioavailability in dog (male Beagle) i.v. administration,,CHEMBL625397,,0,1,,BAO_0000218,,
11165,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625398,,1,1,,BAO_0000218,,
11166,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625399,,1,1,,BAO_0000218,178.0,
11167,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL626074,,1,1,,BAO_0000218,2037.0,
11168,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL626075,,1,1,,BAO_0000218,,
11169,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,CHEMBL626076,,1,1,,BAO_0000218,1969.0,
11170,A,In vivo,9544.0,,50797,Intermediate,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,CHEMBL626077,,1,1,,BAO_0000218,1969.0,
11171,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),,CHEMBL626078,,1,1,,BAO_0000218,178.0,
11172,A,In vivo,,,22224,Autocuration,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),,CHEMBL625846,,0,1,,BAO_0000218,178.0,
11173,A,In vivo,,,22224,Autocuration,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),,CHEMBL625847,,0,1,,BAO_0000218,178.0,
11174,A,In vivo,10116.0,,50597,Expert,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,CHEMBL625848,,1,1,,BAO_0000218,,
11175,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration of compound in plasma administered orally to rats,,CHEMBL625849,,1,1,,BAO_0000218,1969.0,
11176,A,In vivo,9615.0,,50588,Intermediate,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",,CHEMBL626023,,1,1,,BAO_0000218,1969.0,
11177,A,In vivo,9615.0,,50588,Intermediate,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",,CHEMBL626024,,1,1,,BAO_0000218,1969.0,
11178,A,In vivo,9615.0,,50588,Intermediate,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",,CHEMBL626025,,1,1,,BAO_0000218,1969.0,
11179,A,In vivo,,,22224,Autocuration,Maximum concentration after 10 mg/kg by oral administration,,CHEMBL626026,,0,1,,BAO_0000218,,
11180,A,In vivo,,,22224,Autocuration,Maximum concentration at a dose of 1.5 mg/kg,,CHEMBL626027,,0,1,,BAO_0000218,,
11181,A,In vivo,,,22224,Autocuration,Maximum concentration at a dose of 2.0 mg/kg,,CHEMBL626028,,0,1,,BAO_0000218,,
11182,A,In vivo,9615.0,,50588,Intermediate,Maximum concentration in dog plasma,,CHEMBL626029,,1,1,,BAO_0000218,1969.0,
11183,A,In vivo,,,22224,Autocuration,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,,CHEMBL626030,,0,1,,BAO_0000218,1969.0,
11184,A,In vivo,,,22224,Autocuration,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,,CHEMBL626031,,0,1,,BAO_0000218,1969.0,
11185,A,In vivo,,,22224,Autocuration,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,,CHEMBL626032,,0,1,,BAO_0000218,1969.0,
11186,A,In vivo,,,22224,Autocuration,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,,CHEMBL626033,,0,1,,BAO_0000218,1969.0,
11187,A,In vivo,,,22224,Autocuration,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,,CHEMBL626034,,0,1,,BAO_0000218,1969.0,
11188,A,In vivo,9615.0,,50588,Intermediate,Maximum concentration in plasma after oral administration in dog (25 mg/kg),,CHEMBL626035,,1,1,,BAO_0000218,1969.0,
11189,A,In vivo,,,22224,Autocuration,Maximum concentration in plasma at Tmax,,CHEMBL626036,,0,1,,BAO_0000218,1969.0,
11190,A,In vivo,9615.0,,50588,Expert,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,,CHEMBL626037,,1,1,,BAO_0000218,1969.0,
11191,A,In vivo,10026.0,,100712,Intermediate,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,,CHEMBL626038,,1,1,,BAO_0000218,1969.0,
11192,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,,CHEMBL626039,,1,1,,BAO_0000218,1969.0,
11193,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,,CHEMBL626040,,1,1,,BAO_0000218,1969.0,
11194,A,In vivo,9986.0,,50592,Intermediate,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,,CHEMBL626041,,1,1,,BAO_0000218,1969.0,
11195,A,In vivo,,,22224,Autocuration,Maximum concentration was calculated,,CHEMBL626042,,0,1,,BAO_0000218,,
11196,A,In vivo,,,22224,Autocuration,Maximum concentration was calculated.,,CHEMBL626043,,0,1,,BAO_0000218,,
11197,A,In vivo,,,22224,Autocuration,Maximum concentration at a peroral dose of 10 mg/kg,,CHEMBL626044,,0,1,,BAO_0000218,,
11198,A,In vivo,,,22224,Autocuration,Maximum concentration of the drug at 10 uM/dg administered perorally,,CHEMBL626045,,0,1,,BAO_0000218,,
11199,A,In vivo,,,22224,Autocuration,Maximum concentration of the drug at 2 uM/dg administered intravenously,,CHEMBL626046,,0,1,,BAO_0000218,,
11200,A,In vivo,9615.0,,50588,Intermediate,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",,CHEMBL626047,,1,1,,BAO_0000218,1969.0,
11201,A,In vivo,10026.0,,100712,Intermediate,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",,CHEMBL626048,,1,1,,BAO_0000218,1969.0,
11202,A,In vivo,10116.0,,50597,Intermediate,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",,CHEMBL626049,,1,1,,BAO_0000218,1969.0,
11203,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,,CHEMBL626050,,1,1,,BAO_0000218,1969.0,
11204,A,In vivo,9615.0,,50588,Intermediate,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,,CHEMBL874541,,1,1,,BAO_0000218,1969.0,
11205,A,In vivo,10026.0,,100712,Intermediate,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,,CHEMBL622826,,1,1,,BAO_0000218,1969.0,
11206,A,In vivo,10026.0,,100712,Intermediate,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,,CHEMBL622827,,1,1,,BAO_0000218,1969.0,
11207,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,,CHEMBL622828,,1,1,,BAO_0000218,1969.0,
11208,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,,CHEMBL622829,,1,1,,BAO_0000218,1969.0,
11209,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration reached following intravenous administration in male rat,,CHEMBL876806,,1,1,,BAO_0000218,,
11210,A,In vivo,9615.0,,50588,Intermediate,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,CHEMBL622830,,1,1,,BAO_0000218,,
11211,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,CHEMBL622831,,1,1,,BAO_0000218,,
11212,A,In vivo,9615.0,,50588,Intermediate,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,CHEMBL626794,,1,1,,BAO_0000218,,
11213,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,CHEMBL626795,,1,1,,BAO_0000218,,
11214,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,CHEMBL626796,,1,1,,BAO_0000218,,
11215,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,CHEMBL626797,,1,1,,BAO_0000218,,
11216,A,In vivo,10116.0,,50597,Intermediate,Maximum drug concentration is determined after oral dosing in rats.,,CHEMBL626798,,1,1,,BAO_0000218,,
11217,A,In vivo,9615.0,,50588,Intermediate,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,CHEMBL626799,,1,1,,BAO_0000218,,
11218,A,In vivo,9615.0,,50588,Intermediate,Maximum observed concentration in oral (5 mg/kg) fed dogs,,CHEMBL626800,,1,1,,BAO_0000218,,
11219,A,In vivo,,,22224,Autocuration,Maximum plasma concentration,,CHEMBL626801,,0,1,,BAO_0000218,1969.0,
11220,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,,CHEMBL876816,,1,1,,BAO_0000218,1969.0,
11221,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,,CHEMBL626802,,1,1,,BAO_0000218,1969.0,
11222,A,In vivo,9615.0,,50588,Intermediate,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,,CHEMBL626803,,1,1,,BAO_0000218,1969.0,
11223,A,In vivo,,,22224,Autocuration,Maximum plasma concentration following oral administration of 30 umol/kg,,CHEMBL626804,,0,1,,BAO_0000218,1969.0,
11224,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,,CHEMBL626805,,1,1,,BAO_0000218,1969.0,
11225,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,CHEMBL626309,,1,1,,BAO_0000218,1969.0,
11226,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,CHEMBL626310,,1,1,,BAO_0000218,1969.0,
11227,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL626311,,1,1,,BAO_0000218,1969.0,
11228,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL626312,,1,1,,BAO_0000218,1969.0,
11229,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL626313,,1,1,,BAO_0000218,995.0,
11230,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,CHEMBL626314,,1,1,,BAO_0000218,995.0,
11231,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,CHEMBL626315,,1,1,,BAO_0000218,995.0,
11232,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL626316,,1,1,,BAO_0000218,995.0,
11233,A,,10116.0,,50597,Intermediate,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,CHEMBL626317,,1,1,,BAO_0000218,995.0,
11234,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626318,,1,1,,BAO_0000218,,
11235,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL626319,,1,1,,BAO_0000218,,
11236,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626320,,1,1,,BAO_0000218,,
11237,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL875053,,1,1,,BAO_0000218,,
11238,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626321,,1,1,,BAO_0000218,,
11239,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL626322,,1,1,,BAO_0000218,,
11240,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626323,,1,1,,BAO_0000218,,
11241,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL626324,,1,1,,BAO_0000218,,
11242,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626325,,1,1,,BAO_0000218,,
11243,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL626326,,1,1,,BAO_0000218,,
11244,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,CHEMBL626327,,1,1,,BAO_0000218,,
11245,A,,10116.0,,50597,Intermediate,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,CHEMBL626328,,1,1,,BAO_0000218,,
11246,A,,10116.0,,50597,Intermediate,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",,CHEMBL626329,,1,1,,BAO_0000218,178.0,
11247,A,,10116.0,,50597,Intermediate,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",,CHEMBL626330,,1,1,,BAO_0000218,178.0,
11248,A,,10116.0,,50597,Intermediate,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",,CHEMBL626331,,1,1,,BAO_0000218,178.0,
11249,A,,10116.0,,50597,Intermediate,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",,CHEMBL626332,,1,1,,BAO_0000218,178.0,
11250,A,,10116.0,,50597,Intermediate,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",,CHEMBL626333,,1,1,,BAO_0000218,178.0,
11251,A,,10116.0,,50597,Intermediate,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",,CHEMBL626334,,1,1,,BAO_0000218,178.0,
11252,A,,10116.0,,50597,Intermediate,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",,CHEMBL626335,,1,1,,BAO_0000218,178.0,
11253,A,,10116.0,,50597,Intermediate,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",,CHEMBL624798,,1,1,,BAO_0000218,178.0,
11254,A,,10116.0,,50597,Intermediate,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",,CHEMBL624799,,1,1,,BAO_0000218,955.0,
11255,A,,10116.0,,50597,Intermediate,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",,CHEMBL624800,,1,1,,BAO_0000218,955.0,
11256,A,,10116.0,,50597,Intermediate,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",,CHEMBL624801,,1,1,,BAO_0000218,955.0,
11257,A,,10116.0,,50597,Intermediate,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",,CHEMBL624802,,1,1,,BAO_0000218,955.0,
11258,A,,10116.0,,50597,Intermediate,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",,CHEMBL624803,,1,1,,BAO_0000218,955.0,
11259,A,,10116.0,,50597,Intermediate,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",,CHEMBL624804,,1,1,,BAO_0000218,955.0,
11260,A,,10116.0,,50597,Intermediate,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",,CHEMBL624805,,1,1,,BAO_0000218,955.0,
11261,A,,10116.0,,50597,Intermediate,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",,CHEMBL624806,,1,1,,BAO_0000218,955.0,
11262,A,,10116.0,,50597,Intermediate,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,CHEMBL624807,,1,1,,BAO_0000218,,
11263,A,,10116.0,,50597,Intermediate,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,CHEMBL624808,,1,1,,BAO_0000218,,
11264,A,,10116.0,,50597,Intermediate,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,CHEMBL624809,,1,1,,BAO_0000218,,
11265,A,,10116.0,,50597,Intermediate,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,CHEMBL624810,,1,1,,BAO_0000218,,
11266,A,,10116.0,,50597,Intermediate,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,CHEMBL877618,,1,1,,BAO_0000218,,
11267,A,,10116.0,,50597,Intermediate,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,CHEMBL624811,,1,1,,BAO_0000218,,
11268,A,,10116.0,,50597,Intermediate,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,CHEMBL624812,,1,1,,BAO_0000218,,
11269,A,,10116.0,,50597,Intermediate,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,CHEMBL624813,,1,1,,BAO_0000218,,
11270,A,,10116.0,,50597,Intermediate,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,CHEMBL624814,,1,1,,BAO_0000218,,
11271,A,,10116.0,,50597,Intermediate,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,CHEMBL624815,,1,1,,BAO_0000218,,
11272,A,,10116.0,,50597,Intermediate,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,CHEMBL624816,,1,1,,BAO_0000218,,
11273,A,,10116.0,,50597,Intermediate,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,CHEMBL624817,,1,1,,BAO_0000218,,
11274,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,CHEMBL624818,,1,1,,BAO_0000218,,
11275,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,CHEMBL624819,,1,1,,BAO_0000218,,
11276,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,CHEMBL624820,,1,1,,BAO_0000218,,
11277,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL624821,,1,1,,BAO_0000218,,
11278,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,CHEMBL624822,,1,1,,BAO_0000218,,
11279,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,CHEMBL624823,,1,1,,BAO_0000218,,
11280,A,,562.0,,50212,Intermediate,Observed diffusion coefficient in organic solvent for Escherichia coli,,CHEMBL624824,,1,1,,BAO_0000218,,
11281,A,,10116.0,,50597,Intermediate,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624825,,1,1,,BAO_0000218,178.0,
11282,A,,10116.0,,50597,Intermediate,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624826,,1,1,,BAO_0000218,178.0,
11283,A,,10116.0,,50597,Intermediate,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL876817,,1,1,,BAO_0000218,2081.0,
11284,A,,10116.0,,50597,Intermediate,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624827,,1,1,,BAO_0000218,2081.0,
11285,A,,10116.0,,50597,Intermediate,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624828,,1,1,,BAO_0000218,,
11286,A,,10116.0,,50597,Intermediate,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624829,,1,1,,BAO_0000218,,
11287,A,,10116.0,,50597,Intermediate,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624830,,1,1,,BAO_0000218,2107.0,
11288,A,,10116.0,,50597,Intermediate,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624831,,1,1,,BAO_0000218,2107.0,
11289,A,,10116.0,,50597,Intermediate,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624832,,1,1,,BAO_0000218,2081.0,
11290,A,,10116.0,,50597,Intermediate,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624833,,1,1,,BAO_0000218,2081.0,
11291,A,,10116.0,,50597,Intermediate,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624834,,1,1,,BAO_0000218,,
11292,A,,10116.0,,50597,Intermediate,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624835,,1,1,,BAO_0000218,,
11293,A,,10116.0,,50597,Intermediate,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,CHEMBL624836,,1,1,,BAO_0000218,2106.0,
11294,A,,10116.0,,50597,Intermediate,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,CHEMBL624837,,1,1,,BAO_0000218,2106.0,
11295,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,,CHEMBL624838,,1,1,,BAO_0000218,178.0,
11296,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,,CHEMBL622188,,1,1,,BAO_0000218,178.0,
11297,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,,CHEMBL622189,,1,1,,BAO_0000218,948.0,
11298,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,,CHEMBL622190,,1,1,,BAO_0000218,948.0,
11299,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,,CHEMBL625170,,1,1,,BAO_0000218,948.0,
11300,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,CHEMBL625171,,1,1,,BAO_0000218,2113.0,
11301,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,CHEMBL625172,,1,1,,BAO_0000218,2113.0,
11302,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,,CHEMBL625173,,1,1,,BAO_0000218,2113.0,
11303,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,,CHEMBL625174,,1,1,,BAO_0000218,2107.0,
11304,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,,CHEMBL625175,,1,1,,BAO_0000218,2107.0,
11305,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,,CHEMBL625176,,1,1,,BAO_0000218,2107.0,
11306,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,CHEMBL625177,,1,1,,BAO_0000218,2048.0,
11307,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,,CHEMBL625178,,1,1,,BAO_0000218,2048.0,
11308,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,,CHEMBL625179,,1,1,,BAO_0000218,2048.0,
11309,A,,10116.0,,50597,Intermediate,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,CHEMBL625180,,1,1,,BAO_0000218,2048.0,
11310,A,,,,22224,Autocuration,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,CHEMBL625181,,0,1,,BAO_0000218,,
11311,A,,10090.0,,50594,Intermediate,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,,CHEMBL625182,,1,1,,BAO_0000218,1088.0,
11312,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,CHEMBL625183,,1,1,,BAO_0000218,,
11313,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,CHEMBL875848,,1,1,,BAO_0000218,,
11314,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,CHEMBL622260,,1,1,,BAO_0000218,,
11315,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,CHEMBL622261,,1,1,,BAO_0000218,,
11316,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,CHEMBL622262,,1,1,,BAO_0000218,,
11317,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,CHEMBL622263,,1,1,,BAO_0000218,2113.0,
11318,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,CHEMBL622418,,1,1,,BAO_0000218,2113.0,
11319,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,CHEMBL622419,,1,1,,BAO_0000218,2107.0,
11320,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623388,,1,1,,BAO_0000218,,
11321,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623389,,1,1,,BAO_0000218,2107.0,
11322,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623390,,1,1,,BAO_0000218,,
11323,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623391,,1,1,,BAO_0000218,,
11324,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623392,,1,1,,BAO_0000218,178.0,
11325,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623393,,1,1,,BAO_0000218,2037.0,
11326,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL623394,,1,1,,BAO_0000218,,
11327,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL618885,,1,1,,BAO_0000218,,
11328,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL618886,,1,1,,BAO_0000218,2107.0,
11329,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL618887,,1,1,,BAO_0000218,,
11330,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619535,,1,1,,BAO_0000218,,
11331,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619536,,1,1,,BAO_0000218,178.0,
11332,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619537,,1,1,,BAO_0000218,2037.0,
11333,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619705,,1,1,,BAO_0000218,,
11334,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619706,,1,1,,BAO_0000218,,
11335,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619707,,1,1,,BAO_0000218,2107.0,
11336,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL619708,,1,1,,BAO_0000218,,
11337,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625219,,1,1,,BAO_0000218,,
11338,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625220,,1,1,,BAO_0000218,178.0,
11339,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625221,,1,1,,BAO_0000218,2037.0,
11340,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625222,,1,1,,BAO_0000218,,
11341,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625223,,1,1,,BAO_0000218,,
11342,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625224,,1,1,,BAO_0000218,2107.0,
11343,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,CHEMBL625225,,1,1,,BAO_0000218,,
11344,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat blood after 24 hours of iv administration,,CHEMBL625226,,1,1,,BAO_0000218,178.0,
11345,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,,CHEMBL625227,,1,1,,BAO_0000218,178.0,
11346,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat blood after 30 minutes of iv administration,,CHEMBL625228,,1,1,,BAO_0000218,178.0,
11347,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,,CHEMBL875354,,1,1,,BAO_0000218,178.0,
11348,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat blood after 5 minutes of iv administration,,CHEMBL625229,,1,1,,BAO_0000218,178.0,
11349,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,,CHEMBL625230,,1,1,,BAO_0000218,178.0,
11350,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat heart after 24 hours of iv administration,,CHEMBL625231,,1,1,,BAO_0000218,948.0,
11351,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,,CHEMBL625900,,1,1,,BAO_0000218,948.0,
11352,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat heart after 30 minutes of iv administration,,CHEMBL625901,,1,1,,BAO_0000218,948.0,
11353,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,,CHEMBL625902,,1,1,,BAO_0000218,948.0,
11354,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat heart after 5 minutes of iv administration,,CHEMBL625903,,1,1,,BAO_0000218,948.0,
11355,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,,CHEMBL625904,,1,1,,BAO_0000218,948.0,
11356,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat liver after 24 hours of iv administration,,CHEMBL625905,,1,1,,BAO_0000218,2107.0,
11357,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,,CHEMBL627861,,1,1,,BAO_0000218,2107.0,
11358,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat liver after 30 minutes of iv administration,,CHEMBL627862,,1,1,,BAO_0000218,2107.0,
11359,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,CHEMBL627863,,1,1,,BAO_0000218,2107.0,
11360,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat liver after 30 minutes of iv administration,,CHEMBL627769,,1,1,,BAO_0000218,2107.0,
11361,A,In vivo,9615.0,,50588,Intermediate,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,CHEMBL627770,,1,1,,BAO_0000218,1969.0,
11362,A,In vivo,9541.0,,100710,Intermediate,Cmax in cynomolgus monkey (PO dose),,CHEMBL627771,,1,1,,BAO_0000218,,
11363,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat (PO dose),,CHEMBL627772,,1,1,,BAO_0000218,,
11364,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat (PO dose),,CHEMBL627773,,1,1,,BAO_0000218,,
11365,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,,CHEMBL621922,,1,1,,BAO_0000218,1969.0,
11366,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat plasma after oral dose (10 mg/kg),,CHEMBL621923,,1,1,,BAO_0000218,1969.0,
11367,A,In vivo,,,22224,Autocuration,Cmax in plasma after oral dose (10 mg/kg),,CHEMBL621924,,0,1,,BAO_0000218,1969.0,
11368,A,In vivo,9615.0,,50588,Intermediate,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,,CHEMBL621925,,1,1,,BAO_0000218,1969.0,
11369,A,In vivo,314293.0,,22224,Autocuration,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,,CHEMBL621926,,0,1,,BAO_0000218,1969.0,
11370,A,In vivo,9986.0,,50592,Intermediate,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,,CHEMBL621927,,1,1,,BAO_0000218,1969.0,
11371,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,,CHEMBL621928,,1,1,,BAO_0000218,1969.0,
11372,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,,CHEMBL621929,,1,1,,BAO_0000218,1969.0,
11373,A,In vivo,10090.0,,50594,Intermediate,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,,CHEMBL621930,,1,1,,BAO_0000218,1969.0,
11374,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration after oral dosing in rat,,CHEMBL621931,,1,1,,BAO_0000218,1969.0,
11375,A,In vivo,,,22224,Autocuration,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,CHEMBL621932,,0,1,,BAO_0000218,1969.0,
11376,A,In vivo,,,22224,Autocuration,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,CHEMBL621933,,0,1,,BAO_0000218,1969.0,
11377,A,In vivo,9615.0,,50588,Intermediate,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,,CHEMBL621934,,1,1,,BAO_0000218,1969.0,
11378,A,In vivo,9615.0,,50588,Intermediate,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,,CHEMBL621935,,1,1,,BAO_0000218,1969.0,
11379,A,In vivo,10116.0,,50597,Intermediate,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,,CHEMBL621936,,1,1,,BAO_0000218,1969.0,
11380,A,In vivo,,,22224,Autocuration,Maximum plasma concentration was determined,,CHEMBL621937,,0,1,,BAO_0000218,1969.0,
11381,A,In vivo,,,22224,Autocuration,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,CHEMBL621938,,0,1,,BAO_0000218,1969.0,
11382,A,In vivo,,,22224,Autocuration,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,CHEMBL621939,,0,1,,BAO_0000218,1969.0,
11383,A,In vivo,,,22224,Autocuration,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,,CHEMBL621940,,0,1,,BAO_0000218,1969.0,
11384,A,In vivo,,,22224,Autocuration,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,,CHEMBL621941,,0,1,,BAO_0000218,1969.0,
11385,A,In vivo,,,22224,Autocuration,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,CHEMBL621942,,0,1,,BAO_0000218,1969.0,
11386,A,In vivo,,,22224,Autocuration,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,CHEMBL626178,,0,1,,BAO_0000218,1969.0,
11387,A,In vivo,,,22224,Autocuration,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,,CHEMBL626179,,0,1,,BAO_0000218,1969.0,
11388,A,In vivo,,,22224,Autocuration,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,,CHEMBL626180,,0,1,,BAO_0000218,1969.0,
11389,A,In vivo,10116.0,,50597,Intermediate,Plasma Cmax in rat (PO dose),,CHEMBL626181,,1,1,,BAO_0000218,1969.0,
11390,A,In vivo,10116.0,,50597,Intermediate,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,CHEMBL626182,,1,1,,BAO_0000218,,
11391,A,In vivo,10116.0,,50597,Intermediate,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,CHEMBL626183,,1,1,,BAO_0000218,,
11392,A,In vivo,10116.0,,50597,Intermediate,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,CHEMBL626184,,1,1,,BAO_0000218,,
11393,A,In vivo,10116.0,,50597,Intermediate,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,CHEMBL626185,,1,1,,BAO_0000218,,
11394,A,In vivo,9615.0,,50588,Intermediate,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,,CHEMBL626186,,1,1,,BAO_0000218,1969.0,
11395,A,In vivo,9615.0,,50588,Intermediate,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,,CHEMBL877589,,1,1,,BAO_0000218,1969.0,
11396,A,In vivo,,,22224,Autocuration,Maximum concentration of the drug at 1 uM/dg administered intravenously,,CHEMBL626187,,0,1,,BAO_0000218,,
11397,A,In vivo,,,22224,Autocuration,Maximum concentration of the drug at 20 uM/dg administered perorally,,CHEMBL626188,,0,1,,BAO_0000218,,
11398,A,In vivo,,,22224,Autocuration,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,CHEMBL626189,,0,1,,BAO_0000218,,
11399,A,In vivo,,,22224,Autocuration,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL626855,,0,1,,BAO_0000218,178.0,
11400,A,In vivo,,,22224,Autocuration,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL623781,,0,1,,BAO_0000218,178.0,
11401,A,In vivo,,,22224,Autocuration,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL623782,,0,1,,BAO_0000218,178.0,
11402,A,In vivo,10116.0,,50597,Intermediate,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,,CHEMBL623783,,1,1,,BAO_0000218,1969.0,
11403,A,In vivo,9615.0,,50588,Intermediate,Cmax in dog plasma after 1mg/kg oral dose,,CHEMBL623784,,1,1,,BAO_0000218,1969.0,
11404,A,In vivo,9615.0,,50588,Intermediate,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,,CHEMBL623785,,1,1,,BAO_0000218,1969.0,
11405,A,In vivo,10116.0,,50597,Intermediate,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,,CHEMBL623786,,1,1,,BAO_0000218,1969.0,
11406,A,In vivo,10116.0,,50597,Intermediate,Oral maximum concentration in rat,,CHEMBL623787,,1,1,,BAO_0000218,,
11407,A,In vivo,10116.0,,50597,Intermediate,Oral maximum concentration in rat,,CHEMBL623788,,1,1,,BAO_0000218,,
11408,A,In vivo,10090.0,,50594,Intermediate,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,,CHEMBL623789,,1,1,,BAO_0000218,1969.0,
11409,A,In vivo,10090.0,,50594,Intermediate,Peak concentration in blood after intravenous administration to mice,,CHEMBL623790,,1,1,,BAO_0000218,178.0,
11410,A,In vivo,10090.0,,50594,Intermediate,Peak concentration in blood after peroral administration to mice,,CHEMBL623791,,1,1,,BAO_0000218,178.0,
11411,A,In vivo,10116.0,,50597,Intermediate,Peak concentration in rat plasma was determined,,CHEMBL623792,,1,1,,BAO_0000218,1969.0,
11412,A,In vivo,314293.0,,22224,Autocuration,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,,CHEMBL623793,,0,1,,BAO_0000218,1969.0,
11413,A,In vivo,10090.0,,50594,Intermediate,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,,CHEMBL623794,,1,1,,BAO_0000218,1969.0,
11414,A,In vivo,10116.0,,50597,Intermediate,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,,CHEMBL623795,,1,1,,BAO_0000218,1969.0,
11415,A,,10116.0,,50597,Intermediate,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,CHEMBL623796,,1,1,,BAO_0000218,,
11416,A,,10116.0,,50597,Intermediate,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,CHEMBL623797,,1,1,,BAO_0000218,,
11417,A,,10116.0,,50597,Intermediate,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,CHEMBL623798,,1,1,,BAO_0000218,,
11418,A,,10116.0,,50597,Intermediate,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,CHEMBL623799,,1,1,,BAO_0000218,,
11419,A,,10116.0,,50597,Intermediate,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",,CHEMBL624490,,1,1,,BAO_0000218,160.0,
11420,A,,10116.0,,50597,Intermediate,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",,CHEMBL624491,,1,1,,BAO_0000218,160.0,
11421,A,,10116.0,,50597,Intermediate,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",,CHEMBL624492,,1,1,,BAO_0000218,160.0,
11422,A,,10116.0,,50597,Intermediate,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",,CHEMBL624493,,1,1,,BAO_0000218,160.0,
11423,A,,10116.0,,50597,Intermediate,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",,CHEMBL877595,,1,1,,BAO_0000218,160.0,
11424,A,,10116.0,,50597,Intermediate,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",,CHEMBL624494,,1,1,,BAO_0000218,160.0,
11425,A,,10116.0,,50597,Intermediate,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",,CHEMBL624495,,1,1,,BAO_0000218,160.0,
11426,A,,10116.0,,50597,Intermediate,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",,CHEMBL624681,,1,1,,BAO_0000218,160.0,
11427,A,,10116.0,,50597,Intermediate,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,CHEMBL624682,,1,1,,BAO_0000218,,
11428,A,,10116.0,,50597,Intermediate,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,CHEMBL624683,,1,1,,BAO_0000218,,
11429,A,,10116.0,,50597,Intermediate,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,CHEMBL624684,,1,1,,BAO_0000218,,
11430,A,,10116.0,,50597,Intermediate,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,CHEMBL624685,,1,1,,BAO_0000218,,
11431,A,,10116.0,,50597,Intermediate,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,CHEMBL624686,,1,1,,BAO_0000218,,
11432,A,,10116.0,,50597,Intermediate,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,CHEMBL624687,,1,1,,BAO_0000218,,
11433,A,,10116.0,,50597,Intermediate,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,CHEMBL624688,,1,1,,BAO_0000218,,
11434,A,,10116.0,,50597,Intermediate,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,CHEMBL627161,,1,1,,BAO_0000218,,
11435,A,,10116.0,,50597,Intermediate,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,CHEMBL622127,,1,1,,BAO_0000218,,
11436,A,,10116.0,,50597,Intermediate,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,CHEMBL622128,,1,1,,BAO_0000218,,
11437,A,,10116.0,,50597,Intermediate,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,CHEMBL874384,,1,1,,BAO_0000218,,
11438,A,,10116.0,,50597,Intermediate,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,CHEMBL624898,,1,1,,BAO_0000218,,
11439,A,,10116.0,,50597,Intermediate,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,CHEMBL624899,,1,1,,BAO_0000218,,
11440,A,,10116.0,,50597,Intermediate,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,CHEMBL624900,,1,1,,BAO_0000218,,
11441,A,,10116.0,,50597,Intermediate,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,CHEMBL624901,,1,1,,BAO_0000218,,
11442,A,,10116.0,,50597,Intermediate,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,CHEMBL624902,,1,1,,BAO_0000218,,
11443,A,,10116.0,,50597,Intermediate,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,CHEMBL624903,,1,1,,BAO_0000218,,
11444,A,,10116.0,,50597,Intermediate,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,CHEMBL624904,,1,1,,BAO_0000218,,
11445,A,,10116.0,,50597,Intermediate,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,CHEMBL624905,,1,1,,BAO_0000218,,
11446,A,,10116.0,,50597,Intermediate,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,CHEMBL624906,,1,1,,BAO_0000218,,
11447,A,,10116.0,,50597,Intermediate,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,CHEMBL624907,,1,1,,BAO_0000218,,
11448,A,,10116.0,,50597,Intermediate,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,CHEMBL624908,,1,1,,BAO_0000218,,
11449,A,,10116.0,,50597,Intermediate,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,CHEMBL624909,,1,1,,BAO_0000218,,
11450,A,,10116.0,,50597,Intermediate,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,CHEMBL624910,,1,1,,BAO_0000218,,
11451,A,,10116.0,,50597,Intermediate,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",,CHEMBL624911,,1,1,,BAO_0000218,2385.0,
11452,A,,10116.0,,50597,Intermediate,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",,CHEMBL874388,,1,1,,BAO_0000218,2385.0,
11453,A,,10116.0,,50597,Intermediate,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",,CHEMBL624912,,1,1,,BAO_0000218,2385.0,
11454,A,,10116.0,,50597,Intermediate,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",,CHEMBL622930,,1,1,,BAO_0000218,2385.0,
11455,A,,10116.0,,50597,Intermediate,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",,CHEMBL623121,,1,1,,BAO_0000218,2385.0,
11456,A,,10116.0,,50597,Intermediate,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",,CHEMBL623122,,1,1,,BAO_0000218,2385.0,
11457,A,,10116.0,,50597,Intermediate,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",,CHEMBL623123,,1,1,,BAO_0000218,2385.0,
11458,A,,10116.0,,50597,Intermediate,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",,CHEMBL623124,,1,1,,BAO_0000218,2385.0,
11459,A,,10116.0,,50597,Intermediate,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,CHEMBL623125,,1,1,,BAO_0000218,,
11460,A,,10116.0,,50597,Intermediate,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,CHEMBL623126,,1,1,,BAO_0000218,,
11461,A,,10116.0,,50597,Intermediate,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,CHEMBL623127,,1,1,,BAO_0000218,,
11462,A,,10116.0,,50597,Intermediate,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,CHEMBL623128,,1,1,,BAO_0000218,,
11463,A,,10116.0,,50597,Intermediate,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,CHEMBL623129,,1,1,,BAO_0000218,,
11464,A,,10116.0,,50597,Intermediate,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,CHEMBL623130,,1,1,,BAO_0000218,,
11465,A,,10116.0,,50597,Intermediate,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,CHEMBL623131,,1,1,,BAO_0000218,,
11466,A,,10116.0,,50597,Intermediate,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,CHEMBL623132,,1,1,,BAO_0000218,,
11467,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,CHEMBL623133,,1,1,,BAO_0000218,2107.0,
11468,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,CHEMBL623134,,1,1,,BAO_0000218,,
11469,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,CHEMBL874389,,1,1,,BAO_0000218,,
11470,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,CHEMBL623135,,1,1,,BAO_0000218,,
11471,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,CHEMBL623136,,1,1,,BAO_0000218,,
11472,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,CHEMBL623137,,1,1,,BAO_0000218,,
11473,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,CHEMBL623138,,1,1,,BAO_0000218,,
11474,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,CHEMBL623139,,1,1,,BAO_0000218,2113.0,
11475,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,CHEMBL623140,,1,1,,BAO_0000218,2113.0,
11476,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,CHEMBL623141,,1,1,,BAO_0000218,2107.0,
11477,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,CHEMBL623142,,1,1,,BAO_0000218,2107.0,
11478,A,,10116.0,,50597,Intermediate,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,CHEMBL623143,,1,1,,BAO_0000218,,
11479,A,,10090.0,,50594,Intermediate,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,,CHEMBL623144,,1,1,,BAO_0000218,1088.0,
11480,A,,10116.0,,50597,Intermediate,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,,CHEMBL623405,,1,1,,BAO_0000218,1088.0,
11481,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,CHEMBL624074,,1,1,,BAO_0000218,,
11482,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,CHEMBL624075,,1,1,,BAO_0000218,,
11483,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,CHEMBL624076,,1,1,,BAO_0000218,,
11484,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,CHEMBL624077,,1,1,,BAO_0000218,,
11485,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,CHEMBL624078,,1,1,,BAO_0000218,,
11486,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,CHEMBL624079,,1,1,,BAO_0000218,2113.0,
11487,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,CHEMBL624261,,1,1,,BAO_0000218,2113.0,
11488,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,CHEMBL624262,,1,1,,BAO_0000218,,
11489,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,CHEMBL624263,,1,1,,BAO_0000218,,
11490,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,CHEMBL624264,,1,1,,BAO_0000218,,
11491,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,CHEMBL624265,,1,1,,BAO_0000218,,
11492,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,CHEMBL624266,,1,1,,BAO_0000218,,
11493,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,CHEMBL624267,,1,1,,BAO_0000218,,
11494,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,CHEMBL624268,,1,1,,BAO_0000218,,
11495,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,CHEMBL875227,,1,1,,BAO_0000218,,
11496,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,CHEMBL624269,,1,1,,BAO_0000218,2113.0,
11497,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,CHEMBL624270,,1,1,,BAO_0000218,2113.0,
11498,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,CHEMBL624271,,1,1,,BAO_0000218,,
11499,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,CHEMBL624272,,1,1,,BAO_0000218,,
11500,A,,10116.0,,50597,Intermediate,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,CHEMBL624273,,1,1,,BAO_0000218,,
11501,A,,10116.0,,50597,Intermediate,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,,CHEMBL624274,,1,1,,BAO_0000218,1088.0,
11502,A,,10116.0,,50597,Intermediate,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,,CHEMBL624275,,1,1,,BAO_0000218,1088.0,
11503,A,,10116.0,,50597,Intermediate,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,,CHEMBL624276,,1,1,,BAO_0000218,1088.0,
11504,A,,10116.0,,50597,Intermediate,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,,CHEMBL624277,,1,1,,BAO_0000218,1088.0,
11505,A,,,,22224,Autocuration,% dose converted to 2-amino-5-chlorophenyl sulfate,,CHEMBL624278,,0,1,,BAO_0000019,,
11506,A,,,,22224,Autocuration,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,CHEMBL624279,,0,1,,BAO_0000019,,
11507,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,CHEMBL624280,,1,1,,BAO_0000218,1988.0,
11508,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,CHEMBL624281,,1,1,,BAO_0000218,1988.0,
11509,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,CHEMBL622933,,1,1,,BAO_0000218,1988.0,
11510,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,CHEMBL622934,,1,1,,BAO_0000218,1988.0,
11511,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,CHEMBL622935,,1,1,,BAO_0000218,2107.0,
11512,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat liver after 5 minutes of iv administration,,CHEMBL622936,,1,1,,BAO_0000218,2107.0,
11513,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,,CHEMBL875228,,1,1,,BAO_0000218,2107.0,
11514,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat lung after 24 hours of iv administration,,CHEMBL622937,,1,1,,BAO_0000218,2048.0,
11515,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,,CHEMBL622938,,1,1,,BAO_0000218,2048.0,
11516,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat lung after 30 minutes of iv administration,,CHEMBL619736,,1,1,,BAO_0000218,2048.0,
11517,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,,CHEMBL625117,,1,1,,BAO_0000218,2048.0,
11518,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat lung after 5 minutes of iv administration,,CHEMBL625118,,1,1,,BAO_0000218,2048.0,
11519,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,,CHEMBL625119,,1,1,,BAO_0000218,2048.0,
11520,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",,CHEMBL625120,,1,1,,BAO_0000218,2037.0,
11521,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,CHEMBL625121,,1,1,,BAO_0000218,,
11522,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",,CHEMBL625122,,1,1,,BAO_0000218,10000006.0,
11523,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL622204,,1,1,,BAO_0000218,178.0,
11524,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL877503,,1,1,,BAO_0000218,178.0,
11525,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL627127,,1,1,,BAO_0000218,178.0,
11526,A,In vivo,,,22224,Autocuration,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL627128,,0,1,,BAO_0000218,10000000.0,
11527,A,In vivo,,,22224,Autocuration,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL627129,,0,1,,BAO_0000218,10000000.0,
11528,A,In vivo,,,22224,Autocuration,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL627130,,0,1,,BAO_0000218,10000000.0,
11529,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL627131,,1,1,,BAO_0000218,955.0,
11530,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL627132,,1,1,,BAO_0000218,955.0,
11531,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL627133,,1,1,,BAO_0000218,955.0,
11532,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL627134,,1,1,,BAO_0000218,2037.0,
11533,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL627135,,1,1,,BAO_0000218,2037.0,
11534,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL627136,,1,1,,BAO_0000218,2037.0,
11535,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL628435,,1,1,,BAO_0000218,,
11536,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL628436,,1,1,,BAO_0000218,,
11537,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL628437,,1,1,,BAO_0000218,,
11538,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL628438,,1,1,,BAO_0000218,948.0,
11539,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL628439,,1,1,,BAO_0000218,948.0,
11540,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL628440,,1,1,,BAO_0000218,948.0,
11541,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL628441,,1,1,,BAO_0000218,10000000.0,
11542,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL628442,,1,1,,BAO_0000218,10000000.0,
11543,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL628443,,1,1,,BAO_0000218,10000000.0,
11544,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL628444,,1,1,,BAO_0000218,2113.0,
11545,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL628445,,1,1,,BAO_0000218,2113.0,
11546,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL877504,,1,1,,BAO_0000218,2113.0,
11547,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL628446,,1,1,,BAO_0000218,2107.0,
11548,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL626874,,1,1,,BAO_0000218,2107.0,
11549,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL626875,,1,1,,BAO_0000218,2107.0,
11550,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL626876,,1,1,,BAO_0000218,2048.0,
11551,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL626877,,1,1,,BAO_0000218,2048.0,
11552,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL626878,,1,1,,BAO_0000218,2048.0,
11553,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL626879,,1,1,,BAO_0000218,2385.0,
11554,A,In vivo,314293.0,,22224,Autocuration,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,,CHEMBL626880,,0,1,,BAO_0000218,1969.0,
11555,A,In vivo,10090.0,,50594,Intermediate,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,,CHEMBL626881,,1,1,,BAO_0000218,1969.0,
11556,A,In vivo,10116.0,,50597,Intermediate,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,,CHEMBL626882,,1,1,,BAO_0000218,1969.0,
11557,A,In vivo,9615.0,,50588,Intermediate,Peak plasma concentration was measured in dogs,,CHEMBL626883,,1,1,,BAO_0000218,1969.0,
11558,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL626884,,1,1,,BAO_0000218,,
11559,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,CHEMBL626885,,1,1,,BAO_0000218,,
11560,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,CHEMBL626886,,1,1,,BAO_0000218,,
11561,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,CHEMBL626887,,1,1,,BAO_0000218,,
11562,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL626888,,1,1,,BAO_0000218,,
11563,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,CHEMBL626889,,1,1,,BAO_0000218,,
11564,A,In vivo,314293.0,,22224,Autocuration,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,CHEMBL626761,,0,1,,BAO_0000218,,
11565,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,CHEMBL626762,,1,1,,BAO_0000218,,
11566,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,CHEMBL626763,,1,1,,BAO_0000218,,
11567,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,CHEMBL626764,,1,1,,BAO_0000218,,
11568,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,CHEMBL626765,,1,1,,BAO_0000218,,
11569,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,CHEMBL626766,,1,1,,BAO_0000218,,
11570,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,CHEMBL626767,,1,1,,BAO_0000218,,
11571,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,CHEMBL626768,,1,1,,BAO_0000218,,
11572,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,CHEMBL626769,,1,1,,BAO_0000218,,
11573,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,CHEMBL874463,,1,1,,BAO_0000218,,
11574,A,In vivo,314293.0,,22224,Autocuration,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,CHEMBL626770,,0,1,,BAO_0000218,,
11575,A,In vivo,314293.0,,22224,Autocuration,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,CHEMBL626771,,0,1,,BAO_0000218,,
11576,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,CHEMBL626772,,1,1,,BAO_0000218,,
11577,A,In vivo,9541.0,,100710,Intermediate,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,CHEMBL626773,,1,1,,BAO_0000218,,
11578,A,In vivo,10090.0,,50594,Intermediate,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,CHEMBL626774,,1,1,,BAO_0000218,,
11579,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,CHEMBL626775,,1,1,,BAO_0000218,,
11580,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,CHEMBL626776,,1,1,,BAO_0000218,,
11581,A,In vivo,10116.0,,50597,Intermediate,Maximum concentration (Cmax) in rat when administered orally,,CHEMBL626777,,1,1,,BAO_0000218,,
11582,A,In vivo,314293.0,,22224,Autocuration,Maximal concentration in monkey plasma after 25 mg/kg oral dose,,CHEMBL626778,,0,1,,BAO_0000218,1969.0,
11583,A,In vivo,10116.0,,22224,Autocuration,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,CHEMBL626779,,0,1,,BAO_0000218,,
11584,A,In vivo,10116.0,,22224,Autocuration,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,CHEMBL626780,,0,1,,BAO_0000218,,
11585,A,In vivo,,,22224,Autocuration,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,,CHEMBL626781,,0,1,,BAO_0000218,1969.0,
11586,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic profile Cmax was evaluated in rats,,CHEMBL632164,,1,1,,BAO_0000218,,
11587,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,CHEMBL632165,,1,1,,BAO_0000218,,
11588,A,In vivo,10090.0,,50594,Intermediate,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,CHEMBL632166,,1,1,,BAO_0000218,,
11589,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,CHEMBL632167,,1,1,,BAO_0000218,,
11590,A,In vivo,10090.0,,50594,Intermediate,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,CHEMBL632168,,1,1,,BAO_0000218,,
11591,A,In vivo,10116.0,,22224,Autocuration,Cmax in rat plasma,,CHEMBL632169,,0,1,,BAO_0000218,1969.0,
11592,A,In vivo,9615.0,,50588,Intermediate,Cmax in dog plasma after 30mg/kg oral dose,,CHEMBL632170,,1,1,,BAO_0000218,1969.0,
11593,A,In vivo,10116.0,,50597,Intermediate,Cmax in rat plasma after 30mg/kg oral dose,,CHEMBL632171,,1,1,,BAO_0000218,1969.0,
11594,A,In vivo,10116.0,,50597,Intermediate,Plasma level in rats at 30 mg/kg,,CHEMBL632172,,1,1,,BAO_0000218,1969.0,
11595,A,In vivo,10090.0,,50594,Intermediate,Tested for maximum plasma concentration in mice,,CHEMBL632173,,1,1,,BAO_0000218,1969.0,
11596,A,In vivo,10116.0,,50597,Intermediate,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL632174,,1,1,,BAO_0000218,,
11597,A,In vivo,10116.0,,50597,Intermediate,The Cmax values in female wistar rats.,,CHEMBL632175,,1,1,,BAO_0000218,,
11598,A,In vivo,9615.0,,50588,Intermediate,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,,CHEMBL632176,,1,1,,BAO_0000218,1969.0,
11599,A,In vivo,10116.0,,50597,Intermediate,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,,CHEMBL632177,,1,1,,BAO_0000218,1969.0,
11600,A,In vivo,10116.0,,50597,Intermediate,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,,CHEMBL632178,,1,1,,BAO_0000218,1969.0,
11601,A,In vivo,10116.0,,50597,Intermediate,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,CHEMBL632179,,1,1,,BAO_0000218,,
11602,A,In vivo,10116.0,,50597,Intermediate,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,,CHEMBL632180,,1,1,,BAO_0000218,178.0,
11603,A,In vivo,10116.0,,50597,Intermediate,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,,CHEMBL632181,,1,1,,BAO_0000218,178.0,
11604,A,In vivo,10116.0,,50597,Intermediate,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,,CHEMBL632182,,1,1,,BAO_0000218,178.0,
11605,A,In vivo,10090.0,,22224,Autocuration,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,,CHEMBL632183,,0,1,,BAO_0000218,178.0,
11606,A,In vivo,9615.0,,50588,Intermediate,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,CHEMBL632184,,1,1,,BAO_0000218,,
11607,A,In vivo,10116.0,,50597,Intermediate,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,CHEMBL874470,,1,1,,BAO_0000218,,
11608,A,,10116.0,,50597,Intermediate,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,CHEMBL631302,,1,1,,BAO_0000218,,
11609,A,,10116.0,,50597,Intermediate,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,CHEMBL631303,,1,1,,BAO_0000218,,
11610,A,,10116.0,,50597,Intermediate,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,CHEMBL631304,,1,1,,BAO_0000218,,
11611,A,,10116.0,,50597,Intermediate,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,CHEMBL631305,,1,1,,BAO_0000218,,
11612,A,,10116.0,,50597,Intermediate,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,CHEMBL631306,,1,1,,BAO_0000218,,
11613,A,,10116.0,,50597,Intermediate,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,CHEMBL631307,,1,1,,BAO_0000218,,
11614,A,,10116.0,,50597,Intermediate,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,CHEMBL631308,,1,1,,BAO_0000218,,
11615,A,,10116.0,,50597,Intermediate,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,CHEMBL625557,,1,1,,BAO_0000218,,
11616,A,,10116.0,,50597,Intermediate,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",,CHEMBL625558,,1,1,,BAO_0000218,2106.0,
11617,A,,10116.0,,50597,Intermediate,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",,CHEMBL625559,,1,1,,BAO_0000218,2106.0,
11618,A,,10116.0,,50597,Intermediate,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",,CHEMBL625560,,1,1,,BAO_0000218,2106.0,
11619,A,,10116.0,,50597,Intermediate,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",,CHEMBL625561,,1,1,,BAO_0000218,2106.0,
11620,A,,10116.0,,50597,Intermediate,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",,CHEMBL625562,,1,1,,BAO_0000218,2106.0,
11621,A,,10116.0,,50597,Intermediate,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",,CHEMBL875320,,1,1,,BAO_0000218,2106.0,
11622,A,,10116.0,,50597,Intermediate,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",,CHEMBL625563,,1,1,,BAO_0000218,2106.0,
11623,A,,10116.0,,50597,Intermediate,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",,CHEMBL625564,,1,1,,BAO_0000218,2106.0,
11624,A,,10116.0,,50597,Intermediate,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",,CHEMBL625565,,1,1,,BAO_0000218,995.0,
11625,A,,10116.0,,50597,Intermediate,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",,CHEMBL625566,,1,1,,BAO_0000218,995.0,
11626,A,,10116.0,,50597,Intermediate,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",,CHEMBL625567,,1,1,,BAO_0000218,995.0,
11627,A,,10116.0,,50597,Intermediate,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",,CHEMBL625568,,1,1,,BAO_0000218,995.0,
11628,A,,10116.0,,50597,Intermediate,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",,CHEMBL628217,,1,1,,BAO_0000218,995.0,
11629,A,,10116.0,,50597,Intermediate,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",,CHEMBL628218,,1,1,,BAO_0000218,995.0,
11630,A,,10116.0,,50597,Intermediate,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",,CHEMBL628219,,1,1,,BAO_0000218,995.0,
11631,A,,10116.0,,50597,Intermediate,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",,CHEMBL628220,,1,1,,BAO_0000218,995.0,
11632,A,,,,22224,Autocuration,Distribution in the blood after 120 min of intravenous administration,,CHEMBL628221,,0,1,,BAO_0000019,,
11633,A,,,,22224,Autocuration,Distribution in the blood after 15 min of intravenous administration,,CHEMBL628222,,0,1,,BAO_0000019,,
11634,A,,,,22224,Autocuration,Distribution in the blood after 30 min of intravenous administration,,CHEMBL628223,,0,1,,BAO_0000019,,
11635,A,,,,22224,Autocuration,Distribution in the blood after 5 min of intravenous administration,,CHEMBL628224,,0,1,,BAO_0000019,,
11636,A,,,,22224,Autocuration,Distribution in the blood after 60 min of intravenous administration,,CHEMBL628225,,0,1,,BAO_0000019,,
11637,A,,,,22224,Autocuration,Distribution in the blood after 90 min of intravenous administration,,CHEMBL628226,,0,1,,BAO_0000019,,
11638,A,,,,22224,Autocuration,Distribution in the bone after 120 min of intravenous administration,,CHEMBL628227,,0,1,,BAO_0000019,,
11639,A,,,,22224,Autocuration,Distribution in the bone after 15 min of intravenous administration,,CHEMBL875481,,0,1,,BAO_0000019,,
11640,A,,,,22224,Autocuration,Distribution in the bone after 30 min of intravenous administration,,CHEMBL628228,,0,1,,BAO_0000019,,
11641,A,,,,22224,Autocuration,Distribution in the bone after 5 min of intravenous administration,,CHEMBL628229,,0,1,,BAO_0000019,,
11642,A,,,,22224,Autocuration,Distribution in the bone after 60 min of intravenous administration,,CHEMBL628230,,0,1,,BAO_0000019,,
11643,A,,,,22224,Autocuration,Distribution in the bone after 90 min of intravenous administration,,CHEMBL628231,,0,1,,BAO_0000019,,
11644,A,,,,22224,Autocuration,Distribution in the heart after 120 min of intravenous administration,,CHEMBL628232,,0,1,,BAO_0000019,,
11645,A,,,,22224,Autocuration,Distribution in the heart after 15 min of intravenous administration,,CHEMBL628233,,0,1,,BAO_0000019,,
11646,A,,,,22224,Autocuration,Distribution in the heart after 30 min of intravenous administration,,CHEMBL628234,,0,1,,BAO_0000019,,
11647,A,,,,22224,Autocuration,Distribution in the heart after 5 min of intravenous administration,,CHEMBL628235,,0,1,,BAO_0000019,,
11648,A,,,,22224,Autocuration,Distribution in the heart after 60 min of intravenous administration,,CHEMBL628236,,0,1,,BAO_0000019,,
11649,A,,,,22224,Autocuration,Distribution in the heart after 90 min of intravenous administration,,CHEMBL628237,,0,1,,BAO_0000019,,
11650,A,,,,22224,Autocuration,Distribution in the kidneys after 120 min of intravenous administration,,CHEMBL628238,,0,1,,BAO_0000019,,
11651,A,,,,22224,Autocuration,Distribution in the kidneys after 15 min of intravenous administration,,CHEMBL628239,,0,1,,BAO_0000019,,
11652,A,,,,22224,Autocuration,Distribution in the kidneys after 30 min of intravenous administration,,CHEMBL628240,,0,1,,BAO_0000019,,
11653,A,,,,22224,Autocuration,Distribution in the kidneys after 5 min of intravenous administration,,CHEMBL628241,,0,1,,BAO_0000019,,
11654,A,,,,22224,Autocuration,Distribution in the kidneys after 60 min of intravenous administration,,CHEMBL628242,,0,1,,BAO_0000019,,
11655,A,,,,22224,Autocuration,Distribution in the kidneys after 90 min of intravenous administration,,CHEMBL875482,,0,1,,BAO_0000019,,
11656,A,,,,22224,Autocuration,Distribution in the liver after 120 min of intravenous administration,,CHEMBL628243,,0,1,,BAO_0000019,,
11657,A,,,,22224,Autocuration,Distribution in the liver after 15 min of intravenous administration,,CHEMBL628244,,0,1,,BAO_0000019,,
11658,A,,,,22224,Autocuration,Distribution in the liver after 30 min of intravenous administration,,CHEMBL628245,,0,1,,BAO_0000019,,
11659,A,,,,22224,Autocuration,Distribution in the liver after 5 min of intravenous administration,,CHEMBL628246,,0,1,,BAO_0000019,,
11660,A,,,,22224,Autocuration,Distribution in the liver after 60 min of intravenous administration,,CHEMBL628247,,0,1,,BAO_0000019,,
11661,A,,,,22224,Autocuration,Distribution in the liver after 90 min of intravenous administration,,CHEMBL628248,,0,1,,BAO_0000019,,
11662,A,,,,22224,Autocuration,Distribution in the lung after 120 min of intravenous administration,,CHEMBL628249,,0,1,,BAO_0000019,,
11663,A,,10090.0,,50594,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,CHEMBL625452,,1,1,,BAO_0000218,,
11664,A,,10090.0,,50594,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,CHEMBL625453,,1,1,,BAO_0000218,,
11665,A,,10090.0,,50594,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,CHEMBL625454,,1,1,,BAO_0000218,,
11666,A,,10090.0,,50594,Intermediate,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,CHEMBL623844,,1,1,,BAO_0000218,,
11667,A,,10116.0,,50597,Intermediate,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,CHEMBL623845,,1,1,,BAO_0000218,,
11668,A,,10116.0,,50597,Intermediate,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,CHEMBL623846,,1,1,,BAO_0000218,,
11669,A,,,,22224,Autocuration,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,CHEMBL623847,,0,1,,BAO_0000218,,
11670,A,,9541.0,,100710,Intermediate,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,CHEMBL623848,,1,1,,BAO_0000218,,
11671,A,,9541.0,,100710,Intermediate,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,CHEMBL623849,,1,1,,BAO_0000218,,
11672,A,,9541.0,,100710,Intermediate,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,CHEMBL623850,,1,1,,BAO_0000218,,
11673,A,,9541.0,,100710,Intermediate,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,CHEMBL623851,,1,1,,BAO_0000218,,
11674,A,,314293.0,,22224,Autocuration,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,CHEMBL623852,,0,1,,BAO_0000218,,
11675,A,,9669.0,,50506,Intermediate,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,CHEMBL624551,,1,1,,BAO_0000218,,
11676,A,,9669.0,,50506,Intermediate,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,CHEMBL624552,,1,1,,BAO_0000218,,
11677,A,,314293.0,,22224,Autocuration,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,CHEMBL624553,,0,1,,BAO_0000218,,
11678,A,,314293.0,,22224,Autocuration,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,CHEMBL624554,,0,1,,BAO_0000218,,
11679,A,,10116.0,,50597,Intermediate,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,CHEMBL624555,,1,1,,BAO_0000218,,
11680,A,,10116.0,,50597,Intermediate,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,CHEMBL624741,,1,1,,BAO_0000218,,
11681,A,,9615.0,,50588,Intermediate,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,CHEMBL624742,,1,1,,BAO_0000218,,
11682,A,,10026.0,,100712,Intermediate,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,CHEMBL624743,,1,1,,BAO_0000218,,
11683,A,,10116.0,,50597,Intermediate,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,CHEMBL877606,,1,1,,BAO_0000218,,
11684,A,,,,22224,Autocuration,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,CHEMBL624744,,0,1,,BAO_0000218,,
11685,A,,,,22224,Autocuration,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL624745,,0,1,,BAO_0000218,178.0,
11686,A,,,,22224,Autocuration,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL624746,,0,1,,BAO_0000218,178.0,
11687,A,,,,22224,Autocuration,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,CHEMBL624747,,0,1,,BAO_0000218,178.0,
11688,A,,,,22224,Autocuration,Oral absorption expressed as Area under curve was determined,,CHEMBL624748,,0,1,,BAO_0000019,,
11689,A,,9615.0,,50588,Intermediate,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,CHEMBL622504,,1,1,,BAO_0000218,,
11690,A,,9615.0,,50588,Intermediate,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,CHEMBL622505,,1,1,,BAO_0000218,,
11691,A,,10026.0,,100712,Intermediate,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,CHEMBL622506,,1,1,,BAO_0000218,,
11692,A,,10026.0,,100712,Intermediate,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,CHEMBL622507,,1,1,,BAO_0000218,,
11693,A,,10116.0,,50597,Intermediate,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,CHEMBL622508,,1,1,,BAO_0000218,,
11694,A,,,,22224,Autocuration,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,CHEMBL622509,,0,1,,BAO_0000019,,
11695,A,,10116.0,,50597,Intermediate,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL622510,,1,1,,BAO_0000218,,
11696,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,CHEMBL622511,,1,1,,BAO_0000218,,
11697,A,,9541.0,,100710,Intermediate,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,CHEMBL622512,,1,1,,BAO_0000218,,
11698,A,,9541.0,,100710,Intermediate,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,CHEMBL622513,,1,1,,BAO_0000218,,
11699,A,,9541.0,,100710,Intermediate,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,CHEMBL622514,,1,1,,BAO_0000218,,
11700,A,,9615.0,,50588,Intermediate,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,CHEMBL622515,,1,1,,BAO_0000218,,
11701,A,,9615.0,,50588,Intermediate,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,CHEMBL622516,,1,1,,BAO_0000218,,
11702,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,CHEMBL622517,,1,1,,BAO_0000218,,
11703,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,CHEMBL622518,,1,1,,BAO_0000218,,
11704,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,CHEMBL622519,,1,1,,BAO_0000218,,
11705,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL622520,,1,1,,BAO_0000218,2385.0,
11706,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL622521,,1,1,,BAO_0000218,2385.0,
11707,A,In vivo,10090.0,,50594,Intermediate,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL625113,,1,1,,BAO_0000218,14.0,
11708,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL625114,,1,1,,BAO_0000218,14.0,
11709,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL874397,,1,1,,BAO_0000218,14.0,
11710,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL625115,,1,1,,BAO_0000218,2106.0,
11711,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL625116,,1,1,,BAO_0000218,2106.0,
11712,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL623932,,1,1,,BAO_0000218,2106.0,
11713,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL623933,,1,1,,BAO_0000218,2435.0,
11714,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL623934,,1,1,,BAO_0000218,2435.0,
11715,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL623935,,1,1,,BAO_0000218,2435.0,
11716,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,,CHEMBL623936,,1,1,,BAO_0000218,2046.0,
11717,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,,CHEMBL623937,,1,1,,BAO_0000218,2046.0,
11718,A,In vivo,10116.0,,50597,Intermediate,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,,CHEMBL623938,,1,1,,BAO_0000218,2046.0,
11719,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL623939,,1,1,,BAO_0000218,,
11720,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,CHEMBL623940,,1,1,,BAO_0000218,,
11721,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,CHEMBL623941,,1,1,,BAO_0000218,,
11722,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL627216,,1,1,,BAO_0000218,,
11723,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL623942,,1,1,,BAO_0000218,,
11724,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL618793,,1,1,,BAO_0000218,955.0,
11725,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618794,,1,1,,BAO_0000218,955.0,
11726,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618795,,1,1,,BAO_0000218,955.0,
11727,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618796,,1,1,,BAO_0000218,,
11728,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618797,,1,1,,BAO_0000218,,
11729,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,CHEMBL618798,,1,1,,BAO_0000218,2113.0,
11730,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL618799,,1,1,,BAO_0000218,2113.0,
11731,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,CHEMBL618800,,1,1,,BAO_0000218,2113.0,
11732,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,CHEMBL618801,,1,1,,BAO_0000218,2113.0,
11733,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618802,,1,1,,BAO_0000218,2113.0,
11734,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618803,,1,1,,BAO_0000218,2113.0,
11735,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,CHEMBL618804,,1,1,,BAO_0000218,2107.0,
11736,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL618805,,1,1,,BAO_0000218,2107.0,
11737,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,CHEMBL618806,,1,1,,BAO_0000218,2107.0,
11738,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,CHEMBL618807,,1,1,,BAO_0000218,2107.0,
11739,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618808,,1,1,,BAO_0000218,2107.0,
11740,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618809,,1,1,,BAO_0000218,2107.0,
11741,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL618810,,1,1,,BAO_0000218,2385.0,
11742,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,CHEMBL618811,,1,1,,BAO_0000218,2385.0,
11743,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,CHEMBL875844,,1,1,,BAO_0000218,2385.0,
11744,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618812,,1,1,,BAO_0000218,2385.0,
11745,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618813,,1,1,,BAO_0000218,2385.0,
11746,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL618814,,1,1,,BAO_0000218,,
11747,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618815,,1,1,,BAO_0000218,,
11748,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL618816,,1,1,,BAO_0000218,,
11749,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL618817,,1,1,,BAO_0000218,,
11750,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL620544,,1,1,,BAO_0000218,,
11751,A,In vivo,10116.0,,50597,Intermediate,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,CHEMBL626230,,1,1,,BAO_0000218,,
11752,A,In vivo,10116.0,,50597,Intermediate,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,CHEMBL626231,,1,1,,BAO_0000218,,
11753,A,In vivo,10116.0,,50597,Intermediate,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,CHEMBL626232,,1,1,,BAO_0000218,,
11754,A,In vivo,9615.0,,50588,Intermediate,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,,CHEMBL626233,,1,1,,BAO_0000218,1969.0,
11755,A,In vivo,10116.0,,50597,Intermediate,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,,CHEMBL626234,,1,1,,BAO_0000218,1969.0,
11756,A,In vivo,10116.0,,50597,Intermediate,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,,CHEMBL875341,,1,1,,BAO_0000218,1969.0,
11757,A,In vivo,9606.0,,50587,Intermediate,The maximum plasma concentration (100 mg/kg) administered orally in human,,CHEMBL626235,,1,1,,BAO_0000218,1969.0,
11758,A,In vivo,9481.0,,22224,Autocuration,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,,CHEMBL626236,,0,1,,BAO_0000218,1969.0,
11759,A,In vivo,314293.0,,22224,Autocuration,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,,CHEMBL626237,,0,1,,BAO_0000218,1969.0,
11760,A,In vivo,9615.0,,50588,Intermediate,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,,CHEMBL626238,,1,1,,BAO_0000218,1969.0,
11761,A,In vivo,9606.0,,50587,Intermediate,The maximum plasma concentration (200 mg/kg) administered orally in human,,CHEMBL622412,,1,1,,BAO_0000218,1969.0,
11762,A,In vivo,10116.0,,50597,Intermediate,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,,CHEMBL623114,,1,1,,BAO_0000218,1969.0,
11763,A,In vivo,9481.0,,22224,Autocuration,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,,CHEMBL623115,,0,1,,BAO_0000218,1969.0,
11764,A,In vivo,314293.0,,22224,Autocuration,The maximum plasma concentration (25 mg/kg) administered orally in monkey,,CHEMBL623116,,0,1,,BAO_0000218,1969.0,
11765,A,In vivo,9615.0,,22224,Autocuration,The maximum plasma concentration (30 mg/kg) administered orally in dog,,CHEMBL623117,,0,1,,BAO_0000218,1969.0,
11766,A,In vivo,9606.0,,50587,Intermediate,The maximum plasma concentration (400 mg/kg) administered orally in human,,CHEMBL623118,,1,1,,BAO_0000218,1969.0,
11767,A,In vivo,10116.0,,50597,Intermediate,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,,CHEMBL623119,,1,1,,BAO_0000218,1969.0,
11768,A,In vivo,10116.0,,50597,Intermediate,The maximum plasma concentration (50 mg/kg) administered orally in rat,,CHEMBL623120,,1,1,,BAO_0000218,1969.0,
11769,A,In vivo,9606.0,,50587,Intermediate,The maximum plasma concentration (800 mg/kg) administered orally in human,,CHEMBL623286,,1,1,,BAO_0000218,1969.0,
11770,A,In vivo,10116.0,,50597,Intermediate,The maximum plasma concentration was measured on rats,,CHEMBL623287,,1,1,,BAO_0000218,1969.0,
11771,A,In vivo,10116.0,,50597,Intermediate,The maximum plasma concentration was measured on rats after oral administration,,CHEMBL623288,,1,1,,BAO_0000218,1969.0,
11772,A,In vivo,10116.0,,50597,Intermediate,Plasma drug Cmax in rat (PO dose),,CHEMBL623289,,1,1,,BAO_0000218,1969.0,
11773,A,In vivo,,,22224,Autocuration,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,CHEMBL623290,,0,1,,BAO_0000218,,
11774,A,In vivo,9615.0,,50588,Intermediate,maximum Plasma concentration in Dog was determined after Peroral administration,,CHEMBL623291,,1,1,,BAO_0000218,1969.0,
11775,A,In vivo,10116.0,,50597,Intermediate,maximum Plasma concentration in Rats was determined after Peroral administration,,CHEMBL623292,,1,1,,BAO_0000218,1969.0,
11776,A,In vivo,9615.0,,50588,Intermediate,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,CHEMBL623293,,1,1,,BAO_0000218,1969.0,
11777,A,In vivo,314293.0,,22224,Autocuration,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,CHEMBL623294,,0,1,,BAO_0000218,1969.0,
11778,A,In vivo,10116.0,,50597,Intermediate,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,CHEMBL623295,,1,1,,BAO_0000218,1969.0,
11779,A,In vivo,10090.0,,50594,Intermediate,maximum concentration was measured when administered through oral route in mice,,CHEMBL623296,,1,1,,BAO_0000218,,
11780,A,,10090.0,,50594,Intermediate,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,CHEMBL875349,,1,1,,BAO_0000218,,
11781,A,,314293.0,,22224,Autocuration,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,CHEMBL623297,,0,1,,BAO_0000019,,
11782,A,,314293.0,,22224,Autocuration,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,CHEMBL623298,,0,1,,BAO_0000019,,
11783,A,,314293.0,,22224,Autocuration,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,CHEMBL623299,,0,1,,BAO_0000019,,
11784,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter was evaluated in rats,,CHEMBL623300,,1,1,,BAO_0000218,,
11785,A,,10090.0,,50594,Intermediate,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,CHEMBL623301,,1,1,,BAO_0000218,,
11786,A,,10090.0,,50594,Intermediate,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,CHEMBL623302,,1,1,,BAO_0000218,,
11787,A,,10090.0,,50594,Intermediate,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,CHEMBL623303,,1,1,,BAO_0000218,,
11788,A,,10090.0,,50594,Intermediate,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,CHEMBL623304,,1,1,,BAO_0000218,,
11789,A,,10090.0,,50594,Intermediate,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,CHEMBL623305,,1,1,,BAO_0000218,,
11790,A,,10116.0,,50597,Intermediate,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,,CHEMBL623306,,1,1,,BAO_0000218,1969.0,
11791,A,,10116.0,,50597,Intermediate,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,,CHEMBL623307,,1,1,,BAO_0000218,1969.0,
11792,A,,10116.0,,50597,Intermediate,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,,CHEMBL623308,,1,1,,BAO_0000218,1969.0,
11793,A,,10090.0,,50594,Intermediate,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,,CHEMBL623309,,1,1,,BAO_0000218,1969.0,
11794,A,,10090.0,,50594,Intermediate,Plasma Concentration after 120 min of oral administration to mice,,CHEMBL623310,,1,1,,BAO_0000218,,
11795,A,,10090.0,,50594,Intermediate,Plasma Concentration after 30 min of oral administration to mice,,CHEMBL623311,,1,1,,BAO_0000218,,
11796,A,,9541.0,,100710,Intermediate,Plasma Concentration after 60 min of oral administration to mice,,CHEMBL623312,,1,1,,BAO_0000218,,
11797,A,,10090.0,,50594,Intermediate,Plasma Concentration after 60 min of oral administration to mice; Not determined,,CHEMBL875350,,1,1,,BAO_0000218,,
11798,A,,10090.0,,50594,Intermediate,Plasma Concentration after 90 min of oral administration to mice,,CHEMBL628635,,1,1,,BAO_0000218,,
11799,A,,10116.0,,50597,Intermediate,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,CHEMBL628636,,1,1,,BAO_0000218,,
11800,A,,10116.0,,50597,Intermediate,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,CHEMBL628637,,1,1,,BAO_0000218,,
11801,A,,10116.0,,50597,Intermediate,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,CHEMBL628058,,1,1,,BAO_0000218,,
11802,A,,10116.0,,50597,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,CHEMBL628059,,1,1,,BAO_0000218,,
11803,A,,10116.0,,50597,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,CHEMBL628060,,1,1,,BAO_0000218,,
11804,A,,,,22224,Autocuration,Distribution in the lung after 15 min of intravenous administration,,CHEMBL628061,,0,1,,BAO_0000019,,
11805,A,,,,22224,Autocuration,Distribution in the lung after 30 min of intravenous administration,,CHEMBL628062,,0,1,,BAO_0000019,,
11806,A,,,,22224,Autocuration,Distribution in the lung after 5 min of intravenous administration,,CHEMBL628063,,0,1,,BAO_0000019,,
11807,A,,,,22224,Autocuration,Distribution in the lung after 60 min of intravenous administration,,CHEMBL628064,,0,1,,BAO_0000019,,
11808,A,,,,22224,Autocuration,Distribution in the lung after 90 min of intravenous administration,,CHEMBL628065,,0,1,,BAO_0000019,,
11809,A,,,,22224,Autocuration,Distribution in the muscle after 120 min of intravenous administration,,CHEMBL628066,,0,1,,BAO_0000019,2385.0,
11810,A,,,,22224,Autocuration,Distribution in the muscle after 15 min of intravenous administration,,CHEMBL628067,,0,1,,BAO_0000019,2385.0,
11811,A,,10090.0,,50594,Intermediate,Distribution in the muscle after 30 min of intravenous administration,,CHEMBL874646,,1,1,,BAO_0000218,2385.0,
11812,A,,,,22224,Autocuration,Distribution in the muscle after 5 min of intravenous administration,,CHEMBL628068,,0,1,,BAO_0000019,2385.0,
11813,A,,,,22224,Autocuration,Distribution in the muscle after 60 min of intravenous administration,,CHEMBL628069,,0,1,,BAO_0000019,2385.0,
11814,A,,,,22224,Autocuration,Distribution in the muscle after 90 min of intravenous administration,,CHEMBL628070,,0,1,,BAO_0000019,2385.0,
11815,A,,,,22224,Autocuration,Distribution in the spleen after 120 min of intravenous administration,,CHEMBL628071,,0,1,,BAO_0000019,2106.0,
11816,A,,,,22224,Autocuration,Distribution in the spleen after 15 min of intravenous administration,,CHEMBL628072,,0,1,,BAO_0000019,2106.0,
11817,A,,,,22224,Autocuration,Distribution in the spleen after 30 min of intravenous administration,,CHEMBL628073,,0,1,,BAO_0000019,2106.0,
11818,A,,,,22224,Autocuration,Distribution in the spleen after 5 min of intravenous administration,,CHEMBL628074,,0,1,,BAO_0000019,2106.0,
11819,A,,,,22224,Autocuration,Distribution in the spleen after 60 min of intravenous administration,,CHEMBL628075,,0,1,,BAO_0000019,2106.0,
11820,A,,,,22224,Autocuration,Distribution in the spleen after 90 min of intravenous administration,,CHEMBL628076,,0,1,,BAO_0000019,2106.0,
11821,A,,10116.0,,50597,Intermediate,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,,CHEMBL628077,,1,1,,BAO_0000218,1235.0,
11822,A,,10116.0,,50597,Intermediate,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,,CHEMBL628078,,1,1,,BAO_0000218,178.0,
11823,A,,10116.0,,50597,Intermediate,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,,CHEMBL628079,,1,1,,BAO_0000218,2107.0,
11824,A,,10116.0,,50597,Intermediate,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,,CHEMBL628080,,1,1,,BAO_0000218,992.0,
11825,A,,10116.0,,50597,Intermediate,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,,CHEMBL628081,,1,1,,BAO_0000218,2046.0,
11826,A,,10116.0,,50597,Intermediate,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,,CHEMBL628082,,1,1,,BAO_0000218,1235.0,
11827,A,,10116.0,,50597,Intermediate,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,,CHEMBL874647,,1,1,,BAO_0000218,178.0,
11828,A,,10116.0,,50597,Intermediate,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,,CHEMBL626406,,1,1,,BAO_0000218,2107.0,
11829,A,,10116.0,,50597,Intermediate,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,,CHEMBL626407,,1,1,,BAO_0000218,992.0,
11830,A,,10116.0,,50597,Intermediate,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,,CHEMBL626408,,1,1,,BAO_0000218,2046.0,
11831,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",,CHEMBL626409,,1,1,,BAO_0000218,178.0,
11832,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",,CHEMBL626410,,1,1,,BAO_0000218,178.0,
11833,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",,CHEMBL626411,,1,1,,BAO_0000218,178.0,
11834,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",,CHEMBL626412,,1,1,,BAO_0000218,178.0,
11835,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",,CHEMBL626413,,1,1,,BAO_0000218,178.0,
11836,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",,CHEMBL626414,,1,1,,BAO_0000218,178.0,
11837,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",,CHEMBL626415,,1,1,,BAO_0000218,178.0,
11838,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",,CHEMBL626416,,1,1,,BAO_0000218,178.0,
11839,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",,CHEMBL627062,,1,1,,BAO_0000218,178.0,
11840,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",,CHEMBL627063,,1,1,,BAO_0000218,178.0,
11841,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",,CHEMBL627064,,1,1,,BAO_0000218,178.0,
11842,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",,CHEMBL627227,,1,1,,BAO_0000218,178.0,
11843,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",,CHEMBL627228,,1,1,,BAO_0000218,178.0,
11844,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",,CHEMBL627229,,1,1,,BAO_0000218,178.0,
11845,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",,CHEMBL625792,,1,1,,BAO_0000218,178.0,
11846,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",,CHEMBL625793,,1,1,,BAO_0000218,178.0,
11847,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",,CHEMBL625794,,1,1,,BAO_0000218,178.0,
11848,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",,CHEMBL625795,,1,1,,BAO_0000218,178.0,
11849,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,CHEMBL625796,,1,1,,BAO_0000218,,
11850,A,,9615.0,,50588,Intermediate,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,CHEMBL625797,,1,1,,BAO_0000218,,
11851,A,,9615.0,,50588,Intermediate,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,CHEMBL625798,,1,1,,BAO_0000218,,
11852,A,,,,22224,Autocuration,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,CHEMBL875613,,0,1,,BAO_0000218,,
11853,A,,,,22224,Autocuration,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,CHEMBL625799,,0,1,,BAO_0000218,,
11854,A,,,,22224,Autocuration,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,CHEMBL625800,,0,1,,BAO_0000218,,
11855,A,,,,22224,Autocuration,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,CHEMBL625801,,0,1,,BAO_0000218,,
11856,A,,,,22224,Autocuration,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,CHEMBL625802,,0,1,,BAO_0000218,,
11857,A,,,,22224,Autocuration,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,CHEMBL625803,,0,1,,BAO_0000218,,
11858,A,,,,22224,Autocuration,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,CHEMBL625804,,0,1,,BAO_0000019,,
11859,A,,,,22224,Autocuration,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,CHEMBL622530,,0,1,,BAO_0000218,,
11860,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,CHEMBL622531,,1,1,,BAO_0000218,,
11861,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,CHEMBL622532,,1,1,,BAO_0000218,,
11862,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,CHEMBL623176,,1,1,,BAO_0000218,,
11863,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,CHEMBL623177,,1,1,,BAO_0000218,,
11864,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,CHEMBL623178,,1,1,,BAO_0000218,,
11865,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,CHEMBL623179,,1,1,,BAO_0000218,,
11866,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,CHEMBL623180,,1,1,,BAO_0000218,,
11867,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,CHEMBL623181,,1,1,,BAO_0000218,,
11868,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,CHEMBL624131,,1,1,,BAO_0000218,,
11869,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,CHEMBL624132,,1,1,,BAO_0000218,,
11870,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,CHEMBL624133,,1,1,,BAO_0000218,,
11871,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,CHEMBL624846,,1,1,,BAO_0000218,,
11872,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,CHEMBL624847,,1,1,,BAO_0000218,,
11873,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,CHEMBL624848,,1,1,,BAO_0000218,,
11874,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,CHEMBL625012,,1,1,,BAO_0000218,,
11875,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,CHEMBL625013,,1,1,,BAO_0000218,,
11876,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,CHEMBL625014,,1,1,,BAO_0000218,,
11877,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,CHEMBL625015,,1,1,,BAO_0000218,,
11878,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,CHEMBL625016,,1,1,,BAO_0000218,,
11879,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,CHEMBL625017,,1,1,,BAO_0000218,,
11880,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,CHEMBL625018,,1,1,,BAO_0000218,,
11881,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,CHEMBL625019,,1,1,,BAO_0000218,,
11882,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,CHEMBL625020,,1,1,,BAO_0000218,,
11883,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,CHEMBL625021,,1,1,,BAO_0000218,,
11884,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL625022,,1,1,,BAO_0000218,,
11885,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,CHEMBL625023,,1,1,,BAO_0000218,,
11886,A,,9541.0,,100710,Intermediate,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,CHEMBL625024,,1,1,,BAO_0000218,,
11887,A,,9541.0,,100710,Intermediate,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,CHEMBL627626,,1,1,,BAO_0000218,,
11888,A,,,,22224,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,CHEMBL627627,,0,1,,BAO_0000218,955.0,
11889,A,,,,22224,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,,CHEMBL627628,,0,1,,BAO_0000218,1977.0,
11890,A,,,,22224,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,CHEMBL627629,,0,1,,BAO_0000218,955.0,
11891,A,,,,22224,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,,CHEMBL627630,,0,1,,BAO_0000218,1977.0,
11892,A,,,,22224,Autocuration,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,CHEMBL627631,,0,1,,BAO_0000019,,
11893,A,,,,22224,Autocuration,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,CHEMBL629515,,0,1,,BAO_0000218,,
11894,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL629516,,1,1,,BAO_0000218,2106.0,
11895,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL629517,,1,1,,BAO_0000218,2106.0,
11896,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL629518,,1,1,,BAO_0000218,2106.0,
11897,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,CHEMBL877499,,1,1,,BAO_0000218,,
11898,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,CHEMBL629519,,1,1,,BAO_0000218,,
11899,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,CHEMBL629520,,1,1,,BAO_0000218,,
11900,A,,10090.0,,50594,Intermediate,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,CHEMBL629521,,1,1,,BAO_0000218,,
11901,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,CHEMBL629522,,1,1,,BAO_0000218,,
11902,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,CHEMBL629523,,1,1,,BAO_0000218,,
11903,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,CHEMBL629524,,1,1,,BAO_0000218,,
11904,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,CHEMBL629525,,1,1,,BAO_0000218,,
11905,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,CHEMBL629526,,1,1,,BAO_0000218,,
11906,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,CHEMBL629527,,1,1,,BAO_0000218,,
11907,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,CHEMBL629528,,1,1,,BAO_0000218,,
11908,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,CHEMBL629529,,1,1,,BAO_0000218,,
11909,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,CHEMBL629530,,1,1,,BAO_0000218,,
11910,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,CHEMBL629531,,1,1,,BAO_0000218,,
11911,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,CHEMBL628656,,1,1,,BAO_0000218,,
11912,A,,10090.0,,50594,Intermediate,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,CHEMBL628657,,1,1,,BAO_0000218,,
11913,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL628658,,1,1,,BAO_0000218,,
11914,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL628659,,1,1,,BAO_0000218,,
11915,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL877500,,1,1,,BAO_0000218,,
11916,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL628660,,1,1,,BAO_0000218,,
11917,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL628661,,1,1,,BAO_0000218,,
11918,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL628662,,1,1,,BAO_0000218,,
11919,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL628663,,1,1,,BAO_0000218,,
11920,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL628664,,1,1,,BAO_0000218,,
11921,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL628665,,1,1,,BAO_0000218,178.0,
11922,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL628666,,1,1,,BAO_0000218,178.0,
11923,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL628667,,1,1,,BAO_0000218,178.0,
11924,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL628668,,1,1,,BAO_0000218,178.0,
11925,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL628669,,1,1,,BAO_0000218,178.0,
11926,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL628670,,1,1,,BAO_0000218,178.0,
11927,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL628671,,1,1,,BAO_0000218,178.0,
11928,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL628672,,1,1,,BAO_0000218,10000001.0,
11929,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL630300,,1,1,,BAO_0000218,10000001.0,
11930,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL629787,,1,1,,BAO_0000218,10000001.0,
11931,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL629788,,1,1,,BAO_0000218,10000001.0,
11932,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL629789,,1,1,,BAO_0000218,955.0,
11933,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL629790,,1,1,,BAO_0000218,955.0,
11934,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL629791,,1,1,,BAO_0000218,955.0,
11935,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL629792,,1,1,,BAO_0000218,955.0,
11936,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL629793,,1,1,,BAO_0000218,955.0,
11937,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL629794,,1,1,,BAO_0000218,955.0,
11938,A,,10116.0,,50597,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,CHEMBL874459,,1,1,,BAO_0000218,,
11939,A,,10116.0,,50597,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,CHEMBL629795,,1,1,,BAO_0000218,,
11940,A,,10116.0,,50597,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,CHEMBL629796,,1,1,,BAO_0000218,,
11941,A,,10116.0,,50597,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,CHEMBL629797,,1,1,,BAO_0000218,,
11942,A,,10116.0,,50597,Intermediate,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,CHEMBL629798,,1,1,,BAO_0000218,,
11943,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL629799,,1,1,,BAO_0000218,2369.0,
11944,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL629800,,1,1,,BAO_0000218,2369.0,
11945,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL629801,,1,1,,BAO_0000218,2369.0,
11946,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,,CHEMBL629802,,1,1,,BAO_0000218,2369.0,
11947,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL629803,,1,1,,BAO_0000218,2369.0,
11948,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL629804,,1,1,,BAO_0000218,178.0,
11949,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL629805,,1,1,,BAO_0000218,178.0,
11950,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,CHEMBL629806,,1,1,,BAO_0000218,178.0,
11951,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL629807,,1,1,,BAO_0000218,178.0,
11952,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL629808,,1,1,,BAO_0000218,178.0,
11953,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL629809,,1,1,,BAO_0000218,955.0,
11954,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL629810,,1,1,,BAO_0000218,955.0,
11955,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,CHEMBL629811,,1,1,,BAO_0000218,955.0,
11956,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL629812,,1,1,,BAO_0000218,955.0,
11957,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,,CHEMBL629813,,1,1,,BAO_0000218,955.0,
11958,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL874460,,1,1,,BAO_0000218,955.0,
11959,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL629814,,1,1,,BAO_0000218,,
11960,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL629815,,1,1,,BAO_0000218,,
11961,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL629816,,1,1,,BAO_0000218,,
11962,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL629817,,1,1,,BAO_0000218,,
11963,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL626643,,1,1,,BAO_0000218,2113.0,
11964,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL626644,,1,1,,BAO_0000218,2113.0,
11965,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL626806,,1,1,,BAO_0000218,2113.0,
11966,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL626807,,1,1,,BAO_0000218,2113.0,
11967,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627261,,1,1,,BAO_0000218,2107.0,
11968,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627262,,1,1,,BAO_0000218,2107.0,
11969,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627263,,1,1,,BAO_0000218,2107.0,
11970,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627264,,1,1,,BAO_0000218,2107.0,
11971,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627265,,1,1,,BAO_0000218,2048.0,
11972,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627266,,1,1,,BAO_0000218,2048.0,
11973,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627267,,1,1,,BAO_0000218,2048.0,
11974,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627268,,1,1,,BAO_0000218,2048.0,
11975,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627269,,1,1,,BAO_0000218,2385.0,
11976,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627270,,1,1,,BAO_0000218,2385.0,
11977,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,CHEMBL627271,,1,1,,BAO_0000218,,
11978,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,CHEMBL627946,,1,1,,BAO_0000218,,
11979,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,CHEMBL875472,,1,1,,BAO_0000218,,
11980,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,CHEMBL627947,,1,1,,BAO_0000218,,
11981,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,CHEMBL627948,,1,1,,BAO_0000218,,
11982,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,CHEMBL628113,,1,1,,BAO_0000218,,
11983,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,CHEMBL628114,,1,1,,BAO_0000218,,
11984,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,CHEMBL628115,,1,1,,BAO_0000218,,
11985,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,CHEMBL628116,,1,1,,BAO_0000218,,
11986,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,CHEMBL628117,,1,1,,BAO_0000218,,
11987,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,CHEMBL628118,,1,1,,BAO_0000218,,
11988,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,CHEMBL628119,,1,1,,BAO_0000218,,
11989,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,CHEMBL628120,,1,1,,BAO_0000218,,
11990,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,CHEMBL628121,,1,1,,BAO_0000218,,
11991,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,CHEMBL628122,,1,1,,BAO_0000218,,
11992,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,CHEMBL627297,,1,1,,BAO_0000218,,
11993,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,CHEMBL627298,,1,1,,BAO_0000218,,
11994,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,CHEMBL627299,,1,1,,BAO_0000218,,
11995,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,CHEMBL627300,,1,1,,BAO_0000218,,
11996,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,CHEMBL627301,,1,1,,BAO_0000218,,
11997,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,CHEMBL627302,,1,1,,BAO_0000218,,
11998,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,CHEMBL627303,,1,1,,BAO_0000218,,
11999,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,CHEMBL627304,,1,1,,BAO_0000218,,
12000,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,CHEMBL627305,,1,1,,BAO_0000218,,
12001,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,CHEMBL627306,,1,1,,BAO_0000218,,
12002,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,CHEMBL623982,,1,1,,BAO_0000218,,
12003,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,CHEMBL623983,,1,1,,BAO_0000218,,
12004,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,CHEMBL623984,,1,1,,BAO_0000218,,
12005,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,CHEMBL623985,,1,1,,BAO_0000218,,
12006,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,CHEMBL623986,,1,1,,BAO_0000218,,
12007,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,CHEMBL623987,,1,1,,BAO_0000218,,
12008,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,CHEMBL623988,,1,1,,BAO_0000218,,
12009,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,CHEMBL623989,,1,1,,BAO_0000218,,
12010,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,CHEMBL622215,,1,1,,BAO_0000218,,
12011,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,CHEMBL622216,,1,1,,BAO_0000218,,
12012,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,CHEMBL877481,,1,1,,BAO_0000218,,
12013,A,,,,22224,Autocuration,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,CHEMBL622217,,0,1,,BAO_0000218,,
12014,A,,10090.0,,50594,Intermediate,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,CHEMBL622218,,1,1,,BAO_0000218,,
12015,A,,10116.0,,50597,Intermediate,Pharmacokinetic profile AUC was evaluated in rats,,CHEMBL622219,,1,1,,BAO_0000218,,
12016,A,,,,22224,Autocuration,Pharmacokinetic property (Area under curve),,CHEMBL622220,,0,1,,BAO_0000019,,
12017,A,,9615.0,,50588,Intermediate,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,CHEMBL622221,,1,1,,BAO_0000218,,
12018,A,,10090.0,,50594,Intermediate,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,CHEMBL622222,,1,1,,BAO_0000218,,
12019,A,,9615.0,,50588,Intermediate,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,CHEMBL622223,,1,1,,BAO_0000218,,
12020,A,,10090.0,,50594,Intermediate,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,CHEMBL622224,,1,1,,BAO_0000218,,
12021,A,,,,22224,Autocuration,Plasma concentration (AUC) was determined,,CHEMBL622225,,0,1,,BAO_0000019,,
12022,A,,,,22224,Autocuration,Plasma concentration (AUC) was determined; Not detectable,,CHEMBL622226,,0,1,,BAO_0000019,,
12023,A,,10141.0,,50512,Intermediate,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,CHEMBL624154,,1,1,,BAO_0000218,,
12024,A,,10116.0,,50597,Intermediate,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,CHEMBL624155,,1,1,,BAO_0000218,,
12025,A,,10116.0,,50597,Intermediate,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,CHEMBL624156,,1,1,,BAO_0000218,,
12026,A,,10116.0,,50597,Intermediate,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,CHEMBL624157,,1,1,,BAO_0000218,,
12027,A,,10116.0,,50597,Intermediate,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,CHEMBL624158,,1,1,,BAO_0000218,,
12028,A,,10116.0,,50597,Intermediate,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,CHEMBL624159,,1,1,,BAO_0000218,,
12029,A,,10116.0,,50597,Intermediate,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,CHEMBL624160,,1,1,,BAO_0000218,,
12030,A,,10116.0,,50597,Intermediate,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,CHEMBL624161,,1,1,,BAO_0000218,,
12031,A,,10116.0,,50597,Intermediate,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,CHEMBL624162,,1,1,,BAO_0000218,,
12032,A,,9615.0,,50588,Intermediate,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,CHEMBL624163,,1,1,,BAO_0000218,,
12033,A,,10116.0,,50597,Intermediate,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL624164,,1,1,,BAO_0000218,,
12034,A,,10116.0,,50597,Intermediate,The AUC(0-infinity) values in female wistar rats.,,CHEMBL624165,,1,1,,BAO_0000218,,
12035,A,,10116.0,,50597,Intermediate,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL624166,,1,1,,BAO_0000218,,
12036,A,,10116.0,,50597,Intermediate,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,CHEMBL624167,,1,1,,BAO_0000218,,
12037,A,,10116.0,,50597,Intermediate,The AUC(0-t)values in female wistar rats.,,CHEMBL624168,,1,1,,BAO_0000218,,
12038,A,,10116.0,,50597,Intermediate,The Area under the concentration time curve of compound was measured on rats,,CHEMBL624169,,1,1,,BAO_0000218,,
12039,A,,9606.0,,50587,Intermediate,The area under curve (100 mg/kg) administered orally in humans,,CHEMBL624170,,1,1,,BAO_0000218,,
12040,A,,9481.0,,22224,Autocuration,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,CHEMBL624171,,0,1,,BAO_0000218,,
12041,A,,314293.0,,22224,Autocuration,The area under curve (12.5 mg/kg) administered intravenously in monkey,,CHEMBL624172,,0,1,,BAO_0000218,,
12042,A,,9615.0,,50588,Intermediate,The area under curve (15 mg/kg) administered intravenously in dog,,CHEMBL624173,,1,1,,BAO_0000218,,
12043,A,,9606.0,,50587,Intermediate,The area under curve (200 mg/kg) administered orally in humans,,CHEMBL877488,,1,1,,BAO_0000218,,
12044,A,,10116.0,,50597,Intermediate,The area under curve (25 mg/kg) administered intravenously in rat,,CHEMBL624174,,1,1,,BAO_0000218,,
12045,A,,9481.0,,22224,Autocuration,The area under curve (25 mg/kg) administered orally in marmoset,,CHEMBL624175,,0,1,,BAO_0000218,,
12046,A,,314293.0,,22224,Autocuration,The area under curve (25 mg/kg) administered orally in monkey,,CHEMBL624176,,0,1,,BAO_0000218,,
12047,A,,9615.0,,50588,Intermediate,The area under curve (30 mg/kg) administered orally in dog,,CHEMBL624177,,1,1,,BAO_0000218,,
12048,A,,9606.0,,50587,Intermediate,The area under curve (400 mg/kg) administered orally in humans,,CHEMBL624178,,1,1,,BAO_0000218,,
12049,A,,10116.0,,50597,Intermediate,The area under curve (50 mg/kg) administered orally in fasted rat,,CHEMBL624179,,1,1,,BAO_0000218,,
12050,A,,10116.0,,50597,Intermediate,The area under curve (50 mg/kg) administered orally in rat,,CHEMBL627689,,1,1,,BAO_0000218,,
12051,A,,9606.0,,50587,Intermediate,The area under curve (800 mg/kg) administered orally in humans,,CHEMBL627690,,1,1,,BAO_0000218,,
12052,A,,,,22224,Autocuration,The compound was evaluated for area under the curve,,CHEMBL627691,,0,1,,BAO_0000019,,
12053,A,,9481.0,,22224,Autocuration,The compound was evaluated for area under the curve in marmosets,,CHEMBL627692,,0,1,,BAO_0000019,,
12054,A,,9481.0,,22224,Autocuration,The compound was evaluated for area under the curve in marmosets,,CHEMBL627693,,0,1,,BAO_0000019,,
12055,A,,10116.0,,50597,Intermediate,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,CHEMBL627694,,1,1,,BAO_0000218,,
12056,A,,10116.0,,50597,Intermediate,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,CHEMBL627695,,1,1,,BAO_0000218,,
12057,A,,,,22224,Autocuration,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,CHEMBL627696,,0,1,,BAO_0000218,,
12058,A,,10116.0,,50597,Intermediate,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,CHEMBL627697,,1,1,,BAO_0000218,,
12059,A,,10116.0,,50597,Intermediate,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,CHEMBL627698,,1,1,,BAO_0000218,,
12060,A,,10116.0,,50597,Intermediate,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,CHEMBL627699,,1,1,,BAO_0000218,,
12061,A,,10116.0,,50597,Intermediate,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,CHEMBL627700,,1,1,,BAO_0000218,,
12062,A,,10116.0,,50597,Intermediate,Total drug exposure is determined after oral dosing in rats.,,CHEMBL627701,,1,1,,BAO_0000218,,
12063,A,,,,22224,Autocuration,Total drug exposure (5 mg/kg) when administered intravenously,,CHEMBL627702,,0,1,,BAO_0000218,,
12064,A,,,,22224,Autocuration,Total drug exposure (5 mg/kg) when administered orally,,CHEMBL627703,,0,1,,BAO_0000218,,
12065,A,,314293.0,,22224,Autocuration,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,CHEMBL626873,,0,1,,BAO_0000218,,
12066,A,,10116.0,,50597,Intermediate,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,CHEMBL629583,,1,1,,BAO_0000218,,
12067,A,,9615.0,,50588,Intermediate,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,CHEMBL629584,,1,1,,BAO_0000218,,
12068,A,,9615.0,,50588,Intermediate,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,CHEMBL629585,,1,1,,BAO_0000218,,
12069,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL629586,,1,1,,BAO_0000218,955.0,
12070,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL629587,,1,1,,BAO_0000218,955.0,
12071,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL629588,,1,1,,BAO_0000218,,
12072,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL629589,,1,1,,BAO_0000218,,
12073,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL629590,,1,1,,BAO_0000218,,
12074,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL629591,,1,1,,BAO_0000218,,
12075,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL629592,,1,1,,BAO_0000218,,
12076,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL629593,,1,1,,BAO_0000218,,
12077,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL629594,,1,1,,BAO_0000218,,
12078,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL629595,,1,1,,BAO_0000218,948.0,
12079,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL630290,,1,1,,BAO_0000218,948.0,
12080,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL627137,,1,1,,BAO_0000218,948.0,
12081,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL627138,,1,1,,BAO_0000218,948.0,
12082,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL627139,,1,1,,BAO_0000218,948.0,
12083,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL627140,,1,1,,BAO_0000218,948.0,
12084,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL627141,,1,1,,BAO_0000218,948.0,
12085,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL627142,,1,1,,BAO_0000218,2113.0,
12086,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL627143,,1,1,,BAO_0000218,2113.0,
12087,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL874449,,1,1,,BAO_0000218,2113.0,
12088,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL627144,,1,1,,BAO_0000218,2113.0,
12089,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL627145,,1,1,,BAO_0000218,2113.0,
12090,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL627146,,1,1,,BAO_0000218,2113.0,
12091,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL627147,,1,1,,BAO_0000218,2113.0,
12092,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL627148,,1,1,,BAO_0000218,2107.0,
12093,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL627149,,1,1,,BAO_0000218,2048.0,
12094,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL632160,,1,1,,BAO_0000218,2048.0,
12095,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL632161,,1,1,,BAO_0000218,2048.0,
12096,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL632162,,1,1,,BAO_0000218,2048.0,
12097,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL632163,,1,1,,BAO_0000218,2048.0,
12098,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL874469,,1,1,,BAO_0000218,2048.0,
12099,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL627182,,1,1,,BAO_0000218,2048.0,
12100,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",,CHEMBL627183,,1,1,,BAO_0000218,2385.0,
12101,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL627184,,1,1,,BAO_0000218,2385.0,
12102,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL627185,,1,1,,BAO_0000218,2385.0,
12103,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL627186,,1,1,,BAO_0000218,2385.0,
12104,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL627187,,1,1,,BAO_0000218,2385.0,
12105,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL627188,,1,1,,BAO_0000218,2385.0,
12106,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL627189,,1,1,,BAO_0000218,2385.0,
12107,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL627190,,1,1,,BAO_0000218,,
12108,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",,CHEMBL627191,,1,1,,BAO_0000218,2107.0,
12109,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,CHEMBL627192,,1,1,,BAO_0000218,2107.0,
12110,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",,CHEMBL627193,,1,1,,BAO_0000218,2107.0,
12111,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,CHEMBL874590,,1,1,,BAO_0000218,2385.0,
12112,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627194,,1,1,,BAO_0000218,2385.0,
12113,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627195,,1,1,,BAO_0000218,2385.0,
12114,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627196,,1,1,,BAO_0000218,992.0,
12115,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627197,,1,1,,BAO_0000218,992.0,
12116,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627198,,1,1,,BAO_0000218,992.0,
12117,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,,CHEMBL627199,,1,1,,BAO_0000218,992.0,
12118,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627200,,1,1,,BAO_0000218,992.0,
12119,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627201,,1,1,,BAO_0000218,1969.0,
12120,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627202,,1,1,,BAO_0000218,1969.0,
12121,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627203,,1,1,,BAO_0000218,1969.0,
12122,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627204,,1,1,,BAO_0000218,1969.0,
12123,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627205,,1,1,,BAO_0000218,2106.0,
12124,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627206,,1,1,,BAO_0000218,2106.0,
12125,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627207,,1,1,,BAO_0000218,2106.0,
12126,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627208,,1,1,,BAO_0000218,2106.0,
12127,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627209,,1,1,,BAO_0000218,2046.0,
12128,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL627210,,1,1,,BAO_0000218,2046.0,
12129,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL627211,,1,1,,BAO_0000218,2046.0,
12130,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL627212,,1,1,,BAO_0000218,2046.0,
12131,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,CHEMBL627213,,1,1,,BAO_0000218,995.0,
12132,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,CHEMBL626599,,1,1,,BAO_0000218,995.0,
12133,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,CHEMBL626600,,1,1,,BAO_0000218,995.0,
12134,A,In vivo,10116.0,,50597,Intermediate,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,CHEMBL626601,,1,1,,BAO_0000218,995.0,
12135,A,,,,22224,Autocuration,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,CHEMBL627484,,0,1,,BAO_0000019,,
12136,A,,9541.0,,100710,Intermediate,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),,CHEMBL627485,,1,1,,BAO_0000218,1969.0,
12137,A,,9541.0,,100710,Intermediate,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,,CHEMBL628147,,1,1,,BAO_0000218,1969.0,
12138,A,,9541.0,,100710,Intermediate,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,,CHEMBL628148,,1,1,,BAO_0000218,1969.0,
12139,A,,9615.0,,50588,Intermediate,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),,CHEMBL628149,,1,1,,BAO_0000218,1969.0,
12140,A,,9615.0,,50588,Intermediate,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,,CHEMBL628150,,1,1,,BAO_0000218,1969.0,
12141,A,,9615.0,,50588,Intermediate,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,,CHEMBL628318,,1,1,,BAO_0000218,1969.0,
12142,A,,9615.0,,50588,Intermediate,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,,CHEMBL628319,,1,1,,BAO_0000218,1969.0,
12143,A,,9615.0,,50588,Intermediate,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,CHEMBL875609,,1,1,,BAO_0000218,,
12144,A,,,,22224,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,CHEMBL628320,,0,1,,BAO_0000019,,
12145,A,,,,22224,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,CHEMBL628321,,0,1,,BAO_0000019,,
12146,A,,,,22224,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,CHEMBL628322,,0,1,,BAO_0000019,,
12147,A,,,,22224,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,CHEMBL628323,,0,1,,BAO_0000019,,
12148,A,,,,22224,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,CHEMBL628324,,0,1,,BAO_0000019,,
12149,A,,,,22224,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,CHEMBL628325,,0,1,,BAO_0000019,,
12150,A,,,,22224,Autocuration,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,CHEMBL628326,,0,1,,BAO_0000019,,
12151,A,,9615.0,,50588,Intermediate,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",,CHEMBL628327,,1,1,,BAO_0000218,1236.0,
12152,A,,9615.0,,50588,Intermediate,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",,CHEMBL628328,,1,1,,BAO_0000218,1236.0,
12153,A,,9615.0,,50588,Intermediate,"Concentration of compound in blood of dog 1, after administering intravenously",,CHEMBL628329,,1,1,,BAO_0000218,178.0,
12154,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",,CHEMBL628330,,1,1,,BAO_0000218,2107.0,
12155,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",,CHEMBL628331,,1,1,,BAO_0000218,2107.0,
12156,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",,CHEMBL628332,,1,1,,BAO_0000218,2107.0,
12157,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",,CHEMBL628333,,1,1,,BAO_0000218,2107.0,
12158,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",,CHEMBL628334,,1,1,,BAO_0000218,2107.0,
12159,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",,CHEMBL628335,,1,1,,BAO_0000218,2107.0,
12160,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",,CHEMBL628336,,1,1,,BAO_0000218,2107.0,
12161,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,CHEMBL628337,,1,1,,BAO_0000218,2107.0,
12162,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",,CHEMBL628338,,1,1,,BAO_0000218,2107.0,
12163,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",,CHEMBL875610,,1,1,,BAO_0000218,2107.0,
12164,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",,CHEMBL628339,,1,1,,BAO_0000218,2107.0,
12165,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",,CHEMBL628340,,1,1,,BAO_0000218,2107.0,
12166,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",,CHEMBL628341,,1,1,,BAO_0000218,2107.0,
12167,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",,CHEMBL622214,,1,1,,BAO_0000218,2107.0,
12168,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",,CHEMBL623167,,1,1,,BAO_0000218,2107.0,
12169,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",,CHEMBL623168,,1,1,,BAO_0000218,2107.0,
12170,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",,CHEMBL623169,,1,1,,BAO_0000218,2107.0,
12171,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",,CHEMBL623170,,1,1,,BAO_0000218,2107.0,
12172,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",,CHEMBL627224,,1,1,,BAO_0000218,2048.0,
12173,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",,CHEMBL875634,,1,1,,BAO_0000218,2048.0,
12174,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",,CHEMBL627225,,1,1,,BAO_0000218,2048.0,
12175,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",,CHEMBL627226,,1,1,,BAO_0000218,2048.0,
12176,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",,CHEMBL626083,,1,1,,BAO_0000218,2048.0,
12177,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",,CHEMBL626084,,1,1,,BAO_0000218,2048.0,
12178,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",,CHEMBL626085,,1,1,,BAO_0000218,2048.0,
12179,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",,CHEMBL626086,,1,1,,BAO_0000218,2048.0,
12180,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",,CHEMBL626087,,1,1,,BAO_0000218,2048.0,
12181,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",,CHEMBL626088,,1,1,,BAO_0000218,2048.0,
12182,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",,CHEMBL626089,,1,1,,BAO_0000218,2048.0,
12183,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",,CHEMBL626090,,1,1,,BAO_0000218,2048.0,
12184,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",,CHEMBL626091,,1,1,,BAO_0000218,2048.0,
12185,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",,CHEMBL626092,,1,1,,BAO_0000218,2048.0,
12186,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",,CHEMBL626093,,1,1,,BAO_0000218,2048.0,
12187,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",,CHEMBL626094,,1,1,,BAO_0000218,2048.0,
12188,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",,CHEMBL626095,,1,1,,BAO_0000218,2048.0,
12189,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",,CHEMBL626096,,1,1,,BAO_0000218,2048.0,
12190,A,,314293.0,,22224,Autocuration,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,CHEMBL626097,,0,1,,BAO_0000218,,
12191,A,,10116.0,,50597,Intermediate,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,CHEMBL626098,,1,1,,BAO_0000218,,
12192,A,,,,22224,Autocuration,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,,CHEMBL626099,,0,1,,BAO_0000218,1969.0,
12193,A,,,,22224,Autocuration,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,,CHEMBL626100,,0,1,,BAO_0000218,1969.0,
12194,A,,9615.0,,50588,Intermediate,AUC 0-inf in dog,,CHEMBL626101,,1,1,,BAO_0000218,1969.0,
12195,A,,10141.0,,50512,Intermediate,AUC 0-inf in guinea pig,,CHEMBL626102,,1,1,,BAO_0000218,1969.0,
12196,A,,9615.0,,50588,Intermediate,AUC 0-t in dog,,CHEMBL626103,,1,1,,BAO_0000218,1969.0,
12197,A,,10141.0,,50512,Intermediate,AUC 0-t in guinea pig,,CHEMBL628391,,1,1,,BAO_0000218,1969.0,
12198,A,,10116.0,,50597,Intermediate,The compound was tested for brain to plasma partition in rat,,CHEMBL628392,,1,1,,BAO_0000218,,
12199,A,,10116.0,,50597,Intermediate,The compound was tested for brain to plasma partition in rat.,,CHEMBL628393,,1,1,,BAO_0000218,,
12200,A,,,,22224,Autocuration,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,,CHEMBL628394,,0,1,,BAO_0000019,178.0,
12201,A,,9615.0,,50588,Intermediate,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,CHEMBL628395,,1,1,,BAO_0000218,,
12202,A,,314293.0,,22224,Autocuration,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,CHEMBL628396,,0,1,,BAO_0000218,,
12203,A,,9986.0,,50592,Intermediate,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,CHEMBL628397,,1,1,,BAO_0000218,,
12204,A,,10116.0,,50597,Intermediate,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,CHEMBL628398,,1,1,,BAO_0000218,,
12205,A,,9544.0,,50797,Intermediate,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,CHEMBL628399,,1,1,,BAO_0000218,,
12206,A,,9615.0,,50588,Intermediate,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,CHEMBL628400,,1,1,,BAO_0000218,,
12207,A,,10116.0,,50597,Intermediate,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,CHEMBL874907,,1,1,,BAO_0000218,,
12208,A,,,,22224,Autocuration,Area under curve of the compound was determined,,CHEMBL628401,,0,1,,BAO_0000019,,
12209,A,,314293.0,,22224,Autocuration,AUC in monkeys at a dose of 1 mg/kg,,CHEMBL628402,,0,1,,BAO_0000218,1969.0,
12210,A,,10116.0,,50597,Intermediate,AUC in rats at a dose of 1 mg/kg,,CHEMBL628403,,1,1,,BAO_0000218,1969.0,
12211,A,,,,22224,Autocuration,Compound was evaluated for the overall absorbance loss at pH of 2,,CHEMBL628404,,0,1,,BAO_0000019,,
12212,A,,,,22224,Autocuration,Compound was evaluated for the overall absorbance loss at pH of 4,,CHEMBL628405,,0,1,,BAO_0000019,,
12213,A,,,,22224,Autocuration,Compound was evaluated for the overall absorbance loss at pH of 7,,CHEMBL628406,,0,1,,BAO_0000019,,
12214,A,,10116.0,,50597,Intermediate,Compound was evaluated for its absorption in the rats,,CHEMBL628407,,1,1,,BAO_0000218,,
12215,A,,10116.0,,50597,Intermediate,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,CHEMBL628408,,1,1,,BAO_0000218,1088.0,
12216,A,,10116.0,,50597,Intermediate,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,,CHEMBL629171,,1,1,,BAO_0000218,1088.0,
12217,A,,10116.0,,50597,Intermediate,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,CHEMBL629172,,1,1,,BAO_0000218,1088.0,
12218,A,,10116.0,,50597,Intermediate,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,,CHEMBL629173,,1,1,,BAO_0000218,1088.0,
12219,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum,,CHEMBL629174,,1,1,,BAO_0000218,,
12220,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 10-17,,CHEMBL629175,,1,1,,BAO_0000218,,
12221,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 10-18,,CHEMBL629176,,1,1,,BAO_0000218,,
12222,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 10-19,,CHEMBL629177,,1,1,,BAO_0000218,,
12223,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 12-15,,CHEMBL629178,,1,1,,BAO_0000218,,
12224,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 13-19,,CHEMBL631869,,1,1,,BAO_0000218,,
12225,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 14-17,,CHEMBL631870,,1,1,,BAO_0000218,,
12226,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 15-18,,CHEMBL631871,,1,1,,BAO_0000218,,
12227,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 2-5,,CHEMBL631872,,1,1,,BAO_0000218,,
12228,A,,,,22224,Autocuration,In vitro percent permeability into rat ileum; Range is 23-42,,CHEMBL875775,,0,1,,BAO_0000221,2116.0,
12229,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 28-36,,CHEMBL631873,,1,1,,BAO_0000218,,
12230,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 29-35,,CHEMBL631874,,1,1,,BAO_0000218,,
12231,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 46-66,,CHEMBL631875,,1,1,,BAO_0000218,,
12232,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 50-68,,CHEMBL631876,,1,1,,BAO_0000218,,
12233,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; Range is 78-81,,CHEMBL631877,,1,1,,BAO_0000218,,
12234,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,CHEMBL631878,,1,1,,BAO_0000218,,
12235,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; nd indicates not detected,,CHEMBL631879,,1,1,,BAO_0000218,,
12236,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; nt indicates not detected,,CHEMBL631880,,1,1,,BAO_0000218,,
12237,A,,10116.0,,50597,Intermediate,In vitro percent permeability into rat ileum; nt indicates not tested,,CHEMBL631881,,1,1,,BAO_0000218,,
12238,A,,10116.0,,50597,Intermediate,Compound was tested for oral absorption in bile-duct cannulated rats,,CHEMBL631882,,1,1,,BAO_0000218,,
12239,A,,10116.0,,50597,Intermediate,Compound was tested for oral absorption in bile-duct cannulated rats.,,CHEMBL630749,,1,1,,BAO_0000218,,
12240,A,,9606.0,,50587,Intermediate,Oral absorption using Caco-2 cell monolayers.,,CHEMBL630750,,1,1,,BAO_0000218,,
12241,A,,9606.0,,50587,Intermediate,Percent of the drug absorbed after administration to humans was determined,,CHEMBL630253,,1,1,,BAO_0000218,,
12242,A,,10116.0,,50597,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,CHEMBL630254,,1,1,,BAO_0000218,1969.0,
12243,A,,10116.0,,50597,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,CHEMBL630255,,1,1,,BAO_0000218,1969.0,
12244,A,,10116.0,,50597,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,CHEMBL630256,,1,1,,BAO_0000218,1969.0,
12245,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",,CHEMBL875781,,1,1,,BAO_0000218,2107.0,
12246,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,CHEMBL630257,,1,1,,BAO_0000218,2107.0,
12247,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",,CHEMBL630258,,1,1,,BAO_0000218,2107.0,
12248,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,CHEMBL630259,,1,1,,BAO_0000218,,
12249,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",,CHEMBL630260,,1,1,,BAO_0000218,2435.0,
12250,A,,10116.0,,50597,Intermediate,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",,CHEMBL630261,,1,1,,BAO_0000218,2435.0,
12251,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,CHEMBL630262,,1,1,,BAO_0000218,,
12252,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,CHEMBL630263,,1,1,,BAO_0000218,,
12253,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,CHEMBL630264,,1,1,,BAO_0000218,,
12254,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,CHEMBL630265,,1,1,,BAO_0000218,,
12255,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,CHEMBL630266,,1,1,,BAO_0000218,,
12256,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,,CHEMBL630267,,1,1,,BAO_0000218,2113.0,
12257,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,,CHEMBL630268,,1,1,,BAO_0000218,2113.0,
12258,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,CHEMBL630269,,1,1,,BAO_0000218,,
12259,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,CHEMBL630270,,1,1,,BAO_0000218,,
12260,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,,CHEMBL630141,,1,1,,BAO_0000218,2048.0,
12261,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,,CHEMBL630142,,1,1,,BAO_0000218,2048.0,
12262,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,,CHEMBL630143,,1,1,,BAO_0000218,2385.0,
12263,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,,CHEMBL630144,,1,1,,BAO_0000218,2385.0,
12264,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,,CHEMBL630145,,1,1,,BAO_0000218,2367.0,
12265,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,,CHEMBL630146,,1,1,,BAO_0000218,2367.0,
12266,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,CHEMBL630147,,1,1,,BAO_0000218,,
12267,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,CHEMBL630148,,1,1,,BAO_0000218,,
12268,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,CHEMBL630149,,1,1,,BAO_0000218,,
12269,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,,CHEMBL630150,,1,1,,BAO_0000218,2106.0,
12270,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,,CHEMBL630151,,1,1,,BAO_0000218,2106.0,
12271,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,,CHEMBL632031,,1,1,,BAO_0000218,2046.0,
12272,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,,CHEMBL632032,,1,1,,BAO_0000218,2046.0,
12273,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,CHEMBL632033,,1,1,,BAO_0000218,,
12274,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,CHEMBL632034,,1,1,,BAO_0000218,,
12275,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,,CHEMBL632035,,1,1,,BAO_0000218,2385.0,
12276,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,CHEMBL632036,,1,1,,BAO_0000218,,
12277,A,,10116.0,,50597,Intermediate,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,,CHEMBL632037,,1,1,,BAO_0000218,2046.0,
12278,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,CHEMBL632038,,1,1,,BAO_0000218,178.0,
12279,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,CHEMBL632039,,1,1,,BAO_0000218,178.0,
12280,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,CHEMBL632040,,1,1,,BAO_0000218,178.0,
12281,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,CHEMBL632041,,1,1,,BAO_0000218,178.0,
12282,A,,9615.0,,50588,Intermediate,"Concentration of compound in blood of dog 2, after administering intravenously",,CHEMBL632042,,1,1,,BAO_0000218,178.0,
12283,A,,9615.0,,50588,Intermediate,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,CHEMBL632043,,1,1,,BAO_0000218,,
12284,A,,9615.0,,50588,Intermediate,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,CHEMBL632044,,1,1,,BAO_0000218,,
12285,A,,9615.0,,50588,Intermediate,"Concentration of compound in liver of dog 1, after administering intravenously",,CHEMBL632045,,1,1,,BAO_0000218,2107.0,
12286,A,,9615.0,,50588,Intermediate,"Concentration of compound in liver of dog 2, after administering intravenously",,CHEMBL632046,,1,1,,BAO_0000218,2107.0,
12287,A,,9615.0,,50588,Intermediate,"Concentration of compound in lung of dog 1, after administering intravenously",,CHEMBL632047,,1,1,,BAO_0000218,2048.0,
12288,A,,9615.0,,50588,Intermediate,"Concentration of compound in lung of dog 2, after administering intravenously",,CHEMBL632048,,1,1,,BAO_0000218,2048.0,
12289,A,,9615.0,,50588,Intermediate,"Concentration of compound in muscle of dog 1, after administering intravenously",,CHEMBL632049,,1,1,,BAO_0000218,2385.0,
12290,A,,9615.0,,50588,Intermediate,"Concentration of compound in muscle of dog 2, after administering intravenously",,CHEMBL876418,,1,1,,BAO_0000218,2385.0,
12291,A,,9615.0,,50588,Intermediate,"Concentration of compound in spleen of dog 1,after administering intravenously",,CHEMBL632050,,1,1,,BAO_0000218,2106.0,
12292,A,,9615.0,,50588,Intermediate,"Concentration of compound in spleen of dog 2, after administering intravenously",,CHEMBL632051,,1,1,,BAO_0000218,2106.0,
12293,F,,,,22224,Autocuration,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,CHEMBL632052,,0,1,,BAO_0000218,,
12294,F,,,,22224,Autocuration,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,CHEMBL632053,,0,1,,BAO_0000218,,
12295,A,,,,22224,Autocuration,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,CHEMBL632054,,0,1,,BAO_0000218,,
12296,F,,,,22224,Autocuration,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,CHEMBL632055,,0,1,,BAO_0000218,,
12297,F,,,,22224,Autocuration,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,CHEMBL631181,,0,1,,BAO_0000218,,
12298,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,CHEMBL631182,,0,1,,BAO_0000218,,
12299,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,CHEMBL631183,,0,1,,BAO_0000218,,
12300,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,CHEMBL631184,,0,1,,BAO_0000218,,
12301,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,CHEMBL629774,,0,1,,BAO_0000218,,
12302,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,CHEMBL629775,,0,1,,BAO_0000218,,
12303,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,CHEMBL876549,,0,1,,BAO_0000218,,
12304,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,CHEMBL628172,,0,1,,BAO_0000218,,
12305,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,CHEMBL628173,,0,1,,BAO_0000218,,
12306,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,CHEMBL628174,,0,1,,BAO_0000218,,
12307,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,CHEMBL628175,,0,1,,BAO_0000218,,
12308,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,CHEMBL628176,,0,1,,BAO_0000218,,
12309,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,CHEMBL628177,,0,1,,BAO_0000218,,
12310,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,CHEMBL628178,,0,1,,BAO_0000218,,
12311,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,CHEMBL628179,,0,1,,BAO_0000218,,
12312,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,CHEMBL628180,,0,1,,BAO_0000218,,
12313,A,,,,22224,Autocuration,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,CHEMBL628181,,0,1,,BAO_0000218,,
12314,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,CHEMBL628182,,0,1,,BAO_0000218,,
12315,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,CHEMBL628183,,0,1,,BAO_0000218,,
12316,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,CHEMBL628184,,0,1,,BAO_0000218,,
12317,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,CHEMBL628185,,0,1,,BAO_0000218,,
12318,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,CHEMBL875617,,0,1,,BAO_0000218,,
12319,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,CHEMBL628186,,0,1,,BAO_0000218,,
12320,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,CHEMBL628187,,0,1,,BAO_0000218,,
12321,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,CHEMBL628188,,0,1,,BAO_0000218,,
12322,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,CHEMBL628189,,0,1,,BAO_0000218,,
12323,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,CHEMBL628190,,0,1,,BAO_0000218,,
12324,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,CHEMBL628191,,0,1,,BAO_0000218,,
12325,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,CHEMBL626513,,0,1,,BAO_0000218,,
12326,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",,CHEMBL626514,,1,1,,BAO_0000218,2046.0,
12327,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",,CHEMBL626515,,1,1,,BAO_0000218,2046.0,
12328,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",,CHEMBL626516,,1,1,,BAO_0000218,2046.0,
12329,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",,CHEMBL626517,,1,1,,BAO_0000218,2046.0,
12330,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",,CHEMBL626518,,1,1,,BAO_0000218,2046.0,
12331,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",,CHEMBL626519,,1,1,,BAO_0000218,2046.0,
12332,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",,CHEMBL626520,,1,1,,BAO_0000218,2046.0,
12333,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",,CHEMBL626521,,1,1,,BAO_0000218,2046.0,
12334,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",,CHEMBL626522,,1,1,,BAO_0000218,2046.0,
12335,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",,CHEMBL626523,,1,1,,BAO_0000218,2046.0,
12336,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",,CHEMBL626524,,1,1,,BAO_0000218,2046.0,
12337,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",,CHEMBL626688,,1,1,,BAO_0000218,2046.0,
12338,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",,CHEMBL626689,,1,1,,BAO_0000218,2046.0,
12339,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",,CHEMBL626690,,1,1,,BAO_0000218,2046.0,
12340,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",,CHEMBL626691,,1,1,,BAO_0000218,2046.0,
12341,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",,CHEMBL627319,,1,1,,BAO_0000218,2046.0,
12342,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",,CHEMBL624052,,1,1,,BAO_0000218,2046.0,
12343,A,,10116.0,,50597,Intermediate,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",,CHEMBL624053,,1,1,,BAO_0000218,2046.0,
12344,A,,10116.0,,50597,Intermediate,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL624054,,1,1,,BAO_0000218,,
12345,A,,10116.0,,50597,Intermediate,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL624055,,1,1,,BAO_0000218,,
12346,A,,10116.0,,50597,Intermediate,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL624056,,1,1,,BAO_0000218,,
12347,A,,10116.0,,50597,Intermediate,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL624057,,1,1,,BAO_0000218,995.0,
12348,A,,10116.0,,50597,Intermediate,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622281,,1,1,,BAO_0000218,995.0,
12349,A,,10116.0,,50597,Intermediate,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622282,,1,1,,BAO_0000218,995.0,
12350,A,,10116.0,,50597,Intermediate,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622283,,1,1,,BAO_0000218,995.0,
12351,A,,10116.0,,50597,Intermediate,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622284,,1,1,,BAO_0000218,995.0,
12352,A,,10116.0,,50597,Intermediate,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622285,,1,1,,BAO_0000218,995.0,
12353,A,,10116.0,,50597,Intermediate,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,CHEMBL622286,,1,1,,BAO_0000218,995.0,
12354,P,,,,22224,Autocuration,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,CHEMBL622287,,0,1,,BAO_0000100,,
12355,A,,10090.0,,50594,Intermediate,Partition coefficient (logD7.4),,CHEMBL622288,,1,1,,BAO_0000218,,
12356,A,,10090.0,,50594,Intermediate,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,CHEMBL622289,,1,1,,BAO_0000218,,
12357,A,,10090.0,,50594,Intermediate,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,CHEMBL622290,,1,1,,BAO_0000218,955.0,
12358,A,,10090.0,,50594,Intermediate,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,CHEMBL622291,,1,1,,BAO_0000218,,
12359,A,,10090.0,,50594,Intermediate,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,CHEMBL622292,,1,1,,BAO_0000218,955.0,
12360,A,,10090.0,,50594,Intermediate,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,CHEMBL622293,,1,1,,BAO_0000218,,
12361,A,,10090.0,,50594,Intermediate,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,CHEMBL622294,,1,1,,BAO_0000218,955.0,
12362,A,,10090.0,,50594,Intermediate,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,CHEMBL622295,,1,1,,BAO_0000218,,
12363,A,,10116.0,,50597,Intermediate,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,CHEMBL622296,,1,1,,BAO_0000218,955.0,
12364,A,,10116.0,,50597,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,,CHEMBL874409,,1,1,,BAO_0000218,1969.0,
12365,A,,10116.0,,50597,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,CHEMBL622297,,1,1,,BAO_0000218,1969.0,
12366,A,,10116.0,,50597,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,CHEMBL622298,,1,1,,BAO_0000218,1969.0,
12367,A,,10116.0,,50597,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,CHEMBL622299,,1,1,,BAO_0000218,1969.0,
12368,A,,10116.0,,50597,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,CHEMBL622300,,1,1,,BAO_0000218,1969.0,
12369,A,,10116.0,,50597,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,CHEMBL622301,,1,1,,BAO_0000218,1969.0,
12370,A,,10116.0,,50597,Intermediate,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,CHEMBL622302,,1,1,,BAO_0000218,1969.0,
12371,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,CHEMBL622303,,1,1,,BAO_0000218,1969.0,
12372,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,CHEMBL622304,,1,1,,BAO_0000218,1969.0,
12373,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,,CHEMBL622305,,1,1,,BAO_0000218,1969.0,
12374,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,CHEMBL622306,,1,1,,BAO_0000218,1969.0,
12375,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,,CHEMBL626864,,1,1,,BAO_0000218,1969.0,
12376,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,CHEMBL626865,,1,1,,BAO_0000218,1969.0,
12377,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,,CHEMBL626866,,1,1,,BAO_0000218,1969.0,
12378,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,CHEMBL626867,,1,1,,BAO_0000218,1969.0,
12379,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,CHEMBL626868,,1,1,,BAO_0000218,1969.0,
12380,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,,CHEMBL626869,,1,1,,BAO_0000218,1969.0,
12381,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,CHEMBL626870,,1,1,,BAO_0000218,1969.0,
12382,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,,CHEMBL626871,,1,1,,BAO_0000218,1969.0,
12383,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,CHEMBL626872,,1,1,,BAO_0000218,1969.0,
12384,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,CHEMBL632185,,1,1,,BAO_0000218,1969.0,
12385,A,,10116.0,,50597,Intermediate,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,,CHEMBL632186,,1,1,,BAO_0000218,1969.0,
12386,A,,,,22224,Autocuration,Amount of acetic acid produced by the compound,,CHEMBL629310,,0,1,,BAO_0000019,,
12387,A,,,,22224,Autocuration,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,CHEMBL629311,,0,1,,BAO_0000019,,
12388,A,,10116.0,,50597,Intermediate,Log of (Cbrain/Cblood) in rats,,CHEMBL629312,,1,1,,BAO_0000218,,
12389,A,,,,22224,Autocuration,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,CHEMBL629313,,0,1,,BAO_0000221,,
12390,A,,,,22224,Autocuration,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,CHEMBL629314,,0,1,,BAO_0000221,,
12391,A,,,,22224,Autocuration,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,CHEMBL629315,,0,1,,BAO_0000221,,
12392,B,,,,22224,Autocuration,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,CHEMBL629316,,0,1,,BAO_0000219,,
12393,A,,,,22224,Autocuration,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,CHEMBL629317,,0,1,,BAO_0000221,,
12394,A,,,,22224,Autocuration,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,CHEMBL629318,,0,1,,BAO_0000019,,
12395,A,,,,22224,Autocuration,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,CHEMBL877497,,0,1,,BAO_0000019,,
12396,A,,,,22224,Autocuration,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,CHEMBL629319,,0,1,,BAO_0000019,,
12397,A,,,,22224,Autocuration,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,CHEMBL629320,,0,1,,BAO_0000019,,
12398,A,,,,22224,Autocuration,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,CHEMBL629496,,0,1,,BAO_0000019,,
12399,A,,,,22224,Autocuration,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,CHEMBL629497,,0,1,,BAO_0000019,,
12400,A,,,,22224,Autocuration,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,CHEMBL629498,,0,1,,BAO_0000019,,
12401,A,,,,22224,Autocuration,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,CHEMBL629499,,0,1,,BAO_0000019,,
12402,A,,,,22224,Autocuration,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,CHEMBL629500,,0,1,,BAO_0000019,,
12403,A,,,,22224,Autocuration,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,CHEMBL629501,,0,1,,BAO_0000019,,
12404,A,,,,22224,Autocuration,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,CHEMBL629502,,0,1,,BAO_0000019,,
12405,F,In vivo,,,22224,Autocuration,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,CHEMBL629503,,0,1,,BAO_0000218,,
12406,A,,9615.0,,50588,Intermediate,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,CHEMBL629504,,1,1,,BAO_0000218,,
12407,A,,,,22224,Autocuration,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,CHEMBL629505,,0,1,,BAO_0000019,,
12408,A,,,,22224,Autocuration,Compound was evaluated for total body clearance,,CHEMBL629506,,0,1,,BAO_0000019,,
12409,A,,,,22224,Autocuration,Compound was evaluated for volume of distribution at steady state,,CHEMBL629507,,0,1,,BAO_0000019,,
12410,A,,,,22224,Autocuration,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,CHEMBL877498,,0,1,,BAO_0000019,,
12411,A,,,,22224,Autocuration,Percentage of the diamine which is monoprotonated at pH 7.4,,CHEMBL629508,,0,1,,BAO_0000019,,
12412,A,,,,22224,Autocuration,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,CHEMBL629509,,0,1,,BAO_0000019,,
12413,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,CHEMBL629510,,1,1,,BAO_0000218,178.0,
12414,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,CHEMBL629511,,1,1,,BAO_0000218,178.0,
12415,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,CHEMBL629512,,1,1,,BAO_0000218,178.0,
12416,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,CHEMBL629513,,1,1,,BAO_0000218,178.0,
12417,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,CHEMBL629514,,1,1,,BAO_0000218,178.0,
12418,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,CHEMBL628447,,1,1,,BAO_0000218,178.0,
12419,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,CHEMBL628448,,1,1,,BAO_0000218,178.0,
12420,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,CHEMBL628449,,1,1,,BAO_0000218,178.0,
12421,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,CHEMBL631119,,1,1,,BAO_0000218,178.0,
12422,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,CHEMBL631120,,1,1,,BAO_0000218,178.0,
12423,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,CHEMBL631121,,1,1,,BAO_0000218,178.0,
12424,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,,CHEMBL874458,,1,1,,BAO_0000218,178.0,
12425,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,CHEMBL631122,,1,1,,BAO_0000218,178.0,
12426,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,CHEMBL631123,,1,1,,BAO_0000218,178.0,
12427,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,CHEMBL631124,,1,1,,BAO_0000218,178.0,
12428,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,CHEMBL631125,,1,1,,BAO_0000218,178.0,
12429,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,CHEMBL631290,,1,1,,BAO_0000218,178.0,
12430,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,CHEMBL631291,,1,1,,BAO_0000218,178.0,
12431,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,CHEMBL631292,,1,1,,BAO_0000218,178.0,
12432,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,CHEMBL631293,,1,1,,BAO_0000218,178.0,
12433,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,CHEMBL631294,,1,1,,BAO_0000218,178.0,
12434,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,CHEMBL631295,,1,1,,BAO_0000218,178.0,
12435,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,CHEMBL631296,,1,1,,BAO_0000218,178.0,
12436,A,,10116.0,,50597,Intermediate,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,CHEMBL631297,,1,1,,BAO_0000218,178.0,
12437,A,,,,22224,Autocuration,Maximum biodistribution (Bmax) was determined.,,CHEMBL631298,,0,1,,BAO_0000218,,
12438,A,,10090.0,,50594,Intermediate,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,CHEMBL631299,,1,1,,BAO_0000218,,
12439,A,,10090.0,,50594,Intermediate,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,CHEMBL631300,,1,1,,BAO_0000218,,
12440,A,,10090.0,,50594,Intermediate,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,CHEMBL631301,,1,1,,BAO_0000218,,
12441,A,,10090.0,,50594,Intermediate,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,CHEMBL630291,,1,1,,BAO_0000218,,
12442,A,,,,22224,Autocuration,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,CHEMBL630292,,0,1,,BAO_0000218,,
12443,A,,,,22224,Autocuration,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,CHEMBL630293,,0,1,,BAO_0000218,,
12444,A,,,,22224,Autocuration,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,CHEMBL630294,,0,1,,BAO_0000218,,
12445,A,,,,22224,Autocuration,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,CHEMBL630295,,0,1,,BAO_0000218,,
12446,A,,,,22224,Autocuration,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,CHEMBL630296,,0,1,,BAO_0000218,,
12447,A,,,,22224,Autocuration,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,CHEMBL626782,,0,1,,BAO_0000218,,
12448,A,,,,22224,Autocuration,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,CHEMBL626783,,0,1,,BAO_0000218,,
12449,A,,,,22224,Autocuration,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,CHEMBL626784,,0,1,,BAO_0000218,,
12450,A,,,,22224,Autocuration,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,CHEMBL626785,,0,1,,BAO_0000218,,
12451,A,,,,22224,Autocuration,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,CHEMBL626786,,0,1,,BAO_0000218,,
12452,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,CHEMBL626787,,0,1,,BAO_0000218,,
12453,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,CHEMBL626788,,0,1,,BAO_0000218,,
12454,A,,,,22224,Autocuration,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,CHEMBL625927,,0,1,,BAO_0000218,,
12455,A,,10116.0,,50597,Intermediate,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL625928,,1,1,,BAO_0000218,178.0,
12456,A,,10116.0,,50597,Intermediate,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL625929,,1,1,,BAO_0000218,178.0,
12457,A,,10116.0,,50597,Intermediate,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,CHEMBL625930,,1,1,,BAO_0000218,178.0,
12458,A,,10116.0,,50597,Intermediate,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",,CHEMBL625931,,1,1,,BAO_0000218,178.0,
12459,A,,10116.0,,50597,Intermediate,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,,CHEMBL627230,,1,1,,BAO_0000218,178.0,
12460,A,,10116.0,,50597,Intermediate,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627231,,1,1,,BAO_0000218,178.0,
12461,A,,10116.0,,50597,Intermediate,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL627232,,1,1,,BAO_0000218,178.0,
12462,A,,10116.0,,50597,Intermediate,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,CHEMBL627233,,1,1,,BAO_0000218,178.0,
12463,A,,10116.0,,50597,Intermediate,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL875470,,1,1,,BAO_0000218,178.0,
12464,A,,10116.0,,50597,Intermediate,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627234,,1,1,,BAO_0000218,178.0,
12465,A,,10116.0,,50597,Intermediate,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627235,,1,1,,BAO_0000218,178.0,
12466,A,,10116.0,,50597,Intermediate,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627236,,1,1,,BAO_0000218,178.0,
12467,A,,10116.0,,50597,Intermediate,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627237,,1,1,,BAO_0000218,178.0,
12468,A,,10116.0,,50597,Intermediate,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627238,,1,1,,BAO_0000218,178.0,
12469,A,,10116.0,,50597,Intermediate,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627239,,1,1,,BAO_0000218,178.0,
12470,A,,10116.0,,50597,Intermediate,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627240,,1,1,,BAO_0000218,178.0,
12471,A,,10116.0,,50597,Intermediate,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627241,,1,1,,BAO_0000218,178.0,
12472,A,,10116.0,,50597,Intermediate,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627242,,1,1,,BAO_0000218,178.0,
12473,A,,10116.0,,50597,Intermediate,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,,CHEMBL627243,,1,1,,BAO_0000218,178.0,
12474,A,,10116.0,,50597,Intermediate,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL627244,,1,1,,BAO_0000218,178.0,
12475,A,,10116.0,,50597,Intermediate,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627245,,1,1,,BAO_0000218,178.0,
12476,A,,10116.0,,50597,Intermediate,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627246,,1,1,,BAO_0000218,178.0,
12477,A,,10116.0,,50597,Intermediate,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627247,,1,1,,BAO_0000218,178.0,
12478,A,,10116.0,,50597,Intermediate,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627248,,1,1,,BAO_0000218,178.0,
12479,A,,10116.0,,50597,Intermediate,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627249,,1,1,,BAO_0000218,178.0,
12480,A,,10116.0,,50597,Intermediate,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL625569,,1,1,,BAO_0000218,178.0,
12481,A,,10116.0,,50597,Intermediate,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL625570,,1,1,,BAO_0000218,178.0,
12482,A,,10116.0,,50597,Intermediate,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL625571,,1,1,,BAO_0000218,178.0,
12483,A,,10116.0,,50597,Intermediate,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL625572,,1,1,,BAO_0000218,178.0,
12484,A,,10116.0,,50597,Intermediate,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL625573,,1,1,,BAO_0000218,178.0,
12485,A,,10116.0,,50597,Intermediate,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,,CHEMBL625574,,1,1,,BAO_0000218,178.0,
12486,A,,10116.0,,50597,Intermediate,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,CHEMBL626245,,1,1,,BAO_0000218,178.0,
12487,A,,10116.0,,50597,Intermediate,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL626246,,1,1,,BAO_0000218,178.0,
12488,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,CHEMBL626247,,0,1,,BAO_0000218,,
12489,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,CHEMBL626248,,0,1,,BAO_0000218,,
12490,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,CHEMBL626249,,0,1,,BAO_0000218,,
12491,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,CHEMBL626420,,0,1,,BAO_0000218,,
12492,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,CHEMBL626421,,0,1,,BAO_0000218,,
12493,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,CHEMBL626422,,0,1,,BAO_0000218,,
12494,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,CHEMBL626423,,0,1,,BAO_0000218,,
12495,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,CHEMBL626424,,0,1,,BAO_0000218,,
12496,A,,9615.0,,50588,Intermediate,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,CHEMBL626425,,1,1,,BAO_0000218,,
12497,A,,10116.0,,50597,Intermediate,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,CHEMBL875476,,1,1,,BAO_0000218,,
12498,A,,9541.0,,100710,Intermediate,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,CHEMBL626426,,1,1,,BAO_0000218,,
12499,P,,,,22224,Autocuration,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,CHEMBL626427,,0,1,,BAO_0000100,,
12500,P,,,,22224,Autocuration,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,CHEMBL626428,,0,1,,BAO_0000100,,
12501,A,,,,22224,Autocuration,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,CHEMBL626429,,0,1,,BAO_0000019,,
12502,A,,,,22224,Autocuration,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,,CHEMBL625025,,0,1,,BAO_0000019,1088.0,
12503,A,,10116.0,,50597,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL625026,,1,1,,BAO_0000218,178.0,
12504,A,,10116.0,,50597,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL625027,,1,1,,BAO_0000218,178.0,
12505,A,,10116.0,,50597,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL874410,,1,1,,BAO_0000218,178.0,
12506,A,,10116.0,,50597,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL625028,,1,1,,BAO_0000218,178.0,
12507,A,,10116.0,,50597,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL625029,,1,1,,BAO_0000218,178.0,
12508,A,,10116.0,,50597,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL625030,,1,1,,BAO_0000218,178.0,
12509,A,,10116.0,,50597,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL625031,,1,1,,BAO_0000218,178.0,
12510,A,,10116.0,,50597,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL625032,,1,1,,BAO_0000218,178.0,
12511,A,,10116.0,,50597,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL625033,,1,1,,BAO_0000218,178.0,
12512,A,,10116.0,,50597,Intermediate,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL625034,,1,1,,BAO_0000218,178.0,
12513,A,,10116.0,,50597,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL624872,,1,1,,BAO_0000218,948.0,
12514,A,,10116.0,,50597,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL624873,,1,1,,BAO_0000218,948.0,
12515,A,,10116.0,,50597,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL624874,,1,1,,BAO_0000218,948.0,
12516,A,,10116.0,,50597,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL624875,,1,1,,BAO_0000218,948.0,
12517,A,,10116.0,,50597,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL624876,,1,1,,BAO_0000218,948.0,
12518,A,,10116.0,,50597,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL624877,,1,1,,BAO_0000218,948.0,
12519,A,,10116.0,,50597,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL624878,,1,1,,BAO_0000218,948.0,
12520,A,,10116.0,,50597,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL624879,,1,1,,BAO_0000218,948.0,
12521,A,,10116.0,,50597,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL624880,,1,1,,BAO_0000218,948.0,
12522,A,,10116.0,,50597,Intermediate,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,,CHEMBL624881,,1,1,,BAO_0000218,948.0,
12523,A,,10116.0,,50597,Intermediate,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",,CHEMBL624882,,1,1,,BAO_0000218,948.0,
12524,A,,10116.0,,50597,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL624883,,1,1,,BAO_0000218,2113.0,
12525,A,,10116.0,,50597,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL624884,,1,1,,BAO_0000218,2113.0,
12526,A,,10116.0,,50597,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL624885,,1,1,,BAO_0000218,2113.0,
12527,A,,10116.0,,50597,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL624886,,1,1,,BAO_0000218,2113.0,
12528,A,,10116.0,,50597,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL624887,,1,1,,BAO_0000218,2113.0,
12529,A,,10116.0,,50597,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL624888,,1,1,,BAO_0000218,2113.0,
12530,A,,10116.0,,50597,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL624889,,1,1,,BAO_0000218,2113.0,
12531,A,,10116.0,,50597,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL624890,,1,1,,BAO_0000218,2113.0,
12532,A,,10116.0,,50597,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL621964,,1,1,,BAO_0000218,2113.0,
12533,A,,10116.0,,50597,Intermediate,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL621965,,1,1,,BAO_0000218,2113.0,
12534,A,,10116.0,,50597,Intermediate,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL621966,,1,1,,BAO_0000218,2107.0,
12535,A,,10116.0,,50597,Intermediate,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL621967,,1,1,,BAO_0000218,2107.0,
12536,A,,10116.0,,50597,Intermediate,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL622164,,1,1,,BAO_0000218,2107.0,
12537,A,,,,22224,Autocuration,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,CHEMBL623097,,0,1,,BAO_0000019,,
12538,A,,,,22224,Autocuration,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,CHEMBL623098,,0,1,,BAO_0000019,,
12539,A,,,,22224,Autocuration,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,CHEMBL623099,,0,1,,BAO_0000019,,
12540,A,,,,22224,Autocuration,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,CHEMBL623100,,0,1,,BAO_0000019,,
12541,A,,10116.0,,50597,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,CHEMBL628673,,1,1,,BAO_0000218,,
12542,A,,10116.0,,50597,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,CHEMBL628674,,1,1,,BAO_0000218,,
12543,A,,10116.0,,50597,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,CHEMBL628675,,1,1,,BAO_0000218,,
12544,A,,10116.0,,50597,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,CHEMBL627644,,1,1,,BAO_0000218,,
12545,A,,10116.0,,50597,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,CHEMBL627645,,1,1,,BAO_0000218,,
12546,A,,10116.0,,50597,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,CHEMBL627646,,1,1,,BAO_0000218,,
12547,A,,10116.0,,50597,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,CHEMBL627647,,1,1,,BAO_0000218,,
12548,A,,10116.0,,50597,Intermediate,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,CHEMBL627648,,1,1,,BAO_0000218,,
12549,A,,10116.0,,50597,Intermediate,Free level in rat plasma,,CHEMBL627649,,1,1,,BAO_0000218,,
12550,A,,,,22224,Autocuration,Level reaching in blood plasma of rat or human was determined,,CHEMBL628313,,0,1,,BAO_0000019,,
12551,A,,10116.0,,50597,Intermediate,Log (Cbrain/Cblood) in rats,,CHEMBL628314,,1,1,,BAO_0000218,,
12552,A,,,,22224,Autocuration,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,CHEMBL628315,,0,1,,BAO_0000019,,
12553,A,,,,22224,Autocuration,Mean percentage of compound transport through membrane; expressed as membrane transport,,CHEMBL628316,,0,1,,BAO_0000019,,
12554,A,,,,22224,Autocuration,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,CHEMBL628317,,0,1,,BAO_0000218,,
12555,A,,,,22224,Autocuration,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,CHEMBL628473,,0,1,,BAO_0000019,,
12556,A,,,,22224,Autocuration,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,CHEMBL628474,,0,1,,BAO_0000019,,
12557,A,,,,22224,Autocuration,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,CHEMBL628475,,0,1,,BAO_0000019,,
12558,A,,,,22224,Autocuration,Net water uptake by a carrier mediated transport (%cm) mechanism,,CHEMBL628476,,0,1,,BAO_0000019,,
12559,A,,314293.0,,22224,Autocuration,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,CHEMBL628477,,0,1,,BAO_0000218,,
12560,A,,9669.0,,50506,Intermediate,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,CHEMBL628478,,1,1,,BAO_0000218,,
12561,A,,9669.0,,50506,Intermediate,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,CHEMBL628479,,1,1,,BAO_0000218,,
12562,A,,314293.0,,22224,Autocuration,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,CHEMBL628480,,0,1,,BAO_0000218,,
12563,A,,314293.0,,22224,Autocuration,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,CHEMBL628481,,0,1,,BAO_0000218,,
12564,A,,10116.0,,50597,Intermediate,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,CHEMBL628482,,1,1,,BAO_0000218,,
12565,A,,10116.0,,50597,Intermediate,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,CHEMBL628483,,1,1,,BAO_0000218,,
12566,A,,10116.0,,50597,Intermediate,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,CHEMBL628484,,1,1,,BAO_0000218,1969.0,
12567,A,,10116.0,,50597,Intermediate,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,CHEMBL628485,,1,1,,BAO_0000218,1969.0,
12568,A,,9541.0,,100710,Intermediate,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",,CHEMBL628486,,1,1,,BAO_0000218,1969.0,
12569,A,,9606.0,,50587,Intermediate,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",,CHEMBL628487,,1,1,,BAO_0000218,1969.0,
12570,A,,10116.0,,50597,Intermediate,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,CHEMBL628488,,1,1,,BAO_0000218,1969.0,
12571,A,,10116.0,,50597,Intermediate,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,CHEMBL628489,,1,1,,BAO_0000218,1969.0,
12572,A,,10116.0,,50597,Intermediate,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,CHEMBL628490,,1,1,,BAO_0000218,1969.0,
12573,A,,9541.0,,100710,Intermediate,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,CHEMBL628491,,1,1,,BAO_0000218,,
12574,A,,9541.0,,100710,Intermediate,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,CHEMBL877507,,1,1,,BAO_0000218,,
12575,A,,,,22224,Autocuration,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,CHEMBL628492,,0,1,,BAO_0000218,,
12576,A,,314293.0,,22224,Autocuration,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,CHEMBL628493,,0,1,,BAO_0000019,,
12577,A,,314293.0,,22224,Autocuration,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,CHEMBL628494,,0,1,,BAO_0000019,,
12578,A,,314293.0,,22224,Autocuration,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,CHEMBL628495,,0,1,,BAO_0000019,,
12579,A,,9606.0,,50587,Intermediate,Permeability in Caco-2 assay at 10E-6,,CHEMBL628496,,1,1,,BAO_0000218,,
12580,A,,,,22224,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,CHEMBL628497,,0,1,,BAO_0000218,955.0,
12581,A,,,,22224,Autocuration,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,CHEMBL628498,,0,1,,BAO_0000218,955.0,
12582,A,,,,22224,Autocuration,Plasma protein binding was determined,,CHEMBL628499,,0,1,,BAO_0000019,,
12583,A,,,,22224,Autocuration,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,CHEMBL627656,,0,1,,BAO_0000218,,
12584,A,,,,22224,Autocuration,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,CHEMBL627657,,0,1,,BAO_0000218,,
12585,A,,,,22224,Autocuration,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,CHEMBL626808,,0,1,,BAO_0000218,,
12586,A,,,,22224,Autocuration,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,CHEMBL626809,,0,1,,BAO_0000218,,
12587,A,,,,22224,Autocuration,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,CHEMBL626810,,0,1,,BAO_0000218,,
12588,A,,,,22224,Autocuration,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,CHEMBL626811,,0,1,,BAO_0000218,,
12589,A,,,,22224,Autocuration,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,CHEMBL874465,,0,1,,BAO_0000218,,
12590,A,,,,22224,Autocuration,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,CHEMBL626812,,0,1,,BAO_0000218,,
12591,A,,,,22224,Autocuration,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,CHEMBL626813,,0,1,,BAO_0000218,,
12592,A,,,,22224,Autocuration,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,CHEMBL626814,,0,1,,BAO_0000218,,
12593,A,,,,22224,Autocuration,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,CHEMBL626815,,0,1,,BAO_0000019,,
12594,A,,,,22224,Autocuration,Partition coefficient (logP),,CHEMBL628566,,0,1,,BAO_0000019,,
12595,P,,,,22229,Autocuration,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,CHEMBL628567,,0,1,,BAO_0000100,,
12596,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL628568,,0,1,,BAO_0000100,,
12597,A,In vivo,9615.0,,50588,Intermediate,C max in dog,,CHEMBL628569,,1,1,,BAO_0000218,,
12598,A,In vivo,10141.0,,50512,Intermediate,C max in guinea pig,,CHEMBL628570,,1,1,,BAO_0000218,,
12599,A,In vivo,,,22224,Autocuration,C max value was evaluated,,CHEMBL628571,,0,1,,BAO_0000218,,
12600,A,In vivo,,,22224,Autocuration,Cmax value after oral dose of 0.1 mg//kg,,CHEMBL628572,,0,1,,BAO_0000218,,
12601,A,In vivo,,,22224,Autocuration,Cmax value after oral dose of 0.3 mg/kg,,CHEMBL628573,,0,1,,BAO_0000218,,
12602,A,In vivo,,,22224,Autocuration,Cmax value after oral dose of 1 mg/kg,,CHEMBL628574,,0,1,,BAO_0000218,,
12603,A,In vivo,,,22224,Autocuration,Cmax value after oral dose of 10 mg/kg,,CHEMBL628575,,0,1,,BAO_0000218,,
12604,A,In vivo,,,22224,Autocuration,Cmax value after oral dose of 23.4 mg/kg,,CHEMBL628576,,0,1,,BAO_0000218,,
12605,A,In vivo,,,22224,Autocuration,Cmax value after oral dose of 3 mg/kg,,CHEMBL628577,,0,1,,BAO_0000218,,
12606,A,In vivo,,,22224,Autocuration,Cmax value after oral dose of 3.87 mg/kg,,CHEMBL628578,,0,1,,BAO_0000218,,
12607,A,In vivo,9615.0,,50588,Intermediate,Cmax value in female Beagle dogs,,CHEMBL874466,,1,1,,BAO_0000218,,
12608,A,In vivo,10116.0,,50597,Intermediate,Cmax value in male rats,,CHEMBL628579,,1,1,,BAO_0000218,,
12609,A,In vivo,10116.0,,50597,Intermediate,Cmax value in rat plasma when administered 20 mg/kg perorally,,CHEMBL628580,,1,1,,BAO_0000218,1969.0,
12610,A,In vivo,9615.0,,50588,Intermediate,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,CHEMBL628581,,1,1,,BAO_0000218,1969.0,
12611,A,In vivo,9615.0,,50588,Intermediate,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,CHEMBL628582,,1,1,,BAO_0000218,1969.0,
12612,A,,9615.0,,50588,Intermediate,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,CHEMBL628583,,1,1,,BAO_0000218,,
12613,A,,314293.0,,22224,Autocuration,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,CHEMBL625782,,0,1,,BAO_0000218,,
12614,A,,9986.0,,50592,Intermediate,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,CHEMBL625783,,1,1,,BAO_0000218,,
12615,A,,10116.0,,50597,Intermediate,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,CHEMBL625784,,1,1,,BAO_0000218,,
12616,A,,9544.0,,50797,Intermediate,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,,CHEMBL625785,,1,1,,BAO_0000218,1969.0,
12617,A,,10116.0,,50597,Intermediate,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,CHEMBL625786,,1,1,,BAO_0000218,,
12618,A,,,,22224,Autocuration,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,CHEMBL874467,,0,1,,BAO_0000019,,
12619,A,,9615.0,,50588,Intermediate,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,CHEMBL625787,,1,1,,BAO_0000218,,
12620,A,,12721.0,,50677,Intermediate,cytotoxicity against HIV protease enzyme.,,CHEMBL625964,,1,1,,BAO_0000218,,
12621,A,,10090.0,,50594,Intermediate,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,CHEMBL625965,,1,1,,BAO_0000218,,
12622,A,,10090.0,,50594,Intermediate,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,CHEMBL625966,,1,1,,BAO_0000218,,
12623,A,In vivo,9615.0,,50588,Intermediate,The plasma clearance in dog.,,CHEMBL625967,,1,1,,BAO_0000218,1969.0,
12624,A,In vivo,10116.0,,50597,Intermediate,The plasma clearance in rat.,,CHEMBL625968,,1,1,,BAO_0000218,1969.0,
12625,A,In vivo,10116.0,,50597,Intermediate,Clearance from plasma in male Sprague-Dawley rats,,CHEMBL625969,,1,1,,BAO_0000218,1969.0,
12626,A,In vivo,9541.0,,100710,Intermediate,Clearance from plasma in male cynomolgus monkeys,,CHEMBL625970,,1,1,,BAO_0000218,1969.0,
12627,A,In vivo,9615.0,,50588,Intermediate,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",,CHEMBL625971,,1,1,,BAO_0000218,1969.0,
12628,A,In vivo,9615.0,,50588,Intermediate,Clearance of compound in dog plasma,,CHEMBL625972,,1,1,,BAO_0000218,1969.0,
12629,A,In vivo,9606.0,,50587,Intermediate,Clearance of compound in human plasma,,CHEMBL625973,,1,1,,BAO_0000218,1969.0,
12630,A,In vivo,9615.0,,50588,Intermediate,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,CHEMBL625974,,1,1,,BAO_0000218,,
12631,A,In vivo,9615.0,,50588,Intermediate,Clearance of compound when administered intravenously as an individual dose to a single dog.,,CHEMBL625975,,1,1,,BAO_0000218,,
12632,A,In vivo,9615.0,,50588,Intermediate,"Clearance (10 mg/kg, intravenously) in dog plasma",,CHEMBL625976,,1,1,,BAO_0000218,1969.0,
12633,A,In vivo,9615.0,,50588,Intermediate,Clearance value in dog,,CHEMBL625977,,1,1,,BAO_0000218,,
12634,A,In vivo,10141.0,,50512,Intermediate,Clearance value in guinea pig,,CHEMBL625978,,1,1,,BAO_0000218,,
12635,A,In vivo,10116.0,,50597,Intermediate,Clearance values in rats after iv administration.,,CHEMBL874468,,1,1,,BAO_0000218,,
12636,A,In vivo,,,22224,Autocuration,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,,CHEMBL625421,,0,1,,BAO_0000218,1969.0,
12637,A,In vivo,9986.0,,50592,Intermediate,In vivo clearance (5 mg/kg) was determined in rabbits,,CHEMBL625422,,1,1,,BAO_0000218,,
12638,A,In vivo,10116.0,,50597,Intermediate,Plasma Clearance rate was determined for the compound in rats,,CHEMBL625423,,1,1,,BAO_0000218,,
12639,A,In vivo,9520.0,,22224,Autocuration,Plasma Clearance rate was determined for the compound in squirrel monkeys,,CHEMBL625424,,0,1,,BAO_0000218,,
12640,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance in rat,,CHEMBL625425,,1,1,,BAO_0000218,,
12641,A,In vivo,,,22224,Autocuration,Plasma clearance of the compound,,CHEMBL625426,,0,1,,BAO_0000218,,
12642,A,In vivo,10141.0,,50512,Intermediate,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,CHEMBL625427,,1,1,,BAO_0000218,,
12643,A,In vivo,10141.0,,50512,Intermediate,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,CHEMBL625428,,1,1,,BAO_0000218,,
12644,A,In vivo,,,22224,Autocuration,Plasma clearance was determined,,CHEMBL625429,,0,1,,BAO_0000218,,
12645,A,In vivo,9615.0,,50588,Intermediate,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,CHEMBL625430,,1,1,,BAO_0000218,,
12646,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance rate was determined for the compound in rats,,CHEMBL625431,,1,1,,BAO_0000218,,
12647,A,In vivo,9520.0,,22224,Autocuration,Plasma clearance rate was determined for the compound in squirrel monkeys,,CHEMBL627307,,0,1,,BAO_0000218,,
12648,A,In vivo,,,22224,Autocuration,Slow clearance (CL) was determined,,CHEMBL627308,,0,1,,BAO_0000218,,
12649,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,CHEMBL627309,,0,1,,BAO_0000218,,
12650,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,CHEMBL627310,,0,1,,BAO_0000218,,
12651,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,CHEMBL627311,,0,1,,BAO_0000218,,
12652,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,CHEMBL627312,,0,1,,BAO_0000218,,
12653,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,CHEMBL627313,,0,1,,BAO_0000218,,
12654,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,CHEMBL627314,,0,1,,BAO_0000218,,
12655,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,CHEMBL627315,,0,1,,BAO_0000218,,
12656,A,,,,22224,Autocuration,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,CHEMBL627316,,0,1,,BAO_0000218,,
12657,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,CHEMBL627317,,0,1,,BAO_0000218,,
12658,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,CHEMBL627318,,0,1,,BAO_0000218,,
12659,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,CHEMBL627999,,0,1,,BAO_0000218,,
12660,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,CHEMBL628000,,0,1,,BAO_0000218,,
12661,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,CHEMBL628001,,0,1,,BAO_0000218,,
12662,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,CHEMBL628002,,0,1,,BAO_0000218,,
12663,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,CHEMBL625610,,0,1,,BAO_0000218,,
12664,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,CHEMBL625611,,0,1,,BAO_0000218,,
12665,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,CHEMBL625612,,0,1,,BAO_0000218,,
12666,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,CHEMBL625613,,0,1,,BAO_0000218,,
12667,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,CHEMBL875479,,0,1,,BAO_0000218,,
12668,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,CHEMBL625614,,0,1,,BAO_0000218,,
12669,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,CHEMBL625615,,0,1,,BAO_0000218,,
12670,A,,,,22224,Autocuration,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,CHEMBL626302,,0,1,,BAO_0000218,,
12671,A,,10116.0,,50597,Intermediate,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL626303,,1,1,,BAO_0000218,178.0,
12672,A,,10116.0,,50597,Intermediate,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,CHEMBL627420,,1,1,,BAO_0000218,178.0,
12673,A,,10116.0,,50597,Intermediate,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,CHEMBL627421,,1,1,,BAO_0000218,,
12674,A,,10116.0,,50597,Intermediate,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,CHEMBL625695,,1,1,,BAO_0000218,,
12675,A,,10116.0,,50597,Intermediate,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,CHEMBL625696,,1,1,,BAO_0000218,,
12676,A,,10090.0,,50594,Intermediate,Distribution of compound in mice brain was measured after 1 hr,,CHEMBL875606,,1,1,,BAO_0000218,955.0,
12677,A,,10090.0,,50594,Intermediate,Distribution of compound in mice brain was measured after 24 hr r,,CHEMBL625697,,1,1,,BAO_0000218,955.0,
12678,A,,10090.0,,50594,Intermediate,Distribution of compound in mice brain was measured after 2 hr,,CHEMBL625698,,1,1,,BAO_0000218,955.0,
12679,A,,10090.0,,50594,Intermediate,Distribution of compound in mice brain was measured after 3 hr,,CHEMBL625699,,1,1,,BAO_0000218,955.0,
12680,A,,10090.0,,50594,Intermediate,Distribution of compound in mice brain was measured after 6 hr,,CHEMBL625700,,1,1,,BAO_0000218,955.0,
12681,A,,10090.0,,50594,Intermediate,Distribution of compound in mice liver was measured after 1 hr,,CHEMBL625701,,1,1,,BAO_0000218,,
12682,A,,10090.0,,50594,Intermediate,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,CHEMBL625702,,1,1,,BAO_0000218,,
12683,A,,10090.0,,50594,Intermediate,Distribution of compound in mice liver was measured after 2 hr,,CHEMBL625703,,1,1,,BAO_0000218,,
12684,A,,10090.0,,50594,Intermediate,Distribution of compound in mice liver was measured after 3 hr,,CHEMBL625704,,1,1,,BAO_0000218,,
12685,A,,10090.0,,50594,Intermediate,Distribution of compound in mice liver was measured after 6 hr,,CHEMBL625705,,1,1,,BAO_0000218,,
12686,A,,9615.0,,50588,Intermediate,Distribution in dog adrenal medulla 30 min after administration.,,CHEMBL625706,,1,1,,BAO_0000218,1236.0,
12687,A,,9615.0,,50588,Intermediate,Distribution in dog adrenal medulla 72 hours after administration.,,CHEMBL625707,,1,1,,BAO_0000218,1236.0,
12688,A,,9615.0,,50588,Intermediate,Distribution in female dog Ovary 24 hours after administration.,,CHEMBL625708,,1,1,,BAO_0000218,,
12689,A,,9615.0,,50588,Intermediate,Distribution in female dog Ovary 72 hours after administration.,,CHEMBL625709,,1,1,,BAO_0000218,,
12690,A,,9615.0,,50588,Intermediate,Distribution in female dog adipose 24 hours after administration.,,CHEMBL624180,,1,1,,BAO_0000218,,
12691,A,,9615.0,,50588,Intermediate,Distribution in female dog adipose 72 hours after administration.,,CHEMBL624181,,1,1,,BAO_0000218,,
12692,A,,9615.0,,50588,Intermediate,Distribution in female dog adrenal cortex 72 hours after administration.,,CHEMBL624182,,1,1,,BAO_0000218,1235.0,
12693,A,,9615.0,,50588,Intermediate,Distribution in female dog adrenal cortex 72 hours after administration.,,CHEMBL624183,,1,1,,BAO_0000218,1235.0,
12694,A,,10116.0,,50597,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL624184,,1,1,,BAO_0000218,2107.0,
12695,A,,10116.0,,50597,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL877489,,1,1,,BAO_0000218,2107.0,
12696,A,,10116.0,,50597,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL624185,,1,1,,BAO_0000218,2107.0,
12697,A,,10116.0,,50597,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL624186,,1,1,,BAO_0000218,2107.0,
12698,A,,10116.0,,50597,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL624187,,1,1,,BAO_0000218,2107.0,
12699,A,,10116.0,,50597,Intermediate,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL624188,,1,1,,BAO_0000218,2107.0,
12700,A,,10116.0,,50597,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL624189,,1,1,,BAO_0000218,2048.0,
12701,A,,10116.0,,50597,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL624190,,1,1,,BAO_0000218,2048.0,
12702,A,,10116.0,,50597,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL624191,,1,1,,BAO_0000218,2048.0,
12703,A,,10116.0,,50597,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL624192,,1,1,,BAO_0000218,2048.0,
12704,A,,10116.0,,50597,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL624193,,1,1,,BAO_0000218,2048.0,
12705,A,,10116.0,,50597,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL624194,,1,1,,BAO_0000218,2048.0,
12706,A,,10116.0,,50597,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL624891,,1,1,,BAO_0000218,2048.0,
12707,A,,10116.0,,50597,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL624892,,1,1,,BAO_0000218,2048.0,
12708,A,,10116.0,,50597,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL624893,,1,1,,BAO_0000218,2048.0,
12709,A,,10116.0,,50597,Intermediate,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL627632,,1,1,,BAO_0000218,2048.0,
12710,A,,10116.0,,50597,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL627633,,1,1,,BAO_0000218,,
12711,A,,10116.0,,50597,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL627634,,1,1,,BAO_0000218,,
12712,A,,10116.0,,50597,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL627635,,1,1,,BAO_0000218,,
12713,A,,10116.0,,50597,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL627636,,1,1,,BAO_0000218,,
12714,A,,10116.0,,50597,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL626816,,1,1,,BAO_0000218,,
12715,A,,10116.0,,50597,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL626817,,1,1,,BAO_0000218,,
12716,A,,10116.0,,50597,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL626818,,1,1,,BAO_0000218,,
12717,A,,10116.0,,50597,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL626819,,1,1,,BAO_0000218,,
12718,A,,10116.0,,50597,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL626820,,1,1,,BAO_0000218,,
12719,A,,10116.0,,50597,Intermediate,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL626821,,1,1,,BAO_0000218,,
12720,A,,10116.0,,50597,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,CHEMBL626822,,1,1,,BAO_0000218,2046.0,
12721,A,,10116.0,,50597,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,CHEMBL626823,,1,1,,BAO_0000218,2046.0,
12722,A,,10116.0,,50597,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,CHEMBL626824,,1,1,,BAO_0000218,2046.0,
12723,A,,10116.0,,50597,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,CHEMBL626825,,1,1,,BAO_0000218,2046.0,
12724,A,,10116.0,,50597,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,CHEMBL626826,,1,1,,BAO_0000218,2046.0,
12725,A,,10116.0,,50597,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,CHEMBL626827,,1,1,,BAO_0000218,2046.0,
12726,A,,10116.0,,50597,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,CHEMBL626828,,1,1,,BAO_0000218,2046.0,
12727,A,,10116.0,,50597,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,CHEMBL626829,,1,1,,BAO_0000218,2046.0,
12728,A,,10116.0,,50597,Intermediate,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL626830,,1,1,,BAO_0000218,2046.0,
12729,A,,10116.0,,50597,Intermediate,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL627150,,1,1,,BAO_0000218,,
12730,A,,10116.0,,50597,Intermediate,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL627151,,1,1,,BAO_0000218,,
12731,A,,10116.0,,50597,Intermediate,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,CHEMBL627152,,1,1,,BAO_0000218,,
12732,A,,10116.0,,50597,Intermediate,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,CHEMBL627153,,1,1,,BAO_0000218,,
12733,A,,,,22224,Autocuration,Rate of acetate production by the compound was determined,,CHEMBL627154,,0,1,,BAO_0000019,,
12734,A,,,,22224,Autocuration,Rate of acetate production by the compound was determined; Not determined,,CHEMBL627155,,0,1,,BAO_0000019,,
12735,A,,,,22224,Autocuration,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,CHEMBL627156,,0,1,,BAO_0000019,,
12736,A,,,,22224,Autocuration,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,CHEMBL627157,,0,1,,BAO_0000019,,
12737,A,,9986.0,,50592,Intermediate,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,CHEMBL627158,,1,1,,BAO_0000218,,
12738,A,,9986.0,,50592,Intermediate,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,CHEMBL627159,,1,1,,BAO_0000218,1969.0,
12739,A,,10090.0,,50594,Intermediate,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,CHEMBL627160,,1,1,,BAO_0000218,,
12740,A,,10116.0,,50597,Intermediate,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,CHEMBL628540,,1,1,,BAO_0000218,,
12741,A,,10116.0,,50597,Intermediate,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,CHEMBL628541,,1,1,,BAO_0000218,1969.0,
12742,A,,10116.0,,50597,Intermediate,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,CHEMBL628542,,1,1,,BAO_0000218,1969.0,
12743,P,,,,22229,Autocuration,Solubility after at a pH 1.2,,CHEMBL628543,,0,1,,BAO_0000100,,
12744,P,,,,22229,Autocuration,Solubility after at pH 1.2,,CHEMBL628544,,0,1,,BAO_0000100,,
12745,P,,,,22229,Autocuration,Solubility after injection of water,,CHEMBL628545,,0,1,,BAO_0000100,,
12746,A,,,,22224,Autocuration,Statistical significance of IC 50 values; Expressed as R value,,CHEMBL628546,,0,1,,BAO_0000019,,
12747,A,,,,22224,Autocuration,Systemic availability with respect to methyldopa was determined,,CHEMBL874455,,0,1,,BAO_0000019,,
12748,A,,10116.0,,50597,Intermediate,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,CHEMBL628547,,1,1,,BAO_0000218,,
12749,A,,10116.0,,50597,Intermediate,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,,CHEMBL628548,,1,1,,BAO_0000218,1969.0,
12750,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",,CHEMBL628549,,1,1,,BAO_0000218,1988.0,
12751,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",,CHEMBL628550,,1,1,,BAO_0000218,1988.0,
12752,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",,CHEMBL628551,,1,1,,BAO_0000218,1988.0,
12753,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",,CHEMBL628552,,1,1,,BAO_0000218,1088.0,
12754,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",,CHEMBL628553,,1,1,,BAO_0000218,1088.0,
12755,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",,CHEMBL628554,,1,1,,BAO_0000218,1088.0,
12756,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",,CHEMBL628555,,1,1,,BAO_0000218,1088.0,
12757,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",,CHEMBL628556,,1,1,,BAO_0000218,1088.0,
12758,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",,CHEMBL628557,,1,1,,BAO_0000218,2113.0,
12759,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",,CHEMBL628558,,1,1,,BAO_0000218,1988.0,
12760,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",,CHEMBL628559,,1,1,,BAO_0000218,1988.0,
12761,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",,CHEMBL628560,,1,1,,BAO_0000218,1988.0,
12762,A,,9986.0,,50592,Intermediate,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",,CHEMBL874456,,1,1,,BAO_0000218,1088.0,
12763,A,,9986.0,,50592,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",,CHEMBL628561,,1,1,,BAO_0000218,1988.0,
12764,A,,9986.0,,50592,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",,CHEMBL628562,,1,1,,BAO_0000218,1988.0,
12765,A,,9986.0,,50592,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",,CHEMBL628563,,1,1,,BAO_0000218,1088.0,
12766,A,,9986.0,,50592,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",,CHEMBL628564,,1,1,,BAO_0000218,1088.0,
12767,A,,9986.0,,50592,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",,CHEMBL628565,,1,1,,BAO_0000218,1088.0,
12768,A,,9986.0,,50592,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",,CHEMBL631248,,1,1,,BAO_0000218,1088.0,
12769,A,,9986.0,,50592,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",,CHEMBL631249,,1,1,,BAO_0000218,1088.0,
12770,A,,9986.0,,50592,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",,CHEMBL627214,,1,1,,BAO_0000218,2113.0,
12771,A,,9986.0,,50592,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",,CHEMBL874591,,1,1,,BAO_0000218,1988.0,
12772,A,,9986.0,,50592,Intermediate,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",,CHEMBL627215,,1,1,,BAO_0000218,1988.0,
12773,A,,9986.0,,50592,Intermediate,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,,CHEMBL625471,,1,1,,BAO_0000218,1988.0,
12774,A,,9986.0,,50592,Intermediate,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,CHEMBL625472,,1,1,,BAO_0000218,,
12775,A,,9986.0,,50592,Intermediate,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,CHEMBL625473,,1,1,,BAO_0000218,,
12776,A,In vivo,9615.0,,50588,Intermediate,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,CHEMBL625474,,1,1,,BAO_0000218,,
12777,A,In vivo,9615.0,,50588,Intermediate,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,CHEMBL625475,,1,1,,BAO_0000218,,
12778,A,In vivo,10116.0,,50597,Intermediate,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,CHEMBL625476,,1,1,,BAO_0000218,,
12779,A,In vivo,10116.0,,50597,Intermediate,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,CHEMBL625477,,1,1,,BAO_0000218,,
12780,A,In vivo,10116.0,,50597,Intermediate,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,CHEMBL625478,,1,1,,BAO_0000218,,
12781,A,In vitro,10116.0,,50597,Intermediate,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,CHEMBL625479,,1,1,,BAO_0000218,,
12782,A,In vitro,10116.0,,50597,Intermediate,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,CHEMBL625480,,1,1,,BAO_0000218,,
12783,A,In vivo,10116.0,,50597,Intermediate,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,,CHEMBL625481,,1,1,,BAO_0000218,1969.0,
12784,A,In vivo,10116.0,,50597,Intermediate,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,CHEMBL625482,,1,1,,BAO_0000218,,
12785,A,In vivo,10116.0,,50597,Intermediate,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,CHEMBL625483,,1,1,,BAO_0000218,,
12786,A,In vivo,10116.0,,50597,Intermediate,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,CHEMBL625484,,1,1,,BAO_0000218,,
12787,A,In vivo,10116.0,,50597,Intermediate,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,CHEMBL625485,,1,1,,BAO_0000218,,
12788,A,In vivo,9615.0,,50588,Intermediate,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,,CHEMBL625486,,1,1,,BAO_0000218,1969.0,
12789,A,In vivo,10116.0,,50597,Intermediate,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,,CHEMBL625487,,1,1,,BAO_0000218,1969.0,
12790,A,In vivo,10116.0,,50597,Intermediate,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,,CHEMBL625488,,1,1,,BAO_0000218,1969.0,
12791,A,In vivo,10116.0,,50597,Intermediate,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,,CHEMBL625489,,1,1,,BAO_0000218,1969.0,
12792,A,In vivo,10116.0,,50597,Intermediate,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,,CHEMBL625490,,1,1,,BAO_0000218,1969.0,
12793,A,In vivo,9615.0,,50588,Intermediate,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,,CHEMBL625491,,1,1,,BAO_0000218,1969.0,
12794,A,In vivo,10116.0,,50597,Intermediate,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,,CHEMBL625492,,1,1,,BAO_0000218,1969.0,
12795,A,In vivo,9606.0,,50587,Intermediate,plasma clearance in human,,CHEMBL625493,,1,1,,BAO_0000218,1969.0,
12796,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,CHEMBL625494,,1,1,,BAO_0000218,,
12797,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,CHEMBL625495,,1,1,,BAO_0000218,,
12798,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,CHEMBL625496,,1,1,,BAO_0000218,,
12799,P,,,,22229,Autocuration,1-Octanol/water partition coefficient measured at 7.4,,CHEMBL625497,,0,1,,BAO_0000100,,
12800,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625498,,0,1,,BAO_0000100,,
12801,A,,,,22224,Autocuration,Partition coefficient (logP),,CHEMBL625499,,0,1,,BAO_0000019,,
12802,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625500,,0,1,,BAO_0000100,,
12803,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625501,,0,1,,BAO_0000100,,
12804,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625502,,0,1,,BAO_0000100,,
12805,P,,,,22229,Autocuration,Calculated partition coefficient (clogP) (relative to BAY K 8644),,CHEMBL625503,,0,1,,BAO_0000100,,
12806,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625504,,0,1,,BAO_0000100,,
12807,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625505,,0,1,,BAO_0000100,,
12808,P,,,,22229,Autocuration,Calculated partition coefficient of the compound,,CHEMBL625506,,0,1,,BAO_0000100,,
12809,A,,,,22224,Autocuration,Partition coefficient (logP),,CHEMBL625507,,0,1,,BAO_0000019,,
12810,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625508,,0,1,,BAO_0000100,,
12811,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625509,,0,1,,BAO_0000100,,
12812,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625510,,0,1,,BAO_0000100,,
12813,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL883125,,0,1,,BAO_0000100,,
12814,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625511,,0,1,,BAO_0000100,,
12815,A,,,,22224,Autocuration,Partition coefficient of the compound,,CHEMBL874650,,0,1,,BAO_0000019,,
12816,A,,,,22224,Autocuration,Partition coefficient of the compound,,CHEMBL625512,,0,1,,BAO_0000019,,
12817,A,,,,22224,Autocuration,Partition coefficient of compound was determined,,CHEMBL625513,,0,1,,BAO_0000019,,
12818,A,,,,22224,Autocuration,Partition coefficient was determined,,CHEMBL625514,,0,1,,BAO_0000019,,
12819,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625515,,0,1,,BAO_0000100,,
12820,P,,,,22229,Autocuration,partition coefficient of compound was determined,,CHEMBL625516,,0,1,,BAO_0000100,,
12821,A,In vivo,9615.0,,50588,Intermediate,The total body administered intravenously in dog,,CHEMBL625517,,1,1,,BAO_0000218,,
12822,A,In vivo,10116.0,,50597,Intermediate,The total body administered intravenously in rats,,CHEMBL625518,,1,1,,BAO_0000218,,
12823,A,,10090.0,,50594,Intermediate,Time taken for the administration to female NIH mice weighing 25-30 g.,,CHEMBL625519,,1,1,,BAO_0000218,,
12824,A,,,,22224,Autocuration,Time taken for the administration,,CHEMBL625520,,0,1,,BAO_0000019,,
12825,A,In vivo,9615.0,,50588,Intermediate,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,CHEMBL874651,,1,1,,BAO_0000218,,
12826,A,In vivo,314293.0,,22224,Autocuration,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,CHEMBL625521,,0,1,,BAO_0000218,,
12827,A,In vivo,9986.0,,50592,Intermediate,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,CHEMBL623171,,1,1,,BAO_0000218,,
12828,A,In vivo,10116.0,,50597,Intermediate,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,CHEMBL623853,,1,1,,BAO_0000218,,
12829,A,,,,22224,Autocuration,Plasma clearance for the compound was determined.,,CHEMBL623854,,0,1,,BAO_0000019,,
12830,P,,,,22224,Autocuration,CLog P value of the compound,,CHEMBL874405,,0,1,,BAO_0000100,,
12831,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL623855,,0,1,,BAO_0000100,,
12832,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL623856,,0,1,,BAO_0000100,,
12833,P,,,,22224,Autocuration,ClogP value of the compound; nd ='no data',,CHEMBL623857,,0,1,,BAO_0000100,,
12834,P,,,,22224,Autocuration,ClogP value of the compound; nd ='not determined',,CHEMBL623858,,0,1,,BAO_0000100,,
12835,P,,,,22224,Autocuration,CLog P was determined,,CHEMBL623859,,0,1,,BAO_0000100,,
12836,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL839829,,0,1,,BAO_0000100,,
12837,A,,,,22224,Autocuration,CLogP was calculated,,CHEMBL623860,,0,1,,BAO_0000019,,
12838,A,,,,22224,Autocuration,CLogP value was determined,,CHEMBL623861,,0,1,,BAO_0000019,,
12839,A,,,,22224,Autocuration,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,CHEMBL623862,,0,1,,BAO_0000019,,
12840,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL874406,,0,1,,BAO_0000100,,
12841,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL623863,,0,1,,BAO_0000100,,
12842,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624021,,0,1,,BAO_0000100,,
12843,A,,9615.0,,50588,Intermediate,Distribution in female dog adrenal medulla 24 hours after administration.,,CHEMBL624022,,1,1,,BAO_0000218,1236.0,
12844,A,,9615.0,,50588,Intermediate,Distribution in female dog adrenal medulla 72 hours after administration.,,CHEMBL624023,,1,1,,BAO_0000218,1236.0,
12845,A,,9615.0,,50588,Intermediate,Distribution in female dog bile 24 hours after administration.,,CHEMBL624024,,1,1,,BAO_0000218,,
12846,A,,9615.0,,50588,Intermediate,Distribution in female dog bile 72 hr after administration.,,CHEMBL624025,,1,1,,BAO_0000218,,
12847,A,,9615.0,,50588,Intermediate,Distribution in female dog blood 24 hours after administration.,,CHEMBL624026,,1,1,,BAO_0000218,,
12848,A,,9615.0,,50588,Intermediate,Distribution in female dog blood 72 hours after administration.,,CHEMBL624027,,1,1,,BAO_0000218,,
12849,A,,9615.0,,50588,Intermediate,Distribution in female dog heart 24 hours after administration.,,CHEMBL624028,,1,1,,BAO_0000218,,
12850,A,,9615.0,,50588,Intermediate,Distribution in female dog heart 72 hours after administration.,,CHEMBL624029,,1,1,,BAO_0000218,,
12851,A,,9615.0,,50588,Intermediate,Distribution in female dog kidney 24 hours after administration.,,CHEMBL624030,,1,1,,BAO_0000218,,
12852,A,,9615.0,,50588,Intermediate,Distribution in female dog kidney 72 hours after administration.,,CHEMBL624031,,1,1,,BAO_0000218,,
12853,A,,9615.0,,50588,Intermediate,Distribution in female dog large intestine 24 hours after administration.,,CHEMBL624032,,1,1,,BAO_0000218,160.0,
12854,A,,9615.0,,50588,Intermediate,Distribution in female dog large intestine 72 hours after administration.,,CHEMBL874407,,1,1,,BAO_0000218,160.0,
12855,A,,9615.0,,50588,Intermediate,Distribution in female dog liver 24 hours after administration.,,CHEMBL624033,,1,1,,BAO_0000218,,
12856,A,,9615.0,,50588,Intermediate,Distribution in female dog liver 72 hours after administration.,,CHEMBL624034,,1,1,,BAO_0000218,,
12857,A,,9615.0,,50588,Intermediate,Distribution in female dog lung 24 hours after administration.,,CHEMBL624035,,1,1,,BAO_0000218,,
12858,A,,9615.0,,50588,Intermediate,Distribution in female dog lung 72 hours after administration.,,CHEMBL624036,,1,1,,BAO_0000218,,
12859,A,,9615.0,,50588,Intermediate,Distribution in female dog muscle 24 hours after administration.,,CHEMBL624037,,1,1,,BAO_0000218,2385.0,
12860,A,,9615.0,,50588,Intermediate,Distribution in female dog muscle 72 hours after administration.,,CHEMBL624038,,1,1,,BAO_0000218,2385.0,
12861,A,,9615.0,,50588,Intermediate,Distribution in female dog pancreas 24 hours after administration.,,CHEMBL624039,,1,1,,BAO_0000218,,
12862,A,,9615.0,,50588,Intermediate,Distribution in female dog pancreas 72 hours after administration.,,CHEMBL624040,,1,1,,BAO_0000218,,
12863,A,,9615.0,,50588,Intermediate,Distribution in female dog small intestine 24 hours after administration.,,CHEMBL624041,,1,1,,BAO_0000218,160.0,
12864,A,,9615.0,,50588,Intermediate,Distribution in female dog small intestine 72 hours after administration.,,CHEMBL624042,,1,1,,BAO_0000218,160.0,
12865,A,,9615.0,,50588,Intermediate,Distribution in female dog spleen 24 hours after administration.,,CHEMBL624043,,1,1,,BAO_0000218,2106.0,
12866,A,,9615.0,,50588,Intermediate,Distribution in female dog spleen 72 hours after administration.,,CHEMBL624044,,1,1,,BAO_0000218,2106.0,
12867,A,,9615.0,,50588,Intermediate,Distribution in female dog stomach 24 hours after administration.,,CHEMBL624045,,1,1,,BAO_0000218,945.0,
12868,A,,9615.0,,50588,Intermediate,Distribution in female dog stomach 72 hours after administration.,,CHEMBL624046,,1,1,,BAO_0000218,945.0,
12869,A,,9615.0,,50588,Intermediate,Distribution in female dog thyroid 24 hours after administration.,,CHEMBL624047,,1,1,,BAO_0000218,2046.0,
12870,A,,9615.0,,50588,Intermediate,Distribution in female dog thyroid 72 hours after administration.,,CHEMBL624048,,1,1,,BAO_0000218,2046.0,
12871,A,,9615.0,,50588,Intermediate,Distribution in female dog urine 24 hours after administration.,,CHEMBL874408,,1,1,,BAO_0000218,1088.0,
12872,A,,9615.0,,50588,Intermediate,Distribution in female dog urine 72 hr after administration.,,CHEMBL624049,,1,1,,BAO_0000218,1088.0,
12873,A,,,,22224,Autocuration,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,,CHEMBL624050,,0,1,,BAO_0000218,1969.0,
12874,A,,,,22224,Autocuration,Plasma concentration at 7 hr after intravenous dosing,,CHEMBL624051,,0,1,,BAO_0000019,,
12875,A,,10116.0,,50597,Intermediate,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,CHEMBL623278,,1,1,,BAO_0000218,,
12876,A,,10116.0,,50597,Intermediate,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,CHEMBL623279,,1,1,,BAO_0000218,,
12877,A,,10116.0,,50597,Intermediate,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,CHEMBL623280,,1,1,,BAO_0000218,,
12878,A,,10116.0,,50597,Intermediate,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,CHEMBL623963,,1,1,,BAO_0000218,,
12879,A,,10116.0,,50597,Intermediate,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,CHEMBL623964,,1,1,,BAO_0000218,,
12880,A,,10116.0,,50597,Intermediate,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,CHEMBL623965,,1,1,,BAO_0000218,,
12881,A,,10116.0,,50597,Intermediate,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,CHEMBL623966,,1,1,,BAO_0000218,,
12882,A,,10116.0,,50597,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,CHEMBL874415,,1,1,,BAO_0000218,,
12883,A,,10116.0,,50597,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,CHEMBL623967,,1,1,,BAO_0000218,,
12884,A,,10116.0,,50597,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,CHEMBL623968,,1,1,,BAO_0000218,,
12885,A,,10116.0,,50597,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,CHEMBL623969,,1,1,,BAO_0000218,,
12886,A,,10116.0,,50597,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,CHEMBL628409,,1,1,,BAO_0000218,,
12887,A,,10116.0,,50597,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,CHEMBL628410,,1,1,,BAO_0000218,,
12888,A,,10116.0,,50597,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,CHEMBL628411,,1,1,,BAO_0000218,,
12889,A,,10116.0,,50597,Intermediate,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,CHEMBL628412,,1,1,,BAO_0000218,,
12890,A,,,,22224,Autocuration,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,CHEMBL628413,,0,1,,BAO_0000019,,
12891,A,,,,22224,Autocuration,The concentration in plasmat; Not determined,,CHEMBL628414,,0,1,,BAO_0000019,1969.0,
12892,A,,10116.0,,50597,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in blood,,CHEMBL628415,,1,1,,BAO_0000218,,
12893,A,,10116.0,,50597,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,CHEMBL628416,,1,1,,BAO_0000218,,
12894,A,,10116.0,,50597,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in heart,,CHEMBL628417,,1,1,,BAO_0000218,,
12895,A,,10116.0,,50597,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in liver,,CHEMBL874908,,1,1,,BAO_0000218,2107.0,
12896,A,,10116.0,,50597,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in plasma,,CHEMBL628418,,1,1,,BAO_0000218,,
12897,A,,10116.0,,50597,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,,CHEMBL628419,,1,1,,BAO_0000218,2385.0,
12898,A,,10116.0,,50597,Intermediate,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,CHEMBL628420,,1,1,,BAO_0000218,,
12899,A,,,,22224,Autocuration,Water solubility at 37 degree C.,,CHEMBL628421,,0,1,,BAO_0000019,,
12900,P,,,,22229,Autocuration,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,CHEMBL626726,,0,1,,BAO_0000100,,
12901,P,,,,22229,Autocuration,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,CHEMBL626727,,0,1,,BAO_0000100,,
12902,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL626728,,1,1,,BAO_0000218,178.0,
12903,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL626729,,1,1,,BAO_0000218,178.0,
12904,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL626730,,1,1,,BAO_0000218,178.0,
12905,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL626731,,1,1,,BAO_0000218,178.0,
12906,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL626732,,1,1,,BAO_0000218,178.0,
12907,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL626733,,1,1,,BAO_0000218,948.0,
12908,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL626734,,1,1,,BAO_0000218,948.0,
12909,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL626735,,1,1,,BAO_0000218,948.0,
12910,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL874909,,1,1,,BAO_0000218,948.0,
12911,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL626736,,1,1,,BAO_0000218,948.0,
12912,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL626737,,1,1,,BAO_0000218,2113.0,
12913,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL630999,,1,1,,BAO_0000218,2113.0,
12914,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL631000,,1,1,,BAO_0000218,2113.0,
12915,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL631001,,1,1,,BAO_0000218,2113.0,
12916,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL631002,,1,1,,BAO_0000218,2113.0,
12917,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL631003,,1,1,,BAO_0000218,2107.0,
12918,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL631004,,1,1,,BAO_0000218,2107.0,
12919,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL631005,,1,1,,BAO_0000218,2107.0,
12920,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL631006,,1,1,,BAO_0000218,2107.0,
12921,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL631007,,1,1,,BAO_0000218,2107.0,
12922,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL631008,,1,1,,BAO_0000218,2048.0,
12923,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL631009,,1,1,,BAO_0000218,2048.0,
12924,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL631010,,1,1,,BAO_0000218,2048.0,
12925,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL631011,,1,1,,BAO_0000218,2048.0,
12926,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL631012,,1,1,,BAO_0000218,2048.0,
12927,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,CHEMBL630271,,1,1,,BAO_0000218,2046.0,
12928,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,CHEMBL630272,,1,1,,BAO_0000218,2046.0,
12929,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,CHEMBL630273,,1,1,,BAO_0000218,2046.0,
12930,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,CHEMBL630274,,1,1,,BAO_0000218,2046.0,
12931,A,,10116.0,,50597,Intermediate,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,CHEMBL630275,,1,1,,BAO_0000218,2046.0,
12932,A,,10116.0,,50597,Intermediate,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,CHEMBL875782,,1,1,,BAO_0000218,,
12933,A,,10116.0,,50597,Intermediate,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,CHEMBL630276,,1,1,,BAO_0000218,,
12934,A,,10116.0,,50597,Intermediate,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,CHEMBL630277,,1,1,,BAO_0000218,,
12935,A,,10116.0,,50597,Intermediate,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,CHEMBL630278,,1,1,,BAO_0000218,,
12936,A,,10116.0,,50597,Intermediate,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,CHEMBL630279,,1,1,,BAO_0000218,,
12937,A,,,,22224,Autocuration,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,CHEMBL630280,,0,1,,BAO_0000019,,
12938,A,,,,22224,Autocuration,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,CHEMBL630281,,0,1,,BAO_0000019,,
12939,A,,9986.0,,50592,Intermediate,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,CHEMBL630282,,1,1,,BAO_0000218,,
12940,A,,9986.0,,50592,Intermediate,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,CHEMBL630283,,1,1,,BAO_0000218,,
12941,A,,,,22224,Autocuration,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,CHEMBL630284,,0,1,,BAO_0000019,,
12942,A,,,,22224,Autocuration,Alkylating activity was determined,,CHEMBL630285,,0,1,,BAO_0000019,,
12943,A,,,,22224,Autocuration,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,CHEMBL630286,,0,1,,BAO_0000251,,
12944,A,,9986.0,,50592,Intermediate,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,CHEMBL630069,,1,1,,BAO_0000218,,
12945,A,,9986.0,,50592,Intermediate,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,CHEMBL630070,,1,1,,BAO_0000218,,
12946,A,,9986.0,,50592,Intermediate,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,CHEMBL630071,,1,1,,BAO_0000218,,
12947,A,,9986.0,,50592,Intermediate,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,CHEMBL630072,,1,1,,BAO_0000218,,
12948,A,,9986.0,,50592,Intermediate,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,CHEMBL875110,,1,1,,BAO_0000218,,
12949,A,,10116.0,,50597,Intermediate,Compound was tested for antidiuretic activity in rats,,CHEMBL630073,,1,1,,BAO_0000218,,
12950,A,,,,22224,Autocuration,Compound was tested for inactivation kinetic values,,CHEMBL630074,,0,1,,BAO_0000019,,
12951,A,In vivo,,,22224,Autocuration,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,CHEMBL630075,,0,1,,BAO_0000218,,
12952,A,,,,22224,Autocuration,Dissociation rate calculated from the first-order equation using the t1/2 value,,CHEMBL630076,,0,1,,BAO_0000019,,
12953,P,,,,22229,Autocuration,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,CHEMBL630077,,0,1,,BAO_0000100,,
12954,P,,,,22229,Autocuration,Aqueous solubility was measured,,CHEMBL630078,,0,1,,BAO_0000100,,
12955,P,,,,22229,Autocuration,Aqueous solubility was measured at a pH 4,,CHEMBL630079,,0,1,,BAO_0000100,,
12956,P,,,,22229,Autocuration,Aqueous solubility (pH 7),,CHEMBL630080,,0,1,,BAO_0000100,,
12957,P,,,,22229,Autocuration,Aqueous solubility was measured at a pH 9,,CHEMBL630081,,0,1,,BAO_0000100,,
12958,A,,,,22224,Autocuration,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,CHEMBL630082,,0,1,,BAO_0000019,,
12959,A,,,,22224,Autocuration,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,CHEMBL630083,,0,1,,BAO_0000019,,
12960,A,,,,22224,Autocuration,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,CHEMBL630084,,0,1,,BAO_0000019,,
12961,P,,,,22229,Autocuration,Aqueous solubility of the compound,,CHEMBL629198,,0,1,,BAO_0000100,,
12962,P,,,,22229,Autocuration,Aqueous solubility at 37 degree Celsius at pH 7.38,,CHEMBL629199,,0,1,,BAO_0000100,,
12963,P,,,,22229,Autocuration,Aqueous solubility in pH 7.4 phosphate buffer,,CHEMBL629200,,0,1,,BAO_0000100,,
12964,A,,9615.0,,50588,Intermediate,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,CHEMBL629201,,1,1,,BAO_0000218,,
12965,A,,9615.0,,50588,Intermediate,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,CHEMBL629202,,1,1,,BAO_0000218,,
12966,A,,9606.0,,50587,Intermediate,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL875111,,1,1,,BAO_0000218,,
12967,A,,9606.0,,50587,Intermediate,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL629203,,1,1,,BAO_0000218,,
12968,A,,9606.0,,50587,Intermediate,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL629204,,1,1,,BAO_0000218,,
12969,A,,9606.0,,50587,Intermediate,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL629205,,1,1,,BAO_0000218,,
12970,A,,9606.0,,50587,Intermediate,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL629206,,1,1,,BAO_0000218,,
12971,A,,,,22224,Autocuration,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,CHEMBL631185,,0,1,,BAO_0000019,,
12972,A,,10116.0,,50597,Intermediate,Compound was evaluated for the average bile flow rat in rats,,CHEMBL631186,,1,1,,BAO_0000218,,
12973,A,,9986.0,,50592,Intermediate,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,CHEMBL631187,,1,1,,BAO_0000218,,
12974,A,,9986.0,,50592,Intermediate,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,CHEMBL631188,,1,1,,BAO_0000218,,
12975,A,,,,22224,Autocuration,Average half life period was determined,,CHEMBL876419,,0,1,,BAO_0000019,,
12976,A,,,,22224,Autocuration,Average half life period was determined,,CHEMBL631189,,0,1,,BAO_0000019,,
12977,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,CHEMBL631190,,1,1,,BAO_0000218,,
12978,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,CHEMBL631191,,1,1,,BAO_0000218,,
12979,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,CHEMBL631192,,1,1,,BAO_0000218,,
12980,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,CHEMBL632400,,1,1,,BAO_0000218,,
12981,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,CHEMBL630564,,1,1,,BAO_0000218,,
12982,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,CHEMBL630565,,1,1,,BAO_0000218,,
12983,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,CHEMBL630566,,1,1,,BAO_0000218,,
12984,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,CHEMBL631229,,1,1,,BAO_0000218,,
12985,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,CHEMBL631230,,1,1,,BAO_0000218,,
12986,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL876428,,0,1,,BAO_0000100,,
12987,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL631231,,0,1,,BAO_0000100,,
12988,P,,,,22229,Autocuration,Calculated partition coefficient (clogP) (MacLogP),,CHEMBL631232,,0,1,,BAO_0000100,,
12989,A,,,,22224,Autocuration,Hydrophilicity was determined,,CHEMBL631233,,0,1,,BAO_0000019,,
12990,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL631234,,0,1,,BAO_0000100,,
12991,A,,,,22224,Autocuration,Increased absorption was determined,,CHEMBL883126,,0,1,,BAO_0000019,,
12992,P,,,,22224,Autocuration,Lipophilicity value was evaluated,,CHEMBL631235,,0,1,,BAO_0000100,,
12993,P,,,,22224,Autocuration,Log P value of the compound.,,CHEMBL631236,,0,1,,BAO_0000100,,
12994,A,,,,22224,Autocuration,Partition coefficient of compound was determined,,CHEMBL631237,,0,1,,BAO_0000019,,
12995,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL631238,,0,1,,BAO_0000100,,
12996,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL876429,,0,1,,BAO_0000100,,
12997,A,,,,22224,Autocuration,Partition coefficient was measured by medchem software; Not calculated,,CHEMBL631414,,0,1,,BAO_0000019,,
12998,P,,,,22224,Autocuration,Partition coefficient was measured by octanol-water using standard shake-flask method,,CHEMBL631415,,0,1,,BAO_0000100,,
12999,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL631416,,0,1,,BAO_0000100,,
13000,A,,,,22224,Autocuration,Partition coefficient (logP),,CHEMBL631417,,0,1,,BAO_0000019,,
13001,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL631418,,0,1,,BAO_0000100,,
13002,P,,,,22229,Autocuration,The Octanol/Water partition coefficient CLogP,,CHEMBL631419,,0,1,,BAO_0000100,,
13003,A,,,,22224,Autocuration,The pharmacokinetic parameter C Log p was reported,,CHEMBL631420,,0,1,,BAO_0000019,,
13004,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL631421,,0,1,,BAO_0000100,,
13005,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL631422,,0,1,,BAO_0000100,,
13006,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL631423,,0,1,,BAO_0000100,,
13007,A,In vivo,10116.0,,50597,Intermediate,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,CHEMBL876430,,1,1,,BAO_0000218,1969.0,
13008,A,In vivo,10116.0,,50597,Intermediate,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,,CHEMBL631424,,1,1,,BAO_0000218,1969.0,
13009,A,In vivo,9615.0,,50588,Intermediate,Compound was administered intravenously in dog to evaluate plasma clearance values,,CHEMBL631425,,1,1,,BAO_0000218,1969.0,
13010,A,In vivo,314293.0,,22224,Autocuration,Compound was administered intravenously in monkey to evaluate plasma clearance values,,CHEMBL631426,,0,1,,BAO_0000218,1969.0,
13011,A,In vivo,10090.0,,50594,Intermediate,Compound was administered intravenously in mouse to evaluate plasma clearance values,,CHEMBL631427,,1,1,,BAO_0000218,1969.0,
13012,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,,CHEMBL631428,,1,1,,BAO_0000218,1969.0,
13013,A,In vitro,9544.0,,50797,Intermediate,Intrinsic clearance in Rhesus liver microsome,,CHEMBL631429,,1,1,,BAO_0000218,2107.0,
13014,A,In vitro,9615.0,,50588,Intermediate,Intrinsic clearance in dog liver microsome,,CHEMBL631430,,1,1,,BAO_0000218,2107.0,
13015,A,In vitro,10116.0,,50597,Intermediate,Intrinsic clearance in rat liver microsome,,CHEMBL631431,,1,1,,BAO_0000218,2107.0,
13016,A,In vivo,9544.0,,50797,Intermediate,Low plasma clearance was calculated in rhesus monkey,,CHEMBL631432,,1,1,,BAO_0000218,1969.0,
13017,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,CHEMBL631433,,1,1,,BAO_0000218,,
13018,A,In vivo,,,22224,Autocuration,Plasma clearance after intravenous dose of 0.3 mg/kg,,CHEMBL631434,,0,1,,BAO_0000218,,
13019,A,In vivo,,,22224,Autocuration,Plasma clearance after intravenous dose of 1 mg/kg,,CHEMBL631435,,0,1,,BAO_0000218,,
13020,A,In vivo,,,22224,Autocuration,Plasma clearance after intravenous dose of 3 mg/kg,,CHEMBL631436,,0,1,,BAO_0000218,,
13021,A,In vivo,,,22224,Autocuration,Plasma clearance after intravenous dose of 3.87 mg/kg,,CHEMBL631437,,0,1,,BAO_0000218,,
13022,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance after peroral administration at 10 mpk in Rat,,CHEMBL631438,,1,1,,BAO_0000218,,
13023,A,In vivo,9544.0,,50797,Intermediate,Plasma clearance after peroral administration at 10 mpk in Rhesus,,CHEMBL876431,,1,1,,BAO_0000218,,
13024,A,In vivo,9615.0,,50588,Intermediate,Plasma clearance after peroral administration at 10 mpk in dog,,CHEMBL631439,,1,1,,BAO_0000218,,
13025,A,In vivo,10116.0,,50597,Intermediate,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,CHEMBL631440,,1,1,,BAO_0000218,,
13026,A,,,,22224,Autocuration,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,CHEMBL631441,,0,1,,BAO_0000019,,
13027,A,,,,22224,Autocuration,Critical Micellar concentration was determined,,CHEMBL631442,,0,1,,BAO_0000019,,
13028,A,,,,22224,Autocuration,Critical Micellar concentration of the compound. was determined,,CHEMBL626525,,0,1,,BAO_0000019,,
13029,A,,,,22224,Autocuration,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,CHEMBL627168,,0,1,,BAO_0000019,,
13030,A,,,,22224,Autocuration,Critical micellar concentration was measured in water by the dye solubilization method,,CHEMBL875618,,0,1,,BAO_0000019,,
13031,B,,,,22224,Autocuration,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,CHEMBL626612,,0,1,,BAO_0000019,,
13032,A,,,,22224,Autocuration,CMR value (relative to BAY K 8644),,CHEMBL626613,,0,1,,BAO_0000019,,
13033,A,,,,22224,Autocuration,Carbamoylating activity was determined,,CHEMBL626614,,0,1,,BAO_0000019,,
13034,A,,314293.0,,22224,Autocuration,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,CHEMBL626615,,0,1,,BAO_0000218,,
13035,A,,,,22224,Autocuration,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,CHEMBL626616,,0,1,,BAO_0000019,,
13036,A,,,,22224,Autocuration,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,CHEMBL626617,,0,1,,BAO_0000019,,
13037,A,In vivo,9615.0,,50588,Intermediate,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,,CHEMBL626618,,1,1,,BAO_0000218,1969.0,
13038,A,In vivo,10116.0,,50597,Intermediate,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,,CHEMBL626619,,1,1,,BAO_0000218,1969.0,
13039,A,In vivo,9615.0,,50588,Intermediate,"Clearance rate at 0.46 mg/kg, iv, in dogs",,CHEMBL626620,,1,1,,BAO_0000218,,
13040,A,In vivo,10116.0,,50597,Intermediate,"Clearance rate at 5.5 mg/kg, iv, in rat",,CHEMBL626621,,1,1,,BAO_0000218,,
13041,A,In vivo,9541.0,,100710,Intermediate,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,CHEMBL626622,,1,1,,BAO_0000218,,
13042,A,In vivo,9541.0,,100710,Intermediate,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,CHEMBL626623,,1,1,,BAO_0000218,,
13043,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,CHEMBL626624,,1,1,,BAO_0000218,,
13044,A,In vivo,10116.0,,50597,Intermediate,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,CHEMBL626625,,1,1,,BAO_0000218,,
13045,A,Ex vivo,10116.0,,50597,Intermediate,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,CHEMBL626626,,1,1,,BAO_0000218,2107.0,
13046,A,In vivo,,,22224,Autocuration,Tested for the total clearance of the compound,,CHEMBL626627,,0,1,,BAO_0000218,,
13047,A,In vivo,9615.0,,50588,Intermediate,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,CHEMBL626628,,1,1,,BAO_0000218,,
13048,A,In vivo,,,22224,Autocuration,Total body clearance was determined,,CHEMBL626629,,0,1,,BAO_0000218,,
13049,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,CHEMBL626630,,1,1,,BAO_0000218,,
13050,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,CHEMBL626631,,1,1,,BAO_0000218,,
13051,P,,,,22229,Autocuration,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,CHEMBL626632,,0,1,,BAO_0000100,,
13052,P,,,,22229,Autocuration,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,CHEMBL626633,,0,1,,BAO_0000100,,
13053,P,,,,22229,Autocuration,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,CHEMBL626634,,0,1,,BAO_0000100,,
13054,P,,,,22229,Autocuration,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,CHEMBL626635,,0,1,,BAO_0000100,,
13055,P,,,,22229,Autocuration,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,CHEMBL626636,,0,1,,BAO_0000100,,
13056,P,,,,22229,Autocuration,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,CHEMBL626637,,0,1,,BAO_0000100,,
13057,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,CHEMBL626638,,1,1,,BAO_0000218,,
13058,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,CHEMBL626639,,1,1,,BAO_0000218,,
13059,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,CHEMBL626640,,1,1,,BAO_0000218,,
13060,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,CHEMBL626641,,1,1,,BAO_0000218,,
13061,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,CHEMBL627272,,1,1,,BAO_0000218,,
13062,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,CHEMBL627273,,1,1,,BAO_0000218,,
13063,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,CHEMBL627441,,1,1,,BAO_0000218,,
13064,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,CHEMBL628355,,1,1,,BAO_0000218,,
13065,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,CHEMBL628356,,1,1,,BAO_0000218,,
13066,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,CHEMBL628357,,1,1,,BAO_0000218,,
13067,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,CHEMBL628358,,1,1,,BAO_0000218,,
13068,A,,4754.0,,50339,Intermediate,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,CHEMBL622307,,1,1,,BAO_0000218,,
13069,A,,,,22224,Autocuration,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,CHEMBL622527,,0,1,,BAO_0000019,,
13070,A,,,,22224,Autocuration,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,CHEMBL622528,,0,1,,BAO_0000019,,
13071,A,,,,22224,Autocuration,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,CHEMBL622529,,0,1,,BAO_0000019,,
13072,A,,,,22224,Autocuration,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,CHEMBL622992,,0,1,,BAO_0000019,,
13073,A,,,,22224,Autocuration,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,CHEMBL622993,,0,1,,BAO_0000019,,
13074,A,,,,22224,Autocuration,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,CHEMBL622994,,0,1,,BAO_0000019,,
13075,A,,10116.0,,50597,Intermediate,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,CHEMBL622995,,1,1,,BAO_0000218,,
13076,A,,10116.0,,50597,Intermediate,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,CHEMBL622996,,1,1,,BAO_0000218,,
13077,A,,10116.0,,50597,Intermediate,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,CHEMBL622997,,1,1,,BAO_0000218,,
13078,A,,10116.0,,50597,Intermediate,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,CHEMBL622998,,1,1,,BAO_0000218,,
13079,A,,,,22224,Autocuration,Cp max following ip administration at 1 mg/kg,,CHEMBL622999,,0,1,,BAO_0000218,,
13080,A,In vivo,,,22224,Autocuration,Maximum concentration in plasma was reported at 0.5 hour,,CHEMBL623000,,0,1,,BAO_0000218,1969.0,
13081,A,In vivo,,,22224,Autocuration,Maximum concentration in plasma was reported at 2 hour,,CHEMBL623001,,0,1,,BAO_0000218,1969.0,
13082,A,,10090.0,,50594,Intermediate,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,CHEMBL623002,,1,1,,BAO_0000218,,
13083,P,,,,22229,Autocuration,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,CHEMBL623003,,0,1,,BAO_0000100,,
13084,A,,,,22224,Autocuration,Steady state concentration was evaluated,,CHEMBL623004,,0,1,,BAO_0000019,,
13085,A,,,,22224,Autocuration,Partition coefficient (logP),,CHEMBL623005,,0,1,,BAO_0000019,,
13086,A,,,,22224,Autocuration,Partition coefficient (logD7.4),,CHEMBL623006,,0,1,,BAO_0000019,,
13087,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,,CHEMBL623007,,1,1,,BAO_0000218,2107.0,
13088,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,,CHEMBL623008,,1,1,,BAO_0000218,10000001.0,
13089,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,,CHEMBL876654,,1,1,,BAO_0000218,2037.0,
13090,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,CHEMBL623009,,1,1,,BAO_0000218,,
13091,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,CHEMBL623010,,1,1,,BAO_0000218,,
13092,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,,CHEMBL623011,,1,1,,BAO_0000218,948.0,
13093,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,,CHEMBL623012,,1,1,,BAO_0000218,160.0,
13094,A,,,,22224,Autocuration,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,CHEMBL623013,,0,1,,BAO_0000019,,
13095,A,,,,22224,Autocuration,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,CHEMBL623014,,0,1,,BAO_0000019,,
13096,A,,,,22224,Autocuration,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,,CHEMBL623015,,0,1,,BAO_0000019,1088.0,
13097,A,,,,22224,Autocuration,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,CHEMBL623016,,0,1,,BAO_0000019,1088.0,
13098,A,,,,22224,Autocuration,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,,CHEMBL624858,,0,1,,BAO_0000019,1088.0,
13099,A,,10116.0,,50597,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,CHEMBL624859,,1,1,,BAO_0000218,,
13100,A,,10116.0,,50597,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,CHEMBL624860,,1,1,,BAO_0000218,,
13101,A,,10116.0,,50597,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,CHEMBL624861,,1,1,,BAO_0000218,,
13102,A,,10116.0,,50597,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,CHEMBL624862,,1,1,,BAO_0000218,,
13103,A,,10116.0,,50597,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,CHEMBL624863,,1,1,,BAO_0000218,,
13104,A,,10116.0,,50597,Intermediate,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,CHEMBL876655,,1,1,,BAO_0000218,,
13105,A,,9615.0,,50588,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,CHEMBL624864,,1,1,,BAO_0000218,,
13106,A,,9615.0,,50588,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,CHEMBL624865,,1,1,,BAO_0000218,,
13107,A,,9615.0,,50588,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,CHEMBL624866,,1,1,,BAO_0000218,,
13108,F,,9615.0,,50588,Expert,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,CHEMBL624867,,1,1,,BAO_0000218,,
13109,A,,9615.0,,50588,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,CHEMBL624868,,1,1,,BAO_0000218,,
13110,A,,9615.0,,50588,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,CHEMBL628450,,1,1,,BAO_0000218,,
13111,A,,9615.0,,50588,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,CHEMBL628451,,1,1,,BAO_0000218,,
13112,A,,9615.0,,50588,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,CHEMBL628452,,1,1,,BAO_0000218,,
13113,A,,9615.0,,50588,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,CHEMBL628453,,1,1,,BAO_0000218,,
13114,A,,9615.0,,50588,Intermediate,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,CHEMBL628454,,1,1,,BAO_0000218,,
13115,A,,9615.0,,50588,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,CHEMBL628455,,1,1,,BAO_0000218,,
13116,A,,9615.0,,50588,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,CHEMBL628456,,1,1,,BAO_0000218,,
13117,A,,9615.0,,50588,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,CHEMBL628457,,1,1,,BAO_0000218,,
13118,A,,9615.0,,50588,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,CHEMBL877505,,1,1,,BAO_0000218,,
13119,A,,9615.0,,50588,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,CHEMBL628458,,1,1,,BAO_0000218,,
13120,A,,9615.0,,50588,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,CHEMBL628459,,1,1,,BAO_0000218,,
13121,A,,9615.0,,50588,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,CHEMBL628460,,1,1,,BAO_0000218,,
13122,A,,9615.0,,50588,Intermediate,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,CHEMBL628461,,1,1,,BAO_0000218,,
13123,B,,,,22224,Autocuration,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,CHEMBL628462,,0,1,,BAO_0000218,,
13124,A,,9615.0,,50588,Intermediate,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,CHEMBL628463,,1,1,,BAO_0000218,,
13125,F,,10116.0,,50597,Expert,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,CHEMBL625666,,1,1,,BAO_0000218,,
13126,B,,,,22224,Autocuration,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,CHEMBL625667,,0,1,,BAO_0000218,,
13127,A,,10116.0,,50597,Expert,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,CHEMBL625668,,1,1,,BAO_0000218,,
13128,A,,10116.0,,50597,Intermediate,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,CHEMBL625669,,1,1,,BAO_0000218,,
13129,A,,,,22224,Autocuration,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,CHEMBL625670,,0,1,,BAO_0000019,,
13130,A,,10116.0,,50597,Intermediate,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,CHEMBL625671,,1,1,,BAO_0000218,,
13131,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,CHEMBL625672,,1,1,,BAO_0000218,,
13132,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,CHEMBL625673,,1,1,,BAO_0000218,,
13133,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,CHEMBL625674,,1,1,,BAO_0000218,,
13134,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,CHEMBL625675,,1,1,,BAO_0000218,,
13135,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,CHEMBL627637,,1,1,,BAO_0000218,,
13136,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,CHEMBL627638,,1,1,,BAO_0000218,,
13137,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,CHEMBL627639,,1,1,,BAO_0000218,,
13138,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,CHEMBL627640,,1,1,,BAO_0000218,,
13139,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,CHEMBL627641,,1,1,,BAO_0000218,,
13140,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,CHEMBL627642,,1,1,,BAO_0000218,,
13141,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,CHEMBL877506,,1,1,,BAO_0000218,,
13142,A,,10090.0,,50594,Intermediate,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,CHEMBL627275,,1,1,,BAO_0000218,,
13143,A,,9669.0,,50506,Intermediate,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,CHEMBL627643,,1,1,,BAO_0000218,,
13144,A,,9669.0,,50506,Intermediate,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,CHEMBL631246,,1,1,,BAO_0000218,,
13145,A,,9669.0,,50506,Intermediate,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,CHEMBL631247,,1,1,,BAO_0000218,,
13146,A,,9669.0,,50506,Intermediate,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,CHEMBL629532,,1,1,,BAO_0000218,,
13147,A,,9669.0,,50506,Intermediate,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,CHEMBL629533,,1,1,,BAO_0000218,,
13148,A,,9669.0,,50506,Intermediate,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,CHEMBL629534,,1,1,,BAO_0000218,,
13149,A,,9669.0,,50506,Intermediate,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,CHEMBL629535,,1,1,,BAO_0000218,,
13150,A,,,,22224,Autocuration,Pharmacokinetic parameter :drug bound to plasma was reported,,CHEMBL625932,,0,1,,BAO_0000019,,
13151,A,,,,22224,Autocuration,compound was evaluated for drug bound in plasma,,CHEMBL625933,,0,1,,BAO_0000019,,
13152,A,,10116.0,,50597,Intermediate,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,CHEMBL625934,,1,1,,BAO_0000218,,
13153,A,,9347.0,,22224,Autocuration,Bioavailability,,CHEMBL625935,,0,1,,BAO_0000218,,
13154,A,,10116.0,,50597,Intermediate,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,CHEMBL625936,,1,1,,BAO_0000218,,
13155,A,,10116.0,,50597,Intermediate,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,CHEMBL625937,,1,1,,BAO_0000218,,
13156,A,,9615.0,,50588,Intermediate,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,CHEMBL625938,,1,1,,BAO_0000218,,
13157,A,,10116.0,,50597,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,,CHEMBL625939,,1,1,,BAO_0000218,1970.0,
13158,A,,10116.0,,50597,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,,CHEMBL625940,,1,1,,BAO_0000218,1970.0,
13159,A,,10116.0,,50597,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,,CHEMBL874464,,1,1,,BAO_0000218,1970.0,
13160,A,,10116.0,,50597,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,,CHEMBL625941,,1,1,,BAO_0000218,1970.0,
13161,A,,10116.0,,50597,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,,CHEMBL625942,,1,1,,BAO_0000218,1970.0,
13162,A,,10116.0,,50597,Intermediate,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,,CHEMBL625943,,1,1,,BAO_0000218,1970.0,
13163,A,,9606.0,,50587,Intermediate,In vitro protein binding in human serum at 5 ug/ml,,CHEMBL625944,,1,1,,BAO_0000218,1977.0,
13164,A,,,,22224,Autocuration,Serum protein binding ability was measured,,CHEMBL625945,,0,1,,BAO_0000019,,
13165,A,,,,22224,Autocuration,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,CHEMBL625946,,0,1,,BAO_0000019,,
13166,A,In vivo,9615.0,,22224,Autocuration,Oral bioavailability in dog,,CHEMBL625947,,0,1,,BAO_0000218,,
13167,A,In vivo,10116.0,,50597,Intermediate,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,CHEMBL625948,,1,1,,BAO_0000218,,
13168,A,In vivo,,,22224,Autocuration,Absolute oral bioavailability at an iv dose of 14 mg/kg,,CHEMBL625949,,0,1,,BAO_0000218,,
13169,A,In vivo,,,22224,Autocuration,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,CHEMBL625950,,0,1,,BAO_0000218,,
13170,A,In vivo,9347.0,,22224,Autocuration,Oral bioavailability (dose 15 mg/kg i.v.),,CHEMBL625951,,0,1,,BAO_0000218,,
13171,A,In vivo,,,22224,Autocuration,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,CHEMBL625952,,0,1,,BAO_0000218,,
13172,A,In vivo,,,22224,Autocuration,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,CHEMBL625953,,0,1,,BAO_0000218,,
13173,A,In vivo,,,22224,Autocuration,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,CHEMBL625954,,0,1,,BAO_0000218,,
13174,A,In vivo,,,22224,Autocuration,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,CHEMBL882959,,0,1,,BAO_0000218,,
13175,A,In vivo,9615.0,,50588,Intermediate,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,CHEMBL625955,,1,1,,BAO_0000218,,
13176,A,In vivo,9669.0,,22224,Autocuration,Bioavailability in ferret,,CHEMBL625956,,0,1,,BAO_0000218,,
13177,A,In vivo,9541.0,,100710,Intermediate,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,CHEMBL625957,,1,1,,BAO_0000218,,
13178,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,CHEMBL625958,,1,1,,BAO_0000218,,
13179,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,CHEMBL625959,,1,1,,BAO_0000218,,
13180,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,CHEMBL626642,,1,1,,BAO_0000218,,
13181,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,CHEMBL631330,,1,1,,BAO_0000218,,
13182,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,CHEMBL631331,,1,1,,BAO_0000218,,
13183,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,CHEMBL631332,,1,1,,BAO_0000218,,
13184,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,CHEMBL631333,,1,1,,BAO_0000218,,
13185,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,CHEMBL632018,,1,1,,BAO_0000218,,
13186,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,CHEMBL632019,,1,1,,BAO_0000218,,
13187,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,CHEMBL632020,,1,1,,BAO_0000218,,
13188,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,CHEMBL632021,,1,1,,BAO_0000218,,
13189,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,CHEMBL632022,,1,1,,BAO_0000218,,
13190,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,CHEMBL632023,,1,1,,BAO_0000218,,
13191,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,CHEMBL632024,,1,1,,BAO_0000218,,
13192,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,CHEMBL874472,,1,1,,BAO_0000218,,
13193,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,CHEMBL632025,,1,1,,BAO_0000218,,
13194,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,CHEMBL632026,,1,1,,BAO_0000218,,
13195,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,CHEMBL632027,,1,1,,BAO_0000218,,
13196,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,CHEMBL632028,,1,1,,BAO_0000218,,
13197,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,CHEMBL626430,,1,1,,BAO_0000218,,
13198,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,CHEMBL626431,,1,1,,BAO_0000218,,
13199,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,CHEMBL626432,,1,1,,BAO_0000218,,
13200,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,CHEMBL626433,,1,1,,BAO_0000218,,
13201,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,CHEMBL626434,,1,1,,BAO_0000218,,
13202,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,CHEMBL627280,,1,1,,BAO_0000218,,
13203,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,CHEMBL627281,,1,1,,BAO_0000218,,
13204,A,,10116.0,,50597,Intermediate,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,CHEMBL627282,,1,1,,BAO_0000218,,
13205,A,,,,22224,Autocuration,Total body clearance was measured at given dose,,CHEMBL627283,,0,1,,BAO_0000019,,
13206,A,,,,22224,Autocuration,Total body clearance was measured at given dose.,,CHEMBL627284,,0,1,,BAO_0000218,,
13207,A,,10116.0,,50597,Intermediate,Metabolic clearance from the body in rat,,CHEMBL627285,,1,1,,BAO_0000218,,
13208,A,In vivo,,,22224,Autocuration,Renal clearance from the body,,CHEMBL627286,,0,1,,BAO_0000218,,
13209,A,In vivo,10116.0,,50597,Intermediate,Renal clearance from the body in rat,,CHEMBL875477,,1,1,,BAO_0000218,,
13210,A,In vivo,10116.0,,50597,Intermediate,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,CHEMBL627287,,1,1,,BAO_0000218,,
13211,A,In vivo,9615.0,,50588,Intermediate,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,CHEMBL627288,,1,1,,BAO_0000218,,
13212,A,,10116.0,,50597,Intermediate,Total clearance from the body in rat,,CHEMBL627289,,1,1,,BAO_0000218,,
13213,A,In vivo,10116.0,,50597,Intermediate,Clearance into cortex from rat plasma or PBS,,CHEMBL627290,,1,1,,BAO_0000218,1969.0,
13214,A,In vivo,,,22224,Autocuration,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,CHEMBL627291,,0,1,,BAO_0000218,,
13215,A,In vivo,,,22224,Autocuration,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,CHEMBL627292,,0,1,,BAO_0000218,,
13216,A,In vivo,,,22224,Autocuration,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,CHEMBL627293,,0,1,,BAO_0000218,,
13217,A,In vivo,,,22224,Autocuration,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,CHEMBL627294,,0,1,,BAO_0000218,,
13218,A,In vivo,,,22224,Autocuration,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,CHEMBL875478,,0,1,,BAO_0000218,,
13219,A,In vivo,,,22224,Autocuration,Clearance was determined,,CHEMBL627295,,0,1,,BAO_0000218,,
13220,A,In vivo,10090.0,,50594,Intermediate,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,CHEMBL627296,,1,1,,BAO_0000218,,
13221,A,In vivo,9986.0,,50592,Intermediate,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,CHEMBL626119,,1,1,,BAO_0000218,,
13222,A,In vivo,10116.0,,50597,Intermediate,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,CHEMBL626120,,1,1,,BAO_0000218,,
13223,A,In vivo,10116.0,,50597,Intermediate,Clearance in rat after iv dose (100 ug/kg),,CHEMBL626121,,1,1,,BAO_0000218,,
13224,A,In vivo,10141.0,,22224,Autocuration,Clearance in guinea pig,,CHEMBL626122,,0,1,,BAO_0000218,,
13225,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for clearance in rat,,CHEMBL626123,,1,1,,BAO_0000218,,
13226,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for the clearance in dog,,CHEMBL623456,,1,1,,BAO_0000218,,
13227,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for the clearance in rat,,CHEMBL623457,,1,1,,BAO_0000218,,
13228,A,In vivo,10116.0,,50597,Intermediate,Compound was tested in vivo for clearance after iv administration in the rat,,CHEMBL623458,,1,1,,BAO_0000218,,
13229,A,In vivo,,,22224,Autocuration,IV clearance determined at an iv dose of 14 mg/kg,,CHEMBL623459,,0,1,,BAO_0000218,,
13230,A,In vivo,,,22224,Autocuration,IV clearance determined at an iv dose of 15.2 mg/kg,,CHEMBL875484,,0,1,,BAO_0000218,,
13231,A,In vivo,,,22224,Autocuration,IV clearance determined at an iv dose of 15 mg/kg,,CHEMBL623460,,0,1,,BAO_0000218,,
13232,A,In vivo,,,22224,Autocuration,IV clearance determined at an peroral dose of 30 mg/kg.,,CHEMBL623461,,0,1,,BAO_0000218,,
13233,A,In vivo,,,22224,Autocuration,IV clearance determined at an peroral dose of 30.2 mg/kg.,,CHEMBL623462,,0,1,,BAO_0000218,,
13234,A,In vivo,,,22224,Autocuration,IV clearance determined at an peroral dose of 30.3 mg/kg.,,CHEMBL627386,,0,1,,BAO_0000218,,
13235,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,,CHEMBL627387,,1,1,,BAO_0000218,2113.0,
13236,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,,CHEMBL627388,,1,1,,BAO_0000218,2107.0,
13237,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,,CHEMBL627389,,1,1,,BAO_0000218,2048.0,
13238,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,,CHEMBL627390,,1,1,,BAO_0000218,2385.0,
13239,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,,CHEMBL627391,,1,1,,BAO_0000218,1969.0,
13240,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,CHEMBL627392,,1,1,,BAO_0000218,,
13241,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,,CHEMBL627393,,1,1,,BAO_0000218,2106.0,
13242,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,,CHEMBL627394,,1,1,,BAO_0000218,3126.0,
13243,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,,CHEMBL627395,,1,1,,BAO_0000218,10000001.0,
13244,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,,CHEMBL875485,,1,1,,BAO_0000218,2037.0,
13245,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,CHEMBL627396,,1,1,,BAO_0000218,,
13246,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,CHEMBL627397,,1,1,,BAO_0000218,,
13247,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,,CHEMBL627398,,1,1,,BAO_0000218,948.0,
13248,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,,CHEMBL627399,,1,1,,BAO_0000218,10000001.0,
13249,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,,CHEMBL627400,,1,1,,BAO_0000218,2113.0,
13250,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,,CHEMBL627401,,1,1,,BAO_0000218,2107.0,
13251,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,,CHEMBL627402,,1,1,,BAO_0000218,2048.0,
13252,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,,CHEMBL627403,,1,1,,BAO_0000218,2385.0,
13253,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,,CHEMBL627404,,1,1,,BAO_0000218,1969.0,
13254,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,CHEMBL623101,,1,1,,BAO_0000218,,
13255,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,,CHEMBL877480,,1,1,,BAO_0000218,2106.0,
13256,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,,CHEMBL623102,,1,1,,BAO_0000218,3126.0,
13257,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,,CHEMBL623103,,1,1,,BAO_0000218,10000001.0,
13258,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,,CHEMBL623104,,1,1,,BAO_0000218,2037.0,
13259,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,CHEMBL623105,,1,1,,BAO_0000218,,
13260,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,CHEMBL623106,,1,1,,BAO_0000218,,
13261,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,,CHEMBL623107,,1,1,,BAO_0000218,948.0,
13262,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,,CHEMBL623108,,1,1,,BAO_0000218,160.0,
13263,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,,CHEMBL623109,,1,1,,BAO_0000218,2113.0,
13264,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,,CHEMBL623110,,1,1,,BAO_0000218,2107.0,
13265,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,,CHEMBL623111,,1,1,,BAO_0000218,2048.0,
13266,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,,CHEMBL625060,,1,1,,BAO_0000218,2385.0,
13267,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,,CHEMBL625061,,1,1,,BAO_0000218,1969.0,
13268,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,CHEMBL625062,,1,1,,BAO_0000218,,
13269,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,,CHEMBL625063,,1,1,,BAO_0000218,2106.0,
13270,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,,CHEMBL625064,,1,1,,BAO_0000218,3126.0,
13271,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,,CHEMBL625065,,1,1,,BAO_0000218,10000001.0,
13272,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,,CHEMBL625066,,1,1,,BAO_0000218,2037.0,
13273,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,CHEMBL625067,,1,1,,BAO_0000218,,
13274,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,CHEMBL625068,,1,1,,BAO_0000218,,
13275,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,,CHEMBL622159,,1,1,,BAO_0000218,948.0,
13276,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,,CHEMBL622160,,1,1,,BAO_0000218,160.0,
13277,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,,CHEMBL622161,,1,1,,BAO_0000218,2113.0,
13278,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,,CHEMBL622162,,1,1,,BAO_0000218,2048.0,
13279,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,,CHEMBL622163,,1,1,,BAO_0000218,2385.0,
13280,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,,CHEMBL622313,,1,1,,BAO_0000218,1969.0,
13281,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,CHEMBL622314,,1,1,,BAO_0000218,,
13282,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,,CHEMBL622315,,1,1,,BAO_0000218,2106.0,
13283,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,,CHEMBL622316,,1,1,,BAO_0000218,3126.0,
13284,A,,562.0,,50212,Intermediate,Normal diffusion coefficient in water for Escherichia coli,,CHEMBL877486,,1,1,,BAO_0000218,,
13285,A,,,,22224,Autocuration,Average max percent decrease in RVR (renal vascular resistance) was determined,,CHEMBL622317,,0,1,,BAO_0000019,,
13286,A,,,,22224,Autocuration,Average max percent decrease in RVR (renal vascular resistance) was determined.,,CHEMBL622318,,0,1,,BAO_0000019,,
13287,A,,,,22224,Autocuration,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,CHEMBL622319,,0,1,,BAO_0000019,,
13288,A,,,,22224,Autocuration,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,CHEMBL622320,,0,1,,BAO_0000019,,
13289,A,,,,22224,Autocuration,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,CHEMBL622321,,0,1,,BAO_0000019,,
13290,A,,,,22224,Autocuration,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,CHEMBL622322,,0,1,,BAO_0000019,,
13291,A,,,,22224,Autocuration,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,CHEMBL622323,,0,1,,BAO_0000019,,
13292,A,,10116.0,,50597,Intermediate,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,CHEMBL622324,,1,1,,BAO_0000218,,
13293,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,CHEMBL622325,,1,1,,BAO_0000218,1088.0,
13294,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,CHEMBL622326,,1,1,,BAO_0000218,1088.0,
13295,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",,CHEMBL877487,,1,1,,BAO_0000218,1088.0,
13296,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,CHEMBL622327,,1,1,,BAO_0000218,1088.0,
13297,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",,CHEMBL622328,,1,1,,BAO_0000218,1088.0,
13298,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,CHEMBL622329,,1,1,,BAO_0000218,1088.0,
13299,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,CHEMBL622330,,1,1,,BAO_0000218,1088.0,
13300,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,CHEMBL622331,,1,1,,BAO_0000218,1088.0,
13301,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,CHEMBL622332,,1,1,,BAO_0000218,1088.0,
13302,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",,CHEMBL622333,,1,1,,BAO_0000218,1088.0,
13303,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,CHEMBL627658,,0,1,,BAO_0000218,1088.0,
13304,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",,CHEMBL630428,,0,1,,BAO_0000218,1088.0,
13305,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,CHEMBL630429,,0,1,,BAO_0000218,1088.0,
13306,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",,CHEMBL630430,,0,1,,BAO_0000218,1088.0,
13307,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",,CHEMBL630431,,0,1,,BAO_0000218,1088.0,
13308,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,CHEMBL630432,,1,1,,BAO_0000218,1088.0,
13309,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,CHEMBL630433,,1,1,,BAO_0000218,1088.0,
13310,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,CHEMBL630434,,1,1,,BAO_0000218,1088.0,
13311,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,CHEMBL629372,,1,1,,BAO_0000218,1088.0,
13312,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",,CHEMBL629553,,1,1,,BAO_0000218,1088.0,
13313,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,CHEMBL629554,,1,1,,BAO_0000218,1088.0,
13314,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,CHEMBL874447,,1,1,,BAO_0000218,1088.0,
13315,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,CHEMBL629555,,1,1,,BAO_0000218,1088.0,
13316,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,CHEMBL629556,,1,1,,BAO_0000218,1088.0,
13317,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",,CHEMBL629557,,1,1,,BAO_0000218,1088.0,
13318,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,CHEMBL629558,,1,1,,BAO_0000218,1088.0,
13319,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,CHEMBL629559,,1,1,,BAO_0000218,1088.0,
13320,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,CHEMBL629560,,1,1,,BAO_0000218,1088.0,
13321,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,CHEMBL629561,,1,1,,BAO_0000218,1088.0,
13322,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,CHEMBL629562,,1,1,,BAO_0000218,1088.0,
13323,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,CHEMBL629563,,1,1,,BAO_0000218,1088.0,
13324,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,CHEMBL629564,,1,1,,BAO_0000218,1088.0,
13325,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,CHEMBL629565,,1,1,,BAO_0000218,1088.0,
13326,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,CHEMBL629566,,1,1,,BAO_0000218,1088.0,
13327,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",,CHEMBL629567,,1,1,,BAO_0000218,1088.0,
13328,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,CHEMBL629568,,1,1,,BAO_0000218,1088.0,
13329,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",,CHEMBL629569,,1,1,,BAO_0000218,1088.0,
13330,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,CHEMBL629570,,1,1,,BAO_0000218,1088.0,
13331,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,CHEMBL629571,,0,1,,BAO_0000218,1088.0,
13332,A,In vivo,10116.0,,22224,Autocuration,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,CHEMBL629572,,0,1,,BAO_0000218,,
13333,A,In vivo,10116.0,,22224,Autocuration,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,CHEMBL629573,,0,1,,BAO_0000218,,
13334,A,In vivo,9347.0,,22224,Autocuration,Bioavailability (dose 20 mg/kg),,CHEMBL629574,,0,1,,BAO_0000218,,
13335,A,In vivo,9615.0,,22224,Autocuration,Bioavailability in dog,,CHEMBL629575,,0,1,,BAO_0000218,,
13336,A,In vivo,10116.0,,22224,Autocuration,Bioavailability in rat (Sprague-Dawley) (male),,CHEMBL874448,,0,1,,BAO_0000218,,
13337,A,In vivo,9443.0,,22224,Autocuration,Bioavailability in monkey (dose 10 mg/kg i.d.),,CHEMBL629576,,0,1,,BAO_0000218,,
13338,A,In vivo,10116.0,,22224,Autocuration,Bioavailability in rat,,CHEMBL629577,,0,1,,BAO_0000218,,
13339,A,In vivo,10116.0,,22224,Autocuration,Bioavailability in rat,,CHEMBL629578,,0,1,,BAO_0000218,,
13340,A,In vivo,9615.0,,22224,Autocuration,Bioavailability in dog (dose 3.0 mg/kg p.o.),,CHEMBL629579,,0,1,,BAO_0000218,,
13341,A,In vivo,9615.0,,22224,Autocuration,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,CHEMBL882958,,0,1,,BAO_0000218,,
13342,A,In vivo,9598.0,,50505,Intermediate,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,CHEMBL629580,,1,1,,BAO_0000218,,
13343,A,In vivo,9347.0,,22224,Autocuration,Bioavailability,,CHEMBL629581,,0,1,,BAO_0000218,,
13344,A,In vivo,9520.0,,22224,Autocuration,Bioavailability in squirrel monkey,,CHEMBL629582,,0,1,,BAO_0000218,,
13345,A,In vivo,9615.0,,50588,Intermediate,Bioavailability was evaluated in dog,,CHEMBL628522,,1,1,,BAO_0000218,,
13346,A,In vivo,10026.0,,100712,Intermediate,Bioavailability was evaluated in hamster,,CHEMBL625432,,1,1,,BAO_0000218,,
13347,A,In vivo,10116.0,,22224,Autocuration,Bioavailability in rat,,CHEMBL625433,,0,1,,BAO_0000218,,
13348,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,CHEMBL625434,,1,1,,BAO_0000218,1969.0,
13349,A,In vivo,10116.0,,50597,Intermediate,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,,CHEMBL625435,,1,1,,BAO_0000218,1969.0,
13350,A,In vivo,10116.0,,22224,Autocuration,Bioavailability in rat (dose 10 mg/kg p.o.),,CHEMBL625436,,0,1,,BAO_0000218,,
13351,A,In vivo,9541.0,,100710,Intermediate,Bioavailability was measured in cynomolgus monkeys.,,CHEMBL874588,,1,1,,BAO_0000218,,
13352,A,In vivo,10090.0,,50594,Intermediate,Bioavailability was measured in nude mice.,,CHEMBL625437,,1,1,,BAO_0000218,,
13353,A,In vivo,9669.0,,22224,Autocuration,Bioavailability in ferret (dose 10 mg/kg i.d.),,CHEMBL625438,,0,1,,BAO_0000218,,
13354,A,In vivo,314293.0,,22224,Autocuration,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,CHEMBL625439,,0,1,,BAO_0000218,,
13355,A,In vivo,314293.0,,22224,Autocuration,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,CHEMBL625440,,0,1,,BAO_0000218,,
13356,A,In vivo,314293.0,,22224,Autocuration,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,CHEMBL625441,,0,1,,BAO_0000218,,
13357,A,In vivo,10116.0,,22224,Autocuration,Bioavailability in rat (dose 10 mg/kg i.d.),,CHEMBL625442,,0,1,,BAO_0000218,,
13358,A,In vivo,10116.0,,50597,Intermediate,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,CHEMBL625443,,1,1,,BAO_0000218,,
13359,A,In vivo,,,22224,Autocuration,Bioavailability was determined; extremely poor,,CHEMBL625444,,0,1,,BAO_0000218,,
13360,A,In vivo,10090.0,,50594,Intermediate,% bioavailability in mice after oral administration of prodrug,,CHEMBL625445,,1,1,,BAO_0000218,,
13361,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,CHEMBL625446,,1,1,,BAO_0000218,,
13362,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,CHEMBL882960,,1,1,,BAO_0000218,,
13363,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,CHEMBL625447,,1,1,,BAO_0000218,,
13364,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,CHEMBL625448,,1,1,,BAO_0000218,,
13365,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,CHEMBL625449,,1,1,,BAO_0000218,,
13366,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,CHEMBL874589,,1,1,,BAO_0000218,,
13367,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,CHEMBL625450,,1,1,,BAO_0000218,,
13368,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,CHEMBL625451,,1,1,,BAO_0000218,,
13369,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,CHEMBL626584,,1,1,,BAO_0000218,,
13370,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,CHEMBL626585,,1,1,,BAO_0000218,,
13371,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,CHEMBL626586,,1,1,,BAO_0000218,,
13372,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,CHEMBL626587,,1,1,,BAO_0000218,,
13373,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,CHEMBL626588,,1,1,,BAO_0000218,,
13374,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,CHEMBL626589,,1,1,,BAO_0000218,,
13375,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,CHEMBL626590,,1,1,,BAO_0000218,,
13376,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,CHEMBL626591,,1,1,,BAO_0000218,,
13377,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,CHEMBL627181,,1,1,,BAO_0000218,,
13378,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,CHEMBL628083,,1,1,,BAO_0000218,,
13379,A,In vivo,,,22224,Autocuration,IV clearance determined at an peroral dose of 15 mg/kg.,,CHEMBL628084,,0,1,,BAO_0000218,,
13380,F,In vivo,102285.0,,50064,Expert,Mouse oral clearance was measured against Hymenolepiasis nana.,,CHEMBL628085,,1,1,,BAO_0000218,,
13381,F,In vivo,6339.0,,50545,Expert,Mouse oral clearance was measured against Nematospiroides dubius,,CHEMBL628086,,1,1,,BAO_0000218,,
13382,F,In vivo,,,22224,Autocuration,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,CHEMBL628087,,0,1,,BAO_0000218,,
13383,A,In vivo,10090.0,,50594,Intermediate,Mouse oral clearance was measured against N. nana; NT is Not Tested,,CHEMBL628088,,1,1,,BAO_0000218,,
13384,B,In vivo,,,22224,Autocuration,Mouse oral clearance was measured against N. nana; NT is Not Tested,,CHEMBL628089,,0,1,,BAO_0000218,,
13385,A,In vivo,,,22224,Autocuration,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,CHEMBL628090,,0,1,,BAO_0000218,,
13386,A,In vivo,,,22224,Autocuration,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,CHEMBL628091,,0,1,,BAO_0000218,,
13387,A,In vivo,,,22224,Autocuration,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,CHEMBL628092,,0,1,,BAO_0000218,,
13388,A,In vivo,,,22224,Autocuration,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,CHEMBL628093,,0,1,,BAO_0000218,,
13389,A,In vivo,,,22224,Autocuration,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,CHEMBL875607,,0,1,,BAO_0000218,,
13390,A,In vivo,,,22224,Autocuration,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,CHEMBL625710,,0,1,,BAO_0000218,,
13391,A,In vivo,,,22224,Autocuration,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,CHEMBL625711,,0,1,,BAO_0000218,,
13392,A,In vivo,,,22224,Autocuration,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,CHEMBL625712,,0,1,,BAO_0000218,,
13393,A,In vivo,,,22224,Autocuration,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,CHEMBL625713,,0,1,,BAO_0000218,,
13394,A,In vivo,9615.0,,50588,Intermediate,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,CHEMBL625714,,1,1,,BAO_0000218,,
13395,A,In vivo,9544.0,,50797,Intermediate,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,CHEMBL625715,,1,1,,BAO_0000218,,
13396,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,CHEMBL625716,,1,1,,BAO_0000218,,
13397,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,CHEMBL625717,,1,1,,BAO_0000218,,
13398,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance was determined for the compound in rats,,CHEMBL625718,,1,1,,BAO_0000218,,
13399,A,In vivo,10116.0,,50597,Intermediate,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,CHEMBL625719,,1,1,,BAO_0000218,,
13400,A,In vivo,10116.0,,50597,Intermediate,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,CHEMBL625720,,1,1,,BAO_0000218,,
13401,A,In vivo,10116.0,,50597,Intermediate,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,CHEMBL625721,,1,1,,BAO_0000218,,
13402,A,In vivo,10116.0,,50597,Intermediate,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,CHEMBL625722,,1,1,,BAO_0000218,,
13403,A,In vivo,10116.0,,50597,Intermediate,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,CHEMBL625723,,1,1,,BAO_0000218,,
13404,A,In vivo,6339.0,,50545,Intermediate,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,CHEMBL625724,,1,1,,BAO_0000218,,
13405,A,In vivo,6339.0,,50545,Intermediate,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,CHEMBL625725,,1,1,,BAO_0000218,,
13406,A,In vivo,6339.0,,50545,Intermediate,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,CHEMBL625726,,1,1,,BAO_0000218,,
13407,A,In vivo,6339.0,,50545,Intermediate,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,CHEMBL875608,,1,1,,BAO_0000218,,
13408,A,In vivo,6339.0,,50545,Intermediate,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,CHEMBL625727,,1,1,,BAO_0000218,,
13409,A,In vivo,10116.0,,22224,Autocuration,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,,CHEMBL625728,,0,1,,BAO_0000218,1088.0,
13410,A,In vivo,10116.0,,22224,Autocuration,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,CHEMBL625729,,0,1,,BAO_0000218,,
13411,A,In vivo,10116.0,,22224,Autocuration,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,CHEMBL625730,,0,1,,BAO_0000218,,
13412,A,In vivo,10116.0,,22224,Autocuration,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,CHEMBL625731,,0,1,,BAO_0000218,1088.0,
13413,A,In vivo,10116.0,,22224,Autocuration,Urinary clearance was determined in rat at 25 mg/kg os dosage,,CHEMBL626417,,0,1,,BAO_0000218,1088.0,
13414,A,In vivo,9606.0,,50587,Intermediate,Urinary clearance was determined at 100 mg/kg oral dosage in human,,CHEMBL626418,,1,1,,BAO_0000218,1088.0,
13415,A,In vivo,9615.0,,50588,Intermediate,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,,CHEMBL626419,,1,1,,BAO_0000218,1088.0,
13416,A,In vivo,9615.0,,50588,Intermediate,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,CHEMBL626592,,1,1,,BAO_0000218,1969.0,
13417,A,In vivo,10116.0,,50597,Intermediate,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,CHEMBL626593,,1,1,,BAO_0000218,1969.0,
13418,A,In vivo,10116.0,,50597,Intermediate,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,CHEMBL626594,,1,1,,BAO_0000218,,
13419,A,In vivo,9615.0,,50588,Intermediate,Clearance rate in dogs,,CHEMBL625035,,1,1,,BAO_0000218,,
13420,A,In vitro,,,22224,Autocuration,Compound was measured for intrinsic clearance,,CHEMBL625036,,0,1,,BAO_0000019,,
13421,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625037,,0,1,,BAO_0000100,,
13422,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625038,,0,1,,BAO_0000100,,
13423,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625039,,0,1,,BAO_0000100,,
13424,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625040,,0,1,,BAO_0000100,,
13425,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625041,,0,1,,BAO_0000100,,
13426,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625042,,0,1,,BAO_0000100,,
13427,A,,,,22224,Autocuration,Partition coefficient of the compound,,CHEMBL874411,,0,1,,BAO_0000019,,
13428,A,,,,22224,Autocuration,Permeability,,CHEMBL625043,,0,1,,BAO_0000019,,
13429,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625044,,0,1,,BAO_0000100,,
13430,A,,,,22224,Autocuration,Partition coefficient (logD),,CHEMBL625045,,0,1,,BAO_0000019,,
13431,P,,,,22229,Autocuration,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,CHEMBL625046,,0,1,,BAO_0000100,,
13432,P,,,,22229,Autocuration,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,CHEMBL625047,,0,1,,BAO_0000100,,
13433,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625048,,0,1,,BAO_0000100,,
13434,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625049,,0,1,,BAO_0000100,,
13435,P,,,,22229,Autocuration,Calculated logarithm of partition coefficient (P) was determined,,CHEMBL625050,,0,1,,BAO_0000100,,
13436,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625051,,0,1,,BAO_0000100,,
13437,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL874412,,0,1,,BAO_0000100,,
13438,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625052,,0,1,,BAO_0000100,,
13439,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL625053,,0,1,,BAO_0000100,,
13440,A,,,,22224,Autocuration,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,CHEMBL623250,,0,1,,BAO_0000019,,
13441,A,,,,22224,Autocuration,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,CHEMBL623251,,0,1,,BAO_0000019,,
13442,A,,,,22224,Autocuration,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,CHEMBL623252,,0,1,,BAO_0000019,,
13443,A,,,,22224,Autocuration,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,CHEMBL623253,,0,1,,BAO_0000019,,
13444,A,,,,22224,Autocuration,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,CHEMBL623254,,0,1,,BAO_0000019,,
13445,A,,,,22224,Autocuration,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,CHEMBL623255,,0,1,,BAO_0000019,,
13446,A,,,,22224,Autocuration,Percent degradation of compound at a pH of 1 over a 18 hr period,,CHEMBL626831,,0,1,,BAO_0000019,,
13447,A,,,,22224,Autocuration,Percent degradation of compound at pH of 1 over an 18 hr period,,CHEMBL877494,,0,1,,BAO_0000019,,
13448,A,,,,22224,Autocuration,Delta Logarithm of Partition Coefficient value was determined.,,CHEMBL626832,,0,1,,BAO_0000019,,
13449,A,,,,22224,Autocuration,Delta logPoct-cyc,,CHEMBL626833,,0,1,,BAO_0000019,,
13450,P,,,,22224,Autocuration,Lipophilicity estimated on reversed phase TLC,,CHEMBL626834,,0,1,,BAO_0000100,,
13451,A,,,,22224,Autocuration,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,CHEMBL626835,,0,1,,BAO_0000019,,
13452,A,,,,22224,Autocuration,Delta logPoct-cyc,,CHEMBL626836,,0,1,,BAO_0000019,,
13453,P,,,,22229,Autocuration,Change in logarithm of partition coefficient of the compound,,CHEMBL626837,,0,1,,BAO_0000100,,
13454,A,,,,22224,Autocuration,Delta logD (pH 6.5),,CHEMBL626838,,0,1,,BAO_0000019,,
13455,P,,,,22224,Autocuration,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,CHEMBL626839,,0,1,,BAO_0000100,,
13456,A,,,,22224,Autocuration,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,CHEMBL626840,,0,1,,BAO_0000019,,
13457,A,,,,22224,Autocuration,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,CHEMBL626841,,0,1,,BAO_0000019,,
13458,A,,,,22224,Autocuration,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,CHEMBL626842,,0,1,,BAO_0000219,,
13459,A,,,,22224,Autocuration,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,CHEMBL626843,,0,1,,BAO_0000219,,
13460,A,,10116.0,,50597,Intermediate,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,CHEMBL626844,,1,1,,BAO_0000218,,
13461,A,,10116.0,,50597,Intermediate,Amount of deuterium retained was reported after normal workup in rats,,CHEMBL877495,,1,1,,BAO_0000218,,
13462,A,,10116.0,,50597,Intermediate,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,CHEMBL626845,,1,1,,BAO_0000218,,
13463,A,,10116.0,,50597,Intermediate,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,CHEMBL626846,,1,1,,BAO_0000218,,
13464,A,,10116.0,,50597,Intermediate,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,CHEMBL626847,,1,1,,BAO_0000218,,
13465,A,,10116.0,,50597,Intermediate,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,CHEMBL628677,,1,1,,BAO_0000218,,
13466,A,,10116.0,,50597,Intermediate,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,CHEMBL628678,,1,1,,BAO_0000218,,
13467,A,,,,22224,Autocuration,Compound was subjected to electrochemical oxidation,,CHEMBL628679,,0,1,,BAO_0000019,,
13468,A,,,,22224,Autocuration,Compound was subjected to photochemical oxidation,,CHEMBL628680,,0,1,,BAO_0000019,,
13469,A,,,,22224,Autocuration,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,CHEMBL628681,,0,1,,BAO_0000019,,
13470,A,,,,22224,Autocuration,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,CHEMBL628682,,0,1,,BAO_0000019,,
13471,A,,,,22224,Autocuration,Oxidation of compound by methemoglobin in presence of hydroperoxide,,CHEMBL628683,,0,1,,BAO_0000019,,
13472,A,,10116.0,,50597,Intermediate,Percent diffusion through fuzzy rat skin after 48 h of incubation,,CHEMBL628684,,1,1,,BAO_0000218,,
13473,P,,,,22229,Autocuration,Dissociation constant (pKa),,CHEMBL877501,,0,1,,BAO_0000100,,
13474,P,,,,22224,Autocuration,Dissociation constant value of the compound; ND means not determined.,,CHEMBL628685,,0,1,,BAO_0000100,,
13475,A,,10116.0,,50597,Intermediate,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,,CHEMBL628686,,1,1,,BAO_0000218,178.0,
13476,A,,10116.0,,50597,Intermediate,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,CHEMBL628687,,1,1,,BAO_0000218,178.0,
13477,A,,10116.0,,50597,Intermediate,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,CHEMBL628688,,1,1,,BAO_0000218,,
13478,A,,10116.0,,50597,Intermediate,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,CHEMBL628689,,1,1,,BAO_0000218,,
13479,A,,10116.0,,50597,Intermediate,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,,CHEMBL628690,,1,1,,BAO_0000218,2107.0,
13480,A,,10116.0,,50597,Intermediate,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,CHEMBL629363,,1,1,,BAO_0000218,2107.0,
13481,A,,10116.0,,50597,Intermediate,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,,CHEMBL629364,,1,1,,BAO_0000218,2106.0,
13482,A,,10116.0,,50597,Intermediate,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,CHEMBL629365,,1,1,,BAO_0000218,2106.0,
13483,A,,10116.0,,50597,Intermediate,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,CHEMBL629366,,1,1,,BAO_0000218,,
13484,A,,10116.0,,50597,Intermediate,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,,CHEMBL629367,,1,1,,BAO_0000218,1088.0,
13485,A,,10116.0,,50597,Intermediate,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,CHEMBL629368,,1,1,,BAO_0000218,1988.0,
13486,A,,10116.0,,50597,Intermediate,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,CHEMBL877502,,1,1,,BAO_0000218,1088.0,
13487,A,,10090.0,,50594,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,,CHEMBL629369,,1,1,,BAO_0000218,2037.0,
13488,A,,10090.0,,50594,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,,CHEMBL629370,,1,1,,BAO_0000218,955.0,
13489,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",,CHEMBL629371,,0,1,,BAO_0000218,1088.0,
13490,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,CHEMBL626276,,0,1,,BAO_0000218,1088.0,
13491,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,CHEMBL626277,,0,1,,BAO_0000218,1088.0,
13492,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,CHEMBL631250,,0,1,,BAO_0000218,1088.0,
13493,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,CHEMBL631251,,1,1,,BAO_0000218,1088.0,
13494,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,CHEMBL631252,,1,1,,BAO_0000218,1088.0,
13495,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",,CHEMBL631253,,1,1,,BAO_0000218,1088.0,
13496,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,CHEMBL631254,,1,1,,BAO_0000218,1088.0,
13497,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,CHEMBL631255,,1,1,,BAO_0000218,1088.0,
13498,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,CHEMBL631256,,1,1,,BAO_0000218,1088.0,
13499,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,CHEMBL631257,,1,1,,BAO_0000218,1088.0,
13500,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",,CHEMBL628009,,1,1,,BAO_0000218,1088.0,
13501,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,CHEMBL628010,,1,1,,BAO_0000218,1088.0,
13502,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,CHEMBL628011,,1,1,,BAO_0000218,1088.0,
13503,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",,CHEMBL628012,,1,1,,BAO_0000218,1088.0,
13504,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,CHEMBL628013,,1,1,,BAO_0000218,1088.0,
13505,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,CHEMBL628014,,1,1,,BAO_0000218,1088.0,
13506,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",,CHEMBL628015,,1,1,,BAO_0000218,1088.0,
13507,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,CHEMBL628016,,1,1,,BAO_0000218,1088.0,
13508,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",,CHEMBL874461,,1,1,,BAO_0000218,1088.0,
13509,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,CHEMBL628017,,1,1,,BAO_0000218,1088.0,
13510,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,CHEMBL628018,,1,1,,BAO_0000218,1088.0,
13511,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,CHEMBL628019,,1,1,,BAO_0000218,1088.0,
13512,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,CHEMBL628020,,1,1,,BAO_0000218,1088.0,
13513,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,CHEMBL628021,,1,1,,BAO_0000218,1088.0,
13514,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,CHEMBL628022,,1,1,,BAO_0000218,1088.0,
13515,A,,9615.0,,50588,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,CHEMBL628023,,1,1,,BAO_0000218,1088.0,
13516,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,CHEMBL628024,,0,1,,BAO_0000218,1088.0,
13517,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",,CHEMBL628025,,0,1,,BAO_0000218,1088.0,
13518,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,CHEMBL628026,,0,1,,BAO_0000218,1088.0,
13519,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,CHEMBL628027,,0,1,,BAO_0000218,1088.0,
13520,A,,314293.0,,22224,Autocuration,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,CHEMBL628028,,0,1,,BAO_0000218,1088.0,
13521,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,CHEMBL628029,,1,1,,BAO_0000218,1088.0,
13522,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",,CHEMBL628030,,1,1,,BAO_0000218,1088.0,
13523,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,CHEMBL628031,,1,1,,BAO_0000218,1088.0,
13524,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",,CHEMBL628032,,1,1,,BAO_0000218,1088.0,
13525,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,CHEMBL628033,,1,1,,BAO_0000218,1088.0,
13526,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",,CHEMBL628034,,1,1,,BAO_0000218,1088.0,
13527,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,CHEMBL628035,,1,1,,BAO_0000218,1088.0,
13528,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",,CHEMBL628036,,1,1,,BAO_0000218,1088.0,
13529,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,CHEMBL874462,,1,1,,BAO_0000218,1088.0,
13530,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,CHEMBL628037,,1,1,,BAO_0000218,,
13531,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,CHEMBL628123,,1,1,,BAO_0000218,,
13532,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,CHEMBL628124,,1,1,,BAO_0000218,,
13533,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,CHEMBL628125,,1,1,,BAO_0000218,,
13534,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,CHEMBL628126,,1,1,,BAO_0000218,,
13535,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,CHEMBL628127,,1,1,,BAO_0000218,,
13536,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,CHEMBL628128,,1,1,,BAO_0000218,,
13537,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,CHEMBL628129,,1,1,,BAO_0000218,,
13538,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,CHEMBL628130,,1,1,,BAO_0000218,,
13539,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,CHEMBL628131,,1,1,,BAO_0000218,,
13540,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,CHEMBL628132,,1,1,,BAO_0000218,,
13541,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,CHEMBL628133,,1,1,,BAO_0000218,,
13542,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,CHEMBL628134,,1,1,,BAO_0000218,,
13543,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,CHEMBL628135,,1,1,,BAO_0000218,,
13544,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,CHEMBL628136,,1,1,,BAO_0000218,,
13545,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,CHEMBL628137,,1,1,,BAO_0000218,,
13546,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,CHEMBL628138,,1,1,,BAO_0000218,,
13547,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,CHEMBL628139,,1,1,,BAO_0000218,,
13548,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,CHEMBL628140,,1,1,,BAO_0000218,,
13549,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,CHEMBL628141,,1,1,,BAO_0000218,,
13550,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,CHEMBL628142,,1,1,,BAO_0000218,,
13551,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,CHEMBL628143,,1,1,,BAO_0000218,,
13552,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,CHEMBL628144,,1,1,,BAO_0000218,,
13553,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,CHEMBL628145,,1,1,,BAO_0000218,,
13554,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,CHEMBL628146,,1,1,,BAO_0000218,,
13555,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,CHEMBL625355,,1,1,,BAO_0000218,,
13556,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,CHEMBL625356,,1,1,,BAO_0000218,,
13557,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,CHEMBL625357,,1,1,,BAO_0000218,,
13558,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,CHEMBL625527,,1,1,,BAO_0000218,,
13559,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,CHEMBL875473,,1,1,,BAO_0000218,,
13560,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,CHEMBL625528,,1,1,,BAO_0000218,,
13561,A,In vivo,10116.0,,50597,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,CHEMBL626304,,1,1,,BAO_0000218,,
13562,A,In vivo,9615.0,,50588,Intermediate,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,,CHEMBL624138,,1,1,,BAO_0000218,1637.0,
13563,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624139,,0,1,,BAO_0000100,,
13564,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624140,,0,1,,BAO_0000100,,
13565,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624141,,0,1,,BAO_0000100,,
13566,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624142,,0,1,,BAO_0000100,,
13567,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624143,,0,1,,BAO_0000100,,
13568,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624144,,0,1,,BAO_0000100,,
13569,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624145,,0,1,,BAO_0000100,,
13570,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624146,,0,1,,BAO_0000100,,
13571,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624147,,0,1,,BAO_0000100,,
13572,P,,,,22229,Autocuration,Calculated partition coefficient (clogP) (MacLogP),,CHEMBL883123,,0,1,,BAO_0000100,,
13573,A,,,,22224,Autocuration,Partition coefficient (logP),,CHEMBL624148,,0,1,,BAO_0000019,,
13574,A,,,,22224,Autocuration,Kinetic parameter was determined,,CHEMBL874416,,0,1,,BAO_0000019,,
13575,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624149,,0,1,,BAO_0000100,,
13576,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL624150,,0,1,,BAO_0000100,,
13577,P,,,,22224,Autocuration,Lipophilicity was determined,,CHEMBL624151,,0,1,,BAO_0000100,,
13578,P,,,,22224,Autocuration,Lipophilicity was determined,,CHEMBL624152,,0,1,,BAO_0000100,,
13579,P,,,,22224,Autocuration,Lipophilicity was determined,,CHEMBL622139,,0,1,,BAO_0000100,,
13580,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL622140,,0,1,,BAO_0000100,,
13581,P,,,,22224,Autocuration,Lipophilicity was determined,,CHEMBL622141,,0,1,,BAO_0000100,,
13582,P,,,,22224,Autocuration,Lipophilicity in octanol-water,,CHEMBL622142,,0,1,,BAO_0000100,,
13583,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL622143,,0,1,,BAO_0000100,,
13584,P,,,,22229,Autocuration,Octanol-water partition coefficient was determined,,CHEMBL622144,,0,1,,BAO_0000100,,
13585,A,,,,22224,Autocuration,Partition coefficient (logP),,CHEMBL877473,,0,1,,BAO_0000019,,
13586,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL622145,,0,1,,BAO_0000100,,
13587,A,,,,22224,Autocuration,Partition coefficient was determined; ND means not determined,,CHEMBL622146,,0,1,,BAO_0000019,,
13588,P,,,,22229,Autocuration,Calculated partition coefficient (clogP),,CHEMBL622147,,0,1,,BAO_0000100,,
13589,A,,,,22224,Autocuration,Partition coefficient of the compound,,CHEMBL622148,,0,1,,BAO_0000019,,
13590,A,,,,22224,Autocuration,Permeability was determined,,CHEMBL883124,,0,1,,BAO_0000019,,
13591,P,,,,22229,Autocuration,The compound was evaluated for the partition coefficient,,CHEMBL622149,,0,1,,BAO_0000100,,
13592,A,,,,22224,Autocuration,Partition coefficient (logP),,CHEMBL622150,,0,1,,BAO_0000019,,
13593,P,,,,22224,Autocuration,The lipophilicity was reported,,CHEMBL622151,,0,1,,BAO_0000100,,
13594,P,,,,22229,Autocuration,logarithm of the octanol-water partition coefficient for the compound,,CHEMBL622152,,0,1,,BAO_0000100,,
13595,A,,,,22224,Autocuration,Clogp value was determined,,CHEMBL622153,,0,1,,BAO_0000019,,
13596,A,In vivo,,,22224,Autocuration,Clp at a dose of 1.5 mg/kg,,CHEMBL877474,,0,1,,BAO_0000218,,
13597,A,In vivo,,,22224,Autocuration,Clp at a dose of 2.0 mg/kg,,CHEMBL622154,,0,1,,BAO_0000218,,
13598,A,In vivo,,,22224,Autocuration,"Clp, plasma clearance at a dose of 10 mg/kg",,CHEMBL622155,,0,1,,BAO_0000218,1969.0,
13599,A,In vivo,,,22224,Autocuration,"Clp, plasma clearance at a dose of 50 mg/kg",,CHEMBL622156,,0,1,,BAO_0000218,1969.0,
13600,A,In vivo,10116.0,,50597,Intermediate,Compound was tested for plasma clearance in rat,,CHEMBL622157,,1,1,,BAO_0000218,1969.0,
13601,A,In vivo,10116.0,,50597,Intermediate,Compound was tested for plasma clearance in rat; Not determined,,CHEMBL622158,,1,1,,BAO_0000218,1969.0,
13602,A,In vivo,10116.0,,50597,Intermediate,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,CHEMBL622807,,1,1,,BAO_0000218,,
13603,A,In vivo,9544.0,,50797,Intermediate,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,CHEMBL622808,,1,1,,BAO_0000218,,
13604,A,In vivo,,,22224,Autocuration,Plasma clearance by iv administration at a dose 0.003 ug/mL,,CHEMBL622809,,0,1,,BAO_0000218,,
13605,A,In vivo,,,22224,Autocuration,Plasma clearance determined,,CHEMBL622810,,0,1,,BAO_0000218,,
13606,A,In vivo,10026.0,,100712,Intermediate,Plasma clearance after iv administration at 3 mg/kg in hamster,,CHEMBL876653,,1,1,,BAO_0000218,,
13607,A,In vivo,10026.0,,100712,Intermediate,Plasma clearance after iv administration at 4 mg/kg in hamster,,CHEMBL622811,,1,1,,BAO_0000218,,
13608,A,In vivo,10116.0,,50597,Intermediate,Rate of clearance in rat was determined,,CHEMBL622986,,1,1,,BAO_0000218,,
13609,A,In vivo,10116.0,,50597,Intermediate,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,,CHEMBL622987,,1,1,,BAO_0000218,1969.0,
13610,A,In vivo,10116.0,,50597,Intermediate,Total plasma clearance after iv dose of 5.10 mg/kg in rats,,CHEMBL622988,,1,1,,BAO_0000218,1969.0,
13611,A,In vivo,10116.0,,50597,Intermediate,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,,CHEMBL622989,,1,1,,BAO_0000218,1969.0,
13612,A,In vivo,10116.0,,50597,Intermediate,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,,CHEMBL622990,,1,1,,BAO_0000218,1969.0,
13613,A,In vivo,314293.0,,22224,Autocuration,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,CHEMBL622991,,0,1,,BAO_0000218,1969.0,
13614,A,In vivo,10116.0,,50597,Intermediate,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,CHEMBL622227,,1,1,,BAO_0000218,1969.0,
13615,A,In vivo,9615.0,,50588,Intermediate,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,CHEMBL622228,,1,1,,BAO_0000218,1969.0,
13616,A,In vivo,10116.0,,50597,Intermediate,Clpl value in rat,,CHEMBL622229,,1,1,,BAO_0000218,,
13617,A,In vivo,10141.0,,50512,Intermediate,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,CHEMBL622230,,1,1,,BAO_0000218,,
13618,A,In vivo,10116.0,,50597,Intermediate,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,CHEMBL622231,,1,1,,BAO_0000218,,
13619,A,In vivo,9541.0,,100710,Intermediate,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,CHEMBL622232,,1,1,,BAO_0000218,,
13620,A,In vivo,,,22224,Autocuration,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,CHEMBL622233,,0,1,,BAO_0000218,,
13621,A,In vivo,,,22224,Autocuration,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,CHEMBL622234,,0,1,,BAO_0000218,,
13622,A,In vivo,,,22224,Autocuration,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,CHEMBL622235,,0,1,,BAO_0000218,,
13623,A,In vivo,,,22224,Autocuration,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,CHEMBL622236,,0,1,,BAO_0000218,,
13624,A,In vivo,,,22224,Autocuration,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,CHEMBL622237,,0,1,,BAO_0000218,,
13625,A,In vivo,,,22224,Autocuration,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,CHEMBL877482,,0,1,,BAO_0000218,,
13626,A,In vivo,,,22224,Autocuration,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,CHEMBL622238,,0,1,,BAO_0000218,,
13627,A,In vivo,,,22224,Autocuration,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,CHEMBL622239,,0,1,,BAO_0000218,,
13628,A,In vivo,,,22224,Autocuration,Cmax was calculated as maximum concentration reached in the blood,,CHEMBL622240,,0,1,,BAO_0000218,178.0,
13629,A,In vivo,,,22224,Autocuration,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,,CHEMBL622241,,0,1,,BAO_0000218,178.0,
13630,A,In vivo,10116.0,,50597,Intermediate,Cmax was determine after peroral administration at 10 mpk in Rat,,CHEMBL631013,,1,1,,BAO_0000218,,
13631,A,In vivo,9544.0,,50797,Intermediate,Cmax was determine after peroral administration at 10 mpk in Rhesus,,CHEMBL631014,,1,1,,BAO_0000218,,
13632,A,In vivo,9615.0,,50588,Intermediate,Cmax was determine after peroral administration at 10 mpk in dog,,CHEMBL631015,,1,1,,BAO_0000218,,
13633,A,In vivo,10116.0,,50597,Intermediate,Cmax was determine after peroral administration at 160 mpk in Rat,,CHEMBL631016,,1,1,,BAO_0000218,,
13634,A,In vivo,10116.0,,50597,Intermediate,Cmax was determine after peroral administration at 20 mpk in Rat,,CHEMBL631017,,1,1,,BAO_0000218,,
13635,A,In vivo,10116.0,,50597,Intermediate,Cmax was determine after peroral administration at 50 mpk in Rat,,CHEMBL631018,,1,1,,BAO_0000218,,
13636,A,In vivo,,,22224,Autocuration,Cmax was determined,,CHEMBL631019,,0,1,,BAO_0000218,,
13637,A,,10090.0,,50594,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,,CHEMBL875761,,1,1,,BAO_0000218,955.0,
13638,A,,10090.0,,50594,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,,CHEMBL631020,,1,1,,BAO_0000218,955.0,
13639,A,,10090.0,,50594,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,,CHEMBL631669,,1,1,,BAO_0000218,955.0,
13640,A,,10090.0,,50594,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,,CHEMBL631670,,1,1,,BAO_0000218,955.0,
13641,A,,10090.0,,50594,Intermediate,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,,CHEMBL631671,,1,1,,BAO_0000218,2435.0,
13642,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,,CHEMBL631672,,1,1,,BAO_0000218,178.0,
13643,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,,CHEMBL631673,,1,1,,BAO_0000218,178.0,
13644,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,,CHEMBL631856,,1,1,,BAO_0000218,178.0,
13645,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,,CHEMBL631857,,1,1,,BAO_0000218,178.0,
13646,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,,CHEMBL631858,,1,1,,BAO_0000218,178.0,
13647,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,,CHEMBL631859,,1,1,,BAO_0000218,178.0,
13648,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,,CHEMBL631860,,1,1,,BAO_0000218,178.0,
13649,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,,CHEMBL631861,,1,1,,BAO_0000218,178.0,
13650,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,,CHEMBL631862,,1,1,,BAO_0000218,178.0,
13651,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,,CHEMBL631863,,1,1,,BAO_0000218,178.0,
13652,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,,CHEMBL631864,,1,1,,BAO_0000218,178.0,
13653,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,,CHEMBL631865,,1,1,,BAO_0000218,178.0,
13654,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,,CHEMBL631866,,1,1,,BAO_0000218,178.0,
13655,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,,CHEMBL629360,,1,1,,BAO_0000218,178.0,
13656,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,,CHEMBL629361,,1,1,,BAO_0000218,178.0,
13657,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,,CHEMBL629362,,1,1,,BAO_0000218,178.0,
13658,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,,CHEMBL630740,,1,1,,BAO_0000218,178.0,
13659,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,,CHEMBL630741,,1,1,,BAO_0000218,178.0,
13660,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,,CHEMBL630742,,1,1,,BAO_0000218,178.0,
13661,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,CHEMBL630743,,1,1,,BAO_0000218,,
13662,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,CHEMBL630744,,1,1,,BAO_0000218,,
13663,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,CHEMBL630745,,1,1,,BAO_0000218,,
13664,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,CHEMBL630746,,1,1,,BAO_0000218,,
13665,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,CHEMBL630747,,1,1,,BAO_0000218,,
13666,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,CHEMBL630748,,1,1,,BAO_0000218,,
13667,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,CHEMBL632056,,1,1,,BAO_0000218,,
13668,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,CHEMBL632057,,1,1,,BAO_0000218,,
13669,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,CHEMBL632058,,1,1,,BAO_0000218,,
13670,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,CHEMBL632059,,1,1,,BAO_0000218,,
13671,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,CHEMBL632060,,1,1,,BAO_0000218,,
13672,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,CHEMBL632061,,1,1,,BAO_0000218,,
13673,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,CHEMBL629207,,1,1,,BAO_0000218,,
13674,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,CHEMBL629208,,1,1,,BAO_0000218,,
13675,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,CHEMBL629209,,1,1,,BAO_0000218,,
13676,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,CHEMBL629210,,1,1,,BAO_0000218,,
13677,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,CHEMBL629211,,1,1,,BAO_0000218,,
13678,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,CHEMBL629212,,1,1,,BAO_0000218,,
13679,A,,10116.0,,50597,Intermediate,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,CHEMBL629213,,1,1,,BAO_0000218,,
13680,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,CHEMBL629214,,1,1,,BAO_0000218,1088.0,
13681,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",,CHEMBL629215,,1,1,,BAO_0000218,1088.0,
13682,A,,10116.0,,50597,Intermediate,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",,CHEMBL635154,,1,1,,BAO_0000218,1088.0,
13683,A,,10116.0,,50597,Intermediate,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,CHEMBL629216,,1,1,,BAO_0000218,,
13684,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,CHEMBL629217,,1,1,,BAO_0000218,,
13685,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL629218,,1,1,,BAO_0000218,,
13686,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,CHEMBL629219,,1,1,,BAO_0000218,,
13687,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL629220,,1,1,,BAO_0000218,,
13688,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,CHEMBL629221,,1,1,,BAO_0000218,,
13689,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,CHEMBL631127,,1,1,,BAO_0000218,,
13690,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,CHEMBL631128,,1,1,,BAO_0000218,,
13691,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL631129,,1,1,,BAO_0000218,,
13692,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,CHEMBL631130,,1,1,,BAO_0000218,,
13693,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL631131,,1,1,,BAO_0000218,,
13694,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,CHEMBL631132,,1,1,,BAO_0000218,,
13695,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,CHEMBL631133,,1,1,,BAO_0000218,,
13696,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,CHEMBL631134,,1,1,,BAO_0000218,,
13697,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL875120,,1,1,,BAO_0000218,,
13698,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,CHEMBL631135,,1,1,,BAO_0000218,,
13699,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL631136,,1,1,,BAO_0000218,,
13700,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,CHEMBL631137,,1,1,,BAO_0000218,,
13701,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,CHEMBL631138,,1,1,,BAO_0000218,,
13702,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,CHEMBL631139,,1,1,,BAO_0000218,,
13703,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL631140,,1,1,,BAO_0000218,,
13704,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,CHEMBL631141,,1,1,,BAO_0000218,,
13705,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,CHEMBL631142,,1,1,,BAO_0000218,,
13706,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,CHEMBL631143,,1,1,,BAO_0000218,,
13707,A,,10116.0,,50597,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,CHEMBL631144,,1,1,,BAO_0000218,,
13708,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,CHEMBL631145,,1,1,,BAO_0000218,,
13709,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,CHEMBL631146,,1,1,,BAO_0000218,,
13710,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,CHEMBL631147,,1,1,,BAO_0000218,,
13711,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,CHEMBL631148,,1,1,,BAO_0000218,,
13712,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,CHEMBL631149,,1,1,,BAO_0000218,,
13713,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,CHEMBL631150,,1,1,,BAO_0000218,,
13714,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,CHEMBL631151,,1,1,,BAO_0000218,,
13715,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,CHEMBL631152,,1,1,,BAO_0000218,,
13716,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,CHEMBL631443,,1,1,,BAO_0000218,,
13717,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,CHEMBL631444,,1,1,,BAO_0000218,,
13718,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL631445,,1,1,,BAO_0000218,,
13719,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,CHEMBL631446,,1,1,,BAO_0000218,,
13720,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,CHEMBL631447,,1,1,,BAO_0000218,,
13721,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,CHEMBL631448,,1,1,,BAO_0000218,,
13722,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,CHEMBL631449,,1,1,,BAO_0000218,,
13723,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,CHEMBL631450,,1,1,,BAO_0000218,,
13724,A,,9615.0,,50588,Intermediate,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,CHEMBL629724,,1,1,,BAO_0000218,,
13725,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL629725,,1,1,,BAO_0000218,14.0,
13726,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL629726,,1,1,,BAO_0000218,14.0,
13727,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL629727,,1,1,,BAO_0000218,2106.0,
13728,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630404,,1,1,,BAO_0000218,2106.0,
13729,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630405,,1,1,,BAO_0000218,2106.0,
13730,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630406,,1,1,,BAO_0000218,2106.0,
13731,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630407,,1,1,,BAO_0000218,945.0,
13732,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630573,,1,1,,BAO_0000218,945.0,
13733,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630574,,1,1,,BAO_0000218,945.0,
13734,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630575,,1,1,,BAO_0000218,945.0,
13735,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630576,,1,1,,BAO_0000218,,
13736,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630577,,1,1,,BAO_0000218,,
13737,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630578,,1,1,,BAO_0000218,,
13738,A,In vivo,10090.0,,50594,Intermediate,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,CHEMBL630579,,1,1,,BAO_0000218,,
13739,A,,10090.0,,50594,Intermediate,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),,CHEMBL630580,,1,1,,BAO_0000218,2113.0,
13740,A,,10090.0,,50594,Intermediate,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,,CHEMBL630581,,1,1,,BAO_0000218,2113.0,
13741,A,,10090.0,,50594,Intermediate,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),,CHEMBL630582,,1,1,,BAO_0000218,2113.0,
13742,A,,10090.0,,50594,Intermediate,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,CHEMBL630583,,1,1,,BAO_0000218,,
13743,A,,10090.0,,50594,Intermediate,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,CHEMBL630584,,1,1,,BAO_0000218,,
13744,A,,10090.0,,50594,Intermediate,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,CHEMBL630585,,1,1,,BAO_0000218,,
13745,A,,10090.0,,50594,Intermediate,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,CHEMBL630586,,1,1,,BAO_0000218,,
13746,A,,10090.0,,50594,Intermediate,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,CHEMBL630587,,1,1,,BAO_0000218,,
13747,A,,10090.0,,50594,Intermediate,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,CHEMBL630588,,1,1,,BAO_0000218,,
13748,A,,10090.0,,50594,Intermediate,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,CHEMBL630589,,1,1,,BAO_0000218,,
13749,A,,10090.0,,50594,Intermediate,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,CHEMBL630590,,1,1,,BAO_0000218,,
13750,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in feces at 24 h,,CHEMBL630591,,0,1,,BAO_0000019,1988.0,
13751,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),,CHEMBL630592,,0,1,,BAO_0000019,1988.0,
13752,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,CHEMBL630593,,0,1,,BAO_0000019,,
13753,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,CHEMBL630594,,0,1,,BAO_0000019,,
13754,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),,CHEMBL630595,,0,1,,BAO_0000019,1088.0,
13755,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),,CHEMBL630596,,0,1,,BAO_0000019,1088.0,
13756,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in urine after 0-24 h,,CHEMBL630597,,0,1,,BAO_0000019,1088.0,
13757,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),,CHEMBL630598,,0,1,,BAO_0000019,1088.0,
13758,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in urine after 0-4 h,,CHEMBL630599,,0,1,,BAO_0000019,1088.0,
13759,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),,CHEMBL630600,,0,1,,BAO_0000019,1088.0,
13760,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in urine after 4-24 h,,CHEMBL630601,,0,1,,BAO_0000019,1088.0,
13761,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),,CHEMBL630602,,0,1,,BAO_0000019,1088.0,
13762,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),,CHEMBL630603,,0,1,,BAO_0000019,1088.0,
13763,A,,,,22224,Autocuration,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),,CHEMBL630604,,0,1,,BAO_0000019,1088.0,
13764,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL624869,,1,1,,BAO_0000218,178.0,
13765,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL624870,,1,1,,BAO_0000218,178.0,
13766,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL623189,,1,1,,BAO_0000218,178.0,
13767,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623190,,1,1,,BAO_0000218,178.0,
13768,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623191,,1,1,,BAO_0000218,178.0,
13769,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623192,,1,1,,BAO_0000218,,
13770,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623193,,1,1,,BAO_0000218,,
13771,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL623194,,1,1,,BAO_0000218,,
13772,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623195,,1,1,,BAO_0000218,,
13773,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623196,,1,1,,BAO_0000218,,
13774,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,CHEMBL623197,,1,1,,BAO_0000218,,
13775,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,CHEMBL623198,,1,1,,BAO_0000218,,
13776,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,CHEMBL623199,,1,1,,BAO_0000218,,
13777,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,,CHEMBL623200,,1,1,,BAO_0000218,2385.0,
13778,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,,CHEMBL623201,,1,1,,BAO_0000218,2385.0,
13779,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,,CHEMBL623202,,1,1,,BAO_0000218,2385.0,
13780,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,,CHEMBL623203,,1,1,,BAO_0000218,2385.0,
13781,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,,CHEMBL623204,,1,1,,BAO_0000218,2385.0,
13782,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,,CHEMBL623205,,1,1,,BAO_0000218,2385.0,
13783,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,CHEMBL623206,,1,1,,BAO_0000218,2385.0,
13784,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,,CHEMBL623207,,1,1,,BAO_0000218,2385.0,
13785,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,,CHEMBL623208,,1,1,,BAO_0000218,2385.0,
13786,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,CHEMBL623209,,1,1,,BAO_0000218,2385.0,
13787,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,CHEMBL623210,,1,1,,BAO_0000218,2385.0,
13788,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,CHEMBL623211,,1,1,,BAO_0000218,,
13789,A,,10116.0,,50597,Intermediate,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,CHEMBL623212,,1,1,,BAO_0000218,995.0,
13790,A,,,,22224,Autocuration,Tested in vitro for intrinsic activity relative to quinpirole,,CHEMBL623213,,0,1,,BAO_0000019,,
13791,A,,,,22224,Autocuration,"Relative ion enhancement, determined in pulsed ultrafiltration",,CHEMBL623214,,0,1,,BAO_0000019,,
13792,A,,,,22224,Autocuration,% ionization at the pH 7.4 at 37 degree Centigrade,,CHEMBL623215,,0,1,,BAO_0000019,,
13793,A,,,,22224,Autocuration,Percentage ionization was measured,,CHEMBL623216,,0,1,,BAO_0000019,,
13794,A,,9913.0,,50591,Intermediate,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,CHEMBL623217,,1,1,,BAO_0000218,,
13795,A,,,,22224,Autocuration,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,CHEMBL623218,,0,1,,BAO_0000019,,
13796,A,,,,22224,Autocuration,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,CHEMBL623913,,0,1,,BAO_0000019,,
13797,A,,,,22224,Autocuration,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,CHEMBL623914,,0,1,,BAO_0000019,,
13798,P,,,,22229,Autocuration,Compound was evaluated for the partition coefficient in octanol/water,,CHEMBL623915,,0,1,,BAO_0000100,,
13799,P,,,,22229,Autocuration,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,CHEMBL624080,,0,1,,BAO_0000100,,
13800,A,,,,22224,Autocuration,Equilibrium constant measured by the pulse radiolysis at pH 7,,CHEMBL624081,,0,1,,BAO_0000019,,
13801,A,,9606.0,,50587,Intermediate,In vitro hydrolytic rate constant determined in human blood,,CHEMBL624082,,1,1,,BAO_0000218,,
13802,A,,9606.0,,50587,Intermediate,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,CHEMBL625054,,1,1,,BAO_0000218,,
13803,A,,,,22224,Autocuration,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,CHEMBL877485,,0,1,,BAO_0000019,,
13804,A,,10090.0,,50594,Intermediate,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,CHEMBL625055,,1,1,,BAO_0000218,,
13805,A,,10090.0,,50594,Intermediate,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,CHEMBL625056,,1,1,,BAO_0000218,,
13806,A,,9606.0,,50587,Intermediate,In vitro oxidation of compound in presence of human plasma,,CHEMBL625057,,1,1,,BAO_0000218,,
13807,A,,,,22224,Autocuration,In vitro oxidation of compound in presence of hydrogen peroxide,,CHEMBL625058,,0,1,,BAO_0000019,,
13808,A,,10090.0,,50594,Intermediate,In vitro oxidation of compound in presence of mouse brain homogenate,,CHEMBL625059,,1,1,,BAO_0000218,,
13809,A,,10090.0,,50594,Intermediate,In vitro oxidation of compound in presence of mouse liver homogenate,,CHEMBL629536,,1,1,,BAO_0000218,,
13810,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,CHEMBL629537,,1,1,,BAO_0000218,,
13811,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,CHEMBL629538,,1,1,,BAO_0000218,,
13812,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,CHEMBL629539,,1,1,,BAO_0000218,,
13813,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,CHEMBL874445,,1,1,,BAO_0000218,,
13814,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,CHEMBL629540,,1,1,,BAO_0000218,,
13815,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,CHEMBL629541,,1,1,,BAO_0000218,,
13816,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,CHEMBL629542,,1,1,,BAO_0000218,,
13817,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,CHEMBL630243,,1,1,,BAO_0000218,,
13818,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,CHEMBL630244,,1,1,,BAO_0000218,,
13819,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,CHEMBL630245,,1,1,,BAO_0000218,,
13820,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,CHEMBL630246,,1,1,,BAO_0000218,,
13821,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,CHEMBL630247,,1,1,,BAO_0000218,,
13822,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,CHEMBL630248,,1,1,,BAO_0000218,,
13823,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood at 240 minutes after dose administration.,,CHEMBL630249,,1,1,,BAO_0000218,178.0,
13824,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood at 30 minutes after dose administration.,,CHEMBL630250,,1,1,,BAO_0000218,178.0,
13825,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood at 360 minutes after dose administration.,,CHEMBL630251,,1,1,,BAO_0000218,178.0,
13826,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood at 3 hr after dose administration.,,CHEMBL630252,,1,1,,BAO_0000218,178.0,
13827,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood at 60 minutes after dose administration.,,CHEMBL630408,,1,1,,BAO_0000218,178.0,
13828,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cerebellum at 120 minutes after dose administration.,,CHEMBL630409,,1,1,,BAO_0000218,2037.0,
13829,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,,CHEMBL874446,,1,1,,BAO_0000218,2037.0,
13830,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cerebellum at 15 minutes after dose administration.,,CHEMBL630410,,1,1,,BAO_0000218,2037.0,
13831,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cerebellum at 240 minutes after dose administration.,,CHEMBL630411,,1,1,,BAO_0000218,2037.0,
13832,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cerebellum at 30 minutes after dose administration.,,CHEMBL630412,,1,1,,BAO_0000218,2037.0,
13833,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cerebellum at 360 minutes after dose administration.,,CHEMBL630413,,1,1,,BAO_0000218,2037.0,
13834,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cerebellum at 3 hr after dose administration.,,CHEMBL630414,,1,1,,BAO_0000218,2037.0,
13835,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cerebellum at 60 minutes after dose administration.,,CHEMBL630415,,1,1,,BAO_0000218,2037.0,
13836,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cortex at 120 minutes after dose administration.,,CHEMBL630416,,1,1,,BAO_0000218,,
13837,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cortex at 1440 minutes after dose administration.,,CHEMBL630417,,1,1,,BAO_0000218,,
13838,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cortex at 15 minutes after dose administration.,,CHEMBL630418,,1,1,,BAO_0000218,,
13839,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cortex at 240 minutes after dose administration.,,CHEMBL630419,,1,1,,BAO_0000218,,
13840,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cortex at 30 minutes after dose administration.,,CHEMBL630420,,1,1,,BAO_0000218,,
13841,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cortex at 360 minutes after dose administration.,,CHEMBL630421,,1,1,,BAO_0000218,,
13842,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cortex at 3 hr after dose administration.,,CHEMBL630422,,1,1,,BAO_0000218,,
13843,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat cortex at 60 minutes after dose administration.,,CHEMBL630423,,1,1,,BAO_0000218,,
13844,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart at 120 minutes after dose administration.,,CHEMBL630424,,1,1,,BAO_0000218,948.0,
13845,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart at 15 minutes after dose administration.,,CHEMBL630425,,1,1,,BAO_0000218,948.0,
13846,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart at 240 minutes after dose administration.,,CHEMBL629462,,1,1,,BAO_0000218,948.0,
13847,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart at 30 minutes after dose administration.,,CHEMBL630426,,1,1,,BAO_0000218,948.0,
13848,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart at 360 minutes after dose administration.,,CHEMBL630427,,1,1,,BAO_0000218,948.0,
13849,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart at 3 hr after dose administration.,,CHEMBL625877,,1,1,,BAO_0000218,948.0,
13850,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart at 60 minutes after dose administration.,,CHEMBL625878,,1,1,,BAO_0000218,948.0,
13851,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,,CHEMBL625879,,1,1,,BAO_0000218,10000000.0,
13852,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat hippocampus at 240 minutes after dose administration.,,CHEMBL625880,,1,1,,BAO_0000218,10000000.0,
13853,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat hippocampus at 30 minutes after dose administration.,,CHEMBL625881,,1,1,,BAO_0000218,10000000.0,
13854,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat hippocampus at 360 minutes after dose administration.,,CHEMBL625882,,1,1,,BAO_0000218,10000000.0,
13855,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat hippocampus at 15 minutes after dose administration.,,CHEMBL625883,,1,1,,BAO_0000218,10000000.0,
13856,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney at 120 minutes after dose administration.,,CHEMBL625884,,1,1,,BAO_0000218,2113.0,
13857,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney at 1440 minutes after dose administration.,,CHEMBL625885,,1,1,,BAO_0000218,2113.0,
13858,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney at 15 minutes after dose administration.,,CHEMBL628649,,1,1,,BAO_0000218,2113.0,
13859,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney at 240 minutes after dose administration.,,CHEMBL628650,,1,1,,BAO_0000218,2113.0,
13860,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney at 30 minutes after dose administration.,,CHEMBL628651,,1,1,,BAO_0000218,2113.0,
13861,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney at 360 minutes after dose administration.,,CHEMBL628652,,1,1,,BAO_0000218,2113.0,
13862,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney at 60 minutes after dose administration.,,CHEMBL628653,,1,1,,BAO_0000218,2113.0,
13863,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver at 120 minutes after dose administration.,,CHEMBL628654,,1,1,,BAO_0000218,2107.0,
13864,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver at 1440 minutes after dose administration.,,CHEMBL628655,,1,1,,BAO_0000218,2107.0,
13865,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver at 15 minutes after dose administration.,,CHEMBL625238,,1,1,,BAO_0000218,2107.0,
13866,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver at 240 minutes after dose administration.,,CHEMBL625239,,1,1,,BAO_0000218,2107.0,
13867,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver at 30 minutes after dose administration.,,CHEMBL625240,,1,1,,BAO_0000218,2107.0,
13868,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver at 360 minutes after dose administration.,,CHEMBL625241,,1,1,,BAO_0000218,2107.0,
13869,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver at 60 minutes after dose administration.,,CHEMBL625242,,1,1,,BAO_0000218,2107.0,
13870,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat lung at 120 minutes after dose administration.,,CHEMBL874587,,1,1,,BAO_0000218,2048.0,
13871,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat lung at 1440 minutes after dose administration.,,CHEMBL625405,,1,1,,BAO_0000218,2048.0,
13872,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat lung at 15 minutes after dose administration.,,CHEMBL625406,,1,1,,BAO_0000218,2048.0,
13873,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat lung at 240 minutes after dose administration.,,CHEMBL625407,,1,1,,BAO_0000218,2048.0,
13874,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat lung at 30 minutes after dose administration.,,CHEMBL625408,,1,1,,BAO_0000218,2048.0,
13875,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat lung at 360 minutes after dose administration.,,CHEMBL625409,,1,1,,BAO_0000218,2048.0,
13876,A,,10116.0,,50597,Intermediate,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,,CHEMBL625410,,1,1,,BAO_0000218,1515.0,
13877,A,,10116.0,,50597,Intermediate,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,,CHEMBL625411,,1,1,,BAO_0000218,1515.0,
13878,A,,10116.0,,50597,Intermediate,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,,CHEMBL625412,,1,1,,BAO_0000218,1515.0,
13879,A,,10116.0,,50597,Intermediate,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,,CHEMBL625413,,1,1,,BAO_0000218,1515.0,
13880,A,,10116.0,,50597,Intermediate,Percent of maximal contractile response to compound in rat thoracic aorta strips v,,CHEMBL625414,,1,1,,BAO_0000218,1515.0,
13881,A,,10116.0,,50597,Intermediate,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,,CHEMBL625415,,1,1,,BAO_0000218,1515.0,
13882,A,,10116.0,,50597,Intermediate,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,,CHEMBL625416,,1,1,,BAO_0000218,1515.0,
13883,A,,10116.0,,50597,Intermediate,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,,CHEMBL625417,,1,1,,BAO_0000218,1088.0,
13884,A,,10116.0,,50597,Intermediate,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,,CHEMBL625418,,1,1,,BAO_0000218,1988.0,
13885,A,,10116.0,,50597,Intermediate,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,,CHEMBL625419,,1,1,,BAO_0000218,1088.0,
13886,A,,10116.0,,50597,Intermediate,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,CHEMBL625420,,1,1,,BAO_0000218,,
13887,A,,10116.0,,50597,Intermediate,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,CHEMBL626996,,1,1,,BAO_0000218,,
13888,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",,CHEMBL626997,,1,1,,BAO_0000218,1988.0,
13889,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",,CHEMBL626998,,1,1,,BAO_0000218,1088.0,
13890,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,CHEMBL626999,,1,1,,BAO_0000218,,
13891,A,,10090.0,,50594,Intermediate,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,CHEMBL627000,,1,1,,BAO_0000218,,
13892,A,,10090.0,,50594,Intermediate,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,CHEMBL627001,,1,1,,BAO_0000218,,
13893,A,,10090.0,,50594,Intermediate,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,CHEMBL627002,,1,1,,BAO_0000218,,
13894,A,,10090.0,,50594,Intermediate,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,CHEMBL627003,,1,1,,BAO_0000218,,
13895,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,,CHEMBL627004,,1,1,,BAO_0000218,1088.0,
13896,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,,CHEMBL627005,,1,1,,BAO_0000218,1088.0,
13897,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,,CHEMBL874594,,1,1,,BAO_0000218,1088.0,
13898,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,,CHEMBL627006,,1,1,,BAO_0000218,1088.0,
13899,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,,CHEMBL627007,,1,1,,BAO_0000218,1088.0,
13900,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,,CHEMBL627884,,1,1,,BAO_0000218,1088.0,
13901,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,,CHEMBL627885,,1,1,,BAO_0000218,1088.0,
13902,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,,CHEMBL627886,,1,1,,BAO_0000218,1088.0,
13903,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,,CHEMBL627887,,1,1,,BAO_0000218,1088.0,
13904,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,,CHEMBL627888,,1,1,,BAO_0000218,1088.0,
13905,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,,CHEMBL628057,,1,1,,BAO_0000218,1088.0,
13906,A,,10090.0,,50594,Intermediate,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,,CHEMBL627405,,1,1,,BAO_0000218,1088.0,
13907,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,CHEMBL627406,,1,1,,BAO_0000218,1088.0,
13908,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,CHEMBL627407,,1,1,,BAO_0000218,1088.0,
13909,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,CHEMBL627408,,1,1,,BAO_0000218,1088.0,
13910,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,CHEMBL627409,,1,1,,BAO_0000218,1088.0,
13911,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,CHEMBL875486,,1,1,,BAO_0000218,1088.0,
13912,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,CHEMBL627410,,1,1,,BAO_0000218,1088.0,
13913,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,CHEMBL627411,,1,1,,BAO_0000218,1088.0,
13914,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,CHEMBL627412,,1,1,,BAO_0000218,1088.0,
13915,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,CHEMBL627413,,1,1,,BAO_0000218,1088.0,
13916,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,CHEMBL627414,,1,1,,BAO_0000218,1088.0,
13917,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,CHEMBL627415,,1,1,,BAO_0000218,1088.0,
13918,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,,CHEMBL627416,,1,1,,BAO_0000218,1088.0,
13919,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,CHEMBL627417,,1,1,,BAO_0000218,1088.0,
13920,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,CHEMBL627418,,1,1,,BAO_0000218,1088.0,
13921,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,CHEMBL627419,,1,1,,BAO_0000218,1088.0,
13922,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,CHEMBL627320,,1,1,,BAO_0000218,1088.0,
13923,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,CHEMBL627321,,1,1,,BAO_0000218,1088.0,
13924,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627322,,1,1,,BAO_0000218,2113.0,
13925,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627323,,1,1,,BAO_0000218,2113.0,
13926,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL627491,,1,1,,BAO_0000218,2113.0,
13927,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627492,,1,1,,BAO_0000218,2113.0,
13928,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627493,,1,1,,BAO_0000218,2113.0,
13929,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627494,,1,1,,BAO_0000218,2107.0,
13930,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627495,,1,1,,BAO_0000218,2107.0,
13931,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL627496,,1,1,,BAO_0000218,2107.0,
13932,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627497,,1,1,,BAO_0000218,2107.0,
13933,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627498,,1,1,,BAO_0000218,2107.0,
13934,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627499,,1,1,,BAO_0000218,2048.0,
13935,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL627500,,1,1,,BAO_0000218,2048.0,
13936,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL627501,,1,1,,BAO_0000218,2048.0,
13937,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625616,,1,1,,BAO_0000218,2048.0,
13938,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625617,,1,1,,BAO_0000218,2048.0,
13939,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625618,,1,1,,BAO_0000218,2385.0,
13940,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625619,,1,1,,BAO_0000218,2385.0,
13941,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL625620,,1,1,,BAO_0000218,2385.0,
13942,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625621,,1,1,,BAO_0000218,2385.0,
13943,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625622,,1,1,,BAO_0000218,2385.0,
13944,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625788,,1,1,,BAO_0000218,2106.0,
13945,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625789,,1,1,,BAO_0000218,2106.0,
13946,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL625790,,1,1,,BAO_0000218,2106.0,
13947,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL625791,,1,1,,BAO_0000218,2106.0,
13948,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL622334,,1,1,,BAO_0000218,2106.0,
13949,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL622335,,1,1,,BAO_0000218,2046.0,
13950,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL622336,,1,1,,BAO_0000218,2046.0,
13951,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL622337,,1,1,,BAO_0000218,2046.0,
13952,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL622338,,1,1,,BAO_0000218,2046.0,
13953,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL622339,,1,1,,BAO_0000218,2046.0,
13954,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL624153,,1,1,,BAO_0000218,,
13955,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL628430,,1,1,,BAO_0000218,,
13956,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL628431,,1,1,,BAO_0000218,,
13957,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL628432,,1,1,,BAO_0000218,,
13958,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL628433,,1,1,,BAO_0000218,,
13959,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL628434,,1,1,,BAO_0000218,2106.0,
13960,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL626789,,1,1,,BAO_0000218,2106.0,
13961,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",,CHEMBL626790,,1,1,,BAO_0000218,2106.0,
13962,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL626791,,1,1,,BAO_0000218,2106.0,
13963,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL626792,,1,1,,BAO_0000218,2106.0,
13964,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL626793,,1,1,,BAO_0000218,2106.0,
13965,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,CHEMBL627436,,1,1,,BAO_0000218,,
13966,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,CHEMBL627437,,1,1,,BAO_0000218,,
13967,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,CHEMBL627438,,1,1,,BAO_0000218,,
13968,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,CHEMBL627439,,1,1,,BAO_0000218,,
13969,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,CHEMBL627440,,1,1,,BAO_0000218,,
13970,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,CHEMBL627602,,1,1,,BAO_0000218,,
13971,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,CHEMBL627603,,1,1,,BAO_0000218,,
13972,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,CHEMBL627604,,1,1,,BAO_0000218,,
13973,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,CHEMBL627605,,1,1,,BAO_0000218,,
13974,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,CHEMBL627606,,1,1,,BAO_0000218,,
13975,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,CHEMBL627607,,1,1,,BAO_0000218,,
13976,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,CHEMBL627608,,1,1,,BAO_0000218,,
13977,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,CHEMBL627609,,1,1,,BAO_0000218,,
13978,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,CHEMBL627610,,1,1,,BAO_0000218,,
13979,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,CHEMBL627611,,1,1,,BAO_0000218,,
13980,A,,10116.0,,50597,Intermediate,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,CHEMBL627612,,1,1,,BAO_0000218,,
13981,P,,,,22229,Autocuration,Octanol:water partition coefficient is evaluated,,CHEMBL627613,,0,1,,BAO_0000100,,
13982,P,,,,22224,Autocuration,Partition coefficient in 1-octanol/water system,,CHEMBL627614,,0,1,,BAO_0000100,,
13983,P,,,,22224,Autocuration,Partition coefficient in 1-octanol/water system measured using radio active compounds,,CHEMBL627615,,0,1,,BAO_0000100,,
13984,P,,,,22224,Autocuration,Partition coefficient in octanol/water system was determined,,CHEMBL627616,,0,1,,BAO_0000100,,
13985,P,,,,22224,Autocuration,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,CHEMBL627617,,0,1,,BAO_0000100,,
13986,A,,,,22224,Autocuration,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,CHEMBL627618,,0,1,,BAO_0000019,,
13987,A,,,,22224,Autocuration,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,CHEMBL627619,,0,1,,BAO_0000019,,
13988,A,,,,22224,Autocuration,Pseudo-first-order rate constant of the compound,,CHEMBL627620,,0,1,,BAO_0000019,,
13989,A,,,,22224,Autocuration,Pseudo-first-order rate constant with 1-min time point,,CHEMBL627621,,0,1,,BAO_0000019,,
13990,A,,,,22224,Autocuration,Pseudo-first-order rate constant without 1-min time point,,CHEMBL627622,,0,1,,BAO_0000019,,
13991,A,,,,22224,Autocuration,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,CHEMBL627623,,0,1,,BAO_0000019,,
13992,A,,,,22224,Autocuration,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,CHEMBL627624,,0,1,,BAO_0000019,,
13993,A,,,,22224,Autocuration,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,CHEMBL627625,,0,1,,BAO_0000019,,
13994,A,,,,22224,Autocuration,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,CHEMBL628523,,0,1,,BAO_0000019,,
13995,A,,,,22224,Autocuration,The alkaline hydrolysis second order rate constant(K OH) of the compound,,CHEMBL628524,,0,1,,BAO_0000019,,
13996,A,,,,22224,Autocuration,The efflux rate constant of the compound,,CHEMBL628525,,0,1,,BAO_0000019,,
13997,A,,,,22224,Autocuration,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,CHEMBL625732,,0,1,,BAO_0000019,,
13998,A,,,,22224,Autocuration,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,CHEMBL625733,,0,1,,BAO_0000019,,
13999,F,,,,22224,Autocuration,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,CHEMBL625734,,0,1,,BAO_0000019,,
14000,A,,,,22224,Autocuration,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,CHEMBL625913,,0,1,,BAO_0000019,,
14001,A,,,,22224,Autocuration,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,CHEMBL625914,,0,1,,BAO_0000019,,
14002,A,,,,22224,Autocuration,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,CHEMBL625915,,0,1,,BAO_0000019,,
14003,A,,,,22224,Autocuration,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,CHEMBL625916,,0,1,,BAO_0000019,,
14004,A,,,,22224,Autocuration,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,CHEMBL625917,,0,1,,BAO_0000019,,
14005,A,,,,22224,Autocuration,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625918,,0,1,,BAO_0000019,,
14006,A,,,,22224,Autocuration,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625919,,0,1,,BAO_0000019,,
14007,A,,,,22224,Autocuration,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625920,,0,1,,BAO_0000019,,
14008,A,,,,22224,Autocuration,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL874453,,0,1,,BAO_0000019,,
14009,A,,,,22224,Autocuration,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,CHEMBL625921,,0,1,,BAO_0000019,,
14010,A,,,,22224,Autocuration,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,CHEMBL625922,,0,1,,BAO_0000019,,
14011,A,,,,22224,Autocuration,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625923,,0,1,,BAO_0000019,,
14012,A,,,,22224,Autocuration,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625924,,0,1,,BAO_0000019,,
14013,A,,,,22224,Autocuration,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625925,,0,1,,BAO_0000019,,
14014,A,,,,22224,Autocuration,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL625926,,0,1,,BAO_0000019,,
14015,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat lung at 60 minutes after dose administration.,,CHEMBL627704,,1,1,,BAO_0000218,2048.0,
14016,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,CHEMBL627705,,1,1,,BAO_0000218,,
14017,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,CHEMBL627706,,1,1,,BAO_0000218,,
14018,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,CHEMBL627707,,1,1,,BAO_0000218,,
14019,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,CHEMBL627708,,1,1,,BAO_0000218,,
14020,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,CHEMBL628361,,1,1,,BAO_0000218,,
14021,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,CHEMBL628362,,1,1,,BAO_0000218,,
14022,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat striatum at 120 minutes after dose administration.,,CHEMBL628363,,1,1,,BAO_0000218,2435.0,
14023,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat striatum at 1440 minutes after dose administration.,,CHEMBL628364,,1,1,,BAO_0000218,2435.0,
14024,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat striatum at 15 minutes after dose administration.,,CHEMBL628365,,1,1,,BAO_0000218,2435.0,
14025,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat striatum at 240 minutes after dose administration.,,CHEMBL874454,,1,1,,BAO_0000218,2435.0,
14026,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat striatum at 30 minutes after dose administration.,,CHEMBL628531,,1,1,,BAO_0000218,2435.0,
14027,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat striatum at 360 minutes after dose administration.,,CHEMBL628532,,1,1,,BAO_0000218,2435.0,
14028,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat striatum at 3 hr after dose administration.,,CHEMBL628533,,1,1,,BAO_0000218,2435.0,
14029,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat striatum at 60 minutes after dose administration.,,CHEMBL628534,,1,1,,BAO_0000218,2435.0,
14030,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat thyroid at 120 minutes after dose administration.,,CHEMBL628535,,1,1,,BAO_0000218,2046.0,
14031,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat thyroid at 1440 minutes after dose administration.,,CHEMBL628536,,1,1,,BAO_0000218,2046.0,
14032,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat thyroid at 15 minutes after dose administration.,,CHEMBL628537,,1,1,,BAO_0000218,2046.0,
14033,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat thyroid at 240 minutes after dose administration.,,CHEMBL628538,,1,1,,BAO_0000218,2046.0,
14034,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat thyroid at 30 minutes after dose administration.,,CHEMBL628539,,1,1,,BAO_0000218,2046.0,
14035,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat thyroid at 360 minutes after dose administration.,,CHEMBL630297,,1,1,,BAO_0000218,2046.0,
14036,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat thyroid at 60 minutes after dose administration.,,CHEMBL630298,,1,1,,BAO_0000218,2046.0,
14037,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rest of brain of rat 120 minutes after dose administration.,,CHEMBL630299,,1,1,,BAO_0000218,955.0,
14038,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,,CHEMBL628094,,1,1,,BAO_0000218,955.0,
14039,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,,CHEMBL628095,,1,1,,BAO_0000218,955.0,
14040,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,,CHEMBL874648,,1,1,,BAO_0000218,955.0,
14041,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,,CHEMBL628096,,1,1,,BAO_0000218,955.0,
14042,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,,CHEMBL628097,,1,1,,BAO_0000218,955.0,
14043,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,,CHEMBL628098,,1,1,,BAO_0000218,955.0,
14044,A,,,,22224,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,CHEMBL628099,,0,1,,BAO_0000019,,
14045,A,,,,22224,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,CHEMBL628100,,0,1,,BAO_0000019,,
14046,A,,,,22224,Autocuration,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,CHEMBL628101,,0,1,,BAO_0000019,,
14047,A,,,,22224,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,CHEMBL628102,,0,1,,BAO_0000019,,
14048,A,,,,22224,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,CHEMBL628103,,0,1,,BAO_0000019,,
14049,A,,,,22224,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,CHEMBL628104,,0,1,,BAO_0000019,,
14050,A,,,,22224,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,CHEMBL628105,,0,1,,BAO_0000019,,
14051,A,,,,22224,Autocuration,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,CHEMBL628106,,0,1,,BAO_0000019,,
14052,A,,10116.0,,50597,Intermediate,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,CHEMBL628107,,1,1,,BAO_0000218,1088.0,
14053,F,,,,22224,Autocuration,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,CHEMBL628108,,0,1,,BAO_0000218,1088.0,
14054,A,,10116.0,,50597,Intermediate,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,CHEMBL628109,,1,1,,BAO_0000218,1088.0,
14055,F,,,,22224,Autocuration,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,CHEMBL625299,,0,1,,BAO_0000218,1088.0,
14056,A,,10116.0,,50597,Intermediate,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,,CHEMBL625300,,1,1,,BAO_0000218,1088.0,
14057,A,,10116.0,,50597,Intermediate,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,,CHEMBL625301,,1,1,,BAO_0000218,1088.0,
14058,A,,10116.0,,50597,Intermediate,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,,CHEMBL625302,,1,1,,BAO_0000218,1088.0,
14059,A,,10116.0,,50597,Intermediate,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,,CHEMBL874649,,1,1,,BAO_0000218,1088.0,
14060,A,,10116.0,,50597,Intermediate,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,CHEMBL625303,,1,1,,BAO_0000218,,
14061,A,,10116.0,,50597,Intermediate,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,CHEMBL625463,,1,1,,BAO_0000218,,
14062,A,,9606.0,,50587,Intermediate,In vitro metabolism in human liver microsomes,,CHEMBL625464,,1,1,,BAO_0000218,2107.0,
14063,A,,9606.0,,50587,Intermediate,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,CHEMBL625465,,1,1,,BAO_0000218,,
14064,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,CHEMBL625466,,1,1,,BAO_0000218,1088.0,
14065,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,CHEMBL625467,,1,1,,BAO_0000218,1088.0,
14066,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,CHEMBL625468,,1,1,,BAO_0000218,1088.0,
14067,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,,CHEMBL625469,,1,1,,BAO_0000218,1088.0,
14068,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,,CHEMBL625470,,1,1,,BAO_0000218,1088.0,
14069,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,,CHEMBL632418,,1,1,,BAO_0000218,1088.0,
14070,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,,CHEMBL627250,,1,1,,BAO_0000218,1088.0,
14071,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,,CHEMBL627251,,1,1,,BAO_0000218,1088.0,
14072,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,,CHEMBL627252,,1,1,,BAO_0000218,1088.0,
14073,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,,CHEMBL627253,,1,1,,BAO_0000218,1088.0,
14074,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,,CHEMBL627254,,1,1,,BAO_0000218,1088.0,
14075,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,,CHEMBL875471,,1,1,,BAO_0000218,1088.0,
14076,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,,CHEMBL627255,,1,1,,BAO_0000218,1088.0,
14077,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,,CHEMBL627256,,1,1,,BAO_0000218,1088.0,
14078,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,,CHEMBL627257,,1,1,,BAO_0000218,1088.0,
14079,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,,CHEMBL627258,,1,1,,BAO_0000218,1088.0,
14080,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,,CHEMBL627259,,1,1,,BAO_0000218,1088.0,
14081,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,,CHEMBL627260,,1,1,,BAO_0000218,1088.0,
14082,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,,CHEMBL623256,,1,1,,BAO_0000218,1088.0,
14083,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,,CHEMBL874413,,1,1,,BAO_0000218,1088.0,
14084,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,,CHEMBL623257,,1,1,,BAO_0000218,1088.0,
14085,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,,CHEMBL623258,,1,1,,BAO_0000218,1088.0,
14086,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,,CHEMBL623259,,1,1,,BAO_0000218,1088.0,
14087,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,,CHEMBL623260,,1,1,,BAO_0000218,1088.0,
14088,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,,CHEMBL623261,,1,1,,BAO_0000218,1088.0,
14089,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,,CHEMBL623262,,1,1,,BAO_0000218,1088.0,
14090,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,,CHEMBL623263,,1,1,,BAO_0000218,1088.0,
14091,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,,CHEMBL623264,,1,1,,BAO_0000218,1088.0,
14092,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,,CHEMBL623265,,1,1,,BAO_0000218,1088.0,
14093,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,,CHEMBL623266,,1,1,,BAO_0000218,1088.0,
14094,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,,CHEMBL623267,,1,1,,BAO_0000218,1088.0,
14095,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,,CHEMBL623268,,1,1,,BAO_0000218,1088.0,
14096,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,,CHEMBL623269,,1,1,,BAO_0000218,1088.0,
14097,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,,CHEMBL623270,,1,1,,BAO_0000218,1088.0,
14098,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,,CHEMBL623271,,1,1,,BAO_0000218,1088.0,
14099,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,,CHEMBL623272,,1,1,,BAO_0000218,1088.0,
14100,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,,CHEMBL623273,,1,1,,BAO_0000218,1088.0,
14101,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,,CHEMBL623274,,1,1,,BAO_0000218,1088.0,
14102,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,,CHEMBL874414,,1,1,,BAO_0000218,1088.0,
14103,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,,CHEMBL623275,,1,1,,BAO_0000218,1088.0,
14104,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,,CHEMBL629150,,1,1,,BAO_0000218,1088.0,
14105,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,,CHEMBL623276,,1,1,,BAO_0000218,1088.0,
14106,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,,CHEMBL623277,,1,1,,BAO_0000218,1088.0,
14107,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,,CHEMBL623112,,1,1,,BAO_0000218,1088.0,
14108,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,,CHEMBL623113,,1,1,,BAO_0000218,1088.0,
14109,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,,CHEMBL623800,,1,1,,BAO_0000218,1088.0,
14110,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,,CHEMBL623801,,1,1,,BAO_0000218,1088.0,
14111,A,In vivo,10116.0,,50597,Intermediate,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,CHEMBL623802,,1,1,,BAO_0000218,2106.0,
14112,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623803,,1,1,,BAO_0000218,995.0,
14113,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623970,,1,1,,BAO_0000218,995.0,
14114,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL623971,,1,1,,BAO_0000218,995.0,
14115,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),,CHEMBL623972,,1,1,,BAO_0000218,178.0,
14116,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),,CHEMBL623973,,1,1,,BAO_0000218,178.0,
14117,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),,CHEMBL623974,,1,1,,BAO_0000218,178.0,
14118,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),,CHEMBL623975,,1,1,,BAO_0000218,178.0,
14119,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),,CHEMBL623976,,1,1,,BAO_0000218,955.0,
14120,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),,CHEMBL623977,,1,1,,BAO_0000218,955.0,
14121,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),,CHEMBL623978,,1,1,,BAO_0000218,955.0,
14122,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),,CHEMBL623979,,1,1,,BAO_0000218,955.0,
14123,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,CHEMBL623980,,1,1,,BAO_0000218,,
14124,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,CHEMBL623981,,1,1,,BAO_0000218,,
14125,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,CHEMBL626278,,1,1,,BAO_0000218,,
14126,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,CHEMBL626279,,1,1,,BAO_0000218,,
14127,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in mice bladder plus excreted urine was determined,,CHEMBL626280,,1,1,,BAO_0000218,,
14128,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse blood, 10 minutes post injection",,CHEMBL626281,,1,1,,BAO_0000218,,
14129,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse blood, 30 minutes post injection",,CHEMBL626282,,1,1,,BAO_0000218,,
14130,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse blood, 5 minutes post injection",,CHEMBL626283,,1,1,,BAO_0000218,,
14131,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse blood, 60 minutes post injection",,CHEMBL626284,,1,1,,BAO_0000218,,
14132,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse brain, 10 minutes post injection",,CHEMBL626285,,1,1,,BAO_0000218,955.0,
14133,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse brain, 30 minutes post injection",,CHEMBL626286,,1,1,,BAO_0000218,955.0,
14134,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse brain, 5 minutes post injection",,CHEMBL626287,,1,1,,BAO_0000218,955.0,
14135,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse brain, 60 minutes post injection",,CHEMBL626288,,1,1,,BAO_0000218,955.0,
14136,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse heart, 10 minutes post injection",,CHEMBL626289,,1,1,,BAO_0000218,,
14137,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse heart, 30 minutes post injection",,CHEMBL626290,,1,1,,BAO_0000218,,
14138,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse heart, 5 minutes post injection",,CHEMBL626291,,1,1,,BAO_0000218,,
14139,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse heart, 60 minutes post injection",,CHEMBL839888,,1,1,,BAO_0000218,,
14140,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse intestine, 10 minutes post injection",,CHEMBL626292,,1,1,,BAO_0000218,160.0,
14141,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse intestine, 30 minutes post injection",,CHEMBL626293,,1,1,,BAO_0000218,160.0,
14142,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse intestine, 5 minutes post injection",,CHEMBL626294,,1,1,,BAO_0000218,160.0,
14143,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse intestine, 60 minutes post injection",,CHEMBL626295,,1,1,,BAO_0000218,160.0,
14144,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse liver, 10 minutes post injection",,CHEMBL627659,,1,1,,BAO_0000218,2107.0,
14145,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse liver, 30 minutes of post injection",,CHEMBL627660,,1,1,,BAO_0000218,2107.0,
14146,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse liver, 5 minutes post injection",,CHEMBL627661,,1,1,,BAO_0000218,2107.0,
14147,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in mice liver at 60 minutes of post injection,,CHEMBL627662,,1,1,,BAO_0000218,2107.0,
14148,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in mice lungs at 10 min of post injection,,CHEMBL627663,,1,1,,BAO_0000218,2048.0,
14149,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mouse lung, 30 minutes post injection",,CHEMBL627664,,1,1,,BAO_0000218,,
14150,A,,10090.0,,50594,Intermediate,"Percentage biodistribution in mousee lung, 5 minutes post injection",,CHEMBL627665,,1,1,,BAO_0000218,,
14151,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in mice lungs at 60 min of post injection,,CHEMBL627666,,1,1,,BAO_0000218,2048.0,
14152,A,,10090.0,,50594,Intermediate,Percentage biodistribution in mouse spleen,,CHEMBL627667,,1,1,,BAO_0000218,2106.0,
14153,A,,10090.0,,50594,Intermediate,Percentage biodistribution in mouse stomach,,CHEMBL627668,,1,1,,BAO_0000218,945.0,
14154,A,,10090.0,,50594,Intermediate,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,,CHEMBL627669,,1,1,,BAO_0000218,1088.0,
14155,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,,CHEMBL627670,,0,1,,BAO_0000218,1255.0,
14156,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,,CHEMBL627671,,0,1,,BAO_0000218,178.0,
14157,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,,CHEMBL627672,,0,1,,BAO_0000218,1474.0,
14158,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,CHEMBL627673,,0,1,,BAO_0000218,,
14159,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,,CHEMBL627674,,0,1,,BAO_0000218,2113.0,
14160,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,,CHEMBL627675,,0,1,,BAO_0000218,2107.0,
14161,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,,CHEMBL627676,,0,1,,BAO_0000218,2048.0,
14162,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,,CHEMBL627677,,0,1,,BAO_0000218,2385.0,
14163,A,,,,22224,Autocuration,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,CHEMBL627678,,0,1,,BAO_0000019,,
14164,A,,10116.0,,50597,Intermediate,Affinity for protein binding expressed as association constant in fresh rat serum,,CHEMBL627679,,1,1,,BAO_0000218,1977.0,
14165,A,,,,22224,Autocuration,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,CHEMBL627680,,0,1,,BAO_0000019,,
14166,A,,,,22224,Autocuration,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,CHEMBL627681,,0,1,,BAO_0000019,,
14167,A,,,,22224,Autocuration,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,CHEMBL627682,,0,1,,BAO_0000019,,
14168,A,,,,22224,Autocuration,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,CHEMBL627683,,0,1,,BAO_0000019,,
14169,A,,,,22224,Autocuration,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,CHEMBL627684,,0,1,,BAO_0000019,,
14170,A,,,,22224,Autocuration,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,CHEMBL874441,,0,1,,BAO_0000019,,
14171,A,,,,22224,Autocuration,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,CHEMBL627685,,0,1,,BAO_0000019,,
14172,A,,,,22224,Autocuration,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,CHEMBL627686,,0,1,,BAO_0000019,,
14173,A,,,,22224,Autocuration,Apparent rate constant Koff for inactivation of dTMP synthase.,,CHEMBL627687,,0,1,,BAO_0000019,,
14174,A,,,,22224,Autocuration,The irreversible inhibitor activity by second order rate equation.,,CHEMBL627688,,0,1,,BAO_0000019,,
14175,A,,10116.0,,50597,Intermediate,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,CHEMBL628038,,1,1,,BAO_0000218,,
14176,A,,10116.0,,50597,Intermediate,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,CHEMBL628039,,1,1,,BAO_0000218,,
14177,A,,10116.0,,50597,Intermediate,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,CHEMBL628040,,1,1,,BAO_0000218,,
14178,A,,,,22224,Autocuration,Dissociation rate calculated from the first-order equation using t1/2 value,,CHEMBL628041,,0,1,,BAO_0000019,,
14179,A,,,,22224,Autocuration,The compound was tested for Binding constant against DNA,,CHEMBL630226,,0,1,,BAO_0000019,,
14180,A,,,,22224,Autocuration,First order rate constant for cyclization of the compound,,CHEMBL628042,,0,1,,BAO_0000019,,
14181,A,,,,22224,Autocuration,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,CHEMBL625232,,0,1,,BAO_0000019,,
14182,A,,,,22224,Autocuration,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,CHEMBL625233,,0,1,,BAO_0000019,,
14183,A,,,,22224,Autocuration,Hydrolysis rate constant was determined,,CHEMBL625979,,0,1,,BAO_0000019,,
14184,A,,,,22224,Autocuration,Observed first order rate constant,,CHEMBL625980,,0,1,,BAO_0000019,,
14185,A,,,,22224,Autocuration,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,CHEMBL625981,,0,1,,BAO_0000019,,
14186,A,,,,22224,Autocuration,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,CHEMBL625982,,0,1,,BAO_0000019,,
14187,A,,,,22224,Autocuration,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,CHEMBL625983,,0,1,,BAO_0000019,,
14188,A,,,,22224,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625984,,0,1,,BAO_0000019,,
14189,A,,,,22224,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625985,,0,1,,BAO_0000019,,
14190,A,,,,22224,Autocuration,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625986,,0,1,,BAO_0000019,,
14191,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625987,,0,1,,BAO_0000019,,
14192,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625988,,0,1,,BAO_0000019,,
14193,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625989,,0,1,,BAO_0000019,,
14194,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625990,,0,1,,BAO_0000019,,
14195,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625991,,0,1,,BAO_0000019,,
14196,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625992,,0,1,,BAO_0000019,,
14197,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL625993,,0,1,,BAO_0000019,,
14198,A,,,,22224,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL631973,,0,1,,BAO_0000019,,
14199,A,,,,22224,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632143,,0,1,,BAO_0000019,,
14200,A,,,,22224,Autocuration,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632144,,0,1,,BAO_0000019,,
14201,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632145,,0,1,,BAO_0000019,,
14202,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632146,,0,1,,BAO_0000019,,
14203,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632147,,0,1,,BAO_0000019,,
14204,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632148,,0,1,,BAO_0000019,,
14205,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632149,,0,1,,BAO_0000019,,
14206,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632150,,0,1,,BAO_0000019,,
14207,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL632151,,0,1,,BAO_0000019,,
14208,A,,9606.0,,50587,Intermediate,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,CHEMBL632152,,1,1,,BAO_0000218,,
14209,A,,9606.0,,50587,Intermediate,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,CHEMBL632153,,1,1,,BAO_0000218,,
14210,A,,9606.0,,50587,Intermediate,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,CHEMBL632154,,1,1,,BAO_0000218,,
14211,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,CHEMBL632155,,1,1,,BAO_0000218,,
14212,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,CHEMBL632156,,1,1,,BAO_0000218,,
14213,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,CHEMBL632157,,1,1,,BAO_0000218,,
14214,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,CHEMBL632158,,1,1,,BAO_0000218,,
14215,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,CHEMBL632159,,1,1,,BAO_0000218,,
14216,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,CHEMBL626305,,1,1,,BAO_0000218,,
14217,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,CHEMBL626306,,1,1,,BAO_0000218,,
14218,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,CHEMBL626307,,1,1,,BAO_0000218,,
14219,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,CHEMBL626308,,1,1,,BAO_0000218,,
14220,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,CHEMBL626479,,1,1,,BAO_0000218,,
14221,A,,10298.0,,50602,Intermediate,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,CHEMBL626480,,1,1,,BAO_0000218,,
14222,P,,,,22229,Autocuration,Calculated partition coefficient (clogP) (MlogP),,CHEMBL626481,,0,1,,BAO_0000100,,
14223,A,,,,22224,Autocuration,Equipotent potent ratio relative to carbachol (nicotinic activity),,CHEMBL626482,,0,1,,BAO_0000019,,
14224,A,,9615.0,,50588,Intermediate,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,CHEMBL626483,,1,1,,BAO_0000218,,
14225,A,,9615.0,,50588,Intermediate,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,CHEMBL626484,,1,1,,BAO_0000218,,
14226,P,,,,22229,Autocuration,Solubility at pH 7.4 in micro g/mL;NA denotes available,,CHEMBL626485,,0,1,,BAO_0000100,,
14227,P,,,,22229,Autocuration,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,CHEMBL626486,,0,1,,BAO_0000100,,
14228,P,,,,22229,Autocuration,Solubility at pH 7.4 in ug/mL;NA denotes not available,,CHEMBL626487,,0,1,,BAO_0000100,,
14229,A,In vivo,9615.0,,50588,Intermediate,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,CHEMBL626488,,1,1,,BAO_0000218,1969.0,
14230,A,,10116.0,,50597,Intermediate,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,,CHEMBL626489,,1,1,,BAO_0000218,1977.0,
14231,A,,,,22224,Autocuration,Area under the MAP curve measured over 5 min; ND means Not determined,,CHEMBL626490,,0,1,,BAO_0000019,,
14232,P,,,,22224,Autocuration,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,CHEMBL626491,,0,1,,BAO_0000100,,
14233,P,,,,22229,Autocuration,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,CHEMBL626492,,0,1,,BAO_0000100,,
14234,A,,,,22224,Autocuration,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,CHEMBL626493,,0,1,,BAO_0000019,,
14235,A,In vivo,10116.0,,50597,Intermediate,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,CHEMBL626494,,1,1,,BAO_0000218,,
14236,A,In vivo,,,22224,Autocuration,Half life after oral tested,,CHEMBL626495,,0,1,,BAO_0000218,,
14237,A,,10116.0,,50597,Intermediate,Half life was determined in plasma of rat; NT indicates not tested,,CHEMBL626496,,1,1,,BAO_0000218,1969.0,
14238,A,In vivo,10116.0,,50597,Intermediate,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,CHEMBL626497,,1,1,,BAO_0000218,,
14239,A,In vivo,,,22224,Autocuration,Oral bioavailability after oral tested,,CHEMBL626498,,0,1,,BAO_0000218,,
14240,A,,10116.0,,50597,Intermediate,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,CHEMBL626499,,1,1,,BAO_0000218,,
14241,A,,10116.0,,50597,Intermediate,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,CHEMBL626500,,1,1,,BAO_0000218,,
14242,A,,10116.0,,50597,Intermediate,half life was determined in plasma of rat; NT indicates not tested,,CHEMBL626501,,1,1,,BAO_0000218,1969.0,
14243,A,,10116.0,,50597,Intermediate,half life was determined in plasma of rat; NT means not tested,,CHEMBL626502,,1,1,,BAO_0000218,1969.0,
14244,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,CHEMBL626503,,1,1,,BAO_0000218,,
14245,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,CHEMBL626504,,1,1,,BAO_0000218,,
14246,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,CHEMBL626505,,1,1,,BAO_0000218,,
14247,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,CHEMBL626506,,1,1,,BAO_0000218,,
14248,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,CHEMBL626507,,1,1,,BAO_0000218,,
14249,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,CHEMBL626508,,1,1,,BAO_0000218,,
14250,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,CHEMBL626509,,1,1,,BAO_0000218,,
14251,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,CHEMBL875480,,1,1,,BAO_0000218,,
14252,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,CHEMBL626510,,1,1,,BAO_0000218,,
14253,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,CHEMBL626511,,1,1,,BAO_0000218,,
14254,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,CHEMBL626512,,1,1,,BAO_0000218,,
14255,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,CHEMBL628208,,1,1,,BAO_0000218,,
14256,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,CHEMBL628209,,1,1,,BAO_0000218,,
14257,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,CHEMBL628210,,1,1,,BAO_0000218,,
14258,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,CHEMBL628211,,1,1,,BAO_0000218,,
14259,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,CHEMBL628212,,1,1,,BAO_0000218,,
14260,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,CHEMBL628213,,1,1,,BAO_0000218,,
14261,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,,CHEMBL628214,,1,1,,BAO_0000218,1088.0,
14262,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,,CHEMBL628215,,1,1,,BAO_0000218,1088.0,
14263,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,,CHEMBL628216,,1,1,,BAO_0000218,1088.0,
14264,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,,CHEMBL626595,,1,1,,BAO_0000218,1088.0,
14265,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,,CHEMBL626596,,1,1,,BAO_0000218,1088.0,
14266,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,,CHEMBL626597,,1,1,,BAO_0000218,1088.0,
14267,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,,CHEMBL626598,,1,1,,BAO_0000218,1088.0,
14268,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,,CHEMBL622242,,1,1,,BAO_0000218,1088.0,
14269,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,,CHEMBL622243,,1,1,,BAO_0000218,1088.0,
14270,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,,CHEMBL622244,,1,1,,BAO_0000218,1088.0,
14271,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,,CHEMBL622245,,1,1,,BAO_0000218,1088.0,
14272,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,,CHEMBL622246,,1,1,,BAO_0000218,1088.0,
14273,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,,CHEMBL622247,,1,1,,BAO_0000218,1088.0,
14274,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,,CHEMBL622248,,1,1,,BAO_0000218,1088.0,
14275,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,,CHEMBL877483,,1,1,,BAO_0000218,1088.0,
14276,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,,CHEMBL622249,,1,1,,BAO_0000218,1088.0,
14277,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,CHEMBL622250,,1,1,,BAO_0000218,1088.0,
14278,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,CHEMBL622251,,1,1,,BAO_0000218,1088.0,
14279,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,CHEMBL622252,,1,1,,BAO_0000218,1088.0,
14280,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,CHEMBL622253,,1,1,,BAO_0000218,1088.0,
14281,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,CHEMBL622254,,1,1,,BAO_0000218,1088.0,
14282,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,CHEMBL622255,,1,1,,BAO_0000218,1088.0,
14283,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,CHEMBL622256,,1,1,,BAO_0000218,1088.0,
14284,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,CHEMBL622257,,1,1,,BAO_0000218,1088.0,
14285,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,CHEMBL622258,,1,1,,BAO_0000218,1088.0,
14286,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,CHEMBL622259,,1,1,,BAO_0000218,1088.0,
14287,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,CHEMBL622927,,1,1,,BAO_0000218,1088.0,
14288,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,CHEMBL622928,,1,1,,BAO_0000218,1088.0,
14289,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,CHEMBL622929,,1,1,,BAO_0000218,1088.0,
14290,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,CHEMBL623182,,1,1,,BAO_0000218,1088.0,
14291,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,CHEMBL623183,,1,1,,BAO_0000218,1088.0,
14292,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,,CHEMBL623184,,1,1,,BAO_0000218,1088.0,
14293,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,CHEMBL623185,,1,1,,BAO_0000218,1088.0,
14294,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,CHEMBL877484,,1,1,,BAO_0000218,1088.0,
14295,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,CHEMBL627274,,1,1,,BAO_0000218,1088.0,
14296,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,,CHEMBL623186,,1,1,,BAO_0000218,1088.0,
14297,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,,CHEMBL623187,,1,1,,BAO_0000218,1088.0,
14298,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,CHEMBL623188,,1,1,,BAO_0000218,1088.0,
14299,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,,CHEMBL628055,,1,1,,BAO_0000218,1088.0,
14300,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,CHEMBL628056,,1,1,,BAO_0000218,1088.0,
14301,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,,CHEMBL628200,,1,1,,BAO_0000218,1088.0,
14302,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,CHEMBL628201,,1,1,,BAO_0000218,1088.0,
14303,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,,CHEMBL628202,,1,1,,BAO_0000218,1088.0,
14304,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,CHEMBL628203,,1,1,,BAO_0000218,1088.0,
14305,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,,CHEMBL628204,,1,1,,BAO_0000218,1088.0,
14306,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,CHEMBL628205,,1,1,,BAO_0000218,1088.0,
14307,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,,CHEMBL628206,,1,1,,BAO_0000218,1088.0,
14308,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),,CHEMBL628207,,0,1,,BAO_0000218,2367.0,
14309,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,,CHEMBL627220,,0,1,,BAO_0000218,2367.0,
14310,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,,CHEMBL627221,,0,1,,BAO_0000218,2385.0,
14311,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),,CHEMBL627222,,0,1,,BAO_0000218,2367.0,
14312,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,CHEMBL627223,,0,1,,BAO_0000218,,
14313,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,,CHEMBL632062,,0,1,,BAO_0000218,2385.0,
14314,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,,CHEMBL632063,,0,1,,BAO_0000218,2106.0,
14315,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,,CHEMBL632064,,0,1,,BAO_0000218,1255.0,
14316,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,,CHEMBL632065,,0,1,,BAO_0000218,178.0,
14317,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,,CHEMBL632066,,0,1,,BAO_0000218,1474.0,
14318,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,CHEMBL632067,,0,1,,BAO_0000218,,
14319,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,,CHEMBL629188,,0,1,,BAO_0000218,2113.0,
14320,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,,CHEMBL629189,,0,1,,BAO_0000218,2107.0,
14321,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,,CHEMBL629190,,0,1,,BAO_0000218,2048.0,
14322,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,,CHEMBL629191,,0,1,,BAO_0000218,2385.0,
14323,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),,CHEMBL629192,,0,1,,BAO_0000218,2367.0,
14324,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,,CHEMBL629193,,0,1,,BAO_0000218,2385.0,
14325,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),,CHEMBL629194,,0,1,,BAO_0000218,2367.0,
14326,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,CHEMBL629195,,0,1,,BAO_0000218,,
14327,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,,CHEMBL629373,,0,1,,BAO_0000218,2385.0,
14328,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,,CHEMBL629374,,0,1,,BAO_0000218,2106.0,
14329,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,,CHEMBL629375,,0,1,,BAO_0000218,2367.0,
14330,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,,CHEMBL629376,,0,1,,BAO_0000218,1255.0,
14331,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,,CHEMBL629377,,0,1,,BAO_0000218,178.0,
14332,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,,CHEMBL629378,,0,1,,BAO_0000218,1474.0,
14333,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,CHEMBL629379,,0,1,,BAO_0000218,,
14334,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,,CHEMBL629151,,0,1,,BAO_0000218,2113.0,
14335,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,,CHEMBL629152,,0,1,,BAO_0000218,2107.0,
14336,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,,CHEMBL629153,,0,1,,BAO_0000218,2048.0,
14337,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,,CHEMBL629154,,0,1,,BAO_0000218,2385.0,
14338,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),,CHEMBL629155,,0,1,,BAO_0000218,2367.0,
14339,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,,CHEMBL629156,,0,1,,BAO_0000218,2367.0,
14340,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,,CHEMBL629157,,0,1,,BAO_0000218,2385.0,
14341,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),,CHEMBL629158,,0,1,,BAO_0000218,2367.0,
14342,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,CHEMBL629159,,0,1,,BAO_0000218,,
14343,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,,CHEMBL629160,,0,1,,BAO_0000218,2385.0,
14344,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,,CHEMBL629161,,0,1,,BAO_0000218,2106.0,
14345,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,,CHEMBL629162,,0,1,,BAO_0000218,1255.0,
14346,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,,CHEMBL629163,,0,1,,BAO_0000218,178.0,
14347,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,,CHEMBL629164,,0,1,,BAO_0000218,1474.0,
14348,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,CHEMBL629165,,0,1,,BAO_0000218,,
14349,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,,CHEMBL629166,,0,1,,BAO_0000218,2107.0,
14350,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,,CHEMBL629167,,0,1,,BAO_0000218,2048.0,
14351,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,,CHEMBL629168,,0,1,,BAO_0000218,2385.0,
14352,A,,,,22224,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,CHEMBL629169,,0,1,,BAO_0000019,,
14353,A,,,,22224,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,CHEMBL629170,,0,1,,BAO_0000019,,
14354,A,,,,22224,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,CHEMBL631153,,0,1,,BAO_0000019,,
14355,A,,,,22224,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,CHEMBL875121,,0,1,,BAO_0000019,,
14356,A,,,,22224,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,CHEMBL631154,,0,1,,BAO_0000019,,
14357,A,,,,22224,Autocuration,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,CHEMBL631155,,0,1,,BAO_0000019,,
14358,A,,,,22224,Autocuration,Hydrolysis rate constant was determined,,CHEMBL631156,,0,1,,BAO_0000019,,
14359,A,,,,22224,Autocuration,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,CHEMBL631157,,0,1,,BAO_0000019,,
14360,A,,,,22224,Autocuration,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,CHEMBL631158,,0,1,,BAO_0000019,,
14361,A,,,,22224,Autocuration,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,CHEMBL631159,,0,1,,BAO_0000019,,
14362,A,,,,22224,Autocuration,Observed second order rate constant,,CHEMBL631160,,0,1,,BAO_0000019,,
14363,A,,,,22224,Autocuration,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,CHEMBL631161,,0,1,,BAO_0000019,,
14364,A,,,,22224,Autocuration,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,CHEMBL631162,,0,1,,BAO_0000019,,
14365,A,,,,22224,Autocuration,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,CHEMBL630313,,0,1,,BAO_0000019,,
14366,A,,,,22224,Autocuration,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,CHEMBL630314,,0,1,,BAO_0000019,,
14367,A,,,,22224,Autocuration,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,CHEMBL630315,,0,1,,BAO_0000019,,
14368,A,,,,22224,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630316,,0,1,,BAO_0000019,,
14369,A,,,,22224,Autocuration,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630986,,0,1,,BAO_0000019,,
14370,A,,,,22224,Autocuration,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630987,,0,1,,BAO_0000019,,
14371,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630988,,0,1,,BAO_0000019,,
14372,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630989,,0,1,,BAO_0000019,,
14373,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630990,,0,1,,BAO_0000019,,
14374,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630991,,0,1,,BAO_0000019,,
14375,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630992,,0,1,,BAO_0000019,,
14376,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630993,,0,1,,BAO_0000019,,
14377,A,,,,22224,Autocuration,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,CHEMBL630994,,0,1,,BAO_0000019,,
14378,A,,10116.0,,50597,Intermediate,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,CHEMBL630995,,1,1,,BAO_0000218,,
14379,A,,,,22224,Autocuration,Association constant for compound at 31 degree C was determined,,CHEMBL629252,,0,1,,BAO_0000019,,
14380,A,,,,22224,Autocuration,Calculated antagonist equilibrium dissociation constant of the compound,,CHEMBL629253,,0,1,,BAO_0000019,,
14381,A,,,,22224,Autocuration,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,CHEMBL629944,,0,1,,BAO_0000019,,
14382,A,,10141.0,,50512,Intermediate,Dissociation constants vs LTE4 on guinea pig trachea,,CHEMBL629945,,1,1,,BAO_0000218,3126.0,
14383,A,,,,22224,Autocuration,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,CHEMBL629946,,0,1,,BAO_0000019,,
14384,A,,,,22224,Autocuration,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,CHEMBL629947,,0,1,,BAO_0000019,,
14385,A,,,,22224,Autocuration,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,CHEMBL629948,,0,1,,BAO_0000019,,
14386,A,,,,22224,Autocuration,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,CHEMBL856024,,0,1,,BAO_0000019,,
14387,A,,,,22224,Autocuration,Affinity constant KD value was derived from TMP,,CHEMBL629949,,0,1,,BAO_0000019,,
14388,A,,,,22224,Autocuration,Apparent dissociation (binding) rate constant was evaluated,,CHEMBL629950,,0,1,,BAO_0000019,,
14389,P,,,,22224,Autocuration,Dissociation constant (KD) of the compound,,CHEMBL630127,,0,1,,BAO_0000100,,
14390,P,,,,22224,Autocuration,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,CHEMBL630128,,0,1,,BAO_0000100,,
14391,P,,,,22224,Autocuration,Dissociation constant from ESR titration experiments,,CHEMBL630129,,0,1,,BAO_0000100,,
14392,,,,,22224,Autocuration,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,CHEMBL630130,,0,1,,BAO_0000019,,
14393,P,,,,22224,Autocuration,Dissociation constant was evaluated.,,CHEMBL875234,,0,1,,BAO_0000100,,
14394,P,,,,22224,Autocuration,Dissociation constant was reported,,CHEMBL630131,,0,1,,BAO_0000100,,
14395,A,,10116.0,,50597,Intermediate,Dissociation constant was determined in rat pituitary cells.,,CHEMBL630132,,1,1,,BAO_0000218,,
14396,A,,,,22224,Autocuration,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,CHEMBL630133,,0,1,,BAO_0000019,,
14397,A,,,,22224,Autocuration,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,CHEMBL630134,,0,1,,BAO_0000019,,
14398,A,,,,22224,Autocuration,Equilibrium dissociation constant of the compound,,CHEMBL630135,,0,1,,BAO_0000019,,
14399,A,,,,22224,Autocuration,Equilibrium dissociation constant was determined,,CHEMBL630136,,0,1,,BAO_0000019,,
14400,A,,,,22224,Autocuration,Kinetic constant KD was evaluated,,CHEMBL630137,,0,1,,BAO_0000019,,
14401,A,,,,22224,Autocuration,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,CHEMBL630138,,0,1,,BAO_0000019,,
14402,A,,,,22224,Autocuration,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,CHEMBL630139,,0,1,,BAO_0000019,,
14403,A,,,,22224,Autocuration,Rate constant for hydrolysis in aqueous acetone.,,CHEMBL630140,,0,1,,BAO_0000019,,
14404,A,,,,22224,Autocuration,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,CHEMBL875235,,0,1,,BAO_0000019,,
14405,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,CHEMBL876439,,1,1,,BAO_0000218,,
14406,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,CHEMBL630605,,1,1,,BAO_0000218,,
14407,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,CHEMBL630606,,1,1,,BAO_0000218,,
14408,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,CHEMBL630607,,1,1,,BAO_0000218,,
14409,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,CHEMBL630608,,1,1,,BAO_0000218,,
14410,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,CHEMBL630609,,1,1,,BAO_0000218,,
14411,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,CHEMBL630610,,1,1,,BAO_0000218,,
14412,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,CHEMBL630611,,1,1,,BAO_0000218,,
14413,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,CHEMBL629552,,1,1,,BAO_0000218,,
14414,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,CHEMBL629733,,1,1,,BAO_0000218,,
14415,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,CHEMBL629734,,1,1,,BAO_0000218,,
14416,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,CHEMBL629735,,1,1,,BAO_0000218,,
14417,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,CHEMBL629736,,1,1,,BAO_0000218,,
14418,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,CHEMBL629737,,1,1,,BAO_0000218,,
14419,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,CHEMBL629738,,1,1,,BAO_0000218,,
14420,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,CHEMBL629739,,1,1,,BAO_0000218,,
14421,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,CHEMBL629740,,1,1,,BAO_0000218,,
14422,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,CHEMBL629741,,1,1,,BAO_0000218,,
14423,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,CHEMBL629742,,1,1,,BAO_0000218,,
14424,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,CHEMBL629743,,1,1,,BAO_0000218,,
14425,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,CHEMBL629744,,1,1,,BAO_0000218,,
14426,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,CHEMBL629745,,1,1,,BAO_0000218,,
14427,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,CHEMBL629746,,1,1,,BAO_0000218,,
14428,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,CHEMBL629747,,1,1,,BAO_0000218,,
14429,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,CHEMBL629748,,1,1,,BAO_0000218,,
14430,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,CHEMBL629749,,1,1,,BAO_0000218,,
14431,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,CHEMBL629750,,1,1,,BAO_0000218,,
14432,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,CHEMBL629751,,1,1,,BAO_0000218,,
14433,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,CHEMBL629752,,1,1,,BAO_0000218,,
14434,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,CHEMBL629753,,1,1,,BAO_0000218,,
14435,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,CHEMBL629754,,1,1,,BAO_0000218,,
14436,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,CHEMBL629755,,1,1,,BAO_0000218,,
14437,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,CHEMBL629756,,1,1,,BAO_0000218,,
14438,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,CHEMBL629757,,1,1,,BAO_0000218,,
14439,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,CHEMBL629758,,1,1,,BAO_0000218,,
14440,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,CHEMBL629759,,1,1,,BAO_0000218,,
14441,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,CHEMBL629760,,1,1,,BAO_0000218,,
14442,A,,10116.0,,50597,Intermediate,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,CHEMBL876443,,1,1,,BAO_0000218,,
14443,A,,9615.0,,50588,Intermediate,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,CHEMBL629761,,1,1,,BAO_0000218,,
14444,A,,9615.0,,50588,Intermediate,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,CHEMBL629762,,1,1,,BAO_0000218,,
14445,A,,10090.0,,50594,Intermediate,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,CHEMBL629763,,1,1,,BAO_0000218,,
14446,A,,10090.0,,50594,Intermediate,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,CHEMBL629764,,1,1,,BAO_0000218,,
14447,A,,10090.0,,50594,Intermediate,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,CHEMBL629765,,1,1,,BAO_0000218,,
14448,A,,10090.0,,50594,Intermediate,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,CHEMBL629766,,1,1,,BAO_0000218,,
14449,A,,10090.0,,50594,Intermediate,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,CHEMBL629767,,1,1,,BAO_0000218,,
14450,A,,9615.0,,50588,Intermediate,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,CHEMBL629768,,1,1,,BAO_0000218,,
14451,A,,10090.0,,50594,Intermediate,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,CHEMBL629769,,1,1,,BAO_0000218,,
14452,A,,9615.0,,50588,Intermediate,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,CHEMBL629770,,1,1,,BAO_0000218,,
14453,A,,9615.0,,50588,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,CHEMBL629771,,1,1,,BAO_0000218,,
14454,A,,10090.0,,50594,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,CHEMBL629772,,1,1,,BAO_0000218,,
14455,A,,10090.0,,50594,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,CHEMBL629773,,1,1,,BAO_0000218,,
14456,A,,10090.0,,50594,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,CHEMBL625455,,1,1,,BAO_0000218,,
14457,A,,10090.0,,50594,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,CHEMBL625456,,1,1,,BAO_0000218,,
14458,A,,10090.0,,50594,Intermediate,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,CHEMBL625457,,1,1,,BAO_0000218,,
14459,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,CHEMBL625458,,1,1,,BAO_0000218,1088.0,
14460,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,,CHEMBL625459,,1,1,,BAO_0000218,1088.0,
14461,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,CHEMBL875483,,1,1,,BAO_0000218,1088.0,
14462,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,,CHEMBL634779,,1,1,,BAO_0000218,1088.0,
14463,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,,CHEMBL625460,,1,1,,BAO_0000218,1088.0,
14464,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,CHEMBL626117,,1,1,,BAO_0000218,1088.0,
14465,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,,CHEMBL626118,,1,1,,BAO_0000218,1088.0,
14466,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,,CHEMBL628342,,1,1,,BAO_0000218,1088.0,
14467,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,CHEMBL628343,,1,1,,BAO_0000218,1088.0,
14468,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,,CHEMBL628344,,1,1,,BAO_0000218,1088.0,
14469,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,CHEMBL628345,,1,1,,BAO_0000218,1088.0,
14470,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,,CHEMBL628346,,1,1,,BAO_0000218,1088.0,
14471,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,,CHEMBL628347,,1,1,,BAO_0000218,1088.0,
14472,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,CHEMBL628348,,1,1,,BAO_0000218,1088.0,
14473,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,CHEMBL628349,,1,1,,BAO_0000218,1088.0,
14474,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,,CHEMBL875611,,1,1,,BAO_0000218,1088.0,
14475,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,,CHEMBL628350,,1,1,,BAO_0000218,1088.0,
14476,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,CHEMBL628351,,1,1,,BAO_0000218,1088.0,
14477,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,,CHEMBL628352,,1,1,,BAO_0000218,1088.0,
14478,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,CHEMBL628353,,1,1,,BAO_0000218,1088.0,
14479,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,,CHEMBL628354,,1,1,,BAO_0000218,1088.0,
14480,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,CHEMBL626667,,1,1,,BAO_0000218,1088.0,
14481,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,CHEMBL626668,,1,1,,BAO_0000218,1088.0,
14482,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,CHEMBL626669,,1,1,,BAO_0000218,1088.0,
14483,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,,CHEMBL626670,,1,1,,BAO_0000218,1088.0,
14484,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,,CHEMBL626671,,1,1,,BAO_0000218,1088.0,
14485,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,CHEMBL626672,,1,1,,BAO_0000218,1088.0,
14486,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,,CHEMBL626673,,1,1,,BAO_0000218,1088.0,
14487,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,CHEMBL626674,,1,1,,BAO_0000218,1088.0,
14488,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,CHEMBL626675,,1,1,,BAO_0000218,1088.0,
14489,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,,CHEMBL626676,,1,1,,BAO_0000218,1088.0,
14490,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,,CHEMBL626677,,1,1,,BAO_0000218,1088.0,
14491,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,CHEMBL626678,,1,1,,BAO_0000218,1088.0,
14492,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,CHEMBL626679,,1,1,,BAO_0000218,1088.0,
14493,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,CHEMBL875612,,1,1,,BAO_0000218,1088.0,
14494,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,CHEMBL626680,,1,1,,BAO_0000218,1088.0,
14495,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,CHEMBL626681,,1,1,,BAO_0000218,1088.0,
14496,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,CHEMBL626682,,1,1,,BAO_0000218,1088.0,
14497,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,CHEMBL626683,,1,1,,BAO_0000218,1088.0,
14498,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,CHEMBL626684,,1,1,,BAO_0000218,1088.0,
14499,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,CHEMBL626685,,1,1,,BAO_0000218,1088.0,
14500,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,CHEMBL626686,,1,1,,BAO_0000218,1088.0,
14501,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,CHEMBL626687,,1,1,,BAO_0000218,1088.0,
14502,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,CHEMBL624978,,1,1,,BAO_0000218,1088.0,
14503,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,CHEMBL624979,,1,1,,BAO_0000218,1088.0,
14504,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,CHEMBL624980,,1,1,,BAO_0000218,1088.0,
14505,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,CHEMBL624981,,1,1,,BAO_0000218,1088.0,
14506,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,CHEMBL624982,,1,1,,BAO_0000218,1088.0,
14507,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),,CHEMBL627564,,0,1,,BAO_0000218,2367.0,
14508,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),,CHEMBL627565,,0,1,,BAO_0000218,2367.0,
14509,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,CHEMBL627566,,0,1,,BAO_0000218,,
14510,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,,CHEMBL627567,,0,1,,BAO_0000218,2385.0,
14511,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,,CHEMBL627568,,0,1,,BAO_0000218,2106.0,
14512,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,,CHEMBL627569,,0,1,,BAO_0000218,2113.0,
14513,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,,CHEMBL627570,,0,1,,BAO_0000218,1255.0,
14514,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,,CHEMBL627571,,0,1,,BAO_0000218,178.0,
14515,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,,CHEMBL627572,,0,1,,BAO_0000218,1474.0,
14516,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,CHEMBL627573,,0,1,,BAO_0000218,,
14517,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,,CHEMBL627574,,0,1,,BAO_0000218,2113.0,
14518,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,,CHEMBL627575,,0,1,,BAO_0000218,2107.0,
14519,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,,CHEMBL627576,,0,1,,BAO_0000218,2048.0,
14520,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,,CHEMBL627577,,0,1,,BAO_0000218,2385.0,
14521,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),,CHEMBL627578,,0,1,,BAO_0000218,2367.0,
14522,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,,CHEMBL627579,,0,1,,BAO_0000218,2367.0,
14523,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,,CHEMBL627580,,0,1,,BAO_0000218,2385.0,
14524,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),,CHEMBL627581,,0,1,,BAO_0000218,2367.0,
14525,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,CHEMBL627582,,0,1,,BAO_0000218,,
14526,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,,CHEMBL627583,,0,1,,BAO_0000218,2385.0,
14527,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,,CHEMBL627584,,0,1,,BAO_0000218,2106.0,
14528,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,,CHEMBL627585,,0,1,,BAO_0000218,2367.0,
14529,A,In vivo,,,22224,Autocuration,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,,CHEMBL627586,,0,1,,BAO_0000218,2385.0,
14530,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,CHEMBL627587,,1,1,,BAO_0000218,,
14531,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL627588,,1,1,,BAO_0000218,,
14532,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,CHEMBL628250,,1,1,,BAO_0000218,,
14533,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628251,,1,1,,BAO_0000218,,
14534,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,,CHEMBL628252,,1,1,,BAO_0000218,10000000.0,
14535,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628253,,1,1,,BAO_0000218,10000000.0,
14536,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,,CHEMBL628254,,1,1,,BAO_0000218,1898.0,
14537,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL877493,,1,1,,BAO_0000218,1898.0,
14538,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628255,,1,1,,BAO_0000218,,
14539,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628256,,1,1,,BAO_0000218,,
14540,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628257,,1,1,,BAO_0000218,10000000.0,
14541,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628258,,1,1,,BAO_0000218,1898.0,
14542,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628259,,1,1,,BAO_0000218,,
14543,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL628429,,1,1,,BAO_0000218,,
14544,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,CHEMBL626862,,1,1,,BAO_0000218,10000000.0,
14545,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,,CHEMBL626863,,1,1,,BAO_0000218,1898.0,
14546,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,,CHEMBL625886,,1,1,,BAO_0000218,2037.0,
14547,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,,CHEMBL625887,,1,1,,BAO_0000218,2037.0,
14548,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,CHEMBL625888,,1,1,,BAO_0000218,,
14549,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,CHEMBL625889,,1,1,,BAO_0000218,,
14550,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,,CHEMBL625890,,1,1,,BAO_0000218,10000000.0,
14551,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,,CHEMBL625891,,1,1,,BAO_0000218,10000000.0,
14552,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,,CHEMBL625892,,1,1,,BAO_0000218,1898.0,
14553,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,,CHEMBL625893,,1,1,,BAO_0000218,1898.0,
14554,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,,CHEMBL625894,,1,1,,BAO_0000218,2037.0,
14555,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,CHEMBL625895,,1,1,,BAO_0000218,,
14556,A,,,,22224,Autocuration,Reaction rate parameter value for phosphate with transfer with respect to ATP,,CHEMBL625896,,0,1,,BAO_0000019,,
14557,A,,,,22224,Autocuration,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,CHEMBL625897,,0,1,,BAO_0000019,,
14558,A,,,,22224,Autocuration,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,CHEMBL625898,,0,1,,BAO_0000019,,
14559,A,,,,22224,Autocuration,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,CHEMBL625899,,0,1,,BAO_0000019,,
14560,A,,,,22224,Autocuration,Reaction rate parameter value for phosphate with transfer with respect to ATP,,CHEMBL626124,,0,1,,BAO_0000019,,
14561,A,,562.0,,50212,Intermediate,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,CHEMBL628500,,1,1,,BAO_0000218,,
14562,A,,10116.0,,50597,Intermediate,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,CHEMBL857856,,1,1,,BAO_0000218,,
14563,A,,10116.0,,50597,Intermediate,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,CHEMBL628501,,1,1,,BAO_0000218,,
14564,A,,,,22224,Autocuration,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,CHEMBL628502,,0,1,,BAO_0000019,,
14565,A,,,,22224,Autocuration,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,CHEMBL628503,,0,1,,BAO_0000019,,
14566,A,,,,22224,Autocuration,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,CHEMBL628504,,0,1,,BAO_0000019,,
14567,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,CHEMBL628505,,0,1,,BAO_0000019,,
14568,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,CHEMBL874452,,0,1,,BAO_0000019,,
14569,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,CHEMBL628506,,0,1,,BAO_0000019,,
14570,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,CHEMBL628507,,0,1,,BAO_0000019,,
14571,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,CHEMBL628508,,0,1,,BAO_0000019,,
14572,A,,,,22224,Autocuration,Michaelis constant (KM) was evaluated,,CHEMBL628509,,0,1,,BAO_0000019,,
14573,A,,,,22224,Autocuration,Reaction rate parameter value for phosphate with transfer with respect to ATP,,CHEMBL628510,,0,1,,BAO_0000019,,
14574,B,,,,22224,Autocuration,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,CHEMBL628511,,0,1,,BAO_0000019,,
14575,B,,,,22224,Autocuration,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,CHEMBL628512,,0,1,,BAO_0000019,,
14576,B,,,,22224,Autocuration,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,CHEMBL628513,,0,1,,BAO_0000019,,
14577,B,,,,22224,Autocuration,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,CHEMBL628514,,0,1,,BAO_0000019,,
14578,A,,,,22224,Autocuration,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,CHEMBL628515,,0,1,,BAO_0000019,,
14579,A,,,,22224,Autocuration,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,CHEMBL628516,,0,1,,BAO_0000019,,
14580,A,,,,22224,Autocuration,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,CHEMBL628517,,0,1,,BAO_0000019,,
14581,A,,,,22224,Autocuration,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,CHEMBL628518,,0,1,,BAO_0000019,,
14582,A,,,,22224,Autocuration,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,CHEMBL628519,,0,1,,BAO_0000019,,
14583,A,,,,22224,Autocuration,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,CHEMBL628520,,0,1,,BAO_0000019,,
14584,A,,,,22224,Autocuration,Binding constant was determined,,CHEMBL628521,,0,1,,BAO_0000019,,
14585,A,,,,22224,Autocuration,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,CHEMBL630443,,0,1,,BAO_0000019,,
14586,A,,,,22224,Autocuration,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,CHEMBL630444,,0,1,,BAO_0000019,,
14587,A,,,,22224,Autocuration,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,CHEMBL857732,,0,1,,BAO_0000019,,
14588,P,,,,22224,Autocuration,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,CHEMBL630445,,0,1,,BAO_0000100,,
14589,A,,,,22224,Autocuration,Catalytic rate constant of the compound,,CHEMBL630446,,0,1,,BAO_0000019,,
14590,B,,,,22224,Autocuration,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,CHEMBL630447,,0,1,,BAO_0000019,,
14591,A,,,,22224,Autocuration,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,CHEMBL630448,,0,1,,BAO_0000019,,
14592,A,,,,22224,Autocuration,Catalytic rate constant against phospholipase A2 was determined,,CHEMBL630449,,0,1,,BAO_0000019,,
14593,A,,,,22224,Autocuration,"Compound was evaluated for catalytic constant, Kcat",,CHEMBL630450,,0,1,,BAO_0000019,,
14594,A,,,,22224,Autocuration,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,CHEMBL630451,,0,1,,BAO_0000019,,
14595,A,,,,22224,Autocuration,Kcat calculated from 0.693/T1/2,,CHEMBL630452,,0,1,,BAO_0000019,,
14596,A,,,,22224,Autocuration,Kcat was determined,,CHEMBL630453,,0,1,,BAO_0000019,,
14597,A,,,,22224,Autocuration,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,CHEMBL630454,,0,1,,BAO_0000019,,
14598,A,,,,22224,Autocuration,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,CHEMBL630455,,0,1,,BAO_0000019,,
14599,A,,,,22224,Autocuration,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,CHEMBL631487,,0,1,,BAO_0000019,,
14600,A,,,,22224,Autocuration,Kcat value was determined,,CHEMBL631488,,0,1,,BAO_0000019,,
14601,A,,,,22224,Autocuration,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,CHEMBL876440,,0,1,,BAO_0000019,,
14602,A,,,,22224,Autocuration,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,CHEMBL631489,,0,1,,BAO_0000019,,
14603,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,CHEMBL857742,,0,1,,BAO_0000019,,
14604,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,CHEMBL631490,,0,1,,BAO_0000019,,
14605,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,CHEMBL631491,,0,1,,BAO_0000019,,
14606,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,CHEMBL631492,,0,1,,BAO_0000019,,
14607,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,CHEMBL631493,,0,1,,BAO_0000019,,
14608,A,,,,22224,Autocuration,Kinetic parameter for rate of conversion to PABA was determined,,CHEMBL631494,,0,1,,BAO_0000019,,
14609,A,,,,22224,Autocuration,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,CHEMBL631495,,0,1,,BAO_0000019,,
14610,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,CHEMBL631496,,1,1,,BAO_0000218,1988.0,
14611,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,CHEMBL631497,,1,1,,BAO_0000218,1088.0,
14612,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,CHEMBL631498,,1,1,,BAO_0000218,1088.0,
14613,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,CHEMBL629776,,1,1,,BAO_0000218,1088.0,
14614,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,CHEMBL629777,,1,1,,BAO_0000218,1088.0,
14615,A,,10116.0,,50597,Intermediate,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,CHEMBL629778,,1,1,,BAO_0000218,1088.0,
14616,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,CHEMBL630456,,1,1,,BAO_0000218,,
14617,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,CHEMBL630457,,1,1,,BAO_0000218,,
14618,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,CHEMBL630458,,1,1,,BAO_0000218,,
14619,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,CHEMBL630459,,1,1,,BAO_0000218,,
14620,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,CHEMBL630460,,1,1,,BAO_0000218,,
14621,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,CHEMBL876550,,1,1,,BAO_0000218,,
14622,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,CHEMBL630461,,1,1,,BAO_0000218,,
14623,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,CHEMBL630462,,1,1,,BAO_0000218,,
14624,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,CHEMBL630463,,1,1,,BAO_0000218,,
14625,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,CHEMBL630464,,1,1,,BAO_0000218,,
14626,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,CHEMBL630465,,1,1,,BAO_0000218,,
14627,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,CHEMBL630466,,1,1,,BAO_0000218,,
14628,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,CHEMBL630467,,1,1,,BAO_0000218,,
14629,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,CHEMBL630633,,1,1,,BAO_0000218,,
14630,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,CHEMBL630634,,1,1,,BAO_0000218,,
14631,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,CHEMBL630635,,1,1,,BAO_0000218,,
14632,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,CHEMBL630636,,1,1,,BAO_0000218,,
14633,A,,10116.0,,50597,Intermediate,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,CHEMBL630637,,1,1,,BAO_0000218,,
14634,A,,9986.0,,50592,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,CHEMBL630638,,1,1,,BAO_0000218,1988.0,
14635,A,,9986.0,,50592,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,CHEMBL630639,,1,1,,BAO_0000218,1988.0,
14636,A,,9986.0,,50592,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,CHEMBL630640,,1,1,,BAO_0000218,1988.0,
14637,A,,9986.0,,50592,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,CHEMBL876551,,1,1,,BAO_0000218,1988.0,
14638,A,,9986.0,,50592,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",,CHEMBL630641,,1,1,,BAO_0000218,1088.0,
14639,A,,9986.0,,50592,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,CHEMBL630642,,1,1,,BAO_0000218,1088.0,
14640,A,,9986.0,,50592,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,CHEMBL630643,,1,1,,BAO_0000218,1088.0,
14641,A,,9986.0,,50592,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,CHEMBL630644,,1,1,,BAO_0000218,1088.0,
14642,A,,9986.0,,50592,Intermediate,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,CHEMBL630645,,1,1,,BAO_0000218,1088.0,
14643,A,,9986.0,,50592,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,CHEMBL625599,,1,1,,BAO_0000218,1988.0,
14644,A,,9986.0,,50592,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,CHEMBL625600,,1,1,,BAO_0000218,1988.0,
14645,A,,9986.0,,50592,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,CHEMBL625601,,1,1,,BAO_0000218,1988.0,
14646,A,,9986.0,,50592,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,CHEMBL625602,,1,1,,BAO_0000218,1988.0,
14647,A,,9986.0,,50592,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",,CHEMBL627470,,1,1,,BAO_0000218,1088.0,
14648,A,,9986.0,,50592,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,CHEMBL627471,,1,1,,BAO_0000218,1088.0,
14649,A,,9986.0,,50592,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,CHEMBL627472,,1,1,,BAO_0000218,1088.0,
14650,A,,9986.0,,50592,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,CHEMBL627473,,1,1,,BAO_0000218,1088.0,
14651,A,,9986.0,,50592,Intermediate,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,CHEMBL627474,,1,1,,BAO_0000218,1088.0,
14652,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL627475,,1,1,,BAO_0000218,178.0,
14653,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL627476,,1,1,,BAO_0000218,178.0,
14654,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,CHEMBL627477,,1,1,,BAO_0000218,1088.0,
14655,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,CHEMBL627478,,1,1,,BAO_0000218,1088.0,
14656,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,CHEMBL627479,,1,1,,BAO_0000218,1088.0,
14657,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,CHEMBL627480,,1,1,,BAO_0000218,1088.0,
14658,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,CHEMBL627481,,1,1,,BAO_0000218,1088.0,
14659,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,CHEMBL627482,,1,1,,BAO_0000218,1088.0,
14660,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,CHEMBL627483,,1,1,,BAO_0000218,1088.0,
14661,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,CHEMBL875636,,1,1,,BAO_0000218,1088.0,
14662,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,CHEMBL625764,,1,1,,BAO_0000218,1088.0,
14663,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,CHEMBL625765,,1,1,,BAO_0000218,1088.0,
14664,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,,CHEMBL625766,,1,1,,BAO_0000218,1088.0,
14665,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,CHEMBL625767,,1,1,,BAO_0000218,1088.0,
14666,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,CHEMBL625768,,1,1,,BAO_0000218,1088.0,
14667,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,CHEMBL625769,,1,1,,BAO_0000218,1088.0,
14668,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,CHEMBL625770,,1,1,,BAO_0000218,1088.0,
14669,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,CHEMBL625771,,1,1,,BAO_0000218,1088.0,
14670,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,,CHEMBL625772,,1,1,,BAO_0000218,1088.0,
14671,A,,9615.0,,50588,Intermediate,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,CHEMBL625773,,1,1,,BAO_0000218,1088.0,
14672,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,CHEMBL625774,,1,1,,BAO_0000218,1088.0,
14673,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,,CHEMBL625775,,1,1,,BAO_0000218,1088.0,
14674,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,CHEMBL625776,,1,1,,BAO_0000218,1088.0,
14675,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,CHEMBL625777,,1,1,,BAO_0000218,1088.0,
14676,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,CHEMBL625778,,1,1,,BAO_0000218,1088.0,
14677,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,,CHEMBL625779,,1,1,,BAO_0000218,1088.0,
14678,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,,CHEMBL625780,,1,1,,BAO_0000218,1088.0,
14679,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,CHEMBL625781,,1,1,,BAO_0000218,1088.0,
14680,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,,CHEMBL875637,,1,1,,BAO_0000218,1088.0,
14681,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,CHEMBL626473,,1,1,,BAO_0000218,1088.0,
14682,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,,CHEMBL626474,,1,1,,BAO_0000218,1088.0,
14683,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,CHEMBL626475,,1,1,,BAO_0000218,1088.0,
14684,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,,CHEMBL626476,,1,1,,BAO_0000218,1088.0,
14685,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,CHEMBL634397,,1,1,,BAO_0000218,1088.0,
14686,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,,CHEMBL626477,,1,1,,BAO_0000218,1088.0,
14687,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,CHEMBL631069,,1,1,,BAO_0000218,1088.0,
14688,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,,CHEMBL631070,,1,1,,BAO_0000218,1088.0,
14689,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,CHEMBL631071,,1,1,,BAO_0000218,1088.0,
14690,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,,CHEMBL631072,,1,1,,BAO_0000218,1088.0,
14691,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,CHEMBL631073,,1,1,,BAO_0000218,1088.0,
14692,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,,CHEMBL631074,,1,1,,BAO_0000218,1088.0,
14693,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,,CHEMBL631075,,1,1,,BAO_0000218,1088.0,
14694,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,CHEMBL631725,,1,1,,BAO_0000218,1088.0,
14695,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,,CHEMBL631726,,1,1,,BAO_0000218,1088.0,
14696,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,,CHEMBL631727,,1,1,,BAO_0000218,1088.0,
14697,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,CHEMBL631728,,1,1,,BAO_0000218,1088.0,
14698,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,CHEMBL631729,,1,1,,BAO_0000218,1088.0,
14699,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,,CHEMBL631730,,1,1,,BAO_0000218,1088.0,
14700,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,,CHEMBL631731,,1,1,,BAO_0000218,1088.0,
14701,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,CHEMBL631910,,1,1,,BAO_0000218,1088.0,
14702,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,,CHEMBL631911,,1,1,,BAO_0000218,10000000.0,
14703,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,,CHEMBL631912,,1,1,,BAO_0000218,1898.0,
14704,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,,CHEMBL631913,,1,1,,BAO_0000218,1898.0,
14705,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631914,,1,1,,BAO_0000218,178.0,
14706,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631915,,1,1,,BAO_0000218,178.0,
14707,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL875778,,1,1,,BAO_0000218,178.0,
14708,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631916,,1,1,,BAO_0000218,178.0,
14709,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631917,,1,1,,BAO_0000218,178.0,
14710,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631918,,1,1,,BAO_0000218,178.0,
14711,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631919,,1,1,,BAO_0000218,178.0,
14712,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL631920,,1,1,,BAO_0000218,178.0,
14713,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631921,,1,1,,BAO_0000218,178.0,
14714,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631922,,1,1,,BAO_0000218,178.0,
14715,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL631923,,1,1,,BAO_0000218,178.0,
14716,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631924,,1,1,,BAO_0000218,,
14717,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630234,,1,1,,BAO_0000218,,
14718,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630235,,1,1,,BAO_0000218,,
14719,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630236,,1,1,,BAO_0000218,,
14720,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630237,,1,1,,BAO_0000218,,
14721,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630238,,1,1,,BAO_0000218,,
14722,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630239,,1,1,,BAO_0000218,,
14723,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630303,,1,1,,BAO_0000218,,
14724,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630304,,1,1,,BAO_0000218,,
14725,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630305,,1,1,,BAO_0000218,,
14726,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630306,,1,1,,BAO_0000218,2113.0,
14727,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630307,,1,1,,BAO_0000218,2113.0,
14728,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630308,,1,1,,BAO_0000218,2113.0,
14729,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630309,,1,1,,BAO_0000218,2113.0,
14730,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL629309,,1,1,,BAO_0000218,2113.0,
14731,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL629993,,1,1,,BAO_0000218,2113.0,
14732,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL629994,,1,1,,BAO_0000218,2113.0,
14733,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL629995,,1,1,,BAO_0000218,2113.0,
14734,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631993,,1,1,,BAO_0000218,2113.0,
14735,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631994,,1,1,,BAO_0000218,2113.0,
14736,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631995,,1,1,,BAO_0000218,2113.0,
14737,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL631996,,1,1,,BAO_0000218,2107.0,
14738,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631997,,1,1,,BAO_0000218,2107.0,
14739,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631998,,1,1,,BAO_0000218,2107.0,
14740,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631999,,1,1,,BAO_0000218,2107.0,
14741,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL632000,,1,1,,BAO_0000218,2107.0,
14742,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL632001,,1,1,,BAO_0000218,2107.0,
14743,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL874424,,1,1,,BAO_0000218,2107.0,
14744,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL632002,,1,1,,BAO_0000218,2107.0,
14745,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL632003,,1,1,,BAO_0000218,2107.0,
14746,A,,,,22224,Autocuration,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,CHEMBL632004,,0,1,,BAO_0000019,,
14747,A,,,,22224,Autocuration,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,CHEMBL632005,,0,1,,BAO_0000019,,
14748,A,,,,22224,Autocuration,Compound was tested for amidase rate in the presence of N62C screen enzyme,,CHEMBL632006,,0,1,,BAO_0000019,,
14749,A,,,,22224,Autocuration,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,CHEMBL632007,,0,1,,BAO_0000019,,
14750,A,,,,22224,Autocuration,Compound was tested for amidase rate in the presence of S166C screen enzyme,,CHEMBL632008,,0,1,,BAO_0000019,,
14751,A,,,,22224,Autocuration,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,CHEMBL632009,,0,1,,BAO_0000019,,
14752,A,,,,22224,Autocuration,Compound was tested for esterase rate in the presence of N62C screen enzyme,,CHEMBL632010,,0,1,,BAO_0000019,,
14753,A,,,,22224,Autocuration,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,CHEMBL857750,,0,1,,BAO_0000019,,
14754,A,,,,22224,Autocuration,Compound was tested for esterase rate in the presence of S166C screen enzyme,,CHEMBL632011,,0,1,,BAO_0000019,,
14755,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,CHEMBL632012,,0,1,,BAO_0000019,,
14756,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,CHEMBL632013,,0,1,,BAO_0000019,,
14757,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,CHEMBL632014,,0,1,,BAO_0000019,,
14758,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,CHEMBL629622,,0,1,,BAO_0000019,,
14759,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,CHEMBL629623,,0,1,,BAO_0000019,,
14760,A,,,,22224,Autocuration,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,CHEMBL629624,,0,1,,BAO_0000019,,
14761,A,,,,22224,Autocuration,Ratio of Kcat to that of Km was determined,,CHEMBL629625,,0,1,,BAO_0000019,,
14762,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,CHEMBL629626,,0,1,,BAO_0000019,,
14763,A,,,,22224,Autocuration,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,CHEMBL629627,,0,1,,BAO_0000019,,
14764,A,,,,22224,Autocuration,"Compound was evaluated for constant, Kd",,CHEMBL629628,,0,1,,BAO_0000019,,
14765,A,,,,22224,Autocuration,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,CHEMBL629629,,0,1,,BAO_0000019,,
14766,A,,,,22224,Autocuration,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,CHEMBL629630,,0,1,,BAO_0000019,,
14767,A,,,,22224,Autocuration,Dissociation Constant of compound determined,,CHEMBL856030,,0,1,,BAO_0000019,,
14768,B,,,,22224,Autocuration,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,CHEMBL629631,,0,1,,BAO_0000019,,
14769,B,,,,22224,Autocuration,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,CHEMBL629632,,0,1,,BAO_0000019,,
14770,P,,,,22224,Autocuration,Dissociation constant of compound with Fructose was determined,,CHEMBL629633,,0,1,,BAO_0000100,,
14771,P,,,,22224,Autocuration,Dissociation constant of compound with Fructose was determined; Not determined,,CHEMBL629634,,0,1,,BAO_0000100,,
14772,P,,,,22224,Autocuration,Dissociation constant of compound with Lactulose was determined,,CHEMBL629635,,0,1,,BAO_0000100,,
14773,P,,,,22224,Autocuration,Dissociation constant of compound with Lactulose was determined; Not determined,,CHEMBL629636,,0,1,,BAO_0000100,,
14774,P,,,,22224,Autocuration,Dissociation constant of the Compound,,CHEMBL629637,,0,1,,BAO_0000100,,
14775,P,,,,22224,Autocuration,Dissociation constant by non-linear regression analysis,,CHEMBL629638,,0,1,,BAO_0000100,,
14776,P,,,,22224,Autocuration,Dissociation constant was determined,,CHEMBL629639,,0,1,,BAO_0000100,,
14777,P,,,,22224,Autocuration,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,CHEMBL629640,,0,1,,BAO_0000100,,
14778,P,,,,22224,Autocuration,Dissociation constant was determined,,CHEMBL629641,,0,1,,BAO_0000100,,
14779,P,,,,22224,Autocuration,Dissociation constant was determined,,CHEMBL631344,,0,1,,BAO_0000100,,
14780,A,,10116.0,,50597,Intermediate,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,,CHEMBL631345,,1,1,,BAO_0000218,2385.0,
14781,A,,,,22224,Autocuration,The dissociation constant determined by fluorescence displacement assay,,CHEMBL631346,,0,1,,BAO_0000019,,
14782,A,,,,22224,Autocuration,kd value surface plasmon resonance (SPR) method,,CHEMBL631524,,0,1,,BAO_0000019,,
14783,A,,10116.0,,50597,Intermediate,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,,CHEMBL631525,,1,1,,BAO_0000218,2385.0,
14784,F,,,,22224,Autocuration,First dissociation constant of the binding of compound to V30M TTR,,CHEMBL631526,,0,1,,BAO_0000019,,
14785,F,,,,22224,Autocuration,Second dissociation constant of the binding of compound to V30M TTR,,CHEMBL631527,,0,1,,BAO_0000019,,
14786,A,,,,22224,Autocuration,"Compound was evaluated for equilibrium constant, Ke",,CHEMBL631528,,0,1,,BAO_0000019,,
14787,A,,,,22224,Autocuration,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,,CHEMBL631529,,0,1,,BAO_0000019,1898.0,
14788,A,,,,22224,Autocuration,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,,CHEMBL631530,,0,1,,BAO_0000019,1898.0,
14789,A,,,,22224,Autocuration,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,CHEMBL631531,,0,1,,BAO_0000019,,
14790,A,,,,22224,Autocuration,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,CHEMBL631532,,0,1,,BAO_0000019,,
14791,A,,,,22224,Autocuration,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,CHEMBL631533,,0,1,,BAO_0000019,,
14792,A,,10090.0,,50594,Intermediate,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,CHEMBL876552,,1,1,,BAO_0000218,,
14793,A,,10090.0,,50594,Intermediate,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,CHEMBL631534,,1,1,,BAO_0000218,,
14794,A,,10090.0,,50594,Intermediate,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,CHEMBL631535,,1,1,,BAO_0000218,,
14795,A,,10090.0,,50594,Intermediate,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,CHEMBL631536,,1,1,,BAO_0000218,,
14796,A,,10090.0,,50594,Intermediate,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,CHEMBL631537,,1,1,,BAO_0000218,,
14797,A,,10090.0,,50594,Intermediate,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,CHEMBL631538,,1,1,,BAO_0000218,,
14798,A,,10090.0,,50594,Intermediate,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,CHEMBL631539,,1,1,,BAO_0000218,,
14799,A,,10090.0,,50594,Intermediate,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,CHEMBL631540,,1,1,,BAO_0000218,,
14800,A,,10116.0,,50597,Intermediate,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL625637,,1,1,,BAO_0000218,,
14801,A,,10116.0,,50597,Intermediate,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,CHEMBL625638,,1,1,,BAO_0000218,,
14802,A,,10116.0,,50597,Intermediate,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,CHEMBL625639,,1,1,,BAO_0000218,,
14803,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625640,,1,1,,BAO_0000218,955.0,
14804,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625641,,1,1,,BAO_0000218,955.0,
14805,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625642,,1,1,,BAO_0000218,948.0,
14806,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625643,,1,1,,BAO_0000218,948.0,
14807,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625644,,1,1,,BAO_0000218,2113.0,
14808,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625645,,1,1,,BAO_0000218,2113.0,
14809,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625646,,1,1,,BAO_0000218,2107.0,
14810,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625647,,1,1,,BAO_0000218,2107.0,
14811,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625648,,1,1,,BAO_0000218,2048.0,
14812,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,,CHEMBL625649,,1,1,,BAO_0000218,2048.0,
14813,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625650,,1,1,,BAO_0000218,2385.0,
14814,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625651,,1,1,,BAO_0000218,2385.0,
14815,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625652,,1,1,,BAO_0000218,14.0,
14816,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625653,,1,1,,BAO_0000218,14.0,
14817,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625654,,1,1,,BAO_0000218,2106.0,
14818,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,CHEMBL625655,,1,1,,BAO_0000218,2106.0,
14819,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat blood after 15 minutes of administration,,CHEMBL625656,,1,1,,BAO_0000218,178.0,
14820,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat blood after 2 minutes of administration,,CHEMBL625657,,1,1,,BAO_0000218,178.0,
14821,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat brain after 15 minutes of administration,,CHEMBL625658,,1,1,,BAO_0000218,955.0,
14822,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat brain after 2 minutes of administration,,CHEMBL625659,,1,1,,BAO_0000218,955.0,
14823,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat heart after 15 minutes of administration,,CHEMBL625660,,1,1,,BAO_0000218,948.0,
14824,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat heart after 2 minutes of administration,,CHEMBL625661,,1,1,,BAO_0000218,948.0,
14825,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat liver after 15 minutes of administration,,CHEMBL625662,,1,1,,BAO_0000218,2107.0,
14826,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat liver after 2 minutes of administration,,CHEMBL625663,,1,1,,BAO_0000218,2107.0,
14827,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat lung after 15 minutes of administration,,CHEMBL875621,,1,1,,BAO_0000218,2048.0,
14828,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat lung after 2 minutes of administration,,CHEMBL628382,,1,1,,BAO_0000218,2048.0,
14829,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat muscle after 15 minutes of administration,,CHEMBL628383,,1,1,,BAO_0000218,2385.0,
14830,A,In vivo,10116.0,,50597,Intermediate,Biodistribution of Compound in rat muscle after 2 minutes of administration,,CHEMBL628384,,1,1,,BAO_0000218,2385.0,
14831,A,,10116.0,,50597,Intermediate,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,CHEMBL628385,,1,1,,BAO_0000218,,
14832,A,,10116.0,,50597,Intermediate,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,CHEMBL875753,,1,1,,BAO_0000218,,
14833,A,,10116.0,,50597,Intermediate,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,CHEMBL628386,,1,1,,BAO_0000218,,
14834,A,,10116.0,,50597,Intermediate,Organ distribution in rat blood 2 minutes after intravenous injection,,CHEMBL628387,,1,1,,BAO_0000218,,
14835,A,,10116.0,,50597,Intermediate,Organ distribution in rat blood 2 hr after intravenous injection,,CHEMBL628388,,1,1,,BAO_0000218,,
14836,A,,10116.0,,50597,Intermediate,Organ distribution in rat blood 30 minutes after intravenous injection,,CHEMBL628389,,1,1,,BAO_0000218,,
14837,A,,10116.0,,50597,Intermediate,Organ distribution in rat blood 30 min after intravenous injection,,CHEMBL632756,,1,1,,BAO_0000218,,
14838,A,,10116.0,,50597,Intermediate,Organ distribution in rat brain 2 minutes after intravenous injection,,CHEMBL628390,,1,1,,BAO_0000218,,
14839,A,,10116.0,,50597,Intermediate,Organ distribution in rat brain 2 hr after intravenous injection,,CHEMBL631811,,1,1,,BAO_0000218,,
14840,A,,10116.0,,50597,Intermediate,Organ distribution in rat brain 30 minutes after intravenous injection,,CHEMBL631812,,1,1,,BAO_0000218,,
14841,A,,10116.0,,50597,Intermediate,Organ distribution in rat heart 2 minutes after intravenous injection,,CHEMBL631813,,1,1,,BAO_0000218,,
14842,A,,10116.0,,50597,Intermediate,Organ distribution in rat heart 2 hr after intravenous injection,,CHEMBL631814,,1,1,,BAO_0000218,,
14843,A,,10116.0,,50597,Intermediate,Organ distribution in rat heart 30 minutes after intravenous injection,,CHEMBL631815,,1,1,,BAO_0000218,,
14844,A,,10116.0,,50597,Intermediate,Organ distribution in rat kidney 2 minutes after intravenous injection,,CHEMBL631816,,1,1,,BAO_0000218,,
14845,A,,10116.0,,50597,Intermediate,Organ distribution in rat kidney 2 hr after intravenous injection,,CHEMBL875758,,1,1,,BAO_0000218,,
14846,A,,10116.0,,50597,Intermediate,Organ distribution in rat kidney 30 minutes after intravenous injection,,CHEMBL631817,,1,1,,BAO_0000218,,
14847,A,,10116.0,,50597,Intermediate,Organ distribution in rat liver 2 minutes after intravenous injection,,CHEMBL631818,,1,1,,BAO_0000218,2107.0,
14848,A,,10116.0,,50597,Intermediate,Organ distribution in rat liver 2 hr after intravenous injection,,CHEMBL631819,,1,1,,BAO_0000218,2107.0,
14849,A,,10116.0,,50597,Intermediate,Organ distribution in rat liver 30 minutes after intravenous injection,,CHEMBL631820,,1,1,,BAO_0000218,2107.0,
14850,A,,10116.0,,50597,Intermediate,Organ distribution in rat lung 2 minutes after intravenous injection,,CHEMBL631821,,1,1,,BAO_0000218,,
14851,A,,10116.0,,50597,Intermediate,Organ distribution in rat lung 2 hr after intravenous injection,,CHEMBL631822,,1,1,,BAO_0000218,,
14852,A,,10116.0,,50597,Intermediate,Organ distribution in rat lung 30 minutes after intravenous injection,,CHEMBL631823,,1,1,,BAO_0000218,,
14853,A,,10116.0,,50597,Intermediate,Organ distribution in rat muscle 2 minutes after intravenous injection,,CHEMBL631824,,1,1,,BAO_0000218,2385.0,
14854,A,,10116.0,,50597,Intermediate,Organ distribution in rat muscle 2 hr after intravenous injection,,CHEMBL631825,,1,1,,BAO_0000218,2385.0,
14855,A,,10116.0,,50597,Intermediate,Organ distribution in rat muscle 30 minutes after intravenous injection,,CHEMBL631826,,1,1,,BAO_0000218,2385.0,
14856,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,CHEMBL631827,,1,1,,BAO_0000218,,
14857,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,CHEMBL631828,,1,1,,BAO_0000218,,
14858,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,CHEMBL631829,,1,1,,BAO_0000218,,
14859,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,CHEMBL875759,,1,1,,BAO_0000218,1088.0,
14860,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,,CHEMBL631830,,1,1,,BAO_0000218,1088.0,
14861,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,,CHEMBL631831,,1,1,,BAO_0000218,1088.0,
14862,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,CHEMBL631832,,1,1,,BAO_0000218,1088.0,
14863,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,,CHEMBL631833,,1,1,,BAO_0000218,1088.0,
14864,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,CHEMBL631834,,1,1,,BAO_0000218,1088.0,
14865,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,,CHEMBL631835,,1,1,,BAO_0000218,1088.0,
14866,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,CHEMBL631836,,1,1,,BAO_0000218,1088.0,
14867,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,CHEMBL631837,,1,1,,BAO_0000218,1088.0,
14868,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,CHEMBL631838,,1,1,,BAO_0000218,1088.0,
14869,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,,CHEMBL631839,,1,1,,BAO_0000218,1088.0,
14870,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,,CHEMBL631840,,1,1,,BAO_0000218,1088.0,
14871,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,CHEMBL631841,,1,1,,BAO_0000218,1088.0,
14872,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,CHEMBL631842,,1,1,,BAO_0000218,1088.0,
14873,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,CHEMBL631843,,1,1,,BAO_0000218,1088.0,
14874,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,CHEMBL631844,,1,1,,BAO_0000218,1088.0,
14875,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,CHEMBL631845,,1,1,,BAO_0000218,1088.0,
14876,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,CHEMBL631846,,1,1,,BAO_0000218,1088.0,
14877,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,CHEMBL875760,,1,1,,BAO_0000218,1088.0,
14878,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,CHEMBL632199,,1,1,,BAO_0000218,1088.0,
14879,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,CHEMBL631847,,1,1,,BAO_0000218,1088.0,
14880,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,CHEMBL631848,,1,1,,BAO_0000218,1088.0,
14881,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,CHEMBL628707,,1,1,,BAO_0000218,1088.0,
14882,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,CHEMBL628708,,1,1,,BAO_0000218,1088.0,
14883,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,CHEMBL628709,,1,1,,BAO_0000218,1088.0,
14884,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,CHEMBL628710,,1,1,,BAO_0000218,1088.0,
14885,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,CHEMBL628711,,1,1,,BAO_0000218,1088.0,
14886,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,CHEMBL628712,,1,1,,BAO_0000218,1088.0,
14887,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,CHEMBL628713,,1,1,,BAO_0000218,1088.0,
14888,A,,10116.0,,50597,Intermediate,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,CHEMBL628714,,1,1,,BAO_0000218,1088.0,
14889,A,,10116.0,,50597,Intermediate,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,CHEMBL628715,,1,1,,BAO_0000218,,
14890,A,,,,22224,Autocuration,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,CHEMBL629179,,0,1,,BAO_0000019,,
14891,A,,,,22224,Autocuration,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,CHEMBL629180,,0,1,,BAO_0000019,,
14892,A,,,,22224,Autocuration,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,CHEMBL875108,,0,1,,BAO_0000019,,
14893,A,,,,22224,Autocuration,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,CHEMBL629181,,0,1,,BAO_0000019,1235.0,
14894,A,,,,22224,Autocuration,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,CHEMBL629182,,0,1,,BAO_0000019,1235.0,
14895,A,,,,22224,Autocuration,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,CHEMBL629183,,0,1,,BAO_0000019,,
14896,A,,,,22224,Autocuration,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,CHEMBL629184,,0,1,,BAO_0000019,,
14897,A,,,,22224,Autocuration,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,CHEMBL629185,,0,1,,BAO_0000019,1235.0,
14898,A,,,,22224,Autocuration,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,,CHEMBL629186,,0,1,,BAO_0000019,1235.0,
14899,A,,,,22224,Autocuration,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,CHEMBL629187,,0,1,,BAO_0000019,,
14900,A,,,,22224,Autocuration,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,CHEMBL629887,,0,1,,BAO_0000019,,
14901,A,,,,22224,Autocuration,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,CHEMBL629888,,0,1,,BAO_0000019,,
14902,A,,,,22224,Autocuration,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,CHEMBL629889,,0,1,,BAO_0000019,,
14903,A,,,,22224,Autocuration,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,,CHEMBL629890,,0,1,,BAO_0000019,1235.0,
14904,A,,,,22224,Autocuration,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,CHEMBL629891,,0,1,,BAO_0000019,,
14905,A,,,,22224,Autocuration,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,CHEMBL629892,,0,1,,BAO_0000019,,
14906,A,,,,22224,Autocuration,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,CHEMBL629893,,0,1,,BAO_0000019,1235.0,
14907,A,,,,22224,Autocuration,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,CHEMBL629894,,0,1,,BAO_0000019,,
14908,A,,,,22224,Autocuration,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,CHEMBL629895,,0,1,,BAO_0000019,,
14909,A,In vivo,9615.0,,22224,Autocuration,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,CHEMBL875109,,0,1,,BAO_0000218,,
14910,A,In vivo,9541.0,,22224,Autocuration,Absolute bioavailability in male cynomolgus monkeys,,CHEMBL629896,,0,1,,BAO_0000218,,
14911,A,In vivo,10116.0,,22224,Autocuration,Absolute bioavailability in maleSprague-Dawley rats,,CHEMBL629897,,0,1,,BAO_0000218,,
14912,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL629898,,1,1,,BAO_0000218,2107.0,
14913,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630057,,1,1,,BAO_0000218,2107.0,
14914,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630058,,1,1,,BAO_0000218,2107.0,
14915,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630059,,1,1,,BAO_0000218,2048.0,
14916,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630060,,1,1,,BAO_0000218,2048.0,
14917,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630061,,1,1,,BAO_0000218,2048.0,
14918,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630062,,1,1,,BAO_0000218,2048.0,
14919,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630063,,1,1,,BAO_0000218,2048.0,
14920,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630064,,1,1,,BAO_0000218,2048.0,
14921,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630065,,1,1,,BAO_0000218,2048.0,
14922,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630066,,1,1,,BAO_0000218,2048.0,
14923,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630067,,1,1,,BAO_0000218,2048.0,
14924,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630068,,1,1,,BAO_0000218,2048.0,
14925,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631113,,1,1,,BAO_0000218,2385.0,
14926,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631114,,1,1,,BAO_0000218,2385.0,
14927,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL631115,,1,1,,BAO_0000218,2385.0,
14928,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL631116,,1,1,,BAO_0000218,2385.0,
14929,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630528,,1,1,,BAO_0000218,2385.0,
14930,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630529,,1,1,,BAO_0000218,2385.0,
14931,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630530,,1,1,,BAO_0000218,2385.0,
14932,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630531,,1,1,,BAO_0000218,2385.0,
14933,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630532,,1,1,,BAO_0000218,2385.0,
14934,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630533,,1,1,,BAO_0000218,2385.0,
14935,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice blood after 120 hr,,CHEMBL630534,,1,1,,BAO_0000218,178.0,
14936,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice blood after 24 hr,,CHEMBL630535,,1,1,,BAO_0000218,178.0,
14937,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice blood after 4 hr,,CHEMBL630536,,1,1,,BAO_0000218,178.0,
14938,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice bone after 120 hr,,CHEMBL630537,,1,1,,BAO_0000218,10000001.0,
14939,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice bone after 24 hr,,CHEMBL630538,,1,1,,BAO_0000218,10000001.0,
14940,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice bone after 4 hr,,CHEMBL630539,,1,1,,BAO_0000218,10000001.0,
14941,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice heart after 120 hr,,CHEMBL630540,,1,1,,BAO_0000218,948.0,
14942,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice heart after 24 hr,,CHEMBL630541,,1,1,,BAO_0000218,948.0,
14943,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice heart after 4 hr,,CHEMBL630542,,1,1,,BAO_0000218,948.0,
14944,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice kidney after 120 hr,,CHEMBL630543,,1,1,,BAO_0000218,2113.0,
14945,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice kidney after 24 hr,,CHEMBL630544,,1,1,,BAO_0000218,2113.0,
14946,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice kidney after 4 hr,,CHEMBL630545,,1,1,,BAO_0000218,2113.0,
14947,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice liver after 120 hr,,CHEMBL630546,,1,1,,BAO_0000218,2107.0,
14948,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice liver after 24 hr,,CHEMBL630547,,1,1,,BAO_0000218,2107.0,
14949,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice liver after 4 hr,,CHEMBL630548,,1,1,,BAO_0000218,2107.0,
14950,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice spleen after 120 hr,,CHEMBL630549,,1,1,,BAO_0000218,2106.0,
14951,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice spleen after 24 hr,,CHEMBL630550,,1,1,,BAO_0000218,2106.0,
14952,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in normal mice spleen after 4 hr,,CHEMBL876426,,1,1,,BAO_0000218,2106.0,
14953,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630551,,1,1,,BAO_0000218,2106.0,
14954,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630552,,1,1,,BAO_0000218,2106.0,
14955,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630553,,1,1,,BAO_0000218,2106.0,
14956,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630554,,1,1,,BAO_0000218,2106.0,
14957,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630555,,1,1,,BAO_0000218,2106.0,
14958,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630556,,1,1,,BAO_0000218,2106.0,
14959,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630557,,1,1,,BAO_0000218,2106.0,
14960,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,CHEMBL630558,,1,1,,BAO_0000218,2106.0,
14961,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630559,,1,1,,BAO_0000218,2106.0,
14962,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL630560,,1,1,,BAO_0000218,2106.0,
14963,A,In vivo,10116.0,,50597,Intermediate,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,CHEMBL876427,,1,1,,BAO_0000218,2046.0,
14964,A,,10116.0,,50597,Intermediate,The Kel values in female wistar rats.,,CHEMBL630561,,1,1,,BAO_0000218,,
14965,A,,,,22224,Autocuration,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,CHEMBL630562,,0,1,,BAO_0000019,,
14966,A,,,,22224,Autocuration,Hydrolysis rate constant of the compound,,CHEMBL630563,,0,1,,BAO_0000019,,
14967,P,,,,22229,Autocuration,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,CHEMBL629673,,0,1,,BAO_0000100,,
14968,A,,,,22224,Autocuration,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,CHEMBL629674,,0,1,,BAO_0000019,,
14969,A,,,,22224,Autocuration,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,CHEMBL629675,,0,1,,BAO_0000019,,
14970,A,,,,22224,Autocuration,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,CHEMBL629676,,0,1,,BAO_0000019,,
14971,A,,,,22224,Autocuration,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,CHEMBL629677,,0,1,,BAO_0000019,,
14972,A,,,,22224,Autocuration,Apparent inactivation rate constant was evaluated,,CHEMBL629678,,0,1,,BAO_0000019,,
14973,A,,,,22224,Autocuration,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,CHEMBL629679,,0,1,,BAO_0000019,,
14974,A,,,,22224,Autocuration,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,CHEMBL629680,,0,1,,BAO_0000019,,
14975,A,,,,22224,Autocuration,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,CHEMBL629681,,0,1,,BAO_0000019,,
14976,A,,,,22224,Autocuration,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,CHEMBL629682,,0,1,,BAO_0000019,,
14977,A,,,,22224,Autocuration,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,CHEMBL629683,,0,1,,BAO_0000019,,
14978,F,,,,22224,Autocuration,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,CHEMBL629684,,0,1,,BAO_0000019,,
14979,P,,,,22224,Autocuration,Dissociation constant was determined,,CHEMBL629685,,0,1,,BAO_0000100,,
14980,P,,,,22224,Autocuration,Dissociation constant was determined,,CHEMBL629686,,0,1,,BAO_0000100,,
14981,P,,,,22224,Autocuration,Dissociation constant at pH 7.4,,CHEMBL872932,,0,1,,BAO_0000100,,
14982,P,,,,22224,Autocuration,Dissociation constant in presence of 1 mM dithiothreitol,,CHEMBL629687,,0,1,,BAO_0000100,,
14983,A,,,,22224,Autocuration,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,CHEMBL872931,,0,1,,BAO_0000019,,
14984,A,,,,22224,Autocuration,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,CHEMBL628151,,0,1,,BAO_0000019,,
14985,A,,,,22224,Autocuration,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,CHEMBL628152,,0,1,,BAO_0000019,,
14986,A,,,,22224,Autocuration,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,CHEMBL628153,,0,1,,BAO_0000019,,
14987,A,,,,22224,Autocuration,Kinetic constant for aromatization of androstenedione,,CHEMBL628154,,0,1,,BAO_0000019,,
14988,A,,,,22224,Autocuration,Kinetic constant for aromatization of testosterone,,CHEMBL628155,,0,1,,BAO_0000019,,
14989,A,,,,22224,Autocuration,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,CHEMBL628156,,0,1,,BAO_0000019,,
14990,A,,,,22224,Autocuration,Local inhibition constant was determined,,CHEMBL628157,,0,1,,BAO_0000019,,
14991,A,,4932.0,,50347,Intermediate,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,CHEMBL857533,,1,1,,BAO_0000218,,
14992,P,,,,22224,Autocuration,Dissociation constant value of the compound,,CHEMBL628158,,0,1,,BAO_0000100,,
14993,A,,,,22224,Autocuration,In vitro permeability through cornea without epithelium,,CHEMBL628159,,0,1,,BAO_0000019,964.0,
14994,A,,,,22224,Autocuration,In vitro permeability through intact cornea,,CHEMBL875616,,0,1,,BAO_0000019,964.0,
14995,A,,9986.0,,50592,Intermediate,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,,CHEMBL628160,,1,1,,BAO_0000218,964.0,
14996,A,,,,22224,Autocuration,Rate of enzyme inactivation for the compound was determined,,CHEMBL628161,,0,1,,BAO_0000019,,
14997,A,,,,22224,Autocuration,In vitro permeability through cornea without epithelium,,CHEMBL628162,,0,1,,BAO_0000019,964.0,
14998,A,,,,22224,Autocuration,In vitro permeability through intact cornea,,CHEMBL628163,,0,1,,BAO_0000019,964.0,
14999,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628164,,0,1,,BAO_0000019,,
15000,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628165,,0,1,,BAO_0000019,,
15001,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628166,,0,1,,BAO_0000019,,
15002,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628167,,0,1,,BAO_0000019,,
15003,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628168,,0,1,,BAO_0000019,,
15004,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628169,,0,1,,BAO_0000019,,
15005,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628170,,0,1,,BAO_0000019,,
15006,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628171,,0,1,,BAO_0000019,,
15007,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL627434,,0,1,,BAO_0000019,,
15008,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL627435,,0,1,,BAO_0000019,,
15009,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628110,,0,1,,BAO_0000019,,
15010,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628111,,0,1,,BAO_0000019,,
15011,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628112,,0,1,,BAO_0000019,,
15012,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628260,,0,1,,BAO_0000019,,
15013,A,,,,22224,Autocuration,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,CHEMBL628261,,0,1,,BAO_0000019,,
15014,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,CHEMBL628262,,1,1,,BAO_0000218,,
15015,A,In vivo,9606.0,,50587,Intermediate,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,CHEMBL628263,,1,1,,BAO_0000218,,
15016,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,CHEMBL628264,,1,1,,BAO_0000218,,
15017,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,CHEMBL628265,,1,1,,BAO_0000218,,
15018,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,CHEMBL628266,,1,1,,BAO_0000218,,
15019,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,CHEMBL628267,,1,1,,BAO_0000218,,
15020,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,CHEMBL628268,,1,1,,BAO_0000218,,
15021,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,CHEMBL628269,,1,1,,BAO_0000218,,
15022,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,CHEMBL628270,,1,1,,BAO_0000218,,
15023,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,CHEMBL628271,,1,1,,BAO_0000218,,
15024,A,In vivo,10090.0,,50594,Intermediate,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,CHEMBL628272,,1,1,,BAO_0000218,,
1,B,,,,12052,Autocuration,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,CHEMBL615117,,8,1,,BAO_0000019,,
2,F,,,,22226,Autocuration,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,CHEMBL615118,,0,1,,BAO_0000219,,
3,B,,,,22226,Autocuration,,,CHEMBL615119,,0,1,,BAO_0000019,,
4,B,,9913.0,,104729,Autocuration,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,CHEMBL615120,,4,1,,BAO_0000249,,
5,F,,9606.0,,80001,Intermediate,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,CHEMBL615121,,1,1,163.0,BAO_0000219,,
6,F,,9606.0,,80001,Intermediate,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,CHEMBL615122,,1,1,163.0,BAO_0000219,,
7,F,,10090.0,,80001,Intermediate,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,CHEMBL615123,,1,1,163.0,BAO_0000219,,
8,F,,9606.0,,80001,Expert,In vitro cell cytotoxicity was determined against 143B cell line,,CHEMBL615124,,1,1,163.0,BAO_0000219,,
9,F,,9606.0,,80001,Intermediate,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,CHEMBL615125,,1,1,163.0,BAO_0000219,,
10,F,,9606.0,,80001,Intermediate,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,CHEMBL615126,,1,1,163.0,BAO_0000219,,
11,F,,9606.0,,80001,Intermediate,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,CHEMBL615127,,1,1,163.0,BAO_0000219,,
12,F,,9606.0,,80001,Expert,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,CHEMBL615128,,1,1,163.0,BAO_0000219,,
13,F,,1280.0,,50185,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL857900,,1,1,,BAO_0000218,,
14,F,,1280.0,,50185,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL615129,,1,1,,BAO_0000218,,
15,F,,1280.0,,50185,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL615130,,1,1,,BAO_0000218,,
16,F,,1280.0,,50185,Intermediate,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,CHEMBL615131,,1,1,,BAO_0000218,,
17,A,,10116.0,,100122,Expert,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,CHEMBL884521,,9,1,,BAO_0000357,,
18,B,,,,12054,Autocuration,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615132,,8,1,,BAO_0000357,,
19,B,,,,12054,Autocuration,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,CHEMBL615133,,8,1,,BAO_0000019,,
20,B,,,,12054,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615134,,8,1,,BAO_0000357,,
21,B,,,,12054,Autocuration,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615135,,8,1,,BAO_0000357,,
22,B,,,,12054,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,CHEMBL615136,,8,1,,BAO_0000357,,
23,B,,,,12054,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,CHEMBL615137,,8,1,,BAO_0000357,,
24,B,,,,12054,Autocuration,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,CHEMBL615138,,8,1,,BAO_0000357,,
25,B,,,,22226,Autocuration,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,CHEMBL836324,,0,1,,BAO_0000219,,
26,B,,9986.0,,12054,Autocuration,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,CHEMBL615139,,8,1,,BAO_0000357,,
27,B,,9986.0,,12054,Autocuration,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,CHEMBL615140,,8,1,,BAO_0000357,,
28,B,,,,12426,Autocuration,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,CHEMBL615141,,8,1,,BAO_0000219,,
29,B,,3847.0,,12054,Autocuration,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,CHEMBL615142,,8,1,,BAO_0000357,,
30,B,,3847.0,,12054,Autocuration,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,CHEMBL615143,,8,1,,BAO_0000357,,
31,B,,3847.0,,12054,Autocuration,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,CHEMBL615144,,8,1,,BAO_0000357,,
32,B,,3847.0,,12054,Autocuration,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,CHEMBL872867,,8,1,,BAO_0000357,,
33,B,,3847.0,,12054,Autocuration,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,CHEMBL615145,,8,1,,BAO_0000357,,
34,B,,3847.0,,12054,Autocuration,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,CHEMBL615146,,8,1,,BAO_0000357,,
35,B,,3847.0,,12054,Autocuration,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,CHEMBL615147,,8,1,,BAO_0000357,,
36,A,,10116.0,,22226,Autocuration,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,CHEMBL615148,,0,1,,BAO_0000019,,
37,B,,562.0,,22226,Autocuration,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,CHEMBL615149,,0,1,,BAO_0000019,,
38,B,,,,22226,Autocuration,Dissociation constant with dimeric 16S rRNA RNA construct B,,CHEMBL615150,,0,1,,BAO_0000019,,
39,B,,,,22222,Intermediate,Dissociation constant towards 16S rRNA construct A,,CHEMBL615151,,3,1,,BAO_0000225,,
40,B,,,,22222,Intermediate,Dissociation constant towards 16S rRNA construct B,,CHEMBL615152,,3,1,,BAO_0000225,,
41,B,,562.0,,100263,Expert,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,CHEMBL615153,,3,1,,BAO_0000225,,
42,B,,562.0,,100263,Expert,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,CHEMBL615154,,3,1,,BAO_0000225,,
43,B,,,,13053,Autocuration,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,CHEMBL615155,,8,1,,BAO_0000019,,
44,B,,,,13053,Autocuration,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,CHEMBL615156,,8,1,,BAO_0000019,,
45,B,,9606.0,,20001,Autocuration,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,CHEMBL615157,,8,1,,BAO_0000019,,
46,B,,9606.0,,20001,Autocuration,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,CHEMBL615158,,8,1,,BAO_0000019,,
47,B,,10116.0,,12971,Expert,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,CHEMBL615159,,9,1,,BAO_0000019,,
48,B,,10116.0,,12971,Expert,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,CHEMBL615172,,9,1,,BAO_0000019,,
49,B,,10116.0,,12971,Expert,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,CHEMBL615173,,9,1,,BAO_0000019,,
50,B,,10116.0,,12971,Expert,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,CHEMBL615174,,9,1,,BAO_0000019,,
51,B,,,,13053,Autocuration,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,CHEMBL884518,,8,1,,BAO_0000019,,
52,B,,,,11512,Autocuration,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,CHEMBL615175,,8,1,,BAO_0000357,,
53,B,,,,11512,Autocuration,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,CHEMBL615176,,8,1,,BAO_0000357,,
54,B,,,,11512,Autocuration,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,CHEMBL615177,,8,1,,BAO_0000357,,
55,B,,10116.0,,104740,Autocuration,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,CHEMBL615178,,5,1,,BAO_0000249,,
56,F,,9606.0,,80002,Intermediate,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,CHEMBL615179,,1,1,506.0,BAO_0000219,,
57,F,,10116.0,,104835,Autocuration,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,CHEMBL615180,,7,1,,BAO_0000219,,
58,F,,10116.0,,104821,Autocuration,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,CHEMBL615181,,7,1,,BAO_0000219,,
59,F,,10116.0,,104848,Autocuration,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,CHEMBL615182,,7,1,,BAO_0000219,,
60,F,,9606.0,,80002,Expert,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,CHEMBL615183,,1,1,506.0,BAO_0000219,,
61,F,,9606.0,,80002,Intermediate,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,CHEMBL615184,,1,1,506.0,BAO_0000219,,
62,F,,9606.0,,80002,Intermediate,Cytotoxic activity against human ovarian cancer (1A9) cell line,,CHEMBL615185,,1,1,506.0,BAO_0000219,,
63,F,,9606.0,,80002,Intermediate,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,CHEMBL615186,,1,1,506.0,BAO_0000219,,
64,F,,9606.0,,80002,Intermediate,Effective dose of compound against replication of 1A9 cell line was evaluated,,CHEMBL615187,,1,1,506.0,BAO_0000219,,
65,F,,9606.0,,80002,Expert,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,CHEMBL885343,,1,1,506.0,BAO_0000219,,
66,F,,9606.0,,80002,Intermediate,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,CHEMBL615188,,1,1,506.0,BAO_0000219,,
67,F,,9606.0,,80002,Intermediate,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,CHEMBL615189,,1,1,506.0,BAO_0000219,,
68,F,,9606.0,,80002,Intermediate,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,CHEMBL615190,,1,1,506.0,BAO_0000219,,
69,F,,9606.0,,80002,Intermediate,Inhibitory activity against Taxol resistant 1A9 cell lines,,CHEMBL615191,,1,1,506.0,BAO_0000219,,
70,F,,9606.0,,80002,Expert,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,CHEMBL615192,,1,1,506.0,BAO_0000219,,
71,F,,9606.0,,80002,Expert,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,CHEMBL827083,,1,1,506.0,BAO_0000219,,
72,F,,9606.0,,80002,Expert,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,CHEMBL615193,,1,1,506.0,BAO_0000219,,
73,F,,9606.0,,80002,Intermediate,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,CHEMBL615194,,1,1,506.0,BAO_0000219,,
74,F,,9606.0,,80002,Intermediate,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,CHEMBL615195,,1,1,506.0,BAO_0000219,,
75,F,,9606.0,,80002,Intermediate,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,CHEMBL615196,,1,1,506.0,BAO_0000219,,
76,F,,9606.0,,81072,Intermediate,Inhibitory concentration against Jurkat cells,,CHEMBL615197,,1,1,503.0,BAO_0000219,,
77,F,,,,22226,Intermediate,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,CHEMBL615198,,0,1,,BAO_0000019,,
78,A,,10116.0,,100121,Expert,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,CHEMBL615199,,9,1,,BAO_0000357,,
79,B,,,,11231,Expert,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,CHEMBL615200,,8,1,,BAO_0000357,,
80,B,,,,11231,Expert,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,CHEMBL615201,,8,1,,BAO_0000357,,
81,B,,,,11231,Expert,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,CHEMBL615202,,8,1,,BAO_0000357,,
82,B,,5476.0,,11231,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,CHEMBL615203,,8,1,,BAO_0000251,,
83,B,,5476.0,,11231,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,CHEMBL615204,,8,1,,BAO_0000251,,
84,B,,4932.0,,11231,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,CHEMBL615205,,8,1,,BAO_0000251,,
85,B,,4932.0,,11231,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,CHEMBL615206,,8,1,,BAO_0000251,,
86,B,,9823.0,,12083,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,CHEMBL615207,,8,1,,BAO_0000251,2107.0,
87,B,,10116.0,,11231,Autocuration,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,CHEMBL827084,,8,1,,BAO_0000019,,
88,B,,10116.0,,11231,Autocuration,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,CHEMBL615208,,8,1,,BAO_0000019,,
89,B,,10116.0,,11231,Autocuration,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,CHEMBL615209,,8,1,,BAO_0000019,,
90,B,,10116.0,,12083,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,CHEMBL615210,,9,1,,BAO_0000251,2107.0,
91,B,,10116.0,,12083,Autocuration,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,CHEMBL615211,,9,1,,BAO_0000251,2107.0,
92,B,,10116.0,,12083,Autocuration,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,CHEMBL615212,,9,1,,BAO_0000251,2107.0,
93,B,,,,11377,Expert,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,CHEMBL615213,,8,1,,BAO_0000357,,
94,B,,,,11377,Expert,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,CHEMBL615273,,8,1,,BAO_0000357,,
95,F,,9606.0,,81020,Expert,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,CHEMBL615274,,1,1,726.0,BAO_0000219,,
96,F,,9606.0,,81020,Intermediate,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,CHEMBL615275,,1,1,726.0,BAO_0000219,,
97,F,,9606.0,,81020,Intermediate,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,CHEMBL615276,,1,1,726.0,BAO_0000219,,
98,F,,9606.0,,81020,Intermediate,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,CHEMBL615277,,1,1,726.0,BAO_0000219,,
99,F,,9606.0,,81020,Intermediate,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,CHEMBL615326,,1,1,726.0,BAO_0000219,,
100,F,,10407.0,,50606,Expert,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,CHEMBL883130,,1,1,,BAO_0000218,,
101,F,,9606.0,,81020,Intermediate,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,CHEMBL884519,,1,1,726.0,BAO_0000219,,
102,F,,9606.0,,81020,Intermediate,Concentration required to inhibit 50% of 2.2.15 cell line,,CHEMBL615327,,1,1,726.0,BAO_0000219,,
103,A,,9606.0,,81020,Intermediate,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,CHEMBL615328,,1,1,726.0,BAO_0000219,,
104,F,,9606.0,,50587,Intermediate,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,CHEMBL615329,,1,1,,BAO_0000218,,
105,F,,9606.0,,50587,Intermediate,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,CHEMBL615330,,1,1,,BAO_0000218,,
106,F,,10407.0,,50606,Expert,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,CHEMBL615331,,1,1,,BAO_0000218,,
107,F,,9606.0,,50587,Intermediate,In vitro anti-HBV activity in 2.2.15 cells,,CHEMBL615332,,1,1,,BAO_0000218,,
108,F,,9606.0,,50587,Intermediate,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,CHEMBL615333,,1,1,,BAO_0000218,,
109,F,,9606.0,,50587,Intermediate,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,CHEMBL615334,,1,1,,BAO_0000218,,
110,F,,9606.0,,50587,Intermediate,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,CHEMBL615335,,1,1,,BAO_0000218,,
111,F,,9606.0,,50587,Intermediate,Cytotoxicity in 2.2.15 cells,,CHEMBL615336,,1,1,,BAO_0000218,,
112,F,,9606.0,,50587,Intermediate,Cytotoxicity in 2.2.15 cells; Not determined,,CHEMBL615337,,1,1,,BAO_0000218,,
113,F,,9606.0,,50587,Intermediate,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,CHEMBL615338,,1,1,,BAO_0000218,,
114,F,,9606.0,,50587,Intermediate,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,CHEMBL615339,,1,1,,BAO_0000218,,
115,F,,9606.0,,50587,Intermediate,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,CHEMBL615340,,1,1,,BAO_0000218,,
116,F,,9606.0,,81020,Intermediate,Antiviral activity against HBV was determined in 2.215 cell line,,CHEMBL615341,,1,1,726.0,BAO_0000219,,
117,B,,9606.0,,22226,Autocuration,Inhibition of 20-HETE synthesis in human renal microsomes,,CHEMBL615342,,0,1,,BAO_0000251,,
118,B,,,,22226,Autocuration,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,CHEMBL615343,,0,1,,BAO_0000019,,
119,F,,9606.0,,80612,Intermediate,Inhibitory concentration against 2008 (ovarian) cells,,CHEMBL615344,,1,1,388.0,BAO_0000219,,
120,F,,9606.0,,80612,Intermediate,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,CHEMBL615345,,1,1,388.0,BAO_0000219,,
121,F,,9606.0,,80612,Intermediate,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,CHEMBL615346,,1,1,388.0,BAO_0000219,,
122,F,,9606.0,,80612,Intermediate,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,CHEMBL615347,,1,1,388.0,BAO_0000219,,
123,F,,9606.0,,80612,Intermediate,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,CHEMBL615348,,1,1,388.0,BAO_0000219,,
124,F,,9606.0,,80613,Intermediate,In vitro inhibition of 2008/R ovarian cancer cell line,,CHEMBL827085,,1,1,561.0,BAO_0000219,,
125,F,,9606.0,,80613,Intermediate,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,CHEMBL615349,,1,1,561.0,BAO_0000219,,
126,F,,9606.0,,80614,Intermediate,In vitro inhibition of 2008/S ovarian cancer cell line,,CHEMBL615350,,1,1,389.0,BAO_0000219,,
127,F,,9606.0,,80614,Intermediate,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,CHEMBL615351,,1,1,389.0,BAO_0000219,,
128,B,,9606.0,,100256,Expert,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,CHEMBL615352,,2,1,,BAO_0000220,,
129,B,,9606.0,,100256,Intermediate,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,CHEMBL615353,,2,1,,BAO_0000220,,
130,B,,,,100256,Expert,Inhibition of chymotrypsin-like activity of 20S proteasome,,CHEMBL615354,,2,1,,BAO_0000220,,
131,B,,,,100256,Expert,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,CHEMBL615355,,2,1,,BAO_0000220,,
132,B,,,,100256,Intermediate,Inhibitory activity against 20S proteosome,,CHEMBL615356,,2,1,,BAO_0000220,,
133,B,,9606.0,,22226,Autocuration,Compound was tested for inhibitory activity against tryptase,,CHEMBL615357,,0,1,,BAO_0000019,,
134,F,,9606.0,,81020,Intermediate,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,CHEMBL615358,,1,1,726.0,BAO_0000219,,
135,F,,9606.0,,81020,Intermediate,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,CHEMBL827086,,1,1,726.0,BAO_0000219,,
136,B,,,,22226,Autocuration,Compound was tested for the inhibition of Alpha-glucosidase,,CHEMBL615359,,0,1,,BAO_0000019,,
137,B,,,,235,Autocuration,Inhibitory concentration against human neutrophil elastase (HNE),,CHEMBL615360,,8,1,,BAO_0000357,,
138,F,,10116.0,,22226,Autocuration,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,CHEMBL615361,,0,1,,BAO_0000218,948.0,
139,F,,,,19640,Autocuration,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615362,,8,1,,BAO_0000019,,
140,F,,,,19640,Expert,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615363,,8,1,,BAO_0000019,,
141,B,,,,19640,Autocuration,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615364,,8,1,,BAO_0000357,,
142,F,,,,19640,Expert,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,CHEMBL615365,,8,1,,BAO_0000019,,
143,F,,10090.0,,80360,Intermediate,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,CHEMBL615366,,1,1,524.0,BAO_0000219,,
144,F,,10090.0,,80360,Intermediate,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,CHEMBL615367,,1,1,524.0,BAO_0000219,,
145,F,,9606.0,,80384,Intermediate,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,CHEMBL615368,,1,1,554.0,BAO_0000219,,
146,F,,9940.0,,22226,Autocuration,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,CHEMBL615369,,0,1,,BAO_0000019,,
147,F,,9940.0,,22226,Autocuration,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,CHEMBL615370,,0,1,,BAO_0000019,,
148,B,,,,191,Autocuration,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,CHEMBL615673,,8,1,,BAO_0000357,,
149,F,,9606.0,,22226,Autocuration,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,CHEMBL615674,,0,1,,BAO_0000019,,
150,F,,9606.0,,22226,Autocuration,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,CHEMBL615675,,0,1,,BAO_0000019,,
151,F,,9606.0,,22226,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,CHEMBL615676,,0,1,635.0,BAO_0000219,,
152,F,,9606.0,,22226,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,CHEMBL615677,,0,1,635.0,BAO_0000219,,
153,F,,9606.0,,22226,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,CHEMBL615678,,0,1,635.0,BAO_0000219,,
154,F,,9606.0,,22226,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,CHEMBL615679,,0,1,635.0,BAO_0000219,,
155,F,,9606.0,,22226,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,CHEMBL615680,,0,1,,BAO_0000019,,
156,F,,9606.0,,22226,Autocuration,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,CHEMBL615681,,0,1,,BAO_0000019,,
157,B,,,,104290,Autocuration,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,CHEMBL857972,,6,1,,BAO_0000249,,
158,F,,1314.0,,50264,Intermediate,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,CHEMBL857899,,1,1,,BAO_0000218,,
159,F,,10335.0,,50527,Intermediate,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,CHEMBL615371,,1,1,,BAO_0000218,,
160,F,,10335.0,,50527,Expert,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,CHEMBL615372,,1,1,468.0,BAO_0000218,,
161,F,,10335.0,,50527,Intermediate,Antiviral activity against 07/1 strain of VZV; ND: No data,,CHEMBL615373,,1,1,,BAO_0000218,,
162,F,,10335.0,,50527,Intermediate,Antiviral activity against 07/1 strain of VZV; ND=No data,,CHEMBL615374,,1,1,,BAO_0000218,,
163,F,,561.0,,50145,Intermediate,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,CHEMBL615375,,1,1,,BAO_0000218,,
164,B,,,,22226,Autocuration,Ratio of Ki at A2 to Ki at A1 receptors,,CHEMBL615376,,0,1,,BAO_0000019,,
165,B,,5476.0,,11143,Expert,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,CHEMBL615377,,8,1,,BAO_0000249,,
166,B,,284593.0,,18077,Expert,"Inhibition of 1,3-beta-glucan synthase",,CHEMBL615378,,8,1,,BAO_0000357,,
167,F,,9606.0,,80609,Intermediate,Inhibition of growth of 1-87 human tumor cell line,,CHEMBL615379,,1,1,832.0,BAO_0000219,,
168,B,,10116.0,,12166,Expert,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,CHEMBL615380,,9,1,,BAO_0000219,,
169,B,,3847.0,,100171,Autocuration,Inhibitory activity against soybean 1-lipoxygenase (SLO),,CHEMBL615381,,9,1,,BAO_0000357,,
170,B,,3847.0,,100171,Autocuration,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,CHEMBL615382,,9,1,,BAO_0000357,,
171,B,,3847.0,,100171,Autocuration,% inhibition against soybean 1-lipoxygenase (SLO),,CHEMBL615383,,9,1,,BAO_0000357,,
172,B,,3847.0,,100171,Autocuration,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,CHEMBL615384,,9,1,,BAO_0000357,,
173,B,,3847.0,,100171,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,CHEMBL615385,,9,1,,BAO_0000357,,
174,B,,3847.0,,100171,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,CHEMBL615386,,9,1,,BAO_0000357,,
175,B,,3847.0,,100171,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,CHEMBL615387,,9,1,,BAO_0000357,,
176,B,,3847.0,,100171,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,CHEMBL615388,,9,1,,BAO_0000357,,
177,B,,3847.0,,100171,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,CHEMBL615214,,9,1,,BAO_0000357,,
178,B,,3847.0,,100171,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,CHEMBL827087,,9,1,,BAO_0000357,,
179,B,,3847.0,,100171,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,CHEMBL615215,,9,1,,BAO_0000357,,
180,B,,3847.0,,100171,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,CHEMBL615216,,9,1,,BAO_0000357,,
181,B,,3847.0,,100171,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,CHEMBL615217,,9,1,,BAO_0000357,,
182,B,,3847.0,,100171,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,CHEMBL615218,,9,1,,BAO_0000357,,
183,B,,3847.0,,100171,Autocuration,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,CHEMBL615219,,9,1,,BAO_0000357,,
184,B,,10090.0,,22226,Autocuration,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,CHEMBL615220,,0,1,,BAO_0000019,,
185,F,,10090.0,,80049,Intermediate,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,CHEMBL615221,,1,1,294.0,BAO_0000219,,
186,F,,,,22226,Intermediate,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,CHEMBL615222,,0,1,,BAO_0000019,,
187,B,,,,11489,Autocuration,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,CHEMBL615223,,8,1,,BAO_0000357,,
188,B,,,,11862,Autocuration,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,CHEMBL615224,,8,1,,BAO_0000357,,
189,B,,,,11862,Autocuration,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,CHEMBL615225,,8,1,,BAO_0000357,,
190,B,,,,11489,Autocuration,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,CHEMBL615226,,8,1,,BAO_0000357,,
191,B,,,,11862,Autocuration,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,CHEMBL615227,,8,1,,BAO_0000357,,
192,F,,9913.0,,12347,Expert,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,CHEMBL615228,,9,1,,BAO_0000019,,
193,B,,10116.0,,100120,Expert,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,CHEMBL615229,,9,1,,BAO_0000357,,
194,B,,10116.0,,100120,Expert,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,CHEMBL615230,,9,1,,BAO_0000357,2369.0,
195,B,,10116.0,,100120,Expert,Inhibition of rat adrenal 11-beta-hydroxylase,,CHEMBL615231,,9,1,,BAO_0000357,,
196,B,,10116.0,,100120,Expert,Inhibition of rat adrenal 11-beta-hydroxylase,,CHEMBL884520,,9,1,,BAO_0000357,,
197,B,,10116.0,,100120,Expert,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,CHEMBL615232,,9,1,,BAO_0000357,,
198,B,,,,10328,Autocuration,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,CHEMBL615233,,8,1,,BAO_0000019,,
199,B,,,,11490,Autocuration,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,CHEMBL827088,,8,1,,BAO_0000357,,
200,B,,,,11490,Autocuration,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,CHEMBL615234,,8,1,,BAO_0000357,,
201,F,,,,11134,Autocuration,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,CHEMBL615235,,8,1,,BAO_0000019,,
202,B,,,,12052,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,CHEMBL615236,,8,1,,BAO_0000019,,
203,B,,,,11134,Autocuration,Compound was tested in vitro for inhibition of 12-LO human platelet,,CHEMBL615237,,8,1,,BAO_0000019,,
204,F,,,,11134,Autocuration,Inhibitory concentration against human platelet 12-lipoxygenase,,CHEMBL615238,,8,1,,BAO_0000019,,
205,B,,,,11134,Autocuration,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,CHEMBL615239,,8,1,,BAO_0000019,,
206,F,,9606.0,,11134,Autocuration,Inhibitory concentration against human platelet 12-lipoxygenase,,CHEMBL615240,,9,1,,BAO_0000019,,
207,B,,,,11835,Expert,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,CHEMBL615241,,8,1,,BAO_0000019,,
208,B,,,,11601,Expert,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,CHEMBL615242,,8,1,,BAO_0000357,,
209,B,,,,11134,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,CHEMBL615243,,8,1,,BAO_0000019,,
210,B,,,,11134,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase,,CHEMBL615244,,8,1,,BAO_0000019,,
211,B,,,,11134,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,CHEMBL615245,,8,1,,BAO_0000019,,
212,B,,,,11134,Autocuration,% inhibition against human platelet 12-lipoxygenase (12-HLO),,CHEMBL615246,,8,1,,BAO_0000019,,
213,B,,,,11134,Autocuration,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,CHEMBL615247,,8,1,,BAO_0000019,,
214,B,,,,11134,Autocuration,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,CHEMBL615248,,8,1,,BAO_0000019,,
215,B,,,,11601,Autocuration,Inhibitory activity towards porcine 12-lipoxygenase,,CHEMBL615249,,8,1,,BAO_0000357,,
216,B,,,,11601,Autocuration,Tested for inhibition against porcine 12-LO,,CHEMBL615250,,8,1,,BAO_0000357,,
217,B,,,,12052,Autocuration,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,CHEMBL615251,,8,1,,BAO_0000019,,
218,B,,,,12052,Autocuration,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,CHEMBL615252,,8,1,,BAO_0000019,,
219,B,,,,12052,Expert,In vitro inhibition of rat platelet 12-lipoxygenase,,CHEMBL828340,,8,1,,BAO_0000019,,
220,B,,,,12052,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,CHEMBL615253,,8,1,,BAO_0000019,,
221,B,,,,12052,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,CHEMBL615254,,8,1,,BAO_0000019,,
222,B,,,,12052,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,CHEMBL615255,,8,1,,BAO_0000019,,
223,B,,,,12052,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,CHEMBL615256,,8,1,,BAO_0000019,,
224,B,,,,12052,Autocuration,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,CHEMBL615257,,8,1,,BAO_0000019,,
225,B,,,,12052,Autocuration,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,CHEMBL615258,,8,1,,BAO_0000019,,
226,F,,9606.0,,80007,Intermediate,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,CHEMBL615259,,1,1,621.0,BAO_0000219,,
227,F,,9606.0,,80007,Expert,In vitro antitumor activity against 41M cell line.,,CHEMBL615260,,1,1,621.0,BAO_0000219,,
228,F,,9606.0,,80007,Intermediate,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,CHEMBL615261,,1,1,621.0,BAO_0000219,,
229,F,,9606.0,,80007,Intermediate,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,CHEMBL615262,,1,1,621.0,BAO_0000219,,
230,F,,9606.0,,80007,Expert,In vitro antitumor activity against 41McisR cell line.,,CHEMBL615263,,1,1,621.0,BAO_0000219,,
231,F,,9606.0,,80007,Expert,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,CHEMBL838393,,1,1,621.0,BAO_0000219,,
232,F,,9606.0,,80007,Intermediate,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,CHEMBL615264,,1,1,621.0,BAO_0000219,,
233,B,,9606.0,,84,Expert,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,CHEMBL615265,,9,1,,BAO_0000357,,
234,B,,9606.0,,68,Expert,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,CHEMBL615266,,9,1,,BAO_0000357,,
235,B,,,,68,Expert,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,CHEMBL615267,,8,1,,BAO_0000357,,
236,B,,,,10201,Expert,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,CHEMBL615268,,8,1,,BAO_0000357,,
237,B,,,,10201,Expert,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,CHEMBL615269,,8,1,,BAO_0000357,,
238,B,,,,10201,Expert,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,CHEMBL615270,,8,1,,BAO_0000357,,
239,B,,,,12220,Autocuration,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,CHEMBL615271,,8,1,,BAO_0000357,,
240,B,,562.0,,11303,Autocuration,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,CHEMBL615272,,8,1,,BAO_0000357,,
241,B,,562.0,,11303,Autocuration,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,CHEMBL615103,,8,1,,BAO_0000357,,
242,B,,562.0,,11303,Autocuration,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,CHEMBL615104,,8,1,,BAO_0000357,,
243,B,,,,12220,Autocuration,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,CHEMBL615105,,8,1,,BAO_0000357,,
244,B,,,,12220,Autocuration,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,CHEMBL872866,,8,1,,BAO_0000357,,
245,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615106,,8,1,,BAO_0000357,,
246,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,CHEMBL615107,,8,1,,BAO_0000019,,
247,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,CHEMBL615108,,8,1,,BAO_0000357,,
248,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,CHEMBL615109,,8,1,,BAO_0000357,,
249,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615110,,8,1,,BAO_0000357,,
250,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,CHEMBL840105,,8,1,,BAO_0000019,,
251,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,CHEMBL615111,,8,1,,BAO_0000019,,
252,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615112,,8,1,,BAO_0000019,,
253,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,CHEMBL615113,,8,1,,BAO_0000019,,
254,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,CHEMBL615114,,8,1,,BAO_0000019,,
255,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,CHEMBL615115,,8,1,,BAO_0000357,,
256,B,,9823.0,,11303,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,CHEMBL615116,,8,1,,BAO_0000019,,
257,B,,,,11303,Autocuration,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,CHEMBL615698,,8,1,,BAO_0000357,,
258,B,,9823.0,,22226,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,CHEMBL615699,,0,1,,BAO_0000019,,
259,B,,9823.0,,22226,Autocuration,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,CHEMBL615700,,0,1,,BAO_0000019,,
260,B,,4932.0,,100249,Expert,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,CHEMBL615701,,8,1,,BAO_0000357,,
261,B,,10116.0,,22226,Autocuration,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,CHEMBL615702,,0,1,,BAO_0000019,,
262,B,,10116.0,,22226,Autocuration,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,CHEMBL615703,,0,1,,BAO_0000019,,
263,B,,10116.0,,22226,Autocuration,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,CHEMBL615704,,0,1,,BAO_0000019,,
264,F,,,,104698,Autocuration,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,CHEMBL615705,,6,1,,BAO_0000019,,
265,F,,,,104698,Autocuration,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,CHEMBL615706,,6,1,,BAO_0000019,,
266,F,,10141.0,,20033,Intermediate,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,CHEMBL615707,,9,1,,BAO_0000221,2116.0,
267,F,,,,10623,Expert,Stimulatory activity of intragastric pressure was tested in the rat,,CHEMBL615708,,8,1,,BAO_0000019,,
268,B,,,,121,Autocuration,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,CHEMBL615709,,8,1,,BAO_0000357,,
269,F,,10116.0,,22226,Autocuration,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,CHEMBL615710,,0,1,,BAO_0000218,,
270,F,,,,12688,Autocuration,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,CHEMBL615711,,8,1,,BAO_0000019,,
271,B,,9606.0,,121,Expert,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,CHEMBL615712,,9,1,,BAO_0000357,,
272,B,,9606.0,,121,Expert,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,CHEMBL836325,,9,1,,BAO_0000357,,
273,F,,,,12198,Autocuration,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,CHEMBL615713,,8,1,,BAO_0000019,,
274,B,,,,12198,Autocuration,Inhibition constant of high-affinity 5-HT uptake,,CHEMBL615714,,8,1,,BAO_0000357,,
275,F,,,,12198,Autocuration,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,CHEMBL615715,,8,1,,BAO_0000019,,
276,F,,,,12198,Autocuration,Maximum rate was determined for high affinity transport of 5-HT,,CHEMBL615716,,8,1,,BAO_0000019,,
277,F,,,,104714,Autocuration,Compound was tested for agonistic activity against 5-HT uptake,,CHEMBL615717,,4,1,,BAO_0000019,,
278,B,,,,10577,Expert,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,CHEMBL881818,,8,1,,BAO_0000019,,
279,B,,9913.0,,105,Expert,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,CHEMBL884540,,8,1,,BAO_0000357,,
280,B,,10116.0,,104744,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,CHEMBL615718,,5,1,,BAO_0000224,,
281,B,,,,104744,Autocuration,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,CHEMBL615719,,4,1,,BAO_0000224,,
282,B,,,,104744,Autocuration,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,CHEMBL615720,,4,1,,BAO_0000249,,
283,B,,,,104744,Autocuration,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,CHEMBL615721,,4,1,,BAO_0000249,,
284,B,,,,104744,Autocuration,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL615722,,4,1,,BAO_0000019,,
285,F,,,,51,Autocuration,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,CHEMBL615723,,8,1,,BAO_0000019,,
286,B,,,,51,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615724,,8,1,,BAO_0000221,10000000.0,
287,B,,,,51,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615725,,8,1,,BAO_0000221,10000000.0,
288,B,,,,51,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615726,,8,1,,BAO_0000221,10000000.0,
289,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,CHEMBL615727,,8,1,,BAO_0000218,,
290,F,,10141.0,,105570,Intermediate,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,CHEMBL615728,,9,1,,BAO_0000019,,
291,B,,,,279,Autocuration,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL857971,,8,1,449.0,BAO_0000219,,
292,B,,,,107,Autocuration,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,CHEMBL615729,,8,1,,BAO_0000357,,
293,F,,10116.0,,12687,Expert,Efficacy against 5-hydroxytryptamine 2A receptor,,CHEMBL615730,,9,1,,BAO_0000019,,
294,F,,,,12687,Expert,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,CHEMBL615731,,8,1,,BAO_0000019,,
295,F,,,,12687,Expert,Relative potency towards 5-HT2A receptor of rat tail artery,,CHEMBL615732,,8,1,,BAO_0000019,,
296,F,,,,12687,Expert,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,CHEMBL615733,,8,1,,BAO_0000019,,
297,F,,,,12687,Expert,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,CHEMBL615734,,8,1,,BAO_0000019,,
298,F,,,,12687,Autocuration,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,CHEMBL615735,,8,1,,BAO_0000019,,
299,F,,,,12687,Expert,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,CHEMBL615736,,8,1,,BAO_0000019,,
300,F,,10141.0,,20033,Intermediate,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL615737,,9,1,,BAO_0000221,2116.0,
301,F,,10141.0,,20033,Intermediate,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,CHEMBL615738,,9,1,,BAO_0000221,2116.0,
302,F,,10141.0,,20033,Intermediate,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL615739,,9,1,,BAO_0000221,2116.0,
303,B,,,,10623,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,CHEMBL615278,,8,1,,BAO_0000357,,
304,F,,10116.0,,10623,Expert,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,CHEMBL615279,,9,1,,BAO_0000019,,
305,B,,,,168,Expert,Binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL615280,,8,1,,BAO_0000357,,
306,B,,9031.0,,22226,Autocuration,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,CHEMBL615281,,0,1,,BAO_0000019,,
307,F,,9606.0,,22226,Autocuration,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,CHEMBL615282,,0,1,,BAO_0000019,,
308,F,,9606.0,,22226,Autocuration,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,CHEMBL615283,,0,1,,BAO_0000019,,
309,B,,9606.0,,80156,Autocuration,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,CHEMBL615284,,1,1,649.0,BAO_0000219,,
310,B,,9606.0,,22226,Autocuration,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,CHEMBL615285,,0,1,,BAO_0000019,,
311,B,,9606.0,,22226,Autocuration,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,CHEMBL615286,,0,1,,BAO_0000019,,
312,B,,9606.0,,104703,Autocuration,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,CHEMBL615287,,7,1,,BAO_0000219,,
313,F,,,,100256,Intermediate,Chymotryptic inhibitory activity against 26S proteasome,,CHEMBL615288,,2,1,,BAO_0000220,,
314,B,,,,100256,Intermediate,Inhibitory activity against 26S proteasome degradation of IkB,,CHEMBL615289,,2,1,,BAO_0000220,,
315,F,,9606.0,,81034,Intermediate,In vitro inhibition of 2780/DOX ovarian cancer cell line,,CHEMBL615290,,1,1,478.0,BAO_0000219,,
316,F,,9606.0,,81034,Intermediate,In vitro inhibition of 2780/S ovarian cancer cell line,,CHEMBL884522,,1,1,478.0,BAO_0000219,,
317,F,,9606.0,,22226,Autocuration,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,CHEMBL615291,,0,1,,BAO_0000019,,
318,B,,,,22222,Intermediate,Association constant for binding to AATT 28-mer AATT hairpin,,CHEMBL615292,,3,1,,BAO_0000225,,
319,B,,,,22222,Intermediate,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,CHEMBL615293,,3,1,,BAO_0000225,,
320,B,,,,22222,Intermediate,Reaction Rate Parameter for 28-mer AATT hairpin,,CHEMBL615294,,3,1,,BAO_0000225,,
321,B,,,,22222,Intermediate,Reaction Rate Parameter for 28-mer AATT hairpin,,CHEMBL615295,,3,1,,BAO_0000225,,
322,F,,9606.0,,22226,Autocuration,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,CHEMBL825021,,0,1,,BAO_0000019,,
323,F,,9606.0,,22226,Autocuration,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,CHEMBL615296,,0,1,,BAO_0000019,,
324,F,,9606.0,,22226,Autocuration,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,CHEMBL615297,,0,1,,BAO_0000019,,
325,F,,10029.0,,22226,Autocuration,Cytotoxicity against cell line 2SC/20 determined by MTT test,,CHEMBL615298,,0,1,,BAO_0000019,,
326,F,,10029.0,,22226,Autocuration,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,CHEMBL615299,,0,1,,BAO_0000019,,
327,F,,10029.0,,22226,Autocuration,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,CHEMBL615300,,0,1,,BAO_0000019,,
328,B,,,,241,Autocuration,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,CHEMBL615301,,8,1,,BAO_0000357,,
329,B,,9606.0,,241,Expert,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,CHEMBL615302,,9,1,,BAO_0000357,,
330,B,,10116.0,,22226,Autocuration,Selectivity ratio of ID50 in liver and heart,,CHEMBL615303,,0,1,,BAO_0000019,,
331,B,,,,12132,Autocuration,"Selectivity, ratio of relative ID50 in liver and heart",,CHEMBL615304,,8,1,,BAO_0000019,,
332,B,,,,12132,Autocuration,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,CHEMBL615305,,8,1,,BAO_0000019,,
333,B,,,,12132,Autocuration,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615306,,8,1,,BAO_0000218,,
334,B,,,,12132,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615307,,8,1,,BAO_0000218,,
335,B,In vivo,,,12132,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615308,,8,1,,BAO_0000218,,
336,F,In vivo,,,12132,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615309,,8,1,,BAO_0000218,,
337,B,,,,22226,Autocuration,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,CHEMBL615310,,0,1,,BAO_0000019,,
338,B,,,,12132,Autocuration,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,CHEMBL615311,,8,1,,BAO_0000019,,
339,B,,9606.0,,22226,Autocuration,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,CHEMBL615312,,0,1,,BAO_0000019,,
340,B,,,,12132,Autocuration,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,CHEMBL615313,,8,1,,BAO_0000019,,
341,F,,,,12132,Autocuration,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,CHEMBL615314,,8,1,,BAO_0000019,,
342,B,,,,12132,Autocuration,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,CHEMBL615315,,8,1,,BAO_0000019,,
343,B,,10116.0,,22226,Autocuration,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,CHEMBL615316,,0,1,,BAO_0000218,,
344,B,In vivo,,,12132,Autocuration,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,CHEMBL615317,,8,1,,BAO_0000218,,
345,B,,,,12132,Autocuration,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,CHEMBL615318,,8,1,,BAO_0000218,,
346,B,,10116.0,,22226,Autocuration,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,CHEMBL615319,,0,1,,BAO_0000218,,
347,B,,,,12132,Autocuration,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,CHEMBL615320,,8,1,,BAO_0000019,,
348,F,,,,12132,Autocuration,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,CHEMBL615321,,8,1,,BAO_0000019,,
349,B,,10116.0,,22226,Autocuration,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,CHEMBL615322,,0,1,,BAO_0000019,,
350,B,,562.0,,19690,Autocuration,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,CHEMBL615323,,8,1,,BAO_0000357,,
351,B,,562.0,,19690,Autocuration,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,CHEMBL615407,,8,1,,BAO_0000357,,
352,B,,562.0,,19690,Autocuration,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,CHEMBL857267,,8,1,,BAO_0000357,,
353,B,,562.0,,19690,Autocuration,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,CHEMBL615408,,8,1,,BAO_0000357,,
354,B,,,,19690,Autocuration,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,CHEMBL615409,,8,1,,BAO_0000357,,
355,B,,,,19690,Autocuration,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,CHEMBL615410,,8,1,,BAO_0000357,,
356,B,,,,19690,Autocuration,Inhibition constant against 3-dehydroquinate synthase,,CHEMBL615411,,8,1,,BAO_0000357,,
357,B,,,,19690,Autocuration,Association rate constant against 3-dehydroquinate synthase,,CHEMBL615412,,8,1,,BAO_0000357,,
358,B,,,,19690,Autocuration,Rate constant against 3-dehydroquinate synthase,,CHEMBL615413,,8,1,,BAO_0000357,,
359,B,,,,22226,Autocuration,Inhibitory activity against fuc-TVII,,CHEMBL615414,,0,1,,BAO_0000019,,
360,B,,10116.0,,12236,Autocuration,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,CHEMBL615415,,9,1,,BAO_0000251,2107.0,
361,B,,10116.0,,12236,Autocuration,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,CHEMBL615416,,9,1,,BAO_0000251,2107.0,
362,B,,10116.0,,12236,Autocuration,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,CHEMBL615417,,9,1,,BAO_0000251,2107.0,
363,B,,10116.0,,12236,Autocuration,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,CHEMBL615418,,9,1,,BAO_0000251,2107.0,
364,B,,10116.0,,12236,Autocuration,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,CHEMBL615419,,9,1,,BAO_0000251,2107.0,
365,B,,10116.0,,12236,Autocuration,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,CHEMBL615420,,9,1,,BAO_0000251,2107.0,
366,B,,10116.0,,12236,Autocuration,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,CHEMBL615421,,9,1,,BAO_0000251,2107.0,
367,B,,10116.0,,12236,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,CHEMBL615422,,9,1,,BAO_0000251,2107.0,
368,B,,10116.0,,12236,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,CHEMBL615423,,9,1,,BAO_0000251,2107.0,
369,B,,10116.0,,12236,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,CHEMBL872868,,9,1,,BAO_0000251,2107.0,
370,B,,10116.0,,12236,Autocuration,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,CHEMBL615424,,9,1,,BAO_0000251,2107.0,
371,B,,,,104832,Autocuration,Inhibitory activity against 3-phosphoglycerate kinase.,,CHEMBL825022,,4,1,,BAO_0000224,,
372,B,,,,104832,Autocuration,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,CHEMBL615425,,4,1,,BAO_0000224,,
373,B,,,,104832,Autocuration,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,CHEMBL615426,,4,1,,BAO_0000224,,
374,B,,9606.0,,10612,Expert,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,CHEMBL615427,,9,1,,BAO_0000357,,
375,F,,9606.0,,80616,Intermediate,Cytotoxicity on 3677 melanoma cells,,CHEMBL615428,,1,1,844.0,BAO_0000219,,
376,F,,9606.0,,80616,Intermediate,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,CHEMBL615429,,1,1,844.0,BAO_0000219,,
377,F,,10090.0,,80617,Intermediate,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,CHEMBL615430,,1,1,700.0,BAO_0000219,,
378,F,,9606.0,,22226,Intermediate,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,CHEMBL615431,,0,1,,BAO_0000019,,
379,F,,,,22226,Autocuration,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,CHEMBL615432,,0,1,798.0,BAO_0000218,,
380,F,,,,22226,Autocuration,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,CHEMBL615433,,0,1,798.0,BAO_0000218,,
381,F,,12131.0,,12464,Expert,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,CHEMBL615434,,9,1,,BAO_0000019,,
382,F,,169066.0,,50085,Intermediate,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,CHEMBL615435,,1,1,,BAO_0000218,,
383,F,,169066.0,,50679,Intermediate,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,CHEMBL615436,,1,1,,BAO_0000218,,
384,F,,169066.0,,50679,Intermediate,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,CHEMBL615437,,1,1,,BAO_0000218,,
385,F,,12131.0,,12464,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,CHEMBL615438,,9,1,,BAO_0000019,,
386,F,,12131.0,,12464,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,CHEMBL615439,,9,1,,BAO_0000019,,
387,F,,12131.0,,12464,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,CHEMBL615440,,9,1,,BAO_0000019,,
388,F,,12131.0,,12464,Expert,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,CHEMBL615441,,9,1,,BAO_0000019,,
389,F,,12059.0,,50665,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,CHEMBL615641,,1,1,,BAO_0000218,,
390,F,,12059.0,,50665,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,CHEMBL872065,,1,1,,BAO_0000218,,
391,F,,12059.0,,50665,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,CHEMBL825023,,1,1,,BAO_0000218,,
392,F,,12059.0,,50665,Intermediate,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,CHEMBL615642,,1,1,,BAO_0000218,,
393,B,,147712.0,,12464,Expert,Inhibition of human rhinovirus 3C protease,,CHEMBL615643,,8,1,,BAO_0000357,,
394,B,,9606.0,,22226,Autocuration,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,CHEMBL615644,,0,1,,BAO_0000019,,
395,F,,10090.0,,80619,Intermediate,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,CHEMBL615645,,1,1,833.0,BAO_0000218,,
396,F,,10090.0,,80619,Intermediate,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,CHEMBL615646,,1,1,833.0,BAO_0000218,,
397,F,,10090.0,,80619,Intermediate,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,CHEMBL615647,,1,1,833.0,BAO_0000218,,
398,F,,10090.0,,80619,Intermediate,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,CHEMBL615648,,1,1,833.0,BAO_0000218,,
399,F,,10090.0,,80619,Intermediate,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,CHEMBL615649,,1,1,833.0,BAO_0000218,,
400,F,,10090.0,,80619,Intermediate,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,CHEMBL615650,,1,1,833.0,BAO_0000218,,
401,F,,10090.0,,80620,Intermediate,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,CHEMBL615651,,1,1,847.0,BAO_0000218,,
402,F,,10090.0,,80620,Intermediate,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,CHEMBL615652,,1,1,847.0,BAO_0000218,,
403,F,,10090.0,,80620,Expert,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,CHEMBL615653,,1,1,847.0,BAO_0000218,,
404,F,,10090.0,,80620,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,CHEMBL615654,,1,1,847.0,BAO_0000219,,
405,F,,10090.0,,80620,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,CHEMBL615655,,1,1,847.0,BAO_0000219,,
406,F,,10090.0,,80620,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,CHEMBL825024,,1,1,847.0,BAO_0000219,,
407,F,,10090.0,,80620,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,CHEMBL615656,,1,1,847.0,BAO_0000219,,
408,F,,10090.0,,80620,Intermediate,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,CHEMBL615657,,1,1,847.0,BAO_0000219,,
409,F,,10090.0,,80620,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,CHEMBL615658,,1,1,847.0,BAO_0000219,,
410,F,,10090.0,,80620,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,CHEMBL615659,,1,1,847.0,BAO_0000219,,
411,F,,10090.0,,80620,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,CHEMBL615660,,1,1,847.0,BAO_0000219,,
412,F,,10090.0,,80620,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,CHEMBL615661,,1,1,847.0,BAO_0000219,,
413,F,,10090.0,,80620,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,CHEMBL615662,,1,1,847.0,BAO_0000219,,
414,F,,10090.0,,80620,Intermediate,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,CHEMBL615663,,1,1,847.0,BAO_0000219,,
415,F,,10090.0,,80620,Intermediate,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,CHEMBL615664,,1,1,847.0,BAO_0000219,,
416,F,,10090.0,,80620,Intermediate,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,CHEMBL615665,,1,1,847.0,BAO_0000219,,
417,F,,10090.0,,80620,Intermediate,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,CHEMBL615666,,1,1,847.0,BAO_0000219,,
418,F,,10090.0,,80620,Intermediate,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,CHEMBL615667,,1,1,847.0,BAO_0000219,,
419,F,,10090.0,,80620,Intermediate,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,CHEMBL615668,,1,1,847.0,BAO_0000219,,
420,F,,10090.0,,80620,Intermediate,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,CHEMBL615669,,1,1,847.0,BAO_0000219,,
421,F,,10090.0,,80620,Intermediate,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,CHEMBL615670,,1,1,847.0,BAO_0000219,,
422,F,,10090.0,,80620,Intermediate,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,CHEMBL836739,,1,1,847.0,BAO_0000219,,
423,F,,10090.0,,80620,Intermediate,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,CHEMBL615671,,1,1,847.0,BAO_0000219,,
424,F,,10090.0,,80620,Intermediate,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,CHEMBL615672,,1,1,847.0,BAO_0000219,,
425,F,,10090.0,,80620,Intermediate,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,CHEMBL615791,,1,1,847.0,BAO_0000219,,
426,F,,10090.0,,80620,Intermediate,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,CHEMBL615792,,1,1,847.0,BAO_0000219,,
427,F,,10090.0,,80620,Intermediate,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,CHEMBL615793,,1,1,847.0,BAO_0000219,,
428,F,,10090.0,,80620,Intermediate,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,CHEMBL615794,,1,1,847.0,BAO_0000219,,
429,F,,10090.0,,80620,Intermediate,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,CHEMBL615795,,1,1,847.0,BAO_0000219,,
430,F,,9606.0,,80621,Intermediate,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,CHEMBL615590,,1,1,971.0,BAO_0000219,,
431,F,,,,22226,Autocuration,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,CHEMBL615591,,0,1,,BAO_0000218,,
432,F,,,,22226,Autocuration,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,CHEMBL615592,,0,1,,BAO_0000218,,
433,F,,,,22226,Autocuration,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,CHEMBL615593,,0,1,,BAO_0000218,,
434,F,,,,22226,Autocuration,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,CHEMBL615594,,0,1,,BAO_0000218,,
435,F,,10090.0,,80951,Intermediate,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,CHEMBL615595,,1,1,723.0,BAO_0000219,,
436,F,,10090.0,,80951,Intermediate,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,CHEMBL615596,,1,1,723.0,BAO_0000219,,
437,F,,,,11169,Expert,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,CHEMBL615597,,8,1,723.0,BAO_0000219,,
438,F,,10090.0,,80951,Intermediate,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,CHEMBL615598,,1,1,723.0,BAO_0000219,,
439,F,,10090.0,,80951,Intermediate,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,CHEMBL615599,,1,1,723.0,BAO_0000219,,
440,F,,10090.0,,80951,Expert,Effective dose against murine 3T3 fibroblasts cells,,CHEMBL615600,,1,1,723.0,BAO_0000219,,
441,F,,10090.0,,80951,Expert,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,CHEMBL615601,,1,1,723.0,BAO_0000219,,
442,F,,10090.0,,80951,Expert,Cytotoxic effect on 3T3 cells,,CHEMBL615602,,1,1,723.0,BAO_0000219,,
443,F,,10090.0,,80951,Expert,Cytotoxic effect on 3T3 cells,,CHEMBL615603,,1,1,723.0,BAO_0000219,,
444,F,,10090.0,,80951,Intermediate,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,CHEMBL615604,,1,1,723.0,BAO_0000219,,
445,F,,10090.0,,80951,Intermediate,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,CHEMBL615605,,1,1,723.0,BAO_0000219,,
446,F,,10090.0,,80951,Intermediate,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,CHEMBL615606,,1,1,723.0,BAO_0000219,,
447,F,,10090.0,,80951,Expert,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,CHEMBL884526,,1,1,723.0,BAO_0000219,,
448,F,,10090.0,,80951,Expert,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,CHEMBL615607,,1,1,723.0,BAO_0000219,,
449,F,,10090.0,,80951,Intermediate,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,CHEMBL615608,,1,1,723.0,BAO_0000219,,
450,F,,10090.0,,80951,Expert,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,CHEMBL615609,,1,1,723.0,BAO_0000219,,
451,F,,10090.0,,80951,Expert,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,CHEMBL615682,,1,1,723.0,BAO_0000219,,
452,F,,10090.0,,80951,Intermediate,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,CHEMBL615683,,1,1,723.0,BAO_0000219,,
453,F,,10090.0,,80951,Expert,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,CHEMBL615684,,1,1,723.0,BAO_0000218,,
454,F,,10090.0,,104860,Autocuration,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,CHEMBL615685,,7,1,,BAO_0000219,,
455,F,,10090.0,,80951,Expert,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,CHEMBL615686,,1,1,723.0,BAO_0000219,,
456,F,,10090.0,,80951,Intermediate,Inhibitory activity against 3T3 cell line,,CHEMBL615687,,1,1,723.0,BAO_0000219,,
457,F,,10090.0,,80951,Intermediate,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,CHEMBL884523,,1,1,723.0,BAO_0000219,,
458,F,,,,11169,Expert,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,CHEMBL615688,,8,1,,BAO_0000019,,
459,F,,10090.0,,80951,Intermediate,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,CHEMBL615689,,1,1,723.0,BAO_0000219,,
460,F,,10090.0,,80951,Intermediate,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,CHEMBL615690,,1,1,723.0,BAO_0000219,,
461,F,,,,11169,Expert,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,CHEMBL615691,,8,1,,BAO_0000019,,
462,F,,,,11169,Expert,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,CHEMBL615692,,8,1,,BAO_0000019,,
463,F,,10090.0,,80951,Intermediate,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,CHEMBL615693,,1,1,723.0,BAO_0000219,,
464,F,,10090.0,,80951,Expert,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,CHEMBL615324,,1,1,723.0,BAO_0000219,,
465,F,,9606.0,,9,Expert,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,CHEMBL615325,,9,1,723.0,BAO_0000219,,
466,F,,9606.0,,9,Expert,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,CHEMBL615490,,9,1,723.0,BAO_0000219,,
467,F,,9606.0,,188,Expert,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,CHEMBL615491,,9,1,723.0,BAO_0000219,,
468,F,,9606.0,,188,Expert,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,CHEMBL615492,,9,1,723.0,BAO_0000219,,
469,F,,10090.0,,80951,Intermediate,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,CHEMBL615493,,1,1,723.0,BAO_0000219,,
470,F,,10090.0,,80951,Intermediate,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,CHEMBL615494,,1,1,723.0,BAO_0000219,,
471,F,,10090.0,,80951,Intermediate,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,CHEMBL615495,,1,1,723.0,BAO_0000219,,
472,F,,10090.0,,80951,Intermediate,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,CHEMBL615496,,1,1,723.0,BAO_0000219,,
473,F,,10090.0,,80951,Intermediate,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,CHEMBL615497,,1,1,723.0,BAO_0000219,,
474,F,,10090.0,,80951,Expert,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,CHEMBL615498,,1,1,723.0,BAO_0000219,,
475,A,,10090.0,,80951,Intermediate,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,CHEMBL615499,,1,1,723.0,BAO_0000219,,
476,F,,10090.0,,80951,Expert,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,CHEMBL835522,,1,1,723.0,BAO_0000219,,
477,F,,10090.0,,80951,Intermediate,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,CHEMBL615500,,1,1,723.0,BAO_0000219,,
478,F,,10090.0,,80951,Intermediate,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615501,,1,1,723.0,BAO_0000219,,
479,F,,10090.0,,80951,Intermediate,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615502,,1,1,723.0,BAO_0000219,,
480,F,,10090.0,,80951,Intermediate,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615503,,1,1,723.0,BAO_0000219,,
481,F,,10090.0,,80951,Intermediate,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615504,,1,1,723.0,BAO_0000219,,
482,F,,10090.0,,80951,Intermediate,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,CHEMBL615505,,1,1,723.0,BAO_0000219,,
483,F,,10090.0,,80951,Expert,Inhibition of swiss 3T3 mouse fibroblast proliferation,,CHEMBL615506,,1,1,723.0,BAO_0000219,,
484,F,,10090.0,,80951,Intermediate,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,CHEMBL615507,,1,1,723.0,BAO_0000219,,
485,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,CHEMBL615508,,1,1,620.0,BAO_0000218,,
486,F,,10090.0,,80006,Intermediate,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,CHEMBL615509,,1,1,620.0,BAO_0000219,,
487,F,,10090.0,,80006,Intermediate,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,CHEMBL615510,,1,1,620.0,BAO_0000219,,
488,F,,10090.0,,80006,Intermediate,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,CHEMBL615511,,1,1,620.0,BAO_0000219,,
489,F,,10090.0,,80006,Intermediate,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,CHEMBL615512,,1,1,620.0,BAO_0000219,,
490,F,,10090.0,,80006,Intermediate,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,CHEMBL615513,,1,1,620.0,BAO_0000218,,
491,F,,10090.0,,80006,Intermediate,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,CHEMBL615514,,1,1,620.0,BAO_0000218,,
492,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,CHEMBL615515,,1,1,620.0,BAO_0000219,,
493,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,CHEMBL615516,,1,1,620.0,BAO_0000219,,
494,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,CHEMBL615517,,1,1,620.0,BAO_0000219,,
495,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,CHEMBL615518,,1,1,620.0,BAO_0000219,,
496,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,CHEMBL615519,,1,1,620.0,BAO_0000219,,
497,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,CHEMBL615520,,1,1,620.0,BAO_0000218,,
498,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,CHEMBL615521,,1,1,620.0,BAO_0000218,,
499,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,CHEMBL615522,,1,1,620.0,BAO_0000218,,
500,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,CHEMBL615523,,1,1,620.0,BAO_0000218,,
501,F,,,,80006,Expert,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,CHEMBL615524,,1,1,620.0,BAO_0000218,,
502,F,,,,80006,Expert,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,CHEMBL615525,,1,1,620.0,BAO_0000218,,
503,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,CHEMBL615526,,1,1,620.0,BAO_0000218,,
504,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,CHEMBL615527,,1,1,620.0,BAO_0000218,,
505,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,CHEMBL615528,,1,1,620.0,BAO_0000218,,
506,F,,,,80006,Expert,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,CHEMBL615529,,1,1,620.0,BAO_0000218,,
507,F,,,,80006,Expert,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,CHEMBL615530,,1,1,620.0,BAO_0000218,,
508,F,,,,80006,Expert,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,CHEMBL615531,,1,1,620.0,BAO_0000218,,
509,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,CHEMBL615532,,1,1,620.0,BAO_0000219,,
510,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,CHEMBL615533,,1,1,620.0,BAO_0000219,,
511,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,CHEMBL615534,,1,1,620.0,BAO_0000219,,
512,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,CHEMBL615535,,1,1,620.0,BAO_0000218,,
513,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,CHEMBL615536,,1,1,620.0,BAO_0000218,,
514,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,CHEMBL615537,,1,1,620.0,BAO_0000218,,
515,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,CHEMBL615538,,1,1,620.0,BAO_0000218,,
516,F,,,,80006,Intermediate,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,CHEMBL836166,,1,1,620.0,BAO_0000218,,
517,F,,,,11214,Expert,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,CHEMBL615539,,8,1,620.0,BAO_0000219,,
518,F,,10090.0,,80006,Intermediate,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,CHEMBL615540,,1,1,620.0,BAO_0000219,,
519,F,,,,11214,Expert,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,CHEMBL615541,,8,1,620.0,BAO_0000219,,
520,F,,10090.0,,80006,Expert,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,CHEMBL615542,,1,1,620.0,BAO_0000219,,
521,F,,10090.0,,80006,Intermediate,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,CHEMBL615543,,1,1,620.0,BAO_0000219,,
522,F,,10090.0,,80006,Expert,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,CHEMBL615544,,1,1,620.0,BAO_0000219,,
523,F,,10090.0,,80006,Expert,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,CHEMBL615545,,1,1,620.0,BAO_0000219,,
524,F,,10090.0,,80006,Expert,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,CHEMBL615546,,1,1,620.0,BAO_0000219,,
525,F,,10090.0,,80006,Expert,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,CHEMBL615547,,1,1,620.0,BAO_0000219,,
526,F,,10090.0,,80006,Expert,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,CHEMBL615548,,1,1,620.0,BAO_0000219,,
527,F,,10090.0,,80006,Expert,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,CHEMBL615549,,1,1,620.0,BAO_0000219,,
528,F,,10090.0,,80006,Expert,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,CHEMBL615550,,1,1,620.0,BAO_0000219,,
529,F,,10116.0,,80622,Intermediate,Inhibitory activity against rat fibroblast (3Y1) cell line,,CHEMBL615551,,1,1,1118.0,BAO_0000219,,
530,F,,10116.0,,80622,Expert,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,CHEMBL615552,,1,1,1118.0,BAO_0000219,,
531,F,,10116.0,,80622,Expert,Cytotoxicity in 3Y1 cells.,,CHEMBL615553,,1,1,1118.0,BAO_0000219,,
532,F,,10116.0,,80622,Expert,Cytostatic effect in 3Y1 cells.,,CHEMBL615554,,1,1,1118.0,BAO_0000219,,
533,F,,10116.0,,80622,Intermediate,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,CHEMBL615555,,1,1,1118.0,BAO_0000219,,
534,F,,10116.0,,80622,Expert,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,CHEMBL615556,,1,1,1118.0,BAO_0000219,,
535,B,,,,22226,Autocuration,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,CHEMBL615557,,0,1,,BAO_0000019,,
536,B,,,,22226,Autocuration,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,CHEMBL615558,,0,1,,BAO_0000019,,
537,B,,,,22226,Autocuration,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,CHEMBL872066,,0,1,,BAO_0000019,,
538,B,,9823.0,,11607,Expert,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,CHEMBL615559,,9,1,,BAO_0000019,,
539,B,,,,11607,Autocuration,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,CHEMBL615560,,8,1,,BAO_0000019,,
540,B,,,,11607,Autocuration,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,CHEMBL615561,,8,1,,BAO_0000019,,
541,B,,,,11607,Expert,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,CHEMBL857062,,8,1,,BAO_0000019,,
542,B,,,,11607,Expert,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,CHEMBL615562,,8,1,,BAO_0000019,,
543,B,,,,11607,Autocuration,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,CHEMBL615563,,8,1,,BAO_0000019,,
544,B,,,,11607,Autocuration,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,CHEMBL615564,,8,1,,BAO_0000357,,
545,B,,,,11607,Autocuration,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,CHEMBL615565,,8,1,,BAO_0000019,,
546,B,,,,11607,Autocuration,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,CHEMBL615566,,8,1,,BAO_0000019,,
547,B,,9823.0,,11607,Expert,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,CHEMBL615567,,9,1,,BAO_0000019,,
548,B,,,,11607,Autocuration,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,CHEMBL615568,,8,1,,BAO_0000019,,
549,B,,,,11607,Autocuration,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,CHEMBL615569,,8,1,,BAO_0000357,,
550,B,,,,11607,Autocuration,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,CHEMBL615570,,8,1,,BAO_0000019,,
551,B,,,,11607,Autocuration,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,CHEMBL615571,,8,1,,BAO_0000019,,
552,B,,,,104733,Autocuration,Binding affinity against melatonin (MT1) receptor (pC1),,CHEMBL615572,,4,1,,BAO_0000224,,
553,B,,,,22226,Autocuration,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,CHEMBL615573,,0,1,,BAO_0000019,,
554,B,,,,22226,Autocuration,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,CHEMBL615574,,0,1,,BAO_0000019,,
555,B,,,,22226,Autocuration,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,CHEMBL615575,,0,1,,BAO_0000019,,
556,B,,,,10619,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,CHEMBL615576,,8,1,,BAO_0000357,,
557,B,,,,10619,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,CHEMBL615577,,8,1,,BAO_0000357,,
558,B,,,,51,Autocuration,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,CHEMBL615578,,8,1,,BAO_0000221,10000000.0,
559,B,,,,51,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,CHEMBL615579,,8,1,,BAO_0000357,,
560,B,,,,51,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL615580,,8,1,,BAO_0000357,,
561,B,,,,51,Expert,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,CHEMBL615581,,8,1,,BAO_0000019,,
562,B,,,,51,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615582,,8,1,,BAO_0000221,10000000.0,
563,B,,,,51,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615583,,8,1,,BAO_0000221,10000000.0,
564,B,,,,51,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615584,,8,1,,BAO_0000221,10000000.0,
565,B,,,,51,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL833691,,8,1,,BAO_0000221,10000000.0,
566,B,,,,51,Autocuration,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615585,,8,1,,BAO_0000221,10000000.0,
567,B,,,,51,Autocuration,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615586,,8,1,,BAO_0000221,10000000.0,
568,B,,,,51,Autocuration,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL884524,,8,1,,BAO_0000221,10000000.0,
569,B,,,,51,Autocuration,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615587,,8,1,,BAO_0000221,10000000.0,
570,B,,,,51,Autocuration,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,CHEMBL615588,,8,1,,BAO_0000221,10000000.0,
571,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,CHEMBL615589,,9,1,,BAO_0000249,,
572,B,,9913.0,,51,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,CHEMBL615442,,8,1,,BAO_0000221,10000000.0,
573,B,,,,51,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,CHEMBL615443,,8,1,,BAO_0000221,10000000.0,
574,B,,,,51,Autocuration,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,CHEMBL615444,,8,1,,BAO_0000221,10000000.0,
575,B,,,,51,Expert,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,CHEMBL615445,,8,1,,BAO_0000221,10000000.0,
576,B,,,,51,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,CHEMBL615446,,8,1,,BAO_0000221,10000000.0,
577,B,,,,51,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,CHEMBL615447,,8,1,449.0,BAO_0000219,,
578,B,,,,51,Expert,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615448,,8,1,,BAO_0000221,10000000.0,
579,B,,,,51,Expert,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,CHEMBL615449,,8,1,,BAO_0000221,10000000.0,
580,B,,,,51,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL615450,,8,1,449.0,BAO_0000219,,
581,B,,,,51,Expert,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,CHEMBL615451,,8,1,,BAO_0000221,10000000.0,
582,B,,,,51,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,CHEMBL615452,,8,1,,BAO_0000357,,
583,B,,,,51,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615453,,8,1,,BAO_0000221,10000000.0,
584,B,,,,51,Autocuration,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615454,,8,1,,BAO_0000221,10000000.0,
585,B,,,,51,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615455,,8,1,,BAO_0000221,10000000.0,
586,B,,,,51,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615456,,8,1,,BAO_0000221,10000000.0,
587,B,,,,51,Autocuration,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,CHEMBL615457,,8,1,,BAO_0000221,10000000.0,
588,B,,,,51,Expert,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,CHEMBL615458,,8,1,,BAO_0000218,10000000.0,
589,B,,,,51,Expert,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL615459,,8,1,,BAO_0000221,10000000.0,
590,B,,9606.0,,51,Expert,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,CHEMBL615460,,9,1,449.0,BAO_0000219,,
591,F,,10141.0,,51,Autocuration,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,CHEMBL615461,,8,1,,BAO_0000019,,
592,F,,10141.0,,51,Autocuration,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,CHEMBL615462,,8,1,,BAO_0000019,,
593,F,,10141.0,,51,Autocuration,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,CHEMBL615463,,8,1,,BAO_0000221,10000000.0,
594,B,,10141.0,,51,Autocuration,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,CHEMBL615464,,8,1,,BAO_0000221,2116.0,
595,B,,10141.0,,51,Autocuration,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,CHEMBL615465,,8,1,,BAO_0000221,2116.0,
596,B,,10141.0,,51,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,CHEMBL615466,,8,1,,BAO_0000221,2116.0,
597,B,,10141.0,,51,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,CHEMBL615467,,8,1,,BAO_0000221,2116.0,
598,B,,10141.0,,51,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,CHEMBL615468,,8,1,,BAO_0000221,2116.0,
599,B,,10141.0,,51,Autocuration,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,CHEMBL615469,,8,1,,BAO_0000221,2116.0,
600,B,,10141.0,,51,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615470,,8,1,,BAO_0000357,,
601,B,,10141.0,,51,Autocuration,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615471,,8,1,,BAO_0000357,,
602,B,,10141.0,,51,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,CHEMBL615472,,8,1,,BAO_0000357,,
603,B,,10141.0,,106,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,CHEMBL883242,,8,1,,BAO_0000221,10000000.0,
604,F,,10141.0,,106,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,CHEMBL615473,,8,1,,BAO_0000221,10000000.0,
605,B,,10029.0,,11863,Autocuration,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,CHEMBL615474,,8,1,449.0,BAO_0000218,,
606,B,,,,51,Autocuration,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,CHEMBL615475,,8,1,,BAO_0000357,,
607,F,,,,51,Autocuration,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,CHEMBL615476,,8,1,308.0,BAO_0000219,,
608,F,,,,51,Autocuration,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,CHEMBL615477,,8,1,308.0,BAO_0000219,,
609,F,,,,51,Autocuration,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,CHEMBL615478,,8,1,,BAO_0000019,,
610,F,,,,51,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,CHEMBL615160,,8,1,449.0,BAO_0000219,,
611,F,,,,51,Expert,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,CHEMBL615161,,8,1,449.0,BAO_0000219,,
612,F,,,,51,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,CHEMBL615162,,8,1,449.0,BAO_0000219,,
613,F,,,,51,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,CHEMBL615163,,8,1,449.0,BAO_0000219,,
614,B,,,,51,Expert,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL615164,,8,1,449.0,BAO_0000219,,
615,B,,,,51,Expert,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL615165,,8,1,449.0,BAO_0000219,,
616,B,,,,51,Autocuration,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,CHEMBL615166,,8,1,449.0,BAO_0000219,,
617,F,,,,51,Autocuration,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,CHEMBL615167,,8,1,,BAO_0000219,,
618,B,,9606.0,,51,Expert,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,CHEMBL615168,,9,1,308.0,BAO_0000219,,
619,B,,9606.0,,51,Expert,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,CHEMBL615169,,9,1,308.0,BAO_0000219,,
620,B,,9606.0,,51,Expert,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL615170,,9,1,449.0,BAO_0000219,,
621,B,,9606.0,,51,Expert,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,CHEMBL615171,,9,1,449.0,BAO_0000219,,
622,F,,,,51,Autocuration,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,CHEMBL615694,,8,1,,BAO_0000019,,
623,F,,,,51,Autocuration,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,CHEMBL615695,,8,1,,BAO_0000019,,
624,F,,,,51,Autocuration,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,CHEMBL615696,,8,1,,BAO_0000019,,
625,F,,,,51,Autocuration,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHEMBL615697,,8,1,449.0,BAO_0000219,,
626,F,,9606.0,,51,Expert,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,CHEMBL859410,,9,1,449.0,BAO_0000219,,
627,F,,,,51,Autocuration,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,CHEMBL615841,,8,1,449.0,BAO_0000219,,
628,F,,9606.0,,51,Expert,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,CHEMBL615842,,9,1,449.0,BAO_0000219,,
629,F,,,,51,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHEMBL835003,,8,1,449.0,BAO_0000219,,
630,F,,,,51,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,CHEMBL615843,,8,1,449.0,BAO_0000219,,
631,F,,9606.0,,51,Expert,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,CHEMBL615979,,9,1,449.0,BAO_0000219,,
632,F,,,,51,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,CHEMBL615980,,8,1,449.0,BAO_0000219,,
633,F,,9606.0,,51,Expert,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,CHEMBL615981,,9,1,449.0,BAO_0000219,,
634,F,,9606.0,,51,Expert,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,CHEMBL615982,,9,1,,BAO_0000019,,
635,F,,9606.0,,51,Expert,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL615983,,9,1,,BAO_0000019,,
636,F,,9606.0,,51,Expert,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,CHEMBL615984,,9,1,,BAO_0000019,,
637,F,,9606.0,,51,Expert,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL615985,,9,1,,BAO_0000019,,
638,F,,,,51,Autocuration,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHEMBL615986,,8,1,449.0,BAO_0000219,,
639,F,,,,51,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHEMBL615987,,8,1,449.0,BAO_0000219,,
640,F,,,,51,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,CHEMBL615988,,8,1,449.0,BAO_0000219,,
641,F,,,,51,Expert,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,CHEMBL615989,,8,1,449.0,BAO_0000219,,
642,F,,,,51,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,CHEMBL615990,,8,1,449.0,BAO_0000219,,
643,F,,,,51,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,CHEMBL615991,,8,1,449.0,BAO_0000219,,
644,F,,,,51,Autocuration,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHEMBL615992,,8,1,449.0,BAO_0000219,,
645,F,,,,51,Autocuration,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,CHEMBL615993,,8,1,449.0,BAO_0000219,,
646,F,,,,51,Expert,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHEMBL615994,,8,1,449.0,BAO_0000219,,
647,F,,,,51,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,CHEMBL615995,,8,1,449.0,BAO_0000219,,
648,F,,,,51,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,CHEMBL615996,,8,1,449.0,BAO_0000219,,
649,F,,,,51,Autocuration,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,CHEMBL615997,,8,1,449.0,BAO_0000219,,
650,F,,,,51,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615998,,8,1,,BAO_0000019,,
651,F,,,,51,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615999,,8,1,,BAO_0000019,,
652,F,,,,51,Autocuration,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,CHEMBL616000,,8,1,,BAO_0000019,,
653,F,,,,51,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL616001,,8,1,722.0,BAO_0000219,,
654,F,,9606.0,,51,Expert,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,CHEMBL616002,,9,1,,BAO_0000019,,
655,F,,,,51,Expert,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,CHEMBL616003,,8,1,,BAO_0000019,,
656,F,,9606.0,,51,Expert,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,CHEMBL616004,,9,1,,BAO_0000019,,
657,F,,9606.0,,51,Expert,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,CHEMBL616005,,9,1,,BAO_0000019,,
658,F,,,,51,Autocuration,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,CHEMBL616006,,8,1,,BAO_0000019,,
659,F,,,,51,Expert,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,CHEMBL616007,,8,1,,BAO_0000019,,
660,F,,,,51,Autocuration,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,CHEMBL616008,,8,1,,BAO_0000019,,
661,F,,,,51,Autocuration,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,CHEMBL616009,,8,1,,BAO_0000019,,
662,F,,,,51,Expert,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,CHEMBL616010,,8,1,,BAO_0000019,,
663,F,,9606.0,,51,Expert,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,CHEMBL616011,,9,1,,BAO_0000019,,
664,F,,9606.0,,51,Expert,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,CHEMBL615740,,9,1,,BAO_0000019,,
665,F,,,,51,Autocuration,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,CHEMBL615741,,8,1,,BAO_0000019,,
666,F,,,,51,Expert,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,CHEMBL615742,,8,1,,BAO_0000019,,
667,F,,,,51,Autocuration,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,CHEMBL615743,,8,1,,BAO_0000019,,
668,F,,,,51,Autocuration,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,CHEMBL615744,,8,1,449.0,BAO_0000219,,
669,F,,,,51,Expert,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,CHEMBL615745,,8,1,449.0,BAO_0000219,,
670,B,,,,51,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,CHEMBL615746,,8,1,,BAO_0000357,,
671,B,,,,51,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,CHEMBL615747,,8,1,,BAO_0000357,,
672,F,,,,51,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615748,,8,1,,BAO_0000019,,
673,F,,,,51,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,CHEMBL615749,,8,1,,BAO_0000019,,
674,F,,,,51,Autocuration,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,CHEMBL615750,,8,1,,BAO_0000019,,
675,F,,9606.0,,51,Expert,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,CHEMBL616259,,9,1,,BAO_0000019,,
676,F,,,,51,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL616260,,8,1,,BAO_0000019,,
677,F,,9606.0,,51,Expert,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,CHEMBL616261,,9,1,,BAO_0000019,,
678,F,,9606.0,,51,Expert,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL616262,,9,1,,BAO_0000019,,
679,F,,9606.0,,51,Expert,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,CHEMBL616263,,9,1,,BAO_0000019,,
680,F,,9606.0,,51,Expert,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,CHEMBL616264,,9,1,,BAO_0000019,,
681,F,,9606.0,,51,Expert,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,CHEMBL616265,,9,1,,BAO_0000019,,
682,F,,9606.0,,51,Expert,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,CHEMBL616266,,9,1,,BAO_0000019,,
683,F,,9606.0,,51,Expert,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,CHEMBL616267,,9,1,,BAO_0000019,,
684,F,,9606.0,,51,Expert,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,CHEMBL616268,,9,1,,BAO_0000019,,
685,B,,9606.0,,51,Expert,Inhibition of human 5-hydroxytryptamine 1A receptor,,CHEMBL616269,,9,1,,BAO_0000357,,
686,B,,,,51,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL884528,,8,1,449.0,BAO_0000219,,
687,B,,,,105,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,CHEMBL616270,,9,1,722.0,BAO_0000219,,
688,B,,,,51,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,CHEMBL616271,,8,1,449.0,BAO_0000219,,
689,F,,,,51,Autocuration,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHEMBL616272,,8,1,449.0,BAO_0000219,,
690,B,,,,51,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,CHEMBL616273,,8,1,,BAO_0000357,,
691,B,,9606.0,,51,Expert,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616274,,9,1,,BAO_0000357,,
692,B,,,,51,Autocuration,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL616275,,8,1,449.0,BAO_0000219,,
693,B,,,,51,Autocuration,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL616276,,8,1,449.0,BAO_0000219,,
694,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,CHEMBL616277,,0,1,,BAO_0000218,,
695,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,CHEMBL616278,,0,1,,BAO_0000218,,
696,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,CHEMBL616279,,0,1,,BAO_0000218,,
697,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,CHEMBL616280,,0,1,,BAO_0000218,,
698,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,CHEMBL616281,,0,1,,BAO_0000218,,
699,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,CHEMBL616282,,0,1,,BAO_0000218,,
700,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,CHEMBL616283,,0,1,,BAO_0000218,,
701,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,CHEMBL616284,,0,1,,BAO_0000218,,
702,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,CHEMBL616285,,0,1,,BAO_0000218,,
703,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,CHEMBL616286,,0,1,,BAO_0000218,,
704,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,CHEMBL616287,,0,1,,BAO_0000218,,
705,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,CHEMBL616288,,0,1,,BAO_0000218,,
706,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,CHEMBL616289,,0,1,,BAO_0000218,,
707,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,CHEMBL615610,,0,1,,BAO_0000218,,
708,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,CHEMBL615611,,0,1,,BAO_0000218,,
709,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,CHEMBL615612,,0,1,,BAO_0000218,,
710,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,CHEMBL615613,,0,1,,BAO_0000218,,
711,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,CHEMBL615614,,0,1,,BAO_0000218,,
712,F,In vivo,10116.0,,22226,Autocuration,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,CHEMBL615615,,0,1,,BAO_0000218,,
713,B,,,,105093,Autocuration,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,CHEMBL615616,,4,1,,BAO_0000019,,
714,B,,,,11923,Autocuration,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,CHEMBL615617,,8,1,,BAO_0000249,1898.0,
715,B,,,,10577,Autocuration,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,CHEMBL615618,,8,1,,BAO_0000019,,
716,B,,,,10577,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,CHEMBL615619,,8,1,,BAO_0000019,,
717,B,,,,10577,Expert,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,CHEMBL615620,,8,1,,BAO_0000019,,
718,B,,,,55,Autocuration,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,CHEMBL615621,,8,1,,BAO_0000357,,
719,B,,,,55,Autocuration,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,CHEMBL615622,,8,1,,BAO_0000357,,
720,F,,,,12166,Autocuration,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,CHEMBL615623,,8,1,,BAO_0000019,,
721,F,,,,12166,Autocuration,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,CHEMBL615624,,8,1,,BAO_0000019,,
722,F,,,,12166,Autocuration,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,CHEMBL615625,,8,1,,BAO_0000019,,
723,F,,,,12166,Autocuration,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,CHEMBL767045,,8,1,,BAO_0000019,,
724,F,,10141.0,,55,Autocuration,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,CHEMBL615626,,8,1,,BAO_0000019,,
725,F,,10141.0,,55,Autocuration,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,CHEMBL615627,,8,1,,BAO_0000019,,
726,B,,10141.0,,55,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,CHEMBL615628,,8,1,,BAO_0000019,,
727,B,,10141.0,,55,Autocuration,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,CHEMBL615629,,8,1,,BAO_0000357,,
728,B,,9606.0,,55,Expert,Inhibitory concentration against 5-lipoxygenase from human whole blood,,CHEMBL615630,,9,1,,BAO_0000357,,
729,B,,,,55,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,CHEMBL615631,,8,1,,BAO_0000219,,
730,F,,,,17087,Autocuration,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,CHEMBL615632,,8,1,,BAO_0000218,,
731,B,,,,17087,Autocuration,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,CHEMBL615633,,8,1,,BAO_0000357,,
732,F,,,,17087,Autocuration,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,CHEMBL615634,,8,1,,BAO_0000218,,
733,B,,9823.0,,55,Expert,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,CHEMBL615635,,8,1,,BAO_0000019,,
734,B,,,,12166,Expert,In vitro inhibition of rat 5-Lipoxygenase,,CHEMBL615636,,8,1,,BAO_0000357,,
735,B,,10116.0,,12166,Expert,Inhibitory activity against 5-Lipoxygenase,,CHEMBL615637,,9,1,,BAO_0000357,,
736,B,,,,12166,Expert,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,CHEMBL615638,,8,1,702.0,BAO_0000219,,
737,B,,,,12166,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,CHEMBL615639,,8,1,702.0,BAO_0000219,,
738,B,,,,12166,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,CHEMBL615640,,8,1,702.0,BAO_0000219,,
739,B,,,,12166,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,CHEMBL615796,,8,1,,BAO_0000019,,
740,B,,,,12166,Autocuration,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,CHEMBL615845,,8,1,,BAO_0000219,,
741,B,,,,12166,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,CHEMBL615846,,8,1,,BAO_0000357,,
742,B,,,,12166,Autocuration,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,CHEMBL615847,,8,1,702.0,BAO_0000219,,
743,B,,,,12166,Autocuration,The compound was tested for inhibition of isolated 5-Lipoxygenase,,CHEMBL615848,,8,1,,BAO_0000357,,
744,B,,10116.0,,22226,Autocuration,Ratio of IC50 against 5-LO and COX,,CHEMBL615849,,0,1,,BAO_0000019,,
745,B,,,,12166,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,CHEMBL615850,,8,1,,BAO_0000357,,
746,B,,,,12166,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,CHEMBL615851,,8,1,,BAO_0000357,,
747,B,,,,12166,Autocuration,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,CHEMBL615852,,8,1,,BAO_0000219,,
748,F,,,,12166,Autocuration,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,CHEMBL615853,,8,1,,BAO_0000019,,
749,B,,,,120,Autocuration,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,CHEMBL884527,,8,1,,BAO_0000357,2367.0,
750,B,,8932.0,,22226,Autocuration,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,CHEMBL872871,,0,1,,BAO_0000019,,
751,B,,8932.0,,22226,Autocuration,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,CHEMBL615854,,0,1,,BAO_0000019,,
752,B,,8932.0,,22226,Autocuration,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,CHEMBL767046,,0,1,,BAO_0000019,,
753,B,,,,10732,Autocuration,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,CHEMBL615855,,8,1,,BAO_0000357,,
754,F,,10116.0,,12198,Expert,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,CHEMBL615856,,9,1,,BAO_0000019,,
755,F,,10116.0,,12198,Expert,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,CHEMBL615857,,9,1,,BAO_0000019,,
756,F,,10116.0,,12198,Expert,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,CHEMBL615858,,9,1,,BAO_0000019,,
757,B,,,,10576,Expert,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,CHEMBL615859,,8,1,,BAO_0000221,10000000.0,
758,B,,,,51,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,CHEMBL615860,,8,1,,BAO_0000357,,
759,B,,9986.0,,22226,Autocuration,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,CHEMBL615861,,0,1,,BAO_0000019,,
760,B,,9986.0,,22226,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,CHEMBL615862,,0,1,,BAO_0000019,,
761,B,,9986.0,,22226,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,CHEMBL615863,,0,1,,BAO_0000019,,
762,B,,9986.0,,22226,Autocuration,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,CHEMBL615864,,0,1,,BAO_0000019,,
763,B,,,,104744,Autocuration,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,CHEMBL615865,,4,1,,BAO_0000221,10000000.0,
764,B,,,,104744,Autocuration,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,CHEMBL615866,,4,1,,BAO_0000221,10000000.0,
765,B,,,,104744,Autocuration,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,CHEMBL615867,,4,1,,BAO_0000221,10000000.0,
766,B,,,,104744,Autocuration,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,CHEMBL615868,,4,1,,BAO_0000249,,
767,B,,10116.0,,104744,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,CHEMBL615869,,5,1,,BAO_0000249,,
768,B,,10116.0,,104744,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,CHEMBL615870,,5,1,,BAO_0000019,,
769,B,,10116.0,,104744,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,CHEMBL615871,,5,1,,BAO_0000019,,
770,B,,,,104744,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,CHEMBL615872,,4,1,,BAO_0000224,,
771,B,,,,104744,Autocuration,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,CHEMBL833492,,4,1,,BAO_0000221,10000000.0,
772,B,,,,104744,Autocuration,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,CHEMBL615873,,4,1,,BAO_0000221,10000000.0,
773,B,,,,104744,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,CHEMBL615479,,4,1,,BAO_0000224,,
774,B,,,,104744,Autocuration,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,CHEMBL615480,,4,1,,BAO_0000019,,
775,B,,10116.0,,104744,Autocuration,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,CHEMBL615481,,5,1,,BAO_0000249,,
776,B,,,,104744,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL872869,,4,1,,BAO_0000019,,
777,B,,,,104744,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL615482,,4,1,,BAO_0000019,,
778,B,,,,104744,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,CHEMBL615483,,4,1,,BAO_0000221,955.0,
779,B,,,,104744,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,CHEMBL615484,,4,1,,BAO_0000221,955.0,
780,B,,,,104744,Autocuration,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,CHEMBL615485,,4,1,,BAO_0000019,,
781,B,,10116.0,,104744,Autocuration,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,CHEMBL615486,,5,1,,BAO_0000224,,
782,B,,,,104744,Autocuration,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,CHEMBL615487,,4,1,,BAO_0000224,,
783,B,,,,104744,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,CHEMBL615488,,4,1,,BAO_0000224,,
784,B,,,,104744,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,CHEMBL615489,,4,1,,BAO_0000224,,
785,B,,,,104744,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,CHEMBL615389,,4,1,,BAO_0000224,,
786,B,,,,104744,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,CHEMBL615390,,4,1,,BAO_0000019,,
787,B,,,,104744,Autocuration,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,CHEMBL615391,,4,1,,BAO_0000019,,
788,B,,,,104744,Autocuration,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,CHEMBL615392,,4,1,,BAO_0000224,,
789,B,,10116.0,,22226,Autocuration,Affinity for 5-hydroxytryptamine 1 receptor,,CHEMBL615393,,0,1,,BAO_0000019,,
790,B,,,,104744,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,CHEMBL615394,,4,1,,BAO_0000221,955.0,
791,B,,,,104744,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,CHEMBL615395,,4,1,,BAO_0000221,955.0,
792,B,,,,104744,Autocuration,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,CHEMBL615396,,4,1,,BAO_0000224,,
793,B,,,,104744,Autocuration,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,CHEMBL615397,,4,1,,BAO_0000221,955.0,
794,B,,,,104744,Autocuration,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,CHEMBL615398,,4,1,,BAO_0000019,,
795,B,,10116.0,,22226,Autocuration,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,CHEMBL615399,,0,1,,BAO_0000019,,
796,B,,,,104744,Autocuration,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,CHEMBL615400,,4,1,,BAO_0000019,,
797,B,,10116.0,,104744,Autocuration,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,CHEMBL615401,,5,1,,BAO_0000019,,
798,B,,10116.0,,22226,Autocuration,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,CHEMBL615402,,0,1,,BAO_0000019,,
799,B,,,,104744,Autocuration,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,CHEMBL615403,,4,1,,BAO_0000019,,
800,B,,,,104744,Autocuration,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,CHEMBL615404,,4,1,,BAO_0000221,955.0,
801,B,,,,104744,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,CHEMBL615781,,4,1,,BAO_0000019,,
802,B,,,,104744,Autocuration,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,CHEMBL615782,,4,1,,BAO_0000220,955.0,
803,B,,,,104744,Autocuration,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,CHEMBL615783,,4,1,,BAO_0000221,955.0,
804,B,,,,22226,Autocuration,Compound was tested for binding affinity against 5-HT1 receptor,,CHEMBL873481,,0,1,,BAO_0000019,,
805,B,,,,22226,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,CHEMBL615784,,0,1,,BAO_0000019,,
806,B,,,,10576,Expert,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,CHEMBL615785,,8,1,,BAO_0000357,,
807,F,,,,10576,Autocuration,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,CHEMBL615786,,8,1,,BAO_0000249,,
808,F,In vivo,,,10576,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,CHEMBL615787,,8,1,,BAO_0000218,,
809,F,In vivo,,,10576,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,CHEMBL615788,,8,1,,BAO_0000218,,
810,F,,,,10576,Autocuration,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,CHEMBL767044,,8,1,,BAO_0000019,,
811,F,In vivo,,,10576,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,CHEMBL615789,,8,1,,BAO_0000218,,
812,F,In vivo,,,10576,Autocuration,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,CHEMBL615790,,8,1,,BAO_0000218,,
813,F,,,,10576,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,CHEMBL615813,,8,1,,BAO_0000019,,
814,F,,,,10576,Autocuration,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,CHEMBL615814,,8,1,,BAO_0000219,,
815,F,,,,51,Expert,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,CHEMBL615815,,8,1,,BAO_0000219,,
816,F,,,,10576,Autocuration,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,CHEMBL615816,,8,1,,BAO_0000219,,
817,B,,,,10576,Expert,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,CHEMBL615817,,8,1,,BAO_0000249,,
818,B,,,,10576,Autocuration,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,CHEMBL615818,,8,1,,BAO_0000221,10000000.0,
819,B,,,,10576,Autocuration,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,CHEMBL615819,,8,1,,BAO_0000221,10000000.0,
820,B,,,,10576,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,CHEMBL615820,,8,1,,BAO_0000249,,
821,B,,10116.0,,10576,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,CHEMBL615821,,9,1,,BAO_0000221,10000000.0,
822,B,,10116.0,,10576,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,CHEMBL615822,,9,1,,BAO_0000221,10000000.0,
823,B,,,,10576,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,CHEMBL615823,,8,1,,BAO_0000221,10000000.0,
824,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,CHEMBL615824,,9,1,,BAO_0000221,10000000.0,
825,B,,10116.0,,10576,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,CHEMBL615825,,9,1,,BAO_0000221,10000000.0,
826,B,,,,10576,Expert,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,CHEMBL615826,,8,1,,BAO_0000357,,
827,B,,,,10576,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,CHEMBL615827,,8,1,,BAO_0000249,,
828,B,,,,10576,Expert,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,CHEMBL615828,,8,1,,BAO_0000249,10000000.0,
829,B,,,,10576,Expert,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615829,,8,1,,BAO_0000221,10000000.0,
830,B,,,,10576,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,CHEMBL615830,,8,1,,BAO_0000221,10000000.0,
831,B,,,,10576,Expert,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,CHEMBL615831,,8,1,,BAO_0000221,10000000.0,
832,B,,,,10576,Autocuration,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,CHEMBL615832,,8,1,,BAO_0000357,,
833,B,,,,10576,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,CHEMBL615833,,8,1,,BAO_0000019,,
834,B,,,,10576,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,CHEMBL615834,,8,1,,BAO_0000221,10000000.0,
835,B,,,,10576,Intermediate,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,CHEMBL615835,,8,1,,BAO_0000249,,
836,B,,,,10576,Autocuration,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,CHEMBL615836,,8,1,,BAO_0000249,10000000.0,
837,B,,10116.0,,10576,Expert,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,CHEMBL615837,,9,1,,BAO_0000019,,
838,B,,10116.0,,10576,Expert,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,CHEMBL615838,,9,1,,BAO_0000019,,
839,B,,,,10576,Expert,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,CHEMBL615839,,8,1,,BAO_0000249,,
840,B,,,,10576,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,CHEMBL884525,,8,1,,BAO_0000019,,
841,B,,,,10576,Autocuration,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,CHEMBL615840,,8,1,,BAO_0000249,,
842,B,,,,10576,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615405,,8,1,,BAO_0000221,10000000.0,
843,B,,,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,CHEMBL615406,,8,1,,BAO_0000019,,
844,B,,,,10576,Expert,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,CHEMBL615900,,8,1,,BAO_0000221,10000000.0,
845,B,,,,10576,Expert,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,CHEMBL615901,,8,1,,BAO_0000221,10000000.0,
846,B,,,,10576,Expert,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,CHEMBL615902,,8,1,,BAO_0000357,,
847,B,,,,10576,Autocuration,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,CHEMBL615903,,8,1,,BAO_0000221,10000000.0,
848,B,,,,10576,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,CHEMBL615904,,8,1,,BAO_0000357,,
849,B,,,,10576,Expert,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,CHEMBL615905,,8,1,,BAO_0000357,,
850,B,,,,10576,Autocuration,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,CHEMBL615906,,8,1,,BAO_0000019,,
851,F,,,,10576,Autocuration,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,CHEMBL615907,,8,1,,BAO_0000019,,
852,B,,,,10576,Expert,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,CHEMBL615908,,8,1,,BAO_0000019,,
853,B,,,,10576,Autocuration,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,CHEMBL615909,,8,1,,BAO_0000221,10000000.0,
854,B,,,,10576,Autocuration,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,CHEMBL615910,,8,1,,BAO_0000019,,
855,B,,,,10576,Autocuration,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,CHEMBL615911,,8,1,,BAO_0000019,,
856,B,,,,10576,Autocuration,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,CHEMBL615912,,8,1,,BAO_0000019,,
857,B,,,,10576,Expert,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,CHEMBL615913,,8,1,,BAO_0000019,,
858,B,,,,10576,Expert,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,CHEMBL615914,,8,1,,BAO_0000357,,
859,B,,,,10576,Autocuration,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,CHEMBL615915,,8,1,,BAO_0000221,10000000.0,
860,B,,,,10576,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,CHEMBL615916,,8,1,,BAO_0000357,,
861,B,,,,10576,Expert,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,CHEMBL615917,,8,1,,BAO_0000357,,
862,B,,,,10576,Expert,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,CHEMBL615918,,8,1,,BAO_0000357,,
863,B,,,,10576,Expert,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,CHEMBL615919,,8,1,,BAO_0000249,10000000.0,
864,B,,10116.0,,10576,Expert,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,CHEMBL615920,,9,1,,BAO_0000221,10000000.0,
865,B,,,,10576,Autocuration,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,CHEMBL615921,,8,1,,BAO_0000357,,
866,B,,,,10576,Expert,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,CHEMBL615922,,8,1,,BAO_0000357,,
867,F,,10116.0,,10576,Expert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,CHEMBL881290,,9,1,,BAO_0000249,,
868,B,,,,10576,Autocuration,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,CHEMBL615923,,8,1,,BAO_0000221,10000000.0,
869,F,,,,10576,Autocuration,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615924,,8,1,,BAO_0000221,10000000.0,
870,F,,,,10576,Autocuration,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL615925,,8,1,,BAO_0000221,10000000.0,
871,B,,10116.0,,10576,Expert,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,CHEMBL615926,,9,1,,BAO_0000357,,
872,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,CHEMBL615927,,9,1,,BAO_0000019,,
873,B,,,,10576,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL615928,,8,1,,BAO_0000221,10000000.0,
874,B,,10116.0,,10576,Expert,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,CHEMBL615929,,9,1,,BAO_0000357,,
875,B,,,,10576,Autocuration,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,CHEMBL615930,,8,1,,BAO_0000221,10000000.0,
876,B,,,,51,Autocuration,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,CHEMBL615931,,8,1,449.0,BAO_0000219,,
877,F,,,,51,Autocuration,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHEMBL615932,,8,1,449.0,BAO_0000219,,
878,F,,,,51,Autocuration,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,CHEMBL615933,,8,1,449.0,BAO_0000219,,
879,B,,,,51,Autocuration,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,CHEMBL615934,,8,1,,BAO_0000357,,
880,B,,,,51,Autocuration,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,CHEMBL615935,,8,1,,BAO_0000357,,
881,F,,,,51,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,CHEMBL615936,,8,1,,BAO_0000019,,
882,B,,,,51,Autocuration,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,CHEMBL615937,,8,1,449.0,BAO_0000219,,
883,B,,,,51,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,CHEMBL615938,,8,1,,BAO_0000357,,
884,B,,,,51,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,CHEMBL615797,,8,1,,BAO_0000357,,
885,B,,,,51,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615798,,8,1,,BAO_0000357,,
886,B,,,,51,Autocuration,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,CHEMBL872870,,8,1,,BAO_0000357,,
887,B,,,,51,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,CHEMBL615799,,8,1,,BAO_0000357,,
888,B,,,,51,Autocuration,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615800,,8,1,,BAO_0000357,,
889,F,,,,51,Autocuration,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL615801,,8,1,722.0,BAO_0000219,,
890,B,,,,51,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,CHEMBL615802,,8,1,,BAO_0000019,,
891,B,,,,51,Autocuration,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,CHEMBL615803,,8,1,,BAO_0000357,,
892,F,,,,51,Expert,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,CHEMBL835002,,8,1,,BAO_0000019,,
893,F,,,,51,Autocuration,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,CHEMBL615804,,8,1,,BAO_0000019,,
894,B,,,,51,Expert,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,CHEMBL615805,,8,1,308.0,BAO_0000219,,
895,B,,,,51,Autocuration,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,CHEMBL615806,,8,1,449.0,BAO_0000219,,
896,B,,9606.0,,51,Expert,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,CHEMBL615807,,9,1,,BAO_0000357,,
897,B,,,,51,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,CHEMBL615808,,8,1,,BAO_0000357,,
898,B,,9606.0,,51,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL615809,,9,1,,BAO_0000357,,
899,B,,,,51,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,CHEMBL615810,,8,1,308.0,BAO_0000219,,
900,B,,,,51,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615811,,8,1,,BAO_0000357,,
901,B,,,,51,Autocuration,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,CHEMBL615812,,8,1,449.0,BAO_0000219,,
902,B,,,,51,Autocuration,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL615751,,8,1,449.0,BAO_0000219,,
903,B,,,,51,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptor,,CHEMBL615752,,8,1,,BAO_0000357,,
904,B,,,,51,Expert,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,CHEMBL615753,,8,1,449.0,BAO_0000219,,
905,B,,,,51,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,CHEMBL615754,,8,1,449.0,BAO_0000219,,
906,B,,,,51,Autocuration,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,CHEMBL615755,,8,1,,BAO_0000357,,
907,B,,9606.0,,51,Expert,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHEMBL615756,,9,1,449.0,BAO_0000219,,
908,B,,,,51,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,CHEMBL615757,,8,1,,BAO_0000019,,
909,B,,,,51,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,CHEMBL615758,,8,1,,BAO_0000357,,
910,B,,,,51,Expert,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,CHEMBL615759,,8,1,,BAO_0000357,,
911,B,,,,51,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,CHEMBL615760,,8,1,,BAO_0000357,,
912,B,,,,51,Expert,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,CHEMBL615761,,8,1,308.0,BAO_0000219,,
913,B,,,,51,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,CHEMBL872104,,8,1,,BAO_0000357,,
914,B,,,,51,Autocuration,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL615762,,8,1,,BAO_0000357,,
915,B,,,,51,Autocuration,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL615763,,8,1,,BAO_0000357,,
916,B,,,,51,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,CHEMBL615764,,8,1,,BAO_0000357,,
917,B,,,,51,Autocuration,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,CHEMBL615765,,8,1,1167.0,BAO_0000219,,
918,B,,,,51,Autocuration,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,CHEMBL615766,,8,1,,BAO_0000019,,
919,B,,,,51,Autocuration,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615767,,8,1,,BAO_0000357,,
920,B,,,,51,Expert,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615768,,8,1,,BAO_0000357,,
921,B,,,,51,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615769,,8,1,,BAO_0000357,,
922,B,,,,51,Expert,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,CHEMBL615770,,8,1,,BAO_0000357,,
923,B,,,,51,Autocuration,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615771,,8,1,,BAO_0000357,,
924,B,,,,51,Expert,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,CHEMBL615772,,8,1,,BAO_0000357,,
925,B,,,,51,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL615773,,8,1,,BAO_0000357,,
926,B,,,,51,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,CHEMBL615774,,8,1,,BAO_0000357,,
927,B,,,,51,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615775,,8,1,,BAO_0000357,,
928,B,,,,51,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,CHEMBL615776,,8,1,,BAO_0000357,,
929,B,,,,51,Expert,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL615777,,8,1,,BAO_0000357,,
930,B,,,,51,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,CHEMBL615778,,8,1,,BAO_0000219,,
931,B,,9606.0,,51,Expert,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,CHEMBL615779,,9,1,,BAO_0000357,,
932,B,,,,51,Autocuration,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,CHEMBL615780,,8,1,,BAO_0000357,,
933,B,,,,51,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,CHEMBL616298,,8,1,,BAO_0000357,,
934,B,,,,51,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,CHEMBL616299,,8,1,,BAO_0000357,,
935,B,,,,51,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,CHEMBL616300,,8,1,485.0,BAO_0000219,,
936,F,,,,51,Expert,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,CHEMBL616301,,8,1,485.0,BAO_0000219,,
937,B,,,,51,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,CHEMBL616302,,8,1,,BAO_0000019,,
938,B,,,,51,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,CHEMBL616117,,8,1,,BAO_0000019,,
939,B,,,,51,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,CHEMBL616118,,8,1,,BAO_0000019,,
940,B,,,,51,Autocuration,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,CHEMBL616119,,8,1,,BAO_0000019,,
941,B,,9606.0,,51,Expert,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,CHEMBL616120,,9,1,308.0,BAO_0000219,,
942,B,,,,51,Autocuration,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,CHEMBL616121,,8,1,,BAO_0000357,,
943,B,,,,51,Autocuration,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,CHEMBL616122,,8,1,,BAO_0000357,,
944,B,,,,51,Autocuration,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,CHEMBL616123,,8,1,,BAO_0000357,,
945,B,,9606.0,,51,Expert,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,CHEMBL616124,,9,1,,BAO_0000357,,
946,B,,,,51,Expert,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,CHEMBL616125,,8,1,,BAO_0000357,,
947,B,,10116.0,,51,Expert,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,CHEMBL616126,,8,1,,BAO_0000357,,
948,B,,,,51,Autocuration,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,CHEMBL616127,,8,1,449.0,BAO_0000219,,
949,B,,,,51,Expert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,CHEMBL616128,,8,1,,BAO_0000019,,
950,B,,,,51,Autocuration,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,CHEMBL616129,,8,1,,BAO_0000357,,
951,B,,,,51,Expert,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616130,,8,1,,BAO_0000357,,
952,B,,,,51,Autocuration,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,CHEMBL616131,,8,1,,BAO_0000357,,
953,B,,,,51,Autocuration,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,CHEMBL616132,,8,1,308.0,BAO_0000219,,
954,B,,9606.0,,51,Expert,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,CHEMBL616133,,9,1,308.0,BAO_0000219,,
955,B,,,,51,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616134,,8,1,,BAO_0000357,,
956,B,,,,51,Autocuration,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,CHEMBL616135,,8,1,,BAO_0000357,,
957,B,,9606.0,,51,Expert,Affinity for 5-hydroxytryptamine 1A receptor subtype,,CHEMBL616136,,9,1,,BAO_0000357,,
958,B,,,,51,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,CHEMBL616137,,8,1,,BAO_0000019,,
959,B,,,,51,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,CHEMBL872105,,8,1,,BAO_0000019,,
960,B,,,,51,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,CHEMBL616138,,8,1,,BAO_0000357,,
961,B,,9606.0,,51,Expert,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616139,,9,1,,BAO_0000357,,
962,F,,,,51,Autocuration,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,CHEMBL616140,,8,1,,BAO_0000019,,
963,B,,,,51,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,CHEMBL616141,,8,1,,BAO_0000019,,
964,B,,,,51,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616142,,8,1,,BAO_0000357,,
965,B,,,,51,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,CHEMBL616143,,8,1,,BAO_0000357,,
966,B,,,,51,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,CHEMBL616144,,8,1,308.0,BAO_0000219,,
967,B,,,,51,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,CHEMBL616145,,8,1,308.0,BAO_0000219,,
968,B,,,,51,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,CHEMBL616012,,8,1,308.0,BAO_0000219,,
969,B,,,,51,Autocuration,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,CHEMBL616013,,8,1,308.0,BAO_0000219,,
970,F,,,,51,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,CHEMBL616014,,8,1,,BAO_0000019,,
971,F,,,,51,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,CHEMBL616015,,8,1,,BAO_0000019,,
972,F,,,,51,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,CHEMBL616016,,8,1,,BAO_0000019,,
973,F,In vivo,,,51,Autocuration,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,CHEMBL616017,,8,1,,BAO_0000218,,
974,B,,,,51,Autocuration,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,CHEMBL616018,,8,1,,BAO_0000019,,
975,F,,,,51,Autocuration,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,CHEMBL616019,,8,1,,BAO_0000019,,
976,F,,,,51,Autocuration,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,CHEMBL616020,,8,1,,BAO_0000019,,
977,B,,,,51,Autocuration,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,CHEMBL858018,,8,1,,BAO_0000357,,
978,F,,,,51,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL616021,,8,1,722.0,BAO_0000219,,
979,F,,,,51,Expert,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,CHEMBL616022,,8,1,,BAO_0000019,,
980,F,,,,51,Autocuration,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,CHEMBL616023,,8,1,,BAO_0000019,,
981,F,,,,51,Autocuration,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,CHEMBL616024,,8,1,,BAO_0000019,,
982,F,,,,51,Autocuration,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,CHEMBL616025,,8,1,,BAO_0000019,,
983,F,,,,51,Autocuration,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,CHEMBL616026,,8,1,449.0,BAO_0000219,,
984,F,,,,51,Autocuration,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,CHEMBL616027,,8,1,,BAO_0000019,,
985,F,,9606.0,,51,Expert,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,CHEMBL616028,,9,1,,BAO_0000019,,
986,F,,9606.0,,51,Expert,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,CHEMBL616029,,9,1,,BAO_0000019,,
987,B,,,,51,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,CHEMBL616030,,8,1,449.0,BAO_0000219,,
988,B,,,,51,Expert,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,CHEMBL616031,,8,1,,BAO_0000019,,
989,F,,9606.0,,51,Expert,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,CHEMBL616032,,9,1,,BAO_0000019,,
990,F,,9606.0,,51,Expert,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,CHEMBL616033,,9,1,,BAO_0000019,,
991,F,,,,51,Autocuration,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616034,,8,1,,BAO_0000019,,
992,F,,,,51,Autocuration,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616035,,8,1,,BAO_0000019,,
993,F,,,,51,Autocuration,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616036,,8,1,,BAO_0000019,,
994,F,,,,51,Autocuration,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616037,,8,1,,BAO_0000019,,
995,F,,,,51,Autocuration,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616038,,8,1,,BAO_0000019,,
996,F,,,,51,Autocuration,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,CHEMBL616039,,8,1,,BAO_0000019,,
997,F,,,,51,Autocuration,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616040,,8,1,,BAO_0000019,,
998,F,,9606.0,,51,Expert,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,CHEMBL616041,,9,1,308.0,BAO_0000219,,
999,F,,9606.0,,51,Expert,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,CHEMBL616042,,9,1,308.0,BAO_0000219,,
1000,F,,9606.0,,51,Expert,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,CHEMBL616043,,9,1,308.0,BAO_0000219,,
1001,F,,,,51,Autocuration,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,CHEMBL616044,,8,1,,BAO_0000019,,
1002,F,,,,51,Autocuration,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,CHEMBL616045,,8,1,,BAO_0000019,,
1003,F,,,,51,Autocuration,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,CHEMBL616046,,8,1,722.0,BAO_0000219,,
1004,F,,,,51,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,CHEMBL616047,,8,1,449.0,BAO_0000219,,
1005,F,,,,51,Autocuration,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHEMBL616048,,8,1,449.0,BAO_0000219,,
1006,F,,9606.0,,51,Expert,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,CHEMBL616049,,9,1,449.0,BAO_0000219,,
1007,F,,,,51,Autocuration,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,CHEMBL616050,,8,1,449.0,BAO_0000219,,
1008,F,,,,51,Expert,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,CHEMBL616051,,8,1,,BAO_0000219,,
1009,F,,,,51,Autocuration,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,CHEMBL616212,,8,1,,BAO_0000219,,
1010,F,,,,51,Autocuration,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,CHEMBL616213,,8,1,,BAO_0000019,,
1011,B,In vitro,,,51,Expert,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,CHEMBL616214,,8,1,,BAO_0000219,,
1012,B,In vitro,,,51,Expert,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,CHEMBL616215,,8,1,,BAO_0000219,,
1013,B,,,,51,Autocuration,Binding activity radioligand.,,CHEMBL616216,,8,1,,BAO_0000357,,
1014,B,,,,51,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL616217,,8,1,,BAO_0000019,,
1015,B,,,,51,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,CHEMBL616218,,8,1,,BAO_0000357,,
1016,B,,,,51,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,CHEMBL616219,,8,1,,BAO_0000357,,
1017,B,,,,51,Autocuration,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,CHEMBL616220,,8,1,,BAO_0000357,,
1018,B,,9606.0,,51,Expert,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,CHEMBL833493,,9,1,,BAO_0000357,,
1019,B,,,,51,Autocuration,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,CHEMBL616221,,8,1,,BAO_0000357,,
1020,B,,9606.0,,51,Expert,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,CHEMBL616222,,9,1,449.0,BAO_0000219,,
1021,F,,,,51,Autocuration,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616223,,8,1,,BAO_0000019,,
1022,F,,,,51,Autocuration,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,CHEMBL616224,,8,1,,BAO_0000019,,
1023,B,,,,51,Expert,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,CHEMBL616225,,8,1,,BAO_0000019,,
1024,B,,9606.0,,51,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,CHEMBL616226,,9,1,722.0,BAO_0000219,,
1025,B,,,,51,Autocuration,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,CHEMBL616227,,8,1,722.0,BAO_0000219,,
1026,B,,,,51,Autocuration,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,CHEMBL616228,,8,1,722.0,BAO_0000219,,
1027,B,,,,51,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,CHEMBL616229,,8,1,722.0,BAO_0000219,,
1028,B,,,,51,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,CHEMBL616230,,8,1,722.0,BAO_0000219,,
1029,B,,,,51,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,CHEMBL616231,,8,1,722.0,BAO_0000219,,
1030,B,,,,51,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,CHEMBL616232,,8,1,,BAO_0000357,,
1031,B,,,,51,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,CHEMBL616233,,8,1,722.0,BAO_0000219,,
1032,B,,,,51,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,CHEMBL857973,,8,1,722.0,BAO_0000219,,
1033,B,,,,51,Autocuration,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,CHEMBL616234,,8,1,,BAO_0000219,,
1034,B,,,,51,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,CHEMBL616235,,8,1,,BAO_0000357,,
1035,B,,,,51,Expert,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,CHEMBL616236,,8,1,308.0,BAO_0000219,,
1036,B,,,,51,Expert,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,CHEMBL616237,,8,1,,BAO_0000019,,
1037,B,,,,51,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,CHEMBL616238,,8,1,722.0,BAO_0000219,,
1038,B,,,,51,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,CHEMBL616239,,8,1,722.0,BAO_0000219,,
1039,B,,,,51,Autocuration,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,CHEMBL616240,,8,1,,BAO_0000219,,
1040,B,,9606.0,,51,Expert,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,CHEMBL616241,,9,1,308.0,BAO_0000219,,
1041,B,,,,51,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,CHEMBL616242,,8,1,722.0,BAO_0000219,,
1042,B,,,,51,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,CHEMBL616243,,8,1,722.0,BAO_0000219,,
1043,B,,,,51,Expert,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616244,,9,1,,BAO_0000357,,
1044,B,,9606.0,,51,Autocuration,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,CHEMBL616245,,9,1,,BAO_0000357,,
1045,B,,,,106,Autocuration,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,CHEMBL616246,,8,1,,BAO_0000357,,
1046,B,,,,105,Autocuration,Binding affinity against 5-HT1D receptor,,CHEMBL616247,,8,1,,BAO_0000357,,
1047,B,,,,105,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616248,,8,1,,BAO_0000357,,
1048,B,,,,107,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,CHEMBL616249,,8,1,,BAO_0000357,,
1049,B,,9606.0,,10576,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,CHEMBL616250,,8,1,,BAO_0000357,,
1050,B,,,,51,Autocuration,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,CHEMBL616251,,8,1,,BAO_0000357,,
1051,F,In vivo,,,11863,Autocuration,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,CHEMBL616252,,8,1,,BAO_0000218,,
1052,F,In vivo,,,11863,Autocuration,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,CHEMBL616253,,8,1,,BAO_0000218,,
1053,F,In vivo,,,11863,Autocuration,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,CHEMBL616254,,8,1,,BAO_0000218,,
1054,F,,10090.0,,11863,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,CHEMBL616255,,9,1,,BAO_0000218,,
1055,F,,10090.0,,11863,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,CHEMBL832872,,9,1,,BAO_0000218,,
1056,F,,10090.0,,11863,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,CHEMBL616256,,9,1,,BAO_0000218,,
1057,F,,10090.0,,11863,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,CHEMBL616257,,9,1,,BAO_0000218,,
1058,F,,10090.0,,11863,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,CHEMBL616258,,9,1,,BAO_0000218,,
1059,F,,10090.0,,11863,Expert,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,CHEMBL616384,,9,1,,BAO_0000218,,
1060,B,,,,11863,Autocuration,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,CHEMBL616385,,8,1,,BAO_0000221,10000000.0,
1061,B,,,,11863,Expert,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,CHEMBL616386,,8,1,,BAO_0000357,,
1062,B,,10090.0,,11863,Expert,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,CHEMBL616387,,9,1,,BAO_0000221,10000000.0,
1063,B,,,,11863,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,CHEMBL616388,,8,1,,BAO_0000221,10000000.0,
1064,B,,10090.0,,11863,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,CHEMBL616389,,9,1,,BAO_0000221,10000000.0,
1065,B,,,,11863,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,CHEMBL616390,,8,1,,BAO_0000221,10000000.0,
1066,B,,,,11863,Autocuration,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,CHEMBL616391,,8,1,,BAO_0000357,,
1067,B,,10090.0,,11863,Expert,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,CHEMBL616392,,9,1,,BAO_0000221,10000000.0,
1068,B,,9823.0,,51,Autocuration,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,CHEMBL616393,,8,1,,BAO_0000357,,
1069,B,,9823.0,,51,Autocuration,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,CHEMBL616394,,8,1,,BAO_0000357,,
1070,B,,9823.0,,51,Autocuration,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,CHEMBL616395,,8,1,,BAO_0000019,,
1071,B,,9823.0,,51,Autocuration,Compound was evaluated for the binding affinity at 5- HT1A receptor,,CHEMBL616396,,8,1,,BAO_0000357,,
1072,B,,9823.0,,51,Autocuration,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,CHEMBL872907,,8,1,,BAO_0000019,,
1073,B,,9823.0,,51,Autocuration,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,CHEMBL616397,,8,1,,BAO_0000019,,
1074,B,,9823.0,,51,Autocuration,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,CHEMBL616398,,8,1,,BAO_0000019,,
1075,B,,9823.0,,51,Expert,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,CHEMBL616399,,8,1,,BAO_0000357,,
1076,B,,9823.0,,51,Autocuration,Binding activity radioligand.,,CHEMBL857065,,8,1,,BAO_0000357,,
1077,B,,9823.0,,51,Expert,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,CHEMBL616400,,8,1,,BAO_0000019,,
1078,B,,9823.0,,51,Autocuration,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,CHEMBL616401,,8,1,,BAO_0000019,,
1079,B,,,,10624,Expert,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,CHEMBL616402,,8,1,,BAO_0000019,,
1080,B,,9823.0,,51,Expert,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,CHEMBL616403,,8,1,,BAO_0000019,,
1081,B,,9823.0,,51,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,CHEMBL616404,,8,1,,BAO_0000221,10000000.0,
1082,B,,9823.0,,51,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,CHEMBL616405,,8,1,,BAO_0000249,,
1083,B,,9823.0,,51,Autocuration,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,CHEMBL616406,,8,1,,BAO_0000019,,
1084,F,,9823.0,,51,Expert,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,CHEMBL616407,,8,1,,BAO_0000019,,
1085,B,,9986.0,,51,Autocuration,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,CHEMBL616408,,8,1,,BAO_0000019,,
1086,B,,10116.0,,10576,Expert,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,CHEMBL616409,,9,1,,BAO_0000249,,
1087,B,,10116.0,,10576,Expert,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,CHEMBL616410,,9,1,,BAO_0000221,10000000.0,
1088,B,,,,10576,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,CHEMBL616411,,8,1,,BAO_0000357,,
1089,F,,10116.0,,10576,Expert,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,CHEMBL616412,,9,1,,BAO_0000249,,
1090,F,,10116.0,,10576,Expert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,CHEMBL616413,,9,1,,BAO_0000249,10000000.0,
1091,B,,,,10576,Autocuration,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL616414,,8,1,,BAO_0000221,10000000.0,
1092,B,,10116.0,,10576,Expert,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,CHEMBL616415,,9,1,,BAO_0000221,10000000.0,
1093,B,,,,10576,Autocuration,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,CHEMBL616416,,8,1,,BAO_0000019,,
1094,B,,,,10576,Expert,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,CHEMBL616417,,8,1,,BAO_0000357,,
1095,B,,,,10576,Autocuration,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,CHEMBL616418,,8,1,,BAO_0000357,,
1096,B,In vitro,,,10576,Autocuration,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,CHEMBL616419,,8,1,,BAO_0000219,,
1097,B,,,,10576,Autocuration,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,CHEMBL616420,,8,1,,BAO_0000357,,
1098,B,,,,10576,Autocuration,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,CHEMBL616421,,8,1,,BAO_0000249,,
1099,B,,,,10576,Autocuration,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,CHEMBL616422,,8,1,,BAO_0000249,,
1100,B,,,,10576,Expert,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,CHEMBL616423,,8,1,,BAO_0000249,,
1101,B,,10116.0,,10576,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,CHEMBL616424,,9,1,,BAO_0000357,,
1102,B,,,,10576,Expert,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,CHEMBL616425,,8,1,,BAO_0000357,,
1103,B,,,,10576,Expert,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,CHEMBL616426,,8,1,,BAO_0000357,,
1104,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,CHEMBL616427,,8,1,,BAO_0000221,10000000.0,
1105,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,CHEMBL616428,,8,1,,BAO_0000221,10000000.0,
1106,B,,,,10576,Autocuration,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616290,,8,1,,BAO_0000221,10000000.0,
1107,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,CHEMBL616052,,9,1,,BAO_0000357,,
1108,B,,,,10576,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,CHEMBL616053,,8,1,,BAO_0000357,,
1109,B,,,,10576,Autocuration,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,CHEMBL616054,,8,1,,BAO_0000249,,
1110,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616055,,8,1,,BAO_0000357,,
1111,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,CHEMBL616056,,8,1,,BAO_0000357,,
1112,B,,,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,CHEMBL616057,,8,1,,BAO_0000019,,
1113,B,,10116.0,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,CHEMBL616058,,9,1,,BAO_0000221,955.0,
1114,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,CHEMBL616059,,8,1,,BAO_0000221,955.0,
1115,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,CHEMBL616060,,8,1,,BAO_0000249,,
1116,B,,10116.0,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,CHEMBL616061,,9,1,,BAO_0000221,10000000.0,
1117,B,,,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,CHEMBL616062,,8,1,,BAO_0000221,10000000.0,
1118,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,CHEMBL616063,,8,1,,BAO_0000249,,
1119,B,,,,10576,Autocuration,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,CHEMBL616064,,8,1,,BAO_0000249,2435.0,
1120,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,CHEMBL616065,,9,1,,BAO_0000249,,
1121,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,CHEMBL616066,,9,1,,BAO_0000249,,
1122,B,,,,10576,Autocuration,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616067,,8,1,,BAO_0000221,10000000.0,
1123,B,,,,10576,Autocuration,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,CHEMBL616068,,8,1,,BAO_0000221,10000000.0,
1124,B,,,,10576,Intermediate,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616069,,8,1,,BAO_0000221,10000000.0,
1125,B,,,,10576,Expert,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,CHEMBL616070,,8,1,,BAO_0000249,,
1126,B,,,,10576,Autocuration,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616071,,8,1,,BAO_0000221,10000000.0,
1127,B,,,,10576,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,CHEMBL616072,,8,1,,BAO_0000221,10000000.0,
1128,B,,,,10576,Autocuration,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,CHEMBL616073,,8,1,,BAO_0000221,10000000.0,
1129,B,,,,10576,Autocuration,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,CHEMBL616074,,8,1,,BAO_0000221,10000000.0,
1130,B,,,,10576,Expert,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,CHEMBL616075,,8,1,,BAO_0000019,,
1131,B,,,,10576,Autocuration,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,CHEMBL616076,,8,1,,BAO_0000357,,
1132,B,,10116.0,,10576,Expert,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,CHEMBL616077,,9,1,,BAO_0000019,,
1133,B,,10116.0,,10576,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,CHEMBL616078,,9,1,,BAO_0000019,,
1134,B,,10116.0,,10576,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,CHEMBL616079,,9,1,,BAO_0000019,,
1135,B,,10116.0,,10576,Expert,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,CHEMBL616080,,9,1,485.0,BAO_0000219,,
1136,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616081,,8,1,,BAO_0000357,,
1137,B,,10116.0,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,CHEMBL616082,,9,1,,BAO_0000221,10000000.0,
1138,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,CHEMBL616083,,8,1,,BAO_0000221,10000000.0,
1139,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,CHEMBL616084,,8,1,,BAO_0000019,,
1140,B,,,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,CHEMBL616085,,8,1,,BAO_0000019,,
1141,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,CHEMBL616086,,8,1,,BAO_0000019,,
1142,B,,,,10576,Autocuration,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,CHEMBL616087,,8,1,,BAO_0000221,10000000.0,
1143,B,,,,10576,Expert,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,CHEMBL616088,,8,1,,BAO_0000357,,
1144,B,,,,10576,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,CHEMBL616089,,8,1,,BAO_0000019,,
1145,B,,10116.0,,10576,Expert,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,CHEMBL616090,,9,1,,BAO_0000357,,
1146,B,,,,10576,Autocuration,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,CHEMBL616091,,8,1,,BAO_0000357,,
1147,B,,,,10576,Autocuration,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,CHEMBL616092,,8,1,,BAO_0000249,2435.0,
1148,B,,,,10576,Autocuration,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,CHEMBL616093,,8,1,,BAO_0000357,,
1149,B,In vivo,,,10576,Autocuration,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,CHEMBL616094,,8,1,,BAO_0000218,,
1150,B,,,,10576,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,CHEMBL616095,,8,1,,BAO_0000221,955.0,
1151,B,,10116.0,,10576,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,CHEMBL616096,,9,1,,BAO_0000357,,
1152,B,,,,10576,Expert,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,CHEMBL616097,,8,1,,BAO_0000249,,
1153,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,CHEMBL616098,,9,1,,BAO_0000249,,
1154,B,,,,10576,Autocuration,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616099,,8,1,,BAO_0000221,10000000.0,
1155,B,,,,10576,Autocuration,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616100,,8,1,,BAO_0000221,10000000.0,
1156,B,,,,10576,Expert,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,CHEMBL616101,,8,1,,BAO_0000357,,
1157,B,,,,10576,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,CHEMBL616102,,8,1,,BAO_0000249,,
1158,B,,,,10576,Autocuration,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,CHEMBL616103,,8,1,,BAO_0000357,,
1159,B,,,,10576,Expert,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,CHEMBL616104,,8,1,,BAO_0000019,,
1160,B,,,,10576,Expert,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,CHEMBL616105,,8,1,,BAO_0000019,,
1161,B,,10116.0,,10576,Expert,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,CHEMBL616106,,9,1,,BAO_0000019,,
1162,B,,,,10576,Autocuration,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,CHEMBL616107,,8,1,,BAO_0000019,,
1163,B,,,,10576,Expert,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,CHEMBL616108,,8,1,,BAO_0000357,,
1164,B,,,,10576,Expert,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,CHEMBL616109,,8,1,,BAO_0000221,10000000.0,
1165,B,,,,10576,Autocuration,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,CHEMBL616110,,8,1,,BAO_0000357,,
1166,B,,,,10576,Expert,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,CHEMBL616111,,8,1,449.0,BAO_0000219,,
1167,B,,,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,CHEMBL616112,,8,1,,BAO_0000019,,
1168,B,,,,10576,Autocuration,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,CHEMBL616113,,8,1,,BAO_0000221,10000000.0,
1169,B,,,,10576,Autocuration,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,CHEMBL616114,,8,1,,BAO_0000019,,
1170,B,,,,10576,Autocuration,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,CHEMBL616115,,8,1,,BAO_0000019,,
1171,B,,,,10576,Autocuration,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL616116,,8,1,,BAO_0000357,,
1172,B,,,,10576,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,CHEMBL615844,,8,1,,BAO_0000221,955.0,
1173,B,,,,10576,Expert,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL615939,,8,1,,BAO_0000221,10000000.0,
1174,B,,,,10576,Expert,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,CHEMBL615940,,8,1,,BAO_0000019,,
1175,B,,,,10576,Expert,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,CHEMBL615941,,8,1,,BAO_0000221,10000000.0,
1176,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,CHEMBL615942,,8,1,,BAO_0000221,10000000.0,
1177,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,CHEMBL615943,,8,1,,BAO_0000221,10000000.0,
1178,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,CHEMBL615944,,8,1,,BAO_0000221,10000000.0,
1179,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,CHEMBL615945,,8,1,,BAO_0000221,10000000.0,
1180,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,CHEMBL615946,,8,1,,BAO_0000221,10000000.0,
1181,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,CHEMBL615947,,8,1,,BAO_0000221,10000000.0,
1182,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,CHEMBL615948,,8,1,,BAO_0000221,10000000.0,
1183,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,CHEMBL615949,,8,1,,BAO_0000221,10000000.0,
1184,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,CHEMBL615950,,8,1,,BAO_0000221,10000000.0,
1185,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,CHEMBL615951,,8,1,,BAO_0000221,10000000.0,
1186,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,CHEMBL615952,,8,1,,BAO_0000221,10000000.0,
1187,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,CHEMBL615953,,8,1,,BAO_0000221,10000000.0,
1188,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,CHEMBL615954,,8,1,,BAO_0000221,10000000.0,
1189,B,,10116.0,,10576,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,CHEMBL615955,,9,1,,BAO_0000221,10000000.0,
1190,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,CHEMBL615956,,8,1,,BAO_0000221,10000000.0,
1191,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,CHEMBL615957,,8,1,,BAO_0000221,10000000.0,
1192,B,,,,10576,Expert,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,CHEMBL615958,,8,1,,BAO_0000019,,
1193,B,,,,10576,Expert,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,CHEMBL615959,,8,1,,BAO_0000019,,
1194,B,,,,10576,Autocuration,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,CHEMBL615960,,8,1,,BAO_0000019,,
1195,B,,,,10576,Autocuration,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,CHEMBL615961,,8,1,,BAO_0000019,,
1196,B,,,,10576,Expert,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,CHEMBL615962,,8,1,,BAO_0000221,955.0,
1197,B,,,,10576,Expert,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,CHEMBL615963,,8,1,,BAO_0000019,,
1198,B,,,,10576,Autocuration,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,CHEMBL615964,,8,1,,BAO_0000019,,
1199,B,,,,10576,Autocuration,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,CHEMBL615965,,8,1,,BAO_0000019,,
1200,B,,,,10576,Expert,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,CHEMBL615966,,8,1,449.0,BAO_0000219,,
1201,B,,,,10576,Expert,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,CHEMBL615967,,8,1,,BAO_0000249,,
1202,B,,,,10576,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,CHEMBL615968,,8,1,,BAO_0000019,,
1203,B,,,,10576,Autocuration,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,CHEMBL615969,,8,1,449.0,BAO_0000218,,
1204,B,,,,10576,Autocuration,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,CHEMBL615970,,8,1,,BAO_0000218,,
1205,B,,10116.0,,10576,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,CHEMBL615971,,9,1,,BAO_0000357,,
1206,B,,,,10576,Expert,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,CHEMBL615972,,8,1,,BAO_0000249,,
1207,B,,,,10576,Autocuration,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,CHEMBL615973,,8,1,,BAO_0000249,,
1208,B,,,,10576,Autocuration,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,CHEMBL615974,,8,1,,BAO_0000249,,
1209,B,,9606.0,,51,Expert,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,CHEMBL615975,,9,1,449.0,BAO_0000219,,
1210,B,,,,10576,Expert,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,CHEMBL615976,,8,1,,BAO_0000249,,
1211,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,CHEMBL872106,,9,1,,BAO_0000221,10000000.0,
1212,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL615977,,8,1,,BAO_0000357,,
1213,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,CHEMBL615978,,8,1,,BAO_0000357,,
1214,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,CHEMBL616166,,8,1,,BAO_0000357,,
1215,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,CHEMBL616167,,8,1,,BAO_0000357,,
1216,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,CHEMBL616168,,8,1,,BAO_0000357,,
1217,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,CHEMBL616169,,8,1,,BAO_0000357,,
1218,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,CHEMBL616170,,8,1,,BAO_0000357,,
1219,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,CHEMBL616171,,8,1,,BAO_0000357,,
1220,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,CHEMBL616172,,8,1,,BAO_0000357,,
1221,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,CHEMBL616173,,8,1,,BAO_0000357,,
1222,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,CHEMBL616174,,8,1,,BAO_0000357,,
1223,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,CHEMBL616175,,8,1,,BAO_0000357,,
1224,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,CHEMBL616176,,8,1,,BAO_0000357,,
1225,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,CHEMBL616177,,8,1,,BAO_0000357,,
1226,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,CHEMBL616178,,8,1,,BAO_0000357,,
1227,B,,,,10576,Autocuration,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,CHEMBL616179,,8,1,,BAO_0000019,,
1228,B,,,,10576,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,CHEMBL616180,,8,1,,BAO_0000357,,
1229,B,,,,10576,Autocuration,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,CHEMBL616181,,8,1,,BAO_0000357,,
1230,B,,,,10576,Autocuration,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,CHEMBL616182,,8,1,,BAO_0000019,,
1231,B,,,,10576,Autocuration,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616183,,8,1,,BAO_0000221,10000000.0,
1232,B,,,,10576,Expert,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,CHEMBL615874,,8,1,,BAO_0000019,,
1233,B,,10116.0,,10576,Expert,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,CHEMBL615875,,9,1,485.0,BAO_0000219,,
1234,B,,,,10576,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,CHEMBL615876,,8,1,,BAO_0000019,,
1235,B,,,,10576,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,CHEMBL615877,,8,1,,BAO_0000019,,
1236,B,,,,10576,Autocuration,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,CHEMBL615878,,8,1,,BAO_0000357,,
1237,B,,,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,CHEMBL615879,,8,1,,BAO_0000357,,
1238,B,,,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,CHEMBL615880,,8,1,,BAO_0000357,,
1239,B,,,,10576,Autocuration,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,CHEMBL615881,,8,1,,BAO_0000019,,
1240,B,,10116.0,,10576,Expert,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,CHEMBL615882,,9,1,,BAO_0000019,,
1241,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,CHEMBL615883,,8,1,,BAO_0000218,,
1242,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,CHEMBL615884,,8,1,,BAO_0000218,,
1243,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,CHEMBL615885,,8,1,,BAO_0000218,,
1244,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,CHEMBL615886,,8,1,,BAO_0000218,,
1245,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,CHEMBL615887,,8,1,,BAO_0000218,,
1246,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,CHEMBL615888,,8,1,,BAO_0000218,,
1247,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,CHEMBL615889,,8,1,,BAO_0000218,,
1248,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,CHEMBL615890,,8,1,,BAO_0000218,,
1249,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,CHEMBL615891,,8,1,,BAO_0000218,,
1250,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,CHEMBL615892,,8,1,,BAO_0000218,,
1251,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,CHEMBL615893,,8,1,,BAO_0000218,,
1252,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,CHEMBL615894,,8,1,,BAO_0000218,,
1253,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,CHEMBL615895,,8,1,,BAO_0000218,,
1254,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,CHEMBL615896,,8,1,,BAO_0000218,,
1255,F,In vivo,,,10576,Autocuration,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,CHEMBL615897,,8,1,,BAO_0000218,,
1256,F,,10116.0,,10576,Expert,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,CHEMBL615898,,9,1,,BAO_0000249,,
1257,B,,,,10576,Autocuration,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,CHEMBL615899,,8,1,,BAO_0000019,,
1258,B,,,,10576,Autocuration,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,CHEMBL616291,,8,1,,BAO_0000019,,
1259,B,,,,10576,Autocuration,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,CHEMBL616292,,8,1,,BAO_0000357,,
1260,F,,,,10576,Autocuration,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,CHEMBL616293,,8,1,,BAO_0000249,,
1261,B,,,,10576,Expert,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616294,,8,1,,BAO_0000221,10000000.0,
1262,B,,,,10576,Autocuration,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,CHEMBL616295,,8,1,,BAO_0000249,10000000.0,
1263,B,,,,10576,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,CHEMBL616296,,8,1,,BAO_0000221,955.0,
1264,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,CHEMBL616297,,8,1,,BAO_0000019,,
1265,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,CHEMBL616605,,8,1,,BAO_0000019,,
1266,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,CHEMBL616606,,8,1,,BAO_0000019,,
1267,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,CHEMBL616607,,8,1,,BAO_0000019,,
1268,F,,,,10576,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,CHEMBL616608,,8,1,,BAO_0000019,,
1269,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,CHEMBL616609,,8,1,,BAO_0000019,,
1270,F,,10116.0,,10576,Expert,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,CHEMBL616610,,9,1,,BAO_0000019,,
1271,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,CHEMBL616611,,8,1,,BAO_0000019,,
1272,F,,,,10576,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,CHEMBL616612,,8,1,,BAO_0000019,,
1273,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,CHEMBL616613,,8,1,,BAO_0000019,,
1274,F,,,,10576,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,CHEMBL616614,,8,1,,BAO_0000019,,
1275,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,CHEMBL616615,,8,1,,BAO_0000019,,
1276,F,,,,10576,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,CHEMBL616616,,8,1,,BAO_0000019,,
1277,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,CHEMBL616617,,8,1,,BAO_0000019,,
1278,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,CHEMBL616618,,8,1,,BAO_0000019,,
1279,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,CHEMBL616619,,8,1,,BAO_0000019,,
1280,F,,,,10576,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,CHEMBL616620,,8,1,,BAO_0000019,,
1281,F,,,,10576,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,CHEMBL616621,,8,1,,BAO_0000019,,
1282,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,CHEMBL616622,,8,1,,BAO_0000019,,
1283,F,,,,10576,Expert,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,CHEMBL616146,,8,1,,BAO_0000019,,
1284,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,CHEMBL832873,,8,1,,BAO_0000019,,
1285,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,CHEMBL616147,,8,1,,BAO_0000019,,
1286,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,CHEMBL872872,,8,1,,BAO_0000019,,
1287,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,CHEMBL616148,,8,1,,BAO_0000019,,
1288,B,,,,10576,Autocuration,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,CHEMBL616149,,8,1,,BAO_0000221,10000000.0,
1289,B,,,,10576,Expert,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,CHEMBL616150,,8,1,,BAO_0000221,10000000.0,
1290,B,,10116.0,,10576,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,CHEMBL616151,,9,1,,BAO_0000249,,
1291,B,,,,10576,Expert,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,CHEMBL872873,,8,1,,BAO_0000221,10000000.0,
1292,B,,,,10576,Autocuration,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,CHEMBL616670,,8,1,,BAO_0000221,10000000.0,
1293,B,,,,10576,Autocuration,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,CHEMBL616671,,8,1,,BAO_0000221,10000000.0,
1294,F,,10116.0,,10576,Expert,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,CHEMBL884861,,9,1,,BAO_0000249,,
1295,B,,,,10576,Autocuration,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,CHEMBL616672,,8,1,,BAO_0000357,,
1296,B,,,,10576,Autocuration,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,CHEMBL616673,,8,1,,BAO_0000019,,
1297,F,,,,10576,Expert,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,CHEMBL616674,,8,1,,BAO_0000019,,
1298,B,,,,10576,Autocuration,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,CHEMBL616675,,8,1,,BAO_0000357,,
1299,B,,,,10576,Autocuration,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,CHEMBL616676,,8,1,,BAO_0000221,10000000.0,
1300,B,,,,10576,Autocuration,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL616677,,8,1,,BAO_0000221,10000000.0,
1301,B,,,,10576,Autocuration,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL616678,,8,1,,BAO_0000221,10000000.0,
1302,B,,10116.0,,10576,Expert,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,CHEMBL616679,,9,1,,BAO_0000357,,
1303,B,,,,10576,Expert,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,CHEMBL616680,,8,1,,BAO_0000221,10000000.0,
1304,B,,,,10576,Autocuration,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616681,,8,1,,BAO_0000221,10000000.0,
1305,B,,,,10576,Autocuration,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616682,,8,1,,BAO_0000221,10000000.0,
1306,B,,,,10576,Autocuration,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616683,,8,1,,BAO_0000221,10000000.0,
1307,B,,,,10576,Autocuration,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,CHEMBL616684,,8,1,,BAO_0000221,10000000.0,
1308,B,,,,10576,Autocuration,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,CHEMBL616685,,8,1,,BAO_0000221,10000000.0,
1309,B,,,,10576,Autocuration,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,CHEMBL616686,,8,1,,BAO_0000221,955.0,
1310,B,,,,10576,Autocuration,Affinity for 5-hydroxytryptamine 1A receptor site,,CHEMBL616687,,8,1,,BAO_0000357,,
1311,B,,,,10576,Autocuration,Affinity for 5-hydroxytryptamine 1A receptor site,,CHEMBL616688,,8,1,,BAO_0000357,,
1312,B,,,,10576,Autocuration,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,CHEMBL616689,,8,1,,BAO_0000221,10000000.0,
1313,B,,,,10576,Autocuration,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,CHEMBL616690,,8,1,,BAO_0000357,,
1314,B,,,,10576,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,CHEMBL616691,,8,1,,BAO_0000357,,
1315,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,CHEMBL616692,,9,1,,BAO_0000221,10000000.0,
1316,B,,,,10576,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,CHEMBL616693,,8,1,,BAO_0000249,,
1317,B,,10116.0,,10576,Expert,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,CHEMBL616694,,9,1,,BAO_0000019,,
1318,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,CHEMBL616695,,8,1,,BAO_0000221,10000000.0,
1319,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,CHEMBL616696,,8,1,,BAO_0000357,,
1320,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,CHEMBL616697,,8,1,,BAO_0000357,,
1321,B,,,,10576,Autocuration,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,CHEMBL616698,,8,1,,BAO_0000357,,
1322,B,,10116.0,,10576,Expert,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,CHEMBL616949,,9,1,,BAO_0000019,,
1323,B,,,,10576,Autocuration,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,CHEMBL616950,,8,1,,BAO_0000221,10000000.0,
1324,B,,,,10576,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,CHEMBL832875,,8,1,,BAO_0000357,,
1325,B,,,,10576,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,CHEMBL616951,,8,1,,BAO_0000221,955.0,
1326,B,,,,10576,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,CHEMBL616952,,8,1,,BAO_0000221,955.0,
1327,B,,,,10576,Expert,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,CHEMBL616953,,8,1,,BAO_0000357,,
1328,B,,,,10576,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,CHEMBL616954,,8,1,,BAO_0000357,,
1329,B,,,,106,Autocuration,GTPgammaS radioligand binding assay,,CHEMBL616955,,8,1,,BAO_0000357,,
1330,B,,,,106,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,CHEMBL616956,,8,1,,BAO_0000357,,
1331,F,,,,106,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,CHEMBL616957,,8,1,,BAO_0000019,,
1332,F,,,,106,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,CHEMBL616958,,8,1,,BAO_0000019,,
1333,B,,,,106,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,CHEMBL616959,,8,1,,BAO_0000357,,
1334,B,,,,106,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,CHEMBL616960,,8,1,,BAO_0000357,,
1335,F,,,,106,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,CHEMBL616961,,8,1,,BAO_0000019,,
1336,B,,,,106,Expert,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,CHEMBL616962,,8,1,308.0,BAO_0000219,,
1337,B,,,,106,Autocuration,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,CHEMBL616963,,8,1,308.0,BAO_0000219,,
1338,B,,9606.0,,106,Expert,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,CHEMBL616524,,9,1,,BAO_0000357,,
1339,B,,,,106,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616525,,8,1,449.0,BAO_0000219,,
1340,B,,,,106,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,CHEMBL872908,,8,1,,BAO_0000019,,
1341,B,,,,106,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,CHEMBL616526,,8,1,,BAO_0000019,,
1342,B,,9606.0,,106,Expert,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616527,,9,1,,BAO_0000357,,
1343,B,,,,106,Expert,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,CHEMBL616528,,8,1,,BAO_0000219,,
1344,B,,,,106,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,CHEMBL616529,,8,1,,BAO_0000357,,
1345,B,,,,106,Autocuration,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,CHEMBL616530,,8,1,,BAO_0000357,,
1346,B,,,,106,Expert,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616531,,8,1,,BAO_0000357,,
1347,B,,,,106,Autocuration,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616532,,8,1,,BAO_0000357,,
1348,B,,,,106,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor,,CHEMBL616533,,8,1,,BAO_0000357,,
1349,B,,,,106,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616534,,8,1,,BAO_0000357,,
1350,B,,,,106,Expert,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,CHEMBL616535,,8,1,,BAO_0000357,,
1351,B,,,,106,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,CHEMBL616536,,8,1,,BAO_0000357,,
1352,B,,,,106,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,CHEMBL616537,,8,1,,BAO_0000357,,
1353,F,,,,106,Expert,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,CHEMBL616538,,8,1,485.0,BAO_0000219,,
1354,F,,,,106,Expert,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,CHEMBL616539,,8,1,,BAO_0000019,,
1355,B,,,,106,Expert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,CHEMBL616540,,8,1,,BAO_0000019,,
1356,B,,,,106,Autocuration,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,CHEMBL616429,,8,1,,BAO_0000357,,
1357,B,,,,106,Expert,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616430,,8,1,,BAO_0000357,,
1358,B,,9606.0,,106,Expert,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,CHEMBL616431,,9,1,,BAO_0000219,,
1359,B,,9606.0,,106,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,CHEMBL616432,,9,1,,BAO_0000357,,
1360,B,,9606.0,,106,Expert,Affinity for 5-hydroxytryptamine 1B receptor subtype,,CHEMBL616433,,9,1,,BAO_0000357,,
1361,B,,9606.0,,106,Expert,Binding affinity for human 5-hydroxytryptamine 1B receptor,,CHEMBL616434,,9,1,,BAO_0000357,,
1362,B,,,,106,Autocuration,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,CHEMBL616435,,8,1,449.0,BAO_0000219,,
1363,B,,,,106,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,CHEMBL616436,,8,1,,BAO_0000019,,
1364,B,,,,106,Autocuration,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,CHEMBL616437,,8,1,308.0,BAO_0000219,,
1365,B,,,,106,Autocuration,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,CHEMBL616438,,8,1,308.0,BAO_0000219,,
1366,B,,,,106,Autocuration,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,CHEMBL616439,,8,1,308.0,BAO_0000219,,
1367,B,,9606.0,,106,Expert,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,CHEMBL616440,,9,1,,BAO_0000357,,
1368,B,,,,106,Autocuration,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,CHEMBL616441,,8,1,485.0,BAO_0000219,,
1369,B,,,,106,Expert,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,CHEMBL616442,,8,1,,BAO_0000357,,
1370,B,,,,106,Autocuration,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,CHEMBL616443,,8,1,,BAO_0000357,,
1371,B,,,,106,Expert,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,CHEMBL616444,,8,1,485.0,BAO_0000219,,
1372,B,,9606.0,,106,Expert,Binding activity against human 5-hydroxytryptamine 1B receptor,,CHEMBL616445,,9,1,,BAO_0000357,,
1373,B,,9606.0,,106,Expert,Binding activity against human 5-hydroxytryptamine 1B receptor,,CHEMBL616446,,9,1,,BAO_0000357,,
1374,B,,9606.0,,106,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616447,,9,1,449.0,BAO_0000219,,
1375,B,,,,106,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,CHEMBL616448,,8,1,,BAO_0000357,,
1376,B,,,,106,Autocuration,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,CHEMBL616449,,8,1,449.0,BAO_0000219,,
1377,B,,,,106,Autocuration,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,CHEMBL616450,,8,1,449.0,BAO_0000219,,
1378,B,,,,106,Autocuration,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,CHEMBL857974,,8,1,449.0,BAO_0000219,,
1379,B,,,,106,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHEMBL616451,,8,1,449.0,BAO_0000219,,
1380,B,,,,106,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHEMBL616452,,8,1,449.0,BAO_0000219,,
1381,B,,,,106,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,CHEMBL616453,,8,1,449.0,BAO_0000219,,
1382,B,,,,106,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,CHEMBL616454,,8,1,449.0,BAO_0000219,,
1383,B,,9606.0,,106,Expert,Binding affinity for human 5-hydroxytryptamine 1B receptor,,CHEMBL616455,,9,1,,BAO_0000357,,
1384,B,,,,106,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,CHEMBL616456,,8,1,449.0,BAO_0000219,,
1385,B,,,,106,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL616457,,8,1,,BAO_0000357,,
1386,B,,,,106,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,CHEMBL616458,,8,1,449.0,BAO_0000219,,
1387,B,,,,106,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL616459,,8,1,449.0,BAO_0000219,,
1388,F,,,,106,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,CHEMBL616460,,8,1,,BAO_0000019,,
1389,F,,,,106,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,CHEMBL616461,,8,1,,BAO_0000019,,
1390,F,,,,106,Autocuration,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,CHEMBL616462,,8,1,449.0,BAO_0000219,,
1391,F,,,,106,Autocuration,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,CHEMBL616463,,8,1,449.0,BAO_0000219,,
1392,F,,,,105,Autocuration,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,CHEMBL616464,,8,1,,BAO_0000019,,
1393,B,,,,105,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,CHEMBL616465,,8,1,449.0,BAO_0000219,,
1394,B,,,,17105,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL832874,,8,1,,BAO_0000357,,
1395,F,,9986.0,,106,Autocuration,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,CHEMBL616184,,8,1,,BAO_0000019,,
1396,B,,9986.0,,106,Autocuration,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,CHEMBL616185,,8,1,,BAO_0000019,,
1397,B,,9986.0,,106,Intermediate,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,CHEMBL616186,,8,1,,BAO_0000019,,
1398,B,,9986.0,,106,Autocuration,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,CHEMBL616187,,8,1,,BAO_0000019,,
1399,B,,,,10577,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,CHEMBL616188,,8,1,,BAO_0000357,,
1400,B,,,,10577,Intermediate,Binding affinity for 5-hydroxytryptamine 1B receptor,,CHEMBL873475,,9,1,,BAO_0000357,,
1401,B,,10116.0,,10577,Expert,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,CHEMBL616189,,9,1,,BAO_0000019,2435.0,
1402,B,,,,10577,Expert,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,CHEMBL616190,,8,1,,BAO_0000357,,
1403,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,CHEMBL616191,,8,1,,BAO_0000357,,
1404,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,CHEMBL616192,,8,1,,BAO_0000357,,
1405,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,CHEMBL616193,,8,1,,BAO_0000357,,
1406,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,CHEMBL616194,,8,1,,BAO_0000357,,
1407,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,CHEMBL616195,,8,1,,BAO_0000357,,
1408,B,,,,10576,Autocuration,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,CHEMBL616196,,8,1,,BAO_0000357,,
1409,B,,,,10576,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,CHEMBL616197,,8,1,,BAO_0000249,10000000.0,
1410,B,,,,10576,Intermediate,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,CHEMBL616198,,8,1,,BAO_0000019,,
1411,B,,,,10576,Autocuration,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,CHEMBL616199,,8,1,,BAO_0000221,10000000.0,
1412,B,,,,10576,Expert,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,CHEMBL616200,,8,1,,BAO_0000221,10000000.0,
1413,B,,,,10576,Expert,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616201,,8,1,,BAO_0000221,10000000.0,
1414,B,,,,10576,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,CHEMBL616202,,8,1,,BAO_0000221,10000000.0,
1415,B,,,,10576,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,CHEMBL616203,,8,1,,BAO_0000221,10000000.0,
1416,B,,,,10576,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,CHEMBL616204,,8,1,,BAO_0000221,10000000.0,
1417,B,,,,10576,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,CHEMBL616205,,8,1,,BAO_0000221,10000000.0,
1418,B,,,,10576,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,CHEMBL616206,,8,1,,BAO_0000221,10000000.0,
1419,B,,,,10576,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,CHEMBL616207,,8,1,,BAO_0000249,,
1420,B,,,,10576,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,CHEMBL616208,,8,1,,BAO_0000249,,
1421,B,,,,10576,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,CHEMBL616209,,8,1,,BAO_0000249,,
1422,B,,,,10576,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,CHEMBL616210,,8,1,,BAO_0000357,,
1423,B,,,,10576,Expert,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,CHEMBL616211,,8,1,,BAO_0000221,10000000.0,
1424,B,,,,10576,Autocuration,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,CHEMBL616504,,8,1,,BAO_0000221,10000000.0,
1425,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616505,,9,1,,BAO_0000221,10000000.0,
1426,F,,,,10576,Autocuration,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,CHEMBL616506,,8,1,,BAO_0000019,,
1427,B,,,,10576,Autocuration,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,CHEMBL872107,,8,1,,BAO_0000221,10000000.0,
1428,B,,10116.0,,10576,Expert,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,CHEMBL616507,,9,1,,BAO_0000221,10000000.0,
1429,B,,,,10576,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,CHEMBL616303,,8,1,,BAO_0000249,,
1430,B,,,,10576,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,CHEMBL616304,,8,1,,BAO_0000221,10000000.0,
1431,B,,,,10576,Expert,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,CHEMBL616305,,8,1,,BAO_0000221,10000000.0,
1432,F,,,,10576,Intermediate,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,CHEMBL616306,,8,1,,BAO_0000221,10000000.0,
1433,B,,,,10576,Autocuration,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,CHEMBL616307,,8,1,,BAO_0000357,,
1434,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,CHEMBL881829,,9,1,,BAO_0000221,10000000.0,
1435,B,,,,10576,Expert,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,CHEMBL616308,,8,1,,BAO_0000357,,
1436,B,,,,10576,Autocuration,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,CHEMBL616309,,8,1,,BAO_0000019,,
1437,B,,,,10576,Expert,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,CHEMBL616310,,8,1,,BAO_0000019,,
1438,B,,,,10576,Autocuration,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,CHEMBL616311,,8,1,449.0,BAO_0000219,,
1439,B,,,,10576,Expert,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,CHEMBL616312,,8,1,,BAO_0000357,,
1440,B,,,,10576,Autocuration,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,CHEMBL616313,,8,1,,BAO_0000357,,
1441,B,,10116.0,,10576,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,CHEMBL616314,,9,1,,BAO_0000221,10000000.0,
1442,B,,,,10576,Autocuration,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616315,,8,1,,BAO_0000221,10000000.0,
1443,B,,,,10576,Autocuration,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,CHEMBL616567,,8,1,,BAO_0000221,10000000.0,
1444,B,,,,10576,Autocuration,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,CHEMBL616568,,8,1,,BAO_0000221,10000000.0,
1445,B,,,,10576,Intermediate,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,CHEMBL616569,,8,1,,BAO_0000019,,
1446,B,,,,10576,Expert,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,CHEMBL616570,,8,1,,BAO_0000357,,
1447,B,,,,10576,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,CHEMBL616571,,8,1,,BAO_0000357,,
1448,B,,,,10576,Autocuration,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,CHEMBL616572,,8,1,,BAO_0000221,10000000.0,
1449,B,,,,10576,Expert,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,CHEMBL616573,,8,1,,BAO_0000249,,
1450,B,,10116.0,,10576,Expert,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,CHEMBL616574,,9,1,,BAO_0000357,,
1451,B,,,,10576,Expert,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,CHEMBL616575,,8,1,,BAO_0000221,10000000.0,
1452,B,,,,10576,Autocuration,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,CHEMBL872108,,8,1,,BAO_0000221,10000000.0,
1453,B,,,,10576,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,CHEMBL616576,,8,1,,BAO_0000357,,
1454,B,,,,10576,Autocuration,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,CHEMBL616577,,8,1,,BAO_0000249,,
1455,B,,,,10576,Autocuration,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,CHEMBL616578,,8,1,,BAO_0000249,,
1456,B,,,,10576,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,CHEMBL616579,,8,1,,BAO_0000357,,
1457,B,,10116.0,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,CHEMBL616580,,9,1,,BAO_0000019,,
1458,B,,,,10576,Autocuration,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,CHEMBL616581,,8,1,,BAO_0000019,,
1459,B,,,,10576,Autocuration,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616582,,8,1,,BAO_0000221,10000000.0,
1460,B,,,,10576,Expert,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,CHEMBL616583,,8,1,,BAO_0000221,10000000.0,
1461,B,,10116.0,,10576,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,CHEMBL616584,,9,1,,BAO_0000221,10000000.0,
1462,B,,,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616585,,8,1,,BAO_0000357,,
1463,B,,10116.0,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,CHEMBL616586,,9,1,,BAO_0000221,10000000.0,
1464,B,,,,10576,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,CHEMBL616587,,8,1,,BAO_0000221,10000000.0,
1465,B,,,,10576,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,CHEMBL616588,,8,1,,BAO_0000221,10000000.0,
1466,B,,,,10576,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,CHEMBL616589,,8,1,,BAO_0000221,10000000.0,
1467,B,,,,10576,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,CHEMBL616590,,8,1,,BAO_0000221,10000000.0,
1468,B,,,,10576,Expert,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,CHEMBL616591,,8,1,449.0,BAO_0000219,,
1469,B,,,,10576,Expert,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,CHEMBL616592,,8,1,,BAO_0000357,,
1470,B,,,,10576,Autocuration,The inhibition activity of 5-HT1A at 1 uM,,CHEMBL616593,,8,1,,BAO_0000357,,
1471,B,,,,10576,Expert,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,CHEMBL616594,,8,1,485.0,BAO_0000219,,
1472,B,,,,10576,Expert,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,CHEMBL616595,,8,1,,BAO_0000249,,
1473,B,,,,10576,Autocuration,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,CHEMBL616596,,8,1,,BAO_0000357,,
1474,B,,,,10576,Autocuration,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,CHEMBL616597,,8,1,,BAO_0000221,10000000.0,
1475,B,,,,10576,Expert,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,CHEMBL616598,,8,1,,BAO_0000221,10000000.0,
1476,F,,10116.0,,10576,Expert,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,CHEMBL616599,,9,1,,BAO_0000249,,
1477,F,,10116.0,,10576,Expert,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,CHEMBL616600,,9,1,,BAO_0000249,10000000.0,
1478,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,CHEMBL616601,,8,1,,BAO_0000019,,
1479,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,CHEMBL616602,,8,1,,BAO_0000019,,
1480,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,CHEMBL616603,,8,1,,BAO_0000019,,
1481,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,CHEMBL616604,,8,1,,BAO_0000019,,
1482,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,CHEMBL616316,,8,1,,BAO_0000249,,
1483,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,CHEMBL616317,,8,1,,BAO_0000249,,
1484,B,,10116.0,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,CHEMBL616318,,9,1,,BAO_0000019,,
1485,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,CHEMBL616319,,8,1,,BAO_0000221,10000000.0,
1486,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,CHEMBL616320,,8,1,,BAO_0000221,10000000.0,
1487,B,,10116.0,,10576,Expert,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,CHEMBL616321,,9,1,,BAO_0000221,10000000.0,
1488,F,,,,10576,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,CHEMBL616322,,8,1,,BAO_0000019,,
1489,F,,,,10576,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,CHEMBL616323,,8,1,,BAO_0000019,,
1490,B,,,,10576,Autocuration,Ratio of binding affinity to 5-HT 1A and D2 receptor,,CHEMBL616324,,8,1,,BAO_0000357,,
1491,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,CHEMBL616325,,8,1,,BAO_0000221,10000000.0,
1492,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,CHEMBL616326,,8,1,,BAO_0000221,10000000.0,
1493,B,,,,10576,Autocuration,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,CHEMBL616327,,8,1,,BAO_0000221,10000000.0,
1494,B,,,,10576,Autocuration,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,CHEMBL616328,,8,1,,BAO_0000357,,
1495,B,,,,10576,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,CHEMBL858110,,8,1,,BAO_0000249,,
1496,F,,,,10576,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,CHEMBL616329,,8,1,,BAO_0000249,,
1497,B,,,,10576,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,CHEMBL616330,,8,1,,BAO_0000249,,
1498,F,,,,10576,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,CHEMBL616331,,8,1,,BAO_0000249,,
1499,F,,,,10576,Autocuration,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,CHEMBL616332,,8,1,,BAO_0000249,,
1500,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL857063,,8,1,,BAO_0000249,955.0,
1501,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,CHEMBL616333,,8,1,,BAO_0000019,,
1502,F,,,,10576,Expert,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,CHEMBL616334,,8,1,,BAO_0000019,,
1503,B,,,,10576,Autocuration,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,CHEMBL616335,,8,1,,BAO_0000221,10000000.0,
1504,B,,,,10576,Autocuration,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,CHEMBL616336,,8,1,,BAO_0000019,,
1505,B,,,,10576,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,CHEMBL616337,,8,1,,BAO_0000249,,
1506,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,CHEMBL616338,,8,1,,BAO_0000019,,
1507,B,,,,10576,Autocuration,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,CHEMBL616339,,8,1,,BAO_0000221,10000000.0,
1508,B,,,,10576,Autocuration,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,CHEMBL616340,,8,1,,BAO_0000221,10000000.0,
1509,B,,,,10576,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616341,,8,1,,BAO_0000357,,
1510,B,,10116.0,,10576,Expert,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,CHEMBL616342,,9,1,,BAO_0000357,,
1511,B,,10116.0,,10576,Expert,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,CHEMBL616343,,9,1,,BAO_0000019,,
1512,B,,,,10576,Expert,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,CHEMBL616344,,8,1,,BAO_0000019,,
1513,B,,,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,CHEMBL616345,,8,1,,BAO_0000357,,
1514,B,,,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,CHEMBL616346,,8,1,,BAO_0000019,,
1515,B,,,,10576,Autocuration,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,CHEMBL616347,,8,1,,BAO_0000221,10000000.0,
1516,B,,,,10576,Expert,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,CHEMBL616348,,8,1,,BAO_0000019,,
1517,B,,,,10576,Expert,Binding affinity at 5-hydroxytryptamine 1A receptor,,CHEMBL616349,,8,1,,BAO_0000357,,
1518,B,,10116.0,,10576,Expert,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,CHEMBL616152,,9,1,,BAO_0000249,,
1519,B,,,,10576,Autocuration,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,CHEMBL616153,,8,1,,BAO_0000249,,
1520,B,,,,10576,Expert,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,CHEMBL616154,,8,1,,BAO_0000019,,
1521,B,,,,10576,Autocuration,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,CHEMBL616155,,8,1,,BAO_0000019,,
1522,B,,10116.0,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,CHEMBL616156,,9,1,,BAO_0000221,10000000.0,
1523,B,,10116.0,,10576,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,CHEMBL616157,,9,1,,BAO_0000221,10000000.0,
1524,B,,,,10576,Autocuration,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,CHEMBL616158,,8,1,,BAO_0000221,10000000.0,
1525,B,,,,10576,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,CHEMBL616159,,8,1,,BAO_0000357,,
1526,B,,,,10576,Expert,pKi value against rat 5-hydroxytryptamine 1A receptor.,,CHEMBL616160,,8,1,,BAO_0000357,,
1527,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,CHEMBL616161,,8,1,,BAO_0000019,,
1528,F,,,,10576,Autocuration,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,CHEMBL616162,,8,1,,BAO_0000019,,
1529,B,,10116.0,,12687,Expert,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,CHEMBL616163,,9,1,,BAO_0000357,,
1530,B,,,,10626,Expert,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,CHEMBL616164,,8,1,,BAO_0000249,,
1531,B,,,,10576,Autocuration,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,CHEMBL616165,,8,1,,BAO_0000221,955.0,
1532,B,,10116.0,,51,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,CHEMBL616355,,8,1,,BAO_0000019,,
1533,F,,,,10576,Autocuration,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,CHEMBL616356,,8,1,,BAO_0000019,,
1534,B,,,,10576,Autocuration,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,CHEMBL616357,,8,1,,BAO_0000221,955.0,
1535,B,,,,10576,Autocuration,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,CHEMBL616358,,8,1,,BAO_0000019,,
1536,B,,,,51,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616359,,8,1,,BAO_0000357,,
1537,B,,,,51,Expert,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,CHEMBL616360,,8,1,,BAO_0000357,,
1538,B,,,,51,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL616361,,8,1,,BAO_0000357,,
1539,B,,,,51,Autocuration,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL616362,,8,1,,BAO_0000357,,
1540,B,,,,51,Autocuration,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,CHEMBL616363,,8,1,,BAO_0000249,,
1541,B,,,,51,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,CHEMBL616364,,8,1,,BAO_0000357,,
1542,B,,,,51,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,CHEMBL616365,,8,1,,BAO_0000357,,
1543,B,,,,51,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616366,,8,1,,BAO_0000357,,
1544,B,,,,51,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor,,CHEMBL872906,,8,1,,BAO_0000357,,
1545,B,,,,51,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,CHEMBL616367,,8,1,,BAO_0000357,,
1546,B,,,,51,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616368,,8,1,,BAO_0000357,,
1547,B,,,,51,Autocuration,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616369,,8,1,,BAO_0000357,,
1548,B,,9606.0,,51,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,CHEMBL616370,,9,1,,BAO_0000357,,
1549,B,,9606.0,,51,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,CHEMBL616371,,9,1,,BAO_0000357,,
1550,B,,,,51,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL616372,,8,1,449.0,BAO_0000219,,
1551,B,,,,51,Expert,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,CHEMBL616373,,8,1,,BAO_0000219,,
1552,B,In vivo,,,51,Autocuration,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,CHEMBL616374,,8,1,,BAO_0000218,,
1553,B,,,,51,Autocuration,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,CHEMBL616375,,8,1,,BAO_0000221,10000000.0,
1554,B,,,,51,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616376,,8,1,,BAO_0000357,,
1555,B,,,,51,Expert,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,CHEMBL857064,,8,1,,BAO_0000357,,
1556,B,,,,51,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616377,,8,1,,BAO_0000357,,
1557,B,,,,51,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,CHEMBL616378,,8,1,,BAO_0000357,,
1558,B,,,,51,Autocuration,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,CHEMBL616379,,8,1,,BAO_0000357,,
1559,B,,,,11863,Autocuration,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,CHEMBL616380,,8,1,,BAO_0000357,,
1560,B,,,,11863,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,CHEMBL616381,,8,1,,BAO_0000357,,
1561,B,,,,11863,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,CHEMBL616382,,8,1,,BAO_0000357,,
1562,B,,,,11863,Autocuration,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,CHEMBL616383,,8,1,,BAO_0000357,,
1563,B,,10090.0,,11863,Expert,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,CHEMBL616350,,9,1,449.0,BAO_0000219,,
1564,B,,,,11863,Autocuration,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,CHEMBL616351,,8,1,,BAO_0000357,,
1565,B,,,,11863,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,CHEMBL616352,,8,1,,BAO_0000357,,
1566,B,,,,11863,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616353,,8,1,,BAO_0000357,,
1567,B,,,,11863,Autocuration,Binding affinity against serotonergic 5-HT1a receptor,,CHEMBL616354,,8,1,,BAO_0000357,,
1568,B,,,,11863,Autocuration,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,CHEMBL616508,,8,1,,BAO_0000357,,
1569,B,,10090.0,,11863,Expert,Binding affinity for 5-hydroxytryptamine 1A receptor,,CHEMBL616559,,9,1,,BAO_0000357,,
1570,B,,,,11863,Autocuration,Binding affinity at 5-hydroxytryptamine 1A receptor,,CHEMBL616560,,8,1,,BAO_0000357,,
1571,B,,,,11863,Autocuration,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,CHEMBL616561,,8,1,,BAO_0000357,,
1572,B,,,,11863,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL616562,,8,1,449.0,BAO_0000219,,
1573,B,,,,11863,Autocuration,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,CHEMBL616563,,8,1,449.0,BAO_0000219,,
1574,B,,,,11863,Autocuration,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,CHEMBL616564,,8,1,,BAO_0000357,,
1575,B,,,,11863,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,CHEMBL616565,,8,1,,BAO_0000357,,
1576,B,,,,11863,Autocuration,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,CHEMBL616566,,8,1,,BAO_0000218,,
1577,B,,,,11863,Autocuration,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,CHEMBL616989,,8,1,,BAO_0000357,,
1578,B,,,,11863,Autocuration,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,CHEMBL857975,,8,1,,BAO_0000357,,
1579,B,,10090.0,,11863,Expert,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616990,,9,1,,BAO_0000357,,
1580,B,,,,11863,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,CHEMBL616991,,8,1,,BAO_0000357,,
1581,B,,,,11863,Autocuration,Tested against 5-hydroxytryptamine 1A receptor,,CHEMBL616992,,8,1,,BAO_0000357,,
1582,B,,,,11863,Autocuration,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL616993,,8,1,,BAO_0000357,,
1583,B,,9986.0,,106,Expert,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,CHEMBL616994,,8,1,,BAO_0000019,,
1584,B,,9986.0,,106,Autocuration,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,CHEMBL616995,,8,1,,BAO_0000019,,
1585,B,,9593.0,,105571,Intermediate,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,CHEMBL616996,,9,1,722.0,BAO_0000219,,
1586,F,In vivo,10141.0,,106,Autocuration,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,CHEMBL616997,,8,1,,BAO_0000218,,
1587,F,In vivo,10141.0,,106,Autocuration,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,CHEMBL616998,,8,1,,BAO_0000218,,
1588,F,,10141.0,,106,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,CHEMBL616999,,8,1,,BAO_0000019,,
1589,F,,10141.0,,106,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,CHEMBL617000,,8,1,,BAO_0000019,,
1590,F,,10141.0,,106,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,CHEMBL617001,,8,1,,BAO_0000019,,
1591,F,,10141.0,,106,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,CHEMBL858111,,8,1,,BAO_0000019,,
1592,F,,,,106,Autocuration,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,CHEMBL617002,,8,1,,BAO_0000019,,
1593,F,,,,106,Autocuration,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,CHEMBL617003,,8,1,,BAO_0000019,,
1594,F,,,,106,Autocuration,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,CHEMBL617004,,8,1,,BAO_0000019,,
1595,F,,9606.0,,106,Expert,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,CHEMBL617005,,9,1,,BAO_0000019,,
1596,F,,9606.0,,106,Expert,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,CHEMBL616623,,9,1,485.0,BAO_0000219,,
1597,F,,,,106,Autocuration,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,CHEMBL616624,,8,1,449.0,BAO_0000219,,
1598,B,,,,106,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,CHEMBL883243,,8,1,,BAO_0000357,,
1599,F,,,,106,Autocuration,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,CHEMBL616625,,8,1,,BAO_0000019,,
1600,F,,,,106,Expert,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,CHEMBL616626,,8,1,449.0,BAO_0000219,,
1601,F,,,,106,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,CHEMBL616627,,8,1,449.0,BAO_0000219,,
1602,F,,,,106,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,CHEMBL616628,,8,1,449.0,BAO_0000219,,
1603,F,,,,106,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,CHEMBL616629,,8,1,449.0,BAO_0000219,,
1604,F,,,,106,Autocuration,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,CHEMBL616630,,8,1,449.0,BAO_0000219,,
1605,F,,,,106,Expert,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,CHEMBL616631,,8,1,,BAO_0000019,,
1606,F,,,,106,Autocuration,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,CHEMBL616632,,8,1,,BAO_0000019,,
1607,B,,9606.0,,106,Expert,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,CHEMBL616633,,9,1,,BAO_0000357,,
1608,B,,,,106,Expert,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,CHEMBL616634,,8,1,449.0,BAO_0000219,,
1609,B,,,,106,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,CHEMBL616635,,8,1,,BAO_0000357,,
1610,B,,9606.0,,106,Expert,Binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL885358,,9,1,,BAO_0000357,,
1611,B,,9606.0,,106,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,CHEMBL616636,,9,1,449.0,BAO_0000219,,
1612,B,,,,106,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,CHEMBL616637,,8,1,449.0,BAO_0000219,,
1613,B,,,,106,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,CHEMBL616638,,8,1,,BAO_0000357,,
1614,B,,,,106,Expert,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,CHEMBL616639,,8,1,449.0,BAO_0000219,,
1615,B,,,,106,Expert,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,CHEMBL616640,,8,1,449.0,BAO_0000219,,
1616,B,,,,106,Expert,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,CHEMBL616641,,8,1,449.0,BAO_0000219,,
1617,B,,,,106,Expert,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,CHEMBL616642,,8,1,449.0,BAO_0000219,,
1618,B,,,,106,Expert,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,CHEMBL616643,,8,1,449.0,BAO_0000219,,
1619,B,,,,106,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,CHEMBL616644,,8,1,,BAO_0000357,,
1620,B,,,,106,Autocuration,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,CHEMBL616645,,8,1,,BAO_0000357,,
1621,F,,9986.0,,105,Autocuration,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,CHEMBL616646,,8,1,,BAO_0000019,,
1622,F,,9986.0,,105,Expert,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,CHEMBL616647,,8,1,,BAO_0000019,,
1623,B,,,,105,Autocuration,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,CHEMBL616509,,8,1,,BAO_0000357,,
1624,B,,,,105,Autocuration,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,CHEMBL616510,,8,1,,BAO_0000357,,
1625,B,,,,105,Autocuration,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,CHEMBL616511,,8,1,,BAO_0000357,,
1626,B,,9913.0,,105,Expert,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,CHEMBL616512,,8,1,,BAO_0000357,,
1627,B,,9913.0,,105,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,CHEMBL616513,,8,1,,BAO_0000357,,
1628,B,,9913.0,,105,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,CHEMBL616514,,8,1,,BAO_0000019,2435.0,
1629,B,,9913.0,,105,Expert,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,CHEMBL616515,,8,1,,BAO_0000357,,
1630,B,,9913.0,,105,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,CHEMBL616516,,8,1,,BAO_0000019,,
1631,B,,9913.0,,105,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,CHEMBL616517,,8,1,,BAO_0000357,,
1632,B,,9913.0,,105,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,CHEMBL616518,,8,1,,BAO_0000357,,
1633,B,,9913.0,,105,Autocuration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,CHEMBL616519,,8,1,,BAO_0000357,,
1634,B,,9913.0,,105,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,CHEMBL616520,,8,1,,BAO_0000357,,
1635,B,,9913.0,,105,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,CHEMBL616521,,8,1,,BAO_0000357,,
1636,B,,9913.0,,105,Autocuration,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,CHEMBL616522,,8,1,,BAO_0000357,,
1637,B,,9913.0,,105,Autocuration,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,CHEMBL884531,,8,1,,BAO_0000357,,
1638,B,,9913.0,,105,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,CHEMBL616523,,8,1,,BAO_0000357,,
1639,B,,9913.0,,105,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,CHEMBL616731,,8,1,,BAO_0000019,2435.0,
1640,B,,9913.0,,105,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,CHEMBL616732,,8,1,,BAO_0000019,,
1641,B,,9913.0,,105,Autocuration,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,CHEMBL616733,,8,1,,BAO_0000357,,
1642,B,,9913.0,,105,Autocuration,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,CHEMBL616734,,8,1,,BAO_0000357,,
1643,B,,9913.0,,105,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,CHEMBL616735,,8,1,,BAO_0000249,,
1644,B,,9913.0,,105,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,CHEMBL616736,,8,1,,BAO_0000249,,
1645,F,,9913.0,,105,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616737,,8,1,,BAO_0000019,,
1646,B,,9913.0,,105,Autocuration,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,CHEMBL616738,,8,1,,BAO_0000019,,
1647,F,,9913.0,,105,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616739,,8,1,,BAO_0000019,,
1648,F,,9913.0,,105,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616740,,8,1,,BAO_0000019,,
1649,F,,9913.0,,105,Expert,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,CHEMBL616741,,8,1,,BAO_0000019,,
1650,B,,9593.0,,105,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,CHEMBL616742,,8,1,722.0,BAO_0000219,,
1651,B,,10141.0,,105570,Intermediate,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,CHEMBL616743,,9,1,,BAO_0000019,,
1652,B,,10141.0,,105570,Intermediate,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,CHEMBL616744,,9,1,,BAO_0000019,,
1653,F,,10141.0,,105570,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,CHEMBL616745,,9,1,,BAO_0000019,,
1654,F,,10141.0,,105570,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616746,,9,1,,BAO_0000019,,
1655,F,,10141.0,,105570,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,CHEMBL616747,,9,1,,BAO_0000019,,
1656,F,,10141.0,,105570,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,CHEMBL616748,,9,1,,BAO_0000019,,
1657,F,,10141.0,,105570,Intermediate,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,CHEMBL616648,,9,1,,BAO_0000019,,
1658,B,,10141.0,,105570,Intermediate,Binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL616649,,9,1,,BAO_0000357,,
1659,B,,10141.0,,105570,Intermediate,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,CHEMBL616650,,9,1,,BAO_0000357,,
1660,F,,10141.0,,105570,Intermediate,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616651,,9,1,,BAO_0000218,,
1661,F,,10141.0,,105570,Intermediate,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616652,,9,1,,BAO_0000218,,
1662,F,,10141.0,,105570,Intermediate,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,CHEMBL616653,,9,1,,BAO_0000218,,
1663,F,,10141.0,,105570,Intermediate,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,CHEMBL616654,,9,1,,BAO_0000218,,
1664,B,,10141.0,,105570,Intermediate,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,CHEMBL616655,,9,1,,BAO_0000019,,
1665,B,,10141.0,,105570,Intermediate,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,CHEMBL616656,,9,1,,BAO_0000357,,
1666,B,,10141.0,,105,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,CHEMBL616657,,8,1,,BAO_0000019,,
1667,B,,10141.0,,105570,Intermediate,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,CHEMBL616658,,9,1,,BAO_0000357,2435.0,
1668,B,,10141.0,,105570,Intermediate,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,CHEMBL616659,,9,1,,BAO_0000357,,
1669,B,,,,51,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL616660,,8,1,,BAO_0000357,,
1670,B,,,,106,Autocuration,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,CHEMBL616661,,8,1,,BAO_0000357,,
1671,F,,,,105,Expert,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,CHEMBL616662,,8,1,,BAO_0000019,,
1672,F,,,,105,Autocuration,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616663,,8,1,,BAO_0000019,,
1673,F,,,,105,Autocuration,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616664,,8,1,,BAO_0000019,,
1674,F,,9606.0,,105,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,CHEMBL881820,,9,1,449.0,BAO_0000219,,
1675,F,,,,105,Autocuration,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,CHEMBL616665,,8,1,449.0,BAO_0000219,,
1676,B,,,,105,Expert,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,CHEMBL616666,,8,1,449.0,BAO_0000219,,
1677,B,,,,105,Autocuration,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,CHEMBL616667,,8,1,449.0,BAO_0000219,,
1678,F,,,,105,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,CHEMBL616668,,8,1,449.0,BAO_0000219,,
1679,F,,9606.0,,105,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,CHEMBL616669,,9,1,449.0,BAO_0000219,,
1680,F,,,,105,Expert,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,CHEMBL617040,,8,1,449.0,BAO_0000219,,
1681,F,,,,105,Autocuration,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,CHEMBL617041,,8,1,449.0,BAO_0000219,,
1682,F,,,,105,Expert,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,CHEMBL617042,,8,1,449.0,BAO_0000219,,
1683,F,,,,105,Expert,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,CHEMBL617043,,8,1,449.0,BAO_0000219,,
1684,F,,,,105,Autocuration,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,CHEMBL617044,,8,1,,BAO_0000019,,
1685,F,,,,105,Expert,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,CHEMBL617045,,8,1,449.0,BAO_0000219,,
1686,F,,9606.0,,105,Expert,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,CHEMBL617046,,9,1,449.0,BAO_0000219,,
1687,F,,9606.0,,105,Expert,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,CHEMBL617047,,9,1,449.0,BAO_0000219,,
1688,F,,,,105,Expert,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,CHEMBL617048,,8,1,,BAO_0000019,,
1689,F,,,,105,Autocuration,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,CHEMBL616897,,8,1,,BAO_0000019,,
1690,F,,9606.0,,105,Expert,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,CHEMBL616898,,9,1,,BAO_0000019,,
1691,F,,9606.0,,105,Expert,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,CHEMBL858201,,9,1,449.0,BAO_0000219,,
1692,F,,,,105,Autocuration,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,CHEMBL616899,,8,1,,BAO_0000019,,
1693,B,In vitro,,,105,Autocuration,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,CHEMBL616900,,8,1,,BAO_0000219,,
1694,B,,,,105,Expert,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,CHEMBL616901,,8,1,449.0,BAO_0000219,,
1695,B,,,,105,Autocuration,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,CHEMBL616902,,8,1,,BAO_0000357,,
1696,B,,9606.0,,105,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616903,,9,1,449.0,BAO_0000219,,
1697,B,,,,105,Expert,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,CHEMBL616904,,8,1,449.0,BAO_0000219,,
1698,B,,,,105,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,CHEMBL616905,,8,1,,BAO_0000357,,
1699,B,,,,105,Expert,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,CHEMBL616906,,8,1,449.0,BAO_0000219,,
1700,B,,,,105,Expert,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHEMBL616907,,8,1,449.0,BAO_0000219,,
1701,B,,,,105,Expert,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHEMBL616908,,8,1,449.0,BAO_0000219,,
1702,B,,9606.0,,105,Expert,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616909,,9,1,449.0,BAO_0000219,,
1703,B,,9606.0,,105,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616910,,9,1,449.0,BAO_0000219,,
1704,B,,,,105,Expert,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,CHEMBL616911,,8,1,449.0,BAO_0000219,,
1705,B,,,,105,Expert,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,CHEMBL616912,,8,1,449.0,BAO_0000219,,
1706,B,,,,105,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,CHEMBL616913,,8,1,,BAO_0000357,,
1707,B,,9606.0,,105,Expert,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,CHEMBL616914,,9,1,449.0,BAO_0000219,,
1708,B,,,,105,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616915,,8,1,449.0,BAO_0000219,,
1709,B,,,,105,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,CHEMBL616916,,8,1,,BAO_0000019,,
1710,B,,9606.0,,105,Expert,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616917,,9,1,,BAO_0000357,,
1711,B,,,,105,Autocuration,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,CHEMBL616918,,8,1,,BAO_0000357,,
1712,B,,,,105,Expert,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,CHEMBL616919,,8,1,,BAO_0000219,,
1713,B,,,,105,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,CHEMBL616920,,8,1,,BAO_0000357,,
1714,B,,,,105,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,CHEMBL872914,,8,1,,BAO_0000357,,
1715,B,,,,105,Autocuration,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,CHEMBL616921,,8,1,,BAO_0000357,,
1716,B,,,,105,Expert,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616922,,8,1,,BAO_0000357,,
1717,B,,,,105,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor,,CHEMBL616923,,8,1,,BAO_0000357,,
1718,B,,,,105,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616924,,8,1,,BAO_0000357,,
1719,B,,,,105,Expert,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,CHEMBL875909,,8,1,,BAO_0000357,,
1720,B,,,,105,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,CHEMBL616925,,8,1,,BAO_0000357,,
1721,B,,,,105,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,CHEMBL616926,,8,1,,BAO_0000357,,
1722,B,,,,105,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,CHEMBL616927,,8,1,,BAO_0000357,,
1723,F,,,,105,Expert,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,CHEMBL616928,,8,1,485.0,BAO_0000219,,
1724,B,In vitro,9606.0,,105,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,CHEMBL616929,,9,1,,BAO_0000219,,
1725,B,,9606.0,,105,Expert,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,CHEMBL616930,,9,1,,BAO_0000357,,
1726,B,,,,105,Expert,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616931,,8,1,,BAO_0000019,,
1727,B,,,,105,Autocuration,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,CHEMBL616932,,8,1,,BAO_0000357,,
1728,B,,,,105,Expert,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616933,,8,1,,BAO_0000357,,
1729,B,,9606.0,,105,Expert,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,CHEMBL616934,,9,1,,BAO_0000219,,
1730,B,,9606.0,,105,Expert,Binding affinity for human 5-hydroxytryptamine 1D receptor,,CHEMBL616935,,9,1,,BAO_0000357,,
1731,B,,,,105,Autocuration,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,CHEMBL616936,,8,1,,BAO_0000357,,
1732,B,,9606.0,,105,Expert,Affinity for 5-hydroxytryptamine 1D receptor subtype,,CHEMBL616937,,9,1,,BAO_0000357,,
1733,B,,9606.0,,105,Expert,Binding affinity for human 5-hydroxytryptamine 1D receptor,,CHEMBL616938,,9,1,,BAO_0000357,,
1734,B,,,,105,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,CHEMBL616939,,8,1,,BAO_0000019,,
1735,B,,,,105,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,CHEMBL616940,,8,1,,BAO_0000019,,
1736,B,,9606.0,,105,Expert,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,CHEMBL616941,,9,1,,BAO_0000357,,
1737,B,,,,105,Autocuration,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,CHEMBL616942,,8,1,485.0,BAO_0000219,,
1738,B,,,,105,Autocuration,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,CHEMBL616943,,8,1,485.0,BAO_0000219,,
1739,B,,,,104802,Autocuration,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,CHEMBL616944,,4,1,449.0,BAO_0000219,,
1740,F,,,,105,Autocuration,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,CHEMBL616945,,8,1,,BAO_0000019,,
1741,B,,,,105,Autocuration,Binding activity radioligand.,,CHEMBL616946,,8,1,,BAO_0000357,,
1742,B,,,,105,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL616947,,8,1,,BAO_0000019,,
1743,B,,,,105,Expert,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,CHEMBL616948,,8,1,485.0,BAO_0000219,,
1744,B,,,,105,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,CHEMBL616851,,8,1,,BAO_0000357,,
1745,B,,,,105,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,CHEMBL616852,,8,1,,BAO_0000357,,
1746,B,,,,105,Autocuration,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,CHEMBL616853,,8,1,,BAO_0000357,,
1747,B,,9606.0,,105,Expert,Binding activity against human 5-hydroxytryptamine 1D receptor,,CHEMBL616854,,9,1,,BAO_0000357,,
1748,B,,9606.0,,105,Expert,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL616855,,9,1,449.0,BAO_0000219,,
1749,B,,,,105,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,CHEMBL616856,,8,1,449.0,BAO_0000219,,
1750,B,,,,105,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616857,,8,1,449.0,BAO_0000219,,
1751,B,,,,105,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,CHEMBL616858,,8,1,,BAO_0000357,,
1752,B,,,,105,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616859,,8,1,449.0,BAO_0000219,,
1753,B,,,,105,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,CHEMBL616860,,8,1,449.0,BAO_0000219,,
1754,B,,,,105,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,CHEMBL616861,,8,1,722.0,BAO_0000219,,
1755,B,,,,105,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,CHEMBL616541,,8,1,722.0,BAO_0000219,,
1756,B,,,,105,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,CHEMBL616542,,8,1,722.0,BAO_0000219,,
1757,B,,,,105,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,CHEMBL616543,,8,1,449.0,BAO_0000219,,
1758,B,,9606.0,,105,Expert,Binding affinity for human 5-hydroxytryptamine 1D receptor,,CHEMBL616544,,9,1,,BAO_0000357,,
1759,B,,,,105,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,CHEMBL616545,,8,1,449.0,BAO_0000219,,
1760,B,,,,105,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL616546,,8,1,,BAO_0000357,,
1761,B,,,,105,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,CHEMBL616547,,8,1,449.0,BAO_0000219,,
1762,B,,,,105,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL616548,,8,1,449.0,BAO_0000219,,
1763,F,,,,105,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,CHEMBL616549,,8,1,,BAO_0000019,,
1764,F,,,,105,Expert,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,CHEMBL616550,,8,1,,BAO_0000019,,
1765,B,,,,108,Autocuration,Binding affinity against 5-HT2C receptor,,CHEMBL857066,,8,1,,BAO_0000357,,
1766,B,,,,108,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL616551,,8,1,,BAO_0000357,,
1767,B,,,,10577,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,CHEMBL616552,,8,1,,BAO_0000357,,
1768,F,,,,10577,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,CHEMBL832876,,8,1,,BAO_0000019,,
1769,B,,,,10577,Expert,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,CHEMBL616553,,8,1,,BAO_0000019,,
1770,B,,,,10577,Autocuration,Binding affinity towards 5-HT1B was determined,,CHEMBL616554,,8,1,,BAO_0000357,,
1771,B,,,,10577,Expert,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,CHEMBL616555,,8,1,,BAO_0000019,,
1772,B,,,,10577,Expert,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,CHEMBL616556,,8,1,,BAO_0000019,,
1773,B,,,,10577,Autocuration,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,CHEMBL616557,,8,1,,BAO_0000019,,
1774,B,,,,10577,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,CHEMBL616558,,8,1,,BAO_0000019,,
1775,B,,10116.0,,10577,Expert,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,CHEMBL616749,,9,1,,BAO_0000019,,
1776,B,,,,10577,Autocuration,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,CHEMBL616750,,8,1,,BAO_0000357,,
1777,B,,,,10577,Autocuration,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,CHEMBL616751,,8,1,,BAO_0000357,,
1778,B,,,,10577,Autocuration,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,CHEMBL616752,,8,1,,BAO_0000249,,
1779,B,,,,10577,Autocuration,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,CHEMBL616753,,8,1,,BAO_0000019,2435.0,
1780,B,,10116.0,,10577,Expert,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,CHEMBL616754,,9,1,,BAO_0000357,,
1781,B,,,,10577,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,CHEMBL616755,,8,1,,BAO_0000019,,
1782,B,,,,10577,Autocuration,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,CHEMBL616756,,8,1,,BAO_0000019,2435.0,
1783,B,,,,10577,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,CHEMBL616757,,8,1,,BAO_0000019,2435.0,
1784,B,,,,10577,Autocuration,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,CHEMBL616758,,8,1,,BAO_0000357,2435.0,
1785,B,,,,10577,Autocuration,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,CHEMBL616759,,8,1,,BAO_0000249,,
1786,B,,,,10577,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,CHEMBL616760,,8,1,,BAO_0000357,,
1787,B,,,,10577,Autocuration,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,CHEMBL616761,,8,1,,BAO_0000019,2435.0,
1788,B,,,,10577,Autocuration,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,CHEMBL616762,,8,1,,BAO_0000019,2435.0,
1789,B,,,,10577,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,CHEMBL616763,,8,1,,BAO_0000019,,
1790,B,,,,10577,Expert,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,CHEMBL872909,,8,1,,BAO_0000357,,
1791,B,,,,10577,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,CHEMBL616764,,8,1,,BAO_0000357,,
1792,B,,10116.0,,10577,Expert,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,CHEMBL616765,,9,1,,BAO_0000357,,
1793,B,,,,10577,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,CHEMBL616766,,8,1,,BAO_0000357,2435.0,
1794,B,,,,10577,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,CHEMBL616767,,8,1,,BAO_0000357,2435.0,
1795,B,,,,10577,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,CHEMBL616768,,8,1,,BAO_0000357,,
1796,B,,,,10577,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,CHEMBL616769,,8,1,,BAO_0000357,,
1797,B,,,,10577,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,CHEMBL616770,,8,1,,BAO_0000019,,
1798,B,,,,10577,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,CHEMBL616771,,8,1,,BAO_0000019,,
1799,B,,,,10577,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,CHEMBL616772,,8,1,,BAO_0000019,2435.0,
1800,B,,,,10577,Expert,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,CHEMBL616773,,8,1,,BAO_0000019,,
1801,B,,,,10577,Autocuration,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,CHEMBL616774,,8,1,,BAO_0000019,,
1802,B,,,,10577,Autocuration,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,CHEMBL616775,,8,1,,BAO_0000357,,
1803,B,,,,10577,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,CHEMBL616776,,8,1,,BAO_0000249,,
1804,B,,,,10577,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,CHEMBL616777,,8,1,,BAO_0000357,,
1805,B,,,,10577,Autocuration,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,CHEMBL616778,,8,1,,BAO_0000357,,
1806,B,,10116.0,,10577,Expert,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,CHEMBL616779,,9,1,,BAO_0000249,,
1807,B,,10116.0,,10577,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor,,CHEMBL616780,,9,1,,BAO_0000357,,
1808,B,,,,10577,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,CHEMBL616781,,8,1,,BAO_0000019,,
1809,B,,,,10577,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,CHEMBL616782,,8,1,,BAO_0000357,,
1810,B,,,,10577,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,CHEMBL616783,,8,1,,BAO_0000357,,
1811,B,,,,10577,Expert,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,CHEMBL616784,,8,1,,BAO_0000019,2435.0,
1812,B,,,,10577,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,CHEMBL616785,,8,1,,BAO_0000357,,
1813,B,,,,10577,Autocuration,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL857067,,8,1,,BAO_0000249,955.0,
1814,B,,,,10577,Autocuration,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,CHEMBL616786,,8,1,,BAO_0000019,,
1815,B,,,,10577,Autocuration,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL616787,,8,1,,BAO_0000249,955.0,
1816,B,,,,10577,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,CHEMBL616788,,8,1,,BAO_0000357,,
1817,B,,,,10577,Autocuration,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,CHEMBL616789,,8,1,,BAO_0000357,,
1818,B,,10116.0,,10577,Expert,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,CHEMBL616790,,9,1,,BAO_0000019,,
1819,B,,,,10577,Expert,Binding affinity at 5-hydroxytryptamine 1B receptor,,CHEMBL616791,,8,1,,BAO_0000357,,
1820,B,,,,10577,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,CHEMBL616792,,8,1,,BAO_0000019,,
1821,B,,10116.0,,10577,Expert,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,CHEMBL616793,,9,1,,BAO_0000249,,
1822,B,,,,10577,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,CHEMBL616794,,8,1,,BAO_0000357,,
1823,B,,,,10577,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,CHEMBL616795,,8,1,,BAO_0000357,,
1824,B,,,,104686,Autocuration,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,CHEMBL616796,,4,1,,BAO_0000019,,
1825,B,,,,106,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL616797,,8,1,,BAO_0000357,,
1826,B,,,,106,Autocuration,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,CHEMBL616798,,8,1,,BAO_0000249,,
1827,B,,,,106,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,CHEMBL616799,,8,1,,BAO_0000357,,
1828,B,,,,106,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,CHEMBL616800,,8,1,,BAO_0000357,,
1829,B,,,,106,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,CHEMBL616801,,8,1,,BAO_0000357,,
1830,B,,,,106,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,CHEMBL616802,,8,1,,BAO_0000357,,
1831,B,,,,106,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,CHEMBL616803,,8,1,,BAO_0000357,,
1832,B,,,,106,Expert,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,CHEMBL857068,,8,1,,BAO_0000357,,
1833,B,,,,106,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,CHEMBL616804,,8,1,,BAO_0000357,,
1834,B,,,,106,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,CHEMBL616805,,8,1,,BAO_0000357,,
1835,B,,,,106,Autocuration,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,CHEMBL616806,,8,1,,BAO_0000357,,
1836,B,,,,106,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor,,CHEMBL616807,,8,1,,BAO_0000357,,
1837,B,,,,106,Autocuration,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,CHEMBL616808,,8,1,,BAO_0000357,,
1838,B,,,,106,Autocuration,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,CHEMBL616809,,8,1,,BAO_0000357,,
1839,B,,,,106,Autocuration,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,CHEMBL616810,,8,1,,BAO_0000357,,
1840,B,,,,104802,Autocuration,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,CHEMBL616811,,4,1,,BAO_0000224,,
1841,B,,9913.0,,108,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,CHEMBL616812,,8,1,,BAO_0000357,,
1842,B,,9823.0,,108,Autocuration,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,CHEMBL616813,,8,1,,BAO_0000357,,
1843,B,,9823.0,,108,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,CHEMBL616814,,8,1,,BAO_0000357,,
1844,B,,9823.0,,108,Autocuration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,CHEMBL616815,,8,1,,BAO_0000357,,
1845,B,,9823.0,,108,Autocuration,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,CHEMBL616816,,8,1,,BAO_0000357,,
1846,B,,9823.0,,108,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,CHEMBL616817,,8,1,,BAO_0000357,,
1847,B,,9823.0,,108,Autocuration,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,CHEMBL616818,,8,1,,BAO_0000357,,
1848,B,,9823.0,,108,Expert,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,CHEMBL616819,,8,1,,BAO_0000357,,
1849,B,,9823.0,,108,Expert,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,CHEMBL616820,,8,1,,BAO_0000357,,
1850,B,,9823.0,,108,Expert,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,CHEMBL616821,,8,1,,BAO_0000019,,
1851,B,,9823.0,,108,Autocuration,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,CHEMBL616822,,8,1,,BAO_0000357,,
1852,B,,9986.0,,108,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,CHEMBL616823,,8,1,,BAO_0000019,,
1853,B,,10116.0,,12689,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,CHEMBL616824,,9,1,,BAO_0000357,,
1854,B,,10116.0,,12689,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,CHEMBL616825,,9,1,,BAO_0000357,,
1855,B,,10116.0,,12689,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,CHEMBL616826,,9,1,,BAO_0000357,,
1856,B,,10116.0,,12689,Expert,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,CHEMBL616827,,9,1,,BAO_0000019,,
1857,B,,10116.0,,12689,Autocuration,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,CHEMBL616828,,9,1,,BAO_0000357,,
1858,B,,10116.0,,12689,Autocuration,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,CHEMBL616829,,9,1,,BAO_0000357,,
1859,B,,10116.0,,12689,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,CHEMBL616830,,9,1,,BAO_0000019,,
1860,B,,10116.0,,12689,Expert,Binding affinity against 5-hydroxytryptamine 1C receptor,,CHEMBL616831,,9,1,,BAO_0000357,,
1861,B,,10116.0,,12689,Autocuration,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL616832,,9,1,,BAO_0000019,,
1862,B,,10116.0,,12689,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL616833,,9,1,,BAO_0000019,,
1863,B,,10116.0,,12689,Expert,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL616834,,9,1,,BAO_0000019,,
1864,B,,10116.0,,12689,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,CHEMBL829595,,9,1,,BAO_0000019,,
1865,B,,10116.0,,12689,Autocuration,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,CHEMBL616835,,9,1,,BAO_0000357,,
1866,B,,10116.0,,12689,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,CHEMBL872910,,9,1,,BAO_0000249,,
1867,B,,,,12689,Expert,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,CHEMBL616836,,8,1,,BAO_0000357,,
1868,B,,10116.0,,12689,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,CHEMBL616837,,9,1,,BAO_0000357,,
1869,B,,10116.0,,12689,Autocuration,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,CHEMBL616466,,9,1,,BAO_0000019,,
1870,B,,10116.0,,12689,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,CHEMBL616467,,9,1,722.0,BAO_0000219,,
1871,B,,,,108,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,CHEMBL616468,,8,1,,BAO_0000357,,
1872,B,,,,108,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,CHEMBL616469,,8,1,,BAO_0000357,,
1873,B,,,,108,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,CHEMBL616470,,8,1,,BAO_0000357,,
1874,B,,,,12689,Autocuration,Binding affinity against 5-hydroxytryptamine 1C receptor,,CHEMBL616471,,8,1,,BAO_0000357,,
1875,B,,,,12689,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,CHEMBL616472,,8,1,,BAO_0000357,,
1876,B,,,,12689,Autocuration,Binding affinity against 5-hydroxytryptamine 1C receptor,,CHEMBL616473,,8,1,,BAO_0000357,,
1877,B,,,,12689,Autocuration,Binding affinity against serotonergic 5-HT1c receptor,,CHEMBL616474,,8,1,,BAO_0000357,,
1878,B,,,,12689,Autocuration,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,CHEMBL616475,,8,1,,BAO_0000357,,
1879,B,,,,12689,Autocuration,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,CHEMBL616476,,8,1,,BAO_0000357,,
1880,B,,9986.0,,105,Autocuration,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,CHEMBL616477,,8,1,,BAO_0000019,,
1881,B,,,,104686,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,CHEMBL616478,,4,1,,BAO_0000224,,
1882,B,,,,104686,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,CHEMBL616479,,4,1,,BAO_0000224,,
1883,B,,,,104686,Autocuration,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,CHEMBL616480,,4,1,,BAO_0000019,,
1884,B,,10116.0,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,CHEMBL616481,,5,1,,BAO_0000019,,
1885,B,,10116.0,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,CHEMBL616482,,5,1,,BAO_0000249,,
1886,B,,10116.0,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,CHEMBL884713,,5,1,,BAO_0000221,955.0,
1887,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,CHEMBL616483,,4,1,,BAO_0000224,,
1888,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,CHEMBL616484,,4,1,,BAO_0000224,,
1889,B,,,,104686,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,CHEMBL616485,,4,1,,BAO_0000019,,
1890,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,CHEMBL616486,,4,1,,BAO_0000224,,
1891,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,CHEMBL616487,,4,1,,BAO_0000224,,
1892,B,,,,104686,Autocuration,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,CHEMBL616488,,4,1,,BAO_0000224,,
1893,B,,,,104686,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616489,,4,1,,BAO_0000019,,
1894,B,,,,104686,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616490,,4,1,,BAO_0000019,,
1895,B,,,,104686,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,CHEMBL616491,,4,1,,BAO_0000019,,
1896,B,,,,104686,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,CHEMBL616492,,4,1,,BAO_0000019,,
1897,B,,,,104686,Autocuration,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616493,,4,1,,BAO_0000019,,
1898,B,,,,104686,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,CHEMBL616494,,4,1,,BAO_0000019,,
1899,B,,,,104686,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,CHEMBL616495,,4,1,,BAO_0000019,,
1900,B,,,,104686,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,CHEMBL616496,,4,1,,BAO_0000019,,
1901,B,,,,104686,Autocuration,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616497,,4,1,,BAO_0000019,,
1902,B,,,,104686,Autocuration,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,CHEMBL616498,,4,1,,BAO_0000019,,
1903,B,,,,104686,Autocuration,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,CHEMBL616499,,4,1,,BAO_0000019,,
1904,B,,,,104686,Autocuration,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,CHEMBL616500,,4,1,,BAO_0000019,,
1905,B,,10116.0,,104686,Autocuration,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,CHEMBL616501,,5,1,,BAO_0000221,955.0,
1906,B,,,,104686,Autocuration,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,CHEMBL616502,,4,1,,BAO_0000221,955.0,
1907,B,,,,104686,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,CHEMBL884529,,4,1,,BAO_0000249,,
1908,B,,,,104686,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,CHEMBL616503,,4,1,,BAO_0000249,,
1909,B,,,,104686,Autocuration,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,CHEMBL616964,,4,1,,BAO_0000224,,
1910,B,,,,104686,Autocuration,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,CHEMBL616965,,4,1,,BAO_0000249,,
1911,B,,,,104686,Autocuration,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,CHEMBL616966,,4,1,,BAO_0000224,,
1912,B,,,,104686,Autocuration,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,CHEMBL616967,,4,1,,BAO_0000224,,
1913,B,,10116.0,,104686,Autocuration,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,CHEMBL616968,,5,1,,BAO_0000224,,
1914,B,,,,104686,Autocuration,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,CHEMBL616969,,4,1,,BAO_0000224,,
1915,B,,,,104686,Autocuration,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,CHEMBL884530,,4,1,,BAO_0000019,,
1916,B,,,,104686,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,CHEMBL616970,,4,1,,BAO_0000224,,
1917,B,,,,104686,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,CHEMBL616971,,4,1,,BAO_0000224,,
1918,B,,,,104686,Autocuration,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,CHEMBL616972,,4,1,,BAO_0000224,,
1919,B,,,,104686,Autocuration,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,CHEMBL616973,,4,1,,BAO_0000224,,
1920,B,,,,104686,Autocuration,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,CHEMBL616974,,4,1,,BAO_0000224,,
1921,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,CHEMBL616975,,4,1,,BAO_0000019,,
1922,B,,,,104686,Autocuration,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,CHEMBL616976,,4,1,,BAO_0000019,,
1923,B,,,,104686,Autocuration,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,CHEMBL616977,,4,1,,BAO_0000224,,
1924,B,,,,104686,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,CHEMBL616978,,4,1,,BAO_0000224,,
1925,B,,,,104686,Autocuration,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,CHEMBL616979,,4,1,,BAO_0000224,,
1926,B,,,,104686,Autocuration,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,CHEMBL616980,,4,1,,BAO_0000224,,
1927,B,,,,104686,Autocuration,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,CHEMBL616981,,4,1,,BAO_0000249,,
1928,B,,,,104686,Autocuration,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,CHEMBL616982,,4,1,,BAO_0000249,,
1929,B,,,,104686,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,CHEMBL616983,,4,1,,BAO_0000224,,
1930,B,,,,104686,Autocuration,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,CHEMBL616984,,4,1,,BAO_0000019,,
1931,B,,10116.0,,104686,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,CHEMBL616985,,5,1,,BAO_0000224,,
1932,B,,,,104686,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,CHEMBL616986,,4,1,,BAO_0000224,,
1933,B,,,,104686,Autocuration,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,CHEMBL616987,,4,1,,BAO_0000224,,
1934,B,,,,104686,Autocuration,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,CHEMBL616988,,4,1,,BAO_0000019,,
1935,B,,,,104686,Autocuration,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,CHEMBL617243,,4,1,,BAO_0000019,,
1936,B,,,,104686,Autocuration,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,CHEMBL617244,,4,1,,BAO_0000019,,
1937,B,,10116.0,,104686,Autocuration,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHEMBL617245,,5,1,485.0,BAO_0000219,,
1938,B,,,,104686,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,CHEMBL617246,,4,1,,BAO_0000249,,
1939,B,,,,104686,Autocuration,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,CHEMBL617546,,4,1,,BAO_0000224,,
1940,B,,,,104686,Autocuration,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,CHEMBL617547,,4,1,,BAO_0000249,,
1941,B,In vitro,,,104686,Autocuration,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,CHEMBL617548,,4,1,,BAO_0000219,,
1942,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617549,,4,1,,BAO_0000224,,
1943,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,CHEMBL617550,,4,1,,BAO_0000224,,
1944,B,,,,104686,Autocuration,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,CHEMBL617551,,4,1,,BAO_0000224,,
1945,B,,,,104686,Autocuration,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,CHEMBL617552,,4,1,,BAO_0000249,,
1946,B,,,,104686,Autocuration,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,CHEMBL617553,,4,1,,BAO_0000249,,
1947,F,,,,104686,Autocuration,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,CHEMBL617554,,4,1,,BAO_0000019,1515.0,
1948,B,,,,104686,Autocuration,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,CHEMBL617555,,4,1,,BAO_0000019,,
1949,B,,,,104686,Autocuration,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,CHEMBL617556,,4,1,,BAO_0000224,,
1950,B,,,,10624,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,CHEMBL617557,,8,1,,BAO_0000357,,
1951,B,,,,10624,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,CHEMBL617558,,8,1,,BAO_0000357,,
1952,B,,,,17106,Expert,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,CHEMBL617559,,8,1,,BAO_0000357,,
1953,B,,,,17106,Expert,Binding affinity for 5-hydroxytryptamine 1D receptor,,CHEMBL617560,,9,1,,BAO_0000357,,
1954,B,,,,17106,Autocuration,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,CHEMBL617561,,8,1,,BAO_0000249,,
1955,B,,,,17106,Autocuration,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,CHEMBL617562,,8,1,,BAO_0000249,,
1956,B,,,,17106,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,CHEMBL617563,,8,1,,BAO_0000357,2435.0,
1957,F,,,,17106,Autocuration,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,CHEMBL617564,,8,1,,BAO_0000019,,
1958,B,,,,17106,Expert,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,CHEMBL617565,,8,1,,BAO_0000019,,
1959,B,,,,17106,Autocuration,Binding activity radioligand.,,CHEMBL856076,,8,1,,BAO_0000357,,
1960,B,,,,17106,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,CHEMBL617566,,8,1,,BAO_0000019,,
1961,B,,,,17106,Expert,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL875911,,8,1,,BAO_0000019,,
1962,B,,,,17106,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,CHEMBL617567,,8,1,,BAO_0000019,,
1963,B,,,,17106,Autocuration,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,CHEMBL617568,,8,1,,BAO_0000249,,
1964,B,,,,17106,Expert,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,CHEMBL617569,,8,1,,BAO_0000019,,
1965,B,,,,17106,Expert,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,CHEMBL617570,,8,1,,BAO_0000249,,
1966,B,,,,17106,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,CHEMBL617571,,8,1,,BAO_0000357,,
1967,B,,9823.0,,105,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,CHEMBL617572,,8,1,,BAO_0000357,,
1968,B,,9986.0,,105,Expert,The compound was tested for intrinsic activity against 5-HT1D receptor,,CHEMBL617573,,8,1,,BAO_0000357,,
1969,B,,9986.0,,105,Autocuration,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,CHEMBL617574,,8,1,,BAO_0000019,,
1970,B,,9986.0,,105,Expert,The compound was tested for binding affinity against 5-HT1D receptor,,CHEMBL617575,,8,1,,BAO_0000357,,
1971,B,,,,10578,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,CHEMBL617576,,8,1,,BAO_0000357,,
1972,F,,,,10578,Autocuration,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,CHEMBL617577,,8,1,,BAO_0000019,,
1973,F,,,,10578,Autocuration,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,CHEMBL617578,,8,1,,BAO_0000019,,
1974,B,,,,10578,Autocuration,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,CHEMBL617579,,8,1,,BAO_0000357,,
1975,B,,,,10578,Expert,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,CHEMBL617580,,8,1,,BAO_0000019,,
1976,B,,,,10578,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,CHEMBL617581,,8,1,,BAO_0000249,,
1977,B,,,,10578,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,CHEMBL617582,,8,1,,BAO_0000357,,
1978,B,,,,10578,Expert,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,CHEMBL617583,,8,1,,BAO_0000019,,
1979,B,,,,105,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,CHEMBL617584,,8,1,,BAO_0000357,,
1980,B,,,,105,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL617585,,8,1,,BAO_0000357,,
1981,B,,,,105,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,CHEMBL875912,,8,1,,BAO_0000357,,
1982,B,,,,105,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,CHEMBL617586,,8,1,,BAO_0000357,,
1983,B,,,,105,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,CHEMBL617587,,8,1,,BAO_0000357,,
1984,B,,,,105,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,CHEMBL617588,,8,1,,BAO_0000357,,
1985,B,,,,105,Autocuration,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,CHEMBL857980,,8,1,,BAO_0000357,,
1986,B,,,,105,Autocuration,Tested against 5-hydroxytryptamine 1D receptor,,CHEMBL617589,,8,1,,BAO_0000357,,
1987,B,,,,105,Autocuration,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,CHEMBL617590,,8,1,,BAO_0000357,,
1988,B,,,,105,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,CHEMBL617591,,8,1,722.0,BAO_0000219,,
1989,B,,9606.0,,105,Expert,Binding affinity against 5-Hydroxytryptamine 1D receptor,,CHEMBL617592,,9,1,,BAO_0000357,,
1990,B,,,,105,Autocuration,,,CHEMBL617593,,8,1,,BAO_0000357,,
1991,B,,,,106,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHEMBL617594,,8,1,485.0,BAO_0000219,,
1992,B,,,,105,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHEMBL617595,,8,1,485.0,BAO_0000219,,
1993,B,,,,105,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,CHEMBL617596,,8,1,722.0,BAO_0000219,,
1994,B,,,,105,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,CHEMBL617597,,8,1,722.0,BAO_0000219,,
1995,B,,,,105,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,CHEMBL617598,,8,1,,BAO_0000019,,
1996,B,,,,105,Autocuration,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,CHEMBL872916,,8,1,,BAO_0000357,,
1997,B,,,,105,Expert,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,CHEMBL617599,,8,1,,BAO_0000357,,
1998,B,,,,105,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,CHEMBL617091,,8,1,,BAO_0000357,,
1999,B,,,,105,Expert,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,CHEMBL617092,,8,1,485.0,BAO_0000219,,
2000,B,,,,105,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,CHEMBL617093,,8,1,485.0,BAO_0000219,,
2001,F,,,,105,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL617094,,8,1,,BAO_0000019,,
2002,F,,,,105,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL617095,,8,1,,BAO_0000019,,
2003,F,,,,105,Autocuration,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,CHEMBL617096,,8,1,,BAO_0000019,,
2004,F,,,,105,Autocuration,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,CHEMBL617097,,8,1,,BAO_0000019,,
2005,F,,,,105,Autocuration,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,CHEMBL617098,,8,1,,BAO_0000019,,
2006,B,,,,105,Autocuration,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,CHEMBL617301,,8,1,,BAO_0000357,,
2007,B,,,,105,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,CHEMBL617302,,8,1,,BAO_0000357,,
2008,B,,,,105,Autocuration,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617303,,8,1,,BAO_0000357,,
2009,B,,,,105,Expert,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617304,,8,1,,BAO_0000357,,
2010,B,,,,105,Expert,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,CHEMBL617305,,8,1,449.0,BAO_0000219,,
2011,B,,9606.0,,105,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,CHEMBL617306,,9,1,,BAO_0000219,,
2012,B,,,,17106,Autocuration,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,CHEMBL617307,,8,1,,BAO_0000357,,
2013,B,,9986.0,,105,Autocuration,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,CHEMBL617308,,8,1,,BAO_0000019,,
2014,B,,,,105,Autocuration,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617309,,8,1,,BAO_0000357,,
2015,B,,,,105,Autocuration,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617310,,8,1,,BAO_0000357,,
2016,B,,,,105,Autocuration,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617311,,8,1,,BAO_0000357,,
2017,B,,,,105,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,CHEMBL617312,,8,1,,BAO_0000357,,
2018,B,,,,105,Autocuration,Affinity against 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617313,,8,1,,BAO_0000357,,
2019,B,,,,105,Expert,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,CHEMBL617314,,8,1,,BAO_0000357,,
2020,F,,,,106,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL617315,,8,1,,BAO_0000019,,
2021,B,,,,106,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,CHEMBL617316,,8,1,722.0,BAO_0000219,,
2022,B,,,,106,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,CHEMBL617317,,8,1,722.0,BAO_0000219,,
2023,B,,,,106,Autocuration,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,CHEMBL617318,,8,1,449.0,BAO_0000219,,
2024,B,,,,106,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,CHEMBL617319,,8,1,,BAO_0000019,,
2025,B,,,,106,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,CHEMBL617320,,9,1,,BAO_0000357,,
2026,B,,,,106,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,CHEMBL617321,,9,1,,BAO_0000357,,
2027,B,,,,106,Expert,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,CHEMBL617322,,9,1,,BAO_0000357,,
2028,B,,,,106,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616862,,8,1,,BAO_0000357,,
2029,B,,,,106,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,CHEMBL616863,,8,1,,BAO_0000357,,
2030,B,,,,106,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,CHEMBL616864,,8,1,449.0,BAO_0000219,,
2031,B,,,,106,Autocuration,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,CHEMBL616865,,8,1,485.0,BAO_0000219,,
2032,B,,,,106,Autocuration,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,CHEMBL616866,,8,1,485.0,BAO_0000219,,
2033,F,,,,106,Autocuration,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,CHEMBL616867,,8,1,,BAO_0000019,,
2034,B,,,,106,Expert,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,CHEMBL616868,,8,1,485.0,BAO_0000219,,
2035,B,,,,105,Expert,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,CHEMBL616869,,8,1,,BAO_0000357,,
2036,B,,,,106,Expert,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,CHEMBL616870,,8,1,449.0,BAO_0000219,,
2037,F,,,,105,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,CHEMBL616871,,8,1,485.0,BAO_0000219,,
2038,F,,,,105,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,CHEMBL616872,,8,1,485.0,BAO_0000219,,
2039,F,,,,105,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,CHEMBL616873,,8,1,485.0,BAO_0000219,,
2040,F,,,,105,Autocuration,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,CHEMBL616838,,8,1,485.0,BAO_0000219,,
2041,B,,,,105,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,CHEMBL616839,,8,1,,BAO_0000357,,
2042,B,,9986.0,,106,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,CHEMBL616840,,8,1,,BAO_0000019,,
2043,B,,,,105,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,CHEMBL616841,,8,1,,BAO_0000357,,
2044,B,,,,105,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,CHEMBL616842,,8,1,,BAO_0000357,,
2045,B,,,,105,Expert,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,CHEMBL857976,,8,1,,BAO_0000357,,
2046,B,,,,10618,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,CHEMBL616843,,8,1,449.0,BAO_0000219,,
2047,B,,9606.0,,10618,Expert,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,CHEMBL616844,,9,1,,BAO_0000357,,
2048,B,,,,10618,Autocuration,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,CHEMBL616845,,8,1,,BAO_0000357,,
2049,B,,9606.0,,10618,Expert,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,CHEMBL616846,,9,1,,BAO_0000357,,
2050,B,,,,10618,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,CHEMBL616847,,8,1,,BAO_0000357,,
2051,B,,,,10618,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,CHEMBL616848,,8,1,,BAO_0000019,,
2052,B,,,,10618,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,CHEMBL616849,,8,1,,BAO_0000357,,
2053,B,,,,10618,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,CHEMBL872911,,8,1,,BAO_0000357,,
2054,B,,,,10618,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,CHEMBL616850,,8,1,,BAO_0000019,,
2055,B,,9606.0,,10618,Expert,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,CHEMBL616699,,9,1,449.0,BAO_0000219,,
2056,B,,,,10618,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,CHEMBL616700,,8,1,,BAO_0000357,,
2057,B,,,,10618,Autocuration,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616701,,8,1,449.0,BAO_0000219,,
2058,B,,,,10618,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,CHEMBL616702,,8,1,449.0,BAO_0000219,,
2059,B,,,,10618,Autocuration,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,CHEMBL616703,,8,1,449.0,BAO_0000219,,
2060,B,,,,10618,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,CHEMBL616704,,8,1,,BAO_0000357,,
2061,B,,,,10618,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,CHEMBL616705,,8,1,449.0,BAO_0000219,,
2062,B,,,,10618,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,CHEMBL616706,,8,1,,BAO_0000357,,
2063,B,,,,10618,Autocuration,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,CHEMBL616707,,8,1,449.0,BAO_0000219,,
2064,B,,,,10618,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL616708,,8,1,,BAO_0000357,,
2065,B,,,,10618,Autocuration,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,CHEMBL616709,,8,1,,BAO_0000357,,
2066,B,,,,10618,Autocuration,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,CHEMBL616710,,8,1,449.0,BAO_0000219,,
2067,B,,,,10618,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,CHEMBL616711,,8,1,449.0,BAO_0000219,,
2068,B,,,,10618,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL616712,,8,1,449.0,BAO_0000219,,
2069,B,,,,10618,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,CHEMBL616713,,8,1,,BAO_0000357,,
2070,B,,,,10618,Autocuration,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,CHEMBL616714,,8,1,,BAO_0000357,,
2071,B,,,,10618,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,CHEMBL616715,,8,1,,BAO_0000357,,
2072,B,,,,10618,Autocuration,Binding affinity towards 5-hydroxytryptamine 1E receptor,,CHEMBL616716,,8,1,,BAO_0000357,,
2073,F,,,,279,Autocuration,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,CHEMBL616717,,8,1,,BAO_0000019,,
2074,F,,,,279,Expert,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,CHEMBL616718,,8,1,,BAO_0000019,,
2075,F,,,,279,Autocuration,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,CHEMBL875905,,8,1,,BAO_0000019,,
2076,F,,,,279,Autocuration,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,CHEMBL616719,,8,1,,BAO_0000019,,
2077,F,,,,279,Expert,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,CHEMBL616720,,8,1,,BAO_0000019,,
2078,B,,,,279,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,CHEMBL616721,,8,1,,BAO_0000357,,
2079,B,,,,279,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,CHEMBL616722,,8,1,449.0,BAO_0000219,,
2080,B,,,,279,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,CHEMBL616723,,8,1,,BAO_0000357,,
2081,B,,,,279,Autocuration,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,CHEMBL616724,,8,1,449.0,BAO_0000219,,
2082,B,,,,279,Autocuration,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,CHEMBL616725,,8,1,,BAO_0000357,,
2083,B,,,,279,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,CHEMBL616726,,8,1,,BAO_0000357,,
2084,B,,,,279,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,CHEMBL616727,,8,1,,BAO_0000357,,
2085,B,,,,279,Autocuration,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,CHEMBL616728,,8,1,,BAO_0000357,,
2086,B,,,,279,Autocuration,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,CHEMBL616729,,8,1,,BAO_0000357,,
2087,B,,,,279,Expert,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,CHEMBL616730,,8,1,,BAO_0000019,,
2088,B,,,,279,Autocuration,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,CHEMBL617125,,8,1,,BAO_0000357,,
2089,B,,,,279,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,CHEMBL857977,,8,1,,BAO_0000357,,
2090,B,,,,279,Autocuration,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,CHEMBL617126,,8,1,449.0,BAO_0000219,,
2091,B,,,,279,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,CHEMBL617127,,8,1,449.0,BAO_0000219,,
2092,B,,,,279,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,CHEMBL617128,,8,1,,BAO_0000357,,
2093,B,,,,279,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,CHEMBL617129,,8,1,449.0,BAO_0000219,,
2094,B,,,,279,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,CHEMBL617130,,8,1,,BAO_0000357,,
2095,B,,,,279,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,CHEMBL617131,,8,1,449.0,BAO_0000219,,
2096,B,,,,279,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL617132,,8,1,449.0,BAO_0000219,,
2097,B,,,,279,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,CHEMBL617133,,8,1,449.0,BAO_0000219,,
2098,B,,,,279,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,CHEMBL617134,,8,1,,BAO_0000357,,
2099,B,,,,279,Autocuration,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,CHEMBL617135,,8,1,,BAO_0000357,,
2100,B,,,,279,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,CHEMBL617136,,8,1,,BAO_0000357,,
2101,B,,,,104686,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,CHEMBL617137,,4,1,,BAO_0000019,,
2102,B,,,,104686,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,CHEMBL617138,,4,1,,BAO_0000019,,
2103,B,,,,104686,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,CHEMBL617139,,4,1,,BAO_0000019,,
2104,B,,,,12687,Autocuration,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,CHEMBL617140,,8,1,,BAO_0000019,,
2105,F,In vivo,,,104686,Autocuration,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,CHEMBL617141,,4,1,,BAO_0000218,,
2106,F,,,,104686,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL858112,,4,1,,BAO_0000019,,
2107,B,,,,17005,Intermediate,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,CHEMBL617142,,8,1,,BAO_0000019,,
2108,B,,9913.0,,22226,Autocuration,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,CHEMBL617143,,0,1,,BAO_0000019,,
2109,B,,9913.0,,22226,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,CHEMBL617144,,0,1,,BAO_0000019,,
2110,B,,9913.0,,22226,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,CHEMBL617145,,0,1,,BAO_0000019,,
2111,B,,,,22226,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,CHEMBL617146,,0,1,,BAO_0000019,,
2112,B,,10141.0,,104784,Autocuration,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,CHEMBL617147,,4,1,,BAO_0000019,,
2113,B,,10141.0,,104784,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,CHEMBL617148,,4,1,,BAO_0000019,,
2114,B,,10141.0,,104784,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,CHEMBL617149,,4,1,,BAO_0000019,,
2115,B,,,,104784,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617150,,4,1,,BAO_0000224,,
2116,B,,,,104784,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617151,,4,1,,BAO_0000224,,
2117,B,,,,104784,Autocuration,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,CHEMBL617201,,4,1,,BAO_0000224,,
2118,B,,,,10209,Autocuration,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,CHEMBL617202,,8,1,,BAO_0000357,,
2119,B,In vivo,,,104826,Autocuration,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,CHEMBL617203,,4,1,,BAO_0000218,,
2120,B,,,,104826,Autocuration,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,CHEMBL617204,,4,1,,BAO_0000019,,
2121,B,,,,104826,Autocuration,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,CHEMBL617205,,4,1,,BAO_0000224,,
2122,B,,10090.0,,104826,Autocuration,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,CHEMBL617206,,5,1,,BAO_0000019,,
2123,B,In vivo,,,104826,Autocuration,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,CHEMBL617207,,4,1,,BAO_0000218,,
2124,B,,10090.0,,104826,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,CHEMBL617208,,5,1,,BAO_0000019,,
2125,B,,,,104826,Autocuration,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617209,,4,1,,BAO_0000224,,
2126,B,,,,104826,Autocuration,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,CHEMBL617210,,4,1,,BAO_0000224,,
2127,B,,,,104826,Autocuration,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,CHEMBL617211,,4,1,,BAO_0000224,,
2128,B,,10090.0,,104826,Autocuration,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,CHEMBL617212,,5,1,,BAO_0000019,,
2129,B,,9823.0,,104784,Autocuration,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,CHEMBL617213,,4,1,,BAO_0000224,,
2130,B,,9823.0,,104784,Autocuration,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,CHEMBL617214,,4,1,,BAO_0000224,,
2131,B,,,,22226,Autocuration,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,CHEMBL617215,,0,1,,BAO_0000221,,
2132,B,,,,22226,Autocuration,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,CHEMBL617216,,0,1,,BAO_0000221,,
2133,B,,9823.0,,17005,Autocuration,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,CHEMBL617217,,8,1,,BAO_0000357,,
2134,B,,,,104686,Autocuration,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL617218,,4,1,,BAO_0000019,,
2135,B,,,,104686,Autocuration,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL872913,,4,1,,BAO_0000019,,
2136,B,,,,104826,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,CHEMBL617219,,4,1,,BAO_0000019,,
2137,B,,,,104686,Autocuration,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,CHEMBL873482,,4,1,,BAO_0000224,,
2138,B,,10116.0,,104686,Autocuration,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,CHEMBL617220,,5,1,,BAO_0000019,,
2139,B,,,,104686,Autocuration,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,CHEMBL617221,,4,1,,BAO_0000019,,
2140,B,,,,104686,Autocuration,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,CHEMBL617222,,4,1,,BAO_0000019,,
2141,F,,,,104686,Autocuration,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,CHEMBL875906,,4,1,,BAO_0000019,,
2142,B,,,,104686,Autocuration,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,CHEMBL617223,,4,1,,BAO_0000019,,
2143,B,,,,104686,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,CHEMBL617224,,4,1,,BAO_0000224,,
2144,B,,10116.0,,104686,Autocuration,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,CHEMBL617225,,5,1,,BAO_0000224,,
2145,B,,,,104686,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,CHEMBL617226,,4,1,,BAO_0000224,,
2146,B,,,,104686,Autocuration,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,CHEMBL617227,,4,1,,BAO_0000224,,
2147,B,,,,104686,Autocuration,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,CHEMBL617228,,4,1,,BAO_0000224,,
2148,B,,,,104686,Autocuration,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,CHEMBL617229,,4,1,,BAO_0000224,,
2149,B,,,,104686,Autocuration,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,CHEMBL617230,,4,1,,BAO_0000224,,
2150,B,,,,104686,Autocuration,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,CHEMBL617231,,4,1,,BAO_0000224,,
2151,B,,,,104686,Autocuration,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,CHEMBL617232,,4,1,,BAO_0000224,,
2152,B,,,,104686,Autocuration,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,CHEMBL617233,,4,1,,BAO_0000224,,
2153,B,,,,104686,Autocuration,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,CHEMBL617234,,4,1,,BAO_0000224,,
2154,F,,,,104686,Autocuration,Compound was tested for the inhibition of quipazine induced head twitches in rats,,CHEMBL617235,,4,1,,BAO_0000019,,
2155,F,,,,104686,Autocuration,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,CHEMBL617236,,4,1,,BAO_0000019,,
2156,B,,,,104686,Autocuration,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,CHEMBL617237,,4,1,,BAO_0000221,10000000.0,
2157,B,,,,104686,Autocuration,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,CHEMBL617238,,4,1,,BAO_0000221,10000000.0,
2158,B,,10116.0,,104686,Autocuration,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,CHEMBL617239,,5,1,,BAO_0000221,955.0,
2159,B,,,,104686,Autocuration,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,CHEMBL617240,,4,1,,BAO_0000019,,
2160,B,,,,104686,Autocuration,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,CHEMBL617241,,4,1,,BAO_0000249,,
2161,B,,,,104686,Autocuration,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,CHEMBL875907,,4,1,,BAO_0000249,,
2162,B,,,,104686,Autocuration,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,CHEMBL617242,,4,1,,BAO_0000019,,
2163,F,,,,104686,Autocuration,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,CHEMBL617152,,4,1,,BAO_0000019,,
2164,B,,10116.0,,104686,Autocuration,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,CHEMBL617153,,5,1,,BAO_0000221,955.0,
2165,B,,10116.0,,104686,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,CHEMBL617154,,5,1,,BAO_0000249,,
2166,B,,,,104686,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,CHEMBL617155,,4,1,,BAO_0000221,955.0,
2167,F,,,,104686,Autocuration,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,CHEMBL617156,,4,1,,BAO_0000019,,
2168,F,,,,104686,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,CHEMBL617157,,4,1,,BAO_0000019,,
2169,F,,,,104686,Autocuration,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL617158,,4,1,,BAO_0000019,,
2170,F,,,,104686,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,CHEMBL617159,,4,1,,BAO_0000019,,
2171,F,,,,104686,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,CHEMBL617160,,4,1,,BAO_0000019,,
2172,F,,,,104686,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL858113,,4,1,,BAO_0000019,,
2173,B,,,,104686,Autocuration,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,CHEMBL617247,,4,1,,BAO_0000220,955.0,
2174,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,CHEMBL617248,,4,1,,BAO_0000019,,
2175,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,CHEMBL617249,,4,1,,BAO_0000249,955.0,
2176,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,CHEMBL617250,,4,1,,BAO_0000019,,
2177,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,CHEMBL617251,,4,1,,BAO_0000019,,
2178,B,,10116.0,,104686,Autocuration,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,CHEMBL617252,,5,1,,BAO_0000019,,
2179,B,,,,104686,Autocuration,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,CHEMBL617006,,4,1,,BAO_0000019,,
2180,B,,,,104686,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,CHEMBL617007,,4,1,,BAO_0000019,,
2181,F,,,,104686,Autocuration,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,CHEMBL617008,,4,1,,BAO_0000019,,
2182,B,,,,104686,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,CHEMBL617009,,4,1,,BAO_0000019,,
2183,B,,10116.0,,104686,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,CHEMBL617010,,5,1,,BAO_0000224,,
2184,B,,10116.0,,104686,Autocuration,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL857978,,5,1,,BAO_0000019,,
2185,B,,10116.0,,104686,Autocuration,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,CHEMBL617011,,5,1,,BAO_0000019,,
2186,B,,10116.0,,104686,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,CHEMBL617012,,5,1,,BAO_0000019,,
2187,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,CHEMBL617013,,4,1,,BAO_0000224,,
2188,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,CHEMBL617014,,4,1,,BAO_0000249,,
2189,B,,,,104686,Autocuration,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,CHEMBL617015,,4,1,,BAO_0000019,,
2190,B,,,,104686,Autocuration,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,CHEMBL617016,,4,1,,BAO_0000019,,
2191,B,,,,104686,Autocuration,pKi value for 5-hydroxytryptamine 2 receptor binding site,,CHEMBL617017,,4,1,,BAO_0000224,,
2192,B,,,,104686,Autocuration,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,CHEMBL617018,,4,1,,BAO_0000221,955.0,
2193,F,,,,104686,Autocuration,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,CHEMBL617019,,4,1,,BAO_0000019,,
2194,B,,,,105075,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617020,,4,1,,BAO_0000019,,
2195,B,,,,105075,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617021,,4,1,,BAO_0000019,,
2196,B,,,,105075,Autocuration,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617022,,4,1,,BAO_0000019,,
2197,B,,,,105075,Autocuration,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617023,,4,1,,BAO_0000019,,
2198,B,,,,105075,Autocuration,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617024,,4,1,,BAO_0000019,,
2199,B,,,,105075,Autocuration,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,CHEMBL617025,,4,1,,BAO_0000019,,
2200,B,,,,105075,Autocuration,Hill coefficient of compound was determined,,CHEMBL617026,,4,1,,BAO_0000224,,
2201,B,,,,22226,Autocuration,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,CHEMBL617027,,0,1,,BAO_0000019,,
2202,B,,10116.0,,104686,Autocuration,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,CHEMBL617028,,5,1,,BAO_0000019,,
2203,B,,,,12687,Expert,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,CHEMBL617029,,8,1,,BAO_0000019,,
2204,B,,,,12687,Expert,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,CHEMBL875908,,8,1,,BAO_0000019,,
2205,B,,,,12687,Autocuration,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,CHEMBL617030,,8,1,,BAO_0000357,,
2206,B,,,,12687,Autocuration,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,CHEMBL617031,,8,1,,BAO_0000019,,
2207,B,,,,12687,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,CHEMBL617032,,8,1,,BAO_0000019,,
2208,B,,10116.0,,104686,Autocuration,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,CHEMBL617033,,5,1,,BAO_0000224,,
2209,B,,,,104686,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,CHEMBL617034,,4,1,,BAO_0000224,,
2210,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,CHEMBL617035,,4,1,,BAO_0000224,,
2211,B,,,,104686,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,CHEMBL617036,,4,1,,BAO_0000019,,
2212,B,,,,104784,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,CHEMBL617037,,4,1,,BAO_0000224,,
2213,B,,,,22226,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,CHEMBL617038,,0,1,,BAO_0000219,,
2214,B,,,,104784,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,CHEMBL617039,,4,1,,BAO_0000219,,
2215,B,,,,104784,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,CHEMBL617161,,4,1,,BAO_0000224,,
2216,B,,,,104784,Autocuration,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,CHEMBL617162,,4,1,,BAO_0000224,,
2217,B,,,,104784,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617163,,4,1,,BAO_0000224,,
2218,B,,,,104784,Autocuration,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617164,,4,1,,BAO_0000224,,
2219,B,,,,104784,Autocuration,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,CHEMBL617165,,4,1,,BAO_0000249,,
2220,B,,,,104784,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,CHEMBL617166,,4,1,,BAO_0000224,,
2221,B,,,,104784,Autocuration,Binding affinity towards 5-HT2 receptor,,CHEMBL617167,,4,1,,BAO_0000224,,
2222,B,,,,104784,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL872912,,4,1,,BAO_0000224,,
2223,B,,,,104784,Autocuration,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,CHEMBL617168,,4,1,,BAO_0000224,,
2224,B,,,,104686,Autocuration,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,CHEMBL617169,,4,1,,BAO_0000224,,
2225,B,,,,104784,Autocuration,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617170,,4,1,,BAO_0000224,,
2226,B,,,,104784,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,CHEMBL617171,,4,1,,BAO_0000224,,
2227,B,,,,104784,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617172,,4,1,,BAO_0000224,,
2228,B,,,,104784,Autocuration,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617173,,4,1,,BAO_0000224,,
2229,B,,,,22226,Autocuration,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617174,,0,1,,BAO_0000019,,
2230,B,,,,104784,Autocuration,5-hydroxytryptamine 2 receptor binding affinity,,CHEMBL617175,,4,1,,BAO_0000224,,
2231,B,,,,17005,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,CHEMBL617176,,8,1,,BAO_0000357,,
2232,B,,,,17005,Autocuration,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,CHEMBL617177,,8,1,,BAO_0000357,,
2233,B,,,,104784,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,CHEMBL617178,,4,1,,BAO_0000224,,
2234,B,,,,104784,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,CHEMBL617179,,4,1,,BAO_0000224,,
2235,B,,,,104784,Autocuration,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,CHEMBL617180,,4,1,,BAO_0000224,,
2236,B,,,,17005,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,CHEMBL617181,,8,1,,BAO_0000357,,
2237,B,,,,17005,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor,,CHEMBL617182,,8,1,,BAO_0000357,,
2238,B,,,,17005,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor,,CHEMBL617183,,8,1,,BAO_0000357,,
2239,B,,,,17005,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,CHEMBL617184,,8,1,,BAO_0000357,,
2240,B,,,,17005,Autocuration,Binding affinity against serotonergic 5-HT2 receptor,,CHEMBL617185,,8,1,,BAO_0000357,,
2241,B,,,,17005,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,CHEMBL617186,,8,1,,BAO_0000357,,
2242,B,,,,17005,Autocuration,Compound was evaluated for the binding affinity at 5- HT2 receptor,,CHEMBL617187,,8,1,,BAO_0000357,,
2243,B,,,,17005,Autocuration,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,CHEMBL617188,,8,1,,BAO_0000357,,
2244,B,,,,17005,Autocuration,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,CHEMBL617189,,8,1,,BAO_0000218,,
2245,B,,9606.0,,104784,Autocuration,Inhibitory activity against cloned human 5-HT2 receptor,,CHEMBL617190,,5,1,,BAO_0000224,,
2246,B,,9606.0,,104784,Autocuration,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,CHEMBL617191,,5,1,449.0,BAO_0000219,,
2247,B,,9606.0,,104784,Autocuration,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,CHEMBL617192,,5,1,449.0,BAO_0000219,,
2248,B,,9606.0,,104784,Autocuration,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,CHEMBL617193,,5,1,449.0,BAO_0000219,,
2249,B,,9606.0,,104784,Autocuration,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,CHEMBL617194,,5,1,449.0,BAO_0000219,,
2250,B,,,,104784,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617195,,4,1,,BAO_0000224,,
2251,B,,,,104784,Autocuration,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,CHEMBL881830,,4,1,,BAO_0000224,,
2252,B,,,,17005,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617196,,8,1,,BAO_0000357,,
2253,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,CHEMBL617197,,4,1,,BAO_0000224,,
2254,B,,,,17005,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,CHEMBL617198,,8,1,,BAO_0000357,,
2255,B,,,,17005,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL873476,,8,1,,BAO_0000357,,
2256,B,,,,17005,Expert,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,CHEMBL617199,,8,1,,BAO_0000019,,
2257,B,,10141.0,,107,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,CHEMBL617200,,8,1,,BAO_0000357,,
2258,B,,,,51,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617484,,8,1,,BAO_0000357,,
2259,B,,,,107,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617485,,8,1,,BAO_0000357,,
2260,B,,,,51,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617486,,8,1,,BAO_0000357,,
2261,B,,,,107,Autocuration,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,CHEMBL858022,,8,1,,BAO_0000357,,
2262,B,,,,107,Autocuration,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,CHEMBL617049,,8,1,449.0,BAO_0000219,,
2263,F,,9606.0,,107,Expert,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,CHEMBL617050,,9,1,449.0,BAO_0000219,,
2264,F,,,,107,Autocuration,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,CHEMBL617051,,8,1,,BAO_0000219,,
2265,F,,,,107,Autocuration,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,CHEMBL617052,,8,1,,BAO_0000219,,
2266,F,,,,107,Autocuration,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,CHEMBL617053,,8,1,,BAO_0000219,,
2267,B,,,,107,Autocuration,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,CHEMBL617054,,8,1,449.0,BAO_0000219,,
2268,B,,,,107,Autocuration,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,CHEMBL617055,,8,1,449.0,BAO_0000219,,
2269,B,,,,107,Autocuration,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,CHEMBL882924,,8,1,,BAO_0000357,,
2270,B,,9606.0,,107,Expert,Inhibition of human 5-hydroxytryptamine 2A receptor,,CHEMBL617056,,9,1,,BAO_0000357,,
2271,B,,,,107,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL617057,,8,1,449.0,BAO_0000219,,
2272,B,,,,107,Expert,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,CHEMBL617058,,8,1,,BAO_0000219,,
2273,B,,,,107,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,CHEMBL617059,,8,1,,BAO_0000357,,
2274,B,,,,107,Autocuration,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617060,,8,1,449.0,BAO_0000219,,
2275,B,,,,107,Expert,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,CHEMBL617061,,8,1,449.0,BAO_0000219,,
2276,B,,,,107,Expert,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,CHEMBL617062,,8,1,307.0,BAO_0000219,,
2277,B,,,,107,Expert,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL617063,,8,1,449.0,BAO_0000219,,
2278,F,,,,107,Autocuration,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,CHEMBL617064,,8,1,,BAO_0000019,,
2279,F,,,,107,Autocuration,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL617065,,8,1,,BAO_0000019,,
2280,B,,,,107,Autocuration,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,CHEMBL617066,,8,1,449.0,BAO_0000219,,
2281,B,,,,107,Autocuration,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,CHEMBL617067,,8,1,449.0,BAO_0000219,,
2282,F,,,,107,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,CHEMBL617068,,8,1,,BAO_0000019,,
2283,F,,,,107,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,CHEMBL617069,,8,1,,BAO_0000019,,
2284,F,,,,107,Autocuration,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL617070,,8,1,,BAO_0000019,,
2285,B,,,,107,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,CHEMBL617071,,8,1,,BAO_0000357,,
2286,B,,,,107,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL872915,,8,1,,BAO_0000357,,
2287,B,,,,107,Autocuration,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,CHEMBL617072,,8,1,,BAO_0000357,,
2288,B,,,,107,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,CHEMBL617073,,8,1,,BAO_0000357,,
2289,B,,,,107,Autocuration,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,CHEMBL617074,,8,1,,BAO_0000357,,
2290,B,,,,107,Expert,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL617075,,8,1,449.0,BAO_0000219,,
2291,B,,,,107,Autocuration,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,CHEMBL617076,,8,1,,BAO_0000357,,
2292,B,,9606.0,,107,Expert,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,CHEMBL617077,,9,1,,BAO_0000019,,
2293,B,,,,107,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,CHEMBL617078,,8,1,,BAO_0000357,,
2294,B,,9606.0,,107,Expert,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,CHEMBL617079,,9,1,,BAO_0000357,,
2295,B,,,,107,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,CHEMBL617080,,8,1,,BAO_0000357,,
2296,B,,,,107,Expert,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,CHEMBL617081,,8,1,449.0,BAO_0000219,,
2297,B,,,,107,Expert,Binding affinity towards human 5-HT2A receptor in BEK cells,,CHEMBL617082,,8,1,,BAO_0000219,,
2298,B,,,,107,Autocuration,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617083,,8,1,,BAO_0000357,,
2299,B,,,,107,Autocuration,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,CHEMBL617084,,8,1,,BAO_0000357,,
2300,B,,9606.0,,107,Expert,Binding affinity for human 5-hydroxytryptamine 2A receptor,,CHEMBL617085,,9,1,,BAO_0000357,,
2301,B,,,,107,Autocuration,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL617086,,8,1,,BAO_0000357,,
2302,B,,,,107,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,CHEMBL617087,,8,1,,BAO_0000219,,
2303,B,,,,107,Autocuration,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,CHEMBL617088,,8,1,,BAO_0000357,,
2304,B,,,,107,Autocuration,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,CHEMBL617089,,8,1,,BAO_0000357,,
2305,B,,,,107,Expert,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,CHEMBL617090,,8,1,,BAO_0000019,,
2306,B,,,,107,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,CHEMBL617513,,8,1,,BAO_0000357,,
2307,B,,,,107,Autocuration,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,CHEMBL617514,,8,1,722.0,BAO_0000219,,
2308,B,,,,107,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,CHEMBL617515,,8,1,,BAO_0000019,,
2309,B,,,,107,Autocuration,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617516,,8,1,,BAO_0000357,,
2310,B,,9606.0,,107,Expert,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,CHEMBL617517,,9,1,,BAO_0000357,,
2311,B,,9606.0,,107,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,CHEMBL617518,,9,1,449.0,BAO_0000219,,
2312,B,,,,107,Autocuration,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617519,,8,1,,BAO_0000357,,
2313,B,,9606.0,,107,Expert,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,CHEMBL617520,,9,1,,BAO_0000357,,
2314,B,,,,107,Autocuration,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,CHEMBL617521,,8,1,,BAO_0000357,,
2315,B,,9606.0,,107,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,CHEMBL617522,,9,1,,BAO_0000357,,
2316,B,,,,107,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,CHEMBL617523,,8,1,,BAO_0000357,,
2317,B,,,,107,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL617524,,8,1,,BAO_0000357,,
2318,B,,,,104686,Autocuration,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,CHEMBL617525,,4,1,,BAO_0000019,,
2319,B,,10116.0,,104686,Autocuration,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,CHEMBL617526,,5,1,,BAO_0000019,,
2320,B,,,,104686,Autocuration,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,CHEMBL617527,,4,1,,BAO_0000224,,
2321,B,,,,104686,Autocuration,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,CHEMBL617528,,4,1,,BAO_0000019,,
2322,B,,,,104686,Autocuration,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,CHEMBL617529,,4,1,,BAO_0000019,,
2323,B,,,,104686,Autocuration,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,CHEMBL617530,,4,1,,BAO_0000224,,
2324,B,,,,104686,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,CHEMBL617531,,4,1,,BAO_0000019,,
2325,B,,,,104686,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,CHEMBL617532,,4,1,,BAO_0000019,,
2326,B,,,,104686,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,CHEMBL617533,,4,1,,BAO_0000019,,
2327,B,,,,104686,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,CHEMBL617534,,4,1,,BAO_0000019,,
2328,B,,,,104686,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,CHEMBL617535,,4,1,,BAO_0000224,,
2329,B,,,,104686,Autocuration,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,CHEMBL617536,,4,1,,BAO_0000224,,
2330,B,,,,104686,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,CHEMBL617537,,4,1,,BAO_0000224,,
2331,B,,,,104686,Autocuration,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,CHEMBL617538,,4,1,,BAO_0000224,,
2332,B,In vitro,,,104686,Autocuration,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,CHEMBL617539,,4,1,,BAO_0000219,,
2333,B,,10116.0,,104686,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL617540,,5,1,,BAO_0000224,,
2334,B,,10116.0,,104686,Autocuration,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,CHEMBL617541,,5,1,,BAO_0000224,,
2335,B,,,,104686,Autocuration,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,CHEMBL617542,,4,1,,BAO_0000224,,
2336,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,CHEMBL617543,,4,1,,BAO_0000224,,
2337,B,,10116.0,,104686,Autocuration,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHEMBL617544,,5,1,485.0,BAO_0000219,,
2338,B,,10116.0,,104686,Autocuration,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,CHEMBL617545,,5,1,485.0,BAO_0000219,,
2339,B,,10116.0,,104686,Autocuration,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,CHEMBL617413,,5,1,,BAO_0000019,,
2340,B,,,,104686,Autocuration,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,CHEMBL617414,,4,1,,BAO_0000019,,
2341,B,,10116.0,,104686,Autocuration,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,CHEMBL617415,,5,1,,BAO_0000019,,
2342,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617416,,4,1,,BAO_0000224,,
2343,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,CHEMBL617417,,4,1,,BAO_0000224,,
2344,B,,,,104686,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,CHEMBL617418,,4,1,,BAO_0000019,,
2345,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,CHEMBL617419,,4,1,,BAO_0000019,,
2346,B,,,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,CHEMBL617420,,4,1,,BAO_0000224,,
2347,B,,10116.0,,104686,Autocuration,Affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617421,,5,1,,BAO_0000224,,
2348,B,,,,104686,Autocuration,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,CHEMBL617422,,4,1,,BAO_0000224,,
2349,B,,,,104686,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,CHEMBL617423,,4,1,,BAO_0000019,,
2350,B,,,,104686,Autocuration,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,CHEMBL617424,,4,1,,BAO_0000019,,
2351,B,,,,104686,Autocuration,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,CHEMBL617425,,4,1,,BAO_0000019,,
2352,B,,,,104686,Autocuration,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,CHEMBL617426,,4,1,,BAO_0000224,,
2353,B,In vivo,,,104686,Autocuration,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,CHEMBL617427,,4,1,,BAO_0000218,,
2354,B,,,,104686,Autocuration,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,CHEMBL617428,,4,1,,BAO_0000221,955.0,
2355,B,,,,104686,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,CHEMBL617429,,4,1,,BAO_0000224,,
2356,B,,,,104686,Autocuration,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,CHEMBL617430,,4,1,,BAO_0000019,,
2357,B,,,,104686,Autocuration,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,CHEMBL617431,,4,1,,BAO_0000019,,
2358,B,,,,104686,Autocuration,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,CHEMBL617432,,4,1,,BAO_0000019,1870.0,
2359,B,,,,104686,Autocuration,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,CHEMBL617433,,4,1,,BAO_0000224,,
2360,B,,,,104686,Autocuration,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,CHEMBL617434,,4,1,,BAO_0000224,,
2361,B,,10116.0,,104686,Autocuration,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,CHEMBL617435,,5,1,,BAO_0000224,,
2362,B,,,,104686,Autocuration,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,CHEMBL617436,,4,1,,BAO_0000019,,
2363,B,,10116.0,,104686,Autocuration,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,CHEMBL617437,,5,1,,BAO_0000019,2435.0,
2364,B,,,,104686,Autocuration,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,CHEMBL617438,,4,1,,BAO_0000019,,
2365,B,,,,104686,Autocuration,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,CHEMBL617439,,4,1,,BAO_0000019,,
2366,B,,,,104686,Autocuration,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,CHEMBL617440,,4,1,,BAO_0000224,,
2367,B,,,,104686,Autocuration,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,CHEMBL617441,,4,1,,BAO_0000224,,
2368,B,,10116.0,,104686,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,CHEMBL872918,,5,1,,BAO_0000019,,
2369,B,,10116.0,,104686,Autocuration,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,CHEMBL617442,,5,1,,BAO_0000019,,
2370,B,,,,104686,Autocuration,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,CHEMBL617443,,4,1,,BAO_0000019,,
2371,B,,,,104686,Autocuration,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,CHEMBL617444,,4,1,,BAO_0000019,,
2372,B,,,,104686,Autocuration,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,CHEMBL617445,,4,1,,BAO_0000019,,
2373,B,,,,104686,Autocuration,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,CHEMBL617446,,4,1,,BAO_0000019,,
2374,B,,,,104686,Autocuration,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,CHEMBL617447,,4,1,,BAO_0000249,,
2375,B,,,,104686,Autocuration,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,CHEMBL617448,,4,1,,BAO_0000019,,
2376,B,,,,104686,Autocuration,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,CHEMBL617449,,4,1,,BAO_0000019,,
2377,B,,,,104686,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,CHEMBL617450,,4,1,,BAO_0000019,,
2378,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,CHEMBL617451,,4,1,,BAO_0000019,,
2379,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,CHEMBL617452,,4,1,,BAO_0000019,,
2380,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,CHEMBL617453,,4,1,,BAO_0000019,,
2381,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,CHEMBL617660,,4,1,,BAO_0000019,,
2382,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,CHEMBL617661,,4,1,,BAO_0000019,,
2383,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,CHEMBL617662,,4,1,,BAO_0000019,,
2384,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,CHEMBL872919,,4,1,,BAO_0000019,,
2385,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,CHEMBL617663,,4,1,,BAO_0000019,,
2386,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,CHEMBL617664,,4,1,,BAO_0000019,,
2387,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,CHEMBL617665,,4,1,,BAO_0000019,,
2388,B,,,,104686,Autocuration,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,CHEMBL617666,,4,1,,BAO_0000019,,
2389,B,,,,104686,Autocuration,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,CHEMBL617667,,4,1,,BAO_0000019,,
2390,B,,,,104686,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,CHEMBL617668,,4,1,,BAO_0000249,,
2391,B,,,,104686,Autocuration,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,CHEMBL617669,,4,1,,BAO_0000249,,
2392,B,,,,104686,Autocuration,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,CHEMBL617670,,4,1,,BAO_0000224,,
2393,B,,10116.0,,104686,Autocuration,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,CHEMBL617671,,5,1,,BAO_0000224,,
2394,B,,,,104686,Autocuration,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL617672,,4,1,,BAO_0000224,,
2395,B,,,,104686,Autocuration,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,CHEMBL617673,,4,1,,BAO_0000019,,
2396,B,,,,104686,Autocuration,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,CHEMBL617674,,4,1,,BAO_0000224,,
2397,B,,,,104686,Autocuration,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,CHEMBL617675,,4,1,,BAO_0000019,,
2398,B,,,,104686,Autocuration,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,CHEMBL617676,,4,1,,BAO_0000019,,
2399,B,,,,104686,Autocuration,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,CHEMBL617677,,4,1,,BAO_0000019,,
2400,B,,,,104686,Autocuration,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,CHEMBL617678,,5,1,,BAO_0000019,,
2401,B,,,,104686,Autocuration,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,CHEMBL617679,,4,1,,BAO_0000224,,
2402,B,,,,104686,Autocuration,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,CHEMBL617680,,4,1,,BAO_0000224,,
2403,B,,,,104686,Autocuration,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,CHEMBL617681,,4,1,,BAO_0000019,,
2404,B,,,,104686,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,CHEMBL617682,,4,1,,BAO_0000221,955.0,
2405,B,,,,104686,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,CHEMBL617683,,4,1,,BAO_0000224,,
2406,B,,,,104686,Autocuration,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,CHEMBL617684,,4,1,,BAO_0000224,,
2407,B,,10116.0,,104686,Autocuration,Binding affinity towards 5-hydroxytryptamine 2 receptor,,CHEMBL617685,,5,1,,BAO_0000224,,
2408,B,,,,104686,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,CHEMBL617686,,4,1,,BAO_0000019,,
2409,B,,,,104686,Autocuration,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,CHEMBL617687,,4,1,,BAO_0000224,,
2410,B,,,,104686,Autocuration,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,CHEMBL617688,,4,1,,BAO_0000224,,
2411,F,,,,104686,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL617689,,4,1,,BAO_0000019,,
2412,F,,,,104686,Autocuration,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,CHEMBL617690,,4,1,,BAO_0000019,,
2413,F,In vivo,,,104686,Autocuration,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,CHEMBL617691,,4,1,,BAO_0000218,,
2414,F,In vivo,,,104686,Autocuration,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,CHEMBL617692,,4,1,,BAO_0000218,,
2415,F,In vivo,,,104686,Autocuration,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,CHEMBL617693,,4,1,,BAO_0000218,,
2416,F,In vivo,,,104686,Autocuration,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,CHEMBL617694,,4,1,,BAO_0000218,,
2417,B,,,,12687,Expert,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,CHEMBL857985,,8,1,,BAO_0000221,955.0,
2418,B,,10116.0,,12687,Expert,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,CHEMBL617695,,9,1,,BAO_0000019,,
2419,B,,,,12687,Autocuration,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,CHEMBL617696,,8,1,,BAO_0000019,,
2420,B,,,,12687,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617697,,8,1,,BAO_0000357,,
2421,B,,10116.0,,12687,Expert,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,CHEMBL617257,,9,1,,BAO_0000019,,
2422,B,,10116.0,,12687,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,CHEMBL617258,,9,1,,BAO_0000357,,
2423,B,,,,12687,Expert,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,CHEMBL617259,,8,1,,BAO_0000019,,
2424,B,,,,12687,Autocuration,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,CHEMBL617260,,8,1,,BAO_0000357,,
2425,B,,10116.0,,12687,Expert,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617261,,9,1,,BAO_0000357,,
2426,B,,,,12687,Autocuration,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,CHEMBL617262,,8,1,,BAO_0000019,,
2427,B,,,,12687,Expert,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,CHEMBL617263,,8,1,,BAO_0000019,,
2428,B,,,,12687,Autocuration,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,CHEMBL617264,,8,1,,BAO_0000019,,
2429,B,,10116.0,,12687,Expert,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,CHEMBL617265,,9,1,,BAO_0000019,,
2430,B,,,,12687,Autocuration,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,CHEMBL617266,,8,1,,BAO_0000249,,
2431,B,,,,12687,Autocuration,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,CHEMBL617267,,8,1,,BAO_0000019,,
2432,B,,,,12687,Expert,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,CHEMBL617268,,8,1,,BAO_0000019,,
2433,B,,,,12687,Autocuration,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,CHEMBL617269,,8,1,449.0,BAO_0000219,,
2434,B,,,,12687,Expert,Kinetic inhibition constant evaluated by measuring serotonergic activity,,CHEMBL617323,,8,1,,BAO_0000357,,
2435,B,,,,12687,Autocuration,Serotonergic activity of the compound.,,CHEMBL617324,,8,1,,BAO_0000357,,
2436,B,,,,12687,Autocuration,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,CHEMBL617325,,8,1,,BAO_0000249,,
2437,B,,10116.0,,12687,Expert,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,CHEMBL617326,,9,1,,BAO_0000019,,
2438,B,,,,12687,Expert,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,CHEMBL617327,,8,1,,BAO_0000249,,
2439,F,,10116.0,,12687,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617328,,9,1,,BAO_0000019,,
2440,F,,10116.0,,12687,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617329,,9,1,,BAO_0000019,,
2441,F,,10116.0,,12687,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617330,,9,1,,BAO_0000019,,
2442,B,,,,12687,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL617331,,8,1,,BAO_0000357,,
2443,B,,,,12687,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,CHEMBL617332,,8,1,,BAO_0000357,,
2444,B,,,,107,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617333,,8,1,,BAO_0000357,,
2445,B,,,,107,Autocuration,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,CHEMBL617334,,8,1,,BAO_0000357,,
2446,B,,,,107,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,CHEMBL617335,,8,1,,BAO_0000357,,
2447,B,,,,107,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,CHEMBL617336,,8,1,,BAO_0000357,,
2448,B,,,,107,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,CHEMBL617337,,8,1,,BAO_0000357,,
2449,B,,9606.0,,107,Expert,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,CHEMBL617338,,9,1,,BAO_0000357,,
2450,B,,,,107,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,CHEMBL617339,,8,1,,BAO_0000357,,
2451,B,,,,107,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617340,,8,1,,BAO_0000357,,
2452,B,,,,107,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,CHEMBL617341,,8,1,,BAO_0000357,,
2453,B,,,,107,Expert,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617342,,8,1,,BAO_0000357,,
2454,B,,,,107,Expert,Affinity for 5-hydroxytryptamine 2A receptor,,CHEMBL617343,,8,1,,BAO_0000357,,
2455,B,,,,107,Expert,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,CHEMBL617344,,8,1,723.0,BAO_0000219,,
2456,B,,,,107,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,CHEMBL617345,,8,1,,BAO_0000357,,
2457,B,,,,107,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,CHEMBL617346,,8,1,,BAO_0000357,,
2458,B,,,,107,Autocuration,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,CHEMBL617347,,8,1,,BAO_0000357,,
2459,B,,,,107,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617348,,8,1,,BAO_0000357,,
2460,B,,,,107,Autocuration,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617349,,8,1,,BAO_0000357,,
2461,F,,,,107,Autocuration,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,CHEMBL617350,,8,1,,BAO_0000019,,
2462,B,,,,107,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,CHEMBL872339,,8,1,,BAO_0000357,,
2463,B,,,,107,Autocuration,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617351,,8,1,,BAO_0000357,,
2464,B,,,,107,Expert,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617352,,8,1,,BAO_0000357,,
2465,B,,,,107,Autocuration,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617353,,8,1,,BAO_0000357,,
2466,B,,,,107,Autocuration,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,CHEMBL617354,,8,1,,BAO_0000357,,
2467,B,,,,107,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,CHEMBL617355,,8,1,,BAO_0000357,,
2468,B,,10090.0,,107,Expert,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,CHEMBL617356,,8,1,449.0,BAO_0000219,,
2469,B,,,,107,Autocuration,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,CHEMBL617357,,8,1,,BAO_0000357,,
2470,B,,,,107,Autocuration,Binding affinity at 5-hydroxytryptamine 2A receptor,,CHEMBL617358,,8,1,,BAO_0000357,,
2471,B,,,,107,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617359,,8,1,,BAO_0000357,,
2472,B,,,,107,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,CHEMBL617360,,8,1,,BAO_0000357,,
2473,B,,,,107,Autocuration,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,CHEMBL875913,,8,1,,BAO_0000357,,
2474,B,,,,107,Autocuration,Affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617361,,8,1,,BAO_0000357,,
2475,B,,9606.0,,107,Expert,Binding affinity against 5-Hydroxytryptamine 2A receptor,,CHEMBL617362,,9,1,,BAO_0000357,,
2476,B,,,,107,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,CHEMBL617363,,8,1,,BAO_0000357,,
2477,B,,,,107,Autocuration,Tested against 5-hydroxytryptamine 2A receptor,,CHEMBL617364,,8,1,,BAO_0000357,,
2478,B,,,,105075,Autocuration,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,CHEMBL617365,,4,1,,BAO_0000224,,
2479,B,,,,105075,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,CHEMBL617366,,4,1,,BAO_0000224,,
2480,B,,,,105075,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,CHEMBL617367,,4,1,,BAO_0000224,,
2481,B,,,,105075,Autocuration,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,CHEMBL617368,,4,1,,BAO_0000224,,
2482,B,,,,107,Autocuration,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,CHEMBL617369,,8,1,,BAO_0000357,,
2483,B,,9606.0,,227,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,CHEMBL617370,,9,1,722.0,BAO_0000219,,
2484,F,,9606.0,,227,Expert,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,CHEMBL617371,,9,1,449.0,BAO_0000219,,
2485,B,,,,227,Autocuration,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,CHEMBL617372,,8,1,,BAO_0000357,,
2486,B,,9606.0,,227,Expert,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,CHEMBL617373,,9,1,,BAO_0000357,,
2487,F,,,,227,Autocuration,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,CHEMBL617374,,8,1,,BAO_0000019,,
2488,F,,,,227,Autocuration,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,CHEMBL617375,,8,1,,BAO_0000019,,
2489,F,,,,227,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,CHEMBL617376,,8,1,,BAO_0000019,,
2490,F,,,,227,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,CHEMBL617377,,8,1,,BAO_0000019,,
2491,F,,,,227,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,CHEMBL617378,,8,1,,BAO_0000019,,
2492,F,,,,227,Autocuration,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,CHEMBL617379,,8,1,,BAO_0000019,,
2493,B,,,,227,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,CHEMBL617380,,8,1,,BAO_0000357,,
2494,B,,,,227,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,CHEMBL617381,,8,1,,BAO_0000357,,
2495,B,,,,227,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,CHEMBL617382,,8,1,,BAO_0000357,,
2496,B,,,,107,Autocuration,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617383,,8,1,,BAO_0000357,,
2497,B,,,,107,Expert,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,CHEMBL617384,,8,1,,BAO_0000357,,
2498,B,,,,107,Expert,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,CHEMBL617385,,8,1,,BAO_0000357,,
2499,B,,,,107,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,CHEMBL617386,,8,1,,BAO_0000019,,
2500,B,,,,107,Autocuration,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,CHEMBL617387,,8,1,,BAO_0000019,,
2501,B,,,,107,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL617388,,8,1,723.0,BAO_0000219,,
2502,F,,,,107,Autocuration,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617389,,8,1,449.0,BAO_0000219,,
2503,F,,9606.0,,107,Expert,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617390,,9,1,449.0,BAO_0000219,,
2504,B,,,,104817,Autocuration,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,CHEMBL617391,,4,1,,BAO_0000224,,
2505,B,,,,107,Autocuration,Binding activity radioligand.,,CHEMBL617392,,8,1,,BAO_0000357,,
2506,B,,,,107,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,CHEMBL617393,,8,1,,BAO_0000019,,
2507,B,,,,107,Autocuration,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,CHEMBL617394,,8,1,307.0,BAO_0000219,,
2508,B,,,,107,Expert,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,CHEMBL617395,,8,1,307.0,BAO_0000219,,
2509,B,,,,107,Expert,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,CHEMBL617396,,8,1,307.0,BAO_0000219,,
2510,B,,,,107,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,CHEMBL617397,,8,1,307.0,BAO_0000219,,
2511,B,,,,107,Autocuration,Binding affinity against 5-HT2A receptor,,CHEMBL617398,,8,1,,BAO_0000357,,
2512,B,,,,107,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617399,,8,1,,BAO_0000357,,
2513,B,,,,107,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,CHEMBL617400,,8,1,722.0,BAO_0000219,,
2514,B,,,,107,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,CHEMBL617401,,8,1,722.0,BAO_0000219,,
2515,B,,9606.0,,107,Expert,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,CHEMBL617402,,9,1,722.0,BAO_0000219,,
2516,B,,9606.0,,107,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL617403,,9,1,722.0,BAO_0000219,,
2517,B,,,,107,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,CHEMBL617404,,8,1,,BAO_0000357,,
2518,B,,9606.0,,107,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL857981,,9,1,722.0,BAO_0000219,,
2519,B,,9606.0,,107,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL617405,,9,1,722.0,BAO_0000219,,
2520,B,,9606.0,,107,Expert,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,CHEMBL617253,,9,1,722.0,BAO_0000219,,
2521,B,,,,107,Expert,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,CHEMBL617254,,8,1,,BAO_0000357,,
2522,B,,,,107,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL617255,,8,1,722.0,BAO_0000219,,
2523,B,,,,107,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL617256,,8,1,722.0,BAO_0000219,,
2524,B,,,,107,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL616874,,8,1,722.0,BAO_0000219,,
2525,B,,9606.0,,107,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,CHEMBL616875,,9,1,722.0,BAO_0000219,,
2526,B,,,,107,Expert,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,CHEMBL616876,,8,1,722.0,BAO_0000219,,
2527,B,,,,107,Expert,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,CHEMBL616877,,8,1,722.0,BAO_0000219,,
2528,B,,9606.0,,107,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,CHEMBL616878,,9,1,722.0,BAO_0000219,,
2529,B,,,,107,Expert,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,CHEMBL616879,,8,1,722.0,BAO_0000219,,
2530,B,,,,107,Expert,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,CHEMBL616880,,8,1,722.0,BAO_0000219,,
2531,B,,9606.0,,107,Expert,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,CHEMBL616881,,9,1,722.0,BAO_0000219,,
2532,B,,,,107,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,CHEMBL616882,,8,1,723.0,BAO_0000219,,
2533,B,,,,107,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL616883,,8,1,723.0,BAO_0000219,,
2534,B,,,,107,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL616884,,8,1,723.0,BAO_0000219,,
2535,B,,,,107,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,CHEMBL616885,,8,1,722.0,BAO_0000219,,
2536,B,,,,107,Autocuration,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,CHEMBL616886,,8,1,485.0,BAO_0000219,,
2537,B,,,,107,Expert,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,CHEMBL616887,,8,1,485.0,BAO_0000219,,
2538,B,,9606.0,,107,Expert,Binding affinity for human 5-hydroxytryptamine 2A receptor,,CHEMBL616888,,9,1,,BAO_0000357,,
2539,B,,,,107,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,CHEMBL616889,,8,1,722.0,BAO_0000219,,
2540,B,,,,107,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,CHEMBL616890,,8,1,722.0,BAO_0000219,,
2541,B,,9606.0,,107,Expert,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,CHEMBL616891,,9,1,449.0,BAO_0000219,,
2542,B,,,,107,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,CHEMBL616892,,8,1,722.0,BAO_0000219,,
2543,B,,,,107,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,CHEMBL616893,,8,1,722.0,BAO_0000219,,
2544,F,,,,10620,Autocuration,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,CHEMBL616894,,8,1,723.0,BAO_0000219,,
2545,B,,,,107,Expert,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,CHEMBL616895,,8,1,723.0,BAO_0000219,,
2546,F,,,,10620,Autocuration,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,CHEMBL616896,,8,1,,BAO_0000019,,
2547,B,,,,10621,Autocuration,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,CHEMBL617099,,8,1,,BAO_0000357,,
2548,B,,,,10621,Autocuration,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,CHEMBL617100,,8,1,,BAO_0000357,,
2549,B,,9986.0,,107,Autocuration,Binding affinity against rabbit aorta 5-HT2A receptor,,CHEMBL884532,,8,1,,BAO_0000357,,
2550,B,,9986.0,,107,Expert,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,CHEMBL617101,,8,1,,BAO_0000357,,
2551,B,,9986.0,,107,Expert,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,CHEMBL617102,,8,1,,BAO_0000357,,
2552,B,,9986.0,,107,Autocuration,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,CHEMBL617103,,8,1,,BAO_0000019,,
2553,B,,9986.0,,107,Expert,The compound was tested for binding affinity against 5-HT2A receptor,,CHEMBL617104,,8,1,,BAO_0000357,,
2554,B,,,,10576,Autocuration,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,CHEMBL857979,,8,1,485.0,BAO_0000219,,
2555,B,,,,12687,Autocuration,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,CHEMBL857502,,8,1,,BAO_0000019,,
2556,B,,,,12687,Autocuration,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,CHEMBL617105,,8,1,,BAO_0000019,,
2557,B,,,,12687,Autocuration,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,CHEMBL858021,,8,1,,BAO_0000019,945.0,
2558,B,,10116.0,,12687,Expert,Binding affinity for 5-HT 2A in rat stomach fundus,,CHEMBL875910,,9,1,,BAO_0000019,945.0,
2559,B,,,,12687,Autocuration,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,CHEMBL617106,,8,1,,BAO_0000019,,
2560,B,,,,12687,Expert,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,CHEMBL617107,,8,1,723.0,BAO_0000219,,
2561,F,,,,12687,Autocuration,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,CHEMBL617108,,8,1,,BAO_0000019,,
2562,F,,,,12687,Autocuration,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,CHEMBL617109,,8,1,,BAO_0000019,,
2563,B,,,,12687,Autocuration,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,CHEMBL617110,,8,1,,BAO_0000357,,
2564,B,,,,12687,Autocuration,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,CHEMBL617111,,8,1,,BAO_0000357,,
2565,F,,10116.0,,12687,Expert,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,CHEMBL617112,,9,1,,BAO_0000019,,
2566,B,,,,12687,Autocuration,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617113,,8,1,,BAO_0000357,,
2567,B,,,,12687,Autocuration,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617114,,8,1,,BAO_0000357,,
2568,B,,,,12687,Autocuration,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617115,,8,1,,BAO_0000357,,
2569,F,,,,12687,Autocuration,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,CHEMBL617116,,8,1,,BAO_0000219,,
2570,F,,,,12687,Autocuration,Efficacy at 5-hydroxytryptamine 2A receptor,,CHEMBL617117,,8,1,,BAO_0000019,,
2571,B,,,,12687,Autocuration,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,CHEMBL617118,,8,1,,BAO_0000357,,
2572,B,,10116.0,,12687,Expert,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,CHEMBL617119,,9,1,,BAO_0000357,,
2573,B,,10116.0,,12687,Expert,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,CHEMBL617120,,9,1,,BAO_0000357,,
2574,F,,10116.0,,12687,Expert,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,CHEMBL617121,,9,1,,BAO_0000219,,
2575,F,,,,12687,Autocuration,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,CHEMBL617122,,8,1,,BAO_0000219,,
2576,B,,,,12687,Autocuration,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,CHEMBL617123,,8,1,,BAO_0000019,,
2577,B,,,,12687,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,CHEMBL617124,,8,1,,BAO_0000019,,
2578,B,,,,12687,Expert,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,CHEMBL617600,,8,1,,BAO_0000249,,
2579,B,,,,12687,Expert,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,CHEMBL617601,,8,1,,BAO_0000357,,
2580,B,,,,12687,Expert,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,CHEMBL882923,,8,1,,BAO_0000019,,
2581,B,,,,12687,Autocuration,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL617602,,8,1,,BAO_0000357,,
2582,B,,,,12687,Autocuration,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,CHEMBL617603,,8,1,,BAO_0000019,,
2583,B,,,,12687,Autocuration,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,CHEMBL617604,,8,1,,BAO_0000357,,
2584,B,,,,12687,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,CHEMBL617605,,8,1,,BAO_0000019,,
2585,B,,,,12687,Expert,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,CHEMBL617606,,8,1,,BAO_0000019,,
2586,B,,10116.0,,12687,Expert,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,CHEMBL617607,,9,1,,BAO_0000019,,
2587,B,,,,12687,Autocuration,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617455,,8,1,,BAO_0000249,,
2588,B,,10116.0,,12687,Expert,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,CHEMBL617456,,9,1,,BAO_0000019,,
2589,B,,,,12687,Expert,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,CHEMBL617457,,8,1,,BAO_0000357,,
2590,B,,10116.0,,12687,Expert,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,CHEMBL617458,,9,1,,BAO_0000357,,
2591,B,,10116.0,,12687,Expert,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,CHEMBL617459,,9,1,,BAO_0000019,,
2592,B,,,,12687,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,CHEMBL617460,,8,1,,BAO_0000357,,
2593,B,,,,12687,Expert,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,CHEMBL617461,,8,1,,BAO_0000357,,
2594,B,,10116.0,,12687,Expert,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,CHEMBL617462,,9,1,,BAO_0000019,,
2595,B,,,,12687,Autocuration,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,CHEMBL617463,,8,1,,BAO_0000357,,
2596,B,,,,12687,Autocuration,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,CHEMBL617464,,8,1,,BAO_0000019,,
2597,B,,,,12687,Autocuration,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,CHEMBL617465,,8,1,,BAO_0000019,,
2598,B,,,,12687,Expert,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,CHEMBL617466,,8,1,,BAO_0000019,,
2599,B,,,,12687,Autocuration,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,CHEMBL617467,,8,1,,BAO_0000019,,
2600,B,,,,12687,Expert,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,CHEMBL617468,,8,1,,BAO_0000019,,
2601,B,,,,12687,Autocuration,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,CHEMBL617469,,8,1,,BAO_0000019,,
2602,B,,,,12687,Autocuration,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,CHEMBL617470,,8,1,,BAO_0000019,,
2603,B,,,,12687,Autocuration,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,CHEMBL617471,,8,1,,BAO_0000019,,
2604,B,,,,12687,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,CHEMBL617472,,8,1,723.0,BAO_0000219,,
2605,B,,,,12687,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,CHEMBL617473,,8,1,,BAO_0000357,,
2606,B,,10116.0,,12687,Expert,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,CHEMBL617474,,9,1,,BAO_0000019,,
2607,B,,10116.0,,12687,Expert,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,CHEMBL617475,,9,1,,BAO_0000019,,
2608,B,,,,12687,Autocuration,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,CHEMBL617476,,8,1,,BAO_0000221,955.0,
2609,B,,,,12687,Expert,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,CHEMBL617477,,8,1,,BAO_0000357,,
2610,B,,,,12687,Expert,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,CHEMBL617478,,8,1,723.0,BAO_0000219,,
2611,F,,,,12687,Autocuration,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,CHEMBL617479,,8,1,,BAO_0000221,,
2612,B,,,,12687,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,CHEMBL617480,,8,1,,BAO_0000357,,
2613,B,,,,12687,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617481,,8,1,,BAO_0000357,,
2614,B,,,,12687,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,CHEMBL617482,,8,1,,BAO_0000019,,
2615,B,,,,12687,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,CHEMBL617483,,8,1,,BAO_0000019,,
2616,B,,,,12687,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL621528,,8,1,,BAO_0000357,,
2617,B,,10116.0,,12687,Expert,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,CHEMBL621529,,9,1,723.0,BAO_0000219,,
2618,B,,,,12687,Expert,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL621530,,8,1,,BAO_0000357,,
2619,B,,,,12687,Expert,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL621531,,8,1,,BAO_0000357,,
2620,B,,10116.0,,12687,Expert,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,CHEMBL621532,,9,1,,BAO_0000019,,
2621,B,,,,12687,Expert,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL621533,,8,1,,BAO_0000357,,
2622,B,,,,12687,Expert,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,CHEMBL621534,,8,1,449.0,BAO_0000219,,
2623,B,,,,12687,Autocuration,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,CHEMBL621535,,8,1,,BAO_0000019,,
2624,B,,,,12687,Autocuration,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,CHEMBL621536,,8,1,,BAO_0000357,,
2625,B,,,,12687,Autocuration,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,CHEMBL621537,,8,1,,BAO_0000357,,
2626,B,,10116.0,,12687,Expert,Binding affinity for 5-hydroxytryptamine 2A receptor,,CHEMBL621538,,9,1,,BAO_0000357,,
2627,B,,,,12687,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,CHEMBL621539,,8,1,,BAO_0000019,,
2628,B,,,,12687,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,CHEMBL621540,,8,1,,BAO_0000019,,
2629,B,,,,12687,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,CHEMBL621541,,8,1,,BAO_0000019,,
2630,B,,,,12687,Autocuration,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,CHEMBL621542,,8,1,,BAO_0000019,,
2631,B,,,,12687,Expert,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,CHEMBL621543,,8,1,,BAO_0000357,,
2632,B,,,,12687,Expert,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,CHEMBL621544,,8,1,,BAO_0000357,,
2633,B,,10116.0,,12687,Expert,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,CHEMBL621545,,9,1,,BAO_0000357,,
2634,B,,,,12687,Autocuration,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL621546,,8,1,,BAO_0000357,,
2635,B,,,,12687,Autocuration,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,CHEMBL621547,,8,1,,BAO_0000357,,
2636,B,,,,12687,Expert,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,CHEMBL618692,,8,1,723.0,BAO_0000219,,
2637,B,,,,12687,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor,,CHEMBL618693,,8,1,,BAO_0000357,,
2638,B,,,,12687,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,CHEMBL872922,,8,1,,BAO_0000357,,
2639,B,,,,12687,Autocuration,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,CHEMBL618694,,8,1,,BAO_0000357,,
2640,B,,10116.0,,12687,Expert,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,CHEMBL618695,,9,1,,BAO_0000357,,
2641,B,,,,12687,Autocuration,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,CHEMBL618696,,8,1,,BAO_0000357,,
2642,B,,,,12687,Expert,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,CHEMBL618697,,8,1,,BAO_0000357,,
2643,B,,,,12687,Autocuration,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,CHEMBL618892,,8,1,,BAO_0000357,,
2644,B,,,,12687,Autocuration,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,CHEMBL618893,,8,1,,BAO_0000357,,
2645,B,,,,12687,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,CHEMBL618894,,8,1,,BAO_0000357,,
2646,B,,,,12687,Expert,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,CHEMBL618895,,8,1,723.0,BAO_0000219,,
2647,B,,10116.0,,12687,Expert,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,CHEMBL618896,,9,1,,BAO_0000357,,
2648,B,,,,12687,Autocuration,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,CHEMBL618897,,8,1,,BAO_0000019,5383.0,
2649,B,,,,12687,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,CHEMBL618898,,8,1,,BAO_0000357,,
2650,B,,,,12687,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,CHEMBL618899,,8,1,,BAO_0000357,,
2651,B,,,,12687,Autocuration,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,CHEMBL618900,,8,1,,BAO_0000357,,
2652,B,,,,12687,Autocuration,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,CHEMBL618901,,8,1,,BAO_0000019,,
2653,B,,,,12687,Autocuration,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,CHEMBL618902,,8,1,,BAO_0000357,,
2654,B,,10116.0,,12687,Expert,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,CHEMBL618903,,9,1,,BAO_0000221,10000000.0,
2655,B,,,,12687,Autocuration,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,CHEMBL618904,,8,1,,BAO_0000357,,
2656,B,,,,12687,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,CHEMBL618905,,8,1,,BAO_0000357,,
2657,B,,,,12687,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,CHEMBL618906,,8,1,,BAO_0000357,,
2658,B,,,,12687,Expert,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,CHEMBL618907,,8,1,723.0,BAO_0000219,,
2659,B,,,,12687,Autocuration,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,CHEMBL618908,,8,1,,BAO_0000019,,
2660,B,,,,12687,Autocuration,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,CHEMBL617909,,8,1,,BAO_0000357,,
2661,B,,,,12687,Expert,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,CHEMBL617910,,8,1,,BAO_0000019,,
2662,B,,,,12687,Autocuration,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,CHEMBL617911,,8,1,,BAO_0000221,955.0,
2663,B,,,,12687,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL872923,,8,1,,BAO_0000249,,
2664,B,,,,12687,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617912,,8,1,,BAO_0000249,,
2665,B,,10116.0,,12687,Expert,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,CHEMBL617913,,9,1,,BAO_0000019,,
2666,B,,,,12687,Expert,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617914,,8,1,,BAO_0000249,,
2667,B,,,,12687,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617915,,8,1,,BAO_0000249,,
2668,B,,,,12687,Autocuration,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,CHEMBL617916,,8,1,,BAO_0000249,,
2669,B,,10116.0,,12687,Expert,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,CHEMBL617917,,9,1,,BAO_0000019,,
2670,B,,,,12687,Expert,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,CHEMBL617918,,8,1,,BAO_0000019,,
2671,B,,,,12687,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,CHEMBL617919,,8,1,,BAO_0000019,,
2672,B,,10116.0,,12687,Expert,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,CHEMBL617920,,9,1,,BAO_0000019,,
2673,B,,10116.0,,12687,Expert,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,CHEMBL617921,,9,1,,BAO_0000019,,
2674,B,,10116.0,,105102,Expert,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,CHEMBL617922,,5,1,,BAO_0000224,,
2675,B,,,,12687,Autocuration,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,CHEMBL617923,,8,1,,BAO_0000357,,
2676,B,,,,12687,Autocuration,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,CHEMBL617924,,8,1,,BAO_0000357,,
2677,B,,,,12687,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,CHEMBL617925,,8,1,,BAO_0000357,,
2678,B,,10116.0,,12687,Expert,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,CHEMBL617926,,9,1,,BAO_0000357,,
2679,B,,,,12687,Autocuration,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,CHEMBL617927,,8,1,,BAO_0000357,,
2680,B,,,,12687,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,CHEMBL617928,,8,1,,BAO_0000357,,
2681,B,,10116.0,,12687,Expert,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,CHEMBL617929,,9,1,,BAO_0000019,,
2682,B,,,,12687,Expert,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,CHEMBL617930,,8,1,,BAO_0000019,,
2683,B,,,,12687,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,CHEMBL617931,,8,1,,BAO_0000019,,
2684,B,,,,12687,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,CHEMBL617932,,8,1,,BAO_0000019,,
2685,B,,,,12687,Autocuration,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,CHEMBL617933,,8,1,449.0,BAO_0000219,,
2686,B,,,,12687,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,CHEMBL617934,,8,1,,BAO_0000019,,
2687,B,,,,12687,Autocuration,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,CHEMBL617935,,8,1,,BAO_0000019,,
2688,B,,,,12687,Autocuration,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,CHEMBL617936,,8,1,,BAO_0000357,,
2689,B,,,,12687,Autocuration,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,CHEMBL617937,,8,1,,BAO_0000019,,
2690,B,,,,12687,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,CHEMBL617938,,8,1,,BAO_0000019,,
2691,B,,,,12687,Autocuration,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,CHEMBL617939,,8,1,,BAO_0000218,,
2692,B,,,,12687,Autocuration,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,CHEMBL617940,,8,1,,BAO_0000218,,
2693,B,,,,12687,Autocuration,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,CHEMBL617941,,8,1,,BAO_0000218,,
2694,B,,,,12687,Expert,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,CHEMBL617942,,8,1,,BAO_0000357,,
2695,B,,,,12687,Expert,Ratio of pKi of 5-HT2A to that of D2 receptor,,CHEMBL617943,,8,1,,BAO_0000357,,
2696,B,,,,105093,Expert,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,CHEMBL617944,,4,1,,BAO_0000224,,
2697,B,,,,105093,Expert,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,CHEMBL617945,,4,1,,BAO_0000224,,
2698,B,,,,105075,Expert,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,CHEMBL617946,,4,1,,BAO_0000224,,
2699,B,,,,12687,Autocuration,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,CHEMBL617947,,8,1,,BAO_0000357,,
2700,B,,,,12687,Expert,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,CHEMBL617948,,8,1,,BAO_0000357,,
2701,F,,,,12687,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,CHEMBL858116,,8,1,,BAO_0000019,,
2702,F,,,,12687,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,CHEMBL617949,,8,1,,BAO_0000019,,
2703,F,,,,12687,Autocuration,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,CHEMBL617950,,8,1,,BAO_0000019,,
2704,F,,,,12687,Expert,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,CHEMBL617951,,8,1,,BAO_0000019,1515.0,
2705,F,,,,12687,Expert,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,CHEMBL617952,,8,1,,BAO_0000019,1515.0,
2706,F,,,,12687,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,CHEMBL617953,,8,1,,BAO_0000019,1515.0,
2707,B,,,,12687,Autocuration,Binding activity radioligand.,,CHEMBL617954,,8,1,,BAO_0000357,,
2708,B,,,,12687,Expert,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,CHEMBL617955,,8,1,,BAO_0000019,,
2709,B,,,,12687,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,CHEMBL857071,,8,1,,BAO_0000019,,
2710,B,,,,12687,Expert,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,CHEMBL617270,,8,1,,BAO_0000019,,
2711,B,,,,12687,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,CHEMBL617271,,8,1,339.0,BAO_0000219,,
2712,B,,,,12687,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,CHEMBL617272,,8,1,339.0,BAO_0000219,,
2713,B,,,,12687,Autocuration,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,CHEMBL617273,,8,1,,BAO_0000019,,
2714,F,,10116.0,,12687,Expert,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,CHEMBL617274,,9,1,,BAO_0000019,,
2715,B,,,,108,Autocuration,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,CHEMBL617275,,8,1,,BAO_0000357,,
2716,B,,,,108,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617276,,8,1,,BAO_0000357,,
2717,B,,,,108,Autocuration,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,CHEMBL617277,,8,1,,BAO_0000357,,
2718,B,,,,108,Expert,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,CHEMBL617278,,8,1,,BAO_0000019,,
2719,B,,,,108,Expert,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,CHEMBL617279,,8,1,,BAO_0000019,,
2720,B,,,,108,Expert,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,CHEMBL617280,,8,1,,BAO_0000019,,
2721,B,,,,108,Autocuration,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,CHEMBL617281,,8,1,,BAO_0000357,,
2722,B,,,,108,Autocuration,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,CHEMBL617282,,8,1,,BAO_0000357,,
2723,B,,,,108,Expert,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,CHEMBL617283,,8,1,,BAO_0000019,,
2724,B,,,,108,Expert,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,CHEMBL617284,,8,1,,BAO_0000019,,
2725,B,,,,108,Autocuration,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,CHEMBL617285,,8,1,722.0,BAO_0000219,,
2726,B,,,,108,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,CHEMBL617286,,8,1,,BAO_0000019,,
2727,B,,9606.0,,108,Expert,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,CHEMBL617287,,9,1,,BAO_0000357,,
2728,B,,,,108,Expert,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,CHEMBL617288,,8,1,,BAO_0000357,,
2729,B,,,,108,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,CHEMBL617289,,8,1,,BAO_0000357,,
2730,B,,,,108,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL872917,,8,1,,BAO_0000357,,
2731,B,,,,108,Autocuration,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,CHEMBL617290,,8,1,,BAO_0000357,,
2732,B,,,,108,Autocuration,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHEMBL617291,,8,1,449.0,BAO_0000219,,
2733,B,,,,108,Autocuration,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,CHEMBL617292,,8,1,449.0,BAO_0000219,,
2734,B,,,,108,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,CHEMBL617293,,8,1,723.0,BAO_0000219,,
2735,F,,9606.0,,108,Expert,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617294,,9,1,449.0,BAO_0000219,,
2736,B,,,,108,Expert,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,CHEMBL617295,,8,1,,BAO_0000019,,
2737,B,,,,108,Autocuration,Binding activity radioligand.,,CHEMBL617296,,8,1,,BAO_0000357,,
2738,B,,,,108,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,CHEMBL617297,,8,1,,BAO_0000019,,
2739,B,,,,108,Expert,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,CHEMBL617298,,8,1,449.0,BAO_0000219,,
2740,B,,,,108,Expert,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,CHEMBL617299,,8,1,449.0,BAO_0000219,,
2741,B,,,,108,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,CHEMBL617300,,8,1,449.0,BAO_0000219,,
2742,B,,,,108,Autocuration,Binding affinity against 5-HT2C receptor,,CHEMBL617454,,8,1,,BAO_0000357,,
2743,B,,,,108,Autocuration,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,CHEMBL617505,,8,1,722.0,BAO_0000219,,
2744,B,,9606.0,,108,Expert,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,CHEMBL617506,,9,1,722.0,BAO_0000219,,
2745,B,,9606.0,,108,Expert,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,CHEMBL617507,,9,1,722.0,BAO_0000219,,
2746,B,,,,108,Expert,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,CHEMBL617508,,8,1,,BAO_0000357,,
2747,B,,9606.0,,108,Expert,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,CHEMBL857982,,9,1,722.0,BAO_0000219,,
2748,B,,9606.0,,108,Expert,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,CHEMBL617509,,9,1,722.0,BAO_0000219,,
2749,B,,9606.0,,108,Expert,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,CHEMBL617510,,9,1,722.0,BAO_0000219,,
2750,B,,,,108,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,CHEMBL617511,,8,1,,BAO_0000357,,
2751,B,,,,108,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,CHEMBL617512,,8,1,722.0,BAO_0000219,,
2752,B,,,,108,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,CHEMBL617749,,8,1,722.0,BAO_0000219,,
2753,B,,,,108,Autocuration,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL617750,,8,1,722.0,BAO_0000219,,
2754,B,,,,108,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL617751,,8,1,722.0,BAO_0000219,,
2755,B,,,,108,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,CHEMBL617752,,8,1,722.0,BAO_0000219,,
2756,B,,,,108,Autocuration,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,CHEMBL617753,,8,1,722.0,BAO_0000219,,
2757,B,,,,108,Expert,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,CHEMBL617754,,8,1,722.0,BAO_0000219,,
2758,B,,9606.0,,108,Expert,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,CHEMBL617755,,9,1,722.0,BAO_0000219,,
2759,B,,,,108,Autocuration,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,CHEMBL617756,,8,1,722.0,BAO_0000219,,
2760,B,,,,108,Expert,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,CHEMBL617757,,8,1,722.0,BAO_0000219,,
2761,B,,,,108,Expert,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,CHEMBL617758,,8,1,722.0,BAO_0000219,,
2762,B,,,,108,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,CHEMBL617759,,8,1,723.0,BAO_0000219,,
2763,B,,,,108,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,CHEMBL617760,,8,1,722.0,BAO_0000219,,
2764,B,,,,108,Expert,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,CHEMBL617761,,8,1,485.0,BAO_0000219,,
2765,B,,9606.0,,108,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617762,,9,1,,BAO_0000357,,
2766,B,,,,108,Autocuration,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,CHEMBL617763,,8,1,,BAO_0000357,,
2767,B,,,,108,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,CHEMBL857983,,8,1,722.0,BAO_0000219,,
2768,B,,,,108,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,CHEMBL617764,,8,1,722.0,BAO_0000219,,
2769,B,,,,108,Autocuration,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,CHEMBL617765,,8,1,308.0,BAO_0000219,,
2770,F,,,,108,Autocuration,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,CHEMBL617766,,8,1,,BAO_0000019,,
2771,F,,,,108,Autocuration,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,CHEMBL617767,,8,1,,BAO_0000221,10000000.0,
2772,B,,,,108,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,CHEMBL617768,,8,1,722.0,BAO_0000219,,
2773,B,,,,108,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,CHEMBL617769,,8,1,722.0,BAO_0000219,,
2774,B,,,,11864,Autocuration,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,CHEMBL858023,,8,1,,BAO_0000357,,
2775,B,,,,11864,Autocuration,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,CHEMBL617770,,8,1,,BAO_0000019,945.0,
2776,B,,,,11864,Autocuration,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,CHEMBL617771,,8,1,,BAO_0000019,945.0,
2777,F,,,,11864,Autocuration,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,CHEMBL617772,,8,1,625.0,BAO_0000219,,
2778,B,,,,11864,Autocuration,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,CHEMBL617773,,8,1,723.0,BAO_0000219,,
2779,B,,,,11864,Autocuration,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,CHEMBL617850,,8,1,723.0,BAO_0000219,,
2780,B,,,,11864,Autocuration,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,CHEMBL617851,,8,1,723.0,BAO_0000219,,
2781,F,,,,11864,Autocuration,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,CHEMBL617852,,8,1,,BAO_0000019,,
2782,B,,10090.0,,12689,Autocuration,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,CHEMBL858024,,8,1,,BAO_0000019,945.0,
2783,B,,10116.0,,12689,Expert,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,CHEMBL617853,,9,1,,BAO_0000019,945.0,
2784,B,,,,108,Expert,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,CHEMBL617854,,8,1,,BAO_0000357,,
2785,B,,9823.0,,108,Expert,Binding affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL873477,,8,1,,BAO_0000357,,
2786,B,,,,108,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617855,,8,1,,BAO_0000357,,
2787,B,,,,108,Expert,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,CHEMBL617856,,8,1,,BAO_0000019,,
2788,B,,,,108,Autocuration,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,CHEMBL617857,,8,1,,BAO_0000019,,
2789,B,,,,108,Autocuration,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,CHEMBL617858,,8,1,,BAO_0000249,,
2790,B,,,,108,Autocuration,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,CHEMBL617859,,8,1,,BAO_0000357,,
2791,B,,,,108,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617860,,8,1,,BAO_0000357,,
2792,B,,,,108,Autocuration,Binding activity radioligand.,,CHEMBL617861,,8,1,,BAO_0000357,,
2793,B,,,,108,Expert,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,CHEMBL617862,,8,1,,BAO_0000019,,
2794,B,,,,108,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,CHEMBL617863,,8,1,,BAO_0000019,,
2795,B,,,,108,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,CHEMBL617864,,8,1,,BAO_0000249,,
2796,B,,,,108,Autocuration,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,CHEMBL617649,,8,1,,BAO_0000249,,
2797,F,,9823.0,,108,Expert,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,CHEMBL617650,,8,1,,BAO_0000019,,
2798,F,,9823.0,,108,Expert,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,CHEMBL617651,,8,1,,BAO_0000019,,
2799,B,,9823.0,,108,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,CHEMBL617652,,8,1,,BAO_0000357,,
2800,B,,9823.0,,108,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,CHEMBL857072,,8,1,,BAO_0000019,,
2801,B,,9823.0,,108,Autocuration,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,CHEMBL617653,,8,1,,BAO_0000357,,
2802,B,,,,12687,Autocuration,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,CHEMBL617654,,8,1,,BAO_0000019,,
2803,F,,,,12689,Autocuration,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,CHEMBL617655,,8,1,,BAO_0000019,,
2804,B,,,,12689,Expert,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,CHEMBL617656,,8,1,,BAO_0000357,,
2805,B,,,,12689,Autocuration,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,CHEMBL617657,,8,1,,BAO_0000357,,
2806,B,,,,12689,Autocuration,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,CHEMBL617658,,8,1,,BAO_0000357,,
2807,B,,10116.0,,12689,Expert,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,CHEMBL617659,,9,1,,BAO_0000357,,
2808,B,,10116.0,,12689,Expert,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,CHEMBL617838,,9,1,,BAO_0000357,,
2809,B,,10116.0,,12689,Expert,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,CHEMBL617839,,9,1,,BAO_0000249,,
2810,B,,,,12689,Autocuration,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,CHEMBL617840,,8,1,,BAO_0000357,,
2811,B,,,,12689,Autocuration,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,CHEMBL617841,,8,1,,BAO_0000019,,
2812,B,,,,12689,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,CHEMBL875915,,8,1,,BAO_0000019,,
2813,B,In vitro,,,12689,Expert,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,CHEMBL617842,,8,1,,BAO_0000219,,
2814,B,,,,12689,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,CHEMBL617843,,8,1,723.0,BAO_0000219,,
2815,B,,,,12689,Expert,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,CHEMBL617844,,8,1,,BAO_0000357,,
2816,B,,,,12689,Expert,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,CHEMBL617845,,8,1,,BAO_0000357,,
2817,B,,,,12689,Expert,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,CHEMBL617846,,8,1,723.0,BAO_0000219,,
2818,B,,,,12689,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,CHEMBL617847,,8,1,,BAO_0000357,,
2819,B,,,,12689,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617848,,8,1,,BAO_0000357,,
2820,B,,,,12689,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,CHEMBL617849,,8,1,,BAO_0000357,,
2821,B,,,,12689,Expert,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL621507,,8,1,,BAO_0000357,,
2822,B,,,,12689,Expert,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,CHEMBL621508,,8,1,,BAO_0000357,,
2823,B,,,,12689,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,CHEMBL621509,,8,1,,BAO_0000019,,
2824,B,,,,12689,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,CHEMBL621510,,8,1,,BAO_0000019,,
2825,B,,,,12689,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,CHEMBL621511,,8,1,,BAO_0000019,,
2826,B,,,,12689,Expert,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,CHEMBL621512,,8,1,625.0,BAO_0000219,,
2827,B,,,,12689,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,CHEMBL621513,,8,1,,BAO_0000357,,
2828,B,,,,12689,Expert,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,CHEMBL621514,,8,1,,BAO_0000357,,
2829,B,In vitro,,,12689,Expert,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,CHEMBL621515,,8,1,,BAO_0000219,,
2830,B,,,,12689,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,CHEMBL621516,,8,1,,BAO_0000219,,
2831,B,,,,12689,Autocuration,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,CHEMBL621517,,8,1,,BAO_0000019,5383.0,
2832,B,,,,12689,Autocuration,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,CHEMBL621518,,8,1,,BAO_0000357,,
2833,B,,,,12689,Autocuration,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,CHEMBL621519,,8,1,,BAO_0000019,,
2834,B,,,,12689,Autocuration,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,CHEMBL621520,,8,1,,BAO_0000357,,
2835,B,,,,12689,Autocuration,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,CHEMBL621521,,8,1,,BAO_0000357,,
2836,B,,,,12689,Autocuration,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,CHEMBL621522,,8,1,,BAO_0000357,,
2837,B,,,,12689,Expert,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,CHEMBL621523,,8,1,,BAO_0000219,,
2838,B,,,,12689,Autocuration,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,CHEMBL621524,,8,1,,BAO_0000357,,
2839,B,,10116.0,,12689,Expert,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,CHEMBL621525,,9,1,,BAO_0000357,,
2840,B,,,,12689,Autocuration,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,CHEMBL872921,,8,1,,BAO_0000357,,
2841,B,,,,12689,Autocuration,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL621526,,8,1,,BAO_0000357,,
2842,B,,,,12689,Expert,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,CHEMBL621527,,8,1,,BAO_0000219,,
2843,B,,10116.0,,12689,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,CHEMBL617865,,9,1,,BAO_0000019,,
2844,B,,,,12689,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617866,,8,1,,BAO_0000357,,
2845,B,,,,12689,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,CHEMBL617867,,8,1,,BAO_0000019,,
2846,B,,,,12689,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,CHEMBL617487,,8,1,,BAO_0000357,,
2847,B,,,,12689,Expert,Binding affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL617488,,8,1,,BAO_0000357,,
2848,B,,,,12689,Autocuration,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,CHEMBL617489,,8,1,,BAO_0000357,,
2849,B,,,,12689,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,CHEMBL617490,,8,1,,BAO_0000019,,
2850,B,,,,12689,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,CHEMBL617491,,8,1,,BAO_0000019,,
2851,B,,,,12689,Autocuration,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,CHEMBL617492,,8,1,,BAO_0000019,,
2852,B,,,,12689,Autocuration,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,CHEMBL617493,,8,1,,BAO_0000019,,
2853,B,,,,12689,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,CHEMBL617494,,8,1,,BAO_0000357,,
2854,B,,10116.0,,12689,Expert,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,CHEMBL617495,,9,1,,BAO_0000019,,
2855,B,,,,12689,Autocuration,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,CHEMBL617496,,8,1,,BAO_0000357,,
2856,B,,,,12689,Autocuration,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,CHEMBL617497,,8,1,485.0,BAO_0000219,,
2857,B,,,,12689,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL617498,,8,1,,BAO_0000357,,
2858,B,,,,12689,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,CHEMBL617499,,8,1,,BAO_0000357,,
2859,F,,,,12689,Autocuration,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,CHEMBL617500,,8,1,,BAO_0000019,,
2860,B,,,,108,Autocuration,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL617501,,8,1,,BAO_0000357,,
2861,B,,,,108,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor,,CHEMBL617502,,8,1,,BAO_0000357,,
2862,B,,,,227,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,CHEMBL617503,,8,1,,BAO_0000357,,
2863,B,,,,227,Autocuration,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,CHEMBL617504,,8,1,,BAO_0000357,,
2864,B,,,,227,Autocuration,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,CHEMBL617406,,8,1,,BAO_0000357,,
2865,B,,9606.0,,227,Expert,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,CHEMBL617407,,9,1,,BAO_0000019,,
2866,B,,,,227,Autocuration,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,CHEMBL617408,,8,1,,BAO_0000357,,
2867,B,,,,227,Autocuration,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,CHEMBL617409,,8,1,,BAO_0000357,,
2868,B,,,,227,Autocuration,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,CHEMBL617410,,8,1,,BAO_0000357,,
2869,B,,,,227,Autocuration,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,CHEMBL617411,,8,1,,BAO_0000357,,
2870,B,,,,227,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,CHEMBL617412,,8,1,,BAO_0000019,,
2871,B,,9606.0,,227,Expert,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,CHEMBL617774,,9,1,,BAO_0000357,,
2872,B,,9606.0,,227,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,CHEMBL617775,,9,1,722.0,BAO_0000219,,
2873,B,,9606.0,,227,Expert,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,CHEMBL617776,,9,1,722.0,BAO_0000219,,
2874,F,,9606.0,,227,Expert,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617777,,9,1,449.0,BAO_0000219,,
2875,F,,9606.0,,227,Expert,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,CHEMBL617778,,9,1,449.0,BAO_0000219,,
2876,B,,,,227,Autocuration,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,CHEMBL617779,,8,1,722.0,BAO_0000219,,
2877,B,,,,227,Expert,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,CHEMBL617780,,8,1,722.0,BAO_0000219,,
2878,B,,,,227,Autocuration,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,CHEMBL617781,,8,1,722.0,BAO_0000219,,
2879,B,,9606.0,,227,Expert,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,CHEMBL617782,,9,1,722.0,BAO_0000219,,
2880,B,,9606.0,,227,Expert,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,CHEMBL617783,,9,1,722.0,BAO_0000219,,
2881,B,,,,227,Autocuration,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,CHEMBL617784,,8,1,,BAO_0000357,,
2882,B,,,,227,Autocuration,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,CHEMBL617785,,8,1,722.0,BAO_0000219,,
2883,B,,,,227,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,CHEMBL857984,,8,1,722.0,BAO_0000219,,
2884,B,,,,227,Expert,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,CHEMBL617786,,8,1,722.0,BAO_0000219,,
2885,B,,,,227,Expert,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,CHEMBL617787,,8,1,722.0,BAO_0000219,,
2886,B,,9606.0,,227,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,CHEMBL617788,,9,1,722.0,BAO_0000219,,
2887,B,,9606.0,,227,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,CHEMBL617789,,9,1,722.0,BAO_0000219,,
2888,B,,,,227,Autocuration,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,CHEMBL617790,,8,1,722.0,BAO_0000219,,
2889,B,,,,227,Expert,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,CHEMBL617791,,8,1,485.0,BAO_0000219,,
2890,B,,,,227,Expert,Binding affinity against 5-hydroxytryptamine 2B receptor,,CHEMBL617608,,8,1,,BAO_0000357,,
2891,B,,,,227,Autocuration,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,CHEMBL617609,,8,1,722.0,BAO_0000219,,
2892,B,,,,227,Autocuration,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,CHEMBL617610,,8,1,722.0,BAO_0000219,,
2893,B,,,,227,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,CHEMBL617611,,8,1,722.0,BAO_0000219,,
2894,B,,,,227,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,CHEMBL617612,,8,1,722.0,BAO_0000219,,
2895,B,,,,227,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,CHEMBL617613,,8,1,722.0,BAO_0000219,,
2896,B,,9986.0,,227,Autocuration,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,CHEMBL617614,,8,1,,BAO_0000019,,
2897,B,,,,12688,Expert,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,CHEMBL617615,,8,1,,BAO_0000019,945.0,
2898,B,,,,12688,Expert,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,CHEMBL858114,,8,1,,BAO_0000357,945.0,
2899,B,,,,12688,Autocuration,Affinity against serotonergic receptor in the isolated rat stomach fundus,,CHEMBL617616,,8,1,,BAO_0000357,945.0,
2900,F,,10116.0,,12688,Expert,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,CHEMBL617617,,9,1,,BAO_0000019,945.0,
2901,F,,10116.0,,12688,Expert,Antagonistic against 5-hydroxytryptamine 2B receptor,,CHEMBL875914,,9,1,,BAO_0000019,,
2902,F,,,,12688,Autocuration,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,CHEMBL617618,,8,1,,BAO_0000019,945.0,
2903,B,,10116.0,,12688,Expert,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,CHEMBL617619,,9,1,,BAO_0000357,945.0,
2904,F,,,,12688,Autocuration,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,CHEMBL617620,,8,1,,BAO_0000019,,
2905,F,,,,12688,Autocuration,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,CHEMBL617621,,8,1,,BAO_0000019,,
2906,F,,,,12688,Autocuration,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,CHEMBL617622,,8,1,,BAO_0000019,,
2907,B,,10116.0,,12688,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617623,,9,1,,BAO_0000357,945.0,
2908,B,,10116.0,,12688,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617624,,9,1,,BAO_0000357,945.0,
2909,B,,10116.0,,12688,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617625,,9,1,,BAO_0000357,945.0,
2910,B,,10116.0,,12688,Expert,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,CHEMBL617626,,9,1,,BAO_0000357,945.0,
2911,F,,,,12688,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,CHEMBL617627,,8,1,,BAO_0000019,945.0,
2912,F,,,,12688,Expert,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,CHEMBL617628,,8,1,,BAO_0000019,945.0,
2913,F,,,,12688,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,CHEMBL617629,,8,1,,BAO_0000019,945.0,
2914,F,,,,12688,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,CHEMBL858115,,8,1,,BAO_0000019,945.0,
2915,F,,10116.0,,12688,Expert,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,CHEMBL617630,,9,1,,BAO_0000019,945.0,
2916,F,,,,12688,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,CHEMBL617631,,8,1,,BAO_0000019,1515.0,
2917,B,,,,12688,Autocuration,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,CHEMBL617632,,8,1,,BAO_0000357,,
2918,B,,,,12688,Expert,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,CHEMBL617633,,8,1,,BAO_0000357,,
2919,B,,,,12688,Autocuration,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,CHEMBL617634,,8,1,,BAO_0000357,,
2920,B,,,,12688,Autocuration,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,CHEMBL617635,,8,1,,BAO_0000357,,
2922,F,,10116.0,,12688,Autocuration,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,CHEMBL617637,,9,1,,BAO_0000019,945.0,
2923,B,,,,227,Autocuration,Binding affinity against 5-hydroxytryptamine 1A receptor,,CHEMBL617638,,8,1,,BAO_0000357,,
2924,B,,,,227,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,CHEMBL617639,,8,1,,BAO_0000357,,
2925,B,,,,227,Autocuration,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,CHEMBL617640,,8,1,,BAO_0000357,,
2926,B,,,,227,Autocuration,Evaluated for the binding affinity to 5-HT 2B receptor,,CHEMBL617641,,8,1,,BAO_0000357,,
2927,B,,,,227,Autocuration,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,CHEMBL617642,,8,1,,BAO_0000357,,
2928,B,,,,227,Autocuration,Binding affinities against 5-hydroxytryptamine 2B receptor,,CHEMBL617643,,8,1,,BAO_0000357,,
2929,B,,,,227,Autocuration,Binding affinities towards 5-hydroxytryptamine 2B receptor,,CHEMBL617644,,8,1,,BAO_0000357,,
2930,B,,,,227,Autocuration,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,CHEMBL617645,,8,1,,BAO_0000357,,
2931,B,,,,108,Expert,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,CHEMBL617646,,8,1,,BAO_0000357,,
2932,B,,9913.0,,108,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,CHEMBL617647,,8,1,,BAO_0000357,,
2933,B,,9913.0,,108,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,CHEMBL617648,,8,1,,BAO_0000357,,
2934,B,,9913.0,,108,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,CHEMBL617875,,8,1,,BAO_0000357,,
2935,B,,9913.0,,108,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,CHEMBL617876,,8,1,,BAO_0000357,,
2936,B,,9913.0,,108,Expert,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,CHEMBL617877,,8,1,,BAO_0000357,,
2937,B,,9913.0,,108,Expert,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,CHEMBL617878,,8,1,,BAO_0000357,,
2938,B,,9913.0,,108,Autocuration,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,CHEMBL617879,,8,1,,BAO_0000357,,
2939,B,,10141.0,,108,Autocuration,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,CHEMBL617880,,8,1,,BAO_0000019,,
2940,B,,10141.0,,20033,Intermediate,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,CHEMBL617881,,9,1,,BAO_0000357,2435.0,
2941,B,,,,51,Autocuration,Binding affinity against 5-HT1A receptor,,CHEMBL857073,,8,1,,BAO_0000357,,
2942,F,,,,108,Expert,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,CHEMBL617882,,8,1,449.0,BAO_0000219,,
2943,F,,9606.0,,108,Expert,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,CHEMBL617883,,9,1,449.0,BAO_0000219,,
2944,F,,,,108,Autocuration,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,CHEMBL617884,,8,1,,BAO_0000219,,
2945,B,,,,108,Autocuration,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,CHEMBL617885,,8,1,449.0,BAO_0000219,,
2946,B,,,,108,Autocuration,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,CHEMBL617886,,8,1,449.0,BAO_0000219,,
2947,B,,9606.0,,108,Expert,Inhibition of human 5-hydroxytryptamine 2C receptor,,CHEMBL617887,,9,1,,BAO_0000357,,
2948,B,,,,108,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,CHEMBL617888,,8,1,,BAO_0000357,,
2949,B,,,,108,Autocuration,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,CHEMBL617889,,8,1,,BAO_0000019,,
2950,B,,,,108,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,CHEMBL617890,,8,1,,BAO_0000357,,
2951,B,,,,108,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,CHEMBL617891,,8,1,,BAO_0000357,,
2952,B,,,,108,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,CHEMBL617892,,8,1,,BAO_0000357,,
2953,B,,,,108,Expert,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,CHEMBL617893,,8,1,449.0,BAO_0000219,,
2954,B,,,,108,Expert,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,CHEMBL617894,,8,1,449.0,BAO_0000219,,
2955,B,,,,108,Expert,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHEMBL617895,,8,1,449.0,BAO_0000219,,
2956,B,,,,108,Autocuration,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,CHEMBL617896,,8,1,449.0,BAO_0000219,,
2957,B,,9606.0,,108,Expert,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,CHEMBL617897,,9,1,,BAO_0000357,,
2958,F,,,,108,Autocuration,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,CHEMBL617898,,8,1,,BAO_0000019,,
2959,F,,,,108,Autocuration,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,CHEMBL617899,,8,1,,BAO_0000019,,
2960,B,,10116.0,,108,Expert,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,CHEMBL617900,,8,1,449.0,BAO_0000219,,
2961,F,,,,108,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,CHEMBL617901,,8,1,,BAO_0000019,,
2962,F,,,,108,Autocuration,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,CHEMBL617902,,8,1,,BAO_0000019,,
2963,F,,,,108,Autocuration,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL617903,,8,1,,BAO_0000019,,
2964,B,,,,108,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,CHEMBL617904,,8,1,,BAO_0000357,,
2965,B,,,,108,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,CHEMBL617905,,8,1,,BAO_0000357,,
2966,B,,,,108,Autocuration,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,CHEMBL617906,,8,1,,BAO_0000357,,
2967,B,,,,108,Autocuration,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,CHEMBL617907,,8,1,,BAO_0000357,,
2968,B,,,,108,Autocuration,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,CHEMBL617908,,8,1,,BAO_0000357,,
2969,B,,,,108,Expert,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,CHEMBL620617,,8,1,449.0,BAO_0000219,,
2970,B,,9606.0,,108,Expert,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,CHEMBL620618,,9,1,,BAO_0000019,,
2971,B,,,,108,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,CHEMBL620619,,8,1,,BAO_0000357,,
2972,B,,9606.0,,108,Expert,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,CHEMBL620620,,9,1,,BAO_0000357,,
2973,B,,,,108,Autocuration,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,CHEMBL620621,,8,1,,BAO_0000357,,
2974,B,,10116.0,,104698,Autocuration,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,CHEMBL872920,,7,1,,BAO_0000249,,
2975,B,,,,104698,Autocuration,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,CHEMBL620622,,6,1,,BAO_0000223,,
2976,B,,10116.0,,104698,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,CHEMBL620623,,7,1,,BAO_0000019,,
2977,B,,,,104698,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,CHEMBL620624,,6,1,,BAO_0000019,,
2978,B,,,,104698,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,CHEMBL620625,,6,1,,BAO_0000019,,
2979,B,,,,104698,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,CHEMBL620626,,6,1,,BAO_0000219,,
2980,B,,,,104698,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,CHEMBL621307,,6,1,,BAO_0000019,,
2981,B,,,,104698,Autocuration,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,CHEMBL621308,,6,1,,BAO_0000019,,
2982,B,,,,104698,Autocuration,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,CHEMBL621309,,6,1,,BAO_0000223,,
2983,B,,,,104698,Autocuration,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,CHEMBL621310,,6,1,,BAO_0000223,,
2984,B,,,,104698,Autocuration,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,CHEMBL621311,,6,1,,BAO_0000223,,
2985,B,,,,104698,Autocuration,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,CHEMBL621502,,6,1,,BAO_0000249,,
2986,B,,,,104698,Autocuration,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,CHEMBL621503,,6,1,,BAO_0000249,,
2987,B,,,,104698,Autocuration,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,CHEMBL621504,,6,1,,BAO_0000249,,
2988,B,,,,104698,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,CHEMBL621505,,6,1,,BAO_0000223,,
2989,B,,,,104698,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,CHEMBL621506,,6,1,,BAO_0000019,,
2990,B,,,,104698,Autocuration,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,CHEMBL619781,,6,1,,BAO_0000223,,
2991,B,,,,104698,Autocuration,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,CHEMBL619782,,6,1,,BAO_0000223,,
2992,B,,,,104698,Autocuration,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,CHEMBL619783,,6,1,,BAO_0000019,,
2993,B,,10116.0,,104698,Autocuration,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,CHEMBL619784,,7,1,,BAO_0000019,,
2994,B,,,,104698,Autocuration,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,CHEMBL619785,,6,1,,BAO_0000249,,
2995,B,,,,104698,Autocuration,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,CHEMBL619786,,6,1,,BAO_0000223,,
2996,B,,,,104698,Autocuration,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,CHEMBL619787,,6,1,,BAO_0000019,,
2997,B,,,,104698,Autocuration,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,CHEMBL872925,,6,1,,BAO_0000019,,
2998,B,,,,104698,Autocuration,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,CHEMBL619788,,6,1,,BAO_0000019,,
2999,B,,,,104698,Autocuration,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,CHEMBL619789,,6,1,,BAO_0000249,,
3000,B,,,,104698,Autocuration,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,CHEMBL619790,,6,1,,BAO_0000249,,
3001,B,,,,104698,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,CHEMBL619791,,6,1,,BAO_0000019,,
3002,B,,,,104698,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,CHEMBL619792,,6,1,,BAO_0000019,,
3003,B,,,,104698,Autocuration,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,CHEMBL619793,,6,1,,BAO_0000249,,
3004,B,,10116.0,,104698,Autocuration,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,CHEMBL619794,,7,1,,BAO_0000223,,
3005,B,,,,104698,Autocuration,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,CHEMBL619795,,6,1,,BAO_0000221,955.0,
3006,B,,,,104698,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,CHEMBL619796,,6,1,,BAO_0000019,,
3007,B,,,,104698,Autocuration,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,CHEMBL620448,,6,1,,BAO_0000223,,
3008,B,,,,104698,Autocuration,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,CHEMBL620449,,6,1,,BAO_0000223,,
3009,B,,,,104698,Autocuration,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,CHEMBL620450,,6,1,,BAO_0000223,,
3010,B,,,,104698,Autocuration,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,CHEMBL620451,,6,1,,BAO_0000223,,
3011,B,,,,104698,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,CHEMBL620631,,6,1,,BAO_0000223,,
3012,B,,,,104698,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,CHEMBL620632,,6,1,,BAO_0000019,,
3013,B,,,,104698,Autocuration,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,CHEMBL620633,,6,1,,BAO_0000019,,
3014,B,,,,104698,Autocuration,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,CHEMBL620634,,6,1,,BAO_0000223,,
3015,B,,,,104698,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,CHEMBL620635,,6,1,,BAO_0000019,,
3016,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620636,,6,1,,BAO_0000218,,
3017,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620637,,6,1,,BAO_0000218,,
3018,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620638,,6,1,,BAO_0000218,,
3019,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,CHEMBL620639,,6,1,,BAO_0000218,,
3020,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620640,,6,1,,BAO_0000218,,
3021,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620641,,6,1,,BAO_0000218,,
3022,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,CHEMBL620642,,6,1,,BAO_0000218,,
3023,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620643,,6,1,,BAO_0000218,,
3024,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,CHEMBL620644,,6,1,,BAO_0000218,,
3025,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620645,,6,1,,BAO_0000218,,
3026,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620646,,6,1,,BAO_0000218,,
3027,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620647,,6,1,,BAO_0000218,,
3028,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,CHEMBL620648,,6,1,,BAO_0000218,,
3029,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,CHEMBL620649,,6,1,,BAO_0000218,,
3030,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL620650,,6,1,,BAO_0000218,,
3031,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620651,,6,1,,BAO_0000218,,
3032,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,CHEMBL872875,,6,1,,BAO_0000218,,
3033,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,CHEMBL620652,,6,1,,BAO_0000218,,
3034,F,,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,CHEMBL620653,,6,1,,BAO_0000019,,
3035,B,,,,104698,Autocuration,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,CHEMBL857076,,6,1,,BAO_0000019,,
3036,B,,10116.0,,104698,Autocuration,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,CHEMBL620654,,7,1,,BAO_0000019,,
3037,B,,,,104698,Autocuration,Binding activity radioligand.,,CHEMBL620655,,6,1,,BAO_0000223,,
3038,B,,,,104698,Autocuration,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,CHEMBL620656,,6,1,,BAO_0000249,,
3039,B,,,,104698,Autocuration,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,CHEMBL620657,,6,1,,BAO_0000249,,
3040,B,,,,108,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,CHEMBL620658,,8,1,,BAO_0000357,,
3041,B,,,,108,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,CHEMBL620659,,8,1,,BAO_0000357,,
3042,B,,,,108,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,CHEMBL620660,,8,1,,BAO_0000357,,
3043,B,,,,108,Autocuration,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,CHEMBL620661,,8,1,,BAO_0000357,,
3044,B,,,,108,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,CHEMBL620662,,8,1,,BAO_0000357,,
3045,B,,,,108,Expert,Affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL620663,,8,1,,BAO_0000357,,
3046,B,,,,108,Autocuration,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,CHEMBL620664,,8,1,,BAO_0000357,,
3047,B,,,,108,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,CHEMBL620665,,8,1,,BAO_0000357,,
3048,B,,,,108,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,CHEMBL620666,,8,1,,BAO_0000357,,
3049,B,,,,108,Autocuration,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,CHEMBL620667,,8,1,,BAO_0000357,,
3050,B,,,,108,Expert,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,CHEMBL620668,,8,1,,BAO_0000357,,
3051,B,,,,108,Autocuration,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,CHEMBL620669,,8,1,,BAO_0000357,,
3052,B,,,,108,Expert,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,CHEMBL620670,,8,1,,BAO_0000357,,
3053,B,,,,108,Autocuration,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,CHEMBL620671,,8,1,,BAO_0000357,,
3054,B,,,,108,Autocuration,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,CHEMBL620672,,8,1,,BAO_0000357,,
3055,B,,,,108,Autocuration,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,CHEMBL620673,,8,1,,BAO_0000357,,
3056,B,,,,108,Autocuration,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,CHEMBL620674,,8,1,,BAO_0000357,,
3057,B,,,,108,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,CHEMBL620675,,8,1,,BAO_0000357,,
3058,B,,,,108,Autocuration,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,CHEMBL620676,,8,1,,BAO_0000357,,
3059,B,,,,108,Autocuration,Affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL621382,,8,1,,BAO_0000357,,
3060,B,,9606.0,,108,Expert,Binding affinity against 5-hydroxytryptamine 2C receptor,,CHEMBL621383,,9,1,,BAO_0000357,,
3061,B,,,,108,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,CHEMBL621384,,8,1,,BAO_0000357,,
3062,B,,9913.0,,144,Autocuration,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,CHEMBL621385,,8,1,,BAO_0000357,,
3063,B,,9913.0,,144,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,CHEMBL617989,,8,1,,BAO_0000357,,
3064,F,,10141.0,,104714,Expert,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,CHEMBL617990,,4,1,,BAO_0000019,,
3065,B,,10141.0,,104714,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,CHEMBL875085,,4,1,,BAO_0000221,2116.0,
3066,F,,10141.0,,104714,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,CHEMBL617991,,4,1,,BAO_0000019,,
3067,F,,10141.0,,104714,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,CHEMBL617992,,4,1,,BAO_0000019,,
3068,B,,10141.0,,104714,Autocuration,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,CHEMBL617993,,4,1,,BAO_0000221,2116.0,
3069,B,,10141.0,,104714,Autocuration,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,CHEMBL617994,,4,1,,BAO_0000221,2116.0,
3070,F,,10141.0,,104714,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,CHEMBL617995,,4,1,,BAO_0000019,,
3071,F,,10141.0,,104714,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,CHEMBL617996,,4,1,,BAO_0000019,,
3072,F,,10141.0,,104714,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,CHEMBL617997,,4,1,,BAO_0000019,,
3073,F,,10141.0,,104714,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,CHEMBL617998,,4,1,,BAO_0000019,,
3074,F,,10141.0,,104714,Autocuration,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,CHEMBL617999,,4,1,,BAO_0000019,,
3075,F,,10141.0,,104714,Autocuration,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,CHEMBL618000,,4,1,,BAO_0000019,,
3076,F,,10141.0,,104714,Autocuration,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,CHEMBL617815,,4,1,,BAO_0000221,2116.0,
3077,F,,10141.0,,104714,Autocuration,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,CHEMBL617816,,4,1,,BAO_0000221,2116.0,
3078,F,,10141.0,,104714,Autocuration,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,CHEMBL617817,,4,1,,BAO_0000221,2116.0,
3079,B,,10141.0,,104714,Autocuration,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,CHEMBL617818,,4,1,,BAO_0000221,2116.0,
3080,B,,10141.0,,104714,Autocuration,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,CHEMBL617819,,4,1,,BAO_0000221,2116.0,
3081,B,,10141.0,,104714,Autocuration,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,CHEMBL617820,,4,1,,BAO_0000223,,
3082,B,,10141.0,,104714,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,CHEMBL617821,,4,1,,BAO_0000221,2116.0,
3083,F,,10141.0,,104714,Autocuration,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,CHEMBL617822,,4,1,,BAO_0000221,2116.0,
3084,F,,10141.0,,104714,Autocuration,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,CHEMBL617823,,4,1,,BAO_0000221,2116.0,
3085,F,,10141.0,,104714,Autocuration,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,CHEMBL617824,,4,1,,BAO_0000221,2116.0,
3086,F,,10141.0,,104714,Autocuration,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,CHEMBL617825,,4,1,,BAO_0000221,2116.0,
3087,F,,10141.0,,104714,Autocuration,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,CHEMBL617826,,4,1,,BAO_0000221,2116.0,
3088,B,,10141.0,,104714,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,CHEMBL617827,,4,1,,BAO_0000221,2116.0,
3089,F,,10141.0,,104714,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,CHEMBL617828,,4,1,,BAO_0000221,2116.0,
3090,B,,10141.0,,104714,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,CHEMBL617829,,4,1,,BAO_0000221,2116.0,
3091,B,,10141.0,,104714,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,CHEMBL617830,,4,1,,BAO_0000221,2116.0,
3092,B,,10141.0,,104714,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,CHEMBL617831,,4,1,,BAO_0000221,2116.0,
3093,B,,10141.0,,104714,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,CHEMBL617832,,4,1,,BAO_0000221,2116.0,
3094,B,,10141.0,,22226,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,CHEMBL617833,,0,1,,BAO_0000019,,
3095,B,,,,51,Autocuration,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,CHEMBL617834,,8,1,,BAO_0000357,,
3096,B,,9606.0,,104714,Expert,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,CHEMBL617835,,5,1,,BAO_0000223,,
3097,B,,,,104714,Autocuration,Binding affinity towards 5-HT3 receptor,,CHEMBL617836,,4,1,,BAO_0000223,,
3098,B,,,,104714,Autocuration,Binding activity radioligand.,,CHEMBL617837,,4,1,,BAO_0000223,,
3099,B,,,,104714,Autocuration,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,CHEMBL620392,,4,1,,BAO_0000019,,
3100,B,,,,104714,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,CHEMBL620393,,4,1,,BAO_0000223,,
3101,B,,,,104714,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,CHEMBL620394,,4,1,,BAO_0000223,,
3102,B,,,,104714,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,CHEMBL620395,,4,1,,BAO_0000223,,
3103,B,,,,22226,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,CHEMBL620396,,0,1,,BAO_0000019,,
3104,B,,,,105030,Expert,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,CHEMBL620582,,4,1,433.0,BAO_0000219,,
3105,B,In vivo,,,105030,Autocuration,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,CHEMBL620583,,4,1,,BAO_0000218,,
3106,B,,,,105030,Autocuration,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,CHEMBL620584,,4,1,,BAO_0000019,,
3107,B,,,,105030,Autocuration,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,CHEMBL620585,,4,1,,BAO_0000224,,
3108,B,,,,105030,Autocuration,Compound was evaluated for the binding affinity at 5- HT3 receptor,,CHEMBL620586,,4,1,,BAO_0000224,,
3109,B,,,,105030,Autocuration,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,CHEMBL620587,,4,1,,BAO_0000019,,
3110,B,,,,105030,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,CHEMBL620588,,4,1,,BAO_0000019,,
3111,F,,,,105030,Autocuration,5-hydroxytryptamine 3 receptor agonism in mouse,,CHEMBL620589,,4,1,,BAO_0000218,,
3112,B,,,,105030,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,CHEMBL620590,,4,1,,BAO_0000219,,
3113,B,,,,105030,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,CHEMBL617956,,4,1,,BAO_0000019,,
3114,B,,,,105030,Autocuration,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,CHEMBL617957,,4,1,,BAO_0000019,,
3115,B,,,,105030,Autocuration,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,CHEMBL617958,,4,1,,BAO_0000224,,
3116,B,,,,105030,Autocuration,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,CHEMBL617959,,4,1,,BAO_0000219,,
3117,B,,,,105030,Autocuration,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,CHEMBL617960,,4,1,,BAO_0000219,,
3118,B,,,,105030,Autocuration,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,CHEMBL617961,,4,1,,BAO_0000224,,
3119,B,In vitro,,,105030,Autocuration,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,CHEMBL617962,,4,1,,BAO_0000219,,
3120,B,,,,105030,Autocuration,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,CHEMBL617963,,4,1,339.0,BAO_0000219,,
3121,B,,,,11765,Autocuration,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,CHEMBL617964,,8,1,,BAO_0000019,,
3122,B,,,,11765,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,CHEMBL617965,,8,1,,BAO_0000219,,
3123,B,,10090.0,,10630,Autocuration,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,CHEMBL617966,,9,1,,BAO_0000357,,
3124,B,,,,17106,Autocuration,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,CHEMBL857074,,8,1,,BAO_0000019,,
3125,B,,9823.0,,144,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,CHEMBL617967,,8,1,,BAO_0000357,,
3126,B,,9823.0,,144,Autocuration,Binding activity radioligand.,,CHEMBL617968,,8,1,,BAO_0000357,,
3127,B,,9986.0,,104714,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,CHEMBL617969,,4,1,,BAO_0000223,,
3128,B,,9986.0,,104714,Autocuration,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,CHEMBL617970,,4,1,,BAO_0000223,,
3129,B,,9986.0,,104714,Autocuration,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,CHEMBL617971,,4,1,,BAO_0000223,,
3130,B,,9986.0,,104714,Autocuration,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,CHEMBL617972,,4,1,,BAO_0000019,,
3131,F,,9986.0,,104714,Autocuration,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,CHEMBL617973,,4,1,,BAO_0000019,,
3132,F,,9986.0,,104714,Autocuration,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,CHEMBL617974,,4,1,,BAO_0000019,,
3133,F,,9986.0,,104714,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,CHEMBL617975,,4,1,,BAO_0000221,2116.0,
3134,F,,9986.0,,104714,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,CHEMBL617976,,4,1,,BAO_0000019,,
3135,F,,9986.0,,104714,Autocuration,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,CHEMBL617977,,4,1,,BAO_0000019,,
3136,F,,9986.0,,104714,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,CHEMBL617978,,4,1,,BAO_0000019,,
3137,F,,9986.0,,104714,Autocuration,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,CHEMBL617979,,4,1,,BAO_0000019,,
3138,B,,9986.0,,104714,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,CHEMBL617980,,4,1,449.0,BAO_0000219,,
3139,B,,10116.0,,104698,Autocuration,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,CHEMBL617981,,7,1,,BAO_0000019,,
3140,B,,,,12020,Autocuration,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,CHEMBL617982,,8,1,,BAO_0000019,,
3141,B,,,,12020,Autocuration,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,CHEMBL617983,,8,1,,BAO_0000357,,
3142,B,,10116.0,,104698,Autocuration,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,CHEMBL617984,,7,1,,BAO_0000019,,
3143,B,,,,104698,Autocuration,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,CHEMBL617985,,6,1,,BAO_0000019,,
3144,F,In vivo,,,104698,Autocuration,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,CHEMBL617986,,6,1,,BAO_0000218,948.0,
3145,F,,,,104698,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,CHEMBL617987,,6,1,,BAO_0000019,948.0,
3146,F,,,,104698,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,CHEMBL617988,,6,1,,BAO_0000019,948.0,
3147,F,,,,104698,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,CHEMBL617792,,6,1,,BAO_0000019,948.0,
3148,F,,,,104698,Autocuration,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,CHEMBL617793,,6,1,,BAO_0000019,948.0,
3149,F,,,,104698,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617794,,6,1,,BAO_0000019,,
3150,F,,,,104698,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617795,,6,1,,BAO_0000019,,
3151,F,,,,104698,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617796,,6,1,,BAO_0000019,,
3152,F,,,,104698,Autocuration,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,CHEMBL617797,,6,1,,BAO_0000019,,
3153,F,In vivo,10116.0,,104698,Autocuration,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,CHEMBL617798,,7,1,,BAO_0000218,,
3154,F,In vivo,,,104698,Autocuration,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,CHEMBL617799,,6,1,,BAO_0000218,,
3155,F,In vivo,10116.0,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617800,,7,1,,BAO_0000218,,
3156,F,,10116.0,,104698,Autocuration,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,CHEMBL617801,,7,1,,BAO_0000019,,
3157,F,In vivo,10116.0,,104698,Autocuration,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,CHEMBL617802,,7,1,,BAO_0000218,,
3158,F,,10116.0,,104698,Autocuration,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,CHEMBL617803,,7,1,,BAO_0000019,,
3159,B,,,,104698,Autocuration,Binding affinity towards 5-HT3 receptor in rat was evaluated,,CHEMBL617804,,6,1,,BAO_0000019,,
3160,B,,10116.0,,104698,Autocuration,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,CHEMBL617805,,7,1,,BAO_0000019,,
3161,B,,,,104698,Autocuration,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,CHEMBL617806,,6,1,,BAO_0000223,,
3162,B,,,,104698,Autocuration,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,CHEMBL617807,,6,1,,BAO_0000019,,
3163,B,,,,104698,Autocuration,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,CHEMBL617808,,6,1,,BAO_0000019,,
3164,B,,,,104698,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,CHEMBL617809,,6,1,,BAO_0000249,,
3165,B,,,,104698,Autocuration,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,CHEMBL617810,,6,1,,BAO_0000019,,
3166,B,,,,104698,Autocuration,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,CHEMBL617811,,6,1,,BAO_0000249,955.0,
3167,B,,,,104698,Autocuration,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,CHEMBL617812,,6,1,,BAO_0000221,955.0,
3168,B,,,,104698,Autocuration,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,CHEMBL617813,,6,1,,BAO_0000249,,
3169,B,,,,104698,Autocuration,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,CHEMBL617814,,6,1,,BAO_0000249,,
3170,B,,,,104698,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,CHEMBL617698,,6,1,,BAO_0000019,,
3171,B,,10116.0,,104698,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,CHEMBL617699,,7,1,,BAO_0000019,,
3172,B,,10116.0,,104698,Autocuration,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,CHEMBL617700,,7,1,,BAO_0000019,,
3173,B,,10116.0,,104698,Autocuration,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,CHEMBL617701,,7,1,,BAO_0000223,,
3174,B,,,,104698,Autocuration,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,CHEMBL617702,,6,1,,BAO_0000019,,
3175,B,,,,104698,Autocuration,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,CHEMBL617703,,6,1,,BAO_0000249,,
3176,B,,10116.0,,104698,Autocuration,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,CHEMBL617704,,7,1,,BAO_0000019,,
3177,B,,,,104698,Autocuration,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,CHEMBL617705,,6,1,,BAO_0000223,,
3178,B,,10116.0,,104698,Autocuration,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,CHEMBL617706,,7,1,,BAO_0000223,,
3179,B,,,,104698,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,CHEMBL617707,,6,1,433.0,BAO_0000219,,
3180,B,,,,104698,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,CHEMBL617708,,6,1,433.0,BAO_0000219,,
3181,B,,,,104698,Autocuration,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,CHEMBL617709,,6,1,,BAO_0000019,,
3182,B,,,,104698,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,CHEMBL617710,,6,1,,BAO_0000019,,
3183,B,,,,104698,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,CHEMBL882925,,6,1,,BAO_0000019,,
3184,B,,,,104698,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,CHEMBL617711,,6,1,,BAO_0000019,,
3185,F,,,,104698,Autocuration,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,CHEMBL617712,,6,1,,BAO_0000019,,
3186,F,,10116.0,,104698,Autocuration,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,CHEMBL617713,,7,1,,BAO_0000019,,
3187,F,,,,104698,Autocuration,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,CHEMBL617714,,6,1,,BAO_0000019,,
3188,F,,,,104698,Autocuration,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,CHEMBL617715,,6,1,,BAO_0000218,,
3189,F,In vivo,,,104698,Autocuration,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,CHEMBL617716,,6,1,,BAO_0000218,,
3190,F,,,,104698,Autocuration,Inhibition of 5-HT evoked reflex bradycardia in rat.,,CHEMBL617717,,6,1,,BAO_0000218,,
3191,F,In vivo,,,104698,Autocuration,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617718,,6,1,,BAO_0000218,,
3192,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,CHEMBL617719,,6,1,,BAO_0000218,,
3193,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,CHEMBL617720,,6,1,,BAO_0000218,,
3194,F,In vivo,10116.0,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,CHEMBL617721,,7,1,,BAO_0000218,,
3195,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617722,,6,1,,BAO_0000218,,
3196,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,CHEMBL617723,,6,1,,BAO_0000218,,
3197,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,CHEMBL617724,,6,1,,BAO_0000218,,
3198,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,CHEMBL617725,,6,1,,BAO_0000218,,
3199,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,CHEMBL617726,,6,1,,BAO_0000218,,
3200,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617727,,6,1,,BAO_0000218,,
3201,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,CHEMBL617728,,6,1,,BAO_0000218,,
3202,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,CHEMBL617729,,6,1,,BAO_0000218,,
3203,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,CHEMBL617730,,6,1,,BAO_0000218,,
3204,F,In vivo,,,104698,Autocuration,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617731,,6,1,,BAO_0000218,,
3205,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,CHEMBL617732,,6,1,,BAO_0000218,,
3206,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,CHEMBL617733,,6,1,,BAO_0000218,,
3207,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,CHEMBL617734,,6,1,,BAO_0000218,,
3208,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,CHEMBL872874,,6,1,,BAO_0000218,,
3209,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,CHEMBL617735,,6,1,,BAO_0000218,,
3210,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,CHEMBL617736,,6,1,,BAO_0000218,,
3211,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,CHEMBL617737,,6,1,,BAO_0000218,,
3212,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,CHEMBL617738,,6,1,,BAO_0000218,,
3213,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,CHEMBL617739,,6,1,,BAO_0000218,,
3214,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,CHEMBL617740,,6,1,,BAO_0000218,,
3215,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,CHEMBL617741,,6,1,,BAO_0000218,,
3216,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,CHEMBL617742,,6,1,,BAO_0000218,,
3217,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,CHEMBL617743,,6,1,,BAO_0000218,,
3218,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,CHEMBL617744,,6,1,,BAO_0000218,,
3219,F,In vivo,,,104698,Autocuration,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,CHEMBL617745,,6,1,,BAO_0000218,,
3220,F,,,,104698,Autocuration,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,CHEMBL617746,,6,1,,BAO_0000218,,
3221,F,,,,104698,Autocuration,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,CHEMBL617747,,6,1,,BAO_0000218,,
3222,F,In vivo,,,104698,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,CHEMBL617748,,6,1,,BAO_0000218,,
3223,F,In vivo,,,104698,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,CHEMBL618909,,6,1,,BAO_0000218,,
3224,F,In vivo,,,104698,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,CHEMBL618910,,6,1,,BAO_0000218,,
3225,F,In vivo,,,104698,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,CHEMBL618911,,6,1,,BAO_0000218,,
3226,F,In vivo,,,104698,Autocuration,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,CHEMBL618912,,6,1,,BAO_0000218,,
3227,F,In vivo,,,104698,Autocuration,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,CHEMBL618913,,6,1,,BAO_0000218,,
3228,F,,,,104698,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,CHEMBL618914,,6,1,,BAO_0000019,,
3229,F,,,,104698,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,CHEMBL618915,,6,1,,BAO_0000019,,
3230,B,,10116.0,,104698,Autocuration,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,CHEMBL618916,,7,1,,BAO_0000223,,
3231,F,,,,104698,Autocuration,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,CHEMBL618917,,6,1,,BAO_0000019,,
3232,B,,,,104698,Intermediate,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,CHEMBL618918,,7,1,,BAO_0000221,10000000.0,
3233,B,,10116.0,,104698,Autocuration,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,CHEMBL618919,,7,1,,BAO_0000019,,
3234,B,,10116.0,,104698,Autocuration,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,CHEMBL618920,,7,1,,BAO_0000019,,
3235,B,,,,104698,Autocuration,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,CHEMBL618921,,6,1,,BAO_0000223,,
3236,B,,,,104698,Autocuration,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,CHEMBL618922,,6,1,,BAO_0000019,,
3237,B,,,,104698,Autocuration,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,CHEMBL618923,,6,1,,BAO_0000019,,
3238,B,,,,104698,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,CHEMBL618924,,6,1,,BAO_0000019,,
3239,B,,,,104698,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,CHEMBL618925,,6,1,,BAO_0000019,,
3240,B,,,,104698,Autocuration,Binding affinity towards 5-HT3 receptor in rat was evaluated,,CHEMBL618926,,6,1,,BAO_0000019,,
3241,F,,10141.0,,20033,Intermediate,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,CHEMBL618927,,9,1,,BAO_0000221,2116.0,
3242,F,,10141.0,,20033,Intermediate,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,CHEMBL618928,,9,1,,BAO_0000221,2116.0,
3243,F,,10141.0,,20033,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,CHEMBL618929,,9,1,,BAO_0000221,2116.0,
3244,F,,10141.0,,20033,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,CHEMBL618930,,9,1,,BAO_0000221,2116.0,
3245,F,,10141.0,,20033,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,CHEMBL618931,,9,1,,BAO_0000221,2116.0,
3246,F,,10141.0,,20033,Intermediate,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,CHEMBL619594,,9,1,,BAO_0000221,2116.0,
3247,F,,10141.0,,20033,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,CHEMBL619595,,9,1,,BAO_0000221,2116.0,
3248,F,,10141.0,,20033,Intermediate,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,CHEMBL619596,,9,1,,BAO_0000221,2116.0,
3249,F,,10141.0,,20033,Intermediate,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,CHEMBL619755,,9,1,,BAO_0000221,2116.0,
3250,F,,10141.0,,20033,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,CHEMBL619756,,9,1,,BAO_0000221,2116.0,
3251,F,,10141.0,,20033,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,CHEMBL619757,,9,1,,BAO_0000221,2116.0,
3252,F,,10141.0,,20033,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,CHEMBL619758,,9,1,,BAO_0000221,2116.0,
3253,F,,10141.0,,20033,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,CHEMBL619759,,9,1,,BAO_0000221,2116.0,
3254,F,,10141.0,,20033,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,CHEMBL619760,,9,1,,BAO_0000221,2116.0,
3255,F,,10141.0,,20033,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,CHEMBL619761,,9,1,,BAO_0000221,2116.0,
3256,F,,10141.0,,20033,Intermediate,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,CHEMBL619762,,9,1,,BAO_0000221,2116.0,
3257,F,,10141.0,,20033,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,CHEMBL619763,,9,1,,BAO_0000221,2116.0,
3258,F,,10141.0,,20033,Intermediate,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,CHEMBL617868,,9,1,,BAO_0000221,2116.0,
3259,B,,10141.0,,20033,Intermediate,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,CHEMBL617869,,9,1,,BAO_0000357,,
3260,B,,10141.0,,20033,Intermediate,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL882926,,9,1,,BAO_0000249,2435.0,
3261,B,,10141.0,,20033,Intermediate,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL617870,,9,1,,BAO_0000249,2435.0,
3262,B,,10141.0,,20033,Intermediate,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,CHEMBL617871,,9,1,,BAO_0000357,2435.0,
3263,B,,10141.0,,20033,Intermediate,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,CHEMBL617872,,9,1,,BAO_0000357,2435.0,
3264,B,,10141.0,,20033,Intermediate,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,CHEMBL617873,,9,1,,BAO_0000357,2435.0,
3265,B,,10141.0,,20033,Intermediate,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,CHEMBL617874,,9,1,,BAO_0000357,2435.0,
3266,F,,10141.0,,20033,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,CHEMBL619067,,9,1,,BAO_0000221,2116.0,
3267,F,,10141.0,,20033,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,CHEMBL619068,,9,1,,BAO_0000221,2116.0,
3268,F,,10141.0,,20033,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,CHEMBL619069,,9,1,,BAO_0000221,2116.0,
3269,B,,10141.0,,20033,Intermediate,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,CHEMBL619070,,9,1,,BAO_0000357,,
3270,B,,10141.0,,20033,Intermediate,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,CHEMBL619071,,9,1,,BAO_0000357,,
3271,F,,10141.0,,20033,Intermediate,Agonistic activity against 5-hydroxytryptamine 4 receptor,,CHEMBL619072,,9,1,,BAO_0000019,,
3272,F,,10141.0,,20033,Intermediate,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,CHEMBL619073,,9,1,,BAO_0000019,,
3273,F,,10141.0,,20033,Intermediate,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,CHEMBL619074,,9,1,,BAO_0000019,,
3274,B,,10141.0,,20033,Intermediate,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,CHEMBL619075,,9,1,,BAO_0000357,,
3275,B,,10141.0,,20033,Intermediate,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,CHEMBL619076,,9,1,,BAO_0000357,2435.0,
3276,B,,10141.0,,20033,Intermediate,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,CHEMBL619077,,9,1,,BAO_0000357,2435.0,
3277,B,,10141.0,,20033,Intermediate,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL619078,,9,1,,BAO_0000249,2435.0,
3278,B,,10141.0,,20033,Intermediate,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,CHEMBL619079,,9,1,,BAO_0000249,2435.0,
3279,B,,10141.0,,20033,Intermediate,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,CHEMBL619080,,9,1,,BAO_0000221,2116.0,
3280,B,,10141.0,,20033,Expert,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,CHEMBL619081,,9,1,,BAO_0000357,,
3281,B,,10141.0,,20033,Intermediate,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,CHEMBL619082,,9,1,,BAO_0000357,,
3282,B,,10141.0,,20033,Intermediate,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,CHEMBL619083,,9,1,,BAO_0000357,,
3283,B,,10141.0,,20033,Intermediate,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,CHEMBL619084,,9,1,,BAO_0000357,,
3284,F,,10141.0,,20033,Intermediate,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL859397,,9,1,,BAO_0000221,2116.0,
3285,F,,10141.0,,20033,Intermediate,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,CHEMBL619085,,9,1,,BAO_0000221,2116.0,
3286,F,,10141.0,,20033,Intermediate,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,CHEMBL619086,,9,1,,BAO_0000221,2116.0,
3287,F,,10141.0,,20033,Intermediate,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,CHEMBL619087,,9,1,,BAO_0000221,2116.0,
3288,F,,10141.0,,20033,Intermediate,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,CHEMBL619088,,9,1,,BAO_0000221,2116.0,
3289,B,,10141.0,,20033,Intermediate,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,CHEMBL619089,,9,1,,BAO_0000357,,
3290,B,,10141.0,,168,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,CHEMBL619090,,8,1,,BAO_0000357,,
3291,F,,10141.0,,20033,Intermediate,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,CHEMBL619091,,9,1,,BAO_0000019,,
3292,B,,10141.0,,20033,Intermediate,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,CHEMBL619092,,9,1,,BAO_0000357,,
3293,B,,10141.0,,20033,Intermediate,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,CHEMBL619093,,9,1,,BAO_0000019,,
3294,B,,10141.0,,168,Autocuration,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,CHEMBL619094,,8,1,722.0,BAO_0000219,,
3295,B,,10141.0,,20033,Intermediate,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,CHEMBL619095,,9,1,,BAO_0000019,,
3296,B,,10141.0,,20033,Intermediate,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,CHEMBL857988,,9,1,,BAO_0000357,,
3297,B,,10141.0,,20033,Intermediate,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,CHEMBL619096,,9,1,,BAO_0000357,,
3298,B,,10141.0,,20033,Intermediate,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,CHEMBL619097,,9,1,,BAO_0000357,2435.0,
3299,B,,10141.0,,20033,Intermediate,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,CHEMBL619098,,9,1,,BAO_0000221,10000000.0,
3300,B,,10141.0,,20033,Intermediate,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,CHEMBL619751,,9,1,,BAO_0000357,,
3301,B,,10141.0,,20033,Intermediate,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,CHEMBL619752,,9,1,,BAO_0000357,,
3302,F,,10141.0,,20033,Intermediate,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,CHEMBL875096,,9,1,,BAO_0000221,2116.0,
3303,B,,,,108,Autocuration,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,CHEMBL619004,,8,1,,BAO_0000357,,
3304,B,,,,168,Autocuration,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,CHEMBL619005,,8,1,,BAO_0000357,,
3305,B,,,,168,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,CHEMBL619006,,8,1,,BAO_0000019,,
3306,B,,,,168,Autocuration,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,CHEMBL619007,,8,1,308.0,BAO_0000219,,
3307,B,,,,168,Autocuration,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL619008,,8,1,,BAO_0000357,,
3308,B,,,,168,Autocuration,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,CHEMBL619009,,8,1,,BAO_0000357,,
3309,B,,,,168,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,CHEMBL619010,,8,1,308.0,BAO_0000219,,
3310,B,,,,10622,Autocuration,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,CHEMBL619011,,8,1,,BAO_0000357,,
3311,B,,,,10622,Autocuration,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,CHEMBL619012,,8,1,,BAO_0000357,,
3312,B,,,,10622,Autocuration,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,CHEMBL619013,,8,1,,BAO_0000219,,
3313,B,,,,10622,Autocuration,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,CHEMBL619014,,8,1,,BAO_0000357,,
3314,F,,,,11249,Autocuration,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,CHEMBL857503,,8,1,,BAO_0000019,2081.0,
3315,F,,,,11249,Autocuration,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,CHEMBL619015,,8,1,,BAO_0000019,2081.0,
3316,B,,,,11249,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL619016,,8,1,,BAO_0000357,,
3317,B,,,,11249,Autocuration,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,CHEMBL619017,,8,1,,BAO_0000221,10000000.0,
3318,B,,9823.0,,168,Autocuration,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,CHEMBL619018,,8,1,,BAO_0000221,10000000.0,
3319,B,,9986.0,,168,Autocuration,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,CHEMBL619019,,8,1,,BAO_0000019,,
3320,B,,10116.0,,10623,Expert,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,CHEMBL619020,,9,1,,BAO_0000357,,
3321,F,,,,10623,Autocuration,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,CHEMBL619021,,8,1,,BAO_0000019,,
3322,B,,,,10623,Autocuration,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,CHEMBL619022,,8,1,,BAO_0000357,,
3323,B,,,,10623,Autocuration,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,CHEMBL619023,,8,1,,BAO_0000357,,
3324,F,,,,10623,Autocuration,lntrinsic activity relative to 5-HT receptor,,CHEMBL619024,,8,1,,BAO_0000019,,
3325,F,,,,10623,Autocuration,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,CHEMBL619025,,8,1,,BAO_0000019,,
3326,F,,,,10623,Expert,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,CHEMBL619026,,8,1,,BAO_0000019,,
3327,F,,,,10623,Autocuration,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,CHEMBL619027,,8,1,,BAO_0000019,,
3328,F,,,,10623,Autocuration,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,CHEMBL619028,,8,1,,BAO_0000019,,
3329,F,,,,10623,Autocuration,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,CHEMBL619029,,8,1,,BAO_0000019,,
3330,F,,,,10623,Autocuration,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,CHEMBL619030,,8,1,,BAO_0000019,,
3331,B,,,,10623,Expert,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,CHEMBL619031,,8,1,,BAO_0000357,,
3332,F,,,,10623,Autocuration,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,CHEMBL619032,,8,1,,BAO_0000019,,
3333,B,,10116.0,,10623,Expert,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,CHEMBL619033,,9,1,,BAO_0000357,,
3334,B,,,,10623,Autocuration,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,CHEMBL619034,,8,1,,BAO_0000357,,
3335,B,,,,10623,Autocuration,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,CHEMBL619035,,8,1,,BAO_0000357,,
3336,B,,,,10623,Autocuration,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,CHEMBL619036,,8,1,,BAO_0000357,,
3337,B,,10116.0,,10623,Expert,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,CHEMBL619037,,9,1,,BAO_0000019,,
3338,B,,,,10623,Autocuration,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,CHEMBL619038,,8,1,,BAO_0000249,2435.0,
3339,B,,,,10623,Autocuration,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,CHEMBL619039,,8,1,,BAO_0000249,,
3340,B,,,,10623,Expert,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,CHEMBL619040,,8,1,,BAO_0000249,,
3341,B,,10116.0,,10623,Expert,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,CHEMBL619041,,9,1,,BAO_0000019,2435.0,
3342,B,,,,10623,Autocuration,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,CHEMBL619042,,8,1,,BAO_0000019,2435.0,
3343,B,,,,10623,Expert,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,CHEMBL619043,,8,1,,BAO_0000249,2435.0,
3344,B,,,,10623,Expert,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,CHEMBL619044,,8,1,,BAO_0000019,2435.0,
3345,B,,,,10623,Expert,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,CHEMBL619045,,8,1,,BAO_0000249,2435.0,
3346,B,,,,10623,Expert,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,CHEMBL619046,,8,1,,BAO_0000249,2435.0,
3347,B,,,,10623,Expert,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,CHEMBL619047,,8,1,,BAO_0000249,,
3348,F,,,,10623,Autocuration,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,CHEMBL619048,,8,1,,BAO_0000221,955.0,
3349,F,,,,10623,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,CHEMBL859398,,8,1,,BAO_0000019,,
3350,F,,,,10623,Autocuration,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,CHEMBL619049,,8,1,,BAO_0000019,,
3351,F,,,,10623,Autocuration,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,CHEMBL857886,,8,1,,BAO_0000019,,
3352,F,,,,10623,Autocuration,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,CHEMBL619050,,8,1,,BAO_0000019,,
3353,F,,,,10623,Autocuration,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,CHEMBL620591,,8,1,,BAO_0000019,,
3354,B,,10116.0,,10623,Expert,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,CHEMBL620592,,9,1,,BAO_0000357,,
3355,B,,,,10623,Expert,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,CHEMBL620593,,8,1,,BAO_0000249,2435.0,
3356,F,,10116.0,,10623,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,CHEMBL620594,,9,1,,BAO_0000019,,
3357,F,,,,10623,Expert,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,CHEMBL875079,,8,1,,BAO_0000019,,
3358,F,,,,10623,Expert,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,CHEMBL620595,,8,1,,BAO_0000019,,
3359,F,,10116.0,,10623,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,CHEMBL620596,,9,1,,BAO_0000019,,
3360,F,,,,10623,Autocuration,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,CHEMBL620597,,8,1,,BAO_0000019,,
3361,F,,,,10623,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,CHEMBL620598,,8,1,,BAO_0000019,,
3362,F,,,,10623,Expert,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,CHEMBL620599,,8,1,,BAO_0000218,,
3363,F,,,,10623,Autocuration,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,CHEMBL620600,,8,1,,BAO_0000019,,
3364,F,,10116.0,,168,Autocuration,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,CHEMBL620601,,8,1,,BAO_0000019,,
3365,F,,,,168,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,CHEMBL620602,,8,1,,BAO_0000019,,
3366,B,,,,168,Autocuration,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,CHEMBL620603,,8,1,,BAO_0000357,,
3367,B,,,,168,Autocuration,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,CHEMBL620604,,8,1,,BAO_0000357,,
3368,B,,,,168,Autocuration,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,CHEMBL620605,,8,1,,BAO_0000357,,
3369,B,,,,168,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,CHEMBL620606,,8,1,,BAO_0000357,,
3370,F,,,,168,Autocuration,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,CHEMBL620607,,8,1,,BAO_0000019,,
3371,B,,,,168,Autocuration,In vitro binding affinity towards 5-HT4 receptor was determined,,CHEMBL620608,,8,1,,BAO_0000357,,
3372,F,,,,168,Autocuration,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,CHEMBL620609,,8,1,,BAO_0000019,,
3373,F,,,,168,Autocuration,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,CHEMBL620610,,8,1,,BAO_0000019,,
3374,B,,,,168,Autocuration,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,CHEMBL620611,,8,1,,BAO_0000357,,
3375,B,,,,168,Autocuration,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,CHEMBL620612,,8,1,,BAO_0000357,,
3376,B,,,,168,Autocuration,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,CHEMBL620613,,8,1,,BAO_0000357,,
3377,B,,,,168,Autocuration,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,CHEMBL620614,,8,1,,BAO_0000357,,
3378,B,,,,168,Expert,Binding affinity against 5-Hydroxytryptamine 4 receptor,,CHEMBL620615,,8,1,,BAO_0000357,,
3379,B,,,,104698,Autocuration,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,CHEMBL857075,,6,1,,BAO_0000249,,
3380,B,,,,104698,Autocuration,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,CHEMBL620616,,6,1,,BAO_0000249,,
3381,B,,,,104698,Autocuration,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,CHEMBL619411,,6,1,,BAO_0000249,,
3382,B,,,,104698,Autocuration,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,CHEMBL619412,,6,1,,BAO_0000019,,
3383,B,,10116.0,,104698,Autocuration,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,CHEMBL619413,,7,1,,BAO_0000019,,
3384,B,,,,104698,Autocuration,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,CHEMBL619414,,6,1,,BAO_0000221,10000000.0,
3385,B,,,,104698,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,CHEMBL619415,,6,1,,BAO_0000019,,
3386,B,,,,104698,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,CHEMBL619416,,6,1,,BAO_0000019,,
3387,F,,,,104698,Autocuration,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,CHEMBL619417,,6,1,,BAO_0000019,,
3388,B,,10116.0,,104698,Autocuration,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,CHEMBL619418,,7,1,,BAO_0000223,,
3389,B,,10116.0,,104698,Autocuration,Binding affinity against 5-Hydroxytryptamine 3 receptor,,CHEMBL619419,,7,1,,BAO_0000223,,
3390,B,,,,104698,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,CHEMBL619420,,6,1,,BAO_0000019,,
3391,B,,,,104698,Autocuration,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,CHEMBL619421,,6,1,,BAO_0000249,,
3392,B,,10116.0,,104698,Autocuration,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,CHEMBL619422,,7,1,,BAO_0000019,,
3393,B,,,,104698,Autocuration,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,CHEMBL619423,,6,1,,BAO_0000019,,
3394,B,,,,104698,Autocuration,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,CHEMBL875080,,6,1,,BAO_0000019,,
3395,B,,,,104698,Autocuration,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,CHEMBL619424,,6,1,,BAO_0000019,,
3396,B,,,,104698,Autocuration,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,CHEMBL619425,,6,1,,BAO_0000249,,
3397,B,,,,104698,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,CHEMBL619426,,6,1,,BAO_0000223,,
3398,B,,,,104698,Autocuration,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,CHEMBL619427,,6,1,,BAO_0000223,,
3399,B,,10116.0,,104698,Autocuration,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,CHEMBL619645,,7,1,,BAO_0000223,,
3400,B,,,,10576,Expert,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,CHEMBL619646,,9,1,,BAO_0000249,,
3401,F,,,,12020,Autocuration,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,CHEMBL619647,,8,1,,BAO_0000221,955.0,
3402,F,,,,12020,Autocuration,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,CHEMBL619648,,8,1,,BAO_0000019,,
3403,F,,,,12020,Autocuration,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,CHEMBL619165,,8,1,,BAO_0000019,,
3404,F,In vivo,,,12020,Autocuration,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620719,,8,1,,BAO_0000218,,
3405,B,,,,12020,Autocuration,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,CHEMBL872924,,8,1,,BAO_0000019,,
3406,B,,,,12020,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620720,,8,1,,BAO_0000357,,
3407,B,,,,12020,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,CHEMBL620721,,8,1,,BAO_0000019,,
3408,B,,,,12020,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,CHEMBL620722,,8,1,,BAO_0000019,,
3409,B,,,,104698,Autocuration,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,CHEMBL620723,,6,1,,BAO_0000019,,
3410,B,,,,12020,Autocuration,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,CHEMBL620724,,8,1,,BAO_0000019,,
3411,B,,,,104698,Autocuration,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,CHEMBL620725,,6,1,,BAO_0000249,,
3412,F,,10116.0,,12020,Autocuration,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,CHEMBL620726,,9,1,,BAO_0000019,,
3413,B,,,,144,Expert,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620727,,8,1,,BAO_0000357,,
3414,B,,,,104714,Autocuration,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,CHEMBL620728,,4,1,,BAO_0000223,,
3415,B,,,,22226,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,CHEMBL620729,,0,1,,BAO_0000019,,
3416,F,,,,104714,Autocuration,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,CHEMBL858288,,4,1,,BAO_0000019,,
3417,B,,,,104714,Autocuration,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620730,,4,1,,BAO_0000223,,
3418,B,,,,104714,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL620731,,4,1,,BAO_0000223,,
3419,F,,10141.0,,104714,Autocuration,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,CHEMBL620732,,4,1,,BAO_0000019,,
3420,F,,10141.0,,104714,Autocuration,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,CHEMBL618042,,4,1,,BAO_0000019,,
3421,F,,10141.0,,104714,Autocuration,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,CHEMBL618043,,4,1,,BAO_0000019,,
3422,B,,,,104714,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618044,,4,1,,BAO_0000223,,
3423,F,,,,104714,Autocuration,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,CHEMBL618045,,4,1,,BAO_0000019,,
3424,B,,,,104714,Autocuration,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,CHEMBL618046,,4,1,,BAO_0000223,,
3425,F,,,,104714,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,CHEMBL618047,,4,1,,BAO_0000019,,
3426,F,,,,104714,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,CHEMBL875084,,4,1,,BAO_0000019,,
3427,F,,,,104714,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,CHEMBL618048,,4,1,,BAO_0000019,,
3428,B,,,,104714,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,CHEMBL618049,,4,1,,BAO_0000223,,
3429,F,,,,104714,Autocuration,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,CHEMBL619764,,4,1,,BAO_0000019,,
3430,F,,,,104714,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,CHEMBL619765,,4,1,,BAO_0000019,,
3431,F,,,,104714,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,CHEMBL619766,,4,1,,BAO_0000019,,
3432,B,,,,104714,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,CHEMBL619767,,4,1,,BAO_0000223,,
3433,B,,,,104714,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,CHEMBL619768,,4,1,,BAO_0000223,,
3434,F,,,,104714,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,CHEMBL619769,,4,1,,BAO_0000019,,
3435,B,,,,104714,Autocuration,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,CHEMBL619770,,4,1,,BAO_0000223,,
3436,B,,,,104714,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL619771,,4,1,,BAO_0000223,,
3437,B,,,,104714,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,CHEMBL619772,,4,1,,BAO_0000219,,
3438,B,,,,104714,Autocuration,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,CHEMBL619773,,4,1,,BAO_0000223,,
3439,B,,,,104714,Autocuration,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,CHEMBL619774,,4,1,433.0,BAO_0000219,,
3440,B,,,,104714,Autocuration,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,CHEMBL875083,,4,1,,BAO_0000019,,
3441,B,,,,104714,Autocuration,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,CHEMBL620718,,4,1,433.0,BAO_0000219,,
3442,B,,,,104714,Autocuration,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,CHEMBL618127,,4,1,,BAO_0000223,,
3443,B,,,,104714,Autocuration,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,CHEMBL618128,,4,1,,BAO_0000223,,
3444,B,In vitro,,,104714,Autocuration,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,CHEMBL618129,,4,1,,BAO_0000219,,
3445,B,,,,104714,Autocuration,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,CHEMBL618130,,4,1,,BAO_0000223,,
3446,F,,,,104714,Autocuration,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,CHEMBL618131,,4,1,,BAO_0000019,,
3447,F,,10141.0,,104714,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,CHEMBL618132,,4,1,,BAO_0000019,,
3448,F,,10141.0,,104714,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,CHEMBL618133,,4,1,,BAO_0000019,,
3449,F,,10141.0,,104714,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,CHEMBL618134,,4,1,,BAO_0000019,,
3450,F,,10141.0,,104714,Autocuration,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,CHEMBL618135,,4,1,,BAO_0000019,,
3451,B,,,,104714,Autocuration,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,CHEMBL618136,,4,1,,BAO_0000223,,
3452,B,,,,104714,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618137,,4,1,,BAO_0000223,,
3453,B,,,,104714,Autocuration,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,CHEMBL618138,,4,1,,BAO_0000223,,
3454,B,,,,104714,Autocuration,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,CHEMBL618139,,4,1,,BAO_0000223,,
3455,B,,,,104714,Autocuration,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,CHEMBL618140,,4,1,,BAO_0000223,,
3456,B,,,,104714,Autocuration,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,CHEMBL618141,,4,1,,BAO_0000223,,
3457,B,,,,108,Expert,Binding affinity for 5-hydroxytryptamine 2C receptor,,CHEMBL873478,,8,1,,BAO_0000357,,
3458,B,,,,104698,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618142,,6,1,,BAO_0000223,,
3459,B,,,,144,Autocuration,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,CHEMBL618143,,8,1,,BAO_0000357,,
3460,B,,,,144,Autocuration,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618144,,8,1,,BAO_0000357,,
3461,B,,,,144,Autocuration,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,CHEMBL618145,,8,1,,BAO_0000357,,
3462,B,,,,104714,Autocuration,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,CHEMBL618146,,4,1,,BAO_0000223,,
3463,B,,,,104714,Autocuration,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,CHEMBL618147,,4,1,,BAO_0000223,,
3464,B,,,,104714,Autocuration,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,CHEMBL618148,,4,1,,BAO_0000223,,
3465,B,,,,144,Autocuration,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,CHEMBL618149,,8,1,,BAO_0000019,,
3466,B,,,,144,Autocuration,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL872927,,8,1,,BAO_0000357,,
3467,B,,,,144,Autocuration,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,CHEMBL618150,,8,1,,BAO_0000357,,
3468,B,,,,144,Autocuration,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,CHEMBL618151,,8,1,,BAO_0000357,,
3469,B,,,,144,Autocuration,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,CHEMBL875094,,8,1,,BAO_0000357,,
3470,B,,,,144,Autocuration,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,CHEMBL618152,,8,1,,BAO_0000019,,
3471,B,,,,144,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,CHEMBL618153,,8,1,,BAO_0000357,,
3472,B,,,,144,Autocuration,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,CHEMBL618888,,8,1,,BAO_0000357,,
3473,F,,,,144,Autocuration,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,CHEMBL618889,,8,1,,BAO_0000019,,
3474,B,,,,144,Autocuration,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,CHEMBL618890,,8,1,,BAO_0000357,,
3475,B,,,,144,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,CHEMBL618891,,8,1,,BAO_0000019,,
3476,B,,,,144,Autocuration,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,CHEMBL619054,,8,1,,BAO_0000019,,
3477,B,,,,104714,Autocuration,Binding affinity against the 5-hydroxytryptamine 3 receptor,,CHEMBL619055,,4,1,,BAO_0000223,,
3478,B,,,,144,Autocuration,Binding affinity against human 5-hydroxytryptamine 3A receptor,,CHEMBL619056,,8,1,,BAO_0000357,,
3479,F,,,,144,Autocuration,Percent efficacy against 5-hydroxytryptamine 3A receptor,,CHEMBL619057,,8,1,,BAO_0000019,,
3480,B,,,,144,Autocuration,Binding affinity against human 5-hydroxytryptamine 3A receptor,,CHEMBL619058,,8,1,,BAO_0000357,,
3481,F,,10116.0,,12020,Expert,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,CHEMBL619059,,9,1,,BAO_0000219,,
3482,F,,10116.0,,12020,Expert,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,CHEMBL619060,,9,1,,BAO_0000219,,
3483,F,,10116.0,,12020,Expert,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,CHEMBL875095,,9,1,,BAO_0000219,,
3484,F,,10141.0,,20033,Intermediate,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,CHEMBL619061,,9,1,,BAO_0000221,2116.0,
3485,F,,10141.0,,20033,Intermediate,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,CHEMBL619062,,9,1,,BAO_0000221,2116.0,
3486,F,,10141.0,,20033,Intermediate,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,CHEMBL619063,,9,1,,BAO_0000019,,
3487,B,,10141.0,,20033,Intermediate,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,CHEMBL619064,,9,1,,BAO_0000221,2116.0,
3488,B,,10141.0,,20033,Intermediate,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,CHEMBL619065,,9,1,,BAO_0000357,,
3489,B,,10141.0,,20033,Intermediate,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,CHEMBL619066,,9,1,,BAO_0000221,2116.0,
3490,B,,,,10209,Autocuration,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,CHEMBL619775,,8,1,,BAO_0000221,2116.0,
3491,B,,,,10209,Autocuration,Affinity against 5-hydroxytryptamine 7 receptor,,CHEMBL619776,,8,1,,BAO_0000357,,
3492,B,,10141.0,,104841,Autocuration,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,CHEMBL619777,,4,1,,BAO_0000224,,
3493,B,,10141.0,,104841,Autocuration,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,CHEMBL619778,,4,1,,BAO_0000224,,
3494,B,,10141.0,,104841,Autocuration,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,CHEMBL619779,,4,1,,BAO_0000221,2116.0,
3495,B,,10141.0,,104841,Autocuration,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,CHEMBL619780,,4,1,,BAO_0000224,,
3496,B,,10141.0,,104841,Autocuration,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,CHEMBL619166,,4,1,,BAO_0000224,,
3497,F,,10141.0,,104841,Autocuration,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,CHEMBL619167,,4,1,,BAO_0000019,,
3498,F,,10141.0,,104841,Autocuration,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,CHEMBL619168,,4,1,,BAO_0000019,,
3499,B,,9606.0,,168,Expert,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,CHEMBL619169,,9,1,,BAO_0000219,2081.0,
3500,B,,9606.0,,168,Expert,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,CHEMBL619170,,9,1,,BAO_0000219,2081.0,
3501,F,,9606.0,,104841,Autocuration,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,CHEMBL619171,,5,1,,BAO_0000019,,
3502,F,,9606.0,,168,Expert,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,CHEMBL619172,,9,1,,BAO_0000219,2081.0,
3503,B,,10090.0,,22226,Autocuration,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,CHEMBL619173,,0,1,,BAO_0000019,,
3504,B,,10090.0,,22226,Autocuration,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,CHEMBL619174,,0,1,,BAO_0000019,,
3505,B,,,,104705,Autocuration,5-hydroxytryptamine receptor binding affinity was determined in rats,,CHEMBL619175,,4,1,,BAO_0000019,,
3506,B,,,,104705,Autocuration,Binding affinity at rat 5-hydroxytryptamine receptor.,,CHEMBL619176,,4,1,,BAO_0000224,,
3507,B,,,,104705,Autocuration,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,CHEMBL619177,,4,1,,BAO_0000019,,
3508,B,,,,104705,Autocuration,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,CHEMBL619178,,4,1,,BAO_0000224,,
3509,B,,,,104705,Autocuration,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,CHEMBL619179,,4,1,,BAO_0000224,,
3510,F,,,,104705,Autocuration,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,CHEMBL619180,,4,1,,BAO_0000019,945.0,
3511,F,,,,104705,Autocuration,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,CHEMBL619181,,4,1,,BAO_0000019,945.0,
3512,F,,,,104705,Autocuration,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,CHEMBL619182,,4,1,,BAO_0000019,,
3513,B,,,,104705,Autocuration,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,CHEMBL619183,,4,1,,BAO_0000224,,
3514,B,,,,104705,Autocuration,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,CHEMBL619184,,4,1,,BAO_0000224,,
3515,B,,,,10576,Autocuration,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,CHEMBL619185,,8,1,,BAO_0000221,10000000.0,
3516,B,,,,12198,Expert,Binding affinity for rat 5-hydroxytryptamine transporter.,,CHEMBL619186,,8,1,,BAO_0000357,,
3517,B,,,,104705,Autocuration,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,CHEMBL619187,,4,1,,BAO_0000019,,
3518,B,,10116.0,,104705,Autocuration,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,CHEMBL619188,,5,1,,BAO_0000019,,
3519,B,,10116.0,,104705,Autocuration,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,CHEMBL619189,,5,1,,BAO_0000224,,
3520,F,,10116.0,,12198,Expert,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,CHEMBL619190,,9,1,,BAO_0000019,955.0,
3521,F,,10116.0,,12198,Expert,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,CHEMBL619191,,9,1,,BAO_0000221,2037.0,
3522,B,,10116.0,,104705,Autocuration,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,CHEMBL619192,,5,1,,BAO_0000019,,
3523,B,,10116.0,,104705,Autocuration,Percent binding affinity against 5-hydroxytryptamine receptor,,CHEMBL619193,,5,1,,BAO_0000224,,
3524,B,,,,22226,Autocuration,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,CHEMBL619194,,0,1,,BAO_0000019,,
3525,B,,10116.0,,104705,Autocuration,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,CHEMBL619195,,5,1,,BAO_0000224,,
3526,B,,10116.0,,104705,Autocuration,Affinity against 5-hydroxytryptamine receptor was determined,,CHEMBL619196,,5,1,,BAO_0000224,,
3527,B,,10116.0,,104705,Autocuration,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,CHEMBL619197,,5,1,,BAO_0000019,945.0,
3528,B,In vitro,9606.0,,121,Expert,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,CHEMBL619198,,9,1,,BAO_0000219,,
3529,B,In vitro,9606.0,,121,Expert,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,CHEMBL875081,,9,1,,BAO_0000219,,
3530,B,,,,18065,Autocuration,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,CHEMBL884712,,8,1,,BAO_0000357,,
3531,B,,,,121,Expert,Inhibition of 5-hydroxytryptamine reuptake,,CHEMBL884710,,8,1,,BAO_0000357,,
3532,F,,,,18065,Autocuration,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,CHEMBL619199,,8,1,,BAO_0000019,,
3533,F,,,,18065,Autocuration,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,CHEMBL619200,,8,1,,BAO_0000019,,
3534,F,,,,18065,Autocuration,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,CHEMBL619201,,8,1,,BAO_0000019,,
3535,F,,,,18065,Autocuration,Tested for 5-hydroxytryptamine receptor uptake,,CHEMBL619202,,8,1,,BAO_0000019,,
3536,B,,9606.0,,51,Expert,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,CHEMBL619203,,9,1,449.0,BAO_0000219,,
3537,F,,9606.0,,51,Expert,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,CHEMBL619204,,9,1,,BAO_0000019,,
3538,B,,9606.0,,10576,Autocuration,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,CHEMBL619205,,8,1,,BAO_0000249,,
3539,B,,,,10576,Autocuration,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,CHEMBL619206,,8,1,,BAO_0000357,,
3540,B,,,,10576,Expert,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,CHEMBL619207,,8,1,,BAO_0000249,,
3541,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,CHEMBL619208,,8,1,,BAO_0000019,2435.0,
3542,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,CHEMBL619209,,8,1,,BAO_0000019,2435.0,
3543,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,CHEMBL619210,,8,1,,BAO_0000019,2435.0,
3544,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,CHEMBL619211,,8,1,,BAO_0000019,2435.0,
3545,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,CHEMBL619212,,8,1,,BAO_0000019,2435.0,
3546,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,CHEMBL620681,,8,1,,BAO_0000019,2435.0,
3547,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,CHEMBL620682,,8,1,,BAO_0000019,2435.0,
3548,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,CHEMBL620683,,8,1,,BAO_0000019,2435.0,
3549,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,CHEMBL620684,,8,1,,BAO_0000019,2435.0,
3550,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,CHEMBL620685,,8,1,,BAO_0000019,2435.0,
3551,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,CHEMBL620686,,8,1,,BAO_0000019,2435.0,
3552,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,CHEMBL620687,,8,1,,BAO_0000019,349.0,
3553,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,CHEMBL620688,,8,1,,BAO_0000019,349.0,
3554,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,CHEMBL620689,,8,1,,BAO_0000019,349.0,
3555,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,CHEMBL620690,,8,1,,BAO_0000019,349.0,
3556,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,CHEMBL620691,,8,1,,BAO_0000019,349.0,
3557,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,CHEMBL620692,,8,1,,BAO_0000019,349.0,
3558,F,,,,10825,Autocuration,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,CHEMBL620693,,8,1,,BAO_0000019,349.0,
3559,B,,,,168,Expert,Binding affinity against 5-hydroxytryptamine 4 receptor,,CHEMBL620694,,8,1,,BAO_0000357,,
3560,F,,,,168,Autocuration,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,CHEMBL857986,,8,1,,BAO_0000019,,
3561,B,,,,168,Autocuration,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,CHEMBL620695,,8,1,,BAO_0000357,,
3562,B,,,,168,Expert,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,CHEMBL620696,,8,1,,BAO_0000357,,
3563,B,,,,168,Autocuration,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,CHEMBL620697,,8,1,,BAO_0000357,,
3564,B,,,,168,Autocuration,Binding affinity towards 5-hydroxytryptamine 4 receptor,,CHEMBL620698,,8,1,,BAO_0000357,,
3565,B,,,,168,Autocuration,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,CHEMBL620699,,8,1,,BAO_0000357,,
3566,B,,,,168,Autocuration,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,CHEMBL620700,,8,1,,BAO_0000357,,
3567,B,,,,168,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,CHEMBL620701,,8,1,643.0,BAO_0000219,,
3568,B,,,,168,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,CHEMBL875082,,8,1,643.0,BAO_0000219,,
3569,B,,,,168,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,CHEMBL620702,,8,1,643.0,BAO_0000219,,
3570,B,,,,168,Autocuration,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,CHEMBL620703,,8,1,643.0,BAO_0000219,,
3571,B,,,,168,Autocuration,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,CHEMBL620704,,8,1,673.0,BAO_0000219,,
3572,B,,,,168,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,CHEMBL620705,,8,1,673.0,BAO_0000219,,
3573,B,,,,168,Expert,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,CHEMBL620706,,8,1,673.0,BAO_0000219,,
3574,B,,,,168,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,CHEMBL620707,,8,1,673.0,BAO_0000219,,
3575,B,,,,10624,Expert,Binding affinity towards 5-hydroxytryptamine 5 receptor,,CHEMBL620708,,8,1,,BAO_0000357,,
3576,B,,,,105,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,CHEMBL620709,,8,1,,BAO_0000357,,
3577,B,,9606.0,,10624,Expert,Binding affinity against 5-hydroxytryptamine 5A receptor,,CHEMBL620710,,9,1,,BAO_0000357,,
3578,B,,,,10624,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,CHEMBL620711,,8,1,449.0,BAO_0000219,,
3579,B,,9606.0,,10624,Expert,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,CHEMBL620712,,9,1,,BAO_0000357,,
3580,B,,9606.0,,10624,Expert,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,CHEMBL620713,,9,1,,BAO_0000357,,
3581,B,,9606.0,,10624,Expert,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,CHEMBL620714,,9,1,,BAO_0000357,,
3582,B,,9606.0,,10624,Expert,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,CHEMBL620715,,9,1,,BAO_0000357,,
3583,B,,,,10624,Autocuration,Binding affinity towards 5-HT5A receptor,,CHEMBL620716,,8,1,,BAO_0000357,,
3584,B,,,,10624,Expert,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,CHEMBL620717,,8,1,,BAO_0000357,,
3585,B,,,,10624,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,CHEMBL618072,,8,1,,BAO_0000357,,
3586,B,,,,10624,Autocuration,Binding affinity towards cloned human 5-HT5A receptor was determined,,CHEMBL857987,,8,1,,BAO_0000357,,
3587,B,,,,10624,Autocuration,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL618073,,8,1,722.0,BAO_0000219,,
3588,B,,,,10624,Autocuration,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,CHEMBL618074,,8,1,722.0,BAO_0000219,,
3589,B,,,,10624,Autocuration,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,CHEMBL618075,,8,1,722.0,BAO_0000219,,
3590,B,,10090.0,,10625,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,CHEMBL618076,,9,1,,BAO_0000357,,
3591,B,,10090.0,,10625,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,CHEMBL618077,,9,1,,BAO_0000357,,
3592,B,,10090.0,,10625,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,CHEMBL618078,,9,1,,BAO_0000357,,
3593,B,,10090.0,,10625,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,CHEMBL881821,,9,1,,BAO_0000357,,
3594,B,,10090.0,,10625,Expert,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,CHEMBL618079,,9,1,,BAO_0000357,,
3595,B,,,,10625,Expert,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,CHEMBL618080,,8,1,,BAO_0000357,,
3596,B,,,,10576,Autocuration,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,CHEMBL618081,,8,1,722.0,BAO_0000219,,
3597,B,,,,10626,Autocuration,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,CHEMBL618082,,8,1,722.0,BAO_0000219,,
3598,B,,,,10624,Expert,Binding affinity towards 5-HT5a receptor,,CHEMBL618083,,8,1,,BAO_0000357,,
3599,B,,9606.0,,10624,Expert,Binding affinity towards 5-hydroxytryptamine 5A receptor,,CHEMBL618084,,9,1,,BAO_0000357,,
3600,B,,,,10624,Expert,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,CHEMBL618085,,8,1,,BAO_0000357,,
3601,B,,,,10624,Expert,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,CHEMBL618086,,8,1,,BAO_0000357,,
3602,B,,,,10624,Autocuration,Binding affinities against 5-hydroxytryptamine 5A receptor,,CHEMBL875092,,8,1,,BAO_0000357,,
3603,B,,,,10624,Autocuration,Binding affinities towards 5-hydroxytryptamine 5A receptor,,CHEMBL618087,,8,1,,BAO_0000357,,
3604,B,,,,10624,Autocuration,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,CHEMBL872926,,8,1,,BAO_0000357,,
3605,F,,10141.0,,104714,Autocuration,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,CHEMBL618088,,4,1,,BAO_0000019,,
3606,B,,,,104714,Autocuration,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,CHEMBL618089,,4,1,,BAO_0000223,,
3607,B,,9606.0,,10627,Expert,Inhibition of human 5-hydroxytryptamine 6 receptor,,CHEMBL618090,,9,1,,BAO_0000357,,
3608,B,,9606.0,,10627,Expert,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,CHEMBL618091,,9,1,,BAO_0000357,,
3609,B,,,,10627,Autocuration,Inhibition against human 5-hydroxytryptamine 6 receptor,,CHEMBL618092,,8,1,,BAO_0000357,,
3610,B,,9606.0,,10627,Expert,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,CHEMBL618093,,9,1,,BAO_0000357,,
3611,B,,,,10627,Expert,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,CHEMBL618094,,8,1,308.0,BAO_0000219,,
3612,B,,9606.0,,10627,Expert,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,CHEMBL618095,,9,1,,BAO_0000357,,
3613,B,,9606.0,,10627,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL875093,,9,1,,BAO_0000357,,
3614,B,,9606.0,,10627,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,CHEMBL618096,,9,1,,BAO_0000357,,
3615,B,,9606.0,,10627,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,CHEMBL618118,,9,1,,BAO_0000357,,
3616,B,,9606.0,,10627,Expert,Binding affinity against 5-hydroxytryptamine 6 receptor,,CHEMBL618119,,9,1,,BAO_0000357,,
3617,B,,,,10627,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL618120,,8,1,,BAO_0000357,,
3618,B,,,,10627,Autocuration,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL618121,,8,1,,BAO_0000357,,
3619,B,,,,10627,Expert,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,CHEMBL618122,,8,1,722.0,BAO_0000219,,
3620,B,,,,10627,Autocuration,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,CHEMBL618123,,8,1,,BAO_0000357,,
3621,B,,,,10627,Expert,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,CHEMBL618124,,8,1,722.0,BAO_0000219,,
3622,B,,,,10627,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL618125,,8,1,,BAO_0000357,,
3623,B,,9606.0,,10627,Expert,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,CHEMBL618126,,9,1,722.0,BAO_0000219,,
3624,B,,,,10627,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,CHEMBL618236,,8,1,,BAO_0000019,,
3625,B,,,,10627,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,CHEMBL618237,,8,1,,BAO_0000019,,
3626,B,,,,10627,Expert,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,CHEMBL618238,,8,1,643.0,BAO_0000219,,
3627,B,,9606.0,,10627,Expert,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,CHEMBL618239,,9,1,,BAO_0000357,,
3628,B,,,,10627,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,CHEMBL618240,,8,1,,BAO_0000019,,
3629,B,,,,10627,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,CHEMBL618241,,8,1,,BAO_0000357,,
3630,B,,,,10627,Autocuration,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,CHEMBL859399,,8,1,722.0,BAO_0000219,,
3631,F,,,,10627,Autocuration,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,CHEMBL618242,,8,1,,BAO_0000019,,
3632,B,,,,10627,Autocuration,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,CHEMBL857991,,8,1,,BAO_0000357,,
3633,B,,,,10627,Expert,Binding affinity against human 5-hydroxytryptamine 6 receptor,,CHEMBL619951,,8,1,,BAO_0000357,,
3634,B,,9606.0,,10627,Expert,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,CHEMBL619952,,9,1,308.0,BAO_0000219,,
3635,B,,9606.0,,10627,Expert,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,CHEMBL619953,,9,1,308.0,BAO_0000219,,
3636,B,,,,10627,Autocuration,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,CHEMBL619954,,8,1,308.0,BAO_0000219,,
3637,B,,,,10627,Autocuration,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,CHEMBL619955,,8,1,308.0,BAO_0000219,,
3638,B,,,,10627,Autocuration,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,CHEMBL619956,,8,1,308.0,BAO_0000219,,
3639,B,,,,10627,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,CHEMBL619957,,8,1,449.0,BAO_0000219,,
3640,B,,,,10627,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,CHEMBL619958,,8,1,722.0,BAO_0000219,,
3641,B,,,,10627,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,CHEMBL620627,,8,1,722.0,BAO_0000219,,
3642,B,,,,10627,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,CHEMBL620628,,8,1,722.0,BAO_0000219,,
3643,B,,,,10627,Autocuration,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,CHEMBL620629,,8,1,308.0,BAO_0000219,,
3644,B,,,,10627,Autocuration,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL620630,,8,1,,BAO_0000357,,
3645,B,,,,10627,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,CHEMBL620782,,8,1,308.0,BAO_0000219,,
3646,B,,,,10627,Autocuration,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,CHEMBL620783,,8,1,,BAO_0000357,,
3647,B,,,,10627,Expert,Binding affinity against human 5-hydroxytryptamine 6 receptor,,CHEMBL620784,,8,1,,BAO_0000357,,
3648,B,,,,10627,Expert,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,CHEMBL620785,,8,1,308.0,BAO_0000219,,
3649,B,,,,10627,Autocuration,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,CHEMBL857992,,8,1,,BAO_0000357,,
3650,B,,,,10627,Autocuration,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,CHEMBL620786,,8,1,,BAO_0000219,,
3651,B,,,,10627,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,CHEMBL620787,,8,1,308.0,BAO_0000219,,
3652,B,,,,10627,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,CHEMBL620788,,8,1,308.0,BAO_0000219,,
3653,B,,,,10627,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,CHEMBL620789,,8,1,308.0,BAO_0000219,,
3654,B,,,,10627,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,CHEMBL620790,,8,1,308.0,BAO_0000219,,
3655,B,,,,10628,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,CHEMBL620791,,8,1,449.0,BAO_0000219,,
3656,B,,,,10628,Autocuration,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,CHEMBL620792,,8,1,,BAO_0000019,,
3657,B,,,,10628,Autocuration,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,CHEMBL620793,,8,1,,BAO_0000357,,
3658,B,,,,10628,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,CHEMBL620794,,8,1,,BAO_0000357,,
3659,B,,9606.0,,10627,Autocuration,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,CHEMBL620795,,9,1,308.0,BAO_0000219,,
3660,B,,,,10627,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL620796,,8,1,,BAO_0000357,,
3661,B,,,,10627,Autocuration,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,CHEMBL620797,,8,1,,BAO_0000357,,
3662,F,,9606.0,,10627,Expert,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,CHEMBL620798,,9,1,,BAO_0000019,,
3663,B,,,,10627,Autocuration,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,CHEMBL620799,,8,1,,BAO_0000357,,
3664,B,,,,10627,Expert,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,CHEMBL620800,,8,1,,BAO_0000357,,
3665,B,,,,10627,Autocuration,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,CHEMBL620801,,8,1,,BAO_0000357,,
3666,B,,,,10627,Autocuration,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,CHEMBL875100,,8,1,,BAO_0000357,,
3667,B,,,,10627,Autocuration,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,CHEMBL620802,,8,1,,BAO_0000357,,
3668,F,,,,10627,Expert,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,CHEMBL620803,,8,1,,BAO_0000019,,
3669,F,,,,10627,Expert,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,CHEMBL620804,,8,1,,BAO_0000019,,
3670,B,,,,10627,Autocuration,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,CHEMBL620805,,8,1,,BAO_0000357,,
3671,B,,,,10627,Autocuration,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,CHEMBL620806,,8,1,,BAO_0000357,,
3672,B,,,,10627,Autocuration,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,CHEMBL620807,,8,1,,BAO_0000357,,
3673,B,,,,10627,Autocuration,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,CHEMBL620808,,8,1,,BAO_0000357,,
3674,B,,,,10627,Autocuration,Binding affinities against 5-hydroxytryptamine 6 receptor,,CHEMBL620809,,8,1,,BAO_0000357,,
3675,B,,,,10627,Autocuration,Binding affinities towards 5-hydroxytryptamine 6 receptor,,CHEMBL620810,,8,1,,BAO_0000357,,
3676,B,,9606.0,,10627,Expert,Binding affinity towards 5-hydroxytryptamine 6 receptor,,CHEMBL620811,,9,1,,BAO_0000357,,
3677,B,,,,10627,Autocuration,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,CHEMBL620812,,8,1,,BAO_0000357,,
3678,B,,,,10627,Autocuration,Affinity against 5-hydroxytryptamine 6 receptor,,CHEMBL620813,,8,1,,BAO_0000357,,
3679,B,,,,10627,Autocuration,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,CHEMBL620814,,8,1,,BAO_0000357,,
3680,B,,9606.0,,10209,Expert,Inhibition of human 5-hydroxytryptamine 7 receptor,,CHEMBL620815,,9,1,,BAO_0000357,,
3681,B,,,,10209,Autocuration,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,CHEMBL620816,,8,1,722.0,BAO_0000219,,
3682,B,,,,10209,Autocuration,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,CHEMBL620817,,8,1,,BAO_0000357,,
3683,B,,,,10209,Autocuration,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,CHEMBL620818,,8,1,,BAO_0000357,,
3684,B,,,,10209,Expert,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,CHEMBL620819,,8,1,722.0,BAO_0000219,,
3685,B,,9606.0,,10209,Expert,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,CHEMBL620820,,9,1,,BAO_0000357,,
3686,B,,,,10209,Autocuration,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,CHEMBL620821,,8,1,449.0,BAO_0000219,,
3687,B,,9606.0,,10209,Expert,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,CHEMBL620822,,9,1,,BAO_0000357,,
3688,B,,9606.0,,10209,Expert,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,CHEMBL620823,,9,1,,BAO_0000357,,
3689,B,,9606.0,,10209,Expert,Binding affinity against 5-hydroxytryptamine 7 receptor,,CHEMBL620824,,9,1,,BAO_0000357,,
3690,B,,,,10209,Expert,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,CHEMBL620825,,8,1,449.0,BAO_0000219,,
3691,B,,,,10209,Autocuration,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,CHEMBL872930,,8,1,,BAO_0000357,,
3692,B,,,,10209,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor,,CHEMBL620826,,8,1,,BAO_0000357,,
3693,B,,,,10209,Autocuration,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,CHEMBL620827,,8,1,,BAO_0000357,,
3694,B,,,,10209,Autocuration,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,CHEMBL620828,,8,1,,BAO_0000357,,
3695,B,,,,10209,Autocuration,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,CHEMBL620829,,8,1,,BAO_0000357,,
3696,B,,,,10209,Expert,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,CHEMBL620830,,8,1,722.0,BAO_0000219,,
3697,B,,,,10209,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,CHEMBL620831,,8,1,,BAO_0000019,,
3698,B,,,,10209,Expert,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,CHEMBL620832,,8,1,,BAO_0000019,,
3699,B,,9606.0,,10209,Expert,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,CHEMBL621548,,9,1,,BAO_0000357,,
3700,B,,,,10209,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,CHEMBL621549,,8,1,,BAO_0000019,,
3701,B,,,,10209,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,CHEMBL621550,,8,1,,BAO_0000357,,
3702,B,,,,10209,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,CHEMBL621551,,8,1,449.0,BAO_0000219,,
3703,B,,,,10209,Autocuration,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,CHEMBL621552,,8,1,,BAO_0000019,,
3704,B,,,,10209,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,CHEMBL857077,,8,1,,BAO_0000357,,
3705,B,,,,10209,Autocuration,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,CHEMBL618158,,8,1,,BAO_0000357,,
3706,B,,9606.0,,10209,Expert,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,CHEMBL618159,,9,1,643.0,BAO_0000219,,
3707,B,,,,10209,Autocuration,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,CHEMBL875101,,8,1,643.0,BAO_0000219,,
3708,B,,9606.0,,10209,Expert,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,CHEMBL618160,,9,1,722.0,BAO_0000219,,
3709,B,,,,10209,Expert,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,CHEMBL618161,,8,1,,BAO_0000357,,
3710,B,,,,10209,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,CHEMBL618162,,8,1,722.0,BAO_0000219,,
3711,B,,,,10209,Expert,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,CHEMBL618163,,8,1,,BAO_0000357,,
3712,B,,,,10209,Autocuration,Binding affinity against 5-hydroxytryptamine 7 human receptors,,CHEMBL618164,,8,1,,BAO_0000357,,
3713,B,,,,10209,Expert,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,CHEMBL618165,,8,1,,BAO_0000219,,
3714,B,,,,10209,Autocuration,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,CHEMBL618166,,8,1,722.0,BAO_0000219,,
3715,B,,,,10209,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL857989,,8,1,722.0,BAO_0000219,,
3716,B,,,,10209,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL619888,,8,1,722.0,BAO_0000219,,
3717,B,,,,10209,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL619889,,8,1,722.0,BAO_0000219,,
3718,B,,,,10209,Autocuration,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,CHEMBL619890,,8,1,722.0,BAO_0000219,,
3719,B,,,,10209,Autocuration,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,CHEMBL619891,,8,1,449.0,BAO_0000219,,
3720,B,,,,10209,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,CHEMBL619892,,8,1,722.0,BAO_0000219,,
3721,B,,,,10209,Expert,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,CHEMBL619893,,9,1,722.0,BAO_0000219,,
3722,B,,,,10209,Autocuration,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,CHEMBL619894,,8,1,722.0,BAO_0000219,,
3723,B,,,,10209,Intermediate,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,CHEMBL619895,,9,1,722.0,BAO_0000219,,
3724,B,,,,10209,Intermediate,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,CHEMBL619896,,9,1,,BAO_0000357,,
3725,B,,,,10209,Autocuration,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,CHEMBL619897,,8,1,643.0,BAO_0000219,,
3726,B,,,,10209,Autocuration,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,CHEMBL619898,,8,1,722.0,BAO_0000219,,
3727,B,,,,10209,Expert,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,CHEMBL619899,,8,1,722.0,BAO_0000219,,
3728,B,,,,10209,Autocuration,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,CHEMBL619900,,8,1,722.0,BAO_0000219,,
3729,B,,9606.0,,10209,Expert,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,CHEMBL619901,,9,1,722.0,BAO_0000219,,
3730,B,,,,10209,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,CHEMBL620580,,8,1,722.0,BAO_0000219,,
3731,B,,,,10209,Autocuration,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,CHEMBL620581,,8,1,722.0,BAO_0000219,,
3732,B,,,,10209,Autocuration,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,CHEMBL620733,,8,1,722.0,BAO_0000219,,
3733,B,,9606.0,,10209,Autocuration,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,CHEMBL620734,,9,1,,BAO_0000357,,
3734,B,,10090.0,,10022,Expert,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,CHEMBL620735,,9,1,,BAO_0000357,,
3735,B,,9986.0,,10209,Autocuration,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,CHEMBL620736,,8,1,,BAO_0000019,,
3736,B,,,,11923,Autocuration,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,CHEMBL620737,,8,1,449.0,BAO_0000219,,
3737,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,CHEMBL620738,,8,1,449.0,BAO_0000219,,
3738,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,CHEMBL620739,,8,1,449.0,BAO_0000219,,
3739,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,CHEMBL620740,,8,1,449.0,BAO_0000219,,
3740,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,CHEMBL620741,,8,1,449.0,BAO_0000219,,
3741,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,CHEMBL620742,,8,1,449.0,BAO_0000219,,
3742,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,CHEMBL620743,,8,1,449.0,BAO_0000219,,
3743,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,CHEMBL620744,,8,1,449.0,BAO_0000219,,
3744,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,CHEMBL620745,,8,1,449.0,BAO_0000219,,
3745,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,CHEMBL620746,,8,1,449.0,BAO_0000219,,
3746,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,CHEMBL620747,,8,1,449.0,BAO_0000219,,
3747,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,CHEMBL620748,,8,1,449.0,BAO_0000219,,
3748,B,,,,11923,Autocuration,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,CHEMBL620749,,8,1,449.0,BAO_0000219,,
3749,B,,,,11923,Expert,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,CHEMBL620750,,8,1,,BAO_0000357,,
3750,B,,10116.0,,11923,Expert,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,CHEMBL620751,,9,1,,BAO_0000357,,
3751,B,,,,11923,Expert,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,CHEMBL620752,,8,1,,BAO_0000357,,
